Sort code,Jurisdiction,Drug class code,Drug class,Age group,Sex , TPS ($ 000) ,"Proportion 
of TPS (%)","Rate of 
use (%)", Number of active beneficiaries ,Rank
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"1,212,664.57",8.1,0.5,"64,142",1
1,Canada,S01LA,Antineovascularization agents,Total,Total,"750,852.34",5.0,0.6,"80,768",2
1,Canada,L04AA,Selective immunosuppressants,Total,Total,"487,601.16",3.3,0.5,"60,548",3
1,Canada,B01AF,Direct factor Xa inhibitors,Total,Total,"461,010.32",3.1,4.5,"569,670",4
1,Canada,L04AX,Other immunosuppressants,Total,Total,"443,956.33",3.0,0.3,"41,560",5
1,Canada,J05AP,Antivirals for treatment of HCV infections,Total,Total,"359,640.13",2.4,0.1,"7,560",6
1,Canada,N05AX,Other antipsychotics,Total,Total,"342,152.16",2.3,2.3,"295,121",7
1,Canada,C10AA,HMG-CoA reductase inhibitors,Total,Total,"306,088.62",2.0,29.4,"3,725,483",8
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"305,519.39",2.0,4.5,"565,374",9
1,Canada,L04AC,Interleukin inhibitors,Total,Total,"263,793.53",1.8,0.1,"17,530",10
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"263,421.05",1.8,2.7,"346,376",11
1,Canada,A02BC,Proton pump inhibitors,Total,Total,"253,784.71",1.7,21.2,"2,687,375",12
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"252,939.24",1.7,2.2,"283,060",13
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"240,690.35",1.6,2.5,"312,567",14
1,Canada,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,Total,"238,601.93",1.6,2.2,"283,065",15
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"229,202.72",1.5,0.2,"25,739",16
1,Canada,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,Total,"199,448.30",1.3,0.0,"2,803",17
1,Canada,N03AX,Other antiepileptics,Total,Total,"196,625.42",1.3,7.5,"946,313",18
1,Canada,N06AX,Other antidepressants,Total,Total,"190,657.80",1.3,10.6,"1,342,464",19
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"174,922.44",1.2,4.4,"555,113",20
1,Canada,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"164,620.08",1.1,11.5,"1,463,922",21
1,Canada,N02AA,Natural opium alkaloids,Total,Total,"163,600.75",1.1,5.9,"746,965",22
1,Canada,N07BC,Drugs used in opioid dependence,Total,Total,"163,436.78",1.1,0.7,"94,718",23
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,"159,958.47",1.1,0.8,"100,172",24
1,Canada,C08CA,Dihydropyridine derivatives,Total,Total,"157,194.74",1.0,13.5,"1,710,278",25
1,Canada,R03BB,Anticholinergics,Total,Total,"147,328.25",1.0,3.5,"444,920",26
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"135,812.51",0.9,1.5,"194,080",27
1,Canada,C09AA,"ACE inhibitors, plain",Total,Total,"135,485.89",0.9,13.9,"1,769,167",28
1,Canada,N06BA,Centrally acting sympathomimetics,Total,Total,"134,684.41",0.9,2.1,"266,819",29
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"126,628.22",0.8,9.2,"1,171,570",30
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"126,028.10",0.8,0.1,"7,677",31
1,Canada,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,Total,"125,589.64",0.8,0.0,"2,951",32
1,Canada,C07AB,"Beta-blocking agents, selective",Total,Total,"111,106.20",0.7,12.4,"1,570,781",33
1,Canada,L03AA,Colony-stimulating factors,Total,Total,"107,333.94",0.7,0.2,"19,924",34
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"104,827.31",0.7,0.3,"33,793",35
1,Canada,R03BA,Glucocorticoids,Total,Total,"99,267.40",0.7,5.0,"636,167",36
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"97,236.00",0.6,1.7,"219,864",37
1,Canada,H03AA,Thyroid hormones,Total,Total,"94,960.10",0.6,12.1,"1,529,993",38
1,Canada,L01EX,Other protein kinase inhibitors,Total,Total,"90,271.06",0.6,0.0,"3,779",39
1,Canada,B03XA,Other antianemic preparations,Total,Total,"85,851.11",0.6,0.1,"16,465",40
1,Canada,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"82,947.33",0.6,2.1,"272,630",41
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"81,562.38",0.5,2.9,"368,123",42
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"81,138.38",0.5,1.1,"141,983",43
1,Canada,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,Total,"78,257.35",0.5,0.0,"1,363",44
1,Canada,M05BA,Bisphosphonates,Total,Total,"78,241.30",0.5,3.4,"437,567",45
1,Canada,L02BX,Other hormone antagonists and related agents,Total,Total,"76,164.49",0.5,0.0,"4,701",46
1,Canada,H01CB,Somatostatin and analogues,Total,Total,"75,449.50",0.5,0.0,"4,885",47
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"74,129.76",0.5,0.3,"35,337",48
1,Canada,L02BB,Antiandrogens,Total,Total,"73,557.06",0.5,0.1,"16,053",49
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"71,622.76",0.5,5.6,"704,418",50
1,Canada,A10BA,Biguanides,Total,Total,"68,794.24",0.5,9.2,"1,172,343",51
1,Canada,B01AB,Heparin group,Total,Total,"65,103.05",0.4,0.5,"58,603",52
1,Canada,S01EE,Prostaglandin analogues,Total,Total,"62,244.46",0.4,2.4,"306,864",53
1,Canada,L04AD,Calcineurin inhibitors,Total,Total,"62,210.87",0.4,0.2,"19,512",54
1,Canada,A11CC,Vitamin D and analogues,Total,Total,"59,802.50",0.4,6.0,"758,038",55
1,Canada,C10AX,Other lipid-modifying agents,Total,Total,"59,102.89",0.4,2.1,"268,488",56
1,Canada,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,Total,"58,552.26",0.4,0.0,"1,134",57
1,Canada,N05BA,Benzodiazepine derivatives,Total,Total,"57,547.76",0.4,7.7,"971,247",58
1,Canada,S01ED,Beta-blocking agents,Total,Total,"57,171.33",0.4,2.3,"295,935",59
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"56,980.83",0.4,11.3,"1,434,507",60
1,Canada,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,Total,"55,670.42",0.4,0.0,"1,797",61
1,Canada,A07EC,Aminosalicylic acid and similar agents,Total,Total,"54,055.37",0.4,0.7,"88,856",62
1,Canada,A16AB,Enzymes,Total,Total,"53,869.91",0.4,0.0,108,63
1,Canada,C08DB,Benzothiazepine derivatives,Total,Total,"52,253.48",0.3,1.7,"220,166",64
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"50,867.88",0.3,0.2,"27,926",65
1,Canada,N04BA,Dopa and dopa derivatives,Total,Total,"50,405.81",0.3,0.6,"81,162",66
1,Canada,L01XC,Monoclonal antibodies,Total,Total,"45,993.33",0.3,0.0,"4,938",67
1,Canada,C03CA,"Sulfonamides, plain",Total,Total,"42,959.15",0.3,4.9,"625,860",68
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"41,654.39",0.3,3.2,"405,961",69
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"41,485.22",0.3,2.9,"363,903",70
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"40,410.09",0.3,7.3,"924,496",71
1,Canada,N02BA,Salicylic acid and derivatives,Total,Total,"40,199.90",0.3,3.6,"462,021",72
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,Total,"39,592.79",0.3,0.2,"23,503",73
1,Canada,C09BA,ACE inhibitors and diuretics,Total,Total,"39,131.24",0.3,2.4,"306,370",74
1,Canada,A10BB,Sulfonylureas,Total,Total,"38,316.02",0.3,3.5,"441,531",75
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,"37,358.21",0.2,3.2,"405,415",76
1,Canada,L03AB,Interferons,Total,Total,"37,184.12",0.2,0.0,"2,340",77
1,Canada,R01AD,Corticosteroids,Total,Total,"36,747.42",0.2,5.8,"737,507",78
1,Canada,N06DA,Anticholinesterases,Total,Total,"36,429.57",0.2,1.0,"121,746",79
1,Canada,N02BE,Anilides,Total,Total,"35,845.39",0.2,6.4,"813,690",80
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"34,215.22",0.2,0.0,"1,524",81
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"33,716.68",0.2,2.2,"274,362",82
1,Canada,B01AE,Direct thrombin inhibitors,Total,Total,"32,573.70",0.2,0.3,"37,487",83
1,Canada,M09AX,Other drugs for disorders of the musculoskeletal system,Total,Total,"32,553.57",0.2,0.0,88,84
1,Canada,N03AG,Fatty acid derivatives,Total,Total,"32,408.82",0.2,0.7,"94,074",85
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,Total,"31,311.87",0.2,2.5,"316,286",86
1,Canada,N03AE,Benzodiazepine derivatives,Total,Total,"30,492.35",0.2,2.4,"307,963",87
1,Canada,A04AD,Other antiemetics,Total,Total,"29,714.04",0.2,0.4,"47,698",88
1,Canada,L03AX,Other immunostimulants,Total,Total,"29,320.71",0.2,0.0,"2,891",89
1,Canada,B03AA,"Iron bivalent, oral preparations",Total,Total,"28,120.55",0.2,3.2,"410,613",90
1,Canada,R07AX,Other respiratory system products,Total,Total,"27,753.69",0.2,0.0,129,91
1,Canada,J05AJ,Integrase inhibitors,Total,Total,"27,078.16",0.2,0.0,"5,030",92
1,Canada,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,Total,"26,656.92",0.2,0.0,347,93
1,Canada,N07BA,Drugs used in nicotine dependence,Total,Total,"25,189.53",0.2,1.5,"185,481",94
1,Canada,D07AC,"Corticosteroids, potent (group III)",Total,Total,"25,095.12",0.2,8.1,"1,022,035",95
1,Canada,N05AE,Indole derivatives,Total,Total,"24,997.34",0.2,0.1,"17,764",96
1,Canada,H02AB,Glucocorticoids,Total,Total,"24,778.70",0.2,7.2,"918,357",97
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"24,289.79",0.2,0.3,"38,808",98
1,Canada,C01DA,Organic nitrates,Total,Total,"24,240.00",0.2,2.5,"317,733",99
1,Canada,A09AA,Enzyme preparations,Total,Total,"23,729.33",0.2,0.2,"28,089",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,"595,202.71",8.0,0.5,"29,389",1
1,Canada,S01LA,Antineovascularization agents,Total,M,"322,711.51",4.3,0.6,"35,299",2
1,Canada,L04AX,Other immunosuppressants,Total,M,"243,808.34",3.3,0.3,"17,615",3
1,Canada,J05AP,Antivirals for treatment of HCV infections,Total,M,"242,535.41",3.3,0.1,"5,093",4
1,Canada,B01AF,Direct factor Xa inhibitors,Total,M,"237,510.99",3.2,5.3,"298,227",5
1,Canada,N05AX,Other antipsychotics,Total,M,"213,885.53",2.9,2.5,"143,220",6
1,Canada,L04AA,Selective immunosuppressants,Total,M,"179,065.49",2.4,0.4,"23,781",7
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"178,187.68",2.4,0.4,"20,271",8
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"157,864.37",2.1,3.7,"208,715",9
1,Canada,C10AA,HMG-CoA reductase inhibitors,Total,M,"156,964.23",2.1,35.5,"2,016,046",10
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"146,243.60",2.0,2.9,"165,017",11
1,Canada,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,M,"133,441.81",1.8,0.0,"1,872",12
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"133,035.71",1.8,3.0,"169,250",13
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"131,118.01",1.8,4.2,"236,663",14
1,Canada,L04AC,Interleukin inhibitors,Total,M,"124,318.64",1.7,0.1,"7,933",15
1,Canada,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,M,"121,198.88",1.6,2.6,"146,400",16
1,Canada,A02BC,Proton pump inhibitors,Total,M,"105,053.45",1.4,20.1,"1,142,190",17
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"102,522.65",1.4,4.5,"255,367",18
1,Canada,N07BC,Drugs used in opioid dependence,Total,M,"99,430.58",1.3,1.0,"57,448",19
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"94,734.55",1.3,0.5,"29,014",20
1,Canada,N03AX,Other antiepileptics,Total,M,"84,749.17",1.1,6.7,"381,234",21
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,"84,723.08",1.1,0.9,"52,357",22
1,Canada,N02AA,Natural opium alkaloids,Total,M,"82,339.95",1.1,5.8,"327,016",23
1,Canada,N06BA,Centrally acting sympathomimetics,Total,M,"81,153.37",1.1,2.7,"153,589",24
1,Canada,L02BX,Other hormone antagonists and related agents,Total,M,**,**,**,**,25
1,Canada,L02BB,Antiandrogens,Total,M,"73,536.81",1.0,0.3,"16,005",26
1,Canada,R03BB,Anticholinergics,Total,M,"71,483.59",1.0,3.8,"214,754",27
1,Canada,C09AA,"ACE inhibitors, plain",Total,M,"71,089.84",1.0,17.3,"984,156",28
1,Canada,C08CA,Dihydropyridine derivatives,Total,M,"70,848.57",1.0,14.4,"817,667",29
1,Canada,N06AX,Other antidepressants,Total,M,"69,067.04",0.9,8.5,"483,469",30
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"68,822.81",0.9,11.8,"673,015",31
1,Canada,L01EX,Other protein kinase inhibitors,Total,M,"66,337.13",0.9,0.0,"2,662",32
1,Canada,N06AB,Selective serotonin reuptake inhibitors,Total,M,"59,915.77",0.8,8.7,"491,361",33
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,"54,626.70",0.7,0.5,"26,207",34
1,Canada,C07AB,"Beta-blocking agents, selective",Total,M,"54,495.86",0.7,14.4,"820,754",35
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"54,472.44",0.7,2.1,"117,475",36
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"51,269.41",0.7,8.9,"508,393",37
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"50,612.05",0.7,0.1,"2,958",38
1,Canada,B03XA,Other antianemic preparations,Total,M,"47,434.32",0.6,0.2,"8,857",39
1,Canada,L03AA,Colony-stimulating factors,Total,M,"43,395.76",0.6,0.1,"8,067",40
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"42,824.58",0.6,1.3,"73,618",41
1,Canada,R03BA,Glucocorticoids,Total,M,"41,385.95",0.6,4.8,"269,997",42
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"40,067.57",0.5,3.9,"220,103",43
1,Canada,H01CB,Somatostatin and analogues,Total,M,"38,269.14",0.5,0.0,"2,294",44
1,Canada,L04AD,Calcineurin inhibitors,Total,M,"37,793.65",0.5,0.2,"11,852",45
1,Canada,A10BA,Biguanides,Total,M,"35,407.79",0.5,11.2,"635,358",46
1,Canada,A16AB,Enzymes,Total,M,"35,162.04",0.5,0.0,67,47
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"33,579.04",0.5,4.8,"272,667",48
1,Canada,B01AB,Heparin group,Total,M,"31,868.30",0.4,0.5,"25,975",49
1,Canada,C10AX,Other lipid-modifying agents,Total,M,"31,743.10",0.4,2.7,"150,961",50
1,Canada,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,M,"30,697.94",0.4,0.0,964,51
1,Canada,N04BA,Dopa and dopa derivatives,Total,M,"29,967.91",0.4,0.8,"45,617",52
1,Canada,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,M,"29,298.02",0.4,0.0,584,53
1,Canada,G04BD,Drugs for urinary frequency and incontinence,Total,M,"29,094.56",0.4,1.7,"94,372",54
1,Canada,S01EE,Prostaglandin analogues,Total,M,"26,535.71",0.4,2.4,"136,677",55
1,Canada,A07EC,Aminosalicylic acid and similar agents,Total,M,"26,239.99",0.4,0.7,"39,837",56
1,Canada,S01ED,Beta-blocking agents,Total,M,"25,840.61",0.3,2.5,"139,583",57
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"25,627.33",0.3,10.9,"618,166",58
1,Canada,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,M,"25,091.57",0.3,0.0,474,59
1,Canada,H03AA,Thyroid hormones,Total,M,"24,628.49",0.3,6.6,"377,702",60
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,M,"23,392.59",0.3,0.2,"13,091",61
1,Canada,N05BA,Benzodiazepine derivatives,Total,M,"22,298.56",0.3,5.9,"332,870",62
1,Canada,N02BA,Salicylic acid and derivatives,Total,M,"21,213.14",0.3,4.5,"257,194",63
1,Canada,C08DB,Benzothiazepine derivatives,Total,M,"21,187.40",0.3,1.6,"92,395",64
1,Canada,A11CC,Vitamin D and analogues,Total,M,"20,916.68",0.3,4.1,"233,670",65
1,Canada,C09BA,ACE inhibitors and diuretics,Total,M,"20,474.72",0.3,2.9,"164,432",66
1,Canada,A10BB,Sulfonylureas,Total,M,"20,468.70",0.3,4.4,"249,816",67
1,Canada,J05AJ,Integrase inhibitors,Total,M,"20,320.57",0.3,0.1,"3,492",68
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,Total,M,"19,149.60",0.3,0.3,"17,663",69
1,Canada,C03CA,"Sulfonamides, plain",Total,M,"18,975.63",0.3,5.0,"285,187",70
1,Canada,B01AE,Direct thrombin inhibitors,Total,M,"18,805.80",0.3,0.4,"22,306",71
1,Canada,N03AG,Fatty acid derivatives,Total,M,"18,550.93",0.2,0.9,"49,953",72
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"18,236.10",0.2,7.5,"426,451",73
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"17,794.44",0.2,0.2,"8,691",74
1,Canada,M09AX,Other drugs for disorders of the musculoskeletal system,Total,M,"17,681.04",0.2,0.0,50,75
1,Canada,G03BA,3-oxoandrosten (4) derivatives,Total,M,"16,338.20",0.2,0.8,"43,677",76
1,Canada,M05BA,Bisphosphonates,Total,M,"16,316.08",0.2,1.4,"82,001",77
1,Canada,R01AD,Corticosteroids,Total,M,"16,218.44",0.2,5.4,"307,754",78
1,Canada,M04AA,Preparations inhibiting uric acid production,Total,M,"16,016.00",0.2,4.3,"246,472",79
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,"15,516.97",0.2,3.2,"179,813",80
1,Canada,R07AX,Other respiratory system products,Total,M,"15,301.41",0.2,0.0,69,81
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,"14,533.34",0.2,2.2,"126,669",82
1,Canada,L01XC,Monoclonal antibodies,Total,M,"14,060.75",0.2,0.0,"1,637",83
1,Canada,N06DA,Anticholinesterases,Total,M,"13,593.32",0.2,0.8,"47,445",84
1,Canada,N07BA,Drugs used in nicotine dependence,Total,M,"13,376.31",0.2,1.7,"97,766",85
1,Canada,N03AE,Benzodiazepine derivatives,Total,M,"13,173.80",0.2,2.0,"114,493",86
1,Canada,A09AA,Enzyme preparations,Total,M,"13,010.95",0.2,0.2,"13,014",87
1,Canada,N02BE,Anilides,Total,M,"12,771.17",0.2,5.7,"324,161",88
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,"12,601.15",0.2,0.4,"21,203",89
1,Canada,A04AD,Other antiemetics,Total,M,"12,589.50",0.2,0.3,"19,166",90
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,"12,375.42",0.2,0.3,"19,779",91
1,Canada,D07AC,"Corticosteroids, potent (group III)",Total,M,"12,201.64",0.2,8.0,"455,957",92
1,Canada,L01XX,Other antineoplastic agents,Total,M,"12,093.44",0.2,0.1,"5,384",93
1,Canada,V03AC,Iron-chelating agents,Total,M,"12,050.33",0.2,0.0,594,94
1,Canada,C01DA,Organic nitrates,Total,M,"11,945.12",0.2,3.1,"178,465",95
1,Canada,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,M,"11,651.01",0.2,0.0,147,96
1,Canada,C02AC,Imidazoline receptor agonists,Total,M,"11,315.26",0.2,0.6,"35,589",97
1,Canada,H01AC,Somatropin and somatropin agonists,Total,M,"11,111.72",0.1,0.0,"1,062",98
1,Canada,J05AE,Protease inhibitors,Total,M,"10,931.76",0.1,0.0,"1,968",99
1,Canada,B03AA,"Iron bivalent, oral preparations",Total,M,"10,920.55",0.1,2.7,"152,403",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,"617,441.15",8.1,0.5,"34,752",1
1,Canada,S01LA,Antineovascularization agents,Total,F,"428,134.80",5.7,0.6,"45,468",2
1,Canada,L04AA,Selective immunosuppressants,Total,F,"308,519.03",4.1,0.5,"36,761",3
1,Canada,B01AF,Direct factor Xa inhibitors,Total,F,"223,451.53",2.9,3.9,"271,385",4
1,Canada,L04AX,Other immunosuppressants,Total,F,"200,146.63",2.6,0.3,"23,939",5
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"174,340.65",2.3,4.7,"328,611",6
1,Canada,C10AA,HMG-CoA reductase inhibitors,Total,F,"149,037.90",2.0,24.4,"1,708,602",7
1,Canada,A02BC,Proton pump inhibitors,Total,F,"148,663.35",2.0,22.0,"1,544,328",8
1,Canada,L04AC,Interleukin inhibitors,Total,F,"139,474.89",1.8,0.1,"9,597",9
1,Canada,N05AX,Other antipsychotics,Total,F,"128,107.81",1.7,2.2,"151,783",10
1,Canada,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,F,"124,420.81",1.6,0.0,"2,924",11
1,Canada,N06AX,Other antidepressants,Total,F,"121,536.15",1.6,12.3,"858,587",12
1,Canada,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,F,"117,297.58",1.5,1.9,"136,554",13
1,Canada,J05AP,Antivirals for treatment of HCV infections,Total,F,"116,935.04",1.5,0.0,"2,464",14
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"116,641.87",1.5,2.5,"176,384",15
1,Canada,N03AX,Other antiepileptics,Total,F,"111,814.55",1.5,8.1,"564,823",16
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"107,581.11",1.4,2.0,"143,202",17
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"106,506.35",1.4,1.7,"117,850",18
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"105,423.38",1.4,2.0,"137,496",19
1,Canada,N06AB,Selective serotonin reuptake inhibitors,Total,F,"104,656.72",1.4,13.9,"972,222",20
1,Canada,C08CA,Dihydropyridine derivatives,Total,F,"86,296.11",1.1,12.7,"892,191",21
1,Canada,N02AA,Natural opium alkaloids,Total,F,"81,241.57",1.1,6.0,"419,866",22
1,Canada,R03BB,Anticholinergics,Total,F,"75,826.25",1.0,3.3,"230,113",23
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"75,416.05",1.0,0.1,"4,719",24
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"75,321.95",1.0,9.5,"662,901",25
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,"75,194.90",1.0,0.7,"47,788",26
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"72,366.47",1.0,4.3,"299,587",27
1,Canada,H03AA,Thyroid hormones,Total,F,"70,316.92",0.9,16.4,"1,152,097",28
1,Canada,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,F,"66,006.49",0.9,0.0,931,29
1,Canada,C09AA,"ACE inhibitors, plain",Total,F,"64,358.53",0.8,11.2,"784,635",30
1,Canada,N07BC,Drugs used in opioid dependence,Total,F,"63,953.30",0.8,0.5,"37,229",31
1,Canada,L03AA,Colony-stimulating factors,Total,F,"63,935.09",0.8,0.2,"11,856",32
1,Canada,M05BA,Bisphosphonates,Total,F,"61,899.09",0.8,5.1,"355,468",33
1,Canada,R03BA,Glucocorticoids,Total,F,"57,857.55",0.8,5.2,"366,046",34
1,Canada,C07AB,"Beta-blocking agents, selective",Total,F,"56,584.21",0.7,10.7,"749,713",35
1,Canada,G04BD,Drugs for urinary frequency and incontinence,Total,F,"53,839.47",0.7,2.5,"178,215",36
1,Canada,N06BA,Centrally acting sympathomimetics,Total,F,"53,506.43",0.7,1.6,"113,193",37
1,Canada,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,F,"53,165.77",0.7,0.0,889,38
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"49,781.14",0.7,0.1,"5,357",39
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"42,731.55",0.6,1.5,"102,329",40
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"41,474.84",0.5,2.1,"147,934",41
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"40,689.45",0.5,5.1,"359,670",42
1,Canada,A11CC,Vitamin D and analogues,Total,F,"38,879.18",0.5,7.5,"524,281",43
1,Canada,B03XA,Other antianemic preparations,Total,F,"38,416.79",0.5,0.1,"7,608",44
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"38,305.76",0.5,1.0,"68,355",45
1,Canada,H01CB,Somatostatin and analogues,Total,F,"37,180.36",0.5,0.0,"2,591",46
1,Canada,S01EE,Prostaglandin analogues,Total,F,"35,698.49",0.5,2.4,"170,157",47
1,Canada,N05BA,Benzodiazepine derivatives,Total,F,"35,241.17",0.5,9.1,"638,241",48
1,Canada,A10BA,Biguanides,Total,F,"33,361.52",0.4,7.7,"536,650",49
1,Canada,B01AB,Heparin group,Total,F,"33,231.24",0.4,0.5,"32,623",50
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"33,053.69",0.4,0.3,"19,230",51
1,Canada,L01XC,Monoclonal antibodies,Total,F,"31,932.58",0.4,0.0,"3,301",52
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"31,342.01",0.4,11.6,"816,075",53
1,Canada,S01ED,Beta-blocking agents,Total,F,"31,317.78",0.4,2.2,"156,315",54
1,Canada,C08DB,Benzothiazepine derivatives,Total,F,"31,062.30",0.4,1.8,"127,757",55
1,Canada,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,F,"29,254.24",0.4,0.0,550,56
1,Canada,L03AB,Interferons,Total,F,"27,966.28",0.4,0.0,"1,718",57
1,Canada,A07EC,Aminosalicylic acid and similar agents,Total,F,"27,808.28",0.4,0.7,"49,009",58
1,Canada,C10AX,Other lipid-modifying agents,Total,F,"27,349.87",0.4,1.7,"117,473",59
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"27,111.86",0.4,4.0,"279,159",60
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,F,"25,016.10",0.3,3.7,"257,776",61
1,Canada,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,F,"24,972.49",0.3,0.0,833,62
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"24,403.36",0.3,0.0,"1,030",63
1,Canada,L04AD,Calcineurin inhibitors,Total,F,"24,401.21",0.3,0.1,"7,657",64
1,Canada,C03CA,"Sulfonamides, plain",Total,F,"23,977.12",0.3,4.9,"340,589",65
1,Canada,L01EX,Other protein kinase inhibitors,Total,F,"23,933.92",0.3,0.0,"1,117",66
1,Canada,N02BE,Anilides,Total,F,"23,054.84",0.3,7.0,"488,930",67
1,Canada,N06DA,Anticholinesterases,Total,F,"22,830.52",0.3,1.1,"74,281",68
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"22,162.72",0.3,7.1,"497,801",69
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,"21,830.54",0.3,3.2,"225,521",70
1,Canada,L03AX,Other immunostimulants,Total,F,"21,274.93",0.3,0.0,"2,135",71
1,Canada,R01AD,Corticosteroids,Total,F,"20,513.84",0.3,6.1,"429,528",72
1,Canada,N04BA,Dopa and dopa derivatives,Total,F,"20,433.34",0.3,0.5,"35,535",73
1,Canada,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"20,388.25",0.3,5.5,"385,717",74
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,"19,491.70",0.3,0.1,"9,124",75
1,Canada,N02BA,Salicylic acid and derivatives,Total,F,"18,986.74",0.3,2.9,"204,825",76
1,Canada,A16AB,Enzymes,Total,F,"18,707.87",0.2,0.0,41,77
1,Canada,C09BA,ACE inhibitors and diuretics,Total,F,"18,636.14",0.2,2.0,"141,815",78
1,Canada,A10BB,Sulfonylureas,Total,F,"17,832.39",0.2,2.7,"191,581",79
1,Canada,N03AE,Benzodiazepine derivatives,Total,F,"17,313.12",0.2,2.8,"193,403",80
1,Canada,L02BG,Aromatase inhibitors,Total,F,"17,227.63",0.2,0.8,"53,439",81
1,Canada,B03AA,"Iron bivalent, oral preparations",Total,F,"17,183.60",0.2,3.7,"257,947",82
1,Canada,A04AD,Other antiemetics,Total,F,"17,117.10",0.2,0.4,"28,525",83
1,Canada,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,Total,F,"16,830.42",0.2,0.0,309,84
1,Canada,A12AA,Calcium,Total,F,"16,557.75",0.2,3.0,"208,355",85
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,F,"16,149.64",0.2,0.1,"10,389",86
1,Canada,N05AE,Indole derivatives,Total,F,"15,213.39",0.2,0.2,"11,078",87
1,Canada,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,F,"15,005.91",0.2,0.0,200,88
1,Canada,M09AX,Other drugs for disorders of the musculoskeletal system,Total,F,"14,872.54",0.2,0.0,38,89
1,Canada,H02AB,Glucocorticoids,Total,F,"14,118.48",0.2,7.4,"516,423",90
1,Canada,N03AG,Fatty acid derivatives,Total,F,"13,850.75",0.2,0.6,"44,090",91
1,Canada,B01AE,Direct thrombin inhibitors,Total,F,"13,767.24",0.2,0.2,"15,180",92
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"13,479.66",0.2,3.9,"274,620",93
1,Canada,C03AA,"Thiazides, plain",Total,F,"12,983.04",0.2,5.3,"373,678",94
1,Canada,D07AC,"Corticosteroids, potent (group III)",Total,F,"12,880.15",0.2,8.1,"565,794",95
1,Canada,A16AX,Various alimentary tract and metabolism products,Total,F,"12,785.31",0.2,0.0,513,96
1,Canada,L01BA,Folic acid analogues,Total,F,"12,542.84",0.2,1.1,"74,449",97
1,Canada,A05AA,Bile acids and derivatives,Total,F,"12,526.60",0.2,0.2,"11,760",98
1,Canada,R07AX,Other respiratory system products,Total,F,"12,452.28",0.2,0.0,60,99
1,Canada,C01DA,Organic nitrates,Total,F,"12,289.71",0.2,2.0,"139,215",100
1,Canada,S01LA,Antineovascularization agents,65+,Total,"708,621.46",7.6,1.2,"75,833",1
1,Canada,B01AF,Direct factor Xa inhibitors,65+,Total,"434,326.33",4.7,8.6,"520,871",2
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,"419,951.03",4.5,0.4,"22,768",3
1,Canada,L04AX,Other immunosuppressants,65+,Total,"330,794.63",3.6,0.4,"23,146",4
1,Canada,C10AA,HMG-CoA reductase inhibitors,65+,Total,"255,646.98",2.7,49.6,"3,012,741",5
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"230,970.61",2.5,6.3,"384,902",6
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"204,875.32",2.2,4.2,"256,039",7
1,Canada,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,Total,"204,348.55",2.2,3.9,"235,131",8
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"203,137.09",2.2,3.6,"217,873",9
1,Canada,A02BC,Proton pump inhibitors,65+,Total,"186,993.89",2.0,31.3,"1,903,224",10
1,Canada,L04AA,Selective immunosuppressants,65+,Total,"186,936.81",2.0,0.5,"30,676",11
1,Canada,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,Total,"175,413.17",1.9,0.0,"2,469",12
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"173,719.13",1.9,3.6,"220,023",13
1,Canada,C08CA,Dihydropyridine derivatives,65+,Total,"135,769.84",1.5,23.1,"1,405,225",14
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"128,351.41",1.4,3.0,"185,128",15
1,Canada,R03BB,Anticholinergics,65+,Total,"120,774.88",1.3,5.8,"353,356",16
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,"117,553.22",1.3,1.2,"70,771",17
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"112,026.11",1.2,16.3,"992,245",18
1,Canada,C09AA,"ACE inhibitors, plain",65+,Total,"111,323.74",1.2,22.7,"1,378,288",19
1,Canada,L04AC,Interleukin inhibitors,65+,Total,"111,212.69",1.2,0.1,"7,293",20
1,Canada,N06AX,Other antidepressants,65+,Total,"96,482.30",1.0,11.7,"712,656",21
1,Canada,N03AX,Other antiepileptics,65+,Total,"96,458.06",1.0,9.4,"568,768",22
1,Canada,C07AB,"Beta-blocking agents, selective",65+,Total,"95,485.37",1.0,21.9,"1,331,924",23
1,Canada,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,Total,"93,458.19",1.0,0.0,"2,142",24
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"89,409.27",1.0,0.4,"27,293",25
1,Canada,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"79,578.02",0.9,10.8,"654,419",26
1,Canada,L01EX,Other protein kinase inhibitors,65+,Total,"76,847.34",0.8,0.1,"3,229",27
1,Canada,H03AA,Thyroid hormones,65+,Total,"73,745.19",0.8,18.3,"1,113,290",28
1,Canada,B03XA,Other antianemic preparations,65+,Total,"73,039.97",0.8,0.2,"13,487",29
1,Canada,L02BX,Other hormone antagonists and related agents,65+,Total,"73,025.97",0.8,0.1,"4,464",30
1,Canada,M05BA,Bisphosphonates,65+,Total,"72,271.38",0.8,6.6,"402,636",31
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"70,651.97",0.8,0.1,"4,074",32
1,Canada,N02AA,Natural opium alkaloids,65+,Total,"70,317.42",0.8,7.7,"467,191",33
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"69,726.59",0.7,1.9,"117,225",34
1,Canada,L02BB,Antiandrogens,65+,Total,"69,639.62",0.7,0.3,"15,406",35
1,Canada,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"69,339.60",0.7,3.6,"220,287",36
1,Canada,J05AP,Antivirals for treatment of HCV infections,65+,Total,"69,263.46",0.7,0.0,"1,374",37
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"65,827.82",0.7,10.1,"616,134",38
1,Canada,L03AA,Colony-stimulating factors,65+,Total,"64,697.12",0.7,0.2,"12,018",39
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,"63,133.13",0.7,0.5,"29,284",40
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"61,463.36",0.7,2.2,"132,808",41
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"59,697.68",0.6,5.2,"314,862",42
1,Canada,S01EE,Prostaglandin analogues,65+,Total,"58,680.58",0.6,4.6,"280,634",43
1,Canada,R03BA,Glucocorticoids,65+,Total,"58,269.42",0.6,4.6,"277,638",44
1,Canada,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,Total,"58,197.61",0.6,0.0,"1,017",45
1,Canada,H01CB,Somatostatin and analogues,65+,Total,"55,679.97",0.6,0.1,"3,510",46
1,Canada,S01ED,Beta-blocking agents,65+,Total,"53,351.37",0.6,4.4,"266,106",47
1,Canada,N05AX,Other antipsychotics,65+,Total,"51,905.69",0.6,1.8,"108,734",48
1,Canada,A10BA,Biguanides,65+,Total,"51,546.63",0.6,14.0,"849,104",49
1,Canada,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,Total,"50,997.10",0.5,0.0,973,50
1,Canada,C10AX,Other lipid-modifying agents,65+,Total,"48,692.26",0.5,3.8,"229,954",51
1,Canada,C08DB,Benzothiazepine derivatives,65+,Total,"47,296.69",0.5,3.2,"191,625",52
1,Canada,N04BA,Dopa and dopa derivatives,65+,Total,"46,484.26",0.5,1.2,"73,615",53
1,Canada,A11CC,Vitamin D and analogues,65+,Total,"45,486.88",0.5,9.0,"547,634",54
1,Canada,B01AB,Heparin group,65+,Total,"43,687.76",0.5,0.7,"42,007",55
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,"41,534.15",0.4,0.1,"3,806",56
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"40,468.17",0.4,3.7,"227,225",57
1,Canada,C03CA,"Sulfonamides, plain",65+,Total,"37,467.23",0.4,9.1,"551,031",58
1,Canada,A07EC,Aminosalicylic acid and similar agents,65+,Total,"36,580.11",0.4,0.8,"50,619",59
1,Canada,N06DA,Anticholinesterases,65+,Total,"35,862.48",0.4,2.0,"119,898",60
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"34,628.30",0.4,11.7,"708,747",61
1,Canada,N02BA,Salicylic acid and derivatives,65+,Total,"33,567.10",0.4,6.3,"382,320",62
1,Canada,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,Total,"33,025.03",0.4,0.0,"1,103",63
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,"32,938.62",0.4,5.6,"340,285",64
1,Canada,N05BA,Benzodiazepine derivatives,65+,Total,"32,511.81",0.3,9.7,"591,179",65
1,Canada,C09BA,ACE inhibitors and diuretics,65+,Total,"32,511.02",0.3,3.9,"236,353",66
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"32,359.10",0.3,4.1,"246,341",67
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"32,215.72",0.3,4.2,"256,319",68
1,Canada,B01AE,Direct thrombin inhibitors,65+,Total,"31,514.12",0.3,0.6,"35,831",69
1,Canada,A10BB,Sulfonylureas,65+,Total,"29,230.95",0.3,5.4,"327,432",70
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,Total,"26,551.37",0.3,4.3,"263,415",71
1,Canada,L01XC,Monoclonal antibodies,65+,Total,"26,418.58",0.3,0.0,"2,876",72
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"26,350.73",0.3,0.3,"15,641",73
1,Canada,N02BE,Anilides,65+,Total,"26,163.10",0.3,9.2,"559,554",74
1,Canada,L04AD,Calcineurin inhibitors,65+,Total,"25,204.71",0.3,0.1,"8,706",75
1,Canada,R01AD,Corticosteroids,65+,Total,"23,968.97",0.3,6.8,"415,315",76
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"22,667.82",0.2,3.6,"221,033",77
1,Canada,C01DA,Organic nitrates,65+,Total,"22,349.13",0.2,4.6,"277,142",78
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"20,765.84",0.2,7.8,"477,103",79
1,Canada,M04AA,Preparations inhibiting uric acid production,65+,Total,"20,719.92",0.2,4.5,"274,635",80
1,Canada,B03AA,"Iron bivalent, oral preparations",65+,Total,"20,458.47",0.2,4.6,"282,160",81
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,"20,078.63",0.2,0.5,"31,738",82
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"19,999.18",0.2,0.0,845,83
1,Canada,A12AA,Calcium,65+,Total,"18,294.75",0.2,3.6,"216,587",84
1,Canada,H02AB,Glucocorticoids,65+,Total,"17,359.92",0.2,9.1,"555,584",85
1,Canada,C03AA,"Thiazides, plain",65+,Total,"16,971.92",0.2,8.1,"494,076",86
1,Canada,L01XX,Other antineoplastic agents,65+,Total,"16,817.52",0.2,0.2,"10,132",87
1,Canada,D07AC,"Corticosteroids, potent (group III)",65+,Total,"16,483.01",0.2,9.2,"557,832",88
1,Canada,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,Total,"16,275.69",0.2,0.0,218,89
1,Canada,L01XE,Protein kinase inhibitors,65+,Total,"15,756.06",0.2,0.0,"1,807",90
1,Canada,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,"14,852.47",0.2,3.4,"207,369",91
1,Canada,L02BG,Aromatase inhibitors,65+,Total,"14,593.89",0.2,0.7,"41,057",92
1,Canada,A07AA,Antibiotics,65+,Total,"14,531.72",0.2,1.2,"75,251",93
1,Canada,C03DA,Aldosterone antagonists,65+,Total,"14,446.30",0.2,2.8,"167,204",94
1,Canada,A06AB,Contact laxatives,65+,Total,"14,297.69",0.2,4.6,"280,149",95
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,"14,279.41",0.2,0.5,"28,431",96
1,Canada,L01BA,Folic acid analogues,65+,Total,"14,156.10",0.2,1.3,"77,011",97
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,Total,"13,671.28",0.1,0.2,"11,655",98
1,Canada,S01EC,Carbonic anhydrase inhibitors,65+,Total,"13,615.59",0.1,1.5,"88,372",99
1,Canada,B01AA,Vitamin K antagonists,65+,Total,"13,124.26",0.1,2.2,"136,311",100
1,Canada,S01LA,Antineovascularization agents,65+,M,"298,951.51",6.6,1.2,"32,507",1
1,Canada,B01AF,Direct factor Xa inhibitors,65+,M,"221,566.11",4.9,9.8,"269,691",2
1,Canada,L04AX,Other immunosuppressants,65+,M,"193,686.51",4.3,0.4,"10,490",3
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,"183,844.89",4.1,0.3,"9,316",4
1,Canada,C10AA,HMG-CoA reductase inhibitors,65+,M,"129,328.79",2.9,57.9,"1,600,771",5
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"125,904.92",2.8,5.7,"157,791",6
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"118,853.01",2.6,4.6,"128,393",7
1,Canada,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,M,"115,936.68",2.6,0.1,"1,635",8
1,Canada,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,M,"104,020.35",2.3,4.4,"121,621",9
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"100,522.41",2.2,5.9,"163,464",10
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"98,288.54",2.2,4.4,"120,619",11
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"89,313.17",2.0,1.0,"27,256",12
1,Canada,A02BC,Proton pump inhibitors,65+,M,"75,300.03",1.7,29.1,"804,805",13
1,Canada,L02BX,Other hormone antagonists and related agents,65+,M,**,**,**,**,14
1,Canada,L04AA,Selective immunosuppressants,65+,M,"70,430.55",1.6,0.4,"12,352",15
1,Canada,L02BB,Antiandrogens,65+,M,"69,627.62",1.5,0.6,"15,384",16
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,"65,723.35",1.5,1.4,"39,060",17
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"63,415.78",1.4,21.5,"594,441",18
1,Canada,C08CA,Dihydropyridine derivatives,65+,M,"59,226.94",1.3,23.4,"648,093",19
1,Canada,R03BB,Anticholinergics,65+,M,"59,023.41",1.3,6.2,"172,672",20
1,Canada,L01EX,Other protein kinase inhibitors,65+,M,"57,117.18",1.3,0.1,"2,296",21
1,Canada,C09AA,"ACE inhibitors, plain",65+,M,"57,113.27",1.3,27.2,"751,792",22
1,Canada,L04AC,Interleukin inhibitors,65+,M,"48,921.29",1.1,0.1,"3,053",23
1,Canada,J05AP,Antivirals for treatment of HCV infections,65+,M,"47,115.29",1.0,0.0,931,24
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,"46,367.20",1.0,0.8,"21,603",25
1,Canada,C07AB,"Beta-blocking agents, selective",65+,M,"45,274.06",1.0,24.7,"681,424",26
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,"44,496.80",1.0,15.3,"421,841",27
1,Canada,B03XA,Other antianemic preparations,65+,M,"40,689.52",0.9,0.3,"7,195",28
1,Canada,N03AX,Other antiepileptics,65+,M,"39,031.38",0.9,8.2,"225,365",29
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"36,892.27",0.8,2.2,"61,153",30
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,"36,423.01",0.8,0.1,"3,344",31
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"35,341.04",0.8,2.6,"72,267",32
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"32,122.45",0.7,9.2,"255,202",33
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"31,739.80",0.7,0.1,"1,772",34
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"31,477.87",0.7,6.7,"184,148",35
1,Canada,N06AX,Other antidepressants,65+,M,"31,255.17",0.7,9.0,"247,782",36
1,Canada,N02AA,Natural opium alkaloids,65+,M,"30,906.78",0.7,7.2,"200,026",37
1,Canada,L03AA,Colony-stimulating factors,65+,M,"29,957.72",0.7,0.2,"5,523",38
1,Canada,H01CB,Somatostatin and analogues,65+,M,"28,635.47",0.6,0.1,"1,683",39
1,Canada,N04BA,Dopa and dopa derivatives,65+,M,"27,593.72",0.6,1.5,"41,633",40
1,Canada,A10BA,Biguanides,65+,M,"26,643.76",0.6,16.8,"465,023",41
1,Canada,C10AX,Other lipid-modifying agents,65+,M,"26,042.75",0.6,4.6,"128,330",42
1,Canada,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,M,"25,470.11",0.6,0.0,507,43
1,Canada,G04BD,Drugs for urinary frequency and incontinence,65+,M,"25,368.80",0.6,2.9,"79,568",44
1,Canada,N06AB,Selective serotonin reuptake inhibitors,65+,M,"24,909.76",0.6,7.5,"208,083",45
1,Canada,S01EE,Prostaglandin analogues,65+,M,"24,864.72",0.6,4.5,"124,003",46
1,Canada,S01ED,Beta-blocking agents,65+,M,"23,825.60",0.5,4.5,"123,736",47
1,Canada,R03BA,Glucocorticoids,65+,M,"23,415.65",0.5,3.9,"107,839",48
1,Canada,B01AB,Heparin group,65+,M,"22,716.04",0.5,0.7,"19,061",49
1,Canada,N05AX,Other antipsychotics,65+,M,"20,695.93",0.5,1.4,"40,004",50
1,Canada,H03AA,Thyroid hormones,65+,M,"18,914.50",0.4,10.4,"288,283",51
1,Canada,C08DB,Benzothiazepine derivatives,65+,M,"18,770.99",0.4,2.8,"78,177",52
1,Canada,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,M,"18,613.22",0.4,0.0,346,53
1,Canada,B01AE,Direct thrombin inhibitors,65+,M,"18,058.35",0.4,0.8,"21,128",54
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,65+,M,"17,894.82",0.4,0.6,"16,430",55
1,Canada,A07EC,Aminosalicylic acid and similar agents,65+,M,"17,827.11",0.4,0.8,"23,137",56
1,Canada,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,M,"17,800.91",0.4,0.0,580,57
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"17,340.78",0.4,3.4,"93,798",58
1,Canada,N02BA,Salicylic acid and derivatives,65+,M,"17,292.39",0.4,7.6,"210,355",59
1,Canada,C09BA,ACE inhibitors and diuretics,65+,M,"16,800.15",0.4,4.5,"124,241",60
1,Canada,C03CA,"Sulfonamides, plain",65+,M,"16,177.88",0.4,9.0,"248,399",61
1,Canada,A10BB,Sulfonylureas,65+,M,"15,604.91",0.3,6.7,"185,406",62
1,Canada,L04AD,Calcineurin inhibitors,65+,M,"15,604.52",0.3,0.2,"5,453",63
1,Canada,A11CC,Vitamin D and analogues,65+,M,"15,493.87",0.3,6.3,"173,260",64
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"15,455.77",0.3,10.7,"295,666",65
1,Canada,M05BA,Bisphosphonates,65+,M,"14,522.24",0.3,2.7,"73,636",66
1,Canada,M04AA,Preparations inhibiting uric acid production,65+,M,"13,910.90",0.3,7.1,"196,087",67
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,"13,427.67",0.3,5.3,"147,192",68
1,Canada,N06DA,Anticholinesterases,65+,M,"13,300.24",0.3,1.7,"46,553",69
1,Canada,R01AD,Corticosteroids,65+,M,"10,853.58",0.2,6.4,"176,445",70
1,Canada,C01DA,Organic nitrates,65+,M,"10,819.41",0.2,5.5,"152,890",71
1,Canada,N05BA,Benzodiazepine derivatives,65+,M,"10,580.05",0.2,7.0,"193,800",72
1,Canada,L01XX,Other antineoplastic agents,65+,M,"10,198.15",0.2,0.2,"4,323",73
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,"10,163.45",0.2,0.6,"15,951",74
1,Canada,G03BA,3-oxoandrosten (4) derivatives,65+,M,"9,968.22",0.2,0.8,"22,932",75
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,"9,250.50",0.2,8.1,"222,518",76
1,Canada,L01XC,Monoclonal antibodies,65+,M,"8,885.60",0.2,0.0,"1,031",77
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,"8,783.75",0.2,0.2,"4,828",78
1,Canada,N02BE,Anilides,65+,M,"8,505.63",0.2,7.7,"212,145",79
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,"8,481.65",0.2,0.6,"16,766",80
1,Canada,B03AA,"Iron bivalent, oral preparations",65+,M,"8,390.58",0.2,4.4,"121,715",81
1,Canada,D07AC,"Corticosteroids, potent (group III)",65+,M,"8,278.12",0.2,9.3,"258,133",82
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,M,"8,181.14",0.2,0.2,"6,340",83
1,Canada,C03DA,Aldosterone antagonists,65+,M,"8,124.90",0.2,3.1,"85,806",84
1,Canada,L01XE,Protein kinase inhibitors,65+,M,"7,992.22",0.2,0.0,918,85
1,Canada,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,M,"7,817.19",0.2,0.0,97,86
1,Canada,H02AB,Glucocorticoids,65+,M,"7,456.72",0.2,8.9,"245,650",87
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,"6,985.30",0.2,0.8,"23,396",88
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,"6,878.92",0.2,2.4,"67,162",89
1,Canada,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,65+,M,"6,844.18",0.2,0.0,158,90
1,Canada,A07AA,Antibiotics,65+,M,"6,766.13",0.1,1.0,"27,250",91
1,Canada,D05AX,Other antipsoriatics for topical use,65+,M,"6,712.22",0.1,0.8,"23,489",92
1,Canada,N07BC,Drugs used in opioid dependence,65+,M,"6,689.07",0.1,0.2,"5,629",93
1,Canada,B01AA,Vitamin K antagonists,65+,M,"6,656.52",0.1,2.7,"76,008",94
1,Canada,C07AG,Alpha- and beta-blocking agents,65+,M,"6,512.63",0.1,1.2,"31,857",95
1,Canada,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,M,"6,377.80",0.1,3.2,"87,612",96
1,Canada,S01EC,Carbonic anhydrase inhibitors,65+,M,"6,248.21",0.1,1.5,"41,248",97
1,Canada,J05AJ,Integrase inhibitors,65+,M,"6,221.21",0.1,0.0,835,98
1,Canada,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,65+,M,"6,148.59",0.1,0.0,168,99
1,Canada,C03AA,"Thiazides, plain",65+,M,"6,030.07",0.1,6.9,"190,153",100
1,Canada,S01LA,Antineovascularization agents,65+,F,"409,663.92",8.6,1.3,"43,325",1
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,"236,106.14",4.9,0.4,"13,452",2
1,Canada,B01AF,Direct factor Xa inhibitors,65+,F,"212,722.16",4.4,7.6,"251,140",3
1,Canada,L04AX,Other immunosuppressants,65+,F,"137,107.43",2.9,0.4,"12,653",4
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"130,423.74",2.7,6.7,"221,404",5
1,Canada,C10AA,HMG-CoA reductase inhibitors,65+,F,"126,277.46",2.6,42.6,"1,411,646",6
1,Canada,L04AA,Selective immunosuppressants,65+,F,"116,506.07",2.4,0.6,"18,323",7
1,Canada,A02BC,Proton pump inhibitors,65+,F,"111,668.54",2.3,33.1,"1,098,195",8
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"110,441.88",2.3,5.1,"168,674",9
1,Canada,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,F,"100,279.01",2.1,3.4,"113,464",10
1,Canada,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,F,**,**,**,**,11
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"84,204.62",1.8,2.7,"89,408",12
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"78,926.16",1.6,3.0,"98,199",13
1,Canada,C08CA,Dihydropyridine derivatives,65+,F,"76,520.62",1.6,22.8,"756,961",14
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"75,407.42",1.6,3.0,"99,366",15
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"67,509.48",1.4,17.2,"570,285",16
1,Canada,N06AX,Other antidepressants,65+,F,"65,216.56",1.4,14.0,"464,823",17
1,Canada,L04AC,Interleukin inhibitors,65+,F,"62,291.40",1.3,0.1,"4,240",18
1,Canada,R03BB,Anticholinergics,65+,F,"61,743.89",1.3,5.4,"180,664",19
1,Canada,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,F,"59,476.48",1.2,0.0,834,20
1,Canada,M05BA,Bisphosphonates,65+,F,"57,735.90",1.2,9.9,"328,947",21
1,Canada,N03AX,Other antiepileptics,65+,F,"57,415.02",1.2,10.4,"343,341",22
1,Canada,H03AA,Thyroid hormones,65+,F,"54,824.11",1.1,24.9,"824,941",23
1,Canada,N06AB,Selective serotonin reuptake inhibitors,65+,F,"54,658.82",1.1,13.5,"446,284",24
1,Canada,C09AA,"ACE inhibitors, plain",65+,F,"54,194.41",1.1,18.9,"626,363",25
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,"51,823.21",1.1,1.0,"31,707",26
1,Canada,C07AB,"Beta-blocking agents, selective",65+,F,"50,196.83",1.0,19.6,"650,351",27
1,Canada,G04BD,Drugs for urinary frequency and incontinence,65+,F,"43,964.15",0.9,4.2,"140,699",28
1,Canada,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,F,"39,584.39",0.8,0.0,671,29
1,Canada,N02AA,Natural opium alkaloids,65+,F,"39,410.10",0.8,8.1,"267,144",30
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"38,912.16",0.8,0.1,"2,302",31
1,Canada,R03BA,Glucocorticoids,65+,F,"34,845.82",0.7,5.1,"169,775",32
1,Canada,L03AA,Colony-stimulating factors,65+,F,"34,739.40",0.7,0.2,"6,495",33
1,Canada,S01EE,Prostaglandin analogues,65+,F,"33,809.18",0.7,4.7,"156,610",34
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"32,827.23",0.7,1.7,"56,065",35
1,Canada,B03XA,Other antianemic preparations,65+,F,"32,350.45",0.7,0.2,"6,292",36
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"32,284.11",0.7,7.4,"245,818",37
1,Canada,N05AX,Other antipsychotics,65+,F,"31,202.41",0.7,2.1,"68,722",38
1,Canada,A11CC,Vitamin D and analogues,65+,F,"29,990.65",0.6,11.3,"374,354",39
1,Canada,S01ED,Beta-blocking agents,65+,F,"29,517.02",0.6,4.3,"142,347",40
1,Canada,C08DB,Benzothiazepine derivatives,65+,F,"28,523.60",0.6,3.4,"113,441",41
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"28,210.43",0.6,3.9,"130,672",42
1,Canada,H01CB,Somatostatin and analogues,65+,F,"27,044.50",0.6,0.1,"1,827",43
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"26,117.51",0.5,1.8,"60,530",44
1,Canada,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,F,"25,526.98",0.5,0.0,466,45
1,Canada,A10BA,Biguanides,65+,F,"24,891.10",0.5,11.6,"383,952",46
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"23,124.45",0.5,4.0,"133,408",47
1,Canada,C10AX,Other lipid-modifying agents,65+,F,"22,648.10",0.5,3.1,"101,611",48
1,Canada,N06DA,Anticholinesterases,65+,F,"22,556.89",0.5,2.2,"73,328",49
1,Canada,J05AP,Antivirals for treatment of HCV infections,65+,F,"22,148.17",0.5,0.0,443,50
1,Canada,N05BA,Benzodiazepine derivatives,65+,F,"21,930.50",0.5,12.0,"397,350",51
1,Canada,C03CA,"Sulfonamides, plain",65+,F,"21,284.68",0.4,9.1,"302,580",52
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,F,"21,205.10",0.4,6.4,"212,942",53
1,Canada,B01AB,Heparin group,65+,F,"20,969.97",0.4,0.7,"22,944",54
1,Canada,L01EX,Other protein kinase inhibitors,65+,F,"19,730.16",0.4,0.0,933,55
1,Canada,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,"19,504.31",0.4,5.8,"193,049",56
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"19,168.24",0.4,12.5,"413,015",57
1,Canada,N04BA,Dopa and dopa derivatives,65+,F,"18,887.53",0.4,1.0,"31,975",58
1,Canada,A07EC,Aminosalicylic acid and similar agents,65+,F,"18,751.84",0.4,0.8,"27,479",59
1,Canada,N02BE,Anilides,65+,F,"17,649.32",0.4,10.5,"347,240",60
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"17,559.61",0.4,0.3,"10,812",61
1,Canada,L01XC,Monoclonal antibodies,65+,F,"17,532.98",0.4,0.1,"1,845",62
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,"16,765.93",0.4,0.2,"7,681",63
1,Canada,N02BA,Salicylic acid and derivatives,65+,F,"16,274.71",0.3,5.2,"171,965",64
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"15,787.81",0.3,4.6,"153,855",65
1,Canada,C09BA,ACE inhibitors and diuretics,65+,F,"15,705.01",0.3,3.4,"112,084",66
1,Canada,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,F,"15,224.11",0.3,0.0,523,67
1,Canada,L02BG,Aromatase inhibitors,65+,F,"14,551.54",0.3,1.2,"40,741",68
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"14,551.29",0.3,0.0,579,69
1,Canada,A12AA,Calcium,65+,F,"13,916.39",0.3,5.1,"168,978",70
1,Canada,A10BB,Sulfonylureas,65+,F,"13,617.72",0.3,4.3,"141,964",71
1,Canada,B01AE,Direct thrombin inhibitors,65+,F,"13,455.77",0.3,0.4,"14,703",72
1,Canada,R01AD,Corticosteroids,65+,F,"13,112.32",0.3,7.2,"238,836",73
1,Canada,B03AA,"Iron bivalent, oral preparations",65+,F,"12,060.84",0.3,4.8,"160,374",74
1,Canada,C01DA,Organic nitrates,65+,F,"11,525.97",0.2,3.7,"124,223",75
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"11,512.71",0.2,7.7,"254,534",76
1,Canada,C03AA,"Thiazides, plain",65+,F,"10,939.51",0.2,9.2,"303,879",77
1,Canada,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,65+,F,**,**,**,**,78
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,"9,907.24",0.2,0.5,"15,774",79
1,Canada,H02AB,Glucocorticoids,65+,F,"9,901.94",0.2,9.3,"309,898",80
1,Canada,L04AD,Calcineurin inhibitors,65+,F,"9,600.19",0.2,0.1,"3,253",81
1,Canada,S01XA,Other ophthalmologicals,65+,F,"9,456.40",0.2,1.5,"49,092",82
1,Canada,L01BA,Folic acid analogues,65+,F,"9,288.90",0.2,1.5,"49,736",83
1,Canada,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,"8,474.41",0.2,3.6,"119,739",84
1,Canada,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,F,"8,458.50",0.2,0.0,121,85
1,Canada,A06AB,Contact laxatives,65+,F,"8,431.31",0.2,4.7,"156,484",86
1,Canada,D07AC,"Corticosteroids, potent (group III)",65+,F,"8,201.65",0.2,9.0,"299,648",87
1,Canada,A06AA,"Softeners, emollients",65+,F,"7,979.84",0.2,3.4,"112,444",88
1,Canada,L01XE,Protein kinase inhibitors,65+,F,"7,763.84",0.2,0.0,889,89
1,Canada,A07AA,Antibiotics,65+,F,"7,758.26",0.2,1.4,"47,991",90
1,Canada,S01EC,Carbonic anhydrase inhibitors,65+,F,"7,364.81",0.2,1.4,"47,110",91
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,"7,122.94",0.1,3.4,"112,162",92
1,Canada,A06AD,Osmotically acting laxatives,65+,F,"6,960.88",0.1,4.1,"136,552",93
1,Canada,N03AE,Benzodiazepine derivatives,65+,F,"6,909.49",0.1,2.9,"97,073",94
1,Canada,M04AA,Preparations inhibiting uric acid production,65+,F,"6,807.63",0.1,2.4,"78,538",95
1,Canada,A04AD,Other antiemetics,65+,F,"6,696.42",0.1,0.4,"13,792",96
1,Canada,N04BC,Dopamine agonists,65+,F,"6,673.99",0.1,1.0,"32,156",97
1,Canada,L01XX,Other antineoplastic agents,65+,F,"6,619.37",0.1,0.2,"5,809",98
1,Canada,B01AA,Vitamin K antagonists,65+,F,"6,467.01",0.1,1.8,"60,293",99
1,Canada,C07AA,"Beta-blocking agents, non-selective",65+,F,"6,446.80",0.1,1.6,"54,695",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,"792,713.54",13.9,0.6,"41,374",1
1,Canada,L04AA,Selective immunosuppressants,<65,Total,"300,664.35",5.3,0.5,"29,872",2
1,Canada,J05AP,Antivirals for treatment of HCV infections,<65,Total,"290,376.67",5.1,0.1,"6,186",3
1,Canada,N05AX,Other antipsychotics,<65,Total,"290,246.42",5.1,2.8,"186,386",4
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"187,668.57",3.3,0.3,"21,933",5
1,Canada,N07BC,Drugs used in opioid dependence,<65,Total,"153,143.72",2.7,1.3,"85,013",6
1,Canada,L04AC,Interleukin inhibitors,<65,Total,"152,580.84",2.7,0.2,"10,237",7
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"134,454.25",2.4,5.0,"327,887",8
1,Canada,N06BA,Centrally acting sympathomimetics,<65,Total,"128,967.21",2.3,3.8,"252,493",9
1,Canada,L04AX,Other immunosuppressants,<65,Total,"113,161.70",2.0,0.3,"18,414",10
1,Canada,N03AX,Other antiepileptics,<65,Total,"100,167.29",1.8,5.7,"377,543",11
1,Canada,N06AX,Other antidepressants,<65,Total,"94,175.34",1.7,9.5,"629,803",12
1,Canada,N02AA,Natural opium alkaloids,<65,Total,"93,283.32",1.6,4.2,"279,773",13
1,Canada,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"85,041.90",1.5,12.2,"809,499",14
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"74,548.37",1.3,2.7,"180,468",15
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"66,971.22",1.2,1.4,"92,544",16
1,Canada,A02BC,Proton pump inhibitors,<65,Total,"66,790.61",1.2,11.9,"784,143",17
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"58,545.73",1.0,1.4,"90,337",18
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"55,376.13",1.0,0.1,"3,603",19
1,Canada,C10AA,HMG-CoA reductase inhibitors,<65,Total,"50,441.41",0.9,10.8,"712,738",20
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"49,802.15",0.9,1.0,"65,187",21
1,Canada,A16AB,Enzymes,<65,Total,"44,940.66",0.8,0.0,91,22
1,Canada,L03AA,Colony-stimulating factors,<65,Total,"42,636.82",0.7,0.1,"7,906",23
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,"42,405.25",0.7,0.4,"29,401",24
1,Canada,S01LA,Antineovascularization agents,<65,Total,"42,230.88",0.7,0.1,"4,935",25
1,Canada,R03BA,Glucocorticoids,<65,Total,"40,997.87",0.7,5.4,"358,528",26
1,Canada,L04AD,Calcineurin inhibitors,<65,Total,"37,006.16",0.6,0.2,"10,806",27
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"35,772.63",0.6,1.3,"87,056",28
1,Canada,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,Total,"34,253.38",0.6,0.7,"47,934",29
1,Canada,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,"32,553.57",0.6,0.0,88,30
1,Canada,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,Total,"32,131.45",0.6,0.0,809,31
1,Canada,L03AB,Interferons,<65,Total,"28,983.90",0.5,0.0,"1,790",32
1,Canada,R07AX,Other respiratory system products,<65,Total,**,**,**,**,33
1,Canada,B01AF,Direct factor Xa inhibitors,<65,Total,"26,683.64",0.5,0.7,"48,798",34
1,Canada,R03BB,Anticholinergics,<65,Total,"26,553.36",0.5,1.4,"91,564",35
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,Total,"25,921.50",0.5,0.2,"11,848",36
1,Canada,N05BA,Benzodiazepine derivatives,<65,Total,"25,035.95",0.4,5.8,"380,067",37
1,Canada,N03AG,Fatty acid derivatives,<65,Total,"24,634.26",0.4,1.0,"66,680",38
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"24,517.14",0.4,0.2,"12,285",39
1,Canada,L03AX,Other immunostimulants,<65,Total,"24,491.14",0.4,0.0,"2,495",40
1,Canada,C09AA,"ACE inhibitors, plain",<65,Total,"24,161.88",0.4,5.9,"390,877",41
1,Canada,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,Total,"24,035.13",0.4,0.0,334,42
1,Canada,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,Total,"22,645.40",0.4,0.0,694,43
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"22,352.49",0.4,11.0,"725,757",44
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"21,864.70",0.4,0.8,"53,261",45
1,Canada,C08CA,Dihydropyridine derivatives,<65,Total,"21,424.76",0.4,4.6,"305,049",46
1,Canada,B01AB,Heparin group,<65,Total,"21,415.29",0.4,0.3,"16,596",47
1,Canada,H03AA,Thyroid hormones,<65,Total,"21,214.80",0.4,6.3,"416,701",48
1,Canada,N05AE,Indole derivatives,<65,Total,"20,514.66",0.4,0.2,"14,558",49
1,Canada,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"20,393.40",0.4,5.8,"385,838",50
1,Canada,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,Total,"20,059.74",0.4,0.0,346,51
1,Canada,J05AJ,Integrase inhibitors,<65,Total,"19,934.07",0.3,0.1,"4,063",52
1,Canada,N03AE,Benzodiazepine derivatives,<65,Total,"19,926.79",0.3,2.4,"159,184",53
1,Canada,H01CB,Somatostatin and analogues,<65,Total,"19,769.53",0.3,0.0,"1,375",54
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"19,644.25",0.3,6.8,"447,393",55
1,Canada,L01XC,Monoclonal antibodies,<65,Total,"19,574.75",0.3,0.0,"2,062",56
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"18,986.44",0.3,2.8,"184,926",57
1,Canada,N07BA,Drugs used in nicotine dependence,<65,Total,"18,907.99",0.3,2.1,"138,218",58
1,Canada,A04AD,Other antiemetics,<65,Total,"18,529.02",0.3,0.4,"24,957",59
1,Canada,A07EC,Aminosalicylic acid and similar agents,<65,Total,"17,475.20",0.3,0.6,"38,236",60
1,Canada,H01AC,Somatropin and somatropin agonists,<65,Total,"17,423.85",0.3,0.0,"1,681",61
1,Canada,A10BA,Biguanides,<65,Total,"17,247.62",0.3,4.9,"323,239",62
1,Canada,A16AX,Various alimentary tract and metabolism products,<65,Total,"15,858.79",0.3,0.0,377,63
1,Canada,C02AC,Imidazoline receptor agonists,<65,Total,"15,792.74",0.3,0.8,"55,268",64
1,Canada,C07AB,"Beta-blocking agents, selective",<65,Total,"15,620.62",0.3,3.6,"238,852",65
1,Canada,V06C,Infant formulas,<65,Total,"15,567.18",0.3,0.2,"10,450",66
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,"15,418.04",0.3,0.1,"6,500",67
1,Canada,V03AC,Iron-chelating agents,<65,Total,"15,133.11",0.3,0.0,602,68
1,Canada,N03AF,Carboxamide derivatives,<65,Total,"14,921.79",0.3,0.5,"33,423",69
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,"14,601.98",0.3,2.7,"179,322",70
1,Canada,A11CC,Vitamin D and analogues,<65,Total,"14,315.53",0.3,3.2,"210,399",71
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"14,216.04",0.2,0.0,679,72
1,Canada,V06,General nutrients,<65,Total,"13,683.17",0.2,0.0,413,73
1,Canada,G04BD,Drugs for urinary frequency and incontinence,<65,Total,"13,607.74",0.2,0.8,"52,343",74
1,Canada,L01EX,Other protein kinase inhibitors,<65,Total,"13,423.72",0.2,0.0,550,75
1,Canada,M03BX,Other centrally acting agents,<65,Total,"13,255.09",0.2,4.0,"264,474",76
1,Canada,B03XA,Other antianemic preparations,<65,Total,"12,811.14",0.2,0.0,"2,978",77
1,Canada,A09AA,Enzyme preparations,<65,Total,"12,804.34",0.2,0.2,"11,087",78
1,Canada,R01AD,Corticosteroids,<65,Total,"12,778.42",0.2,4.9,"322,191",79
1,Canada,M01AE,Propionic acid derivatives,<65,Total,"12,452.70",0.2,8.6,"565,341",80
1,Canada,C01CA,Adrenergic and dopaminergic agents,<65,Total,"12,252.59",0.2,1.6,"108,770",81
1,Canada,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,Total,"11,940.50",0.2,0.3,"21,507",82
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,"11,411.79",0.2,0.4,"24,758",83
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,"10,996.63",0.2,0.1,"6,053",84
1,Canada,G02BA,Intrauterine contraceptives,<65,Total,"10,944.98",0.2,1.0,"65,024",85
1,Canada,J05AE,Protease inhibitors,<65,Total,"10,413.82",0.2,0.0,"1,999",86
1,Canada,C10AX,Other lipid-modifying agents,<65,Total,"10,410.63",0.2,0.6,"38,534",87
1,Canada,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,Total,"10,381.23",0.2,0.0,129,88
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"10,157.06",0.2,3.6,"234,993",89
1,Canada,N02CC,Selective serotonin (5HT1) agonists,<65,Total,"10,026.06",0.2,1.3,"86,427",90
1,Canada,N02BE,Anilides,<65,Total,"9,682.25",0.2,3.8,"254,132",91
1,Canada,J02AC,Triazole derivatives,<65,Total,"9,459.50",0.2,1.2,"80,545",92
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,"9,126.12",0.2,1.8,"117,562",93
1,Canada,A10BB,Sulfonylureas,<65,Total,"9,085.06",0.2,1.7,"114,099",94
1,Canada,B02AB,Proteinase inhibitors,<65,Total,"8,887.13",0.2,0.0,87,95
1,Canada,R05CB,Mucolytics,<65,Total,"8,709.04",0.2,0.0,"1,186",96
1,Canada,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,Total,"8,704.54",0.2,0.0,189,97
1,Canada,D07AC,"Corticosteroids, potent (group III)",<65,Total,"8,612.10",0.2,7.0,"464,203",98
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"7,904.93",0.1,0.1,"8,154",99
1,Canada,J01CA,Penicillins with extended spectrum,<65,Total,"7,699.13",0.1,12.4,"822,561",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,"411,357.81",14.1,0.7,"20,073",1
1,Canada,J05AP,Antivirals for treatment of HCV infections,<65,M,"195,420.12",6.7,0.1,"4,162",2
1,Canada,N05AX,Other antipsychotics,<65,M,"193,189.60",6.6,3.5,"103,216",3
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"141,764.67",4.9,0.6,"16,927",4
1,Canada,L04AA,Selective immunosuppressants,<65,M,"108,634.94",3.7,0.4,"11,429",5
1,Canada,N07BC,Drugs used in opioid dependence,<65,M,"92,741.51",3.2,1.8,"51,819",6
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"85,181.88",2.9,5.5,"161,569",7
1,Canada,N06BA,Centrally acting sympathomimetics,<65,M,"78,470.98",2.7,5.0,"146,729",8
1,Canada,L04AC,Interleukin inhibitors,<65,M,"75,397.35",2.6,0.2,"4,880",9
1,Canada,N02AA,Natural opium alkaloids,<65,M,"51,433.16",1.8,4.4,"126,990",10
1,Canada,L04AX,Other immunosuppressants,<65,M,"50,121.83",1.7,0.2,"7,125",11
1,Canada,N03AX,Other antiepileptics,<65,M,"45,717.75",1.6,5.3,"155,868",12
1,Canada,N06AX,Other antidepressants,<65,M,"37,811.87",1.3,8.1,"235,687",13
1,Canada,N06AB,Selective serotonin reuptake inhibitors,<65,M,"35,006.01",1.2,9.7,"283,278",14
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"34,747.17",1.2,1.7,"48,631",15
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"31,959.45",1.1,1.7,"50,924",16
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"30,595.60",1.1,2.5,"73,199",17
1,Canada,A16AB,Enzymes,<65,M,"30,455.62",1.0,0.0,59,18
1,Canada,A02BC,Proton pump inhibitors,<65,M,"29,753.42",1.0,11.6,"337,385",19
1,Canada,C10AA,HMG-CoA reductase inhibitors,<65,M,"27,635.41",0.9,14.2,"415,274",20
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,"27,390.59",0.9,1.3,"36,624",21
1,Canada,S01LA,Antineovascularization agents,<65,M,"23,760.00",0.8,0.1,"2,792",22
1,Canada,L04AD,Calcineurin inhibitors,<65,M,"22,189.12",0.8,0.2,"6,399",23
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"19,131.40",0.7,1.6,"45,208",24
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,"18,999.73",0.7,0.5,"13,297",25
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"18,872.24",0.6,0.0,"1,186",26
1,Canada,R03BA,Glucocorticoids,<65,M,"17,970.30",0.6,5.6,"162,158",27
1,Canada,M09AX,Other drugs for disorders of the musculoskeletal system,<65,M,"17,681.04",0.6,0.0,50,28
1,Canada,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,M,"17,505.12",0.6,0.0,237,29
1,Canada,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,M,"17,178.53",0.6,0.8,"24,779",30
1,Canada,B01AF,Direct factor Xa inhibitors,<65,M,"15,944.53",0.5,1.0,"28,535",31
1,Canada,R07AX,Other respiratory system products,<65,M,**,**,**,**,32
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,M,"15,211.46",0.5,0.2,"6,751",33
1,Canada,N03AG,Fatty acid derivatives,<65,M,"14,913.29",0.5,1.3,"37,819",34
1,Canada,J05AJ,Integrase inhibitors,<65,M,"14,099.36",0.5,0.1,"2,657",35
1,Canada,C09AA,"ACE inhibitors, plain",<65,M,"13,976.56",0.5,8.0,"232,363",36
1,Canada,L03AA,Colony-stimulating factors,<65,M,"13,438.04",0.5,0.1,"2,544",37
1,Canada,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,M,"12,897.03",0.4,0.0,384,38
1,Canada,R03BB,Anticholinergics,<65,M,"12,460.18",0.4,1.4,"42,082",39
1,Canada,N05BA,Benzodiazepine derivatives,<65,M,"11,718.51",0.4,4.8,"139,070",40
1,Canada,C08CA,Dihydropyridine derivatives,<65,M,"11,621.63",0.4,5.8,"169,574",41
1,Canada,H01AC,Somatropin and somatropin agonists,<65,M,"10,939.01",0.4,0.0,"1,016",42
1,Canada,C02AC,Imidazoline receptor agonists,<65,M,"10,635.10",0.4,1.0,"29,052",43
1,Canada,N07BA,Drugs used in nicotine dependence,<65,M,"10,221.33",0.4,2.5,"73,821",44
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"10,171.54",0.3,11.1,"322,499",45
1,Canada,H01CB,Somatostatin and analogues,<65,M,"9,633.67",0.3,0.0,611,46
1,Canada,N03AE,Benzodiazepine derivatives,<65,M,"9,518.16",0.3,2.2,"62,797",47
1,Canada,C07AB,"Beta-blocking agents, selective",<65,M,"9,221.79",0.3,4.8,"139,329",48
1,Canada,L01EX,Other protein kinase inhibitors,<65,M,"9,219.96",0.3,0.0,366,49
1,Canada,B01AB,Heparin group,<65,M,"9,152.26",0.3,0.2,"6,914",50
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"9,010.69",0.3,0.1,"3,863",51
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,"8,985.60",0.3,7.0,"203,933",52
1,Canada,A10BA,Biguanides,<65,M,"8,764.03",0.3,5.8,"170,335",53
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"8,589.70",0.3,1.2,"35,955",54
1,Canada,A07EC,Aminosalicylic acid and similar agents,<65,M,"8,412.88",0.3,0.6,"16,700",55
1,Canada,N05AE,Indole derivatives,<65,M,"8,322.84",0.3,0.2,"5,646",56
1,Canada,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,"8,259.50",0.3,0.2,"4,604",57
1,Canada,N03AF,Carboxamide derivatives,<65,M,"8,133.11",0.3,0.6,"17,112",58
1,Canada,A04AD,Other antiemetics,<65,M,"8,101.15",0.3,0.4,"10,218",59
1,Canada,J05AE,Protease inhibitors,<65,M,"7,872.16",0.3,0.1,"1,460",60
1,Canada,V06C,Infant formulas,<65,M,"7,753.39",0.3,0.2,"4,675",61
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"7,654.36",0.3,2.0,"59,506",62
1,Canada,A09AA,Enzyme preparations,<65,M,"7,546.99",0.3,0.2,"5,300",63
1,Canada,L03AB,Interferons,<65,M,"7,413.66",0.3,0.0,465,64
1,Canada,V03AC,Iron-chelating agents,<65,M,"7,007.79",0.2,0.0,287,65
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,"6,772.61",0.2,3.0,"86,552",66
1,Canada,B03XA,Other antianemic preparations,<65,M,"6,744.81",0.2,0.1,"1,662",67
1,Canada,V06,General nutrients,<65,M,"6,668.47",0.2,0.0,191,68
1,Canada,L03AX,Other immunostimulants,<65,M,"6,611.18",0.2,0.0,642,69
1,Canada,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,M,"6,478.35",0.2,0.0,128,70
1,Canada,G03BA,3-oxoandrosten (4) derivatives,<65,M,"6,369.98",0.2,0.7,"20,745",71
1,Canada,C01CA,Adrenergic and dopaminergic agents,<65,M,"5,977.16",0.2,1.7,"49,310",72
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,"5,932.31",0.2,0.4,"12,465",73
1,Canada,M03BX,Other centrally acting agents,<65,M,"5,834.14",0.2,3.7,"108,550",74
1,Canada,H03AA,Thyroid hormones,<65,M,"5,713.99",0.2,3.1,"89,419",75
1,Canada,C10AX,Other lipid-modifying agents,<65,M,"5,700.35",0.2,0.8,"22,631",76
1,Canada,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,M,"5,644.09",0.2,0.3,"9,135",77
1,Canada,A16AX,Various alimentary tract and metabolism products,<65,M,"5,584.06",0.2,0.0,141,78
1,Canada,M01AE,Propionic acid derivatives,<65,M,"5,478.19",0.2,8.0,"234,137",79
1,Canada,A11CC,Vitamin D and analogues,<65,M,"5,422.81",0.2,2.1,"60,410",80
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,<65,M,"5,421.37",0.2,0.1,"1,758",81
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,<65,M,"5,407.00",0.2,2.7,"78,573",82
1,Canada,R01AD,Corticosteroids,<65,M,"5,364.86",0.2,4.5,"131,309",83
1,Canada,B02AB,Proteinase inhibitors,<65,M,"5,300.77",0.2,0.0,49,84
1,Canada,L01XC,Monoclonal antibodies,<65,M,"5,175.15",0.2,0.0,606,85
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,"5,026.81",0.2,0.2,"5,136",86
1,Canada,A10BB,Sulfonylureas,<65,M,"4,863.79",0.2,2.2,"64,410",87
1,Canada,R05CB,Mucolytics,<65,M,"4,719.66",0.2,0.0,610,88
1,Canada,J02AC,Triazole derivatives,<65,M,"4,607.72",0.2,0.3,"9,388",89
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,"4,363.98",0.2,0.0,228,90
1,Canada,N02BE,Anilides,<65,M,"4,265.54",0.1,3.8,"112,016",91
1,Canada,N05AF,Thioxanthene derivatives,<65,M,"4,232.75",0.1,0.2,"6,116",92
1,Canada,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,"4,176.97",0.1,0.0,886,93
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,"4,119.51",0.1,0.2,"4,437",94
1,Canada,J01GB,Other aminoglycosides,<65,M,"3,978.34",0.1,0.0,830,95
1,Canada,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,<65,M,"3,961.40",0.1,0.0,76,96
1,Canada,D07AC,"Corticosteroids, potent (group III)",<65,M,"3,923.52",0.1,6.8,"197,824",97
1,Canada,N02BA,Salicylic acid and derivatives,<65,M,"3,920.75",0.1,1.6,"46,839",98
1,Canada,L02BB,Antiandrogens,<65,M,"3,909.20",0.1,0.0,621,99
1,Canada,V03AB,Antidotes,<65,M,"3,843.17",0.1,0.6,"16,968",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,"381,335.01",13.7,0.6,"21,300",1
1,Canada,L04AA,Selective immunosuppressants,<65,F,"192,012.96",6.9,0.5,"18,438",2
1,Canada,N05AX,Other antipsychotics,<65,F,"96,905.39",3.5,2.3,"83,061",3
1,Canada,J05AP,Antivirals for treatment of HCV infections,<65,F,"94,786.87",3.4,0.1,"2,021",4
1,Canada,L04AC,Interleukin inhibitors,<65,F,"77,183.49",2.8,0.1,"5,357",5
1,Canada,L04AX,Other immunosuppressants,<65,F,"63,039.20",2.3,0.3,"11,286",6
1,Canada,N07BC,Drugs used in opioid dependence,<65,F,"60,349.37",2.2,0.9,"33,154",7
1,Canada,N06AX,Other antidepressants,<65,F,"56,319.59",2.0,10.7,"393,764",8
1,Canada,N03AX,Other antiepileptics,<65,F,"54,399.53",2.0,6.0,"221,482",9
1,Canada,N06BA,Centrally acting sympathomimetics,<65,F,"50,471.61",1.8,2.9,"105,727",10
1,Canada,N06AB,Selective serotonin reuptake inhibitors,<65,F,"49,997.89",1.8,14.3,"525,938",11
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"49,242.03",1.8,4.5,"166,179",12
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"44,733.63",1.6,0.1,"4,899",13
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"43,916.91",1.6,2.9,"107,207",14
1,Canada,N02AA,Natural opium alkaloids,<65,F,"41,831.47",1.5,4.1,"152,722",15
1,Canada,A02BC,Proton pump inhibitors,<65,F,"36,994.81",1.3,12.1,"446,133",16
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"36,503.89",1.3,0.1,"2,417",17
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"32,173.70",1.2,1.2,"43,836",18
1,Canada,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,F,**,**,**,**,19
1,Canada,L03AA,Colony-stimulating factors,<65,F,"29,195.69",1.0,0.1,"5,361",20
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"26,497.21",1.0,1.1,"39,297",21
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,"23,371.68",0.8,0.4,"16,081",22
1,Canada,R03BA,Glucocorticoids,<65,F,"23,011.73",0.8,5.3,"196,271",23
1,Canada,C10AA,HMG-CoA reductase inhibitors,<65,F,"22,760.35",0.8,8.0,"296,955",24
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,"22,301.73",0.8,0.8,"28,442",25
1,Canada,L03AB,Interferons,<65,F,"21,570.25",0.8,0.0,"1,325",26
1,Canada,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,"20,378.61",0.7,10.4,"385,624",27
1,Canada,S01LA,Antineovascularization agents,<65,F,"18,470.88",0.7,0.1,"2,143",28
1,Canada,L03AX,Other immunostimulants,<65,F,"17,879.96",0.6,0.1,"1,853",29
1,Canada,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,F,"17,018.57",0.6,0.6,"23,090",30
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"16,614.04",0.6,1.1,"41,799",31
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"15,494.08",0.6,0.2,"8,418",32
1,Canada,H03AA,Thyroid hormones,<65,F,"15,492.76",0.6,8.9,"327,155",33
1,Canada,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,"14,872.54",0.5,0.0,38,34
1,Canada,L04AD,Calcineurin inhibitors,<65,F,"14,801.02",0.5,0.1,"4,404",35
1,Canada,A16AB,Enzymes,<65,F,"14,485.03",0.5,0.0,32,36
1,Canada,L01XC,Monoclonal antibodies,<65,F,"14,399.60",0.5,0.0,"1,456",37
1,Canada,R03BB,Anticholinergics,<65,F,"14,082.36",0.5,1.3,"49,449",38
1,Canada,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,F,"13,581.38",0.5,0.0,218,39
1,Canada,N05BA,Benzodiazepine derivatives,<65,F,"13,310.67",0.5,6.5,"240,891",40
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"13,264.41",0.5,0.5,"17,262",41
1,Canada,B01AB,Heparin group,<65,F,"12,261.27",0.4,0.3,"9,679",42
1,Canada,N05AE,Indole derivatives,<65,F,"12,183.24",0.4,0.2,"8,905",43
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"12,173.77",0.4,10.9,"403,060",44
1,Canada,R07AX,Other respiratory system products,<65,F,**,**,**,**,45
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"11,324.05",0.4,3.4,"125,304",46
1,Canada,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,47
1,Canada,B01AF,Direct factor Xa inhibitors,<65,F,"10,729.37",0.4,0.5,"20,245",48
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,F,"10,672.08",0.4,0.1,"5,084",49
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,"10,650.01",0.4,6.6,"243,267",50
1,Canada,A04AD,Other antiemetics,<65,F,"10,420.68",0.4,0.4,"14,733",51
1,Canada,N03AE,Benzodiazepine derivatives,<65,F,"10,403.63",0.4,2.6,"96,330",52
1,Canada,A16AX,Various alimentary tract and metabolism products,<65,F,"10,274.73",0.4,0.0,236,53
1,Canada,C09AA,"ACE inhibitors, plain",<65,F,"10,164.12",0.4,4.3,"158,272",54
1,Canada,H01CB,Somatostatin and analogues,<65,F,"10,135.86",0.4,0.0,764,55
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,<65,F,"9,991.79",0.4,0.1,"4,740",56
1,Canada,G04BD,Drugs for urinary frequency and incontinence,<65,F,"9,875.32",0.4,1.0,"37,516",57
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"9,852.07",0.4,0.0,451,58
1,Canada,C08CA,Dihydropyridine derivatives,<65,F,"9,775.49",0.4,3.7,"135,230",59
1,Canada,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,F,"9,748.37",0.3,0.0,310,60
1,Canada,N03AG,Fatty acid derivatives,<65,F,"9,713.90",0.3,0.8,"28,832",61
1,Canada,A07EC,Aminosalicylic acid and similar agents,<65,F,"9,056.44",0.3,0.6,"21,530",62
1,Canada,A11CC,Vitamin D and analogues,<65,F,"8,888.53",0.3,4.1,"149,927",63
1,Canada,N07BA,Drugs used in nicotine dependence,<65,F,"8,685.36",0.3,1.7,"64,382",64
1,Canada,A10BA,Biguanides,<65,F,"8,470.43",0.3,4.1,"152,698",65
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,"8,405.34",0.3,3.1,"113,852",66
1,Canada,V03AC,Iron-chelating agents,<65,F,"8,125.32",0.3,0.0,315,67
1,Canada,N02CC,Selective serotonin (5HT1) agonists,<65,F,"7,851.43",0.3,1.9,"71,295",68
1,Canada,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,"7,812.47",0.3,2.5,"92,616",69
1,Canada,V06C,Infant formulas,<65,F,"7,806.05",0.3,0.2,"5,774",70
1,Canada,M03BX,Other centrally acting agents,<65,F,"7,415.55",0.3,4.2,"155,824",71
1,Canada,R01AD,Corticosteroids,<65,F,"7,401.52",0.3,5.2,"190,692",72
1,Canada,V06,General nutrients,<65,F,"7,014.70",0.3,0.0,222,73
1,Canada,M01AE,Propionic acid derivatives,<65,F,"6,964.78",0.2,9.0,"330,834",74
1,Canada,N03AF,Carboxamide derivatives,<65,F,"6,785.28",0.2,0.4,"16,291",75
1,Canada,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,F,"6,547.41",0.2,0.0,79,76
1,Canada,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,F,"6,530.01",0.2,0.0,97,77
1,Canada,H01AC,Somatropin and somatropin agonists,<65,F,"6,484.83",0.2,0.0,665,78
1,Canada,C07AB,"Beta-blocking agents, selective",<65,F,"6,387.38",0.2,2.7,"99,362",79
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,"6,356.71",0.2,4.4,"162,458",80
1,Canada,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,F,"6,291.99",0.2,0.3,"12,361",81
1,Canada,C01CA,Adrenergic and dopaminergic agents,<65,F,"6,272.06",0.2,1.6,"59,444",82
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,<65,F,"6,199.99",0.2,0.2,"7,710",83
1,Canada,A05AA,Bile acids and derivatives,<65,F,"6,147.04",0.2,0.1,"4,451",84
1,Canada,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,**,**,**,**,85
1,Canada,B03XA,Other antianemic preparations,<65,F,"6,066.34",0.2,0.0,"1,316",86
1,Canada,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,<65,F,**,**,**,**,87
1,Canada,J05AJ,Integrase inhibitors,<65,F,"5,743.64",0.2,0.0,"1,390",88
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,"5,478.54",0.2,0.3,"12,290",89
1,Canada,N02BE,Anilides,<65,F,"5,405.53",0.2,3.8,"141,690",90
1,Canada,A09AA,Enzyme preparations,<65,F,"5,252.01",0.2,0.2,"5,785",91
1,Canada,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,F,"5,176.90",0.2,0.0,126,92
1,Canada,C02AC,Imidazoline receptor agonists,<65,F,"5,155.12",0.2,0.7,"26,199",93
1,Canada,B03AA,"Iron bivalent, oral preparations",<65,F,"5,122.76",0.2,2.6,"97,573",94
1,Canada,A04AA,Serotonin (5HT3) antagonists,<65,F,"5,003.20",0.2,0.4,"14,603",95
1,Canada,J02AC,Triazole derivatives,<65,F,"4,850.59",0.2,1.9,"71,133",96
1,Canada,C10AX,Other lipid-modifying agents,<65,F,"4,701.76",0.2,0.4,"15,862",97
1,Canada,D07AC,"Corticosteroids, potent (group III)",<65,F,"4,678.50",0.2,7.2,"266,146",98
1,Canada,G03AC,Progestogens,<65,F,"4,513.44",0.2,2.2,"82,688",99
1,Canada,H02AB,Glucocorticoids,<65,F,"4,216.54",0.2,5.6,"206,525",100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"11,726.37",7.5,0.7,712,1
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,Total,Total,"8,514.96",5.4,0.5,475,2
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,Total,Total,"7,162.34",4.6,2.5,"2,473",3
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,Total,Total,"4,120.16",2.6,39.2,"39,317",4
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"4,016.56",2.6,5.5,"5,478",5
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,Total,Total,"3,745.58",2.4,38.5,"38,661",6
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"3,618.93",2.3,5.3,"5,313",7
2,Newfoundland and Labrador,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,Total,"3,378.63",2.2,0.0,47,8
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,Total,Total,"3,366.27",2.1,0.3,290,9
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"3,304.17",2.1,18.3,"18,403",10
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,Total,Total,"2,984.62",1.9,15.1,"15,176",11
2,Newfoundland and Labrador,R03BA,Glucocorticoids,Total,Total,"2,956.15",1.9,8.8,"8,859",12
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,Total,Total,"2,934.58",1.9,0.3,323,13
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,Total,Total,"2,856.51",1.8,0.1,67,14
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",Total,Total,"2,623.63",1.7,22.8,"22,926",15
2,Newfoundland and Labrador,N06AX,Other antidepressants,Total,Total,"2,597.06",1.7,13.9,"13,911",16
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,Total,Total,"2,427.18",1.5,0.3,286,17
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"2,318.95",1.5,2.5,"2,494",18
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",Total,Total,"2,186.10",1.4,23.1,"23,216",19
2,Newfoundland and Labrador,N05AX,Other antipsychotics,Total,Total,"2,157.51",1.4,2.7,"2,670",20
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"2,032.76",1.3,5.2,"5,248",21
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,Total,Total,"1,836.39",1.2,3.5,"3,512",22
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,Total,Total,"1,676.22",1.1,5.2,"5,204",23
2,Newfoundland and Labrador,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,Total,"1,628.77",1.0,0.0,30,24
2,Newfoundland and Labrador,R03BB,Anticholinergics,Total,Total,"1,594.99",1.0,6.6,"6,644",25
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,Total,Total,"1,551.19",1.0,15.7,"15,769",26
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,Total,Total,"1,471.92",0.9,10.6,"10,609",27
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,308.36",0.8,19.6,"19,654",28
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,Total,Total,"1,205.49",0.8,0.4,449,29
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,Total,Total,"1,201.63",0.8,1.5,"1,482",30
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"1,189.92",0.8,10.2,"10,214",31
2,Newfoundland and Labrador,H03AA,Thyroid hormones,Total,Total,"1,110.50",0.7,12.3,"12,308",32
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"1,074.77",0.7,7.8,"7,822",33
2,Newfoundland and Labrador,A10BA,Biguanides,Total,Total,"1,073.14",0.7,15.1,"15,181",34
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"1,057.97",0.7,8.0,"8,030",35
2,Newfoundland and Labrador,L01EX,Other protein kinase inhibitors,Total,Total,"1,029.64",0.7,0.1,53,36
2,Newfoundland and Labrador,L02BB,Antiandrogens,Total,Total,"1,018.70",0.6,0.2,228,37
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"1,015.98",0.6,0.4,362,38
2,Newfoundland and Labrador,N03AX,Other antiepileptics,Total,Total,993.02,0.6,3.0,"3,007",39
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,929.05,0.6,0.1,96,40
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,Total,Total,922.76,0.6,5.4,"5,463",41
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,891.68,0.6,2.0,"2,042",42
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,Total,Total,890.53,0.6,5.7,"5,733",43
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,Total,Total,889.18,0.6,0.0,48,44
2,Newfoundland and Labrador,A10BB,Sulfonylureas,Total,Total,886.64,0.6,8.3,"8,355",45
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,860.14,0.5,1.1,"1,154",46
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,823.70,0.5,6.8,"6,858",47
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,759.00,0.5,4.9,"4,947",48
2,Newfoundland and Labrador,L03AB,Interferons,Total,Total,743.28,0.5,0.0,37,49
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,Total,Total,696.01,0.4,0.8,795,50
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,Total,Total,684.84,0.4,12.7,"12,700",51
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",Total,Total,678.49,0.4,9.6,"9,645",52
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,Total,Total,637.82,0.4,1.5,"1,506",53
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,Total,Total,633.08,0.4,0.1,127,54
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,Total,Total,632.13,0.4,1.8,"1,835",55
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,Total,Total,629.68,0.4,3.3,"3,304",56
2,Newfoundland and Labrador,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,Total,609.34,0.4,0.0,15,57
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,**,**,**,**,58
2,Newfoundland and Labrador,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,Total,541.57,0.3,0.0,12,59
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,Total,Total,530.94,0.3,2.0,"2,034",60
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,Total,Total,528.94,0.3,2.3,"2,292",61
2,Newfoundland and Labrador,H02AB,Glucocorticoids,Total,Total,528.46,0.3,12.8,"12,895",62
2,Newfoundland and Labrador,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,Total,525.79,0.3,0.0,15,63
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",Total,Total,522.98,0.3,10.7,"10,700",64
2,Newfoundland and Labrador,C01DA,Organic nitrates,Total,Total,508.65,0.3,3.9,"3,961",65
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,Total,Total,501.12,0.3,3.9,"3,903",66
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,Total,Total,492.57,0.3,2.9,"2,885",67
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,474.72,0.3,3.2,"3,227",68
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,Total,Total,453.69,0.3,6.7,"6,771",69
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,Total,Total,436.56,0.3,5.1,"5,167",70
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,405.80,0.3,0.8,818,71
2,Newfoundland and Labrador,M05BA,Bisphosphonates,Total,Total,399.58,0.3,3.3,"3,332",72
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,Total,Total,398.17,0.3,0.0,36,73
2,Newfoundland and Labrador,L03AX,Other immunostimulants,Total,Total,391.30,0.2,0.0,36,74
2,Newfoundland and Labrador,A16AB,Enzymes,Total,Total,**,**,**,*,75
2,Newfoundland and Labrador,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,Total,**,**,**,**,76
2,Newfoundland and Labrador,R01AD,Corticosteroids,Total,Total,378.97,0.2,7.7,"7,748",77
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,Total,Total,377.54,0.2,6.6,"6,631",78
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,Total,Total,375.28,0.2,0.6,575,79
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,Total,Total,370.68,0.2,0.0,47,80
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,Total,Total,370.54,0.2,1.2,"1,183",81
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,Total,Total,362.47,0.2,0.0,22,82
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,353.59,0.2,0.0,18,83
2,Newfoundland and Labrador,A12BA,Potassium,Total,Total,340.57,0.2,3.6,"3,584",84
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,Total,Total,320.74,0.2,0.8,810,85
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",Total,Total,319.46,0.2,6.3,"6,321",86
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,302.80,0.2,2.8,"2,801",87
2,Newfoundland and Labrador,A09AA,Enzyme preparations,Total,Total,297.45,0.2,0.1,149,88
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,Total,Total,289.31,0.2,3.0,"3,046",89
2,Newfoundland and Labrador,A05AA,Bile acids and derivatives,Total,Total,286.83,0.2,0.2,166,90
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",Total,Total,281.45,0.2,1.5,"1,526",91
2,Newfoundland and Labrador,C10AB,Fibrates,Total,Total,281.37,0.2,1.9,"1,904",92
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,Total,Total,278.76,0.2,0.7,675,93
2,Newfoundland and Labrador,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,278.74,0.2,1.8,"1,794",94
2,Newfoundland and Labrador,B02AB,Proteinase inhibitors,Total,Total,**,**,**,*,95
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,Total,270.47,0.2,7.3,"7,300",96
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,Total,Total,268.89,0.2,4.1,"4,146",97
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,Total,Total,260.41,0.2,2.7,"2,757",98
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,Total,Total,254.43,0.2,13.4,"13,454",99
2,Newfoundland and Labrador,J01FA,Macrolides,Total,Total,251.18,0.2,6.9,"6,911",100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,"5,336.87",7.4,0.7,322,1
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,Total,M,"4,617.60",6.4,0.4,192,2
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,Total,M,"4,364.20",6.1,3.5,"1,489",3
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,Total,M,"1,912.73",2.7,42.3,"18,213",4
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,Total,M,"1,834.41",2.6,0.1,44,5
2,Newfoundland and Labrador,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,M,"1,818.91",2.5,0.1,31,6
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"1,748.47",2.4,5.7,"2,443",7
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,624.91",2.3,5.5,"2,358",8
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,Total,M,"1,502.68",2.1,35.8,"15,452",9
2,Newfoundland and Labrador,N05AX,Other antipsychotics,Total,M,"1,453.41",2.0,3.4,"1,479",10
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,Total,M,"1,418.96",2.0,0.3,127,11
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,Total,M,"1,333.84",1.9,15.5,"6,693",12
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"1,293.82",1.8,5.6,"2,432",13
2,Newfoundland and Labrador,R03BA,Glucocorticoids,Total,M,"1,234.21",1.7,8.1,"3,502",14
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",Total,M,"1,221.60",1.7,25.8,"11,101",15
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,Total,M,"1,178.63",1.6,0.3,129,16
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,Total,M,"1,164.85",1.6,5.2,"2,222",17
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,149.21",1.6,13.8,"5,966",18
2,Newfoundland and Labrador,L02BB,Antiandrogens,Total,M,"1,018.70",1.4,0.5,228,19
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"1,015.42",1.4,2.5,"1,096",20
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",Total,M,976.57,1.4,25.0,"10,797",21
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,Total,M,929.01,1.3,0.8,325,22
2,Newfoundland and Labrador,N06AX,Other antidepressants,Total,M,920.18,1.3,11.2,"4,827",23
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,Total,M,798.18,1.1,5.3,"2,266",24
2,Newfoundland and Labrador,R03BB,Anticholinergics,Total,M,786.50,1.1,7.3,"3,149",25
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,Total,M,740.91,1.0,14.4,"6,198",26
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,707.65,1.0,0.2,74,27
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,Total,M,699.53,1.0,10.0,"4,322",28
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,Total,M,661.90,0.9,0.2,76,29
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,Total,M,631.91,0.9,0.5,220,30
2,Newfoundland and Labrador,L01EX,Other protein kinase inhibitors,Total,M,584.06,0.8,0.1,30,31
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,571.51,0.8,19.1,"8,232",32
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,Total,M,568.03,0.8,11.9,"5,139",33
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,Total,M,554.11,0.8,1.6,679,34
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,504.98,0.7,8.2,"3,525",35
2,Newfoundland and Labrador,A10BA,Biguanides,Total,M,489.29,0.7,16.3,"7,006",36
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,Total,M,430.25,0.6,5.8,"2,507",37
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,418.46,0.6,8.6,"3,697",38
2,Newfoundland and Labrador,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,M,**,**,**,**,39
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,Total,M,398.17,0.6,0.1,36,40
2,Newfoundland and Labrador,N03AX,Other antiepileptics,Total,M,391.13,0.5,2.7,"1,181",41
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,390.94,0.5,2.0,872,42
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,Total,M,387.70,0.5,5.0,"2,159",43
2,Newfoundland and Labrador,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,M,386.42,0.5,0.0,10,44
2,Newfoundland and Labrador,A10BB,Sulfonylureas,Total,M,382.70,0.5,8.7,"3,761",45
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,375.51,0.5,6.2,"2,660",46
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,356.94,0.5,6.2,"2,654",47
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,Total,M,356.28,0.5,1.8,763,48
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,Total,M,345.35,0.5,0.0,21,49
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,Total,M,330.46,0.5,0.8,355,50
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,326.26,0.5,1.0,444,51
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,Total,M,283.39,0.4,0.1,40,52
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,Total,M,278.45,0.4,11.8,"5,102",53
2,Newfoundland and Labrador,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,277.06,0.4,4.1,"1,778",54
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,Total,M,269.88,0.4,4.9,"2,132",55
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,Total,M,264.01,0.4,7.3,"3,131",56
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",Total,M,258.82,0.4,9.2,"3,964",57
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,Total,M,256.98,0.4,1.7,730,58
2,Newfoundland and Labrador,H03AA,Thyroid hormones,Total,M,249.69,0.3,6.3,"2,733",59
2,Newfoundland and Labrador,C01DA,Organic nitrates,Total,M,240.43,0.3,4.9,"2,097",60
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,Total,M,226.51,0.3,0.0,21,61
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,221.39,0.3,1.0,423,62
2,Newfoundland and Labrador,H02AB,Glucocorticoids,Total,M,220.38,0.3,12.3,"5,316",63
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,Total,M,220.19,0.3,2.2,946,64
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,**,**,**,**,65
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,Total,M,213.06,0.3,6.2,"2,689",66
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,Total,M,201.82,0.3,1.8,792,67
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,Total,M,197.12,0.3,2.6,"1,114",68
2,Newfoundland and Labrador,L03AB,Interferons,Total,M,187.17,0.3,0.0,9,69
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,Total,M,184.79,0.3,1.3,539,70
2,Newfoundland and Labrador,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,M,**,**,**,*,71
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,Total,M,179.11,0.3,1.0,420,72
2,Newfoundland and Labrador,A09AA,Enzyme preparations,Total,M,177.14,0.2,0.2,88,73
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",Total,M,174.02,0.2,8.5,"3,663",74
2,Newfoundland and Labrador,L01XX,Other antineoplastic agents,Total,M,165.29,0.2,0.1,47,75
2,Newfoundland and Labrador,M05BX,Other drugs affecting bone structure and mineralization,Total,M,161.58,0.2,0.1,28,76
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,**,**,**,**,77
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,Total,M,157.88,0.2,0.0,10,78
2,Newfoundland and Labrador,R01AD,Corticosteroids,Total,M,144.21,0.2,6.3,"2,712",79
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,Total,M,143.64,0.2,1.9,803,80
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",Total,M,135.59,0.2,5.8,"2,518",81
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,Total,M,132.24,0.2,5.3,"2,293",82
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,Total,M,131.05,0.2,3.3,"1,435",83
2,Newfoundland and Labrador,C10AB,Fibrates,Total,M,128.91,0.2,2.0,876,84
2,Newfoundland and Labrador,R05CB,Mucolytics,Total,M,123.58,0.2,0.1,23,85
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,Total,M,122.10,0.2,1.5,640,86
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,Total,M,120.80,0.2,3.0,"1,304",87
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,120.78,0.2,0.6,242,88
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,Total,M,117.72,0.2,0.5,235,89
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,M,112.28,0.2,6.8,"2,949",90
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,106.22,0.1,2.3,993,91
2,Newfoundland and Labrador,N05AF,Thioxanthene derivatives,Total,M,104.82,0.1,0.3,149,92
2,Newfoundland and Labrador,J01FA,Macrolides,Total,M,103.95,0.1,5.9,"2,523",93
2,Newfoundland and Labrador,J05AJ,Integrase inhibitors,Total,M,103.61,0.1,0.0,10,94
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",Total,M,102.10,0.1,1.2,523,95
2,Newfoundland and Labrador,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,100.82,0.1,0.1,44,96
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,Total,M,99.22,0.1,11.8,"5,090",97
2,Newfoundland and Labrador,A12BA,Potassium,Total,M,98.95,0.1,2.6,"1,111",98
2,Newfoundland and Labrador,A04AD,Other antiemetics,Total,M,97.00,0.1,0.4,154,99
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,Total,M,93.76,0.1,6.5,"2,801",100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,"6,389.50",7.5,0.7,390,1
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,Total,F,"3,897.36",4.6,0.5,283,2
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,Total,F,"2,796.89",3.3,1.7,983,3
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"2,268.09",2.7,5.3,"3,035",4
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,Total,F,"2,242.00",2.6,40.5,"23,201",5
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,Total,F,"2,206.42",2.6,36.8,"21,094",6
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,153.99",2.5,21.7,"12,434",7
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,994.02",2.3,5.2,"2,955",8
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,Total,F,"1,947.30",2.3,0.3,163,9
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,Total,F,"1,765.28",2.1,0.4,210,10
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,Total,F,"1,755.95",2.1,0.3,194,11
2,Newfoundland and Labrador,R03BA,Glucocorticoids,Total,F,"1,720.80",2.0,9.4,"5,354",12
2,Newfoundland and Labrador,N06AX,Other antidepressants,Total,F,"1,676.48",2.0,15.9,"9,079",13
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,Total,F,"1,650.52",1.9,14.8,"8,480",14
2,Newfoundland and Labrador,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,F,"1,628.77",1.9,0.1,30,15
2,Newfoundland and Labrador,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,F,"1,559.72",1.8,0.0,16,16
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",Total,F,"1,400.85",1.6,20.6,"11,817",17
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"1,303.53",1.5,2.4,"1,398",18
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",Total,F,"1,208.63",1.4,21.7,"12,410",19
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,Total,F,"1,022.10",1.2,0.0,23,20
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,Total,F,982.79,1.2,18.6,"10,625",21
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,Total,F,878.04,1.0,5.1,"2,938",22
2,Newfoundland and Labrador,H03AA,Thyroid hormones,Total,F,860.46,1.0,16.7,"9,572",23
2,Newfoundland and Labrador,R03BB,Anticholinergics,Total,F,807.96,0.9,6.1,"3,492",24
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,Total,F,772.04,0.9,11.0,"6,283",25
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,771.03,0.9,11.4,"6,513",26
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,738.86,0.9,4.9,"2,815",27
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,736.74,0.9,19.9,"11,420",28
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,717.66,0.8,9.0,"5,166",29
2,Newfoundland and Labrador,N05AX,Other antipsychotics,Total,F,704.09,0.8,2.1,"1,191",30
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,Total,F,671.54,0.8,2.3,"1,290",31
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,Total,F,644.93,0.8,1.4,801,32
2,Newfoundland and Labrador,N03AX,Other antiepileptics,Total,F,601.89,0.7,3.2,"1,826",33
2,Newfoundland and Labrador,A10BA,Biguanides,Total,F,583.46,0.7,14.3,"8,169",34
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,Total,F,573.58,0.7,0.4,229,35
2,Newfoundland and Labrador,L03AB,Interferons,Total,F,556.10,0.7,0.0,28,36
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,552.82,0.6,7.9,"4,504",37
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,Total,F,543.84,0.6,0.0,27,38
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,533.89,0.6,1.2,710,39
2,Newfoundland and Labrador,A10BB,Sulfonylureas,Total,F,503.67,0.6,8.0,"4,592",40
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,Total,F,502.82,0.6,6.2,"3,573",41
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,500.74,0.6,2.0,"1,170",42
2,Newfoundland and Labrador,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,F,**,**,**,**,43
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,Total,F,492.28,0.6,5.2,"2,954",44
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,Total,F,486.03,0.6,4.4,"2,500",45
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,464.96,0.5,5.6,"3,181",46
2,Newfoundland and Labrador,L01EX,Other protein kinase inhibitors,Total,F,445.58,0.5,0.0,23,47
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",Total,F,419.43,0.5,9.9,"5,679",48
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,Total,F,406.35,0.5,13.3,"7,597",49
2,Newfoundland and Labrador,A16AB,Enzymes,Total,F,**,**,**,*,50
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,383.49,0.5,4.0,"2,287",51
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,Total,F,375.15,0.4,1.9,"1,105",52
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,**,**,**,**,53
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,Total,F,365.54,0.4,0.8,440,54
2,Newfoundland and Labrador,M05BA,Bisphosphonates,Total,F,352.59,0.4,5.2,"2,961",55
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,Total,F,349.68,0.4,0.2,87,56
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",Total,F,348.82,0.4,12.3,"7,033",57
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,Total,F,328.99,0.4,2.2,"1,241",58
2,Newfoundland and Labrador,L03AX,Other immunostimulants,Total,F,316.76,0.4,0.0,26,59
2,Newfoundland and Labrador,H02AB,Glucocorticoids,Total,F,308.00,0.4,13.2,"7,574",60
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,Total,F,307.90,0.4,2.3,"1,343",61
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,Total,F,295.24,0.3,3.1,"1,769",62
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,Total,F,281.54,0.3,1.3,743,63
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,Total,F,**,**,**,**,64
2,Newfoundland and Labrador,A05AA,Bile acids and derivatives,Total,F,275.29,0.3,0.3,148,65
2,Newfoundland and Labrador,B02AB,Proteinase inhibitors,Total,F,**,**,**,*,66
2,Newfoundland and Labrador,C01DA,Organic nitrates,Total,F,268.20,0.3,3.3,"1,863",67
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,Total,F,257.56,0.3,0.6,340,68
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,Total,F,245.25,0.3,7.6,"4,337",69
2,Newfoundland and Labrador,A12BA,Potassium,Total,F,241.62,0.3,4.3,"2,473",70
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,Total,F,240.62,0.3,7.1,"4,080",71
2,Newfoundland and Labrador,R01AD,Corticosteroids,Total,F,234.76,0.3,8.8,"5,036",72
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,Total,F,231.06,0.3,3.1,"1,768",73
2,Newfoundland and Labrador,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,**,**,**,**,74
2,Newfoundland and Labrador,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,F,222.92,0.3,0.0,5,75
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,221.40,0.3,0.0,22,76
2,Newfoundland and Labrador,G03AB,"Progestogens and estrogens, sequential preparations",Total,F,**,**,**,**,77
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,Total,F,204.59,0.2,0.0,12,78
2,Newfoundland and Labrador,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,F,**,**,**,*,79
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,196.31,0.2,3.2,"1,806",80
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,**,**,**,**,81
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,Total,F,185.75,0.2,1.1,644,82
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,184.41,0.2,0.7,395,83
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",Total,F,183.87,0.2,6.6,"3,803",84
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,Total,F,183.50,0.2,5.0,"2,836",85
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",Total,F,179.27,0.2,1.8,"1,002",86
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,Total,F,174.12,0.2,1.3,772,87
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,Total,F,173.72,0.2,9.8,"5,609",88
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,Total,F,172.50,0.2,3.6,"2,035",89
2,Newfoundland and Labrador,A03FA,Propulsives,Total,F,167.42,0.2,4.3,"2,486",90
2,Newfoundland and Labrador,A07AA,Antibiotics,Total,F,159.98,0.2,1.7,994,91
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,F,158.16,0.2,7.6,"4,350",92
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,Total,F,157.77,0.2,2.8,"1,610",93
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,Total,F,155.46,0.2,0.9,496,94
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,Total,F,155.20,0.2,14.6,"8,362",95
2,Newfoundland and Labrador,C10AB,Fibrates,Total,F,152.38,0.2,1.8,"1,027",96
2,Newfoundland and Labrador,L01BA,Folic acid analogues,Total,F,149.28,0.2,1.3,731,97
2,Newfoundland and Labrador,J01FA,Macrolides,Total,F,147.23,0.2,7.7,"4,388",98
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,Total,F,144.74,0.2,4.1,"2,359",99
2,Newfoundland and Labrador,A04AD,Other antiemetics,Total,F,144.28,0.2,0.4,227,100
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,65+,Total,"6,038.28",7.2,0.4,229,1
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,"3,900.47",4.7,0.4,229,2
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,65+,Total,"3,074.73",3.7,54.9,"31,052",3
2,Newfoundland and Labrador,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,Total,"2,856.41",3.4,0.1,39,4
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,65+,Total,"2,485.99",3.0,0.5,275,5
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,65+,Total,"2,467.10",3.0,22.5,"12,751",6
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"2,421.54",2.9,6.3,"3,568",7
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,65+,Total,"2,334.31",2.8,45.8,"25,949",8
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"2,125.94",2.5,5.8,"3,304",9
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",65+,Total,"1,986.94",2.4,31.7,"17,935",10
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",65+,Total,"1,766.34",2.1,34.4,"19,496",11
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"1,683.74",2.0,3.2,"1,806",12
2,Newfoundland and Labrador,R03BA,Glucocorticoids,65+,Total,"1,587.09",1.9,7.9,"4,470",13
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,367.62",1.6,15.6,"8,806",14
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,65+,Total,"1,214.28",1.5,0.2,94,15
2,Newfoundland and Labrador,R03BB,Anticholinergics,65+,Total,"1,171.74",1.4,8.8,"4,968",16
2,Newfoundland and Labrador,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,Total,**,**,**,**,17
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,65+,Total,"1,051.54",1.3,2.2,"1,271",18
2,Newfoundland and Labrador,N06AX,Other antidepressants,65+,Total,"1,047.58",1.3,12.0,"6,781",19
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,959.99,1.2,14.9,"8,441",20
2,Newfoundland and Labrador,L02BB,Antiandrogens,65+,Total,914.98,1.1,0.4,219,21
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,849.49,1.0,0.5,297,22
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,65+,Total,836.96,1.0,0.6,315,23
2,Newfoundland and Labrador,L01EX,Other protein kinase inhibitors,65+,Total,814.45,1.0,0.1,40,24
2,Newfoundland and Labrador,H03AA,Thyroid hormones,65+,Total,774.30,0.9,16.5,"9,332",25
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,744.68,0.9,1.8,"1,012",26
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,65+,Total,726.50,0.9,16.1,"9,095",27
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,721.80,0.9,10.6,"6,013",28
2,Newfoundland and Labrador,A10BA,Biguanides,65+,Total,706.17,0.8,19.6,"11,106",29
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,65+,Total,682.66,0.8,7.4,"4,192",30
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,668.64,0.8,19.4,"10,971",31
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,65+,Total,653.87,0.8,0.2,110,32
2,Newfoundland and Labrador,A10BB,Sulfonylureas,65+,Total,644.99,0.8,11.3,"6,379",33
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,65+,Total,599.34,0.7,5.7,"3,224",34
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,592.23,0.7,2.5,"1,405",35
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,564.38,0.7,7.4,"4,206",36
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",65+,Total,551.09,0.7,14.2,"8,043",37
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,547.06,0.7,8.2,"4,635",38
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,65+,Total,544.97,0.7,2.8,"1,596",39
2,Newfoundland and Labrador,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,Total,**,**,**,**,40
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,65+,Total,494.66,0.6,10.2,"5,766",41
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,65+,Total,470.11,0.6,3.2,"1,820",42
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,65+,Total,469.50,0.6,3.6,"2,057",43
2,Newfoundland and Labrador,C01DA,Organic nitrates,65+,Total,466.26,0.6,6.2,"3,512",44
2,Newfoundland and Labrador,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,Total,**,**,**,**,45
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,65+,Total,438.56,0.5,0.9,510,46
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,433.32,0.5,4.0,"2,269",47
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,65+,Total,419.96,0.5,0.1,79,48
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,65+,Total,415.38,0.5,6.0,"3,399",49
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,65+,Total,410.04,0.5,3.9,"2,185",50
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",65+,Total,389.20,0.5,15.3,"8,651",51
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,65+,Total,380.90,0.5,0.0,21,52
2,Newfoundland and Labrador,M05BA,Bisphosphonates,65+,Total,372.91,0.4,5.6,"3,148",53
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,365.02,0.4,7.8,"4,420",54
2,Newfoundland and Labrador,H02AB,Glucocorticoids,65+,Total,361.88,0.4,15.9,"9,023",55
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,65+,Total,346.89,0.4,7.6,"4,275",56
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,342.25,0.4,4.3,"2,461",57
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,65+,Total,**,**,**,**,58
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,303.27,0.4,1.0,592,59
2,Newfoundland and Labrador,N03AX,Other antiepileptics,65+,Total,302.56,0.4,2.3,"1,306",60
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,289.02,0.3,0.0,9,61
2,Newfoundland and Labrador,A12BA,Potassium,65+,Total,284.62,0.3,5.4,"3,045",62
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,65+,Total,281.68,0.3,1.3,721,63
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,65+,Total,268.00,0.3,9.6,"5,410",64
2,Newfoundland and Labrador,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,259.46,0.3,3.0,"1,686",65
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,253.82,0.3,4.2,"2,357",66
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,65+,Total,252.81,0.3,0.1,29,67
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,65+,Total,241.46,0.3,0.8,478,68
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,65+,Total,240.16,0.3,3.2,"1,784",69
2,Newfoundland and Labrador,N05AX,Other antipsychotics,65+,Total,226.09,0.3,1.5,844,70
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,65+,Total,225.06,0.3,0.9,533,71
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,65+,Total,218.29,0.3,4.0,"2,271",72
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,65+,Total,212.23,0.3,5.8,"3,280",73
2,Newfoundland and Labrador,R01AD,Corticosteroids,65+,Total,207.33,0.2,7.9,"4,456",74
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,65+,Total,201.93,0.2,4.0,"2,271",75
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,65+,Total,198.94,0.2,4.1,"2,326",76
2,Newfoundland and Labrador,L01XX,Other antineoplastic agents,65+,Total,195.82,0.2,0.2,97,77
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",65+,Total,192.09,0.2,6.9,"3,923",78
2,Newfoundland and Labrador,C10AB,Fibrates,65+,Total,183.10,0.2,2.4,"1,330",79
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,65+,Total,175.61,0.2,0.9,482,80
2,Newfoundland and Labrador,N06DA,Anticholinesterases,65+,Total,172.92,0.2,1.4,777,81
2,Newfoundland and Labrador,C03BA,"Sulfonamides, plain",65+,Total,167.73,0.2,4.6,"2,617",82
2,Newfoundland and Labrador,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,**,**,**,**,83
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",65+,Total,153.95,0.2,1.6,888,84
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,65+,Total,153.85,0.2,9.9,"5,602",85
2,Newfoundland and Labrador,A07AA,Antibiotics,65+,Total,153.46,0.2,1.7,935,86
2,Newfoundland and Labrador,A03FA,Propulsives,65+,Total,152.68,0.2,4.4,"2,479",87
2,Newfoundland and Labrador,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,Total,**,**,**,**,88
2,Newfoundland and Labrador,J01FA,Macrolides,65+,Total,148.30,0.2,6.6,"3,738",89
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,143.90,0.2,0.0,10,90
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,Total,141.24,0.2,7.2,"4,095",91
2,Newfoundland and Labrador,C01AA,Digitalis glycosides,65+,Total,140.28,0.2,1.5,867,92
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,65+,Total,**,**,**,*,93
2,Newfoundland and Labrador,L01BA,Folic acid analogues,65+,Total,135.78,0.2,1.2,666,94
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,65+,Total,134.60,0.2,7.6,"4,284",95
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,134.24,0.2,0.6,320,96
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,**,**,**,**,97
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,65+,Total,123.66,0.1,3.7,"2,087",98
2,Newfoundland and Labrador,A05AA,Bile acids and derivatives,65+,Total,123.01,0.1,0.2,123,99
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,65+,Total,122.98,0.1,5.4,"3,032",100
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,65+,M,"3,361.73",9.1,0.4,102,1
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,"1,657.84",4.5,0.4,94,2
2,Newfoundland and Labrador,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,M,**,**,**,**,3
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,65+,M,"1,392.47",3.8,59.4,"14,268",4
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"1,109.65",3.0,6.6,"1,594",5
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,65+,M,"1,058.58",2.9,22.6,"5,439",6
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,982.62,2.7,6.1,"1,464",7
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,65+,M,**,**,**,**,8
2,Newfoundland and Labrador,L02BB,Antiandrogens,65+,M,914.98,2.5,0.9,219,9
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",65+,M,901.36,2.5,35.8,"8,597",10
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,65+,M,891.40,2.4,43.0,"10,318",11
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,65+,M,849.49,2.3,1.2,297,12
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,770.13,2.1,3.5,836,13
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",65+,M,754.62,2.1,37.3,"8,948",14
2,Newfoundland and Labrador,R03BA,Glucocorticoids,65+,M,682.88,1.9,7.5,"1,804",15
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,65+,M,649.92,1.8,22.9,"5,509",16
2,Newfoundland and Labrador,R03BB,Anticholinergics,65+,M,574.94,1.6,10.0,"2,402",17
2,Newfoundland and Labrador,L01EX,Other protein kinase inhibitors,65+,M,537.72,1.5,0.1,25,18
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,65+,M,467.77,1.3,2.4,570,19
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,65+,M,447.52,1.2,0.6,144,20
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,65+,M,421.15,1.1,0.1,35,21
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,65+,M,387.29,1.1,10.6,"2,557",22
2,Newfoundland and Labrador,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,M,**,**,**,**,23
2,Newfoundland and Labrador,N06AX,Other antidepressants,65+,M,326.36,0.9,9.3,"2,240",24
2,Newfoundland and Labrador,A10BA,Biguanides,65+,M,322.63,0.9,21.8,"5,233",25
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,317.69,0.9,12.4,"2,979",26
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,65+,M,309.85,0.8,8.0,"1,917",27
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,65+,M,**,**,**,**,28
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,298.39,0.8,9.3,"2,223",29
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,296.74,0.8,19.7,"4,726",30
2,Newfoundland and Labrador,A10BB,Sulfonylureas,65+,M,276.51,0.8,12.0,"2,891",31
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,273.77,0.7,1.6,377,32
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,65+,M,262.43,0.7,5.7,"1,375",33
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,260.39,0.7,2.5,602,34
2,Newfoundland and Labrador,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,258.52,0.7,7.0,"1,676",35
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,65+,M,219.76,0.6,11.5,"2,759",36
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,65+,M,217.99,0.6,7.7,"1,845",37
2,Newfoundland and Labrador,C01DA,Organic nitrates,65+,M,215.48,0.6,7.6,"1,835",38
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,65+,M,214.62,0.6,2.6,621,39
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",65+,M,204.95,0.6,13.8,"3,308",40
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,203.43,0.6,3.9,938,41
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,65+,M,203.00,0.6,0.9,219,42
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,65+,M,200.75,0.5,10.6,"2,535",43
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,65+,M,190.79,0.5,3.5,835,44
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,65+,M,181.35,0.5,0.1,14,45
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,65+,M,177.11,0.5,0.1,27,46
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,65+,M,176.54,0.5,8.8,"2,117",47
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,175.12,0.5,8.4,"2,007",48
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,65+,M,170.06,0.5,2.9,694,49
2,Newfoundland and Labrador,H03AA,Thyroid hormones,65+,M,168.89,0.5,8.6,"2,059",50
2,Newfoundland and Labrador,L01XX,Other antineoplastic agents,65+,M,163.13,0.4,0.2,42,51
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,159.53,0.4,6.4,"1,530",52
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,156.80,0.4,1.2,300,53
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,65+,M,153.74,0.4,1.5,367,54
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,**,**,**,*,55
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,65+,M,150.72,0.4,0.1,27,56
2,Newfoundland and Labrador,H02AB,Glucocorticoids,65+,M,148.53,0.4,16.0,"3,842",57
2,Newfoundland and Labrador,M05BX,Other drugs affecting bone structure and mineralization,65+,M,**,**,**,**,58
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",65+,M,125.33,0.3,12.4,"2,981",59
2,Newfoundland and Labrador,N05AX,Other antipsychotics,65+,M,124.71,0.3,1.4,348,60
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,65+,M,120.62,0.3,10.2,"2,456",61
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,65+,M,115.88,0.3,0.0,9,62
2,Newfoundland and Labrador,N03AX,Other antiepileptics,65+,M,115.28,0.3,2.1,500,63
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,**,**,**,**,64
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,65+,M,93.64,0.3,4.5,"1,091",65
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,65+,M,92.83,0.3,4.7,"1,124",66
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,65+,M,87.52,0.2,2.7,651,67
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,65+,M,86.92,0.2,2.1,500,68
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,86.07,0.2,3.5,833,69
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",65+,M,83.47,0.2,6.9,"1,654",70
2,Newfoundland and Labrador,A12BA,Potassium,65+,M,**,**,**,**,71
2,Newfoundland and Labrador,C10AB,Fibrates,65+,M,79.81,0.2,2.5,598,72
2,Newfoundland and Labrador,R01AD,Corticosteroids,65+,M,79.61,0.2,6.7,"1,605",73
2,Newfoundland and Labrador,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,**,**,**,**,74
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,65+,M,79.21,0.2,0.8,194,75
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,65+,M,75.89,0.2,3.2,775,76
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,75.38,0.2,0.7,175,77
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,65+,M,**,**,**,*,78
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,65+,M,65.36,0.2,4.4,"1,059",79
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,65+,M,64.85,0.2,8.5,"2,049",80
2,Newfoundland and Labrador,J01FA,Macrolides,65+,M,62.42,0.2,6.1,"1,455",81
2,Newfoundland and Labrador,C01AA,Digitalis glycosides,65+,M,61.13,0.2,1.6,386,82
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,M,60.48,0.2,7.2,"1,720",83
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,65+,M,58.26,0.2,5.4,"1,291",84
2,Newfoundland and Labrador,C03BA,"Sulfonamides, plain",65+,M,57.54,0.2,3.9,948,85
2,Newfoundland and Labrador,N06DA,Anticholinesterases,65+,M,57.33,0.2,1.1,255,86
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,65+,M,56.34,0.2,0.6,150,87
2,Newfoundland and Labrador,S01EC,Carbonic anhydrase inhibitors,65+,M,55.15,0.2,1.2,291,88
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,**,**,**,*,89
2,Newfoundland and Labrador,C04AD,Purine derivatives,65+,M,50.50,0.1,0.4,94,90
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,65+,M,50.31,0.1,0.1,28,91
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,65+,M,49.78,0.1,4.3,"1,034",92
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,65+,M,49.27,0.1,0.5,124,93
2,Newfoundland and Labrador,D07CA,"Corticosteroids, weak, combinations with antibiotics",65+,M,48.79,0.1,2.1,514,94
2,Newfoundland and Labrador,A03FA,Propulsives,65+,M,48.62,0.1,3.7,883,95
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,65+,M,48.60,0.1,1.3,323,96
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,48.46,0.1,1.9,448,97
2,Newfoundland and Labrador,C01BD,"Antiarrhythmics, class III",65+,M,47.23,0.1,1.3,310,98
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",65+,M,46.76,0.1,1.2,284,99
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,65+,M,46.11,0.1,0.8,201,100
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,65+,F,"2,676.55",5.7,0.4,127,1
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,"2,242.63",4.8,0.4,135,2
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,65+,F,"1,681.35",3.6,51.5,"16,775",3
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,65+,F,**,**,**,**,4
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,65+,F,"1,442.09",3.1,48.0,"15,624",5
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,65+,F,"1,408.37",3.0,22.5,"7,310",6
2,Newfoundland and Labrador,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,F,**,**,**,**,7
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"1,311.89",2.8,6.1,"1,974",8
2,Newfoundland and Labrador,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,F,"1,164.86",2.5,0.1,20,9
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"1,143.32",2.4,5.7,"1,840",10
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",65+,F,"1,084.67",2.3,28.7,"9,331",11
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",65+,F,"1,011.01",2.2,32.4,"10,541",12
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,65+,F,980.33,2.1,19.2,"6,249",13
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,913.61,2.0,3.0,970,14
2,Newfoundland and Labrador,R03BA,Glucocorticoids,65+,F,903.06,1.9,8.2,"2,663",15
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,65+,F,793.12,1.7,0.2,59,16
2,Newfoundland and Labrador,N06AX,Other antidepressants,65+,F,720.97,1.5,13.9,"4,538",17
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,641.98,1.4,16.8,"5,459",18
2,Newfoundland and Labrador,H03AA,Thyroid hormones,65+,F,605.13,1.3,22.3,"7,271",19
2,Newfoundland and Labrador,R03BB,Anticholinergics,65+,F,596.27,1.3,7.9,"2,563",20
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,65+,F,581.18,1.2,2.1,699,21
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,65+,F,506.36,1.1,19.4,"6,331",22
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,65+,F,503.16,1.1,0.3,83,23
2,Newfoundland and Labrador,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,F,**,**,**,**,24
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,470.90,1.0,2.0,635,25
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,65+,F,389.44,0.8,0.5,171,26
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,387.35,0.8,9.5,"3,103",27
2,Newfoundland and Labrador,A10BA,Biguanides,65+,F,383.16,0.8,18.0,"5,867",28
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,65+,F,372.58,0.8,7.0,"2,273",29
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,371.79,0.8,19.2,"6,243",30
2,Newfoundland and Labrador,A10BB,Sulfonylureas,65+,F,368.22,0.8,10.7,"3,486",31
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",65+,F,345.89,0.7,14.5,"4,733",32
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,**,**,**,**,33
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,65+,F,336.91,0.7,5.7,"1,849",34
2,Newfoundland and Labrador,M05BA,Bisphosphonates,65+,F,336.38,0.7,8.7,"2,839",35
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,331.84,0.7,2.5,803,36
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,65+,F,330.35,0.7,3.0,975,37
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,65+,F,323.12,0.7,5.2,"1,684",38
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,65+,F,317.98,0.7,11.2,"3,647",39
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,65+,F,299.92,0.6,3.5,"1,125",40
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,65+,F,278.33,0.6,3.7,"1,221",41
2,Newfoundland and Labrador,L01EX,Other protein kinase inhibitors,65+,F,276.73,0.6,0.0,15,42
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,265.99,0.6,6.1,"1,983",43
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,65+,F,265.02,0.6,0.0,12,44
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",65+,F,263.79,0.6,17.4,"5,668",45
2,Newfoundland and Labrador,C01DA,Organic nitrates,65+,F,250.76,0.5,5.1,"1,676",46
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,65+,F,242.85,0.5,0.2,52,47
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,65+,F,235.56,0.5,0.9,291,48
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,229.82,0.5,4.1,"1,330",49
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,65+,F,**,**,**,**,50
2,Newfoundland and Labrador,H02AB,Glucocorticoids,65+,F,213.28,0.5,15.9,"5,177",51
2,Newfoundland and Labrador,A12BA,Potassium,65+,F,**,**,**,**,52
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,65+,F,197.22,0.4,4.8,"1,551",53
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,189.73,0.4,7.4,"2,412",54
2,Newfoundland and Labrador,N03AX,Other antiepileptics,65+,F,187.29,0.4,2.5,806,55
2,Newfoundland and Labrador,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,167.47,0.4,4.7,"1,522",56
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,65+,F,162.25,0.3,0.9,284,57
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,65+,F,152.43,0.3,3.5,"1,131",58
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,65+,F,147.36,0.3,9.1,"2,953",59
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,65+,F,146.86,0.3,6.8,"2,220",60
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,146.47,0.3,0.9,292,61
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,65+,F,146.14,0.3,5.3,"1,740",62
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,65+,F,142.38,0.3,4.6,"1,495",63
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,**,**,**,**,64
2,Newfoundland and Labrador,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,F,**,**,**,*,65
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,65+,F,127.94,0.3,1.1,354,66
2,Newfoundland and Labrador,R01AD,Corticosteroids,65+,F,127.72,0.3,8.8,"2,851",67
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,65+,F,126.34,0.3,1.1,358,68
2,Newfoundland and Labrador,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,F,**,**,**,*,69
2,Newfoundland and Labrador,N06DA,Anticholinesterases,65+,F,115.59,0.2,1.6,522,70
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,65+,F,114.83,0.2,11.4,"3,700",71
2,Newfoundland and Labrador,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,F,**,**,**,*,72
2,Newfoundland and Labrador,A05AA,Bile acids and derivatives,65+,F,114.11,0.2,0.3,113,73
2,Newfoundland and Labrador,C03BA,"Sulfonamides, plain",65+,F,110.19,0.2,5.1,"1,669",74
2,Newfoundland and Labrador,A07AA,Antibiotics,65+,F,109.14,0.2,2.0,639,75
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",65+,F,108.62,0.2,7.0,"2,269",76
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,65+,F,108.17,0.2,3.6,"1,179",77
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",65+,F,107.11,0.2,1.9,603,78
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,65+,F,106.11,0.2,3.7,"1,202",79
2,Newfoundland and Labrador,A03FA,Propulsives,65+,F,104.06,0.2,4.9,"1,596",80
2,Newfoundland and Labrador,C10AB,Fibrates,65+,F,103.21,0.2,2.2,731,81
2,Newfoundland and Labrador,N05AX,Other antipsychotics,65+,F,101.39,0.2,1.5,496,82
2,Newfoundland and Labrador,L01BA,Folic acid analogues,65+,F,96.43,0.2,1.4,468,83
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,65+,F,89.01,0.2,10.9,"3,553",84
2,Newfoundland and Labrador,J01FA,Macrolides,65+,F,85.88,0.2,7.0,"2,283",85
2,Newfoundland and Labrador,L03AB,Interferons,65+,F,**,**,**,*,86
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,F,80.73,0.2,7.3,"2,374",87
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,65+,F,79.26,0.2,4.2,"1,375",88
2,Newfoundland and Labrador,C01AA,Digitalis glycosides,65+,F,79.15,0.2,1.5,481,89
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,**,**,**,**,90
2,Newfoundland and Labrador,M01AH,Coxibs,65+,F,75.53,0.2,4.3,"1,393",91
2,Newfoundland and Labrador,A03AX,Other drugs for functional gastrointestinal disorders,65+,F,73.14,0.2,1.0,339,92
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,65+,F,71.88,0.2,1.5,504,93
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,65+,F,71.46,0.2,0.0,15,94
2,Newfoundland and Labrador,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,65+,F,**,**,**,*,95
2,Newfoundland and Labrador,C05AA,Corticosteroids,65+,F,69.03,0.1,3.4,"1,094",96
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,65+,F,67.47,0.1,4.8,"1,556",97
2,Newfoundland and Labrador,S01EC,Carbonic anhydrase inhibitors,65+,F,66.06,0.1,1.2,375,98
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,65+,F,**,**,**,*,99
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,65+,F,64.89,0.1,3.9,"1,271",100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,"7,825.90",10.7,1.1,483,1
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,<65,Total,"7,100.50",9.7,5.6,"2,435",2
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,<65,Total,**,**,**,**,3
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,<65,Total,"2,476.68",3.4,0.6,246,4
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,<65,Total,"2,151.99",2.9,0.4,196,5
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"1,936.45",2.6,21.9,"9,596",6
2,Newfoundland and Labrador,N05AX,Other antipsychotics,<65,Total,"1,931.41",2.6,4.2,"1,826",7
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,<65,Total,"1,819.25",2.5,7.9,"3,468",8
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,<65,Total,"1,773.30",2.4,0.4,176,9
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"1,599.43",2.2,6.8,"2,979",10
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"1,595.02",2.2,4.4,"1,910",11
2,Newfoundland and Labrador,N06AX,Other antidepressants,<65,Total,"1,549.48",2.1,16.3,"7,130",12
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,492.98",2.0,4.6,"2,009",13
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,<65,Total,"1,411.19",1.9,29.0,"12,711",14
2,Newfoundland and Labrador,R03BA,Glucocorticoids,<65,Total,"1,369.05",1.9,10.0,"4,389",15
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,<65,Total,"1,076.88",1.5,4.5,"1,980",16
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,045.21",1.4,18.9,"8,262",17
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,<65,Total,977.11,1.3,11.1,"4,841",18
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,<65,Total,824.70,1.1,15.2,"6,674",19
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,785.15,1.1,0.2,86,20
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,692.95,0.9,8.2,"3,610",21
2,Newfoundland and Labrador,N03AX,Other antiepileptics,<65,Total,690.41,0.9,3.9,"1,700",22
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,<65,Total,672.24,0.9,7.9,"3,462",23
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,639.71,0.9,19.8,"8,682",24
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",<65,Total,636.41,0.9,11.4,"4,989",25
2,Newfoundland and Labrador,L03AB,Interferons,<65,Total,636.22,0.9,0.1,31,26
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,635.21,0.9,1.6,688,27
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,527.65,0.7,7.3,"3,186",28
2,Newfoundland and Labrador,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,Total,522.22,0.7,0.0,8,29
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,<65,Total,521.73,0.7,2.7,"1,162",30
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,<65,Total,517.41,0.7,5.5,"2,424",31
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,<65,Total,508.29,0.7,0.1,27,32
2,Newfoundland and Labrador,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,Total,**,**,**,**,33
2,Newfoundland and Labrador,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,Total,**,**,**,**,34
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,**,**,**,**,35
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,<65,Total,448.60,0.6,0.1,48,36
2,Newfoundland and Labrador,R03BB,Anticholinergics,<65,Total,423.25,0.6,3.8,"1,676",37
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",<65,Total,419.57,0.6,8.5,"3,717",38
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,<65,Total,416.83,0.6,16.7,"7,290",39
2,Newfoundland and Labrador,A16AB,Enzymes,<65,Total,**,**,**,*,40
2,Newfoundland and Labrador,L03AX,Other immunostimulants,<65,Total,**,**,**,**,41
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,<65,Total,368.53,0.5,0.3,134,42
2,Newfoundland and Labrador,A10BA,Biguanides,<65,Total,366.97,0.5,9.3,"4,075",43
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,<65,Total,362.47,0.5,0.1,22,44
2,Newfoundland and Labrador,H03AA,Thyroid hormones,<65,Total,336.08,0.5,6.8,"2,974",45
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,<65,Total,330.71,0.5,8.5,"3,739",46
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,299.45,0.4,1.5,637,47
2,Newfoundland and Labrador,B02AB,Proteinase inhibitors,<65,Total,**,**,**,*,48
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,<65,Total,269.93,0.4,1.6,695,49
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,<65,Total,260.24,0.4,9.2,"4,040",50
2,Newfoundland and Labrador,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,Total,**,**,**,*,51
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,<65,Total,257.45,0.4,0.7,285,52
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,<65,Total,252.41,0.3,2.5,"1,101",53
2,Newfoundland and Labrador,R05CB,Mucolytics,<65,Total,**,**,**,**,54
2,Newfoundland and Labrador,A09AA,Enzyme preparations,<65,Total,241.67,0.3,0.2,103,55
2,Newfoundland and Labrador,A10BB,Sulfonylureas,<65,Total,241.64,0.3,4.5,"1,976",56
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,<65,Total,240.07,0.3,2.9,"1,270",57
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,229.82,0.3,4.0,"1,772",58
2,Newfoundland and Labrador,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,227.04,0.3,4.3,"1,894",59
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,<65,Total,219.64,0.3,2.6,"1,119",60
2,Newfoundland and Labrador,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,215.67,0.3,2.7,"1,196",61
2,Newfoundland and Labrador,L01EX,Other protein kinase inhibitors,<65,Total,215.19,0.3,0.0,13,62
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,<65,Total,213.12,0.3,0.1,48,63
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,<65,Total,195.68,0.3,1.9,823,64
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,194.63,0.3,1.7,741,65
2,Newfoundland and Labrador,R01AD,Corticosteroids,<65,Total,171.64,0.2,7.5,"3,292",66
2,Newfoundland and Labrador,H02AB,Glucocorticoids,<65,Total,166.57,0.2,8.8,"3,871",67
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,166.49,0.2,0.1,65,68
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,<65,Total,166.32,0.2,17.6,"7,699",69
2,Newfoundland and Labrador,A04AD,Other antiemetics,<65,Total,164.92,0.2,0.5,232,70
2,Newfoundland and Labrador,A05AA,Bile acids and derivatives,<65,Total,163.82,0.2,0.1,43,71
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,<65,Total,149.74,0.2,0.5,210,72
2,Newfoundland and Labrador,N05BE,Azaspirodecanedione derivatives,<65,Total,139.33,0.2,1.0,448,73
2,Newfoundland and Labrador,G03AC,Progestogens,<65,Total,**,**,**,**,74
2,Newfoundland and Labrador,A16AX,Various alimentary tract and metabolism products,<65,Total,**,**,**,*,75
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,<65,Total,133.82,0.2,0.2,97,76
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",<65,Total,133.72,0.2,4.7,"2,047",77
2,Newfoundland and Labrador,J05AE,Protease inhibitors,<65,Total,**,**,**,**,78
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,132.47,0.2,1.8,766,79
2,Newfoundland and Labrador,J05AJ,Integrase inhibitors,<65,Total,**,**,**,**,80
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,129.23,0.2,7.3,"3,205",81
2,Newfoundland and Labrador,N05AF,Thioxanthene derivatives,<65,Total,**,**,**,**,82
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",<65,Total,127.50,0.2,1.5,638,83
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",<65,Total,127.37,0.2,5.5,"2,398",84
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",<65,Total,127.36,0.2,3.7,"1,601",85
2,Newfoundland and Labrador,G02BA,Intrauterine contraceptives,<65,Total,**,**,**,**,86
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,<65,Total,119.26,0.2,1.2,510,87
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,<65,Total,117.87,0.2,0.0,18,88
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,114.86,0.2,0.3,141,89
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,<65,Total,106.21,0.1,3.4,"1,488",90
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,104.49,0.1,2.6,"1,137",91
2,Newfoundland and Labrador,L02BB,Antiandrogens,<65,Total,103.72,0.1,0.0,9,92
2,Newfoundland and Labrador,J01FA,Macrolides,<65,Total,102.88,0.1,7.2,"3,173",93
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,102.52,0.1,0.5,226,94
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,<65,Total,101.85,0.1,1.9,844,95
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,<65,Total,99.42,0.1,7.5,"3,293",96
2,Newfoundland and Labrador,C10AB,Fibrates,<65,Total,98.27,0.1,1.3,574,97
2,Newfoundland and Labrador,A03FA,Propulsives,<65,Total,95.28,0.1,3.0,"1,300",98
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,<65,Total,**,**,**,*,99
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,<65,Total,90.96,0.1,3.7,"1,621",100
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,<65,M,"4,313.89",12.4,7.7,"1,461",1
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,"3,679.03",10.5,1.2,228,2
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,<65,M,**,**,**,**,3
2,Newfoundland and Labrador,N05AX,Other antipsychotics,<65,M,"1,328.71",3.8,5.9,"1,131",4
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,<65,M,"1,255.87",3.6,0.5,90,5
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,<65,M,"1,154.69",3.3,11.5,"2,199",6
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"1,090.39",3.1,7.8,"1,494",7
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,<65,M,997.81,2.9,0.5,92,8
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,<65,M,761.91,2.2,17.9,"3,409",9
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,642.28,1.8,4.7,894,10
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",<65,M,638.82,1.8,4.4,849,11
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,<65,M,611.28,1.8,26.9,"5,134",12
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,**,**,**,**,13
2,Newfoundland and Labrador,N06AX,Other antidepressants,<65,M,593.82,1.7,13.6,"2,587",14
2,Newfoundland and Labrador,R03BA,Glucocorticoids,<65,M,551.32,1.6,8.9,"1,698",15
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,<65,M,535.75,1.5,4.7,891,16
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,<65,M,522.96,1.5,11.5,"2,204",17
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,<65,M,520.23,1.5,20.7,"3,944",18
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,<65,M,511.18,1.5,0.3,49,19
2,Newfoundland and Labrador,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,M,**,**,**,**,20
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,<65,M,348.27,1.0,12.5,"2,380",21
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,329.86,0.9,8.0,"1,518",22
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",<65,M,320.23,0.9,13.1,"2,503",23
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,<65,M,311.81,0.9,7.3,"1,384",24
2,Newfoundland and Labrador,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,M,**,**,**,**,25
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,<65,M,299.94,0.9,3.2,613,26
2,Newfoundland and Labrador,N03AX,Other antiepileptics,<65,M,275.81,0.8,3.6,680,27
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,<65,M,275.26,0.8,6.6,"1,254",28
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,274.76,0.8,18.4,"3,505",29
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,245.29,0.7,1.4,260,30
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,<65,M,229.47,0.7,0.1,12,31
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",<65,M,221.94,0.6,9.7,"1,848",32
2,Newfoundland and Labrador,R03BB,Anticholinergics,<65,M,211.56,0.6,3.9,747,33
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,<65,M,**,**,**,**,34
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,197.34,0.6,5.9,"1,123",35
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,<65,M,184.39,0.5,0.4,76,36
2,Newfoundland and Labrador,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,M,**,**,**,*,37
2,Newfoundland and Labrador,A10BA,Biguanides,<65,M,166.66,0.5,9.3,"1,773",38
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,**,**,**,**,39
2,Newfoundland and Labrador,L03AB,Interferons,<65,M,**,**,**,**,40
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,<65,M,157.88,0.5,0.1,10,41
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,<65,M,157.84,0.5,13.9,"2,646",42
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,<65,M,154.80,0.4,7.3,"1,398",43
2,Newfoundland and Labrador,A09AA,Enzyme preparations,<65,M,151.67,0.4,0.3,60,44
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,<65,M,138.68,0.4,1.8,338,45
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,130.56,0.4,1.4,270,46
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,<65,M,127.47,0.4,0.7,136,47
2,Newfoundland and Labrador,R05CB,Mucolytics,<65,M,**,**,**,**,48
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,<65,M,120.39,0.3,3.1,590,49
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,<65,M,109.60,0.3,2.4,463,50
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,<65,M,106.28,0.3,0.1,13,51
2,Newfoundland and Labrador,A10BB,Sulfonylureas,<65,M,106.19,0.3,4.6,870,52
2,Newfoundland and Labrador,L02BB,Antiandrogens,<65,M,103.72,0.3,0.0,9,53
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,100.77,0.3,3.8,718,54
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,<65,M,**,**,**,*,55
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,<65,M,90.95,0.3,3.6,688,56
2,Newfoundland and Labrador,N05AF,Thioxanthene derivatives,<65,M,**,**,**,**,57
2,Newfoundland and Labrador,J05AJ,Integrase inhibitors,<65,M,**,**,**,**,58
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,<65,M,85.99,0.2,0.6,108,59
2,Newfoundland and Labrador,J05AE,Protease inhibitors,<65,M,**,**,**,**,60
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,<65,M,82.46,0.2,6.6,"1,259",61
2,Newfoundland and Labrador,H03AA,Thyroid hormones,<65,M,80.80,0.2,3.5,674,62
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,<65,M,79.52,0.2,0.1,28,63
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,77.12,0.2,2.3,437,64
2,Newfoundland and Labrador,L03AX,Other immunostimulants,<65,M,**,**,**,**,65
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,<65,M,73.49,0.2,1.7,317,66
2,Newfoundland and Labrador,H02AB,Glucocorticoids,<65,M,71.85,0.2,7.7,"1,474",67
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,<65,M,68.95,0.2,1.5,286,68
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,<65,M,66.73,0.2,15.5,"2,961",69
2,Newfoundland and Labrador,R01AD,Corticosteroids,<65,M,64.59,0.2,5.8,"1,107",70
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,64.59,0.2,0.6,123,71
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,<65,M,63.26,0.2,3.1,596,72
2,Newfoundland and Labrador,A04AD,Other antiemetics,<65,M,62.34,0.2,0.5,87,73
2,Newfoundland and Labrador,L01EJ,Janus-associated kinase (JAK) inhibitors,<65,M,**,**,**,*,74
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,<65,M,56.73,0.2,1.6,303,75
2,Newfoundland and Labrador,N05BE,Azaspirodecanedione derivatives,<65,M,56.72,0.2,0.9,166,76
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",<65,M,55.34,0.2,1.3,239,77
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",<65,M,53.82,0.2,3.4,655,78
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",<65,M,52.12,0.1,4.5,864,79
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,<65,M,51.89,0.1,1.5,287,80
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,51.88,0.1,0.3,66,81
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,51.80,0.1,6.4,"1,229",82
2,Newfoundland and Labrador,C10AB,Fibrates,<65,M,49.10,0.1,1.5,278,83
2,Newfoundland and Labrador,N05AD,Butyrophenone derivatives,<65,M,49.01,0.1,0.5,102,84
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",<65,M,48.69,0.1,3.6,682,85
2,Newfoundland and Labrador,N05AN,Lithium,<65,M,48.34,0.1,0.9,166,86
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,<65,M,47.13,0.1,7.1,"1,346",87
2,Newfoundland and Labrador,L01EX,Other protein kinase inhibitors,<65,M,46.34,0.1,0.0,5,88
2,Newfoundland and Labrador,N03AA,Barbiturates and derivatives,<65,M,45.60,0.1,0.6,119,89
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,45.40,0.1,0.4,67,90
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,<65,M,45.16,0.1,0.0,7,91
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,<65,M,43.65,0.1,3.5,665,92
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,<65,M,42.35,0.1,0.6,109,93
2,Newfoundland and Labrador,N05AA,Phenothiazines with aliphatic side-chain,<65,M,42.11,0.1,0.7,131,94
2,Newfoundland and Labrador,J01FA,Macrolides,<65,M,41.54,0.1,5.6,"1,068",95
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,<65,M,40.73,0.1,2.6,504,96
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,<65,M,38.51,0.1,0.2,41,97
2,Newfoundland and Labrador,N04AC,Ethers of tropine or tropine derivatives,<65,M,38.27,0.1,1.0,200,98
2,Newfoundland and Labrador,A07AA,Antibiotics,<65,M,38.27,0.1,0.9,167,99
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,<65,M,38.22,0.1,1.6,311,100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,"4,146.87",10.8,1.0,255,1
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,<65,F,"2,785.36",7.2,3.9,973,2
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,<65,F,"1,262.12",3.3,0.5,127,3
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,<65,F,"1,220.81",3.2,0.6,156,4
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,173.66",3.0,25.1,"6,185",5
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,<65,F,"1,154.18",3.0,0.4,104,6
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,<65,F,**,**,**,**,7
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",<65,F,956.20,2.5,4.3,"1,061",8
2,Newfoundland and Labrador,N06AX,Other antidepressants,<65,F,955.51,2.5,18.4,"4,541",9
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,850.70,2.2,4.5,"1,115",10
2,Newfoundland and Labrador,R03BA,Glucocorticoids,<65,F,817.73,2.1,10.9,"2,691",11
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,<65,F,799.91,2.1,30.7,"7,577",12
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,<65,F,664.56,1.7,5.1,"1,269",13
2,Newfoundland and Labrador,N05AX,Other antipsychotics,<65,F,602.70,1.6,2.8,695,14
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,<65,F,541.13,1.4,4.4,"1,089",15
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,<65,F,524.98,1.4,17.5,"4,318",16
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,509.04,1.3,6.0,"1,485",17
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,<65,F,476.43,1.2,17.4,"4,294",18
2,Newfoundland and Labrador,L03AB,Interferons,<65,F,**,**,**,**,19
2,Newfoundland and Labrador,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,F,463.91,1.2,0.0,10,20
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,<65,F,454.06,1.2,10.7,"2,636",21
2,Newfoundland and Labrador,N03AX,Other antiepileptics,<65,F,414.60,1.1,4.1,"1,020",22
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,389.92,1.0,1.7,428,23
2,Newfoundland and Labrador,A16AB,Enzymes,<65,F,**,**,**,*,24
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,364.95,0.9,21.0,"5,177",25
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,363.08,0.9,8.5,"2,092",26
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,<65,F,360.43,0.9,8.4,"2,078",27
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,330.31,0.9,8.4,"2,063",28
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",<65,F,316.18,0.8,10.1,"2,486",29
2,Newfoundland and Labrador,L03AX,Other immunostimulants,<65,F,**,**,**,**,30
2,Newfoundland and Labrador,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,**,**,**,**,31
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,<65,F,278.82,0.7,0.1,15,32
2,Newfoundland and Labrador,B02AB,Proteinase inhibitors,<65,F,**,**,**,*,33
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,<65,F,259.00,0.7,18.8,"4,644",34
2,Newfoundland and Labrador,H03AA,Thyroid hormones,<65,F,255.28,0.7,9.3,"2,300",35
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,<65,F,**,**,**,**,36
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,<65,F,242.15,0.6,4.7,"1,170",37
2,Newfoundland and Labrador,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,**,**,**,**,38
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,<65,F,221.79,0.6,2.2,549,39
2,Newfoundland and Labrador,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,**,**,**,**,40
2,Newfoundland and Labrador,R03BB,Anticholinergics,<65,F,211.69,0.6,3.8,929,41
2,Newfoundland and Labrador,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,F,**,**,**,*,42
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,<65,F,204.59,0.5,0.0,12,43
2,Newfoundland and Labrador,A10BA,Biguanides,<65,F,200.31,0.5,9.3,"2,302",44
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",<65,F,197.62,0.5,7.6,"1,869",45
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,<65,F,184.14,0.5,0.2,58,46
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,**,**,**,**,47
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,<65,F,177.78,0.5,11.3,"2,781",48
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,<65,F,175.91,0.5,9.5,"2,341",49
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,168.89,0.4,1.5,367,50
2,Newfoundland and Labrador,L01EX,Other protein kinase inhibitors,<65,F,168.85,0.4,0.0,8,51
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,<65,F,162.91,0.4,3.3,816,52
2,Newfoundland and Labrador,A05AA,Bile acids and derivatives,<65,F,161.18,0.4,0.1,35,53
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,<65,F,142.81,0.4,2.6,638,54
2,Newfoundland and Labrador,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,*,55
2,Newfoundland and Labrador,A10BB,Sulfonylureas,<65,F,135.45,0.4,4.5,"1,106",56
2,Newfoundland and Labrador,G03AC,Progestogens,<65,F,**,**,**,**,57
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,<65,F,131.25,0.3,1.4,357,58
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,<65,F,129.98,0.3,0.6,149,59
2,Newfoundland and Labrador,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,129.05,0.3,4.3,"1,054",60
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,<65,F,126.73,0.3,2.2,537,61
2,Newfoundland and Labrador,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,62
2,Newfoundland and Labrador,R05CB,Mucolytics,<65,F,**,**,**,**,63
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,**,**,**,**,64
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,<65,F,119.67,0.3,2.8,680,65
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,117.50,0.3,1.2,304,66
2,Newfoundland and Labrador,R01AD,Corticosteroids,<65,F,107.04,0.3,8.9,"2,185",67
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,<65,F,106.83,0.3,0.1,35,68
2,Newfoundland and Labrador,A04AD,Other antiemetics,<65,F,102.57,0.3,0.6,145,69
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,<65,F,99.59,0.3,19.2,"4,738",70
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,<65,F,95.31,0.2,0.2,56,71
2,Newfoundland and Labrador,H02AB,Glucocorticoids,<65,F,94.72,0.2,9.7,"2,397",72
2,Newfoundland and Labrador,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,F,**,**,**,*,73
2,Newfoundland and Labrador,A09AA,Enzyme preparations,<65,F,90.00,0.2,0.2,43,74
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,<65,F,86.98,0.2,0.1,37,75
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",<65,F,85.03,0.2,5.5,"1,365",76
2,Newfoundland and Labrador,N05BE,Azaspirodecanedione derivatives,<65,F,82.29,0.2,1.1,281,77
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,77.43,0.2,8.0,"1,976",78
2,Newfoundland and Labrador,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,F,**,**,**,*,79
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",<65,F,75.25,0.2,6.2,"1,534",80
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",<65,F,73.53,0.2,3.8,946,81
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,<65,F,72.71,0.2,0.0,11,82
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",<65,F,72.16,0.2,1.6,399,83
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,69.82,0.2,3.5,856,84
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,<65,F,65.48,0.2,4.0,984,85
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,<65,F,63.75,0.2,0.4,102,86
2,Newfoundland and Labrador,A03FA,Propulsives,<65,F,63.36,0.2,3.6,890,87
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,62.98,0.2,0.3,75,88
2,Newfoundland and Labrador,J01FA,Macrolides,<65,F,61.34,0.2,8.5,"2,105",89
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,<65,F,58.89,0.2,7.7,"1,909",90
2,Newfoundland and Labrador,J02AC,Triazole derivatives,<65,F,58.77,0.2,7.0,"1,719",91
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,**,**,**,**,92
2,Newfoundland and Labrador,B01AB,Heparin group,<65,F,**,**,**,**,93
2,Newfoundland and Labrador,A03BB,"Belladonna alkaloids, semisynthetic, quaternary ammonium compounds",<65,F,53.74,0.1,3.6,893,94
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,<65,F,**,**,**,**,95
2,Newfoundland and Labrador,L01BA,Folic acid analogues,<65,F,52.84,0.1,1.1,263,96
2,Newfoundland and Labrador,M01AH,Coxibs,<65,F,52.50,0.1,2.9,727,97
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,<65,F,52.29,0.1,7.9,"1,947",98
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,<65,F,51.66,0.1,1.7,408,99
2,Newfoundland and Labrador,A07AA,Antibiotics,<65,F,50.84,0.1,1.4,355,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"4,779.61",12.2,0.7,323,1
3,Prince Edward Island,S01LA,Antineovascularization agents,Total,Total,"1,727.75",4.4,0.3,145,2
3,Prince Edward Island,L04AX,Other immunosuppressants,Total,Total,"1,720.64",4.4,0.4,220,3
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,Total,Total,"1,434.62",3.7,1.7,849,4
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"1,420.43",3.6,5.6,"2,779",5
3,Prince Edward Island,L04AA,Selective immunosuppressants,Total,Total,"1,420.27",3.6,0.2,111,6
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,Total,Total,800.48,2.0,31.8,"15,690",7
3,Prince Edward Island,A02BC,Proton pump inhibitors,Total,Total,747.79,1.9,27.7,"13,641",8
3,Prince Edward Island,A16AB,Enzymes,Total,Total,**,**,**,*,9
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,Total,Total,692.63,1.8,1.9,947,10
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,661.39,1.7,2.6,"1,280",11
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,Total,Total,656.06,1.7,16.0,"7,883",12
3,Prince Edward Island,L01EX,Other protein kinase inhibitors,Total,Total,**,**,**,**,13
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,619.35,1.6,4.6,"2,273",14
3,Prince Edward Island,N05AX,Other antipsychotics,Total,Total,585.96,1.5,1.9,917,15
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,Total,Total,560.61,1.4,1.4,674,16
3,Prince Edward Island,R03BA,Glucocorticoids,Total,Total,530.21,1.4,4.6,"2,276",17
3,Prince Edward Island,R03BB,Anticholinergics,Total,Total,509.71,1.3,5.0,"2,470",18
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,502.35,1.3,1.6,773,19
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,497.65,1.3,0.4,194,20
3,Prince Edward Island,N02AA,Natural opium alkaloids,Total,Total,496.50,1.3,5.5,"2,708",21
3,Prince Edward Island,N03AX,Other antiepileptics,Total,Total,455.75,1.2,5.9,"2,933",22
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,Total,Total,449.44,1.1,14.8,"7,301",23
3,Prince Edward Island,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,434.17,1.1,0.9,432,24
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",Total,Total,428.33,1.1,16.7,"8,255",25
3,Prince Edward Island,N06AX,Other antidepressants,Total,Total,426.66,1.1,10.7,"5,286",26
3,Prince Edward Island,L04AC,Interleukin inhibitors,Total,Total,425.74,1.1,0.1,27,27
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,363.99,0.9,11.8,"5,804",28
3,Prince Edward Island,L02BB,Antiandrogens,Total,Total,356.72,0.9,0.2,112,29
3,Prince Edward Island,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,Total,**,**,**,*,30
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",Total,Total,312.49,0.8,15.9,"7,829",31
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,310.07,0.8,1.0,497,32
3,Prince Edward Island,N07BA,Drugs used in nicotine dependence,Total,Total,297.13,0.8,3.2,"1,583",33
3,Prince Edward Island,H03AA,Thyroid hormones,Total,Total,282.72,0.7,14.4,"7,113",34
3,Prince Edward Island,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,Total,**,**,**,**,35
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,Total,Total,261.93,0.7,6.8,"3,342",36
3,Prince Edward Island,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,Total,**,**,**,**,37
3,Prince Edward Island,S01EE,Prostaglandin analogues,Total,Total,251.28,0.6,3.2,"1,584",38
3,Prince Edward Island,L03AB,Interferons,Total,Total,234.64,0.6,0.0,17,39
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,219.94,0.6,12.7,"6,259",40
3,Prince Edward Island,A10BA,Biguanides,Total,Total,210.17,0.5,14.2,"6,989",41
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,Total,Total,191.31,0.5,0.7,357,42
3,Prince Edward Island,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,Total,**,**,**,**,43
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,182.83,0.5,3.0,"1,485",44
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,180.49,0.5,4.8,"2,374",45
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,Total,Total,178.03,0.5,2.0,975,46
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,Total,Total,175.56,0.4,2.3,"1,149",47
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,174.80,0.4,0.6,294,48
3,Prince Edward Island,A10BB,Sulfonylureas,Total,Total,164.07,0.4,6.3,"3,125",49
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,Total,Total,155.75,0.4,1.9,943,50
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,152.71,0.4,6.2,"3,061",51
3,Prince Edward Island,R01AD,Corticosteroids,Total,Total,152.22,0.4,10.0,"4,932",52
3,Prince Edward Island,N03AG,Fatty acid derivatives,Total,Total,149.20,0.4,1.1,529,53
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,Total,Total,147.17,0.4,2.5,"1,249",54
3,Prince Edward Island,S01ED,Beta-blocking agents,Total,Total,145.66,0.4,2.4,"1,161",55
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,141.09,0.4,4.8,"2,381",56
3,Prince Edward Island,C01DA,Organic nitrates,Total,Total,131.01,0.3,2.5,"1,252",57
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,130.93,0.3,5.5,"2,711",58
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,Total,Total,124.06,0.3,1.1,526,59
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",Total,Total,118.71,0.3,1.8,869,60
3,Prince Edward Island,C03CA,"Sulfonamides, plain",Total,Total,113.84,0.3,6.7,"3,282",61
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,Total,Total,113.84,0.3,2.1,"1,014",62
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,Total,Total,113.24,0.3,0.0,12,63
3,Prince Edward Island,H02AB,Glucocorticoids,Total,Total,112.21,0.3,11.2,"5,532",64
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,108.78,0.3,0.8,397,65
3,Prince Edward Island,R07AX,Other respiratory system products,Total,Total,**,**,**,*,66
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,Total,Total,100.00,0.3,0.8,376,67
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,Total,Total,95.34,0.2,1.2,581,68
3,Prince Edward Island,L03AX,Other immunostimulants,Total,Total,94.12,0.2,0.0,16,69
3,Prince Edward Island,C03AA,"Thiazides, plain",Total,Total,92.56,0.2,8.7,"4,312",70
3,Prince Edward Island,L01XC,Monoclonal antibodies,Total,Total,89.51,0.2,0.0,6,71
3,Prince Edward Island,L01XE,Protein kinase inhibitors,Total,Total,**,**,**,**,72
3,Prince Edward Island,L03AA,Colony-stimulating factors,Total,Total,84.57,0.2,0.1,39,73
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,84.11,0.2,0.3,156,74
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,81.44,0.2,2.7,"1,336",75
3,Prince Edward Island,M05BA,Bisphosphonates,Total,Total,80.72,0.2,3.4,"1,674",76
3,Prince Edward Island,B01AA,Vitamin K antagonists,Total,Total,78.51,0.2,2.8,"1,378",77
3,Prince Edward Island,N06DA,Anticholinesterases,Total,Total,75.77,0.2,1.0,515,78
3,Prince Edward Island,M01AE,Propionic acid derivatives,Total,Total,74.49,0.2,6.1,"2,994",79
3,Prince Edward Island,L02BG,Aromatase inhibitors,Total,Total,73.68,0.2,0.7,336,80
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,Total,Total,73.37,0.2,0.2,106,81
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,70.91,0.2,2.5,"1,251",82
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,**,**,**,**,83
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",Total,Total,69.96,0.2,6.0,"2,957",84
3,Prince Edward Island,N02BE,Anilides,Total,Total,63.20,0.2,1.8,890,85
3,Prince Edward Island,A09AA,Enzyme preparations,Total,Total,63.04,0.2,0.2,77,86
3,Prince Edward Island,A06AB,Contact laxatives,Total,Total,59.95,0.2,1.4,702,87
3,Prince Edward Island,R06AE,Piperazine derivatives,Total,Total,58.63,0.1,0.6,293,88
3,Prince Edward Island,L01BA,Folic acid analogues,Total,Total,56.55,0.1,1.0,511,89
3,Prince Edward Island,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,Total,55.66,0.1,0.2,78,90
3,Prince Edward Island,N04BC,Dopamine agonists,Total,Total,54.56,0.1,0.7,343,91
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,54.24,0.1,2.0,"1,003",92
3,Prince Edward Island,A02BA,H2-receptor antagonists,Total,Total,53.37,0.1,1.9,933,93
3,Prince Edward Island,A07AA,Antibiotics,Total,Total,52.14,0.1,1.1,542,94
3,Prince Edward Island,M03BX,Other centrally acting agents,Total,Total,51.85,0.1,0.8,372,95
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,48.95,0.1,0.2,110,96
3,Prince Edward Island,J02AC,Triazole derivatives,Total,Total,48.02,0.1,0.0,22,97
3,Prince Edward Island,S01BA,"Corticosteroids, plain",Total,Total,45.54,0.1,4.1,"2,031",98
3,Prince Edward Island,J01AA,Tetracyclines,Total,Total,45.38,0.1,5.9,"2,898",99
3,Prince Edward Island,B02BX,Other systemic hemostatics,Total,Total,**,**,**,*,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,"2,128.53",11.3,0.7,150,1
3,Prince Edward Island,L04AX,Other immunosuppressants,Total,M,979.53,5.2,0.4,96,2
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,Total,M,**,**,**,**,3
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",Total,M,755.26,4.0,6.8,"1,553",4
3,Prince Edward Island,S01LA,Antineovascularization agents,Total,M,733.59,3.9,0.3,62,5
3,Prince Edward Island,A16AB,Enzymes,Total,M,**,**,**,*,6
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,Total,M,**,**,**,**,7
3,Prince Edward Island,L01EX,Other protein kinase inhibitors,Total,M,**,**,**,**,8
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,Total,M,427.67,2.3,38.0,"8,630",9
3,Prince Edward Island,N05AX,Other antipsychotics,Total,M,404.58,2.2,2.1,483,10
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,396.08,2.1,2.8,645,11
3,Prince Edward Island,L02BB,Antiandrogens,Total,M,356.72,1.9,0.5,112,12
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,Total,M,356.38,1.9,1.8,404,13
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,Total,M,353.64,1.9,2.1,476,14
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,341.01,1.8,5.6,"1,262",15
3,Prince Edward Island,A02BC,Proton pump inhibitors,Total,M,331.23,1.8,26.2,"5,952",16
3,Prince Edward Island,R03BB,Anticholinergics,Total,M,266.70,1.4,5.6,"1,268",17
3,Prince Edward Island,L04AA,Selective immunosuppressants,Total,M,251.65,1.3,0.1,30,18
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,Total,M,245.47,1.3,12.2,"2,769",19
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,221.15,1.2,1.6,353,20
3,Prince Edward Island,N02AA,Natural opium alkaloids,Total,M,218.65,1.2,5.1,"1,157",21
3,Prince Edward Island,R03BA,Glucocorticoids,Total,M,217.70,1.2,4.1,940,22
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",Total,M,217.54,1.2,19.9,"4,519",23
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,Total,M,215.65,1.1,15.9,"3,615",24
3,Prince Edward Island,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,215.16,1.1,1.0,218,25
3,Prince Edward Island,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,M,**,**,**,*,26
3,Prince Edward Island,N03AX,Other antiepileptics,Total,M,194.65,1.0,5.3,"1,195",27
3,Prince Edward Island,N06AX,Other antidepressants,Total,M,169.28,0.9,8.4,"1,914",28
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,165.12,0.9,1.2,276,29
3,Prince Edward Island,N07BA,Drugs used in nicotine dependence,Total,M,160.28,0.9,3.6,827,30
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",Total,M,157.48,0.8,18.3,"4,143",31
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,150.56,0.8,11.2,"2,533",32
3,Prince Edward Island,L04AC,Interleukin inhibitors,Total,M,147.19,0.8,0.0,10,33
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,Total,M,128.69,0.7,11.7,"2,655",34
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,121.96,0.6,0.9,209,35
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,Total,M,121.33,0.6,5.3,"1,212",36
3,Prince Edward Island,A10BA,Biguanides,Total,M,118.71,0.6,17.6,"3,999",37
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,Total,M,113.24,0.6,0.1,12,38
3,Prince Edward Island,S01EE,Prostaglandin analogues,Total,M,98.67,0.5,3.0,670,39
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,96.19,0.5,11.8,"2,675",40
3,Prince Edward Island,A10BB,Sulfonylureas,Total,M,90.69,0.5,8.0,"1,814",41
3,Prince Edward Island,N03AG,Fatty acid derivatives,Total,M,85.56,0.5,1.3,295,42
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,Total,M,84.83,0.5,1.7,387,43
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,Total,M,80.09,0.4,2.0,452,44
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,Total,M,76.15,0.4,0.6,142,45
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,74.21,0.4,5.6,"1,270",46
3,Prince Edward Island,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,M,**,**,**,*,47
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,71.62,0.4,6.4,"1,462",48
3,Prince Edward Island,H03AA,Thyroid hormones,Total,M,70.36,0.4,8.0,"1,818",49
3,Prince Edward Island,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,M,**,**,**,*,50
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,Total,M,67.47,0.4,1.0,216,51
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,Total,M,67.29,0.4,1.7,385,52
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,65.30,0.3,3.3,754,53
3,Prince Edward Island,C01DA,Organic nitrates,Total,M,64.14,0.3,2.9,660,54
3,Prince Edward Island,R01AD,Corticosteroids,Total,M,63.46,0.3,8.7,"1,976",55
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,Total,M,61.47,0.3,2.4,553,56
3,Prince Edward Island,S01ED,Beta-blocking agents,Total,M,61.25,0.3,2.2,501,57
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,Total,M,59.03,0.3,1.5,348,58
3,Prince Edward Island,L01XE,Protein kinase inhibitors,Total,M,**,**,**,**,59
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,Total,M,55.39,0.3,0.8,182,60
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,54.08,0.3,4.4,997,61
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,51.90,0.3,0.8,190,62
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",Total,M,46.63,0.2,1.6,372,63
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,Total,M,45.68,0.2,0.3,66,64
3,Prince Edward Island,H02AB,Glucocorticoids,Total,M,44.44,0.2,10.6,"2,408",65
3,Prince Edward Island,B01AA,Vitamin K antagonists,Total,M,44.23,0.2,3.4,764,66
3,Prince Edward Island,C03CA,"Sulfonamides, plain",Total,M,43.84,0.2,6.4,"1,452",67
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,41.47,0.2,0.3,71,68
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,Total,M,41.38,0.2,1.7,378,69
3,Prince Edward Island,L03AB,Interferons,Total,M,**,**,**,*,70
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,36.34,0.2,2.7,618,71
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",Total,M,35.04,0.2,5.8,"1,318",72
3,Prince Edward Island,C03AA,"Thiazides, plain",Total,M,34.02,0.2,7.2,"1,628",73
3,Prince Edward Island,M01AE,Propionic acid derivatives,Total,M,32.02,0.2,5.6,"1,273",74
3,Prince Edward Island,A09AA,Enzyme preparations,Total,M,31.41,0.2,0.2,35,75
3,Prince Edward Island,N06DA,Anticholinesterases,Total,M,29.82,0.2,0.9,199,76
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,**,**,**,**,77
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,26.95,0.1,1.8,403,78
3,Prince Edward Island,J01XX,Other antibacterials,Total,M,26.07,0.1,0.0,7,79
3,Prince Edward Island,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,M,**,**,**,**,80
3,Prince Edward Island,M03BX,Other centrally acting agents,Total,M,25.46,0.1,0.7,151,81
3,Prince Edward Island,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,Total,M,**,**,**,*,82
3,Prince Edward Island,N03AF,Carboxamide derivatives,Total,M,25.11,0.1,0.7,155,83
3,Prince Edward Island,N04BC,Dopamine agonists,Total,M,24.64,0.1,0.5,105,84
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,Total,M,24.00,0.1,4.4,994,85
3,Prince Edward Island,L03AA,Colony-stimulating factors,Total,M,22.79,0.1,0.1,13,86
3,Prince Edward Island,N02BE,Anilides,Total,M,22.70,0.1,1.4,329,87
3,Prince Edward Island,A02BA,H2-receptor antagonists,Total,M,22.56,0.1,1.6,364,88
3,Prince Edward Island,A06AB,Contact laxatives,Total,M,22.56,0.1,1.2,268,89
3,Prince Edward Island,C01AA,Digitalis glycosides,Total,M,22.11,0.1,0.9,205,90
3,Prince Edward Island,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,21.43,0.1,0.1,20,91
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,M,20.89,0.1,4.3,986,92
3,Prince Edward Island,C10AC,Bile acid sequestrants,Total,M,**,**,**,**,93
3,Prince Edward Island,L01BA,Folic acid analogues,Total,M,20.42,0.1,0.8,191,94
3,Prince Edward Island,B01AB,Heparin group,Total,M,20.29,0.1,0.2,53,95
3,Prince Edward Island,J01DB,First-generation cephalosporins,Total,M,20.09,0.1,6.2,"1,403",96
3,Prince Edward Island,S01BA,"Corticosteroids, plain",Total,M,19.55,0.1,3.7,850,97
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,Total,M,19.00,0.1,9.8,"2,230",98
3,Prince Edward Island,A07AA,Antibiotics,Total,M,18.03,0.1,0.8,178,99
3,Prince Edward Island,J01AA,Tetracyclines,Total,M,17.71,0.1,5.6,"1,260",100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,"2,651.08",13.0,0.6,173,1
3,Prince Edward Island,L04AA,Selective immunosuppressants,Total,F,"1,168.62",5.7,0.3,81,2
3,Prince Edward Island,S01LA,Antineovascularization agents,Total,F,994.15,4.9,0.3,83,3
3,Prince Edward Island,L04AX,Other immunosuppressants,Total,F,741.11,3.6,0.5,124,4
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",Total,F,665.16,3.3,4.6,"1,226",5
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,Total,F,**,**,**,**,6
3,Prince Edward Island,A02BC,Proton pump inhibitors,Total,F,416.56,2.0,28.9,"7,689",7
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,Total,F,410.59,2.0,19.2,"5,114",8
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,Total,F,372.81,1.8,26.5,"7,060",9
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,Total,F,338.99,1.7,1.8,471,10
3,Prince Edward Island,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,F,**,**,**,*,11
3,Prince Edward Island,R03BA,Glucocorticoids,Total,F,312.51,1.5,5.0,"1,336",12
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,281.20,1.4,1.6,420,13
3,Prince Edward Island,L04AC,Interleukin inhibitors,Total,F,278.54,1.4,0.1,17,14
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,278.35,1.4,3.8,"1,011",15
3,Prince Edward Island,N02AA,Natural opium alkaloids,Total,F,277.85,1.4,5.8,"1,551",16
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,265.31,1.3,2.4,635,17
3,Prince Edward Island,N03AX,Other antiepileptics,Total,F,261.11,1.3,6.5,"1,738",18
3,Prince Edward Island,N06AX,Other antidepressants,Total,F,257.37,1.3,12.7,"3,372",19
3,Prince Edward Island,R03BB,Anticholinergics,Total,F,243.01,1.2,4.5,"1,202",20
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,Total,F,233.80,1.1,13.8,"3,686",21
3,Prince Edward Island,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,219.01,1.1,0.8,214,22
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,213.43,1.0,12.3,"3,271",23
3,Prince Edward Island,H03AA,Thyroid hormones,Total,F,212.36,1.0,19.9,"5,295",24
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",Total,F,210.79,1.0,14.0,"3,736",25
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,Total,F,204.22,1.0,1.0,270,26
3,Prince Edward Island,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,F,**,**,**,**,27
3,Prince Edward Island,L01EX,Other protein kinase inhibitors,Total,F,**,**,**,**,28
3,Prince Edward Island,L03AB,Interferons,Total,F,**,**,**,**,29
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,182.09,0.9,5.6,"1,479",30
3,Prince Edward Island,N05AX,Other antipsychotics,Total,F,181.38,0.9,1.6,434,31
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",Total,F,155.00,0.8,13.8,"3,686",32
3,Prince Edward Island,S01EE,Prostaglandin analogues,Total,F,152.61,0.7,3.4,914,33
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,144.95,0.7,0.8,221,34
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,Total,F,140.59,0.7,8.0,"2,130",35
3,Prince Edward Island,N07BA,Drugs used in nicotine dependence,Total,F,136.84,0.7,2.8,756,36
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,123.75,0.6,13.5,"3,584",37
3,Prince Edward Island,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,F,**,**,**,**,38
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,115.20,0.6,6.1,"1,620",39
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,Total,F,115.16,0.6,0.8,215,40
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,Total,F,110.74,0.5,2.2,590,41
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,Total,F,105.79,0.5,3.3,871,42
3,Prince Edward Island,R07AX,Other respiratory system products,Total,F,**,**,**,*,43
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,Total,F,95.47,0.5,2.6,697,44
3,Prince Edward Island,A10BA,Biguanides,Total,F,91.46,0.4,11.2,"2,990",45
3,Prince Edward Island,L01XC,Monoclonal antibodies,Total,F,89.51,0.4,0.0,6,46
3,Prince Edward Island,R01AD,Corticosteroids,Total,F,88.76,0.4,11.1,"2,956",47
3,Prince Edward Island,S01ED,Beta-blocking agents,Total,F,84.41,0.4,2.5,660,48
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,81.08,0.4,6.0,"1,599",49
3,Prince Edward Island,L03AX,Other immunostimulants,Total,F,**,**,**,**,50
3,Prince Edward Island,A10BB,Sulfonylureas,Total,F,73.38,0.4,4.9,"1,311",51
3,Prince Edward Island,L02BG,Aromatase inhibitors,Total,F,**,**,**,**,52
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",Total,F,72.08,0.4,1.9,497,53
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,Total,F,70.92,0.3,2.1,556,54
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,70.71,0.3,3.2,850,55
3,Prince Edward Island,C03CA,"Sulfonamides, plain",Total,F,70.00,0.3,6.9,"1,830",56
3,Prince Edward Island,H02AB,Glucocorticoids,Total,F,67.77,0.3,11.7,"3,124",57
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,66.88,0.3,4.2,"1,111",58
3,Prince Edward Island,C01DA,Organic nitrates,Total,F,66.86,0.3,2.2,592,59
3,Prince Edward Island,M05BA,Bisphosphonates,Total,F,64.59,0.3,5.3,"1,403",60
3,Prince Edward Island,N03AG,Fatty acid derivatives,Total,F,63.63,0.3,0.9,234,61
3,Prince Edward Island,L03AA,Colony-stimulating factors,Total,F,61.78,0.3,0.1,26,62
3,Prince Edward Island,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,F,**,**,**,*,63
3,Prince Edward Island,C03AA,"Thiazides, plain",Total,F,58.54,0.3,10.1,"2,684",64
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,56.88,0.3,0.8,207,65
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,Total,F,56.58,0.3,1.2,310,66
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,52.84,0.3,0.3,85,67
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,Total,F,52.37,0.3,1.7,461,68
3,Prince Edward Island,N06DA,Anticholinesterases,Total,F,45.96,0.2,1.2,316,69
3,Prince Edward Island,B02BX,Other systemic hemostatics,Total,F,**,**,**,*,70
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,45.10,0.2,2.7,718,71
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,Total,F,44.61,0.2,0.7,194,72
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,**,**,**,**,73
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,43.97,0.2,3.2,848,74
3,Prince Edward Island,R06AE,Piperazine derivatives,Total,F,42.67,0.2,0.8,208,75
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,42.63,0.2,0.3,85,76
3,Prince Edward Island,M01AE,Propionic acid derivatives,Total,F,42.46,0.2,6.5,"1,721",77
3,Prince Edward Island,N02BE,Anilides,Total,F,40.50,0.2,2.1,561,78
3,Prince Edward Island,A06AB,Contact laxatives,Total,F,37.40,0.2,1.6,434,79
3,Prince Edward Island,J02AC,Triazole derivatives,Total,F,36.47,0.2,0.0,13,80
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,Total,F,36.31,0.2,0.9,233,81
3,Prince Edward Island,L01BA,Folic acid analogues,Total,F,36.13,0.2,1.2,320,82
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",Total,F,34.92,0.2,6.2,"1,639",83
3,Prince Edward Island,B01AA,Vitamin K antagonists,Total,F,34.28,0.2,2.3,614,84
3,Prince Edward Island,A07AA,Antibiotics,Total,F,34.11,0.2,1.4,364,85
3,Prince Edward Island,G03AB,"Progestogens and estrogens, sequential preparations",Total,F,32.52,0.2,1.0,272,86
3,Prince Edward Island,A09AA,Enzyme preparations,Total,F,31.63,0.2,0.2,42,87
3,Prince Edward Island,A02BA,H2-receptor antagonists,Total,F,30.81,0.2,2.1,569,88
3,Prince Edward Island,M05BX,Other drugs affecting bone structure and mineralization,Total,F,**,**,**,**,89
3,Prince Edward Island,N04BC,Dopamine agonists,Total,F,29.92,0.1,0.9,238,90
3,Prince Edward Island,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,F,**,**,**,**,91
3,Prince Edward Island,R06AA,Aminoalkyl ethers,Total,F,29.48,0.1,0.9,232,92
3,Prince Edward Island,L01XE,Protein kinase inhibitors,Total,F,**,**,**,**,93
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,Total,F,27.69,0.1,0.2,40,94
3,Prince Edward Island,J01AA,Tetracyclines,Total,F,27.67,0.1,6.2,"1,638",95
3,Prince Edward Island,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",Total,F,27.61,0.1,0.5,126,96
3,Prince Edward Island,A03AX,Other drugs for functional gastrointestinal disorders,Total,F,27.11,0.1,0.6,170,97
3,Prince Edward Island,J01XE,Nitrofuran derivatives,Total,F,26.92,0.1,8.0,"2,125",98
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,Total,F,**,**,**,**,99
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,Total,F,26.47,0.1,1.3,334,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,"1,517.10",7.2,0.4,105,1
3,Prince Edward Island,L04AX,Other immunosuppressants,65+,Total,"1,213.60",5.7,0.5,135,2
3,Prince Edward Island,S01LA,Antineovascularization agents,65+,Total,"1,200.96",5.7,0.4,106,3
3,Prince Edward Island,L04AA,Selective immunosuppressants,65+,Total,919.62,4.3,0.2,56,4
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,781.41,3.7,4.9,"1,455",5
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,65+,Total,647.07,3.1,3.0,887,6
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,65+,Total,645.46,3.0,45.1,"13,331",7
3,Prince Edward Island,L01EX,Other protein kinase inhibitors,65+,Total,**,**,**,**,8
3,Prince Edward Island,A02BC,Proton pump inhibitors,65+,Total,463.80,2.2,33.9,"10,014",9
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,452.27,2.1,0.6,177,10
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,418.91,2.0,2.2,653,11
3,Prince Edward Island,R03BB,Anticholinergics,65+,Total,416.02,2.0,7.1,"2,108",12
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,65+,Total,379.71,1.8,21.3,"6,300",13
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",65+,Total,335.07,1.6,22.9,"6,776",14
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,304.60,1.4,3.4,"1,014",15
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,303.30,1.4,16.7,"4,953",16
3,Prince Edward Island,R03BA,Glucocorticoids,65+,Total,298.79,1.4,4.5,"1,331",17
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,289.11,1.4,1.5,456,18
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",65+,Total,259.38,1.2,23.1,"6,835",19
3,Prince Edward Island,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,Total,**,**,**,**,20
3,Prince Edward Island,L02BB,Antiandrogens,65+,Total,**,**,**,**,21
3,Prince Edward Island,S01EE,Prostaglandin analogues,65+,Total,242.46,1.1,5.2,"1,523",22
3,Prince Edward Island,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,Total,**,**,**,*,23
3,Prince Edward Island,H03AA,Thyroid hormones,65+,Total,219.18,1.0,22.1,"6,535",24
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,65+,Total,215.91,1.0,14.1,"4,168",25
3,Prince Edward Island,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,213.19,1.0,0.7,213,26
3,Prince Edward Island,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,Total,**,**,**,**,27
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,65+,Total,162.20,0.8,3.0,891,28
3,Prince Edward Island,N03AX,Other antiepileptics,65+,Total,161.81,0.8,6.0,"1,760",29
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,158.49,0.7,4.3,"1,284",30
3,Prince Edward Island,N02AA,Natural opium alkaloids,65+,Total,146.68,0.7,7.2,"2,132",31
3,Prince Edward Island,N06AX,Other antidepressants,65+,Total,144.11,0.7,9.9,"2,931",32
3,Prince Edward Island,S01ED,Beta-blocking agents,65+,Total,138.81,0.7,3.8,"1,109",33
3,Prince Edward Island,L04AC,Interleukin inhibitors,65+,Total,133.55,0.6,0.0,7,34
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,65+,Total,124.99,0.6,0.9,264,35
3,Prince Edward Island,A10BA,Biguanides,65+,Total,118.19,0.6,14.1,"4,163",36
3,Prince Edward Island,C01DA,Organic nitrates,65+,Total,117.38,0.6,3.7,"1,107",37
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,116.14,0.5,8.4,"2,491",38
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,113.82,0.5,0.6,186,39
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,112.40,0.5,13.6,"4,023",40
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,65+,Total,109.70,0.5,3.4,"1,020",41
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,105.51,0.5,5.8,"1,703",42
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,65+,Total,**,**,**,**,43
3,Prince Edward Island,A10BB,Sulfonylureas,65+,Total,103.34,0.5,6.5,"1,923",44
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,102.20,0.5,6.8,"2,006",45
3,Prince Edward Island,R01AD,Corticosteroids,65+,Total,100.11,0.5,11.9,"3,526",46
3,Prince Edward Island,C03CA,"Sulfonamides, plain",65+,Total,89.88,0.4,9.7,"2,881",47
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,65+,Total,88.09,0.4,2.7,808,48
3,Prince Edward Island,H02AB,Glucocorticoids,65+,Total,87.91,0.4,15.0,"4,432",49
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",65+,Total,87.22,0.4,2.2,653,50
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,65+,Total,83.85,0.4,1.1,334,51
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,65+,Total,79.69,0.4,8.3,"2,465",52
3,Prince Edward Island,C03AA,"Thiazides, plain",65+,Total,76.72,0.4,12.3,"3,623",53
3,Prince Edward Island,N06DA,Anticholinesterases,65+,Total,**,**,**,**,54
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,74.85,0.4,0.9,268,55
3,Prince Edward Island,N05AX,Other antipsychotics,65+,Total,72.68,0.3,1.4,402,56
3,Prince Edward Island,L03AB,Interferons,65+,Total,**,**,**,**,57
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,69.61,0.3,3.9,"1,140",58
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,69.24,0.3,8.1,"2,409",59
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,67.90,0.3,0.4,129,60
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,65+,Total,66.73,0.3,1.5,458,61
3,Prince Edward Island,M05BA,Bisphosphonates,65+,Total,66.66,0.3,5.2,"1,548",62
3,Prince Edward Island,B01AA,Vitamin K antagonists,65+,Total,64.80,0.3,4.1,"1,221",63
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,63.77,0.3,0.8,223,64
3,Prince Edward Island,L02BG,Aromatase inhibitors,65+,Total,63.06,0.3,0.9,279,65
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,65+,Total,**,**,**,**,66
3,Prince Edward Island,A09AA,Enzyme preparations,65+,Total,58.58,0.3,0.2,68,67
3,Prince Edward Island,N07BA,Drugs used in nicotine dependence,65+,Total,**,**,**,**,68
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",65+,Total,48.62,0.2,7.6,"2,261",69
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,**,**,**,**,70
3,Prince Edward Island,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,Total,**,**,**,**,71
3,Prince Edward Island,L03AA,Colony-stimulating factors,65+,Total,45.76,0.2,0.1,17,72
3,Prince Edward Island,B02BX,Other systemic hemostatics,65+,Total,**,**,**,*,73
3,Prince Edward Island,N04BC,Dopamine agonists,65+,Total,**,**,**,**,74
3,Prince Edward Island,N02BE,Anilides,65+,Total,**,**,**,**,75
3,Prince Edward Island,S01BA,"Corticosteroids, plain",65+,Total,40.35,0.2,6.3,"1,874",76
3,Prince Edward Island,L01BA,Folic acid analogues,65+,Total,37.61,0.2,1.3,385,77
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,36.80,0.2,2.8,827,78
3,Prince Edward Island,L01XC,Monoclonal antibodies,65+,Total,**,**,**,*,79
3,Prince Edward Island,S01EC,Carbonic anhydrase inhibitors,65+,Total,36.32,0.2,1.5,432,80
3,Prince Edward Island,C01AA,Digitalis glycosides,65+,Total,**,**,**,**,81
3,Prince Edward Island,A07AA,Antibiotics,65+,Total,35.04,0.2,1.3,384,82
3,Prince Edward Island,A02BA,H2-receptor antagonists,65+,Total,**,**,**,**,83
3,Prince Edward Island,C10AC,Bile acid sequestrants,65+,Total,**,**,**,**,84
3,Prince Edward Island,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,**,**,**,**,85
3,Prince Edward Island,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,**,**,**,**,86
3,Prince Edward Island,N03AG,Fatty acid derivatives,65+,Total,30.60,0.1,0.6,163,87
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,65+,Total,30.27,0.1,4.3,"1,265",88
3,Prince Edward Island,M01AE,Propionic acid derivatives,65+,Total,30.10,0.1,4.9,"1,447",89
3,Prince Edward Island,M01AH,Coxibs,65+,Total,29.17,0.1,3.0,893,90
3,Prince Edward Island,A06AB,Contact laxatives,65+,Total,29.14,0.1,1.5,444,91
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,**,**,**,**,92
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,65+,Total,28.58,0.1,0.4,119,93
3,Prince Edward Island,L01XX,Other antineoplastic agents,65+,Total,27.72,0.1,0.2,69,94
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,Total,26.16,0.1,4.8,"1,424",95
3,Prince Edward Island,B01AB,Heparin group,65+,Total,26.03,0.1,0.4,120,96
3,Prince Edward Island,J01AA,Tetracyclines,65+,Total,25.15,0.1,6.7,"1,977",97
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,65+,Total,24.19,0.1,1.5,449,98
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,65+,Total,23.90,0.1,1.8,538,99
3,Prince Edward Island,C03DA,Aldosterone antagonists,65+,Total,23.25,0.1,2.3,687,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,756.80,7.6,0.3,46,1
3,Prince Edward Island,L04AX,Other immunosuppressants,65+,M,718.27,7.3,0.4,59,2
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,65+,M,452.27,4.6,1.3,177,3
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",65+,M,426.13,4.3,6.0,814,4
3,Prince Edward Island,L01EX,Other protein kinase inhibitors,65+,M,**,**,**,**,5
3,Prince Edward Island,S01LA,Antineovascularization agents,65+,M,**,**,**,**,6
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,65+,M,339.20,3.4,53.8,"7,296",7
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,65+,M,322.97,3.3,3.3,441,8
3,Prince Edward Island,L02BB,Antiandrogens,65+,M,246.35,2.5,0.8,104,9
3,Prince Edward Island,R03BB,Anticholinergics,65+,M,218.57,2.2,8.1,"1,104",10
3,Prince Edward Island,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,M,**,**,**,*,11
3,Prince Edward Island,A02BC,Proton pump inhibitors,65+,M,195.31,2.0,32.3,"4,379",12
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,185.81,1.9,2.3,306,13
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,65+,M,177.63,1.8,22.4,"3,036",14
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,166.03,1.7,4.2,569,15
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",65+,M,164.10,1.7,26.9,"3,652",16
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,**,**,**,**,17
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",65+,M,126.37,1.3,26.3,"3,563",18
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,123.28,1.2,15.6,"2,112",19
3,Prince Edward Island,R03BA,Glucocorticoids,65+,M,119.27,1.2,3.9,523,20
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,65+,M,114.68,1.2,18.1,"2,452",21
3,Prince Edward Island,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,114.24,1.2,0.8,113,22
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,65+,M,**,**,**,**,23
3,Prince Edward Island,S01EE,Prostaglandin analogues,65+,M,**,**,**,**,24
3,Prince Edward Island,L04AA,Selective immunosuppressants,65+,M,93.10,0.9,0.1,15,25
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,78.18,0.8,1.0,130,26
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,65+,M,73.65,0.7,10.5,"1,417",27
3,Prince Edward Island,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,M,**,**,**,*,28
3,Prince Edward Island,N03AX,Other antiepileptics,65+,M,69.16,0.7,5.4,733,29
3,Prince Edward Island,A10BA,Biguanides,65+,M,67.46,0.7,17.8,"2,408",30
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,65+,M,**,**,**,**,31
3,Prince Edward Island,A10BB,Sulfonylureas,65+,M,58.34,0.6,8.2,"1,116",32
3,Prince Edward Island,S01ED,Beta-blocking agents,65+,M,**,**,**,**,33
3,Prince Edward Island,C01DA,Organic nitrates,65+,M,56.48,0.6,4.2,565,34
3,Prince Edward Island,H03AA,Thyroid hormones,65+,M,54.39,0.5,12.3,"1,664",35
3,Prince Edward Island,N02AA,Natural opium alkaloids,65+,M,53.54,0.5,6.8,919,36
3,Prince Edward Island,N06AX,Other antidepressants,65+,M,52.23,0.5,7.9,"1,074",37
3,Prince Edward Island,L04AC,Interleukin inhibitors,65+,M,**,**,**,*,38
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,48.91,0.5,7.7,"1,037",39
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,48.81,0.5,12.7,"1,723",40
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,65+,M,47.87,0.5,3.3,441,41
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,**,**,**,**,42
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,65+,M,47.63,0.5,0.7,101,43
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,65+,M,43.68,0.4,1.2,162,44
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,41.81,0.4,0.9,122,45
3,Prince Edward Island,R01AD,Corticosteroids,65+,M,**,**,**,**,46
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,65+,M,**,**,**,**,47
3,Prince Edward Island,N05AX,Other antipsychotics,65+,M,38.70,0.4,1.2,163,48
3,Prince Edward Island,N07BA,Drugs used in nicotine dependence,65+,M,**,**,**,**,49
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,37.25,0.4,3.9,523,50
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,36.47,0.4,8.7,"1,182",51
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,65+,M,**,**,**,**,52
3,Prince Edward Island,H02AB,Glucocorticoids,65+,M,35.25,0.4,14.4,"1,952",53
3,Prince Edward Island,B01AA,Vitamin K antagonists,65+,M,34.70,0.4,4.9,662,54
3,Prince Edward Island,C03CA,"Sulfonamides, plain",65+,M,34.55,0.3,9.3,"1,265",55
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,65+,M,**,**,**,**,56
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,33.40,0.3,0.9,125,57
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,**,**,**,**,58
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,65+,M,30.64,0.3,6.3,850,59
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,30.53,0.3,3.8,521,60
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",65+,M,29.55,0.3,2.0,273,61
3,Prince Edward Island,N06DA,Anticholinesterases,65+,M,**,**,**,**,62
3,Prince Edward Island,A09AA,Enzyme preparations,65+,M,**,**,**,**,63
3,Prince Edward Island,C03AA,"Thiazides, plain",65+,M,27.96,0.3,9.8,"1,335",64
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",65+,M,25.21,0.3,7.7,"1,046",65
3,Prince Edward Island,N04BC,Dopamine agonists,65+,M,**,**,**,**,66
3,Prince Edward Island,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,M,**,**,**,**,67
3,Prince Edward Island,C01AA,Digitalis glycosides,65+,M,**,**,**,**,68
3,Prince Edward Island,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,**,**,**,**,69
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,65+,M,18.09,0.2,6.5,876,70
3,Prince Edward Island,C10AC,Bile acid sequestrants,65+,M,**,**,**,**,71
3,Prince Edward Island,S01BA,"Corticosteroids, plain",65+,M,**,**,**,**,72
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,**,**,**,**,73
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,**,**,**,**,74
3,Prince Edward Island,A02BA,H2-receptor antagonists,65+,M,**,**,**,**,75
3,Prince Edward Island,S01EC,Carbonic anhydrase inhibitors,65+,M,**,**,**,**,76
3,Prince Edward Island,N03AG,Fatty acid derivatives,65+,M,**,**,**,**,77
3,Prince Edward Island,L01BA,Folic acid analogues,65+,M,14.18,0.1,1.1,144,78
3,Prince Edward Island,A07AA,Antibiotics,65+,M,**,**,**,**,79
3,Prince Edward Island,M01AE,Propionic acid derivatives,65+,M,13.96,0.1,5.0,676,80
3,Prince Edward Island,L01XX,Other antineoplastic agents,65+,M,**,**,**,**,81
3,Prince Edward Island,C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,65+,M,**,**,**,**,82
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,M,12.60,0.1,5.0,677,83
3,Prince Edward Island,B01AB,Heparin group,65+,M,**,**,**,**,84
3,Prince Edward Island,N02BE,Anilides,65+,M,**,**,**,**,85
3,Prince Edward Island,M05BA,Bisphosphonates,65+,M,12.22,0.1,1.7,237,86
3,Prince Edward Island,C03DA,Aldosterone antagonists,65+,M,11.68,0.1,2.7,369,87
3,Prince Edward Island,M01AH,Coxibs,65+,M,**,**,**,**,88
3,Prince Edward Island,L03AA,Colony-stimulating factors,65+,M,10.96,0.1,0.0,6,89
3,Prince Edward Island,L01BC,Pyrimidine analogues,65+,M,10.71,0.1,1.5,198,90
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,65+,M,10.11,0.1,2.2,294,91
3,Prince Edward Island,C02CA,Alpha-adrenoreceptor antagonists,65+,M,10.02,0.1,0.5,66,92
3,Prince Edward Island,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,M,**,**,**,*,93
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,65+,M,**,**,**,**,94
3,Prince Edward Island,J01AA,Tetracyclines,65+,M,9.92,0.1,6.7,905,95
3,Prince Edward Island,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,65+,M,**,**,**,*,96
3,Prince Edward Island,A06AB,Contact laxatives,65+,M,9.32,0.1,1.2,157,97
3,Prince Edward Island,D06AX,Other antibiotics for topical use,65+,M,**,**,**,**,98
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,65+,M,9.08,0.1,1.5,210,99
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,65+,M,**,**,**,**,100
3,Prince Edward Island,L04AA,Selective immunosuppressants,65+,F,826.52,7.3,0.3,41,1
3,Prince Edward Island,S01LA,Antineovascularization agents,65+,F,**,**,**,**,2
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,760.30,6.7,0.4,59,3
3,Prince Edward Island,L04AX,Other immunosuppressants,65+,F,495.33,4.4,0.5,76,4
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",65+,F,355.28,3.1,4.0,641,5
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,65+,F,324.10,2.9,2.8,446,6
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,65+,F,306.26,2.7,37.7,"6,035",7
3,Prince Edward Island,A02BC,Proton pump inhibitors,65+,F,268.49,2.4,35.2,"5,635",8
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,233.10,2.1,2.2,347,9
3,Prince Edward Island,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,F,**,**,**,*,10
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,65+,F,202.08,1.8,20.4,"3,264",11
3,Prince Edward Island,R03BB,Anticholinergics,65+,F,197.44,1.7,6.3,"1,004",12
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,180.02,1.6,17.7,"2,841",13
3,Prince Edward Island,R03BA,Glucocorticoids,65+,F,179.53,1.6,5.0,808,14
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",65+,F,170.97,1.5,19.5,"3,124",15
3,Prince Edward Island,H03AA,Thyroid hormones,65+,F,164.79,1.5,30.4,"4,871",16
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,158.49,1.4,8.0,"1,284",17
3,Prince Edward Island,L01EX,Other protein kinase inhibitors,65+,F,**,**,**,**,18
3,Prince Edward Island,S01EE,Prostaglandin analogues,65+,F,**,**,**,**,19
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,65+,F,142.26,1.3,17.2,"2,751",20
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,138.57,1.2,2.8,445,21
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",65+,F,133.01,1.2,20.4,"3,272",22
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,**,**,**,**,23
3,Prince Edward Island,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,F,**,**,**,**,24
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,65+,F,**,**,**,**,25
3,Prince Edward Island,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,98.96,0.9,0.6,100,26
3,Prince Edward Island,N02AA,Natural opium alkaloids,65+,F,93.14,0.8,7.6,"1,213",27
3,Prince Edward Island,N03AX,Other antiepileptics,65+,F,92.65,0.8,6.4,"1,027",28
3,Prince Edward Island,N06AX,Other antidepressants,65+,F,91.88,0.8,11.6,"1,857",29
3,Prince Edward Island,L04AC,Interleukin inhibitors,65+,F,**,**,**,*,30
3,Prince Edward Island,S01ED,Beta-blocking agents,65+,F,**,**,**,**,31
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,65+,F,77.37,0.7,1.0,163,32
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,65+,F,**,**,**,**,33
3,Prince Edward Island,L03AB,Interferons,65+,F,**,**,**,*,34
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,68.26,0.6,7.4,"1,180",35
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,63.59,0.6,14.4,"2,300",36
3,Prince Edward Island,L02BG,Aromatase inhibitors,65+,F,**,**,**,**,37
3,Prince Edward Island,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,F,**,**,**,*,38
3,Prince Edward Island,C01DA,Organic nitrates,65+,F,60.90,0.5,3.4,542,39
3,Prince Edward Island,R01AD,Corticosteroids,65+,F,**,**,**,**,40
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",65+,F,57.67,0.5,2.4,380,41
3,Prince Edward Island,C03CA,"Sulfonamides, plain",65+,F,55.33,0.5,10.1,"1,616",42
3,Prince Edward Island,M05BA,Bisphosphonates,65+,F,54.44,0.5,8.2,"1,311",43
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,53.28,0.5,6.0,969,44
3,Prince Edward Island,H02AB,Glucocorticoids,65+,F,52.66,0.5,15.5,"2,480",45
3,Prince Edward Island,A10BA,Biguanides,65+,F,50.73,0.4,11.0,"1,755",46
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,65+,F,49.05,0.4,10.1,"1,615",47
3,Prince Edward Island,C03AA,"Thiazides, plain",65+,F,48.76,0.4,14.3,"2,288",48
3,Prince Edward Island,N06DA,Anticholinesterases,65+,F,**,**,**,**,49
3,Prince Edward Island,B02BX,Other systemic hemostatics,65+,F,**,**,**,*,50
3,Prince Edward Island,A10BB,Sulfonylureas,65+,F,45.00,0.4,5.0,807,51
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,65+,F,40.22,0.4,2.3,367,52
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,65+,F,40.18,0.4,1.1,172,53
3,Prince Edward Island,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,39.08,0.3,3.9,619,54
3,Prince Edward Island,L01XC,Monoclonal antibodies,65+,F,**,**,**,*,55
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,35.64,0.3,0.3,56,56
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,**,**,**,**,57
3,Prince Edward Island,L03AA,Colony-stimulating factors,65+,F,34.79,0.3,0.1,11,58
3,Prince Edward Island,N05AX,Other antipsychotics,65+,F,33.97,0.3,1.5,239,59
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,33.05,0.3,0.9,146,60
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,32.77,0.3,7.7,"1,227",61
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,30.37,0.3,0.6,98,62
3,Prince Edward Island,A09AA,Enzyme preparations,65+,F,**,**,**,**,63
3,Prince Edward Island,B01AA,Vitamin K antagonists,65+,F,30.10,0.3,3.5,559,64
3,Prince Edward Island,M05BX,Other drugs affecting bone structure and mineralization,65+,F,**,**,**,**,65
3,Prince Edward Island,N02BE,Anilides,65+,F,**,**,**,**,66
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,65+,F,**,**,**,**,67
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,65+,F,**,**,**,**,68
3,Prince Edward Island,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,F,**,**,**,**,69
3,Prince Edward Island,S01BA,"Corticosteroids, plain",65+,F,**,**,**,**,70
3,Prince Edward Island,L01BA,Folic acid analogues,65+,F,23.42,0.2,1.5,241,71
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",65+,F,23.41,0.2,7.6,"1,215",72
3,Prince Edward Island,N04BC,Dopamine agonists,65+,F,**,**,**,**,73
3,Prince Edward Island,N07BA,Drugs used in nicotine dependence,65+,F,**,**,**,**,74
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,**,**,**,**,75
3,Prince Edward Island,A07AA,Antibiotics,65+,F,**,**,**,**,76
3,Prince Edward Island,S01EC,Carbonic anhydrase inhibitors,65+,F,**,**,**,**,77
3,Prince Edward Island,A06AB,Contact laxatives,65+,F,19.81,0.2,1.8,287,78
3,Prince Edward Island,A02BA,H2-receptor antagonists,65+,F,**,**,**,**,79
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,**,**,**,*,80
3,Prince Edward Island,C05BA,Heparins or heparinoids for topical use,65+,F,**,**,**,**,81
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,65+,F,**,**,**,**,82
3,Prince Edward Island,M01AH,Coxibs,65+,F,**,**,**,**,83
3,Prince Edward Island,J01XE,Nitrofuran derivatives,65+,F,**,**,**,**,84
3,Prince Edward Island,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",65+,F,16.87,0.1,0.5,79,85
3,Prince Edward Island,C01AA,Digitalis glycosides,65+,F,**,**,**,**,86
3,Prince Edward Island,M01AE,Propionic acid derivatives,65+,F,16.14,0.1,4.8,771,87
3,Prince Edward Island,C10AC,Bile acid sequestrants,65+,F,**,**,**,**,88
3,Prince Edward Island,N03AG,Fatty acid derivatives,65+,F,**,**,**,**,89
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,65+,F,**,**,**,**,90
3,Prince Edward Island,A03AX,Other drugs for functional gastrointestinal disorders,65+,F,15.35,0.1,0.7,114,91
3,Prince Edward Island,J01AA,Tetracyclines,65+,F,15.23,0.1,6.7,"1,072",92
3,Prince Edward Island,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,**,**,**,**,93
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,65+,F,14.81,0.1,2.0,328,94
3,Prince Edward Island,L01XX,Other antineoplastic agents,65+,F,**,**,**,**,95
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,F,13.56,0.1,4.7,747,96
3,Prince Edward Island,B01AB,Heparin group,65+,F,**,**,**,**,97
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,65+,F,**,**,**,**,98
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,**,**,**,**,99
3,Prince Edward Island,A03FA,Propulsives,65+,F,13.16,0.1,3.3,526,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,"3,262.51",18.2,1.1,218,1
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,<65,Total,**,**,**,**,2
3,Prince Edward Island,A16AB,Enzymes,<65,Total,**,**,**,*,3
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,639.02,3.6,6.7,"1,324",4
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,586.54,3.3,5.1,"1,012",5
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,<65,Total,556.59,3.1,3.3,660,6
3,Prince Edward Island,S01LA,Antineovascularization agents,<65,Total,526.79,2.9,0.2,39,7
3,Prince Edward Island,N05AX,Other antipsychotics,<65,Total,513.29,2.9,2.6,515,8
3,Prince Edward Island,L04AX,Other immunosuppressants,<65,Total,507.04,2.8,0.4,85,9
3,Prince Edward Island,L04AA,Selective immunosuppressants,<65,Total,500.65,2.8,0.3,55,10
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,<65,Total,440.15,2.5,18.8,"3,715",11
3,Prince Edward Island,N02AA,Natural opium alkaloids,<65,Total,349.82,1.9,2.9,576,12
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,314.75,1.8,6.4,"1,259",13
3,Prince Edward Island,N03AX,Other antiepileptics,<65,Total,293.95,1.6,5.9,"1,173",14
3,Prince Edward Island,L04AC,Interleukin inhibitors,<65,Total,292.18,1.6,0.1,20,15
3,Prince Edward Island,A02BC,Proton pump inhibitors,<65,Total,283.99,1.6,18.4,"3,627",16
3,Prince Edward Island,N06AX,Other antidepressants,<65,Total,282.55,1.6,11.9,"2,355",17
3,Prince Edward Island,N07BA,Drugs used in nicotine dependence,<65,Total,**,**,**,**,18
3,Prince Edward Island,R03BA,Glucocorticoids,<65,Total,231.42,1.3,4.8,945,19
3,Prince Edward Island,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,220.97,1.2,1.1,219,20
3,Prince Edward Island,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,Total,**,**,**,**,21
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,<65,Total,182.23,1.0,4.4,877,22
3,Prince Edward Island,L03AB,Interferons,<65,Total,**,**,**,**,23
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,<65,Total,155.02,0.9,11.9,"2,359",24
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,<65,Total,154.97,0.9,3.3,650,25
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,<65,Total,131.86,0.7,2.1,405,26
3,Prince Edward Island,N03AG,Fatty acid derivatives,<65,Total,118.60,0.7,1.9,366,27
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,<65,Total,118.13,0.7,2.2,438,28
3,Prince Edward Island,L02BB,Antiandrogens,<65,Total,**,**,**,**,29
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,107.54,0.6,11.3,"2,236",30
3,Prince Edward Island,R07AX,Other respiratory system products,<65,Total,**,**,**,*,31
3,Prince Edward Island,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,Total,**,**,**,*,32
3,Prince Edward Island,R03BB,Anticholinergics,<65,Total,93.70,0.5,1.8,362,33
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",<65,Total,93.26,0.5,7.5,"1,479",34
3,Prince Edward Island,A10BA,Biguanides,<65,Total,91.98,0.5,14.3,"2,826",35
3,Prince Edward Island,L03AX,Other immunostimulants,<65,Total,**,**,**,**,36
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,83.47,0.5,3.3,652,37
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,83.43,0.5,0.6,120,38
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,74.98,0.4,3.4,671,39
3,Prince Edward Island,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,Total,**,**,**,*,40
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,70.79,0.4,4.3,851,41
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,<65,Total,69.73,0.4,5.1,"1,001",42
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,<65,Total,66.32,0.4,0.5,93,43
3,Prince Edward Island,L01XE,Protein kinase inhibitors,<65,Total,**,**,**,**,44
3,Prince Edward Island,H03AA,Thyroid hormones,<65,Total,63.54,0.4,2.9,578,45
3,Prince Edward Island,L01EX,Other protein kinase inhibitors,<65,Total,**,**,**,**,46
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,60.98,0.3,0.5,108,47
3,Prince Edward Island,A10BB,Sulfonylureas,<65,Total,60.73,0.3,6.1,"1,202",48
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,60.69,0.3,4.3,851,49
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",<65,Total,53.11,0.3,5.0,994,50
3,Prince Edward Island,L01XC,Monoclonal antibodies,<65,Total,**,**,**,*,51
3,Prince Edward Island,R01AD,Corticosteroids,<65,Total,52.11,0.3,7.1,"1,406",52
3,Prince Edward Island,J02AC,Triazole derivatives,<65,Total,**,**,**,**,53
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,<65,Total,45.56,0.3,0.3,60,54
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,45.38,0.3,0.1,17,55
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,45.01,0.3,0.9,174,56
3,Prince Edward Island,M01AE,Propionic acid derivatives,<65,Total,44.38,0.2,7.8,"1,547",57
3,Prince Edward Island,M03BX,Other centrally acting agents,<65,Total,43.20,0.2,1.0,198,58
3,Prince Edward Island,R06AE,Piperazine derivatives,<65,Total,43.17,0.2,1.0,200,59
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,38.89,0.2,1.9,375,60
3,Prince Edward Island,L03AA,Colony-stimulating factors,<65,Total,38.81,0.2,0.1,22,61
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,<65,Total,37.47,0.2,1.2,229,62
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,34.11,0.2,2.1,424,63
3,Prince Edward Island,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,32.52,0.2,1.4,272,64
3,Prince Edward Island,N03AF,Carboxamide derivatives,<65,Total,32.15,0.2,0.8,156,65
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",<65,Total,31.49,0.2,1.1,216,66
3,Prince Edward Island,A06AB,Contact laxatives,<65,Total,30.82,0.2,1.3,258,67
3,Prince Edward Island,R06AA,Aminoalkyl ethers,<65,Total,30.50,0.2,1.1,223,68
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,<65,Total,28.62,0.2,0.6,123,69
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,<65,Total,28.34,0.2,12.4,"2,442",70
3,Prince Edward Island,J01DB,First-generation cephalosporins,<65,Total,27.03,0.2,5.3,"1,045",71
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,**,**,**,**,72
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,<65,Total,25.75,0.1,1.0,206,73
3,Prince Edward Island,G03AC,Progestogens,<65,Total,**,**,**,**,74
3,Prince Edward Island,J01XX,Other antibacterials,<65,Total,**,**,**,*,75
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,24.34,0.1,1.0,201,76
3,Prince Edward Island,H02AB,Glucocorticoids,<65,Total,24.30,0.1,5.6,"1,100",77
3,Prince Edward Island,C03CA,"Sulfonamides, plain",<65,Total,23.96,0.1,2.0,401,78
3,Prince Edward Island,N05AA,Phenothiazines with aliphatic side-chain,<65,Total,22.22,0.1,0.6,109,79
3,Prince Edward Island,A06AD,Osmotically acting laxatives,<65,Total,22.01,0.1,0.8,160,80
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",<65,Total,21.34,0.1,3.5,696,81
3,Prince Edward Island,N02BE,Anilides,<65,Total,**,**,**,**,82
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,20.96,0.1,0.2,41,83
3,Prince Edward Island,J01AA,Tetracyclines,<65,Total,20.23,0.1,4.7,921,84
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,**,**,**,**,85
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,19.12,0.1,3.8,749,86
3,Prince Edward Island,L01BA,Folic acid analogues,<65,Total,18.95,0.1,0.6,126,87
3,Prince Edward Island,A02BA,H2-receptor antagonists,<65,Total,**,**,**,**,88
3,Prince Edward Island,N02CC,Selective serotonin (5HT1) agonists,<65,Total,**,**,**,**,89
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,<65,Total,18.19,0.1,0.5,97,90
3,Prince Edward Island,A07AA,Antibiotics,<65,Total,17.10,0.1,0.8,158,91
3,Prince Edward Island,A03FA,Propulsives,<65,Total,16.85,0.1,1.7,327,92
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,16.20,0.1,0.1,27,93
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,<65,Total,16.14,0.1,0.2,42,94
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,<65,Total,15.84,0.1,0.4,84,95
3,Prince Edward Island,C03AA,"Thiazides, plain",<65,Total,15.84,0.1,3.5,689,96
3,Prince Edward Island,C02CA,Alpha-adrenoreceptor antagonists,<65,Total,15.44,0.1,0.4,75,97
3,Prince Edward Island,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,<65,Total,**,**,**,*,98
3,Prince Edward Island,D10BA,Retinoids for treatment of acne,<65,Total,15.20,0.1,0.3,50,99
3,Prince Edward Island,D06AX,Other antibiotics for topical use,<65,Total,**,**,**,**,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,"1,371.73",15.5,1.1,104,1
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,<65,M,**,**,**,**,2
3,Prince Edward Island,A16AB,Enzymes,<65,M,**,**,**,*,3
3,Prince Edward Island,N05AX,Other antipsychotics,<65,M,365.87,4.1,3.5,320,4
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,<65,M,355.86,4.0,4.3,396,5
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,354.28,4.0,5.7,523,6
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",<65,M,329.13,3.7,8.1,739,7
3,Prince Edward Island,S01LA,Antineovascularization agents,<65,M,**,**,**,**,8
3,Prince Edward Island,L04AX,Other immunosuppressants,<65,M,261.26,2.9,0.4,37,9
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,174.98,2.0,7.6,693,10
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,<65,M,171.83,1.9,14.8,"1,352",11
3,Prince Edward Island,N02AA,Natural opium alkaloids,<65,M,165.11,1.9,2.6,238,12
3,Prince Edward Island,L04AA,Selective immunosuppressants,<65,M,158.55,1.8,0.2,15,13
3,Prince Edward Island,A02BC,Proton pump inhibitors,<65,M,135.92,1.5,17.2,"1,573",14
3,Prince Edward Island,N03AX,Other antiepileptics,<65,M,125.49,1.4,5.1,462,15
3,Prince Edward Island,N07BA,Drugs used in nicotine dependence,<65,M,**,**,**,**,16
3,Prince Edward Island,N06AX,Other antidepressants,<65,M,117.05,1.3,9.2,840,17
3,Prince Edward Island,L02BB,Antiandrogens,<65,M,110.37,1.2,0.1,8,18
3,Prince Edward Island,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,100.92,1.1,1.1,105,19
3,Prince Edward Island,R03BA,Glucocorticoids,<65,M,98.44,1.1,4.6,417,20
3,Prince Edward Island,L04AC,Interleukin inhibitors,<65,M,**,**,**,**,21
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,<65,M,90.69,1.0,4.0,362,22
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,<65,M,88.47,1.0,14.6,"1,334",23
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,<65,M,75.75,0.9,1.9,177,24
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,<65,M,**,**,**,**,25
3,Prince Edward Island,N03AG,Fatty acid derivatives,<65,M,**,**,**,**,26
3,Prince Edward Island,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,M,**,**,**,*,27
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,<65,M,**,**,**,**,28
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",<65,M,53.44,0.6,9.5,867,29
3,Prince Edward Island,A10BA,Biguanides,<65,M,51.25,0.6,17.4,"1,591",30
3,Prince Edward Island,L01XE,Protein kinase inhibitors,<65,M,**,**,**,*,31
3,Prince Edward Island,R03BB,Anticholinergics,<65,M,48.13,0.5,1.8,164,32
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,47.38,0.5,10.4,952,33
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,43.77,0.5,0.9,79,34
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,<65,M,38.01,0.4,6.3,579,35
3,Prince Edward Island,L03AB,Interferons,<65,M,**,**,**,*,36
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,35.34,0.4,0.5,47,37
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,35.15,0.4,3.1,280,38
3,Prince Edward Island,A10BB,Sulfonylureas,<65,M,32.35,0.4,7.6,698,39
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",<65,M,31.11,0.4,6.3,580,40
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,<65,M,30.68,0.3,0.4,35,41
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,<65,M,28.52,0.3,0.4,41,42
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,28.05,0.3,2.5,231,43
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,27.28,0.3,4.6,421,44
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,25.30,0.3,2.5,233,45
3,Prince Edward Island,J01XX,Other antibacterials,<65,M,**,**,**,*,46
3,Prince Edward Island,R01AD,Corticosteroids,<65,M,**,**,**,**,47
3,Prince Edward Island,M03BX,Other centrally acting agents,<65,M,21.14,0.2,0.9,78,48
3,Prince Edward Island,N03AF,Carboxamide derivatives,<65,M,19.12,0.2,0.9,84,49
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,<65,M,**,**,**,**,50
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,<65,M,18.77,0.2,0.1,7,51
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,18.50,0.2,0.7,65,52
3,Prince Edward Island,M01AE,Propionic acid derivatives,<65,M,18.06,0.2,6.5,597,53
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",<65,M,17.07,0.2,1.1,99,54
3,Prince Edward Island,L03AX,Other immunostimulants,<65,M,**,**,**,*,55
3,Prince Edward Island,H03AA,Thyroid hormones,<65,M,15.96,0.2,1.7,154,56
3,Prince Edward Island,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,<65,M,**,**,**,*,57
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,<65,M,14.02,0.2,2.2,203,58
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,<65,M,13.60,0.2,1.2,112,59
3,Prince Edward Island,A06AB,Contact laxatives,<65,M,13.23,0.1,1.2,111,60
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,**,**,**,**,61
3,Prince Edward Island,J01DB,First-generation cephalosporins,<65,M,**,**,**,**,62
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,<65,M,12.00,0.1,11.1,"1,012",63
3,Prince Edward Island,L03AA,Colony-stimulating factors,<65,M,11.82,0.1,0.1,7,64
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,<65,M,11.71,0.1,0.2,20,65
3,Prince Edward Island,R06AE,Piperazine derivatives,<65,M,11.56,0.1,0.6,55,66
3,Prince Edward Island,L01EX,Other protein kinase inhibitors,<65,M,**,**,**,*,67
3,Prince Edward Island,N05AA,Phenothiazines with aliphatic side-chain,<65,M,**,**,**,**,68
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,**,**,**,**,69
3,Prince Edward Island,J02AC,Triazole derivatives,<65,M,**,**,**,**,70
3,Prince Edward Island,A06AD,Osmotically acting laxatives,<65,M,10.58,0.1,0.8,76,71
3,Prince Edward Island,N02BE,Anilides,<65,M,**,**,**,**,72
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",<65,M,9.84,0.1,3.0,272,73
3,Prince Edward Island,B01AA,Vitamin K antagonists,<65,M,9.53,0.1,1.1,102,74
3,Prince Edward Island,C03CA,"Sulfonamides, plain",<65,M,9.30,0.1,2.0,187,75
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,<65,M,**,**,**,**,76
3,Prince Edward Island,H02AB,Glucocorticoids,<65,M,9.19,0.1,5.0,456,77
3,Prince Edward Island,N05AD,Butyrophenone derivatives,<65,M,8.54,0.1,0.4,36,78
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,**,**,**,**,79
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,8.28,0.1,3.4,309,80
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,<65,M,**,**,**,**,81
3,Prince Edward Island,J01AA,Tetracyclines,<65,M,7.79,0.1,3.9,355,82
3,Prince Edward Island,N03AB,Hydantoin derivatives,<65,M,**,**,**,**,83
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,<65,M,**,**,**,*,84
3,Prince Edward Island,B01AB,Heparin group,<65,M,**,**,**,*,85
3,Prince Edward Island,C01DA,Organic nitrates,<65,M,7.66,0.1,1.0,95,86
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,<65,M,**,**,**,**,87
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,<65,M,**,**,**,**,88
3,Prince Edward Island,G03HA,"Antiandrogens, plain",<65,M,**,**,**,**,89
3,Prince Edward Island,A02BA,H2-receptor antagonists,<65,M,**,**,**,**,90
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,**,**,**,**,91
3,Prince Edward Island,N04AC,Ethers of tropine or tropine derivatives,<65,M,**,**,**,**,92
3,Prince Edward Island,D10BA,Retinoids for treatment of acne,<65,M,6.56,0.1,0.2,17,93
3,Prince Edward Island,N07BB,Drugs used in alcohol dependence,<65,M,**,**,**,**,94
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,<65,M,**,**,**,**,95
3,Prince Edward Island,D06BB,Antivirals,<65,M,**,**,**,**,96
3,Prince Edward Island,L01BA,Folic acid analogues,<65,M,6.23,0.1,0.5,47,97
3,Prince Edward Island,C03AA,"Thiazides, plain",<65,M,6.06,0.1,3.2,293,98
3,Prince Edward Island,D06AX,Other antibiotics for topical use,<65,M,**,**,**,**,99
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,<65,M,5.93,0.1,1.3,122,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,"1,890.78",20.8,1.1,114,1
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,<65,F,**,**,**,**,2
3,Prince Edward Island,L04AA,Selective immunosuppressants,<65,F,342.10,3.8,0.4,40,3
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",<65,F,309.88,3.4,5.5,585,4
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,<65,F,268.33,3.0,22.3,"2,363",5
3,Prince Edward Island,L04AX,Other immunosuppressants,<65,F,245.78,2.7,0.5,48,6
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,232.26,2.6,4.6,489,7
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,<65,F,200.73,2.2,2.5,264,8
3,Prince Edward Island,S01LA,Antineovascularization agents,<65,F,**,**,**,**,9
3,Prince Edward Island,L04AC,Interleukin inhibitors,<65,F,**,**,**,**,10
3,Prince Edward Island,N02AA,Natural opium alkaloids,<65,F,184.72,2.0,3.2,338,11
3,Prince Edward Island,N03AX,Other antiepileptics,<65,F,168.46,1.9,6.7,711,12
3,Prince Edward Island,N06AX,Other antidepressants,<65,F,165.50,1.8,14.3,"1,515",13
3,Prince Edward Island,A02BC,Proton pump inhibitors,<65,F,148.07,1.6,19.4,"2,054",14
3,Prince Edward Island,N05AX,Other antipsychotics,<65,F,147.41,1.6,1.8,195,15
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,139.78,1.5,5.3,566,16
3,Prince Edward Island,R03BA,Glucocorticoids,<65,F,132.98,1.5,5.0,528,17
3,Prince Edward Island,L03AB,Interferons,<65,F,**,**,**,**,18
3,Prince Edward Island,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,F,**,**,**,*,19
3,Prince Edward Island,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,120.05,1.3,1.1,114,20
3,Prince Edward Island,N07BA,Drugs used in nicotine dependence,<65,F,**,**,**,**,21
3,Prince Edward Island,R07AX,Other respiratory system products,<65,F,**,**,**,*,22
3,Prince Edward Island,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,F,**,**,**,*,23
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,<65,F,91.55,1.0,4.9,515,24
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,<65,F,**,**,**,**,25
3,Prince Edward Island,L03AX,Other immunostimulants,<65,F,**,**,**,**,26
3,Prince Edward Island,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,F,**,**,**,*,27
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,70.71,0.8,8.0,850,28
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,<65,F,66.55,0.7,9.7,"1,025",29
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,60.16,0.7,12.1,"1,284",30
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,<65,F,56.11,0.6,2.2,228,31
3,Prince Edward Island,L01XC,Monoclonal antibodies,<65,F,**,**,**,*,32
3,Prince Edward Island,L01EX,Other protein kinase inhibitors,<65,F,**,**,**,*,33
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,<65,F,**,**,**,**,34
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,48.32,0.5,3.5,372,35
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,48.09,0.5,0.7,73,36
3,Prince Edward Island,N03AG,Fatty acid derivatives,<65,F,**,**,**,**,37
3,Prince Edward Island,H03AA,Thyroid hormones,<65,F,47.57,0.5,4.0,424,38
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,46.94,0.5,4.2,440,39
3,Prince Edward Island,R03BB,Anticholinergics,<65,F,45.57,0.5,1.9,198,40
3,Prince Edward Island,A10BA,Biguanides,<65,F,40.73,0.4,11.7,"1,235",41
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",<65,F,39.82,0.4,5.8,612,42
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,<65,F,37.80,0.4,0.5,52,43
3,Prince Edward Island,J02AC,Triazole derivatives,<65,F,**,**,**,**,44
3,Prince Edward Island,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,33.41,0.4,4.1,430,45
3,Prince Edward Island,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,32.52,0.4,2.6,272,46
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,<65,F,31.72,0.3,4.0,422,47
3,Prince Edward Island,R06AE,Piperazine derivatives,<65,F,31.50,0.3,1.4,144,48
3,Prince Edward Island,R01AD,Corticosteroids,<65,F,**,**,**,**,49
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,<65,F,**,**,**,**,50
3,Prince Edward Island,A10BB,Sulfonylureas,<65,F,28.38,0.3,4.8,504,51
3,Prince Edward Island,R06AA,Aminoalkyl ethers,<65,F,**,**,**,**,52
3,Prince Edward Island,L03AA,Colony-stimulating factors,<65,F,26.99,0.3,0.1,15,53
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,<65,F,26.61,0.3,0.1,10,54
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,26.51,0.3,1.0,109,55
3,Prince Edward Island,M01AE,Propionic acid derivatives,<65,F,26.32,0.3,9.0,950,56
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,**,**,**,*,57
3,Prince Edward Island,G03AC,Progestogens,<65,F,**,**,**,**,58
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,23.60,0.3,1.8,195,59
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,**,**,**,**,60
3,Prince Edward Island,M03BX,Other centrally acting agents,<65,F,22.06,0.2,1.1,120,61
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",<65,F,21.99,0.2,3.9,414,62
3,Prince Edward Island,A06AB,Contact laxatives,<65,F,17.58,0.2,1.4,147,63
3,Prince Edward Island,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,17.21,0.2,0.3,29,64
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,<65,F,16.34,0.2,13.5,"1,430",65
3,Prince Edward Island,L01XE,Protein kinase inhibitors,<65,F,**,**,**,*,66
3,Prince Edward Island,N02CC,Selective serotonin (5HT1) agonists,<65,F,**,**,**,**,67
3,Prince Edward Island,H02AB,Glucocorticoids,<65,F,15.11,0.2,6.1,644,68
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,<65,F,14.89,0.2,0.2,25,69
3,Prince Edward Island,C03CA,"Sulfonamides, plain",<65,F,14.66,0.2,2.0,214,70
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",<65,F,14.42,0.2,1.1,117,71
3,Prince Edward Island,J01DB,First-generation cephalosporins,<65,F,**,**,**,**,72
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,**,**,**,**,73
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,13.60,0.1,1.3,142,74
3,Prince Edward Island,G02BA,Intrauterine contraceptives,<65,F,13.24,0.1,0.3,35,75
3,Prince Edward Island,A07AA,Antibiotics,<65,F,**,**,**,**,76
3,Prince Edward Island,N03AF,Carboxamide derivatives,<65,F,13.03,0.1,0.7,72,77
3,Prince Edward Island,L01BA,Folic acid analogues,<65,F,12.71,0.1,0.7,79,78
3,Prince Edward Island,J01AA,Tetracyclines,<65,F,12.44,0.1,5.3,566,79
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,<65,F,12.15,0.1,0.9,94,80
3,Prince Edward Island,A02BA,H2-receptor antagonists,<65,F,**,**,**,**,81
3,Prince Edward Island,A03AX,Other drugs for functional gastrointestinal disorders,<65,F,11.77,0.1,0.5,56,82
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",<65,F,11.51,0.1,4.0,424,83
3,Prince Edward Island,A06AD,Osmotically acting laxatives,<65,F,11.43,0.1,0.8,84,84
3,Prince Edward Island,A03FA,Propulsives,<65,F,11.42,0.1,2.2,231,85
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,<65,F,**,**,**,**,86
3,Prince Edward Island,N05AA,Phenothiazines with aliphatic side-chain,<65,F,**,**,**,**,87
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,10.84,0.1,4.2,440,88
3,Prince Edward Island,N02BE,Anilides,<65,F,**,**,**,**,89
3,Prince Edward Island,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",<65,F,10.74,0.1,0.4,47,90
3,Prince Edward Island,L02BG,Aromatase inhibitors,<65,F,**,**,**,**,91
3,Prince Edward Island,M05BA,Bisphosphonates,<65,F,10.15,0.1,0.9,92,92
3,Prince Edward Island,C02CA,Alpha-adrenoreceptor antagonists,<65,F,10.00,0.1,0.4,44,93
3,Prince Edward Island,J01XE,Nitrofuran derivatives,<65,F,**,**,**,**,94
3,Prince Edward Island,C03AA,"Thiazides, plain",<65,F,9.77,0.1,3.7,396,95
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,<65,F,**,**,**,**,96
3,Prince Edward Island,N05BB,Diphenylmethane derivatives,<65,F,9.62,0.1,1.1,114,97
3,Prince Edward Island,D06AX,Other antibiotics for topical use,<65,F,**,**,**,**,98
3,Prince Edward Island,N05AE,Indole derivatives,<65,F,**,**,**,**,99
3,Prince Edward Island,N05BE,Azaspirodecanedione derivatives,<65,F,**,**,**,**,100
4,Novascotia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"26,518.10",10.7,1.0,"1,551",1
4,Novascotia,L04AX,Other immunosuppressants,Total,Total,"14,367.10",5.8,0.5,830,2
4,Novascotia,L04AA,Selective immunosuppressants,Total,Total,"8,626.00",3.5,0.5,835,3
4,Novascotia,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"7,282.01",2.9,5.3,"8,371",4
4,Novascotia,C10AA,HMG-CoA reductase inhibitors,Total,Total,"7,109.60",2.9,45.8,"72,651",5
4,Novascotia,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,Total,"5,776.33",2.3,0.0,78,6
4,Novascotia,A02BC,Proton pump inhibitors,Total,Total,"5,759.33",2.3,37.3,"59,210",7
4,Novascotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"4,940.44",2.0,4.0,"6,398",8
4,Novascotia,L04AC,Interleukin inhibitors,Total,Total,"4,692.32",1.9,0.2,343,9
4,Novascotia,B01AF,Direct factor Xa inhibitors,Total,Total,"4,121.97",1.7,3.4,"5,334",10
4,Novascotia,C08CA,Dihydropyridine derivatives,Total,Total,"3,968.90",1.6,20.1,"31,926",11
4,Novascotia,J05AP,Antivirals for treatment of HCV infections,Total,Total,"3,625.36",1.5,0.1,83,12
4,Novascotia,C09AA,"ACE inhibitors, plain",Total,Total,"3,592.88",1.4,22.3,"35,391",13
4,Novascotia,R03BB,Anticholinergics,Total,Total,"3,477.07",1.4,7.9,"12,522",14
4,Novascotia,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"3,410.51",1.4,16.4,"26,041",15
4,Novascotia,C07AB,"Beta-blocking agents, selective",Total,Total,"3,296.19",1.3,23.3,"36,954",16
4,Novascotia,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,Total,"3,230.08",1.3,0.1,80,17
4,Novascotia,N02AA,Natural opium alkaloids,Total,Total,"3,047.42",1.2,7.8,"12,414",18
4,Novascotia,L01EX,Other protein kinase inhibitors,Total,Total,"3,045.87",1.2,0.1,119,19
4,Novascotia,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"3,014.53",1.2,3.7,"5,809",20
4,Novascotia,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"2,973.53",1.2,0.6,957,21
4,Novascotia,H03AA,Thyroid hormones,Total,Total,"2,852.48",1.1,21.6,"34,229",22
4,Novascotia,L02BX,Other hormone antagonists and related agents,Total,Total,"2,730.47",1.1,0.1,147,23
4,Novascotia,N06AX,Other antidepressants,Total,Total,"2,665.59",1.1,13.1,"20,761",24
4,Novascotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"2,632.29",1.1,14.3,"22,775",25
4,Novascotia,R03BA,Glucocorticoids,Total,Total,"2,483.85",1.0,5.9,"9,438",26
4,Novascotia,M09AX,Other drugs for disorders of the musculoskeletal system,Total,Total,"2,419.97",1.0,0.0,5,27
4,Novascotia,N03AX,Other antiepileptics,Total,Total,"2,023.30",0.8,5.4,"8,632",28
4,Novascotia,L02BB,Antiandrogens,Total,Total,"1,978.69",0.8,0.3,466,29
4,Novascotia,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"1,978.00",0.8,0.1,120,30
4,Novascotia,N05AX,Other antipsychotics,Total,Total,"1,882.91",0.8,1.9,"2,995",31
4,Novascotia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"1,814.64",0.7,2.3,"3,584",32
4,Novascotia,R07AX,Other respiratory system products,Total,Total,"1,759.42",0.7,0.0,6,33
4,Novascotia,A10BA,Biguanides,Total,Total,"1,748.48",0.7,15.8,"25,067",34
4,Novascotia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,593.77",0.6,15.5,"24,677",35
4,Novascotia,H01CB,Somatostatin and analogues,Total,Total,"1,485.06",0.6,0.1,112,36
4,Novascotia,N07BC,Drugs used in opioid dependence,Total,Total,"1,472.54",0.6,0.8,"1,221",37
4,Novascotia,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"1,402.53",0.6,7.4,"11,683",38
4,Novascotia,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,379.93",0.6,3.9,"6,252",39
4,Novascotia,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,Total,"1,353.97",0.5,0.0,31,40
4,Novascotia,S01EE,Prostaglandin analogues,Total,Total,"1,347.19",0.5,3.6,"5,741",41
4,Novascotia,N05BA,Benzodiazepine derivatives,Total,Total,"1,314.28",0.5,10.4,"16,455",42
4,Novascotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"1,299.48",0.5,3.9,"6,118",43
4,Novascotia,B01AB,Heparin group,Total,Total,"1,289.24",0.5,0.8,"1,229",44
4,Novascotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"1,248.06",0.5,1.8,"2,851",45
4,Novascotia,C03CA,"Sulfonamides, plain",Total,Total,"1,241.46",0.5,10.4,"16,520",46
4,Novascotia,C09BA,ACE inhibitors and diuretics,Total,Total,"1,235.64",0.5,5.2,"8,269",47
4,Novascotia,A10BB,Sulfonylureas,Total,Total,"1,228.03",0.5,8.0,"12,722",48
4,Novascotia,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,212.80",0.5,1.0,"1,523",49
4,Novascotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"1,207.34",0.5,5.0,"7,920",50
4,Novascotia,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"1,136.53",0.5,4.2,"6,703",51
4,Novascotia,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"1,136.50",0.5,7.2,"11,358",52
4,Novascotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,Total,"1,130.35",0.5,9.0,"14,253",53
4,Novascotia,S01ED,Beta-blocking agents,Total,Total,"1,130.01",0.5,3.2,"5,076",54
4,Novascotia,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,Total,"1,085.59",0.4,0.0,34,55
4,Novascotia,C08DB,Benzothiazepine derivatives,Total,Total,"1,083.18",0.4,2.7,"4,351",56
4,Novascotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"1,074.78",0.4,0.3,505,57
4,Novascotia,M05BA,Bisphosphonates,Total,Total,"1,065.97",0.4,5.5,"8,770",58
4,Novascotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"1,046.20",0.4,0.9,"1,485",59
4,Novascotia,L01XE,Protein kinase inhibitors,Total,Total,"1,024.55",0.4,0.1,80,60
4,Novascotia,C01DA,Organic nitrates,Total,Total,"1,014.39",0.4,5.9,"9,402",61
4,Novascotia,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,Total,"1,006.93",0.4,0.0,36,62
4,Novascotia,N05CF,Benzodiazepine-related drugs,Total,Total,962.96,0.4,7.8,"12,399",63
4,Novascotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,887.66,0.4,5.3,"8,353",64
4,Novascotia,C03AA,"Thiazides, plain",Total,Total,875.94,0.4,11.3,"17,913",65
4,Novascotia,H02AB,Glucocorticoids,Total,Total,873.69,0.4,11.6,"18,484",66
4,Novascotia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,866.33,0.3,0.2,366,67
4,Novascotia,N04BA,Dopa and dopa derivatives,Total,Total,865.10,0.3,1.1,"1,694",68
4,Novascotia,L01XC,Monoclonal antibodies,Total,Total,838.87,0.3,0.1,81,69
4,Novascotia,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,795.02,0.3,5.7,"9,110",70
4,Novascotia,B01AA,Vitamin K antagonists,Total,Total,773.52,0.3,4.5,"7,150",71
4,Novascotia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,Total,772.34,0.3,0.5,768,72
4,Novascotia,A16AB,Enzymes,Total,Total,**,**,**,*,73
4,Novascotia,B03XA,Other antianemic preparations,Total,Total,687.89,0.3,0.0,35,74
4,Novascotia,M04AA,Preparations inhibiting uric acid production,Total,Total,677.29,0.3,4.8,"7,619",75
4,Novascotia,A12BA,Potassium,Total,Total,659.74,0.3,3.7,"5,939",76
4,Novascotia,N03AE,Benzodiazepine derivatives,Total,Total,645.84,0.3,3.8,"6,044",77
4,Novascotia,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,603.07,0.2,2.5,"4,022",78
4,Novascotia,L01AX,Other alkylating agents,Total,Total,582.77,0.2,0.1,98,79
4,Novascotia,R01AD,Corticosteroids,Total,Total,572.93,0.2,6.3,"9,934",80
4,Novascotia,C07AG,Alpha- and beta-blocking agents,Total,Total,564.31,0.2,1.4,"2,154",81
4,Novascotia,N06DA,Anticholinesterases,Total,Total,557.03,0.2,1.5,"2,392",82
4,Novascotia,C07AA,"Beta-blocking agents, non-selective",Total,Total,555.89,0.2,1.9,"3,053",83
4,Novascotia,N06BA,Centrally acting sympathomimetics,Total,Total,552.91,0.2,0.9,"1,388",84
4,Novascotia,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,Total,Total,537.66,0.2,0.0,10,85
4,Novascotia,A04AD,Other antiemetics,Total,Total,534.72,0.2,0.6,929,86
4,Novascotia,C10AX,Other lipid-modifying agents,Total,Total,533.89,0.2,2.7,"4,332",87
4,Novascotia,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,Total,Total,533.23,0.2,0.0,9,88
4,Novascotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,521.61,0.2,0.5,784,89
4,Novascotia,S01XA,Other ophthalmologicals,Total,Total,519.20,0.2,4.2,"6,621",90
4,Novascotia,A16AX,Various alimentary tract and metabolism products,Total,Total,**,**,**,*,91
4,Novascotia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,507.99,0.2,0.0,28,92
4,Novascotia,D07AC,"Corticosteroids, potent (group III)",Total,Total,507.38,0.2,7.8,"12,343",93
4,Novascotia,C05BA,Heparins or heparinoids for topical use,Total,Total,476.45,0.2,0.1,235,94
4,Novascotia,L01XJ,Hedgehog pathway inhibitors,Total,Total,467.40,0.2,0.0,8,95
4,Novascotia,A05AA,Bile acids and derivatives,Total,Total,462.57,0.2,0.1,217,96
4,Novascotia,B01AE,Direct thrombin inhibitors,Total,Total,461.54,0.2,0.3,513,97
4,Novascotia,A03FA,Propulsives,Total,Total,459.81,0.2,3.7,"5,867",98
4,Novascotia,L02BG,Aromatase inhibitors,Total,Total,459.41,0.2,0.8,"1,247",99
4,Novascotia,A07AA,Antibiotics,Total,Total,435.57,0.2,1.6,"2,514",100
4,Novascotia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,"11,526.52",9.7,1.0,652,1
4,Novascotia,L04AX,Other immunosuppressants,Total,M,"8,330.97",7.0,0.5,360,2
4,Novascotia,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"3,939.07",3.3,6.3,"4,309",3
4,Novascotia,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,M,"3,847.22",3.2,0.1,56,4
4,Novascotia,C10AA,HMG-CoA reductase inhibitors,Total,M,"3,590.18",3.0,53.8,"36,941",5
4,Novascotia,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"2,860.22",2.4,1.3,908,6
4,Novascotia,L02BX,Other hormone antagonists and related agents,Total,M,"2,730.47",2.3,0.2,147,7
4,Novascotia,J05AP,Antivirals for treatment of HCV infections,Total,M,"2,705.79",2.3,0.1,62,8
4,Novascotia,L04AA,Selective immunosuppressants,Total,M,"2,391.24",2.0,0.3,227,9
4,Novascotia,A02BC,Proton pump inhibitors,Total,M,"2,294.01",1.9,34.9,"23,960",10
4,Novascotia,L01EX,Other protein kinase inhibitors,Total,M,"2,248.50",1.9,0.1,79,11
4,Novascotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,207.77",1.9,4.1,"2,814",12
4,Novascotia,L04AC,Interleukin inhibitors,Total,M,"2,123.96",1.8,0.2,147,13
4,Novascotia,B01AF,Direct factor Xa inhibitors,Total,M,"2,083.60",1.8,3.9,"2,699",14
4,Novascotia,L02BB,Antiandrogens,Total,M,**,**,**,**,15
4,Novascotia,M09AX,Other drugs for disorders of the musculoskeletal system,Total,M,**,**,**,*,16
4,Novascotia,C08CA,Dihydropyridine derivatives,Total,M,"1,792.83",1.5,21.2,"14,560",17
4,Novascotia,C09AA,"ACE inhibitors, plain",Total,M,"1,786.92",1.5,26.4,"18,101",18
4,Novascotia,R03BB,Anticholinergics,Total,M,"1,687.70",1.4,8.6,"5,914",19
4,Novascotia,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,629.78",1.4,4.3,"2,959",20
4,Novascotia,C07AB,"Beta-blocking agents, selective",Total,M,"1,562.30",1.3,26.5,"18,181",21
4,Novascotia,N02AA,Natural opium alkaloids,Total,M,"1,442.10",1.2,7.6,"5,189",22
4,Novascotia,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,100.87",0.9,12.0,"8,229",23
4,Novascotia,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"1,094.28",0.9,15.9,"10,916",24
4,Novascotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"1,029.76",0.9,13.4,"9,173",25
4,Novascotia,R03BA,Glucocorticoids,Total,M,952.53,0.8,5.0,"3,464",26
4,Novascotia,A10BA,Biguanides,Total,M,933.42,0.8,19.6,"13,437",27
4,Novascotia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,916.97,0.8,2.5,"1,749",28
4,Novascotia,N05AX,Other antipsychotics,Total,M,911.53,0.8,1.8,"1,235",29
4,Novascotia,N07BC,Drugs used in opioid dependence,Total,M,905.09,0.8,1.1,737,30
4,Novascotia,N06AX,Other antidepressants,Total,M,874.24,0.7,10.1,"6,961",31
4,Novascotia,R07AX,Other respiratory system products,Total,M,**,**,**,*,32
4,Novascotia,N03AX,Other antiepileptics,Total,M,856.62,0.7,4.9,"3,340",33
4,Novascotia,L01XE,Protein kinase inhibitors,Total,M,790.28,0.7,0.1,46,34
4,Novascotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,785.72,0.7,0.5,373,35
4,Novascotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,745.95,0.6,1.5,"1,026",36
4,Novascotia,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,M,709.87,0.6,0.0,16,37
4,Novascotia,H03AA,Thyroid hormones,Total,M,706.05,0.6,12.4,"8,534",38
4,Novascotia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,699.07,0.6,14.6,"10,029",39
4,Novascotia,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,682.69,0.6,0.1,35,40
4,Novascotia,B01AB,Heparin group,Total,M,646.67,0.5,0.9,601,41
4,Novascotia,A10BB,Sulfonylureas,Total,M,645.89,0.5,10.0,"6,833",42
4,Novascotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,644.80,0.5,2.1,"1,414",43
4,Novascotia,C09BA,ACE inhibitors and diuretics,Total,M,634.58,0.5,6.1,"4,185",44
4,Novascotia,H01CB,Somatostatin and analogues,Total,M,631.02,0.5,0.1,45,45
4,Novascotia,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,602.33,0.5,5.8,"4,014",46
4,Novascotia,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,M,**,**,**,**,47
4,Novascotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,588.54,0.5,6.2,"4,286",48
4,Novascotia,A07EC,Aminosalicylic acid and similar agents,Total,M,568.61,0.5,1.0,663,49
4,Novascotia,N04BA,Dopa and dopa derivatives,Total,M,560.91,0.5,1.3,921,50
4,Novascotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,544.02,0.5,3.6,"2,459",51
4,Novascotia,C03CA,"Sulfonamides, plain",Total,M,527.00,0.4,10.5,"7,224",52
4,Novascotia,C01DA,Organic nitrates,Total,M,507.94,0.4,7.5,"5,137",53
4,Novascotia,S01EE,Prostaglandin analogues,Total,M,507.85,0.4,3.4,"2,327",54
4,Novascotia,S01ED,Beta-blocking agents,Total,M,473.63,0.4,3.2,"2,186",55
4,Novascotia,N05BA,Benzodiazepine derivatives,Total,M,462.94,0.4,7.8,"5,351",56
4,Novascotia,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,458.26,0.4,5.4,"3,702",57
4,Novascotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,M,448.93,0.4,8.4,"5,745",58
4,Novascotia,C08DB,Benzothiazepine derivatives,Total,M,435.79,0.4,2.6,"1,751",59
4,Novascotia,M04AA,Preparations inhibiting uric acid production,Total,M,428.89,0.4,7.3,"5,000",60
4,Novascotia,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,Total,M,**,**,**,**,61
4,Novascotia,B01AA,Vitamin K antagonists,Total,M,420.23,0.4,5.7,"3,901",62
4,Novascotia,L01AX,Other alkylating agents,Total,M,416.15,0.4,0.1,61,63
4,Novascotia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,M,408.94,0.3,0.6,396,64
4,Novascotia,H02AB,Glucocorticoids,Total,M,393.33,0.3,11.7,"8,021",65
4,Novascotia,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,M,377.35,0.3,0.0,12,66
4,Novascotia,B03XA,Other antianemic preparations,Total,M,374.57,0.3,0.0,19,67
4,Novascotia,N05CF,Benzodiazepine-related drugs,Total,M,355.65,0.3,6.6,"4,504",68
4,Novascotia,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,351.92,0.3,5.9,"4,070",69
4,Novascotia,G04BD,Drugs for urinary frequency and incontinence,Total,M,351.69,0.3,2.6,"1,782",70
4,Novascotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,350.60,0.3,4.9,"3,384",71
4,Novascotia,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,Total,M,**,**,**,**,72
4,Novascotia,L01XC,Monoclonal antibodies,Total,M,337.48,0.3,0.0,29,73
4,Novascotia,C07AG,Alpha- and beta-blocking agents,Total,M,332.25,0.3,1.8,"1,264",74
4,Novascotia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,316.80,0.3,0.2,132,75
4,Novascotia,N06BA,Centrally acting sympathomimetics,Total,M,316.13,0.3,1.2,791,76
4,Novascotia,C03AA,"Thiazides, plain",Total,M,307.18,0.3,9.3,"6,386",77
4,Novascotia,L01XJ,Hedgehog pathway inhibitors,Total,M,**,**,**,**,78
4,Novascotia,C10AX,Other lipid-modifying agents,Total,M,289.38,0.2,3.4,"2,312",79
4,Novascotia,C02CA,Alpha-adrenoreceptor antagonists,Total,M,277.65,0.2,2.5,"1,731",80
4,Novascotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,258.68,0.2,0.6,378,81
4,Novascotia,R01AD,Corticosteroids,Total,M,257.25,0.2,5.9,"4,047",82
4,Novascotia,B01AE,Direct thrombin inhibitors,Total,M,246.31,0.2,0.4,282,83
4,Novascotia,D07AC,"Corticosteroids, potent (group III)",Total,M,242.86,0.2,7.8,"5,352",84
4,Novascotia,C07AA,"Beta-blocking agents, non-selective",Total,M,235.55,0.2,1.9,"1,306",85
4,Novascotia,N03AE,Benzodiazepine derivatives,Total,M,235.21,0.2,3.1,"2,145",86
4,Novascotia,A16AX,Various alimentary tract and metabolism products,Total,M,**,**,**,*,87
4,Novascotia,A12BA,Potassium,Total,M,220.14,0.2,2.9,"2,012",88
4,Novascotia,A04AD,Other antiemetics,Total,M,217.95,0.2,0.5,373,89
4,Novascotia,N06DA,Anticholinesterases,Total,M,214.16,0.2,1.3,911,90
4,Novascotia,C03DA,Aldosterone antagonists,Total,M,210.71,0.2,3.3,"2,266",91
4,Novascotia,B03AC,"Iron, parenteral preparations",Total,M,186.07,0.2,0.4,264,92
4,Novascotia,M05BX,Other drugs affecting bone structure and mineralization,Total,M,186.04,0.2,0.1,65,93
4,Novascotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,179.98,0.2,0.6,405,94
4,Novascotia,A07AA,Antibiotics,Total,M,176.13,0.1,1.3,860,95
4,Novascotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,167.69,0.1,2.1,"1,467",96
4,Novascotia,D01AC,Imidazole and triazole derivatives,Total,M,163.59,0.1,3.6,"2,488",97
4,Novascotia,N05CD,Benzodiazepine derivatives,Total,M,163.39,0.1,1.6,"1,110",98
4,Novascotia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,162.23,0.1,0.2,162,99
4,Novascotia,C01AA,Digitalis glycosides,Total,M,156.14,0.1,1.4,969,100
4,Novascotia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,"14,991.58",11.6,1.0,899,1
4,Novascotia,L04AA,Selective immunosuppressants,Total,F,"6,234.76",4.8,0.7,608,2
4,Novascotia,L04AX,Other immunosuppressants,Total,F,"6,036.13",4.7,0.5,470,3
4,Novascotia,C10AA,HMG-CoA reductase inhibitors,Total,F,"3,519.42",2.7,39.6,"35,710",4
4,Novascotia,A02BC,Proton pump inhibitors,Total,F,"3,465.33",2.7,39.1,"35,250",5
4,Novascotia,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"3,342.94",2.6,4.5,"4,062",6
4,Novascotia,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,F,**,**,**,**,7
4,Novascotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"2,732.67",2.1,4.0,"3,584",8
4,Novascotia,L04AC,Interleukin inhibitors,Total,F,"2,568.36",2.0,0.2,196,9
4,Novascotia,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,309.65",1.8,19.8,"17,812",10
4,Novascotia,C08CA,Dihydropyridine derivatives,Total,F,"2,176.07",1.7,19.3,"17,366",11
4,Novascotia,H03AA,Thyroid hormones,Total,F,"2,146.43",1.7,28.5,"25,695",12
4,Novascotia,B01AF,Direct factor Xa inhibitors,Total,F,"2,038.37",1.6,2.9,"2,635",13
4,Novascotia,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,F,"1,929.10",1.5,0.0,22,14
4,Novascotia,C09AA,"ACE inhibitors, plain",Total,F,"1,805.96",1.4,19.2,"17,290",15
4,Novascotia,N06AX,Other antidepressants,Total,F,"1,791.35",1.4,15.3,"13,800",16
4,Novascotia,R03BB,Anticholinergics,Total,F,"1,789.38",1.4,7.3,"6,608",17
4,Novascotia,C07AB,"Beta-blocking agents, selective",Total,F,"1,733.89",1.3,20.8,"18,773",18
4,Novascotia,N02AA,Natural opium alkaloids,Total,F,"1,605.32",1.2,8.0,"7,225",19
4,Novascotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"1,602.53",1.2,15.1,"13,602",20
4,Novascotia,R03BA,Glucocorticoids,Total,F,"1,531.32",1.2,6.6,"5,974",21
4,Novascotia,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,384.75",1.1,3.2,"2,850",22
4,Novascotia,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"1,295.32",1.0,0.1,85,23
4,Novascotia,N03AX,Other antiepileptics,Total,F,"1,166.68",0.9,5.9,"5,292",24
4,Novascotia,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"1,133.27",0.9,7.4,"6,680",25
4,Novascotia,G04BD,Drugs for urinary frequency and incontinence,Total,F,"1,028.23",0.8,5.0,"4,470",26
4,Novascotia,N05AX,Other antipsychotics,Total,F,971.37,0.8,2.0,"1,760",27
4,Novascotia,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,944.26,0.7,8.9,"7,981",28
4,Novascotia,J05AP,Antivirals for treatment of HCV infections,Total,F,919.57,0.7,0.0,21,29
4,Novascotia,M05BA,Bisphosphonates,Total,F,910.87,0.7,8.3,"7,501",30
4,Novascotia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,897.68,0.7,2.0,"1,835",31
4,Novascotia,R07AX,Other respiratory system products,Total,F,**,**,**,*,32
4,Novascotia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,894.70,0.7,16.2,"14,648",33
4,Novascotia,H01CB,Somatostatin and analogues,Total,F,854.04,0.7,0.1,67,34
4,Novascotia,N05BA,Benzodiazepine derivatives,Total,F,851.34,0.7,12.3,"11,104",35
4,Novascotia,S01EE,Prostaglandin analogues,Total,F,839.34,0.6,3.8,"3,414",36
4,Novascotia,A10BA,Biguanides,Total,F,815.06,0.6,12.9,"11,630",37
4,Novascotia,L01EX,Other protein kinase inhibitors,Total,F,797.37,0.6,0.0,40,38
4,Novascotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,755.47,0.6,4.1,"3,659",39
4,Novascotia,C03CA,"Sulfonamides, plain",Total,F,714.46,0.6,10.3,"9,296",40
4,Novascotia,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,F,708.24,0.5,0.0,22,41
4,Novascotia,A16AB,Enzymes,Total,F,**,**,**,*,42
4,Novascotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,F,681.42,0.5,9.4,"8,508",43
4,Novascotia,S01ED,Beta-blocking agents,Total,F,656.38,0.5,3.2,"2,890",44
4,Novascotia,C08DB,Benzothiazepine derivatives,Total,F,647.39,0.5,2.9,"2,600",45
4,Novascotia,A07EC,Aminosalicylic acid and similar agents,Total,F,644.19,0.5,1.0,860,46
4,Novascotia,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,F,644.10,0.5,0.0,15,47
4,Novascotia,B01AB,Heparin group,Total,F,642.57,0.5,0.7,628,48
4,Novascotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,618.81,0.5,4.0,"3,634",49
4,Novascotia,N05CF,Benzodiazepine-related drugs,Total,F,607.31,0.5,8.8,"7,895",50
4,Novascotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,603.26,0.5,1.6,"1,437",51
4,Novascotia,C09BA,ACE inhibitors and diuretics,Total,F,601.07,0.5,4.5,"4,084",52
4,Novascotia,M09AX,Other drugs for disorders of the musculoskeletal system,Total,F,**,**,**,*,53
4,Novascotia,A10BB,Sulfonylureas,Total,F,582.14,0.4,6.5,"5,889",54
4,Novascotia,C03AA,"Thiazides, plain",Total,F,568.76,0.4,12.8,"11,527",55
4,Novascotia,N07BC,Drugs used in opioid dependence,Total,F,567.45,0.4,0.5,484,56
4,Novascotia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,549.52,0.4,0.3,234,57
4,Novascotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,537.06,0.4,5.5,"4,969",58
4,Novascotia,C01DA,Organic nitrates,Total,F,506.45,0.4,4.7,"4,265",59
4,Novascotia,L01XC,Monoclonal antibodies,Total,F,501.39,0.4,0.1,52,60
4,Novascotia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,489.29,0.4,0.0,23,61
4,Novascotia,H02AB,Glucocorticoids,Total,F,480.36,0.4,11.6,"10,463",62
4,Novascotia,L02BG,Aromatase inhibitors,Total,F,456.66,0.4,1.4,"1,240",63
4,Novascotia,A05AA,Bile acids and derivatives,Total,F,449.39,0.3,0.2,179,64
4,Novascotia,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,443.11,0.3,5.6,"5,040",65
4,Novascotia,A12BA,Potassium,Total,F,439.60,0.3,4.4,"3,927",66
4,Novascotia,N03AE,Benzodiazepine derivatives,Total,F,410.62,0.3,4.3,"3,899",67
4,Novascotia,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,F,**,**,**,**,68
4,Novascotia,C05BA,Heparins or heparinoids for topical use,Total,F,377.38,0.3,0.2,189,69
4,Novascotia,S01XA,Other ophthalmologicals,Total,F,372.13,0.3,5.1,"4,595",70
4,Novascotia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,F,363.41,0.3,0.4,372,71
4,Novascotia,B01AA,Vitamin K antagonists,Total,F,353.28,0.3,3.6,"3,249",72
4,Novascotia,N06DA,Anticholinesterases,Total,F,342.87,0.3,1.6,"1,481",73
4,Novascotia,C07AA,"Beta-blocking agents, non-selective",Total,F,320.34,0.2,1.9,"1,747",74
4,Novascotia,A04AD,Other antiemetics,Total,F,316.77,0.2,0.6,556,75
4,Novascotia,R01AD,Corticosteroids,Total,F,315.68,0.2,6.5,"5,887",76
4,Novascotia,B03XA,Other antianemic preparations,Total,F,313.33,0.2,0.0,16,77
4,Novascotia,A03FA,Propulsives,Total,F,306.88,0.2,4.1,"3,733",78
4,Novascotia,N04BA,Dopa and dopa derivatives,Total,F,304.19,0.2,0.9,773,79
4,Novascotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,300.25,0.2,0.5,459,80
4,Novascotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,289.07,0.2,0.1,132,81
4,Novascotia,L01BA,Folic acid analogues,Total,F,280.90,0.2,1.7,"1,498",82
4,Novascotia,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,Total,F,279.73,0.2,0.0,5,83
4,Novascotia,A16AX,Various alimentary tract and metabolism products,Total,F,**,**,**,*,84
4,Novascotia,A02BA,H2-receptor antagonists,Total,F,271.10,0.2,3.8,"3,395",85
4,Novascotia,D01AC,Imidazole and triazole derivatives,Total,F,269.07,0.2,4.5,"4,051",86
4,Novascotia,D07AC,"Corticosteroids, potent (group III)",Total,F,264.53,0.2,7.8,"6,991",87
4,Novascotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,262.92,0.2,0.5,406,88
4,Novascotia,A07AA,Antibiotics,Total,F,259.44,0.2,1.8,"1,654",89
4,Novascotia,M04AA,Preparations inhibiting uric acid production,Total,F,248.39,0.2,2.9,"2,619",90
4,Novascotia,C10AX,Other lipid-modifying agents,Total,F,244.51,0.2,2.2,"2,020",91
4,Novascotia,N06BA,Centrally acting sympathomimetics,Total,F,236.78,0.2,0.7,597,92
4,Novascotia,J01XE,Nitrofuran derivatives,Total,F,235.21,0.2,9.3,"8,351",93
4,Novascotia,L01XE,Protein kinase inhibitors,Total,F,234.27,0.2,0.0,34,94
4,Novascotia,L01XX,Other antineoplastic agents,Total,F,233.37,0.2,0.2,153,95
4,Novascotia,C07AG,Alpha- and beta-blocking agents,Total,F,232.07,0.2,1.0,890,96
4,Novascotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,228.44,0.2,3.6,"3,236",97
4,Novascotia,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,Total,F,**,**,**,**,98
4,Novascotia,B01AE,Direct thrombin inhibitors,Total,F,215.22,0.2,0.3,231,99
4,Novascotia,M01AH,Coxibs,Total,F,211.78,0.2,3.4,"3,031",100
4,Novascotia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,"13,283.66",6.8,0.5,706,1
4,Novascotia,L04AX,Other immunosuppressants,65+,Total,"10,987.62",5.6,0.4,526,2
4,Novascotia,C10AA,HMG-CoA reductase inhibitors,65+,Total,"6,819.39",3.5,50.3,"67,141",3
4,Novascotia,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"6,356.84",3.2,5.2,"6,971",4
4,Novascotia,A02BC,Proton pump inhibitors,65+,Total,"5,369.27",2.7,39.5,"52,817",5
4,Novascotia,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,Total,"4,971.59",2.5,0.1,67,6
4,Novascotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"4,654.60",2.4,4.4,"5,886",7
4,Novascotia,L04AA,Selective immunosuppressants,65+,Total,"4,586.40",2.3,0.4,469,8
4,Novascotia,B01AF,Direct factor Xa inhibitors,65+,Total,"4,015.39",2.0,3.8,"5,094",9
4,Novascotia,C08CA,Dihydropyridine derivatives,65+,Total,"3,823.60",1.9,22.3,"29,843",10
4,Novascotia,C09AA,"ACE inhibitors, plain",65+,Total,"3,429.40",1.7,24.2,"32,327",11
4,Novascotia,R03BB,Anticholinergics,65+,Total,"3,293.76",1.7,8.6,"11,528",12
4,Novascotia,C07AB,"Beta-blocking agents, selective",65+,Total,"3,176.50",1.6,25.8,"34,428",13
4,Novascotia,L04AC,Interleukin inhibitors,65+,Total,"2,981.37",1.5,0.1,199,14
4,Novascotia,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"2,939.15",1.5,15.7,"20,947",15
4,Novascotia,L01EX,Other protein kinase inhibitors,65+,Total,"2,803.76",1.4,0.1,102,16
4,Novascotia,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"2,777.61",1.4,0.7,880,17
4,Novascotia,L02BX,Other hormone antagonists and related agents,65+,Total,**,**,**,**,18
4,Novascotia,H03AA,Thyroid hormones,65+,Total,"2,711.69",1.4,23.4,"31,264",19
4,Novascotia,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"2,566.94",1.3,3.5,"4,648",20
4,Novascotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"2,553.61",1.3,16.0,"21,325",21
4,Novascotia,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,Total,"2,521.71",1.3,0.0,58,22
4,Novascotia,N02AA,Natural opium alkaloids,65+,Total,"2,292.83",1.2,7.8,"10,379",23
4,Novascotia,N06AX,Other antidepressants,65+,Total,"2,268.12",1.2,12.7,"16,911",24
4,Novascotia,R03BA,Glucocorticoids,65+,Total,"2,267.09",1.2,6.0,"8,007",25
4,Novascotia,L02BB,Antiandrogens,65+,Total,"1,864.05",0.9,0.3,451,26
4,Novascotia,A10BA,Biguanides,65+,Total,"1,628.34",0.8,16.5,"22,063",27
4,Novascotia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"1,623.27",0.8,2.3,"3,067",28
4,Novascotia,N03AX,Other antiepileptics,65+,Total,"1,552.45",0.8,5.0,"6,734",29
4,Novascotia,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"1,522.73",0.8,0.1,73,30
4,Novascotia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"1,438.19",0.7,15.6,"20,882",31
4,Novascotia,S01EE,Prostaglandin analogues,65+,Total,"1,332.70",0.7,4.2,"5,605",32
4,Novascotia,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"1,291.07",0.7,4.3,"5,680",33
4,Novascotia,H01CB,Somatostatin and analogues,65+,Total,"1,237.27",0.6,0.1,91,34
4,Novascotia,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"1,223.70",0.6,7.4,"9,842",35
4,Novascotia,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,Total,"1,213.69",0.6,0.0,26,36
4,Novascotia,C03CA,"Sulfonamides, plain",65+,Total,"1,189.00",0.6,11.5,"15,370",37
4,Novascotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"1,180.58",0.6,2.0,"2,620",38
4,Novascotia,C09BA,ACE inhibitors and diuretics,65+,Total,"1,172.61",0.6,5.6,"7,508",39
4,Novascotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"1,165.61",0.6,5.5,"7,395",40
4,Novascotia,A10BB,Sulfonylureas,65+,Total,"1,159.31",0.6,8.5,"11,340",41
4,Novascotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,"1,124.89",0.6,10.6,"14,155",42
4,Novascotia,N05BA,Benzodiazepine derivatives,65+,Total,"1,120.35",0.6,10.4,"13,944",43
4,Novascotia,S01ED,Beta-blocking agents,65+,Total,"1,115.83",0.6,3.7,"4,948",44
4,Novascotia,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"1,114.56",0.6,8.2,"10,907",45
4,Novascotia,A07EC,Aminosalicylic acid and similar agents,65+,Total,"1,080.24",0.5,0.9,"1,262",46
4,Novascotia,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"1,077.53",0.5,4.5,"6,056",47
4,Novascotia,C08DB,Benzothiazepine derivatives,65+,Total,"1,059.50",0.5,3.1,"4,139",48
4,Novascotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"1,047.58",0.5,3.5,"4,688",49
4,Novascotia,M05BA,Bisphosphonates,65+,Total,"1,041.71",0.5,6.4,"8,487",50
4,Novascotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,997.14,0.5,0.3,452,51
4,Novascotia,B01AB,Heparin group,65+,Total,991.89,0.5,0.8,"1,012",52
4,Novascotia,C01DA,Organic nitrates,65+,Total,988.95,0.5,6.7,"8,914",53
4,Novascotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,975.98,0.5,1.0,"1,333",54
4,Novascotia,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,Total,966.15,0.5,0.0,28,55
4,Novascotia,N05AX,Other antipsychotics,65+,Total,939.46,0.5,1.7,"2,241",56
4,Novascotia,J05AP,Antivirals for treatment of HCV infections,65+,Total,895.90,0.5,0.0,19,57
4,Novascotia,L01XE,Protein kinase inhibitors,65+,Total,895.48,0.5,0.1,68,58
4,Novascotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,858.09,0.4,5.8,"7,779",59
4,Novascotia,C03AA,"Thiazides, plain",65+,Total,843.67,0.4,12.5,"16,649",60
4,Novascotia,N05CF,Benzodiazepine-related drugs,65+,Total,832.02,0.4,7.9,"10,589",61
4,Novascotia,N04BA,Dopa and dopa derivatives,65+,Total,829.67,0.4,1.2,"1,618",62
4,Novascotia,H02AB,Glucocorticoids,65+,Total,782.07,0.4,12.0,"16,035",63
4,Novascotia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,Total,749.80,0.4,0.6,738,64
4,Novascotia,B01AA,Vitamin K antagonists,65+,Total,744.24,0.4,5.1,"6,749",65
4,Novascotia,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,678.96,0.3,5.8,"7,694",66
4,Novascotia,B03XA,Other antianemic preparations,65+,Total,**,**,**,**,67
4,Novascotia,M04AA,Preparations inhibiting uric acid production,65+,Total,657.09,0.3,5.4,"7,202",68
4,Novascotia,L01XC,Monoclonal antibodies,65+,Total,631.13,0.3,0.0,55,69
4,Novascotia,A12BA,Potassium,65+,Total,626.00,0.3,4.1,"5,514",70
4,Novascotia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,610.00,0.3,0.2,281,71
4,Novascotia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,598.03,0.3,3.0,"3,950",72
4,Novascotia,N06DA,Anticholinesterases,65+,Total,552.90,0.3,1.8,"2,377",73
4,Novascotia,R01AD,Corticosteroids,65+,Total,535.63,0.3,6.7,"8,953",74
4,Novascotia,C07AA,"Beta-blocking agents, non-selective",65+,Total,522.63,0.3,2.0,"2,659",75
4,Novascotia,C07AG,Alpha- and beta-blocking agents,65+,Total,519.98,0.3,1.4,"1,906",76
4,Novascotia,S01XA,Other ophthalmologicals,65+,Total,502.85,0.3,4.8,"6,410",77
4,Novascotia,C10AX,Other lipid-modifying agents,65+,Total,502.41,0.3,3.0,"4,050",78
4,Novascotia,N03AE,Benzodiazepine derivatives,65+,Total,487.00,0.2,3.4,"4,535",79
4,Novascotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,486.17,0.2,0.5,723,80
4,Novascotia,D07AC,"Corticosteroids, potent (group III)",65+,Total,471.06,0.2,8.2,"10,966",81
4,Novascotia,B01AE,Direct thrombin inhibitors,65+,Total,457.29,0.2,0.4,505,82
4,Novascotia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,**,**,**,**,83
4,Novascotia,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,Total,441.14,0.2,0.0,19,84
4,Novascotia,C05BA,Heparins or heparinoids for topical use,65+,Total,434.31,0.2,0.2,202,85
4,Novascotia,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,65+,Total,**,**,**,**,86
4,Novascotia,L02BG,Aromatase inhibitors,65+,Total,424.68,0.2,0.8,"1,108",87
4,Novascotia,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,65+,Total,**,**,**,**,88
4,Novascotia,D01AC,Imidazole and triazole derivatives,65+,Total,394.59,0.2,4.4,"5,847",89
4,Novascotia,A04AD,Other antiemetics,65+,Total,392.89,0.2,0.5,710,90
4,Novascotia,A03FA,Propulsives,65+,Total,391.35,0.2,3.8,"5,077",91
4,Novascotia,A02BA,H2-receptor antagonists,65+,Total,388.44,0.2,3.4,"4,547",92
4,Novascotia,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,**,**,**,**,93
4,Novascotia,L01XJ,Hedgehog pathway inhibitors,65+,Total,**,**,**,**,94
4,Novascotia,L01BA,Folic acid analogues,65+,Total,363.33,0.2,1.4,"1,815",95
4,Novascotia,C03DA,Aldosterone antagonists,65+,Total,357.89,0.2,2.9,"3,811",96
4,Novascotia,A07AA,Antibiotics,65+,Total,357.24,0.2,1.6,"2,152",97
4,Novascotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,343.98,0.2,2.9,"3,933",98
4,Novascotia,C02CA,Alpha-adrenoreceptor antagonists,65+,Total,309.59,0.2,1.4,"1,895",99
4,Novascotia,M01AH,Coxibs,65+,Total,307.52,0.2,3.2,"4,222",100
4,Novascotia,L04AX,Other immunosuppressants,65+,M,"6,424.53",6.8,0.4,245,1
4,Novascotia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,"5,410.45",5.7,0.5,275,2
4,Novascotia,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"3,508.15",3.7,6.3,"3,663",3
4,Novascotia,C10AA,HMG-CoA reductase inhibitors,65+,M,"3,440.81",3.6,58.8,"34,128",4
4,Novascotia,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,M,**,**,**,**,5
4,Novascotia,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"2,777.61",2.9,1.5,880,6
4,Novascotia,L02BX,Other hormone antagonists and related agents,65+,M,**,**,**,**,7
4,Novascotia,A02BC,Proton pump inhibitors,65+,M,"2,139.15",2.3,37.0,"21,488",8
4,Novascotia,L01EX,Other protein kinase inhibitors,65+,M,"2,112.63",2.2,0.1,70,9
4,Novascotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"2,090.71",2.2,4.5,"2,612",10
4,Novascotia,B01AF,Direct factor Xa inhibitors,65+,M,"2,023.06",2.1,4.4,"2,574",11
4,Novascotia,L02BB,Antiandrogens,65+,M,"1,864.05",2.0,0.8,451,12
4,Novascotia,C08CA,Dihydropyridine derivatives,65+,M,"1,715.05",1.8,23.3,"13,497",13
4,Novascotia,C09AA,"ACE inhibitors, plain",65+,M,"1,700.39",1.8,28.5,"16,508",14
4,Novascotia,R03BB,Anticholinergics,65+,M,"1,603.74",1.7,9.4,"5,468",15
4,Novascotia,C07AB,"Beta-blocking agents, selective",65+,M,"1,495.80",1.6,29.0,"16,834",16
4,Novascotia,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"1,406.63",1.5,4.1,"2,403",17
4,Novascotia,L04AC,Interleukin inhibitors,65+,M,"1,335.02",1.4,0.1,86,18
4,Novascotia,L04AA,Selective immunosuppressants,65+,M,"1,327.02",1.4,0.2,138,19
4,Novascotia,N02AA,Natural opium alkaloids,65+,M,"1,084.71",1.2,7.4,"4,301",20
4,Novascotia,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"1,074.13",1.1,18.1,"10,517",21
4,Novascotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,994.93,1.1,14.8,"8,582",22
4,Novascotia,N06AB,Selective serotonin reuptake inhibitors,65+,M,934.12,1.0,11.4,"6,637",23
4,Novascotia,R03BA,Glucocorticoids,65+,M,877.13,0.9,5.1,"2,942",24
4,Novascotia,A10BA,Biguanides,65+,M,873.84,0.9,20.6,"11,979",25
4,Novascotia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,821.64,0.9,2.6,"1,512",26
4,Novascotia,J05AP,Antivirals for treatment of HCV infections,65+,M,**,**,**,**,27
4,Novascotia,N06AX,Other antidepressants,65+,M,746.74,0.8,9.9,"5,744",28
4,Novascotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,730.97,0.8,0.6,332,29
4,Novascotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,701.19,0.7,1.6,934,30
4,Novascotia,L01XE,Protein kinase inhibitors,65+,M,676.44,0.7,0.1,39,31
4,Novascotia,H03AA,Thyroid hormones,65+,M,674.33,0.7,13.6,"7,902",32
4,Novascotia,N03AX,Other antiepileptics,65+,M,659.05,0.7,4.6,"2,648",33
4,Novascotia,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,M,**,**,**,**,34
4,Novascotia,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,**,**,**,**,35
4,Novascotia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,637.02,0.7,14.8,"8,578",36
4,Novascotia,A10BB,Sulfonylureas,65+,M,614.43,0.7,10.7,"6,190",37
4,Novascotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,612.09,0.6,2.3,"1,309",38
4,Novascotia,C09BA,ACE inhibitors and diuretics,65+,M,601.67,0.6,6.6,"3,803",39
4,Novascotia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,**,**,**,**,40
4,Novascotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,560.60,0.6,6.8,"3,958",41
4,Novascotia,N04BA,Dopa and dopa derivatives,65+,M,540.30,0.6,1.5,881,42
4,Novascotia,B01AB,Heparin group,65+,M,528.02,0.6,0.8,491,43
4,Novascotia,A07EC,Aminosalicylic acid and similar agents,65+,M,510.89,0.5,1.0,556,44
4,Novascotia,C03CA,"Sulfonamides, plain",65+,M,504.32,0.5,11.6,"6,711",45
4,Novascotia,H01CB,Somatostatin and analogues,65+,M,501.89,0.5,0.1,34,46
4,Novascotia,S01EE,Prostaglandin analogues,65+,M,500.95,0.5,3.9,"2,272",47
4,Novascotia,C01DA,Organic nitrates,65+,M,493.28,0.5,8.3,"4,835",48
4,Novascotia,S01ED,Beta-blocking agents,65+,M,466.32,0.5,3.7,"2,133",49
4,Novascotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,M,447.29,0.5,9.9,"5,721",50
4,Novascotia,C08DB,Benzothiazepine derivatives,65+,M,423.58,0.4,2.9,"1,657",51
4,Novascotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,422.61,0.4,3.1,"1,825",52
4,Novascotia,M04AA,Preparations inhibiting uric acid production,65+,M,414.47,0.4,8.1,"4,700",53
4,Novascotia,B01AA,Vitamin K antagonists,65+,M,402.35,0.4,6.3,"3,669",54
4,Novascotia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,M,399.10,0.4,0.7,385,55
4,Novascotia,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,397.57,0.4,5.4,"3,129",56
4,Novascotia,N05BA,Benzodiazepine derivatives,65+,M,383.20,0.4,7.8,"4,524",57
4,Novascotia,B03XA,Other antianemic preparations,65+,M,**,**,**,**,58
4,Novascotia,H02AB,Glucocorticoids,65+,M,353.32,0.4,12.2,"7,079",59
4,Novascotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,337.88,0.4,5.4,"3,146",60
4,Novascotia,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,M,**,**,**,**,61
4,Novascotia,G04BD,Drugs for urinary frequency and incontinence,65+,M,333.57,0.4,2.8,"1,649",62
4,Novascotia,N05AX,Other antipsychotics,65+,M,316.63,0.3,1.4,796,63
4,Novascotia,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,305.84,0.3,6.1,"3,525",64
4,Novascotia,C07AG,Alpha- and beta-blocking agents,65+,M,304.95,0.3,2.0,"1,132",65
4,Novascotia,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,65+,M,**,**,**,**,66
4,Novascotia,N05CF,Benzodiazepine-related drugs,65+,M,302.57,0.3,6.6,"3,858",67
4,Novascotia,L01XC,Monoclonal antibodies,65+,M,297.39,0.3,0.0,22,68
4,Novascotia,C03AA,"Thiazides, plain",65+,M,294.07,0.3,10.2,"5,931",69
4,Novascotia,L01XJ,Hedgehog pathway inhibitors,65+,M,**,**,**,**,70
4,Novascotia,C10AX,Other lipid-modifying agents,65+,M,274.18,0.3,3.7,"2,156",71
4,Novascotia,C02CA,Alpha-adrenoreceptor antagonists,65+,M,269.76,0.3,2.8,"1,643",72
4,Novascotia,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,M,259.10,0.3,0.0,10,73
4,Novascotia,B01AE,Direct thrombin inhibitors,65+,M,**,**,**,**,74
4,Novascotia,R01AD,Corticosteroids,65+,M,**,**,**,**,75
4,Novascotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,242.67,0.3,0.6,349,76
4,Novascotia,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,65+,M,**,**,**,**,77
4,Novascotia,D07AC,"Corticosteroids, potent (group III)",65+,M,228.96,0.2,8.4,"4,878",78
4,Novascotia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,**,**,**,**,79
4,Novascotia,C07AA,"Beta-blocking agents, non-selective",65+,M,223.21,0.2,2.0,"1,142",80
4,Novascotia,N06DA,Anticholinesterases,65+,M,211.98,0.2,1.6,906,81
4,Novascotia,A12BA,Potassium,65+,M,208.91,0.2,3.2,"1,861",82
4,Novascotia,C03DA,Aldosterone antagonists,65+,M,193.20,0.2,3.4,"1,981",83
4,Novascotia,M05BX,Other drugs affecting bone structure and mineralization,65+,M,**,**,**,**,84
4,Novascotia,N03AE,Benzodiazepine derivatives,65+,M,168.19,0.2,2.8,"1,608",85
4,Novascotia,L01AX,Other alkylating agents,65+,M,166.98,0.2,0.0,27,86
4,Novascotia,B03AC,"Iron, parenteral preparations",65+,M,157.37,0.2,0.4,207,87
4,Novascotia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,156.65,0.2,0.3,153,88
4,Novascotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,156.05,0.2,0.6,359,89
4,Novascotia,A04AD,Other antiemetics,65+,M,154.26,0.2,0.5,281,90
4,Novascotia,N07BC,Drugs used in opioid dependence,65+,M,152.36,0.2,0.2,126,91
4,Novascotia,A07AA,Antibiotics,65+,M,149.72,0.2,1.3,735,92
4,Novascotia,D01AC,Imidazole and triazole derivatives,65+,M,148.56,0.2,3.8,"2,221",93
4,Novascotia,C01AA,Digitalis glycosides,65+,M,147.62,0.2,1.5,895,94
4,Novascotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,146.79,0.2,2.2,"1,251",95
4,Novascotia,M05BA,Bisphosphonates,65+,M,146.28,0.2,2.1,"1,196",96
4,Novascotia,S01XA,Other ophthalmologicals,65+,M,142.37,0.2,3.4,"1,949",97
4,Novascotia,N05CD,Benzodiazepine derivatives,65+,M,141.51,0.2,1.7,966,98
4,Novascotia,A02BA,H2-receptor antagonists,65+,M,140.03,0.1,2.8,"1,603",99
4,Novascotia,A03FA,Propulsives,65+,M,133.18,0.1,3.2,"1,862",100
4,Novascotia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,"7,873.21",7.7,0.6,431,1
4,Novascotia,L04AX,Other immunosuppressants,65+,F,"4,563.09",4.5,0.4,281,2
4,Novascotia,C10AA,HMG-CoA reductase inhibitors,65+,F,"3,378.58",3.3,43.7,"33,013",3
4,Novascotia,L04AA,Selective immunosuppressants,65+,F,"3,259.38",3.2,0.4,331,4
4,Novascotia,A02BC,Proton pump inhibitors,65+,F,"3,230.13",3.2,41.5,"31,329",5
4,Novascotia,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"2,848.69",2.8,4.4,"3,308",6
4,Novascotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,563.89",2.5,4.3,"3,274",7
4,Novascotia,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,F,**,**,**,**,8
4,Novascotia,C08CA,Dihydropyridine derivatives,65+,F,"2,108.55",2.1,21.6,"16,346",9
4,Novascotia,H03AA,Thyroid hormones,65+,F,"2,037.36",2.0,30.9,"23,362",10
4,Novascotia,N06AB,Selective serotonin reuptake inhibitors,65+,F,"2,005.04",2.0,18.9,"14,310",11
4,Novascotia,B01AF,Direct factor Xa inhibitors,65+,F,"1,992.33",1.9,3.3,"2,520",12
4,Novascotia,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,F,**,**,**,**,13
4,Novascotia,C09AA,"ACE inhibitors, plain",65+,F,"1,729.01",1.7,20.9,"15,819",14
4,Novascotia,R03BB,Anticholinergics,65+,F,"1,690.02",1.7,8.0,"6,060",15
4,Novascotia,C07AB,"Beta-blocking agents, selective",65+,F,"1,680.69",1.6,23.3,"17,594",16
4,Novascotia,L04AC,Interleukin inhibitors,65+,F,"1,646.36",1.6,0.1,113,17
4,Novascotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"1,558.68",1.5,16.9,"12,743",18
4,Novascotia,N06AX,Other antidepressants,65+,F,"1,521.38",1.5,14.8,"11,167",19
4,Novascotia,R03BA,Glucocorticoids,65+,F,"1,389.96",1.4,6.7,"5,065",20
4,Novascotia,N02AA,Natural opium alkaloids,65+,F,"1,208.11",1.2,8.0,"6,078",21
4,Novascotia,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"1,160.31",1.1,3.0,"2,245",22
4,Novascotia,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,**,**,**,**,23
4,Novascotia,G04BD,Drugs for urinary frequency and incontinence,65+,F,957.51,0.9,5.3,"4,031",24
4,Novascotia,M05BA,Bisphosphonates,65+,F,895.43,0.9,9.6,"7,291",25
4,Novascotia,N03AX,Other antiepileptics,65+,F,893.40,0.9,5.4,"4,086",26
4,Novascotia,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,**,**,**,**,27
4,Novascotia,S01EE,Prostaglandin analogues,65+,F,831.75,0.8,4.4,"3,333",28
4,Novascotia,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,826.13,0.8,8.9,"6,713",29
4,Novascotia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,801.63,0.8,2.1,"1,555",30
4,Novascotia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,801.17,0.8,16.3,"12,304",31
4,Novascotia,A10BA,Biguanides,65+,F,754.50,0.7,13.3,"10,084",32
4,Novascotia,N05BA,Benzodiazepine derivatives,65+,F,737.15,0.7,12.5,"9,420",33
4,Novascotia,H01CB,Somatostatin and analogues,65+,F,735.39,0.7,0.1,57,34
4,Novascotia,L01EX,Other protein kinase inhibitors,65+,F,691.13,0.7,0.0,32,35
4,Novascotia,C03CA,"Sulfonamides, plain",65+,F,684.68,0.7,11.5,"8,659",36
4,Novascotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,677.60,0.7,11.2,"8,434",37
4,Novascotia,S01ED,Beta-blocking agents,65+,F,649.51,0.6,3.7,"2,815",38
4,Novascotia,C08DB,Benzothiazepine derivatives,65+,F,635.92,0.6,3.3,"2,482",39
4,Novascotia,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,F,**,**,**,**,40
4,Novascotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,624.97,0.6,3.8,"2,863",41
4,Novascotia,N05AX,Other antipsychotics,65+,F,622.83,0.6,1.9,"1,445",42
4,Novascotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,605.01,0.6,4.5,"3,437",43
4,Novascotia,C09BA,ACE inhibitors and diuretics,65+,F,570.94,0.6,4.9,"3,705",44
4,Novascotia,A07EC,Aminosalicylic acid and similar agents,65+,F,569.35,0.6,0.9,706,45
4,Novascotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,568.49,0.6,1.7,"1,311",46
4,Novascotia,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,F,**,**,**,**,47
4,Novascotia,C03AA,"Thiazides, plain",65+,F,549.60,0.5,14.2,"10,718",48
4,Novascotia,A10BB,Sulfonylureas,65+,F,544.88,0.5,6.8,"5,150",49
4,Novascotia,N05CF,Benzodiazepine-related drugs,65+,F,529.45,0.5,8.9,"6,731",50
4,Novascotia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,520.22,0.5,6.1,"4,633",51
4,Novascotia,C01DA,Organic nitrates,65+,F,495.67,0.5,5.4,"4,079",52
4,Novascotia,B01AB,Heparin group,65+,F,463.86,0.5,0.7,521,53
4,Novascotia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,**,**,**,**,54
4,Novascotia,H02AB,Glucocorticoids,65+,F,428.75,0.4,11.9,"8,956",55
4,Novascotia,L02BG,Aromatase inhibitors,65+,F,**,**,**,**,56
4,Novascotia,A12BA,Potassium,65+,F,417.09,0.4,4.8,"3,653",57
4,Novascotia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,**,**,**,**,58
4,Novascotia,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,373.12,0.4,5.5,"4,169",59
4,Novascotia,S01XA,Other ophthalmologicals,65+,F,360.47,0.4,5.9,"4,461",60
4,Novascotia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,F,350.69,0.3,0.5,353,61
4,Novascotia,B01AA,Vitamin K antagonists,65+,F,341.89,0.3,4.1,"3,080",62
4,Novascotia,N06DA,Anticholinesterases,65+,F,340.91,0.3,1.9,"1,471",63
4,Novascotia,C05BA,Heparins or heparinoids for topical use,65+,F,**,**,**,**,64
4,Novascotia,L01XC,Monoclonal antibodies,65+,F,333.74,0.3,0.0,33,65
4,Novascotia,N03AE,Benzodiazepine derivatives,65+,F,318.81,0.3,3.9,"2,927",66
4,Novascotia,B03XA,Other antianemic preparations,65+,F,**,**,**,**,67
4,Novascotia,C07AA,"Beta-blocking agents, non-selective",65+,F,299.43,0.3,2.0,"1,517",68
4,Novascotia,R01AD,Corticosteroids,65+,F,**,**,**,**,69
4,Novascotia,N04BA,Dopa and dopa derivatives,65+,F,289.37,0.3,1.0,737,70
4,Novascotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,274.79,0.3,0.5,399,71
4,Novascotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,266.17,0.3,0.2,120,72
4,Novascotia,A03FA,Propulsives,65+,F,258.17,0.3,4.3,"3,215",73
4,Novascotia,A02BA,H2-receptor antagonists,65+,F,248.41,0.2,3.9,"2,944",74
4,Novascotia,L01BA,Folic acid analogues,65+,F,247.90,0.2,1.6,"1,231",75
4,Novascotia,D01AC,Imidazole and triazole derivatives,65+,F,246.03,0.2,4.8,"3,626",76
4,Novascotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,243.50,0.2,0.5,374,77
4,Novascotia,M04AA,Preparations inhibiting uric acid production,65+,F,242.62,0.2,3.3,"2,502",78
4,Novascotia,D07AC,"Corticosteroids, potent (group III)",65+,F,242.09,0.2,8.1,"6,088",79
4,Novascotia,A04AD,Other antiemetics,65+,F,238.62,0.2,0.6,429,80
4,Novascotia,L01XX,Other antineoplastic agents,65+,F,231.20,0.2,0.2,146,81
4,Novascotia,C10AX,Other lipid-modifying agents,65+,F,228.23,0.2,2.5,"1,894",82
4,Novascotia,L01XE,Protein kinase inhibitors,65+,F,219.04,0.2,0.0,29,83
4,Novascotia,J01XE,Nitrofuran derivatives,65+,F,217.63,0.2,9.7,"7,302",84
4,Novascotia,C07AG,Alpha- and beta-blocking agents,65+,F,215.04,0.2,1.0,774,85
4,Novascotia,B01AE,Direct thrombin inhibitors,65+,F,**,**,**,**,86
4,Novascotia,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,65+,F,**,**,**,**,87
4,Novascotia,M05BX,Other drugs affecting bone structure and mineralization,65+,F,**,**,**,**,88
4,Novascotia,A07AA,Antibiotics,65+,F,207.52,0.2,1.9,"1,417",89
4,Novascotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,197.19,0.2,3.5,"2,682",90
4,Novascotia,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,65+,F,**,**,**,*,91
4,Novascotia,M01AH,Coxibs,65+,F,193.09,0.2,3.5,"2,658",92
4,Novascotia,A05AA,Bile acids and derivatives,65+,F,185.67,0.2,0.2,151,93
4,Novascotia,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,F,182.05,0.2,0.0,9,94
4,Novascotia,A09AA,Enzyme preparations,65+,F,**,**,**,**,95
4,Novascotia,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,65+,F,**,**,**,*,96
4,Novascotia,N04BC,Dopamine agonists,65+,F,170.87,0.2,1.2,900,97
4,Novascotia,S01BA,"Corticosteroids, plain",65+,F,167.54,0.2,4.4,"3,306",98
4,Novascotia,C03DA,Aldosterone antagonists,65+,F,164.68,0.2,2.4,"1,830",99
4,Novascotia,N05CD,Benzodiazepine derivatives,65+,F,159.62,0.2,1.8,"1,332",100
4,Novascotia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,"13,234.43",25.6,3.4,845,1
4,Novascotia,L04AA,Selective immunosuppressants,<65,Total,"4,039.60",7.8,1.5,366,2
4,Novascotia,L04AX,Other immunosuppressants,<65,Total,"3,379.49",6.5,1.2,304,3
4,Novascotia,J05AP,Antivirals for treatment of HCV infections,<65,Total,"2,729.46",5.3,0.3,64,4
4,Novascotia,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,"2,419.97",4.7,0.0,5,5
4,Novascotia,R07AX,Other respiratory system products,<65,Total,"1,759.42",3.4,0.0,6,6
4,Novascotia,L04AC,Interleukin inhibitors,<65,Total,"1,710.95",3.3,0.6,144,7
4,Novascotia,N07BC,Drugs used in opioid dependence,<65,Total,"1,242.87",2.4,3.9,995,8
4,Novascotia,N05AX,Other antipsychotics,<65,Total,943.44,1.8,3.0,754,9
4,Novascotia,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,925.17,1.8,5.6,"1,400",10
4,Novascotia,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,Total,804.74,1.6,0.0,11,11
4,Novascotia,N02AA,Natural opium alkaloids,<65,Total,754.60,1.5,8.1,"2,035",12
4,Novascotia,A16AB,Enzymes,<65,Total,**,**,**,*,13
4,Novascotia,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,Total,708.38,1.4,0.1,22,14
4,Novascotia,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,Total,565.79,1.1,0.1,17,15
4,Novascotia,A16AX,Various alimentary tract and metabolism products,<65,Total,**,**,**,*,16
4,Novascotia,N06AB,Selective serotonin reuptake inhibitors,<65,Total,471.36,0.9,20.2,"5,094",17
4,Novascotia,N03AX,Other antiepileptics,<65,Total,470.85,0.9,7.5,"1,898",18
4,Novascotia,N06BA,Centrally acting sympathomimetics,<65,Total,464.38,0.9,4.6,"1,152",19
4,Novascotia,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,455.27,0.9,0.2,47,20
4,Novascotia,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,447.59,0.9,4.6,"1,161",21
4,Novascotia,N06AX,Other antidepressants,<65,Total,397.47,0.8,15.3,"3,850",22
4,Novascotia,A02BC,Proton pump inhibitors,<65,Total,390.06,0.8,25.4,"6,393",23
4,Novascotia,L01AX,Other alkylating agents,<65,Total,354.93,0.7,0.2,57,24
4,Novascotia,B01AB,Heparin group,<65,Total,297.35,0.6,0.9,217,25
4,Novascotia,C10AA,HMG-CoA reductase inhibitors,<65,Total,290.21,0.6,21.9,"5,510",26
4,Novascotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,285.84,0.6,2.0,512,27
4,Novascotia,A05AA,Bile acids and derivatives,<65,Total,264.03,0.5,0.1,33,28
4,Novascotia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,256.33,0.5,0.3,85,29
4,Novascotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,251.91,0.5,5.7,"1,430",30
4,Novascotia,H01CB,Somatostatin and analogues,<65,Total,247.79,0.5,0.1,21,31
4,Novascotia,L01EX,Other protein kinase inhibitors,<65,Total,242.11,0.5,0.1,17,32
4,Novascotia,R03BA,Glucocorticoids,<65,Total,216.76,0.4,5.7,"1,431",33
4,Novascotia,L01XC,Monoclonal antibodies,<65,Total,207.73,0.4,0.1,26,34
4,Novascotia,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,195.93,0.4,0.3,77,35
4,Novascotia,N05BA,Benzodiazepine derivatives,<65,Total,193.94,0.4,10.0,"2,511",36
4,Novascotia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,191.38,0.4,2.1,517,37
4,Novascotia,R03BB,Anticholinergics,<65,Total,183.31,0.4,3.9,994,38
4,Novascotia,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,178.83,0.3,7.3,"1,841",39
4,Novascotia,C09AA,"ACE inhibitors, plain",<65,Total,163.48,0.3,12.2,"3,064",40
4,Novascotia,N03AE,Benzodiazepine derivatives,<65,Total,158.84,0.3,6.0,"1,509",41
4,Novascotia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,155.58,0.3,15.1,"3,795",42
4,Novascotia,C08CA,Dihydropyridine derivatives,<65,Total,145.30,0.3,8.3,"2,083",43
4,Novascotia,A04AD,Other antiemetics,<65,Total,141.83,0.3,0.9,219,44
4,Novascotia,H03AA,Thyroid hormones,<65,Total,140.79,0.3,11.8,"2,965",45
4,Novascotia,L01EJ,Janus-associated kinase (JAK) inhibitors,<65,Total,140.28,0.3,0.0,5,46
4,Novascotia,A07EC,Aminosalicylic acid and similar agents,<65,Total,132.56,0.3,1.0,261,47
4,Novascotia,N05CF,Benzodiazepine-related drugs,<65,Total,130.94,0.3,7.2,"1,810",48
4,Novascotia,L01XE,Protein kinase inhibitors,<65,Total,129.07,0.2,0.0,12,49
4,Novascotia,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,<65,Total,**,**,**,*,50
4,Novascotia,A10BA,Biguanides,<65,Total,120.14,0.2,11.9,"3,004",51
4,Novascotia,C07AB,"Beta-blocking agents, selective",<65,Total,119.69,0.2,10.0,"2,526",52
4,Novascotia,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,Total,119.44,0.2,0.0,6,53
4,Novascotia,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,116.06,0.2,5.6,"1,416",54
4,Novascotia,M03BX,Other centrally acting agents,<65,Total,114.80,0.2,5.5,"1,398",55
4,Novascotia,L02BB,Antiandrogens,<65,Total,114.64,0.2,0.1,15,56
4,Novascotia,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,<65,Total,**,**,**,*,57
4,Novascotia,B01AF,Direct factor Xa inhibitors,<65,Total,106.58,0.2,1.0,240,58
4,Novascotia,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,<65,Total,**,**,**,*,59
4,Novascotia,L01XJ,Hedgehog pathway inhibitors,<65,Total,**,**,**,*,60
4,Novascotia,H02AB,Glucocorticoids,<65,Total,91.62,0.2,9.7,"2,449",61
4,Novascotia,G04BD,Drugs for urinary frequency and incontinence,<65,Total,88.85,0.2,2.3,572,62
4,Novascotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,78.68,0.2,5.8,"1,450",63
4,Novascotia,A07AA,Antibiotics,<65,Total,78.33,0.2,1.4,362,64
4,Novascotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,77.65,0.2,0.2,53,65
4,Novascotia,N03AG,Fatty acid derivatives,<65,Total,71.97,0.1,1.5,371,66
4,Novascotia,L03AX,Other immunostimulants,<65,Total,**,**,**,*,67
4,Novascotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,70.22,0.1,0.6,152,68
4,Novascotia,B02BX,Other systemic hemostatics,<65,Total,**,**,**,*,69
4,Novascotia,A10BB,Sulfonylureas,<65,Total,68.71,0.1,5.5,"1,382",70
4,Novascotia,A03FA,Propulsives,<65,Total,68.46,0.1,3.1,790,71
4,Novascotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,67.47,0.1,0.9,231,72
4,Novascotia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,**,**,**,**,73
4,Novascotia,A04AA,Serotonin (5HT3) antagonists,<65,Total,64.95,0.1,1.2,290,74
4,Novascotia,C09BA,ACE inhibitors and diuretics,<65,Total,63.03,0.1,3.0,761,75
4,Novascotia,V03AC,Iron-chelating agents,<65,Total,**,**,**,*,76
4,Novascotia,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,59.01,0.1,2.6,647,77
4,Novascotia,M01AE,Propionic acid derivatives,<65,Total,55.95,0.1,7.1,"1,780",78
4,Novascotia,C03CA,"Sulfonamides, plain",<65,Total,52.46,0.1,4.6,"1,150",79
4,Novascotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,52.15,0.1,3.1,770,80
4,Novascotia,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,49.83,0.1,3.5,882,81
4,Novascotia,B03AC,"Iron, parenteral preparations",<65,Total,49.31,0.1,0.4,96,82
4,Novascotia,L03AA,Colony-stimulating factors,<65,Total,47.86,0.1,0.0,11,83
4,Novascotia,N02AB,Phenylpiperidine derivatives,<65,Total,47.12,0.1,0.4,89,84
4,Novascotia,N03AF,Carboxamide derivatives,<65,Total,45.84,0.1,0.8,195,85
4,Novascotia,L01BA,Folic acid analogues,<65,Total,45.59,0.1,1.5,377,86
4,Novascotia,C07AG,Alpha- and beta-blocking agents,<65,Total,44.33,0.1,1.0,248,87
4,Novascotia,J02AC,Triazole derivatives,<65,Total,43.78,0.1,2.5,626,88
4,Novascotia,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,Total,43.73,0.1,0.3,82,89
4,Novascotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,42.75,0.1,0.3,79,90
4,Novascotia,N05CD,Benzodiazepine derivatives,<65,Total,42.20,0.1,1.2,310,91
4,Novascotia,C05BA,Heparins or heparinoids for topical use,<65,Total,42.15,0.1,0.1,33,92
4,Novascotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,41.74,0.1,2.1,525,93
4,Novascotia,D01AC,Imidazole and triazole derivatives,<65,Total,38.07,0.1,2.7,692,94
4,Novascotia,L01XX,Other antineoplastic agents,<65,Total,37.70,0.1,0.0,12,95
4,Novascotia,R01AD,Corticosteroids,<65,Total,37.30,0.1,3.9,981,96
4,Novascotia,N04BC,Dopamine agonists,<65,Total,36.44,0.1,0.8,195,97
4,Novascotia,D07AC,"Corticosteroids, potent (group III)",<65,Total,36.33,0.1,5.5,"1,377",98
4,Novascotia,N05AA,Phenothiazines with aliphatic side-chain,<65,Total,36.17,0.1,0.8,210,99
4,Novascotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,35.44,0.1,0.2,61,100
4,Novascotia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,"6,116.07",25.0,3.6,377,1
4,Novascotia,J05AP,Antivirals for treatment of HCV infections,<65,M,**,**,**,**,2
4,Novascotia,L04AX,Other immunosuppressants,<65,M,"1,906.44",7.8,1.1,115,3
4,Novascotia,M09AX,Other drugs for disorders of the musculoskeletal system,<65,M,**,**,**,*,4
4,Novascotia,L04AA,Selective immunosuppressants,<65,M,"1,064.22",4.3,0.8,89,5
4,Novascotia,R07AX,Other respiratory system products,<65,M,**,**,**,*,6
4,Novascotia,L04AC,Interleukin inhibitors,<65,M,788.94,3.2,0.6,61,7
4,Novascotia,N07BC,Drugs used in opioid dependence,<65,M,752.73,3.1,5.8,611,8
4,Novascotia,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,M,**,**,**,**,9
4,Novascotia,N05AX,Other antipsychotics,<65,M,594.90,2.4,4.1,439,10
4,Novascotia,A10AE,"Insulins and analogues for injection, long-acting",<65,M,430.92,1.8,6.1,646,11
4,Novascotia,N02AA,Natural opium alkaloids,<65,M,357.39,1.5,8.4,888,12
4,Novascotia,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,M,337.31,1.4,0.1,9,13
4,Novascotia,N06BA,Centrally acting sympathomimetics,<65,M,271.72,1.1,6.3,669,14
4,Novascotia,L01AX,Other alkylating agents,<65,M,249.17,1.0,0.3,34,15
4,Novascotia,A16AX,Various alimentary tract and metabolism products,<65,M,**,**,**,*,16
4,Novascotia,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,223.15,0.9,5.2,556,17
4,Novascotia,N03AX,Other antiepileptics,<65,M,197.57,0.8,6.5,692,18
4,Novascotia,N06AB,Selective serotonin reuptake inhibitors,<65,M,166.75,0.7,15.0,"1,592",19
4,Novascotia,A02BC,Proton pump inhibitors,<65,M,154.86,0.6,23.3,"2,472",20
4,Novascotia,C10AA,HMG-CoA reductase inhibitors,<65,M,149.37,0.6,26.5,"2,813",21
4,Novascotia,L01EX,Other protein kinase inhibitors,<65,M,135.87,0.6,0.1,9,22
4,Novascotia,H01CB,Somatostatin and analogues,<65,M,129.14,0.5,0.1,11,23
4,Novascotia,N06AX,Other antidepressants,<65,M,127.51,0.5,11.5,"1,217",24
4,Novascotia,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,<65,M,**,**,**,*,25
4,Novascotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,121.41,0.5,6.0,634,26
4,Novascotia,B01AB,Heparin group,<65,M,118.64,0.5,1.0,110,27
4,Novascotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,117.06,0.5,1.9,202,28
4,Novascotia,L02BB,Antiandrogens,<65,M,114.64,0.5,0.1,15,29
4,Novascotia,L01XE,Protein kinase inhibitors,<65,M,113.84,0.5,0.1,7,30
4,Novascotia,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,<65,M,**,**,**,*,31
4,Novascotia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,95.33,0.4,2.2,237,32
4,Novascotia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,**,**,**,**,33
4,Novascotia,C09AA,"ACE inhibitors, plain",<65,M,86.53,0.4,15.0,"1,593",34
4,Novascotia,R03BB,Anticholinergics,<65,M,83.95,0.3,4.2,446,35
4,Novascotia,L02AE,Gonadotropin-releasing hormone analogues,<65,M,82.61,0.3,0.3,28,36
4,Novascotia,N05BA,Benzodiazepine derivatives,<65,M,79.74,0.3,7.8,827,37
4,Novascotia,C08CA,Dihydropyridine derivatives,<65,M,77.78,0.3,10.0,"1,063",38
4,Novascotia,R03BA,Glucocorticoids,<65,M,75.40,0.3,4.9,522,39
4,Novascotia,L03AX,Other immunostimulants,<65,M,**,**,**,*,40
4,Novascotia,N03AE,Benzodiazepine derivatives,<65,M,67.02,0.3,5.1,537,41
4,Novascotia,C07AB,"Beta-blocking agents, selective",<65,M,66.49,0.3,12.7,"1,347",42
4,Novascotia,A04AD,Other antiemetics,<65,M,63.68,0.3,0.9,92,43
4,Novascotia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,62.05,0.3,13.7,"1,451",44
4,Novascotia,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,60.70,0.2,5.4,573,45
4,Novascotia,B01AF,Direct factor Xa inhibitors,<65,M,60.54,0.2,1.2,125,46
4,Novascotia,L01EJ,Janus-associated kinase (JAK) inhibitors,<65,M,**,**,**,*,47
4,Novascotia,A10BA,Biguanides,<65,M,59.58,0.2,13.8,"1,458",48
4,Novascotia,A07EC,Aminosalicylic acid and similar agents,<65,M,57.72,0.2,1.0,107,49
4,Novascotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,54.75,0.2,0.4,41,50
4,Novascotia,N05CF,Benzodiazepine-related drugs,<65,M,53.08,0.2,6.1,646,51
4,Novascotia,B02BX,Other systemic hemostatics,<65,M,**,**,**,*,52
4,Novascotia,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,46.08,0.2,5.1,545,53
4,Novascotia,M03BX,Other centrally acting agents,<65,M,45.99,0.2,4.3,452,54
4,Novascotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,44.76,0.2,0.9,92,55
4,Novascotia,N03AG,Fatty acid derivatives,<65,M,**,**,**,**,56
4,Novascotia,L01XC,Monoclonal antibodies,<65,M,40.09,0.2,0.1,7,57
4,Novascotia,H02AB,Glucocorticoids,<65,M,40.01,0.2,8.9,942,58
4,Novascotia,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,M,**,**,**,*,59
4,Novascotia,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,**,**,**,**,60
4,Novascotia,L01XX,Other antineoplastic agents,<65,M,35.53,0.1,0.0,5,61
4,Novascotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,34.83,0.1,5.6,591,62
4,Novascotia,C09BA,ACE inhibitors and diuretics,<65,M,32.91,0.1,3.6,382,63
4,Novascotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,32.70,0.1,1.0,105,64
4,Novascotia,H03AA,Thyroid hormones,<65,M,31.72,0.1,6.0,632,65
4,Novascotia,A10BB,Sulfonylureas,<65,M,31.46,0.1,6.1,643,66
4,Novascotia,B03AC,"Iron, parenteral preparations",<65,M,28.70,0.1,0.5,57,67
4,Novascotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,27.94,0.1,3.1,328,68
4,Novascotia,C07AG,Alpha- and beta-blocking agents,<65,M,27.30,0.1,1.2,132,69
4,Novascotia,A07AA,Antibiotics,<65,M,26.41,0.1,1.2,125,70
4,Novascotia,A04AA,Serotonin (5HT3) antagonists,<65,M,26.10,0.1,1.1,121,71
4,Novascotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,23.93,0.1,0.4,46,72
4,Novascotia,C03CA,"Sulfonamides, plain",<65,M,22.69,0.1,4.8,513,73
4,Novascotia,N05CD,Benzodiazepine derivatives,<65,M,21.88,0.1,1.4,144,74
4,Novascotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,20.91,0.1,2.0,216,75
4,Novascotia,M01AE,Propionic acid derivatives,<65,M,20.78,0.1,5.6,593,76
4,Novascotia,N04BA,Dopa and dopa derivatives,<65,M,20.62,0.1,0.4,40,77
4,Novascotia,N05AA,Phenothiazines with aliphatic side-chain,<65,M,20.37,0.1,0.9,97,78
4,Novascotia,G04CA,Alpha-adrenoreceptor antagonists,<65,M,20.15,0.1,3.8,399,79
4,Novascotia,A16AB,Enzymes,<65,M,**,**,**,*,80
4,Novascotia,A03FA,Propulsives,<65,M,19.74,0.1,2.6,272,81
4,Novascotia,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,M,19.42,0.1,0.4,39,82
4,Novascotia,G04BD,Drugs for urinary frequency and incontinence,<65,M,18.13,0.1,1.3,133,83
4,Novascotia,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,M,**,**,**,*,84
4,Novascotia,B01AA,Vitamin K antagonists,<65,M,17.88,0.1,2.2,232,85
4,Novascotia,C03DA,Aldosterone antagonists,<65,M,17.51,0.1,2.7,285,86
4,Novascotia,N02AB,Phenylpiperidine derivatives,<65,M,16.12,0.1,0.3,37,87
4,Novascotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,16.01,0.1,0.3,29,88
4,Novascotia,N03AF,Carboxamide derivatives,<65,M,15.36,0.1,0.8,83,89
4,Novascotia,C10AX,Other lipid-modifying agents,<65,M,15.21,0.1,1.5,156,90
4,Novascotia,D01AC,Imidazole and triazole derivatives,<65,M,15.03,0.1,2.5,267,91
4,Novascotia,C02AC,Imidazoline receptor agonists,<65,M,**,**,**,**,92
4,Novascotia,M05BX,Other drugs affecting bone structure and mineralization,<65,M,**,**,**,*,93
4,Novascotia,C01DA,Organic nitrates,<65,M,14.66,0.1,2.8,302,94
4,Novascotia,M04AA,Preparations inhibiting uric acid production,<65,M,14.43,0.1,2.8,300,95
4,Novascotia,D07AC,"Corticosteroids, potent (group III)",<65,M,13.89,0.1,4.5,474,96
4,Novascotia,J01DB,First-generation cephalosporins,<65,M,13.69,0.1,6.3,668,97
4,Novascotia,G03BA,3-oxoandrosten (4) derivatives,<65,M,13.64,0.1,1.0,105,98
4,Novascotia,C01CA,Adrenergic and dopaminergic agents,<65,M,13.57,0.1,0.9,92,99
4,Novascotia,R01AD,Corticosteroids,<65,M,**,**,**,**,100
4,Novascotia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,"7,118.36",26.2,3.2,468,1
4,Novascotia,L04AA,Selective immunosuppressants,<65,F,"2,975.38",11.0,1.9,277,2
4,Novascotia,L04AX,Other immunosuppressants,<65,F,"1,473.04",5.4,1.3,189,3
4,Novascotia,L04AC,Interleukin inhibitors,<65,F,922.01,3.4,0.6,83,4
4,Novascotia,R07AX,Other respiratory system products,<65,F,**,**,**,*,5
4,Novascotia,J05AP,Antivirals for treatment of HCV infections,<65,F,**,**,**,**,6
4,Novascotia,A16AB,Enzymes,<65,F,**,**,**,*,7
4,Novascotia,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,F,**,**,**,**,8
4,Novascotia,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,**,**,**,*,9
4,Novascotia,A10AE,"Insulins and analogues for injection, long-acting",<65,F,494.25,1.8,5.2,754,10
4,Novascotia,N07BC,Drugs used in opioid dependence,<65,F,490.14,1.8,2.6,384,11
4,Novascotia,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,**,**,**,**,12
4,Novascotia,N02AA,Natural opium alkaloids,<65,F,397.21,1.5,7.9,"1,147",13
4,Novascotia,N05AX,Other antipsychotics,<65,F,348.54,1.3,2.2,315,14
4,Novascotia,N06AB,Selective serotonin reuptake inhibitors,<65,F,304.61,1.1,24.0,"3,502",15
4,Novascotia,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,*,16
4,Novascotia,N03AX,Other antiepileptics,<65,F,273.27,1.0,8.3,"1,206",17
4,Novascotia,N06AX,Other antidepressants,<65,F,269.97,1.0,18.0,"2,633",18
4,Novascotia,A05AA,Bile acids and derivatives,<65,F,263.72,1.0,0.2,28,19
4,Novascotia,A02BC,Proton pump inhibitors,<65,F,235.20,0.9,26.9,"3,921",20
4,Novascotia,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,F,228.47,0.8,0.1,8,21
4,Novascotia,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,224.44,0.8,4.1,605,22
4,Novascotia,N06BA,Centrally acting sympathomimetics,<65,F,192.66,0.7,3.3,483,23
4,Novascotia,B01AB,Heparin group,<65,F,178.71,0.7,0.7,107,24
4,Novascotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,168.79,0.6,2.1,310,25
4,Novascotia,L01XC,Monoclonal antibodies,<65,F,167.64,0.6,0.1,19,26
4,Novascotia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,**,**,**,**,27
4,Novascotia,R03BA,Glucocorticoids,<65,F,141.36,0.5,6.2,909,28
4,Novascotia,C10AA,HMG-CoA reductase inhibitors,<65,F,140.85,0.5,18.5,"2,697",29
4,Novascotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,130.50,0.5,5.5,796,30
4,Novascotia,H01CB,Somatostatin and analogues,<65,F,118.65,0.4,0.1,10,31
4,Novascotia,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,118.13,0.4,8.7,"1,268",32
4,Novascotia,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,F,**,**,**,*,33
4,Novascotia,N05BA,Benzodiazepine derivatives,<65,F,114.19,0.4,11.5,"1,684",34
4,Novascotia,L02AE,Gonadotropin-releasing hormone analogues,<65,F,113.32,0.4,0.3,49,35
4,Novascotia,H03AA,Thyroid hormones,<65,F,109.07,0.4,16.0,"2,333",36
4,Novascotia,L01EX,Other protein kinase inhibitors,<65,F,106.24,0.4,0.1,8,37
4,Novascotia,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,<65,F,**,**,**,*,38
4,Novascotia,L01AX,Other alkylating agents,<65,F,105.76,0.4,0.2,23,39
4,Novascotia,L01XJ,Hedgehog pathway inhibitors,<65,F,**,**,**,*,40
4,Novascotia,R03BB,Anticholinergics,<65,F,99.36,0.4,3.8,548,41
4,Novascotia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,96.05,0.4,1.9,280,42
4,Novascotia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,93.53,0.3,16.1,"2,344",43
4,Novascotia,N03AE,Benzodiazepine derivatives,<65,F,91.82,0.3,6.7,972,44
4,Novascotia,L01EJ,Janus-associated kinase (JAK) inhibitors,<65,F,**,**,**,*,45
4,Novascotia,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,F,**,**,**,*,46
4,Novascotia,A04AD,Other antiemetics,<65,F,78.15,0.3,0.9,127,47
4,Novascotia,N05CF,Benzodiazepine-related drugs,<65,F,77.86,0.3,8.0,"1,164",48
4,Novascotia,C09AA,"ACE inhibitors, plain",<65,F,76.95,0.3,10.1,"1,471",49
4,Novascotia,A07EC,Aminosalicylic acid and similar agents,<65,F,74.84,0.3,1.1,154,50
4,Novascotia,G04BD,Drugs for urinary frequency and incontinence,<65,F,70.73,0.3,3.0,439,51
4,Novascotia,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,69.98,0.3,6.0,871,52
4,Novascotia,M03BX,Other centrally acting agents,<65,F,68.81,0.3,6.5,946,53
4,Novascotia,C08CA,Dihydropyridine derivatives,<65,F,67.52,0.2,7.0,"1,020",54
4,Novascotia,A10BA,Biguanides,<65,F,60.57,0.2,10.6,"1,546",55
4,Novascotia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,**,**,**,**,56
4,Novascotia,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,**,**,**,**,57
4,Novascotia,C07AB,"Beta-blocking agents, selective",<65,F,53.20,0.2,8.1,"1,179",58
4,Novascotia,A07AA,Antibiotics,<65,F,51.92,0.2,1.6,237,59
4,Novascotia,H02AB,Glucocorticoids,<65,F,51.61,0.2,10.3,"1,507",60
4,Novascotia,V03AC,Iron-chelating agents,<65,F,**,**,**,*,61
4,Novascotia,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,49.83,0.2,6.0,882,62
4,Novascotia,A03FA,Propulsives,<65,F,48.71,0.2,3.5,518,63
4,Novascotia,B01AF,Direct factor Xa inhibitors,<65,F,46.04,0.2,0.8,115,64
4,Novascotia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,43.84,0.2,5.9,859,65
4,Novascotia,C05BA,Heparins or heparinoids for topical use,<65,F,**,**,**,**,66
4,Novascotia,A04AA,Serotonin (5HT3) antagonists,<65,F,38.85,0.1,1.2,169,67
4,Novascotia,L03AA,Colony-stimulating factors,<65,F,**,**,**,**,68
4,Novascotia,A10BB,Sulfonylureas,<65,F,37.26,0.1,5.1,739,69
4,Novascotia,M01AE,Propionic acid derivatives,<65,F,35.16,0.1,8.1,"1,187",70
4,Novascotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,34.77,0.1,0.9,126,71
4,Novascotia,L02BG,Aromatase inhibitors,<65,F,**,**,**,**,72
4,Novascotia,L01BA,Folic acid analogues,<65,F,32.99,0.1,1.8,267,73
4,Novascotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,31.24,0.1,3.8,554,74
4,Novascotia,N02AB,Phenylpiperidine derivatives,<65,F,30.99,0.1,0.4,52,75
4,Novascotia,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,30.87,0.1,2.6,375,76
4,Novascotia,J02AC,Triazole derivatives,<65,F,30.53,0.1,3.7,537,77
4,Novascotia,N03AF,Carboxamide derivatives,<65,F,30.48,0.1,0.8,112,78
4,Novascotia,C09BA,ACE inhibitors and diuretics,<65,F,30.12,0.1,2.6,379,79
4,Novascotia,C03CA,"Sulfonamides, plain",<65,F,29.78,0.1,4.4,637,80
4,Novascotia,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,81
4,Novascotia,N03AG,Fatty acid derivatives,<65,F,**,**,**,**,82
4,Novascotia,N04BC,Dopamine agonists,<65,F,28.02,0.1,0.9,128,83
4,Novascotia,N05AE,Indole derivatives,<65,F,**,**,**,**,84
4,Novascotia,G03AC,Progestogens,<65,F,**,**,**,**,85
4,Novascotia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,25.46,0.1,0.4,60,86
4,Novascotia,N02CC,Selective serotonin (5HT1) agonists,<65,F,25.20,0.1,1.5,226,87
4,Novascotia,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,F,24.31,0.1,0.3,43,88
4,Novascotia,R01AD,Corticosteroids,<65,F,**,**,**,**,89
4,Novascotia,D01AC,Imidazole and triazole derivatives,<65,F,23.04,0.1,2.9,425,90
4,Novascotia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,F,22.90,0.1,0.1,12,91
4,Novascotia,A02BA,H2-receptor antagonists,<65,F,22.69,0.1,3.1,451,92
4,Novascotia,A12BA,Potassium,<65,F,22.52,0.1,1.9,274,93
4,Novascotia,D07AC,"Corticosteroids, potent (group III)",<65,F,22.43,0.1,6.2,903,94
4,Novascotia,C07AA,"Beta-blocking agents, non-selective",<65,F,20.91,0.1,1.6,230,95
4,Novascotia,B03AC,"Iron, parenteral preparations",<65,F,20.61,0.1,0.3,39,96
4,Novascotia,N05CD,Benzodiazepine derivatives,<65,F,20.32,0.1,1.1,166,97
4,Novascotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,19.42,0.1,0.2,32,98
4,Novascotia,C03AA,"Thiazides, plain",<65,F,19.16,0.1,5.5,809,99
4,Novascotia,B02BX,Other systemic hemostatics,<65,F,**,**,**,*,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"25,812.87",9.1,1.1,"1,392",1
5,New Brunswick,S01LA,Antineovascularization agents,Total,Total,"16,522.53",5.8,1.3,"1,636",2
5,New Brunswick,L04AX,Other immunosuppressants,Total,Total,"11,596.58",4.1,0.6,754,3
5,New Brunswick,L04AA,Selective immunosuppressants,Total,Total,"10,751.89",3.8,0.9,"1,095",4
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,Total,Total,"10,175.93",3.6,0.2,206,5
5,New Brunswick,N05AX,Other antipsychotics,Total,Total,"8,356.00",2.9,5.5,"6,929",6
5,New Brunswick,N07BC,Drugs used in opioid dependence,Total,Total,"7,472.03",2.6,2.2,"2,716",7
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"6,179.34",2.2,5.6,"6,986",8
5,New Brunswick,L04AC,Interleukin inhibitors,Total,Total,"5,986.91",2.1,0.3,369,9
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"5,927.71",2.1,5.4,"6,744",10
5,New Brunswick,B01AF,Direct factor Xa inhibitors,Total,Total,"5,848.35",2.1,5.4,"6,712",11
5,New Brunswick,A02BC,Proton pump inhibitors,Total,Total,"5,811.03",2.0,41.0,"51,210",12
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"5,219.50",1.8,9.7,"12,129",13
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,Total,Total,"4,608.21",1.6,40.8,"51,076",14
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"4,385.59",1.5,20.3,"25,393",15
5,New Brunswick,J05AH,Neuraminidase inhibitors,Total,Total,"4,171.92",1.5,9.0,"11,284",16
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"4,016.57",1.4,0.3,334,17
5,New Brunswick,N02AA,Natural opium alkaloids,Total,Total,"3,887.41",1.4,9.3,"11,570",18
5,New Brunswick,N03AX,Other antiepileptics,Total,Total,"3,887.07",1.4,13.3,"16,650",19
5,New Brunswick,N06AX,Other antidepressants,Total,Total,"3,841.45",1.4,14.6,"18,220",20
5,New Brunswick,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,Total,"3,666.32",1.3,3.2,"3,961",21
5,New Brunswick,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,Total,"3,319.38",1.2,0.0,42,22
5,New Brunswick,R03BB,Anticholinergics,Total,Total,"3,299.03",1.2,8.4,"10,470",23
5,New Brunswick,R03BA,Glucocorticoids,Total,Total,"3,253.15",1.1,9.0,"11,219",24
5,New Brunswick,C08CA,Dihydropyridine derivatives,Total,Total,"3,145.11",1.1,18.2,"22,756",25
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"2,739.98",1.0,3.5,"4,435",26
5,New Brunswick,C09AA,"ACE inhibitors, plain",Total,Total,"2,679.72",0.9,22.0,"27,492",27
5,New Brunswick,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,Total,"2,444.05",0.9,0.1,68,28
5,New Brunswick,N05CF,Benzodiazepine-related drugs,Total,Total,"2,300.59",0.8,14.1,"17,682",29
5,New Brunswick,N05BA,Benzodiazepine derivatives,Total,Total,"2,224.27",0.8,18.3,"22,886",30
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"2,096.70",0.7,5.6,"6,955",31
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"2,095.09",0.7,0.1,126,32
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"2,089.22",0.7,2.0,"2,444",33
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,Total,Total,"2,005.83",0.7,0.0,5,34
5,New Brunswick,L01EX,Other protein kinase inhibitors,Total,Total,"1,923.95",0.7,0.1,83,35
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"1,902.57",0.7,0.5,581,36
5,New Brunswick,N06BA,Centrally acting sympathomimetics,Total,Total,"1,891.36",0.7,2.4,"3,060",37
5,New Brunswick,B03XA,Other antianemic preparations,Total,Total,"1,818.26",0.6,0.3,333,38
5,New Brunswick,C07AB,"Beta-blocking agents, selective",Total,Total,"1,799.34",0.6,19.8,"24,820",39
5,New Brunswick,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,Total,"1,734.82",0.6,0.0,37,40
5,New Brunswick,H03AA,Thyroid hormones,Total,Total,"1,728.09",0.6,18.3,"22,930",41
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,696.07",0.6,3.8,"4,805",42
5,New Brunswick,L02BB,Antiandrogens,Total,Total,"1,634.86",0.6,0.2,266,43
5,New Brunswick,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,Total,"1,633.30",0.6,0.0,46,44
5,New Brunswick,N03AE,Benzodiazepine derivatives,Total,Total,"1,596.06",0.6,5.9,"7,379",45
5,New Brunswick,L04AD,Calcineurin inhibitors,Total,Total,"1,548.97",0.5,0.4,493,46
5,New Brunswick,L02BX,Other hormone antagonists and related agents,Total,Total,"1,540.70",0.5,0.1,91,47
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"1,520.90",0.5,10.5,"13,134",48
5,New Brunswick,L03AA,Colony-stimulating factors,Total,Total,"1,516.68",0.5,0.2,230,49
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"1,514.61",0.5,1.3,"1,578",50
5,New Brunswick,C08DB,Benzothiazepine derivatives,Total,Total,"1,460.39",0.5,4.0,"4,976",51
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"1,400.37",0.5,1.3,"1,577",52
5,New Brunswick,C09BA,ACE inhibitors and diuretics,Total,Total,"1,345.61",0.5,6.0,"7,527",53
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,300.95",0.5,19.0,"23,754",54
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,283.96",0.5,1.1,"1,437",55
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"1,283.29",0.5,0.4,532,56
5,New Brunswick,H01CB,Somatostatin and analogues,Total,Total,"1,271.61",0.4,0.1,72,57
5,New Brunswick,A10BA,Biguanides,Total,Total,"1,057.31",0.4,14.8,"18,457",58
5,New Brunswick,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,Total,"1,056.62",0.4,0.0,20,59
5,New Brunswick,R07AX,Other respiratory system products,Total,Total,"1,041.36",0.4,0.0,5,60
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"1,019.91",0.4,8.5,"10,591",61
5,New Brunswick,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,Total,985.77,0.3,0.0,9,62
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,983.50,0.3,5.7,"7,081",63
5,New Brunswick,L03AB,Interferons,Total,Total,945.51,0.3,0.0,57,64
5,New Brunswick,A04AD,Other antiemetics,Total,Total,944.19,0.3,1.0,"1,189",65
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,910.30,0.3,7.8,"9,711",66
5,New Brunswick,S01EE,Prostaglandin analogues,Total,Total,875.49,0.3,2.6,"3,222",67
5,New Brunswick,S01ED,Beta-blocking agents,Total,Total,840.79,0.3,2.7,"3,413",68
5,New Brunswick,C03CA,"Sulfonamides, plain",Total,Total,811.17,0.3,10.0,"12,562",69
5,New Brunswick,N03AG,Fatty acid derivatives,Total,Total,796.62,0.3,1.8,"2,277",70
5,New Brunswick,M05BA,Bisphosphonates,Total,Total,779.28,0.3,5.1,"6,428",71
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,769.81,0.3,3.3,"4,155",72
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,769.47,0.3,1.3,"1,574",73
5,New Brunswick,B01AB,Heparin group,Total,Total,698.48,0.2,0.5,588,74
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,693.69,0.2,0.7,915,75
5,New Brunswick,R01AD,Corticosteroids,Total,Total,693.16,0.2,9.7,"12,121",76
5,New Brunswick,A09AA,Enzyme preparations,Total,Total,686.03,0.2,0.3,369,77
5,New Brunswick,A10BB,Sulfonylureas,Total,Total,633.26,0.2,6.2,"7,757",78
5,New Brunswick,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,Total,Total,620.22,0.2,0.0,22,79
5,New Brunswick,C01DA,Organic nitrates,Total,Total,604.30,0.2,4.9,"6,088",80
5,New Brunswick,C02AC,Imidazoline receptor agonists,Total,Total,598.63,0.2,1.2,"1,503",81
5,New Brunswick,M03BX,Other centrally acting agents,Total,Total,550.24,0.2,5.2,"6,520",82
5,New Brunswick,A16AX,Various alimentary tract and metabolism products,Total,Total,**,**,**,*,83
5,New Brunswick,N04BA,Dopa and dopa derivatives,Total,Total,531.60,0.2,1.1,"1,416",84
5,New Brunswick,N07BA,Drugs used in nicotine dependence,Total,Total,531.36,0.2,2.8,"3,440",85
5,New Brunswick,B01AE,Direct thrombin inhibitors,Total,Total,518.16,0.2,0.4,514,86
5,New Brunswick,N05CD,Benzodiazepine derivatives,Total,Total,517.89,0.2,3.0,"3,770",87
5,New Brunswick,L01XX,Other antineoplastic agents,Total,Total,516.67,0.2,0.2,200,88
5,New Brunswick,M01AH,Coxibs,Total,Total,481.81,0.2,5.1,"6,426",89
5,New Brunswick,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,Total,Total,473.95,0.2,0.0,9,90
5,New Brunswick,M01AE,Propionic acid derivatives,Total,Total,453.14,0.2,6.2,"7,769",91
5,New Brunswick,C10AX,Other lipid-modifying agents,Total,Total,451.28,0.2,3.3,"4,124",92
5,New Brunswick,J05AJ,Integrase inhibitors,Total,Total,442.55,0.2,0.1,66,93
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),Total,Total,440.95,0.2,1.5,"1,824",94
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,Total,Total,419.70,0.1,1.4,"1,720",95
5,New Brunswick,H01AC,Somatropin and somatropin agonists,Total,Total,418.90,0.1,0.0,30,96
5,New Brunswick,L01XC,Monoclonal antibodies,Total,Total,410.52,0.1,0.0,34,97
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",Total,Total,409.15,0.1,4.9,"6,119",98
5,New Brunswick,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,408.93,0.1,2.8,"3,470",99
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,405.32,0.1,0.2,306,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,"11,701.37",8.4,1.1,624,1
5,New Brunswick,S01LA,Antineovascularization agents,Total,M,"7,177.15",5.2,1.3,714,2
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,Total,M,"7,119.63",5.1,0.3,141,3
5,New Brunswick,L04AX,Other immunosuppressants,Total,M,"6,409.50",4.6,0.6,332,4
5,New Brunswick,N05AX,Other antipsychotics,Total,M,"5,553.20",4.0,6.5,"3,588",5
5,New Brunswick,N07BC,Drugs used in opioid dependence,Total,M,"4,327.69",3.1,2.9,"1,591",6
5,New Brunswick,L04AA,Selective immunosuppressants,Total,M,"3,957.47",2.8,0.9,477,7
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"3,278.23",2.4,0.5,268,8
5,New Brunswick,L04AC,Interleukin inhibitors,Total,M,"3,211.44",2.3,0.3,189,9
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"3,102.40",2.2,6.3,"3,450",10
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"3,088.07",2.2,10.4,"5,696",11
5,New Brunswick,B01AF,Direct factor Xa inhibitors,Total,M,"2,709.50",1.9,5.7,"3,117",12
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,579.63",1.9,5.1,"2,822",13
5,New Brunswick,A02BC,Proton pump inhibitors,Total,M,"2,364.01",1.7,38.1,"20,903",14
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,Total,M,"2,270.59",1.6,46.2,"25,372",15
5,New Brunswick,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,M,**,**,**,**,16
5,New Brunswick,J05AH,Neuraminidase inhibitors,Total,M,"2,167.48",1.6,8.0,"4,391",17
5,New Brunswick,N02AA,Natural opium alkaloids,Total,M,"2,040.77",1.5,9.0,"4,914",18
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"1,727.65",1.2,1.0,527,19
5,New Brunswick,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,M,"1,717.70",1.2,3.4,"1,881",20
5,New Brunswick,N03AX,Other antiepileptics,Total,M,"1,686.69",1.2,11.9,"6,551",21
5,New Brunswick,L02BB,Antiandrogens,Total,M,**,**,**,**,22
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,618.36",1.2,15.8,"8,695",23
5,New Brunswick,R03BB,Anticholinergics,Total,M,"1,577.42",1.1,8.9,"4,908",24
5,New Brunswick,L02BX,Other hormone antagonists and related agents,Total,M,**,**,**,**,25
5,New Brunswick,N06AX,Other antidepressants,Total,M,"1,537.97",1.1,11.9,"6,514",26
5,New Brunswick,C08CA,Dihydropyridine derivatives,Total,M,"1,395.08",1.0,18.3,"10,046",27
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,371.73",1.0,3.9,"2,139",28
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,Total,M,**,**,**,*,29
5,New Brunswick,R03BA,Glucocorticoids,Total,M,"1,295.91",0.9,7.9,"4,347",30
5,New Brunswick,C09AA,"ACE inhibitors, plain",Total,M,"1,273.56",0.9,24.6,"13,509",31
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"1,222.36",0.9,2.6,"1,434",32
5,New Brunswick,L01EX,Other protein kinase inhibitors,Total,M,"1,145.61",0.8,0.1,50,33
5,New Brunswick,N06BA,Centrally acting sympathomimetics,Total,M,"1,132.62",0.8,3.2,"1,754",34
5,New Brunswick,N05CF,Benzodiazepine-related drugs,Total,M,"1,068.66",0.8,13.0,"7,155",35
5,New Brunswick,L04AD,Calcineurin inhibitors,Total,M,957.78,0.7,0.6,310,36
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,913.65,0.7,0.7,379,37
5,New Brunswick,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,M,896.78,0.6,0.0,20,38
5,New Brunswick,N05BA,Benzodiazepine derivatives,Total,M,894.61,0.6,14.5,"7,947",39
5,New Brunswick,B03XA,Other antianemic preparations,Total,M,888.24,0.6,0.3,153,40
5,New Brunswick,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,M,879.16,0.6,0.0,25,41
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,842.77,0.6,1.6,873,42
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,Total,M,832.82,0.6,16.6,"9,106",43
5,New Brunswick,C07AB,"Beta-blocking agents, selective",Total,M,830.22,0.6,21.7,"11,899",44
5,New Brunswick,H01CB,Somatostatin and analogues,Total,M,794.56,0.6,0.1,40,45
5,New Brunswick,N03AE,Benzodiazepine derivatives,Total,M,771.03,0.6,5.2,"2,845",46
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,759.46,0.5,1.6,875,47
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,718.39,0.5,6.7,"3,681",48
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,715.44,0.5,0.1,36,49
5,New Brunswick,R07AX,Other respiratory system products,Total,M,**,**,**,*,50
5,New Brunswick,C09BA,ACE inhibitors and diuretics,Total,M,645.66,0.5,6.6,"3,620",51
5,New Brunswick,L03AA,Colony-stimulating factors,Total,M,595.13,0.4,0.1,81,52
5,New Brunswick,C08DB,Benzothiazepine derivatives,Total,M,593.84,0.4,3.7,"2,025",53
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,560.32,0.4,17.5,"9,592",54
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,554.74,0.4,9.0,"4,949",55
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,Total,M,544.97,0.4,1.1,596,56
5,New Brunswick,A10BA,Biguanides,Total,M,514.37,0.4,17.0,"9,314",57
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,Total,M,481.88,0.3,2.6,"1,413",58
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,466.83,0.3,8.6,"4,698",59
5,New Brunswick,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,M,**,**,**,*,60
5,New Brunswick,N03AG,Fatty acid derivatives,Total,M,436.29,0.3,2.2,"1,203",61
5,New Brunswick,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,M,**,**,**,**,62
5,New Brunswick,H03AA,Thyroid hormones,Total,M,421.22,0.3,10.4,"5,703",63
5,New Brunswick,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,393.64,0.3,5.3,"2,909",64
5,New Brunswick,A04AD,Other antiemetics,Total,M,372.02,0.3,0.9,469,65
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,369.60,0.3,1.4,754,66
5,New Brunswick,A09AA,Enzyme preparations,Total,M,361.92,0.3,0.3,178,67
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,346.99,0.2,4.0,"2,191",68
5,New Brunswick,S01ED,Beta-blocking agents,Total,M,338.20,0.2,2.6,"1,425",69
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,334.67,0.2,0.8,428,70
5,New Brunswick,J05AJ,Integrase inhibitors,Total,M,334.31,0.2,0.1,45,71
5,New Brunswick,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,Total,M,**,**,**,**,72
5,New Brunswick,B01AB,Heparin group,Total,M,324.53,0.2,0.5,248,73
5,New Brunswick,S01EE,Prostaglandin analogues,Total,M,319.50,0.2,2.3,"1,254",74
5,New Brunswick,A10BB,Sulfonylureas,Total,M,316.31,0.2,7.2,"3,972",75
5,New Brunswick,C03CA,"Sulfonamides, plain",Total,M,313.85,0.2,9.2,"5,045",76
5,New Brunswick,H01AC,Somatropin and somatropin agonists,Total,M,312.79,0.2,0.0,20,77
5,New Brunswick,A16AX,Various alimentary tract and metabolism products,Total,M,**,**,**,*,78
5,New Brunswick,N04BA,Dopa and dopa derivatives,Total,M,287.65,0.2,1.3,728,79
5,New Brunswick,J05AE,Protease inhibitors,Total,M,282.81,0.2,0.1,50,80
5,New Brunswick,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,Total,M,**,**,**,**,81
5,New Brunswick,B01AE,Direct thrombin inhibitors,Total,M,278.94,0.2,0.5,280,82
5,New Brunswick,C01DA,Organic nitrates,Total,M,276.11,0.2,5.7,"3,141",83
5,New Brunswick,R01AD,Corticosteroids,Total,M,274.39,0.2,8.1,"4,465",84
5,New Brunswick,C02AC,Imidazoline receptor agonists,Total,M,269.09,0.2,1.2,650,85
5,New Brunswick,N07BA,Drugs used in nicotine dependence,Total,M,265.38,0.2,3.1,"1,685",86
5,New Brunswick,L01XX,Other antineoplastic agents,Total,M,258.82,0.2,0.1,76,87
5,New Brunswick,C10AX,Other lipid-modifying agents,Total,M,241.56,0.2,4.0,"2,178",88
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,Total,M,241.29,0.2,1.8,"1,003",89
5,New Brunswick,M03BX,Other centrally acting agents,Total,M,237.97,0.2,4.5,"2,455",90
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,Total,M,237.42,0.2,0.1,64,91
5,New Brunswick,N03AF,Carboxamide derivatives,Total,M,219.58,0.2,1.2,642,92
5,New Brunswick,L01AX,Other alkylating agents,Total,M,**,**,**,**,93
5,New Brunswick,N05CD,Benzodiazepine derivatives,Total,M,203.89,0.1,2.8,"1,516",94
5,New Brunswick,M04AA,Preparations inhibiting uric acid production,Total,M,203.58,0.1,5.2,"2,856",95
5,New Brunswick,J05AX,Other antivirals,Total,M,**,**,**,**,96
5,New Brunswick,M01AE,Propionic acid derivatives,Total,M,191.41,0.1,5.6,"3,062",97
5,New Brunswick,M01AH,Coxibs,Total,M,189.93,0.1,4.3,"2,368",98
5,New Brunswick,B01AA,Vitamin K antagonists,Total,M,188.19,0.1,4.5,"2,470",99
5,New Brunswick,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,162.63,0.1,0.7,362,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,"14,111.50",9.8,1.1,768,1
5,New Brunswick,S01LA,Antineovascularization agents,Total,F,"9,345.38",6.5,1.3,922,2
5,New Brunswick,L04AA,Selective immunosuppressants,Total,F,"6,794.42",4.7,0.9,618,3
5,New Brunswick,L04AX,Other immunosuppressants,Total,F,"5,187.08",3.6,0.6,422,4
5,New Brunswick,A02BC,Proton pump inhibitors,Total,F,"3,446.98",2.4,43.2,"30,305",5
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"3,347.98",2.3,5.6,"3,921",6
5,New Brunswick,N07BC,Drugs used in opioid dependence,Total,F,"3,144.34",2.2,1.6,"1,125",7
5,New Brunswick,B01AF,Direct factor Xa inhibitors,Total,F,"3,138.85",2.2,5.1,"3,595",8
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"3,076.94",2.1,5.0,"3,536",9
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,Total,F,"3,056.30",2.1,0.1,65,10
5,New Brunswick,N05AX,Other antipsychotics,Total,F,"2,802.80",1.9,4.8,"3,341",11
5,New Brunswick,L04AC,Interleukin inhibitors,Total,F,"2,775.47",1.9,0.3,180,12
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,767.18",1.9,23.8,"16,696",13
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,Total,F,"2,337.62",1.6,36.6,"25,704",14
5,New Brunswick,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,F,**,**,**,**,15
5,New Brunswick,N06AX,Other antidepressants,Total,F,"2,303.34",1.6,16.7,"11,704",16
5,New Brunswick,N03AX,Other antiepileptics,Total,F,"2,200.37",1.5,14.4,"10,099",17
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"2,131.42",1.5,9.2,"6,433",18
5,New Brunswick,J05AH,Neuraminidase inhibitors,Total,F,"2,004.44",1.4,9.8,"6,893",19
5,New Brunswick,R03BA,Glucocorticoids,Total,F,"1,957.14",1.4,9.8,"6,871",20
5,New Brunswick,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,F,"1,948.62",1.3,3.0,"2,080",21
5,New Brunswick,N02AA,Natural opium alkaloids,Total,F,"1,846.64",1.3,9.5,"6,656",22
5,New Brunswick,C08CA,Dihydropyridine derivatives,Total,F,"1,750.03",1.2,18.1,"12,710",23
5,New Brunswick,R03BB,Anticholinergics,Total,F,"1,721.61",1.2,7.9,"5,562",24
5,New Brunswick,C09AA,"ACE inhibitors, plain",Total,F,"1,406.15",1.0,19.9,"13,983",25
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"1,379.64",1.0,0.1,90,26
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"1,378.32",1.0,4.7,"3,274",27
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,368.25",0.9,3.3,"2,296",28
5,New Brunswick,N05BA,Benzodiazepine derivatives,Total,F,"1,329.66",0.9,21.3,"14,939",29
5,New Brunswick,H03AA,Thyroid hormones,Total,F,"1,306.87",0.9,24.6,"17,227",30
5,New Brunswick,N05CF,Benzodiazepine-related drugs,Total,F,"1,231.93",0.9,15.0,"10,527",31
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,Total,F,"1,214.18",0.8,4.8,"3,392",32
5,New Brunswick,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,F,**,**,**,**,33
5,New Brunswick,C07AB,"Beta-blocking agents, selective",Total,F,969.12,0.7,18.4,"12,921",34
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,966.14,0.7,11.7,"8,184",35
5,New Brunswick,B03XA,Other antianemic preparations,Total,F,930.02,0.6,0.3,180,36
5,New Brunswick,L03AA,Colony-stimulating factors,Total,F,921.56,0.6,0.2,149,37
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,866.85,0.6,1.4,"1,010",38
5,New Brunswick,C08DB,Benzothiazepine derivatives,Total,F,865.97,0.6,4.2,"2,949",39
5,New Brunswick,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,F,838.05,0.6,0.0,17,40
5,New Brunswick,N03AE,Benzodiazepine derivatives,Total,F,825.02,0.6,6.5,"4,533",41
5,New Brunswick,L03AB,Interferons,Total,F,814.42,0.6,0.1,48,42
5,New Brunswick,L01EX,Other protein kinase inhibitors,Total,F,778.34,0.5,0.0,33,43
5,New Brunswick,N06BA,Centrally acting sympathomimetics,Total,F,758.73,0.5,1.9,"1,306",44
5,New Brunswick,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,F,754.14,0.5,0.0,21,45
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,752.36,0.5,5.8,"4,064",46
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,740.62,0.5,20.2,"14,161",47
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,Total,F,738.99,0.5,1.2,841,48
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,738.34,0.5,0.1,66,49
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,Total,F,**,**,**,*,50
5,New Brunswick,C09BA,ACE inhibitors and diuretics,Total,F,699.90,0.5,5.6,"3,906",51
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,671.85,0.5,1.0,705,52
5,New Brunswick,M05BA,Bisphosphonates,Total,F,645.08,0.4,7.5,"5,289",53
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,640.91,0.4,1.0,702,54
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,636.44,0.4,7.0,"4,889",55
5,New Brunswick,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,F,**,**,**,**,56
5,New Brunswick,L04AD,Calcineurin inhibitors,Total,F,591.19,0.4,0.3,183,57
5,New Brunswick,A04AD,Other antiemetics,Total,F,572.17,0.4,1.0,720,58
5,New Brunswick,S01EE,Prostaglandin analogues,Total,F,556.00,0.4,2.8,"1,968",59
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,553.08,0.4,8.4,"5,893",60
5,New Brunswick,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,F,**,**,**,**,61
5,New Brunswick,A10BA,Biguanides,Total,F,542.94,0.4,13.0,"9,143",62
5,New Brunswick,S01ED,Beta-blocking agents,Total,F,502.59,0.3,2.8,"1,988",63
5,New Brunswick,C03CA,"Sulfonamides, plain",Total,F,497.32,0.3,10.7,"7,517",64
5,New Brunswick,H01CB,Somatostatin and analogues,Total,F,477.05,0.3,0.0,32,65
5,New Brunswick,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,Total,F,476.79,0.3,0.0,17,66
5,New Brunswick,R01AD,Corticosteroids,Total,F,418.77,0.3,10.9,"7,656",67
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,399.87,0.3,1.2,820,68
5,New Brunswick,B01AB,Heparin group,Total,F,373.95,0.3,0.5,340,69
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,369.64,0.3,0.2,153,70
5,New Brunswick,N03AG,Fatty acid derivatives,Total,F,360.33,0.2,1.5,"1,074",71
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,359.02,0.2,0.7,487,72
5,New Brunswick,L02BG,Aromatase inhibitors,Total,F,339.03,0.2,1.2,846,73
5,New Brunswick,R07AX,Other respiratory system products,Total,F,**,**,**,*,74
5,New Brunswick,C02AC,Imidazoline receptor agonists,Total,F,329.54,0.2,1.2,853,75
5,New Brunswick,C01DA,Organic nitrates,Total,F,328.19,0.2,4.2,"2,947",76
5,New Brunswick,A09AA,Enzyme preparations,Total,F,324.11,0.2,0.3,191,77
5,New Brunswick,A10BB,Sulfonylureas,Total,F,316.95,0.2,5.4,"3,785",78
5,New Brunswick,N05CD,Benzodiazepine derivatives,Total,F,314.00,0.2,3.2,"2,254",79
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,312.39,0.2,0.0,16,80
5,New Brunswick,M03BX,Other centrally acting agents,Total,F,312.27,0.2,5.8,"4,065",81
5,New Brunswick,M01AH,Coxibs,Total,F,291.88,0.2,5.8,"4,058",82
5,New Brunswick,L03AX,Other immunostimulants,Total,F,286.59,0.2,0.0,24,83
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),Total,F,285.52,0.2,1.7,"1,186",84
5,New Brunswick,L01XC,Monoclonal antibodies,Total,F,282.41,0.2,0.0,24,85
5,New Brunswick,A05AA,Bile acids and derivatives,Total,F,280.08,0.2,0.2,148,86
5,New Brunswick,A12BA,Potassium,Total,F,271.35,0.2,4.4,"3,076",87
5,New Brunswick,N07BA,Drugs used in nicotine dependence,Total,F,265.98,0.2,2.5,"1,755",88
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",Total,F,263.22,0.2,5.6,"3,942",89
5,New Brunswick,M01AE,Propionic acid derivatives,Total,F,261.73,0.2,6.7,"4,707",90
5,New Brunswick,N06DA,Anticholinesterases,Total,F,259.72,0.2,1.6,"1,137",91
5,New Brunswick,L01XX,Other antineoplastic agents,Total,F,257.86,0.2,0.2,124,92
5,New Brunswick,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,257.44,0.2,3.1,"2,183",93
5,New Brunswick,A03FA,Propulsives,Total,F,246.59,0.2,4.7,"3,286",94
5,New Brunswick,L01BA,Folic acid analogues,Total,F,244.69,0.2,1.6,"1,121",95
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,244.45,0.2,0.2,116,96
5,New Brunswick,N04BA,Dopa and dopa derivatives,Total,F,243.95,0.2,1.0,688,97
5,New Brunswick,G03XB,Progesterone receptor modulators,Total,F,**,**,**,**,98
5,New Brunswick,B01AE,Direct thrombin inhibitors,Total,F,239.22,0.2,0.3,234,99
5,New Brunswick,A16AX,Various alimentary tract and metabolism products,Total,F,**,**,**,*,100
5,New Brunswick,S01LA,Antineovascularization agents,65+,Total,"15,118.09",9.7,1.8,"1,488",1
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,"9,316.64",6.0,0.6,511,2
5,New Brunswick,L04AX,Other immunosuppressants,65+,Total,"9,159.31",5.9,0.5,418,3
5,New Brunswick,B01AF,Direct factor Xa inhibitors,65+,Total,"5,409.81",3.5,7.4,"6,141",4
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"4,529.04",2.9,6.2,"5,119",5
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"3,967.39",2.6,5.9,"4,855",6
5,New Brunswick,A02BC,Proton pump inhibitors,65+,Total,"3,966.36",2.6,46.8,"38,626",7
5,New Brunswick,L04AA,Selective immunosuppressants,65+,Total,"3,680.94",2.4,0.5,454,8
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,65+,Total,"3,594.74",2.3,51.9,"42,818",9
5,New Brunswick,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,Total,"2,977.02",1.9,3.9,"3,231",10
5,New Brunswick,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,Total,**,**,**,**,11
5,New Brunswick,C08CA,Dihydropyridine derivatives,65+,Total,"2,670.35",1.7,24.0,"19,828",12
5,New Brunswick,R03BB,Anticholinergics,65+,Total,"2,586.53",1.7,9.8,"8,085",13
5,New Brunswick,L04AC,Interleukin inhibitors,65+,Total,"2,249.80",1.4,0.2,131,14
5,New Brunswick,J05AH,Neuraminidase inhibitors,65+,Total,"2,140.67",1.4,9.8,"8,119",15
5,New Brunswick,C09AA,"ACE inhibitors, plain",65+,Total,"2,092.60",1.3,27.6,"22,824",16
5,New Brunswick,R03BA,Glucocorticoids,65+,Total,"2,017.26",1.3,8.2,"6,774",17
5,New Brunswick,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,Total,"1,940.83",1.3,0.1,52,18
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,912.67",1.2,18.4,"15,175",19
5,New Brunswick,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,Total,**,**,**,**,20
5,New Brunswick,B03XA,Other antianemic preparations,65+,Total,"1,679.66",1.1,0.4,290,21
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"1,646.63",1.1,3.5,"2,884",22
5,New Brunswick,N02AA,Natural opium alkaloids,65+,Total,"1,609.57",1.0,9.8,"8,056",23
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"1,597.52",1.0,0.6,487,24
5,New Brunswick,L02BX,Other hormone antagonists and related agents,65+,Total,**,**,**,**,25
5,New Brunswick,N03AX,Other antiepileptics,65+,Total,"1,506.38",1.0,12.4,"10,275",26
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"1,493.63",1.0,2.1,"1,760",27
5,New Brunswick,L02BB,Antiandrogens,65+,Total,"1,469.98",0.9,0.3,249,28
5,New Brunswick,C07AB,"Beta-blocking agents, selective",65+,Total,"1,451.80",0.9,26.1,"21,512",29
5,New Brunswick,N06AX,Other antidepressants,65+,Total,"1,377.88",0.9,12.3,"10,147",30
5,New Brunswick,L01EX,Other protein kinase inhibitors,65+,Total,"1,373.15",0.9,0.1,64,31
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"1,311.03",0.8,14.0,"11,539",32
5,New Brunswick,C08DB,Benzothiazepine derivatives,65+,Total,"1,286.70",0.8,5.4,"4,446",33
5,New Brunswick,H03AA,Thyroid hormones,65+,Total,"1,254.44",0.8,23.0,"18,950",34
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"1,194.82",0.8,4.4,"3,641",35
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"1,184.89",0.8,1.6,"1,313",36
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"1,164.45",0.8,1.5,"1,210",37
5,New Brunswick,N05BA,Benzodiazepine derivatives,65+,Total,"1,092.51",0.7,18.9,"15,594",38
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"1,090.92",0.7,6.3,"5,216",39
5,New Brunswick,N05AX,Other antipsychotics,65+,Total,"1,086.75",0.7,3.4,"2,789",40
5,New Brunswick,L03AA,Colony-stimulating factors,65+,Total,"1,085.17",0.7,0.2,157,41
5,New Brunswick,C09BA,ACE inhibitors and diuretics,65+,Total,"1,059.65",0.7,7.4,"6,083",42
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,"1,034.89",0.7,0.5,422,43
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,966.72,0.6,0.1,51,44
5,New Brunswick,H01CB,Somatostatin and analogues,65+,Total,962.57,0.6,0.1,48,45
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,65+,Total,922.89,0.6,1.2,"1,023",46
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,850.57,0.5,7.5,"6,173",47
5,New Brunswick,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,Total,**,**,**,**,48
5,New Brunswick,S01EE,Prostaglandin analogues,65+,Total,815.72,0.5,3.7,"3,020",49
5,New Brunswick,N05CF,Benzodiazepine-related drugs,65+,Total,794.13,0.5,14.1,"11,673",50
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,786.73,0.5,10.6,"8,758",51
5,New Brunswick,S01ED,Beta-blocking agents,65+,Total,775.67,0.5,3.8,"3,158",52
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,746.59,0.5,18.5,"15,307",53
5,New Brunswick,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,Total,711.30,0.5,0.0,22,54
5,New Brunswick,M05BA,Bisphosphonates,65+,Total,697.54,0.4,7.1,"5,870",55
5,New Brunswick,A10BA,Biguanides,65+,Total,667.81,0.4,17.0,"14,074",56
5,New Brunswick,C03CA,"Sulfonamides, plain",65+,Total,641.04,0.4,13.0,"10,722",57
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,65+,Total,623.38,0.4,0.0,13,58
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,576.71,0.4,3.9,"3,238",59
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,567.06,0.4,1.5,"1,205",60
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,564.80,0.4,0.9,764,61
5,New Brunswick,C01DA,Organic nitrates,65+,Total,559.30,0.4,6.6,"5,443",62
5,New Brunswick,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,Total,**,**,**,**,63
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,511.15,0.3,0.0,41,64
5,New Brunswick,L04AD,Calcineurin inhibitors,65+,Total,500.08,0.3,0.2,185,65
5,New Brunswick,B01AE,Direct thrombin inhibitors,65+,Total,499.35,0.3,0.6,494,66
5,New Brunswick,N04BA,Dopa and dopa derivatives,65+,Total,478.77,0.3,1.6,"1,304",67
5,New Brunswick,R01AD,Corticosteroids,65+,Total,467.15,0.3,10.4,"8,569",68
5,New Brunswick,B01AB,Heparin group,65+,Total,456.06,0.3,0.5,443,69
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,447.31,0.3,5.3,"4,409",70
5,New Brunswick,A10BB,Sulfonylureas,65+,Total,444.01,0.3,7.2,"5,922",71
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,442.15,0.3,7.3,"6,041",72
5,New Brunswick,A04AD,Other antiemetics,65+,Total,425.98,0.3,0.8,696,73
5,New Brunswick,L01XX,Other antineoplastic agents,65+,Total,405.48,0.3,0.2,179,74
5,New Brunswick,N06DA,Anticholinesterases,65+,Total,397.01,0.3,2.1,"1,774",75
5,New Brunswick,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,65+,Total,**,**,**,**,76
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,382.54,0.2,0.4,290,77
5,New Brunswick,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,378.33,0.2,3.4,"2,823",78
5,New Brunswick,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,65+,Total,378.15,0.2,0.0,14,79
5,New Brunswick,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,355.13,0.2,3.7,"3,067",80
5,New Brunswick,A12BA,Potassium,65+,Total,334.27,0.2,4.7,"3,915",81
5,New Brunswick,B01AA,Vitamin K antagonists,65+,Total,331.75,0.2,5.2,"4,292",82
5,New Brunswick,C10AX,Other lipid-modifying agents,65+,Total,325.20,0.2,4.3,"3,568",83
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,65+,Total,318.57,0.2,1.7,"1,375",84
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),65+,Total,314.68,0.2,1.6,"1,321",85
5,New Brunswick,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,65+,Total,**,**,**,**,86
5,New Brunswick,L03AB,Interferons,65+,Total,308.08,0.2,0.0,19,87
5,New Brunswick,M01AH,Coxibs,65+,Total,304.98,0.2,5.8,"4,781",88
5,New Brunswick,L02BG,Aromatase inhibitors,65+,Total,293.58,0.2,0.9,729,89
5,New Brunswick,N05CD,Benzodiazepine derivatives,65+,Total,290.93,0.2,3.1,"2,586",90
5,New Brunswick,L01BA,Folic acid analogues,65+,Total,288.78,0.2,1.6,"1,343",91
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",65+,Total,286.61,0.2,5.9,"4,887",92
5,New Brunswick,N03AE,Benzodiazepine derivatives,65+,Total,278.02,0.2,3.9,"3,179",93
5,New Brunswick,M04AA,Preparations inhibiting uric acid production,65+,Total,277.86,0.2,4.9,"4,017",94
5,New Brunswick,H02AB,Glucocorticoids,65+,Total,270.58,0.2,10.7,"8,867",95
5,New Brunswick,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,246.32,0.2,6.4,"5,260",96
5,New Brunswick,B02BX,Other systemic hemostatics,65+,Total,**,**,**,**,97
5,New Brunswick,L01XC,Monoclonal antibodies,65+,Total,228.85,0.1,0.0,21,98
5,New Brunswick,A05AA,Bile acids and derivatives,65+,Total,226.62,0.1,0.2,140,99
5,New Brunswick,A03FA,Propulsives,65+,Total,222.94,0.1,4.4,"3,594",100
5,New Brunswick,S01LA,Antineovascularization agents,65+,M,"6,479.49",8.9,1.8,634,1
5,New Brunswick,L04AX,Other immunosuppressants,65+,M,"5,463.71",7.5,0.6,195,2
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,"3,903.50",5.3,0.6,210,3
5,New Brunswick,B01AF,Direct factor Xa inhibitors,65+,M,"2,473.25",3.4,8.1,"2,838",4
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"2,061.23",2.8,6.9,"2,422",5
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"2,024.40",2.8,6.3,"2,223",6
5,New Brunswick,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,M,**,**,**,**,7
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,65+,M,"1,735.30",2.4,59.9,"21,098",8
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,65+,M,**,**,**,**,9
5,New Brunswick,L02BX,Other hormone antagonists and related agents,65+,M,**,**,**,**,10
5,New Brunswick,A02BC,Proton pump inhibitors,65+,M,"1,513.20",2.1,44.0,"15,503",11
5,New Brunswick,L02BB,Antiandrogens,65+,M,**,**,**,**,12
5,New Brunswick,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,M,"1,416.89",1.9,4.4,"1,557",13
5,New Brunswick,L04AA,Selective immunosuppressants,65+,M,"1,223.44",1.7,0.6,203,14
5,New Brunswick,R03BB,Anticholinergics,65+,M,"1,221.94",1.7,10.8,"3,790",15
5,New Brunswick,C08CA,Dihydropyridine derivatives,65+,M,"1,141.53",1.6,24.2,"8,503",16
5,New Brunswick,J05AH,Neuraminidase inhibitors,65+,M,"1,127.11",1.5,8.8,"3,108",17
5,New Brunswick,L04AC,Interleukin inhibitors,65+,M,"1,104.66",1.5,0.2,62,18
5,New Brunswick,C09AA,"ACE inhibitors, plain",65+,M,948.99,1.3,31.3,"11,013",19
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,914.59,1.3,3.1,"1,076",20
5,New Brunswick,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,M,**,**,**,**,21
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,859.74,1.2,4.0,"1,407",22
5,New Brunswick,L01EX,Other protein kinase inhibitors,65+,M,836.75,1.1,0.1,40,23
5,New Brunswick,B03XA,Other antianemic preparations,65+,M,823.15,1.1,0.4,129,24
5,New Brunswick,R03BA,Glucocorticoids,65+,M,789.10,1.1,7.3,"2,586",25
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,729.95,1.0,0.9,302,26
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,65+,M,717.08,1.0,23.4,"8,242",27
5,New Brunswick,N02AA,Natural opium alkaloids,65+,M,706.75,1.0,9.4,"3,322",28
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,667.62,0.9,1.9,684,29
5,New Brunswick,H01CB,Somatostatin and analogues,65+,M,646.42,0.9,0.1,30,30
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,638.36,0.9,2.1,726,31
5,New Brunswick,C07AB,"Beta-blocking agents, selective",65+,M,635.31,0.9,28.6,"10,076",32
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,65+,M,596.28,0.8,13.7,"4,810",33
5,New Brunswick,N03AX,Other antiepileptics,65+,M,588.32,0.8,11.1,"3,907",34
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,65+,M,**,**,**,**,35
5,New Brunswick,C08DB,Benzothiazepine derivatives,65+,M,516.08,0.7,5.1,"1,792",36
5,New Brunswick,C09BA,ACE inhibitors and diuretics,65+,M,498.21,0.7,8.2,"2,883",37
5,New Brunswick,L03AA,Colony-stimulating factors,65+,M,490.21,0.7,0.2,64,38
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,488.87,0.7,5.9,"2,081",39
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,**,**,**,**,40
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,461.29,0.6,12.1,"4,258",41
5,New Brunswick,N05AX,Other antipsychotics,65+,M,455.05,0.6,3.1,"1,081",42
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,454.47,0.6,9.1,"3,202",43
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,**,**,**,**,44
5,New Brunswick,N06AX,Other antidepressants,65+,M,449.56,0.6,9.6,"3,364",45
5,New Brunswick,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,M,429.92,0.6,0.0,13,46
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,65+,M,389.27,0.5,1.2,434,47
5,New Brunswick,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,M,**,**,**,**,48
5,New Brunswick,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,**,**,**,**,49
5,New Brunswick,N05BA,Benzodiazepine derivatives,65+,M,366.50,0.5,14.2,"5,009",50
5,New Brunswick,L04AD,Calcineurin inhibitors,65+,M,338.73,0.5,0.4,126,51
5,New Brunswick,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,65+,M,**,**,**,**,52
5,New Brunswick,A10BA,Biguanides,65+,M,326.90,0.4,20.5,"7,201",53
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,65+,M,326.44,0.4,3.1,"1,080",54
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,317.82,0.4,17.6,"6,190",55
5,New Brunswick,S01ED,Beta-blocking agents,65+,M,306.31,0.4,3.7,"1,299",56
5,New Brunswick,H03AA,Thyroid hormones,65+,M,304.86,0.4,13.4,"4,701",57
5,New Brunswick,N05CF,Benzodiazepine-related drugs,65+,M,302.10,0.4,12.7,"4,461",58
5,New Brunswick,S01EE,Prostaglandin analogues,65+,M,294.66,0.4,3.3,"1,164",59
5,New Brunswick,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,65+,M,**,**,**,**,60
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,281.30,0.4,1.0,362,61
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,278.97,0.4,1.7,593,62
5,New Brunswick,B01AE,Direct thrombin inhibitors,65+,M,266.52,0.4,0.8,267,63
5,New Brunswick,N04BA,Dopa and dopa derivatives,65+,M,256.08,0.4,1.9,670,64
5,New Brunswick,C01DA,Organic nitrates,65+,M,251.24,0.3,7.8,"2,763",65
5,New Brunswick,L01XX,Other antineoplastic agents,65+,M,243.25,0.3,0.2,68,66
5,New Brunswick,C03CA,"Sulfonamides, plain",65+,M,237.05,0.3,12.0,"4,241",67
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,65+,M,223.02,0.3,0.2,58,68
5,New Brunswick,B01AB,Heparin group,65+,M,221.96,0.3,0.5,190,69
5,New Brunswick,A10BB,Sulfonylureas,65+,M,219.24,0.3,8.7,"3,062",70
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,200.24,0.3,7.8,"2,745",71
5,New Brunswick,R01AD,Corticosteroids,65+,M,190.11,0.3,9.2,"3,235",72
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,65+,M,181.13,0.2,2.3,814,73
5,New Brunswick,C10AX,Other lipid-modifying agents,65+,M,179.07,0.2,5.3,"1,880",74
5,New Brunswick,A04AD,Other antiemetics,65+,M,175.20,0.2,0.8,276,75
5,New Brunswick,M04AA,Preparations inhibiting uric acid production,65+,M,164.45,0.2,7.0,"2,478",76
5,New Brunswick,B01AA,Vitamin K antagonists,65+,M,159.11,0.2,6.3,"2,209",77
5,New Brunswick,J05AX,Other antivirals,65+,M,**,**,**,*,78
5,New Brunswick,N06DA,Anticholinesterases,65+,M,141.58,0.2,1.9,653,79
5,New Brunswick,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,M,**,**,**,*,80
5,New Brunswick,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,128.21,0.2,3.2,"1,120",81
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,122.58,0.2,3.6,"1,269",82
5,New Brunswick,N07BC,Drugs used in opioid dependence,65+,M,114.62,0.2,0.1,50,83
5,New Brunswick,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,113.46,0.2,0.8,293,84
5,New Brunswick,L01BA,Folic acid analogues,65+,M,112.12,0.2,1.5,515,85
5,New Brunswick,M01AH,Coxibs,65+,M,112.06,0.2,5.0,"1,765",86
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),65+,M,108.12,0.1,1.3,464,87
5,New Brunswick,H02AB,Glucocorticoids,65+,M,107.83,0.1,10.6,"3,730",88
5,New Brunswick,M05BA,Bisphosphonates,65+,M,107.49,0.1,2.7,954,89
5,New Brunswick,N05CD,Benzodiazepine derivatives,65+,M,106.49,0.1,2.8,989,90
5,New Brunswick,A12BA,Potassium,65+,M,105.81,0.1,3.5,"1,234",91
5,New Brunswick,L01AX,Other alkylating agents,65+,M,**,**,**,**,92
5,New Brunswick,D07AC,"Corticosteroids, potent (group III)",65+,M,104.75,0.1,7.3,"2,561",93
5,New Brunswick,C10AC,Bile acid sequestrants,65+,M,104.58,0.1,0.7,247,94
5,New Brunswick,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,101.39,0.1,0.3,104,95
5,New Brunswick,J05AJ,Integrase inhibitors,65+,M,**,**,**,**,96
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",65+,M,98.29,0.1,5.1,"1,794",97
5,New Brunswick,C03DA,Aldosterone antagonists,65+,M,98.26,0.1,3.9,"1,365",98
5,New Brunswick,L01XC,Monoclonal antibodies,65+,M,**,**,**,**,99
5,New Brunswick,A09AA,Enzyme preparations,65+,M,**,**,**,**,100
5,New Brunswick,S01LA,Antineovascularization agents,65+,F,"8,638.60",10.5,1.8,854,1
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,"5,413.14",6.6,0.6,301,2
5,New Brunswick,L04AX,Other immunosuppressants,65+,F,"3,695.60",4.5,0.5,223,3
5,New Brunswick,B01AF,Direct factor Xa inhibitors,65+,F,"2,936.55",3.6,7.0,"3,303",4
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,504.64",3.0,6.1,"2,896",5
5,New Brunswick,L04AA,Selective immunosuppressants,65+,F,"2,457.50",3.0,0.5,251,6
5,New Brunswick,A02BC,Proton pump inhibitors,65+,F,"2,453.16",3.0,48.8,"23,123",7
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"1,906.16",2.3,5.1,"2,433",8
5,New Brunswick,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,F,**,**,**,**,9
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,65+,F,"1,859.43",2.3,45.9,"21,720",10
5,New Brunswick,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,F,"1,560.14",1.9,3.5,"1,674",11
5,New Brunswick,C08CA,Dihydropyridine derivatives,65+,F,"1,528.82",1.9,23.9,"11,325",12
5,New Brunswick,R03BB,Anticholinergics,65+,F,"1,364.59",1.7,9.1,"4,295",13
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,65+,F,"1,316.39",1.6,21.9,"10,365",14
5,New Brunswick,R03BA,Glucocorticoids,65+,F,"1,228.16",1.5,8.8,"4,188",15
5,New Brunswick,L04AC,Interleukin inhibitors,65+,F,"1,145.15",1.4,0.1,69,16
5,New Brunswick,C09AA,"ACE inhibitors, plain",65+,F,"1,143.60",1.4,24.9,"11,811",17
5,New Brunswick,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,F,**,**,**,**,18
5,New Brunswick,J05AH,Neuraminidase inhibitors,65+,F,"1,013.57",1.2,10.6,"5,011",19
5,New Brunswick,H03AA,Thyroid hormones,65+,F,949.57,1.2,30.1,"14,249",20
5,New Brunswick,N06AX,Other antidepressants,65+,F,928.32,1.1,14.3,"6,783",21
5,New Brunswick,N03AX,Other antiepileptics,65+,F,918.05,1.1,13.4,"6,368",22
5,New Brunswick,N02AA,Natural opium alkaloids,65+,F,902.82,1.1,10.0,"4,734",23
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,65+,F,868.38,1.1,5.4,"2,561",24
5,New Brunswick,B03XA,Other antianemic preparations,65+,F,856.51,1.0,0.3,161,25
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,849.74,1.0,15.4,"7,281",26
5,New Brunswick,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,F,**,**,**,**,27
5,New Brunswick,C07AB,"Beta-blocking agents, selective",65+,F,816.48,1.0,24.2,"11,436",28
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,786.89,1.0,3.1,"1,477",29
5,New Brunswick,C08DB,Benzothiazepine derivatives,65+,F,770.62,0.9,5.6,"2,654",30
5,New Brunswick,N05BA,Benzodiazepine derivatives,65+,F,726.01,0.9,22.4,"10,585",31
5,New Brunswick,N05AX,Other antipsychotics,65+,F,631.70,0.8,3.6,"1,708",32
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,602.05,0.7,6.6,"3,135",33
5,New Brunswick,L03AA,Colony-stimulating factors,65+,F,594.96,0.7,0.2,93,34
5,New Brunswick,M05BA,Bisphosphonates,65+,F,590.05,0.7,10.4,"4,916",35
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,579.04,0.7,1.4,684,36
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,570.70,0.7,6.7,"3,196",37
5,New Brunswick,C09BA,ACE inhibitors and diuretics,65+,F,561.44,0.7,6.8,"3,200",38
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,546.53,0.7,1.2,587,39
5,New Brunswick,L01EX,Other protein kinase inhibitors,65+,F,536.40,0.7,0.1,24,40
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,65+,F,533.62,0.6,1.2,589,41
5,New Brunswick,S01EE,Prostaglandin analogues,65+,F,521.07,0.6,3.9,"1,856",42
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,**,**,**,**,43
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,496.82,0.6,1.1,526,44
5,New Brunswick,N05CF,Benzodiazepine-related drugs,65+,F,492.02,0.6,15.2,"7,212",45
5,New Brunswick,S01ED,Beta-blocking agents,65+,F,469.36,0.6,3.9,"1,859",46
5,New Brunswick,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,F,**,**,**,**,47
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,428.77,0.5,19.3,"9,117",48
5,New Brunswick,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,F,**,**,**,*,49
5,New Brunswick,C03CA,"Sulfonamides, plain",65+,F,404.00,0.5,13.7,"6,481",50
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,396.11,0.5,6.3,"2,971",51
5,New Brunswick,A10BA,Biguanides,65+,F,340.92,0.4,14.5,"6,873",52
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,324.74,0.4,6.6,"3,140",53
5,New Brunswick,H01CB,Somatostatin and analogues,65+,F,316.16,0.4,0.0,18,54
5,New Brunswick,C01DA,Organic nitrates,65+,F,308.06,0.4,5.7,"2,680",55
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,304.94,0.4,0.3,120,56
5,New Brunswick,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,65+,F,**,**,**,**,57
5,New Brunswick,L02BG,Aromatase inhibitors,65+,F,**,**,**,**,58
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,288.10,0.4,1.3,612,59
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,283.49,0.3,0.8,402,60
5,New Brunswick,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,F,281.38,0.3,0.0,9,61
5,New Brunswick,R01AD,Corticosteroids,65+,F,277.04,0.3,11.3,"5,334",62
5,New Brunswick,L03AB,Interferons,65+,F,**,**,**,**,63
5,New Brunswick,N06DA,Anticholinesterases,65+,F,255.43,0.3,2.4,"1,121",64
5,New Brunswick,A04AD,Other antiemetics,65+,F,250.77,0.3,0.9,420,65
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,241.91,0.3,7.0,"3,296",66
5,New Brunswick,B01AB,Heparin group,65+,F,234.10,0.3,0.5,253,67
5,New Brunswick,B01AE,Direct thrombin inhibitors,65+,F,232.82,0.3,0.5,227,68
5,New Brunswick,A12BA,Potassium,65+,F,228.46,0.3,5.7,"2,681",69
5,New Brunswick,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,226.91,0.3,4.1,"1,947",70
5,New Brunswick,A10BB,Sulfonylureas,65+,F,224.77,0.3,6.0,"2,860",71
5,New Brunswick,N04BA,Dopa and dopa derivatives,65+,F,222.69,0.3,1.3,634,72
5,New Brunswick,A05AA,Bile acids and derivatives,65+,F,213.39,0.3,0.2,107,73
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),65+,F,206.57,0.3,1.8,857,74
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,**,**,**,**,75
5,New Brunswick,M01AH,Coxibs,65+,F,192.91,0.2,6.4,"3,016",76
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",65+,F,188.32,0.2,6.5,"3,093",77
5,New Brunswick,N05CD,Benzodiazepine derivatives,65+,F,184.44,0.2,3.4,"1,597",78
5,New Brunswick,N03AE,Benzodiazepine derivatives,65+,F,182.05,0.2,4.5,"2,113",79
5,New Brunswick,L01BA,Folic acid analogues,65+,F,176.66,0.2,1.7,828,80
5,New Brunswick,B01AA,Vitamin K antagonists,65+,F,172.64,0.2,4.4,"2,083",81
5,New Brunswick,H02AB,Glucocorticoids,65+,F,162.75,0.2,10.8,"5,137",82
5,New Brunswick,L01XX,Other antineoplastic agents,65+,F,162.22,0.2,0.2,111,83
5,New Brunswick,L04AD,Calcineurin inhibitors,65+,F,161.35,0.2,0.1,59,84
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,65+,F,159.52,0.2,0.5,232,85
5,New Brunswick,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,155.18,0.2,7.1,"3,358",86
5,New Brunswick,C05BA,Heparins or heparinoids for topical use,65+,F,**,**,**,**,87
5,New Brunswick,A03FA,Propulsives,65+,F,152.11,0.2,5.0,"2,359",88
5,New Brunswick,B02BX,Other systemic hemostatics,65+,F,**,**,**,**,89
5,New Brunswick,C10AX,Other lipid-modifying agents,65+,F,146.12,0.2,3.6,"1,688",90
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,**,**,**,**,91
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,65+,F,137.44,0.2,1.2,561,92
5,New Brunswick,A07AA,Antibiotics,65+,F,136.35,0.2,1.7,821,93
5,New Brunswick,N04BC,Dopamine agonists,65+,F,135.30,0.2,1.4,666,94
5,New Brunswick,C07AA,"Beta-blocking agents, non-selective",65+,F,133.13,0.2,1.8,835,95
5,New Brunswick,C03AA,"Thiazides, plain",65+,F,133.04,0.2,9.8,"4,630",96
5,New Brunswick,L01XC,Monoclonal antibodies,65+,F,**,**,**,**,97
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,125.68,0.2,3.2,"1,498",98
5,New Brunswick,D01AC,Imidazole and triazole derivatives,65+,F,119.29,0.1,4.1,"1,950",99
5,New Brunswick,C08DA,Phenylalkylamine derivatives,65+,F,117.18,0.1,0.7,318,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,"16,496.23",12.9,2.1,881,1
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,<65,Total,"9,552.55",7.4,0.5,193,2
5,New Brunswick,N07BC,Drugs used in opioid dependence,<65,Total,"7,316.22",5.7,6.2,"2,638",3
5,New Brunswick,N05AX,Other antipsychotics,<65,Total,"7,269.25",5.7,9.7,"4,140",4
5,New Brunswick,L04AA,Selective immunosuppressants,<65,Total,"7,070.95",5.5,1.5,641,5
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"4,128.58",3.2,16.3,"6,913",6
5,New Brunswick,L04AC,Interleukin inhibitors,<65,Total,"3,737.11",2.9,0.6,238,7
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"3,505.42",2.7,0.7,293,8
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"2,472.86",1.9,24.1,"10,216",9
5,New Brunswick,N06AX,Other antidepressants,<65,Total,"2,463.43",1.9,19.0,"8,071",10
5,New Brunswick,L04AX,Other immunosuppressants,<65,Total,"2,437.27",1.9,0.8,336,11
5,New Brunswick,N03AX,Other antiepileptics,<65,Total,"2,380.69",1.9,15.0,"6,375",12
5,New Brunswick,N02AA,Natural opium alkaloids,<65,Total,"2,277.84",1.8,8.3,"3,514",13
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"2,211.95",1.7,5.0,"2,131",14
5,New Brunswick,J05AH,Neuraminidase inhibitors,<65,Total,"2,031.24",1.6,7.5,"3,165",15
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,"2,005.83",1.6,0.0,5,16
5,New Brunswick,A02BC,Proton pump inhibitors,<65,Total,"1,844.63",1.4,29.6,"12,582",17
5,New Brunswick,N06BA,Centrally acting sympathomimetics,<65,Total,"1,831.21",1.4,6.8,"2,884",18
5,New Brunswick,N05CF,Benzodiazepine-related drugs,<65,Total,"1,506.46",1.2,14.1,"6,009",19
5,New Brunswick,S01LA,Antineovascularization agents,<65,Total,"1,404.43",1.1,0.3,148,20
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"1,398.57",1.1,3.8,"1,624",21
5,New Brunswick,N03AE,Benzodiazepine derivatives,<65,Total,"1,318.03",1.0,9.9,"4,199",22
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"1,246.13",1.0,1.8,782,23
5,New Brunswick,R03BA,Glucocorticoids,<65,Total,"1,235.78",1.0,10.5,"4,444",24
5,New Brunswick,N05BA,Benzodiazepine derivatives,<65,Total,"1,131.76",0.9,17.2,"7,292",25
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"1,128.36",0.9,0.2,75,26
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,093.35",0.9,3.7,"1,551",27
5,New Brunswick,L04AD,Calcineurin inhibitors,<65,Total,"1,048.89",0.8,0.7,308,28
5,New Brunswick,R07AX,Other respiratory system products,<65,Total,"1,041.36",0.8,0.0,5,29
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,013.47",0.8,19.4,"8,258",30
5,New Brunswick,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,Total,922.00,0.7,0.1,24,31
5,New Brunswick,R03BB,Anticholinergics,<65,Total,712.50,0.6,5.6,"2,385",32
5,New Brunswick,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,Total,689.29,0.5,1.7,730,33
5,New Brunswick,L03AB,Interferons,<65,Total,637.43,0.5,0.1,38,34
5,New Brunswick,N03AG,Fatty acid derivatives,<65,Total,611.03,0.5,3.8,"1,627",35
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,595.58,0.5,1.6,684,36
5,New Brunswick,C09AA,"ACE inhibitors, plain",<65,Total,587.12,0.5,11.0,"4,668",37
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,577.77,0.5,10.7,"4,550",38
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,554.34,0.4,19.9,"8,446",39
5,New Brunswick,L01EX,Other protein kinase inhibitors,<65,Total,550.79,0.4,0.0,19,40
5,New Brunswick,A16AX,Various alimentary tract and metabolism products,<65,Total,**,**,**,*,41
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,536.12,0.4,6.3,"2,671",42
5,New Brunswick,C02AC,Imidazoline receptor agonists,<65,Total,531.65,0.4,2.4,"1,029",43
5,New Brunswick,A04AD,Other antiemetics,<65,Total,518.21,0.4,1.2,493,44
5,New Brunswick,A09AA,Enzyme preparations,<65,Total,505.49,0.4,0.4,170,45
5,New Brunswick,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,Total,503.23,0.4,0.0,16,46
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,<65,Total,501.25,0.4,2.7,"1,164",47
5,New Brunswick,C08CA,Dihydropyridine derivatives,<65,Total,474.75,0.4,6.9,"2,928",48
5,New Brunswick,H03AA,Thyroid hormones,<65,Total,473.66,0.4,9.4,"3,980",49
5,New Brunswick,B01AF,Direct factor Xa inhibitors,<65,Total,438.54,0.3,1.3,571,50
5,New Brunswick,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,Total,**,**,**,*,51
5,New Brunswick,L03AA,Colony-stimulating factors,<65,Total,431.52,0.3,0.2,73,52
5,New Brunswick,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,Total,**,**,**,**,53
5,New Brunswick,H01AC,Somatropin and somatropin agonists,<65,Total,418.90,0.3,0.1,30,54
5,New Brunswick,A10BA,Biguanides,<65,Total,389.50,0.3,10.3,"4,383",55
5,New Brunswick,M03BX,Other centrally acting agents,<65,Total,384.44,0.3,8.1,"3,437",56
5,New Brunswick,N07BA,Drugs used in nicotine dependence,<65,Total,365.15,0.3,5.3,"2,238",57
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,<65,Total,361.07,0.3,1.0,414,58
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,350.17,0.3,0.9,368,59
5,New Brunswick,C07AB,"Beta-blocking agents, selective",<65,Total,347.55,0.3,7.8,"3,308",60
5,New Brunswick,M01AE,Propionic acid derivatives,<65,Total,336.93,0.3,10.6,"4,502",61
5,New Brunswick,J05AJ,Integrase inhibitors,<65,Total,**,**,**,**,62
5,New Brunswick,R05CB,Mucolytics,<65,Total,310.56,0.2,0.1,31,63
5,New Brunswick,H01CB,Somatostatin and analogues,<65,Total,309.03,0.2,0.1,24,64
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,305.05,0.2,0.2,94,65
5,New Brunswick,N05AE,Indole derivatives,<65,Total,300.78,0.2,0.6,234,66
5,New Brunswick,C09BA,ACE inhibitors and diuretics,<65,Total,285.91,0.2,3.4,"1,443",67
5,New Brunswick,N03AF,Carboxamide derivatives,<65,Total,281.93,0.2,1.7,710,68
5,New Brunswick,N05BE,Azaspirodecanedione derivatives,<65,Total,266.17,0.2,1.0,444,69
5,New Brunswick,J05AE,Protease inhibitors,<65,Total,264.45,0.2,0.1,48,70
5,New Brunswick,J01GB,Other aminoglycosides,<65,Total,258.52,0.2,0.1,48,71
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,248.40,0.2,0.3,110,72
5,New Brunswick,B01AB,Heparin group,<65,Total,242.42,0.2,0.3,145,73
5,New Brunswick,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,Total,242.07,0.2,0.0,8,74
5,New Brunswick,G03XB,Progesterone receptor modulators,<65,Total,242.01,0.2,1.7,706,75
5,New Brunswick,N05CD,Benzodiazepine derivatives,<65,Total,226.96,0.2,2.8,"1,184",76
5,New Brunswick,R01AD,Corticosteroids,<65,Total,226.01,0.2,8.4,"3,552",77
5,New Brunswick,L03AX,Other immunostimulants,<65,Total,219.82,0.2,0.0,21,78
5,New Brunswick,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,Total,**,**,**,*,79
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,215.48,0.2,0.6,264,80
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,209.85,0.2,3.8,"1,594",81
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,202.41,0.2,0.9,369,82
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,195.12,0.2,0.2,79,83
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,193.10,0.2,2.2,917,84
5,New Brunswick,A10BB,Sulfonylureas,<65,Total,189.25,0.1,4.3,"1,835",85
5,New Brunswick,L01XC,Monoclonal antibodies,<65,Total,181.67,0.1,0.0,13,86
5,New Brunswick,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,179.20,0.1,0.4,183,87
5,New Brunswick,M01AH,Coxibs,<65,Total,176.84,0.1,3.9,"1,645",88
5,New Brunswick,C08DB,Benzothiazepine derivatives,<65,Total,173.11,0.1,1.2,528,89
5,New Brunswick,C03CA,"Sulfonamides, plain",<65,Total,170.12,0.1,4.3,"1,840",90
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,169.99,0.1,0.0,9,91
5,New Brunswick,L02BB,Antiandrogens,<65,Total,164.89,0.1,0.0,17,92
5,New Brunswick,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,**,**,**,**,93
5,New Brunswick,L01AX,Other alkylating agents,<65,Total,**,**,**,**,94
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,160.32,0.1,2.4,"1,032",95
5,New Brunswick,A03FA,Propulsives,<65,Total,152.76,0.1,3.3,"1,415",96
5,New Brunswick,J02AC,Triazole derivatives,<65,Total,150.91,0.1,2.5,"1,049",97
5,New Brunswick,G02BA,Intrauterine contraceptives,<65,Total,**,**,**,**,98
5,New Brunswick,B03XA,Other antianemic preparations,<65,Total,138.60,0.1,0.1,43,99
5,New Brunswick,N05AF,Thioxanthene derivatives,<65,Total,137.05,0.1,0.5,231,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,"7,797.87",11.8,2.1,414,1
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,<65,M,**,**,**,**,2
5,New Brunswick,N05AX,Other antipsychotics,<65,M,"5,098.15",7.7,12.7,"2,507",3
5,New Brunswick,N07BC,Drugs used in opioid dependence,<65,M,"4,213.07",6.4,7.8,"1,541",4
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,**,**,**,**,5
5,New Brunswick,L04AA,Selective immunosuppressants,<65,M,"2,734.03",4.1,1.4,274,6
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"2,599.21",3.9,18.4,"3,615",7
5,New Brunswick,L04AC,Interleukin inhibitors,<65,M,"2,106.78",3.2,0.6,127,8
5,New Brunswick,N02AA,Natural opium alkaloids,<65,M,"1,334.03",2.0,8.1,"1,592",9
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,<65,M,**,**,**,*,10
5,New Brunswick,N06BA,Centrally acting sympathomimetics,<65,M,"1,114.67",1.7,8.6,"1,687",11
5,New Brunswick,N03AX,Other antiepileptics,<65,M,"1,098.37",1.7,13.4,"2,644",12
5,New Brunswick,N06AX,Other antidepressants,<65,M,"1,088.41",1.6,16.0,"3,150",13
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"1,041.17",1.6,5.2,"1,028",14
5,New Brunswick,J05AH,Neuraminidase inhibitors,<65,M,"1,040.37",1.6,6.5,"1,283",15
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,<65,M,"1,022.07",1.5,19.7,"3,885",16
5,New Brunswick,L04AX,Other immunosuppressants,<65,M,945.80,1.4,0.7,137,17
5,New Brunswick,A02BC,Proton pump inhibitors,<65,M,850.80,1.3,27.4,"5,400",18
5,New Brunswick,N05CF,Benzodiazepine-related drugs,<65,M,766.56,1.2,13.7,"2,694",19
5,New Brunswick,R07AX,Other respiratory system products,<65,M,**,**,**,*,20
5,New Brunswick,S01LA,Antineovascularization agents,<65,M,697.65,1.1,0.4,80,21
5,New Brunswick,N03AE,Benzodiazepine derivatives,<65,M,675.06,1.0,9.0,"1,779",22
5,New Brunswick,L04AD,Calcineurin inhibitors,<65,M,619.05,0.9,0.9,184,23
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,555.23,0.8,3.0,599,24
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,<65,M,535.29,0.8,21.7,"4,274",25
5,New Brunswick,N05BA,Benzodiazepine derivatives,<65,M,528.11,0.8,14.9,"2,938",26
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,511.99,0.8,3.7,732,27
5,New Brunswick,R03BA,Glucocorticoids,<65,M,506.81,0.8,9.0,"1,761",28
5,New Brunswick,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,M,449.24,0.7,0.1,12,29
5,New Brunswick,R03BB,Anticholinergics,<65,M,355.48,0.5,5.7,"1,118",30
5,New Brunswick,N03AG,Fatty acid derivatives,<65,M,344.62,0.5,4.6,901,31
5,New Brunswick,C09AA,"ACE inhibitors, plain",<65,M,324.57,0.5,12.7,"2,496",32
5,New Brunswick,H01AC,Somatropin and somatropin agonists,<65,M,312.79,0.5,0.1,20,33
5,New Brunswick,A16AX,Various alimentary tract and metabolism products,<65,M,**,**,**,*,34
5,New Brunswick,L01EX,Other protein kinase inhibitors,<65,M,308.86,0.5,0.1,10,35
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,307.77,0.5,1.8,358,36
5,New Brunswick,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,M,**,**,**,*,37
5,New Brunswick,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,M,**,**,**,*,38
5,New Brunswick,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,M,300.82,0.5,1.6,324,39
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,266.59,0.4,9.9,"1,953",40
5,New Brunswick,A09AA,Enzyme preparations,<65,M,**,**,**,**,41
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,263.92,0.4,2.4,479,42
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,**,**,**,**,43
5,New Brunswick,C02AC,Imidazoline receptor agonists,<65,M,254.31,0.4,2.7,535,44
5,New Brunswick,C08CA,Dihydropyridine derivatives,<65,M,253.55,0.4,7.8,"1,543",45
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,242.50,0.4,17.3,"3,402",46
5,New Brunswick,B01AF,Direct factor Xa inhibitors,<65,M,236.24,0.4,1.4,279,47
5,New Brunswick,J05AJ,Integrase inhibitors,<65,M,**,**,**,**,48
5,New Brunswick,J05AE,Protease inhibitors,<65,M,235.03,0.4,0.2,42,49
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,224.41,0.3,4.7,922,50
5,New Brunswick,A04AD,Other antiemetics,<65,M,196.81,0.3,1.0,193,51
5,New Brunswick,C07AB,"Beta-blocking agents, selective",<65,M,194.91,0.3,9.3,"1,823",52
5,New Brunswick,A10BA,Biguanides,<65,M,187.48,0.3,10.7,"2,113",53
5,New Brunswick,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,183.70,0.3,0.4,77,54
5,New Brunswick,N07BA,Drugs used in nicotine dependence,<65,M,182.19,0.3,5.5,"1,082",55
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,175.14,0.3,1.0,189,56
5,New Brunswick,N03AF,Carboxamide derivatives,<65,M,172.61,0.3,2.0,387,57
5,New Brunswick,L02BB,Antiandrogens,<65,M,**,**,**,**,58
5,New Brunswick,M03BX,Other centrally acting agents,<65,M,164.79,0.2,6.4,"1,250",59
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,<65,M,155.69,0.2,0.8,162,60
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,<65,M,155.45,0.2,1.7,333,61
5,New Brunswick,H01CB,Somatostatin and analogues,<65,M,148.14,0.2,0.1,10,62
5,New Brunswick,C09BA,ACE inhibitors and diuretics,<65,M,147.45,0.2,3.7,737,63
5,New Brunswick,M01AE,Propionic acid derivatives,<65,M,138.89,0.2,8.6,"1,686",64
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,<65,M,**,**,**,**,65
5,New Brunswick,N05AE,Indole derivatives,<65,M,127.51,0.2,0.5,101,66
5,New Brunswick,J01GB,Other aminoglycosides,<65,M,126.83,0.2,0.1,28,67
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,121.10,0.2,0.8,149,68
5,New Brunswick,N05BE,Azaspirodecanedione derivatives,<65,M,118.52,0.2,0.9,169,69
5,New Brunswick,H03AA,Thyroid hormones,<65,M,116.36,0.2,5.1,"1,002",70
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,<65,M,115.74,0.2,4.4,864,71
5,New Brunswick,R05CB,Mucolytics,<65,M,114.32,0.2,0.1,12,72
5,New Brunswick,L01AX,Other alkylating agents,<65,M,**,**,**,**,73
5,New Brunswick,L03AA,Colony-stimulating factors,<65,M,104.92,0.2,0.1,17,74
5,New Brunswick,B01AB,Heparin group,<65,M,102.57,0.2,0.3,58,75
5,New Brunswick,N05CD,Benzodiazepine derivatives,<65,M,97.40,0.1,2.7,527,76
5,New Brunswick,A10BB,Sulfonylureas,<65,M,97.08,0.1,4.6,910,77
5,New Brunswick,N05AF,Thioxanthene derivatives,<65,M,94.88,0.1,0.8,150,78
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,**,**,**,**,79
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,93.45,0.1,3.5,691,80
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,90.63,0.1,0.8,161,81
5,New Brunswick,N05AD,Butyrophenone derivatives,<65,M,87.62,0.1,1.1,211,82
5,New Brunswick,N07BB,Drugs used in alcohol dependence,<65,M,84.54,0.1,0.5,95,83
5,New Brunswick,R01AD,Corticosteroids,<65,M,84.28,0.1,6.3,"1,230",84
5,New Brunswick,L03AB,Interferons,<65,M,**,**,**,**,85
5,New Brunswick,V03AC,Iron-chelating agents,<65,M,**,**,**,*,86
5,New Brunswick,N07XX,Other nervous system drugs,<65,M,79.66,0.1,0.1,19,87
5,New Brunswick,M01AH,Coxibs,<65,M,77.87,0.1,3.1,603,88
5,New Brunswick,C08DB,Benzothiazepine derivatives,<65,M,77.76,0.1,1.2,233,89
5,New Brunswick,C03CA,"Sulfonamides, plain",<65,M,76.80,0.1,4.1,804,90
5,New Brunswick,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,**,**,**,**,91
5,New Brunswick,N04AC,Ethers of tropine or tropine derivatives,<65,M,70.09,0.1,2.3,455,92
5,New Brunswick,B03XA,Other antianemic preparations,<65,M,65.09,0.1,0.1,24,93
5,New Brunswick,C10AX,Other lipid-modifying agents,<65,M,62.49,0.1,1.5,298,94
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,<65,M,60.17,0.1,1.0,189,95
5,New Brunswick,A07AA,Antibiotics,<65,M,60.13,0.1,0.9,182,96
5,New Brunswick,A03FA,Propulsives,<65,M,58.28,0.1,2.5,488,97
5,New Brunswick,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,M,**,**,**,*,98
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,**,**,**,*,99
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,53.71,0.1,1.4,285,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,"8,698.36",14.0,2.0,467,1
5,New Brunswick,L04AA,Selective immunosuppressants,<65,F,"4,336.93",7.0,1.6,367,2
5,New Brunswick,N07BC,Drugs used in opioid dependence,<65,F,"3,103.15",5.0,4.8,"1,097",3
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,<65,F,**,**,**,**,4
5,New Brunswick,N05AX,Other antipsychotics,<65,F,"2,171.10",3.5,7.2,"1,633",5
5,New Brunswick,L04AC,Interleukin inhibitors,<65,F,"1,630.32",2.6,0.5,111,6
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"1,529.37",2.5,14.5,"3,298",7
5,New Brunswick,L04AX,Other immunosuppressants,<65,F,"1,491.48",2.4,0.9,199,8
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,450.79",2.3,27.8,"6,331",9
5,New Brunswick,N06AX,Other antidepressants,<65,F,"1,375.02",2.2,21.6,"4,921",10
5,New Brunswick,N03AX,Other antiepileptics,<65,F,"1,282.32",2.1,16.4,"3,731",11
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"1,170.78",1.9,4.8,"1,103",12
5,New Brunswick,A02BC,Proton pump inhibitors,<65,F,993.83,1.6,31.5,"7,182",13
5,New Brunswick,J05AH,Neuraminidase inhibitors,<65,F,990.87,1.6,8.3,"1,882",14
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,982.21,1.6,1.3,303,15
5,New Brunswick,N02AA,Natural opium alkaloids,<65,F,943.82,1.5,8.4,"1,922",16
5,New Brunswick,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,**,**,**,**,17
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,843.34,1.4,4.5,"1,025",18
5,New Brunswick,N05CF,Benzodiazepine-related drugs,<65,F,739.90,1.2,14.5,"3,315",19
5,New Brunswick,R03BA,Glucocorticoids,<65,F,728.97,1.2,11.8,"2,683",20
5,New Brunswick,N06BA,Centrally acting sympathomimetics,<65,F,716.54,1.1,5.2,"1,197",21
5,New Brunswick,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,**,**,**,*,22
5,New Brunswick,S01LA,Antineovascularization agents,<65,F,706.78,1.1,0.3,68,23
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,**,**,**,**,24
5,New Brunswick,N03AE,Benzodiazepine derivatives,<65,F,642.97,1.0,10.6,"2,420",25
5,New Brunswick,N05BA,Benzodiazepine derivatives,<65,F,603.66,1.0,19.1,"4,354",26
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,581.36,0.9,3.6,819,27
5,New Brunswick,L03AB,Interferons,<65,F,**,**,**,**,28
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,<65,F,478.18,0.8,17.5,"3,984",29
5,New Brunswick,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,F,472.76,0.8,0.1,12,30
5,New Brunswick,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,F,**,**,**,**,31
5,New Brunswick,L04AD,Calcineurin inhibitors,<65,F,429.84,0.7,0.5,124,32
5,New Brunswick,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,F,388.48,0.6,1.8,406,33
5,New Brunswick,H03AA,Thyroid hormones,<65,F,357.30,0.6,13.1,"2,978",34
5,New Brunswick,R03BB,Anticholinergics,<65,F,357.02,0.6,5.6,"1,267",35
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,<65,F,345.80,0.6,3.6,831,36
5,New Brunswick,R07AX,Other respiratory system products,<65,F,**,**,**,*,37
5,New Brunswick,L03AA,Colony-stimulating factors,<65,F,326.60,0.5,0.2,56,38
5,New Brunswick,A04AD,Other antiemetics,<65,F,321.40,0.5,1.3,300,39
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,311.84,0.5,22.1,"5,044",40
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,311.71,0.5,7.7,"1,749",41
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,311.17,0.5,11.4,"2,597",42
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,287.81,0.5,1.4,326,43
5,New Brunswick,C02AC,Imidazoline receptor agonists,<65,F,277.35,0.4,2.2,494,44
5,New Brunswick,N03AG,Fatty acid derivatives,<65,F,266.41,0.4,3.2,726,45
5,New Brunswick,C09AA,"ACE inhibitors, plain",<65,F,262.55,0.4,9.5,"2,172",46
5,New Brunswick,L01EX,Other protein kinase inhibitors,<65,F,241.93,0.4,0.0,9,47
5,New Brunswick,G03XB,Progesterone receptor modulators,<65,F,**,**,**,**,48
5,New Brunswick,A09AA,Enzyme preparations,<65,F,**,**,**,**,49
5,New Brunswick,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,*,50
5,New Brunswick,C08CA,Dihydropyridine derivatives,<65,F,221.20,0.4,6.1,"1,385",51
5,New Brunswick,M03BX,Other centrally acting agents,<65,F,219.65,0.4,9.6,"2,187",52
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,<65,F,205.37,0.3,1.1,252,53
5,New Brunswick,B01AF,Direct factor Xa inhibitors,<65,F,202.30,0.3,1.3,292,54
5,New Brunswick,A10BA,Biguanides,<65,F,202.02,0.3,10.0,"2,270",55
5,New Brunswick,M01AE,Propionic acid derivatives,<65,F,198.04,0.3,12.4,"2,816",56
5,New Brunswick,R05CB,Mucolytics,<65,F,196.24,0.3,0.1,19,57
5,New Brunswick,L03AX,Other immunostimulants,<65,F,**,**,**,**,58
5,New Brunswick,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,F,**,**,**,**,59
5,New Brunswick,N07BA,Drugs used in nicotine dependence,<65,F,182.96,0.3,5.1,"1,156",60
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,181.66,0.3,3.8,868,61
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,175.02,0.3,0.8,179,62
5,New Brunswick,N05AE,Indole derivatives,<65,F,173.27,0.3,0.6,133,63
5,New Brunswick,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,F,**,**,**,*,64
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,<65,F,**,**,**,**,65
5,New Brunswick,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,**,**,**,**,66
5,New Brunswick,H01CB,Somatostatin and analogues,<65,F,160.89,0.3,0.1,14,67
5,New Brunswick,C07AB,"Beta-blocking agents, selective",<65,F,152.64,0.2,6.5,"1,485",68
5,New Brunswick,L01XC,Monoclonal antibodies,<65,F,**,**,**,**,69
5,New Brunswick,N05BE,Azaspirodecanedione derivatives,<65,F,147.65,0.2,1.2,275,70
5,New Brunswick,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,71
5,New Brunswick,R01AD,Corticosteroids,<65,F,141.74,0.2,10.2,"2,322",72
5,New Brunswick,B01AB,Heparin group,<65,F,139.85,0.2,0.4,87,73
5,New Brunswick,C09BA,ACE inhibitors and diuretics,<65,F,138.46,0.2,3.1,706,74
5,New Brunswick,G03AC,Progestogens,<65,F,**,**,**,**,75
5,New Brunswick,J01GB,Other aminoglycosides,<65,F,131.70,0.2,0.1,20,76
5,New Brunswick,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,F,**,**,**,*,77
5,New Brunswick,N05CD,Benzodiazepine derivatives,<65,F,129.56,0.2,2.9,657,78
5,New Brunswick,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,126.24,0.2,0.5,115,79
5,New Brunswick,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,F,**,**,**,*,80
5,New Brunswick,J02AC,Triazole derivatives,<65,F,120.66,0.2,4.1,928,81
5,New Brunswick,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,116.40,0.2,4.0,903,82
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,**,**,**,**,83
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,111.78,0.2,0.9,208,84
5,New Brunswick,N03AF,Carboxamide derivatives,<65,F,109.32,0.2,1.4,323,85
5,New Brunswick,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,**,**,**,**,86
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,106.60,0.2,3.3,747,87
5,New Brunswick,H01AC,Somatropin and somatropin agonists,<65,F,106.11,0.2,0.0,10,88
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,**,**,**,**,89
5,New Brunswick,J05AJ,Integrase inhibitors,<65,F,**,**,**,**,90
5,New Brunswick,M01AH,Coxibs,<65,F,98.97,0.2,4.6,"1,042",91
5,New Brunswick,L01XX,Other antineoplastic agents,<65,F,95.63,0.2,0.1,13,92
5,New Brunswick,C08DB,Benzothiazepine derivatives,<65,F,95.35,0.2,1.3,295,93
5,New Brunswick,A03FA,Propulsives,<65,F,94.48,0.2,4.1,927,94
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,94.38,0.2,0.5,115,95
5,New Brunswick,C03CA,"Sulfonamides, plain",<65,F,93.32,0.1,4.5,"1,036",96
5,New Brunswick,A10BB,Sulfonylureas,<65,F,92.17,0.1,4.1,925,97
5,New Brunswick,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,<65,F,**,**,**,*,98
5,New Brunswick,N02CC,Selective serotonin (5HT1) agonists,<65,F,83.21,0.1,1.9,422,99
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),<65,F,78.95,0.1,1.4,329,100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"298,242.04",6.9,0.5,"14,284",1
6,Quebec,S01LA,Antineovascularization agents,Total,Total,"218,525.42",5.0,0.7,"22,061",2
6,Quebec,L04AA,Selective immunosuppressants,Total,Total,"134,648.04",3.1,0.5,"14,616",3
6,Quebec,B01AF,Direct factor Xa inhibitors,Total,Total,"124,006.30",2.8,5.2,"158,931",4
6,Quebec,C10AA,HMG-CoA reductase inhibitors,Total,Total,"111,170.53",2.6,31.9,"984,591",5
6,Quebec,A02BC,Proton pump inhibitors,Total,Total,"99,353.08",2.3,28.5,"879,655",6
6,Quebec,L04AX,Other immunosuppressants,Total,Total,"96,386.91",2.2,0.2,"7,548",7
6,Quebec,N05AX,Other antipsychotics,Total,Total,"89,604.58",2.1,2.7,"82,906",8
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"79,067.77",1.8,4.7,"146,123",9
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"72,640.94",1.7,6.1,"188,536",10
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"72,262.48",1.7,0.3,"9,454",11
6,Quebec,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,Total,"66,102.14",1.5,0.0,"1,011",12
6,Quebec,N03AX,Other antiepileptics,Total,Total,"65,173.41",1.5,8.5,"261,180",13
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"63,262.68",1.5,2.9,"89,730",14
6,Quebec,L04AC,Interleukin inhibitors,Total,Total,"62,134.80",1.4,0.1,"3,746",15
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"58,253.01",1.3,2.7,"82,032",16
6,Quebec,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,Total,"57,649.35",1.3,2.7,"82,318",17
6,Quebec,C08CA,Dihydropyridine derivatives,Total,Total,"56,614.75",1.3,15.3,"471,413",18
6,Quebec,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,Total,"53,856.70",1.2,0.0,"1,319",19
6,Quebec,N06BA,Centrally acting sympathomimetics,Total,Total,"53,545.11",1.2,3.2,"99,610",20
6,Quebec,A11CC,Vitamin D and analogues,Total,Total,"53,267.01",1.2,22.8,"704,152",21
6,Quebec,N06AX,Other antidepressants,Total,Total,"52,990.32",1.2,11.7,"361,767",22
6,Quebec,R03BB,Anticholinergics,Total,Total,"49,589.32",1.1,4.4,"136,615",23
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,"48,327.59",1.1,1.0,"31,463",24
6,Quebec,J05AP,Antivirals for treatment of HCV infections,Total,Total,"45,673.28",1.0,0.0,967,25
6,Quebec,C07AB,"Beta-blocking agents, selective",Total,Total,"44,196.80",1.0,13.3,"409,549",26
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"42,734.59",1.0,10.5,"323,958",27
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"40,146.90",0.9,1.9,"57,211",28
6,Quebec,N02BA,Salicylic acid and derivatives,Total,Total,"40,133.28",0.9,15.0,"460,900",29
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"39,362.60",0.9,10.6,"325,549",30
6,Quebec,C09AA,"ACE inhibitors, plain",Total,Total,"38,827.11",0.9,11.4,"349,945",31
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"38,064.58",0.9,1.7,"52,325",32
6,Quebec,B03XA,Other antianemic preparations,Total,Total,"37,665.49",0.9,0.3,"8,798",33
6,Quebec,H03AA,Thyroid hormones,Total,Total,"37,560.06",0.9,13.6,"419,395",34
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"37,092.89",0.9,0.1,"2,434",35
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"34,544.28",0.8,0.4,"11,878",36
6,Quebec,N02AA,Natural opium alkaloids,Total,Total,"34,531.33",0.8,9.0,"276,457",37
6,Quebec,R03BA,Glucocorticoids,Total,Total,"33,730.86",0.8,6.7,"206,578",38
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,Total,"31,275.02",0.7,10.2,"315,977",39
6,Quebec,L03AA,Colony-stimulating factors,Total,Total,"30,217.85",0.7,0.2,"6,263",40
6,Quebec,L02BB,Antiandrogens,Total,Total,"29,056.10",0.7,0.2,"5,490",41
6,Quebec,A10BA,Biguanides,Total,Total,"28,124.59",0.6,9.7,"299,330",42
6,Quebec,N05BA,Benzodiazepine derivatives,Total,Total,"26,220.96",0.6,11.1,"342,637",43
6,Quebec,H01CB,Somatostatin and analogues,Total,Total,"24,094.98",0.6,0.1,"1,787",44
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"24,084.41",0.6,0.4,"11,288",45
6,Quebec,L01EX,Other protein kinase inhibitors,Total,Total,"23,043.60",0.5,0.0,939,46
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"22,440.97",0.5,11.1,"341,203",47
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"22,147.82",0.5,2.5,"76,293",48
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"21,692.35",0.5,1.5,"46,799",49
6,Quebec,A12AA,Calcium,Total,Total,"21,666.87",0.5,8.5,"260,962",50
6,Quebec,M05BA,Bisphosphonates,Total,Total,"21,477.94",0.5,5.0,"152,717",51
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"21,266.42",0.5,1.2,"36,334",52
6,Quebec,N02BE,Anilides,Total,Total,"21,137.05",0.5,13.4,"413,732",53
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"21,132.43",0.5,6.1,"186,680",54
6,Quebec,L02BX,Other hormone antagonists and related agents,Total,Total,"21,002.93",0.5,0.1,"1,620",55
6,Quebec,B01AB,Heparin group,Total,Total,"20,853.82",0.5,0.8,"24,430",56
6,Quebec,C10AX,Other lipid-modifying agents,Total,Total,"20,633.41",0.5,2.8,"85,274",57
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"20,453.42",0.5,3.1,"96,543",58
6,Quebec,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,Total,"20,264.55",0.5,0.0,358,59
6,Quebec,C03CA,"Sulfonamides, plain",Total,Total,"18,395.39",0.4,4.5,"137,887",60
6,Quebec,A16AB,Enzymes,Total,Total,"17,812.81",0.4,0.0,21,61
6,Quebec,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,Total,"17,096.73",0.4,0.0,605,62
6,Quebec,S01ED,Beta-blocking agents,Total,Total,"16,733.62",0.4,2.7,"82,310",63
6,Quebec,L04AD,Calcineurin inhibitors,Total,Total,"16,684.97",0.4,0.2,"5,524",64
6,Quebec,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,Total,"16,413.24",0.4,0.0,359,65
6,Quebec,N06DA,Anticholinesterases,Total,Total,"15,803.06",0.4,1.3,"39,352",66
6,Quebec,S01EE,Prostaglandin analogues,Total,Total,"15,727.53",0.4,2.5,"76,926",67
6,Quebec,A10BB,Sulfonylureas,Total,Total,"15,669.92",0.4,4.4,"134,512",68
6,Quebec,C08DB,Benzothiazepine derivatives,Total,Total,"14,790.63",0.3,1.9,"59,722",69
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,"14,706.52",0.3,4.7,"144,245",70
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,Total,"14,693.78",0.3,4.5,"140,223",71
6,Quebec,A07EC,Aminosalicylic acid and similar agents,Total,Total,"13,599.08",0.3,0.6,"19,911",72
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"12,653.18",0.3,3.1,"94,111",73
6,Quebec,R01AD,Corticosteroids,Total,Total,"12,618.52",0.3,8.5,"263,111",74
6,Quebec,N04BA,Dopa and dopa derivatives,Total,Total,"12,490.95",0.3,0.5,"16,028",75
6,Quebec,L01XC,Monoclonal antibodies,Total,Total,"12,354.36",0.3,0.0,"1,131",76
6,Quebec,R07AX,Other respiratory system products,Total,Total,"12,182.58",0.3,0.0,62,77
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"12,181.92",0.3,0.2,"5,639",78
6,Quebec,S01XA,Other ophthalmologicals,Total,Total,"12,178.35",0.3,1.1,"34,769",79
6,Quebec,A06AA,"Softeners, emollients",Total,Total,"11,997.66",0.3,4.1,"126,990",80
6,Quebec,J05AJ,Integrase inhibitors,Total,Total,"11,466.53",0.3,0.1,"2,231",81
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"11,456.12",0.3,4.3,"131,893",82
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,"11,415.22",0.3,0.3,"10,446",83
6,Quebec,V06C,Infant formulas,Total,Total,"11,145.35",0.3,0.3,"8,938",84
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"10,831.45",0.2,3.3,"102,463",85
6,Quebec,N03AE,Benzodiazepine derivatives,Total,Total,"10,354.06",0.2,3.5,"107,689",86
6,Quebec,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,Total,"10,252.47",0.2,0.3,"7,734",87
6,Quebec,B03AA,"Iron bivalent, oral preparations",Total,Total,"10,118.08",0.2,4.5,"138,989",88
6,Quebec,N07XX,Other nervous system drugs,Total,Total,"9,933.33",0.2,0.0,"1,433",89
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"9,767.99",0.2,0.0,392,90
6,Quebec,N07BC,Drugs used in opioid dependence,Total,Total,"9,725.03",0.2,0.3,"8,134",91
6,Quebec,C01DA,Organic nitrates,Total,Total,"9,718.47",0.2,3.2,"99,861",92
6,Quebec,N07BA,Drugs used in nicotine dependence,Total,Total,"9,386.13",0.2,2.3,"69,803",93
6,Quebec,C09BA,ACE inhibitors and diuretics,Total,Total,"9,358.62",0.2,2.2,"68,203",94
6,Quebec,L03AB,Interferons,Total,Total,"9,010.87",0.2,0.0,672,95
6,Quebec,N03AG,Fatty acid derivatives,Total,Total,"8,881.47",0.2,0.8,"24,644",96
6,Quebec,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,Total,"8,819.97",0.2,0.0,114,97
6,Quebec,A06AD,Osmotically acting laxatives,Total,Total,"8,645.64",0.2,5.2,"159,391",98
6,Quebec,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,Total,Total,"8,557.57",0.2,0.0,173,99
6,Quebec,C02AC,Imidazoline receptor agonists,Total,Total,"8,305.44",0.2,0.7,"22,261",100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,"147,812.32",7.0,0.5,"6,541",1
6,Quebec,S01LA,Antineovascularization agents,Total,M,"92,061.67",4.4,0.7,"9,397",2
6,Quebec,B01AF,Direct factor Xa inhibitors,Total,M,"64,139.77",3.0,6.2,"83,809",3
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"57,998.20",2.7,0.6,"7,705",4
6,Quebec,N05AX,Other antipsychotics,Total,M,"57,524.56",2.7,3.0,"39,763",5
6,Quebec,C10AA,HMG-CoA reductase inhibitors,Total,M,"57,339.04",2.7,39.7,"534,382",6
6,Quebec,L04AX,Other immunosuppressants,Total,M,"54,272.23",2.6,0.2,"3,307",7
6,Quebec,L04AA,Selective immunosuppressants,Total,M,"53,110.61",2.5,0.4,"6,031",8
6,Quebec,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,M,"44,331.92",2.1,0.1,673,9
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"43,557.21",2.1,6.4,"86,469",10
6,Quebec,A02BC,Proton pump inhibitors,Total,M,"41,297.53",2.0,27.8,"373,609",11
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"38,260.16",1.8,4.1,"54,892",12
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"34,680.08",1.6,3.7,"49,600",13
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"33,494.89",1.6,4.5,"60,005",14
6,Quebec,J05AP,Antivirals for treatment of HCV infections,Total,M,"31,935.64",1.5,0.0,671,15
6,Quebec,N06BA,Centrally acting sympathomimetics,Total,M,"31,484.42",1.5,4.0,"54,200",16
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"31,311.55",1.5,0.7,"10,096",17
6,Quebec,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,M,"29,412.25",1.4,3.2,"43,239",18
6,Quebec,L02BB,Antiandrogens,Total,M,"29,052.58",1.4,0.4,"5,480",19
6,Quebec,L04AC,Interleukin inhibitors,Total,M,"28,300.84",1.3,0.1,"1,643",20
6,Quebec,N03AX,Other antiepileptics,Total,M,"27,280.59",1.3,7.8,"105,069",21
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,"26,680.20",1.3,1.3,"17,451",22
6,Quebec,C08CA,Dihydropyridine derivatives,Total,M,"25,714.74",1.2,16.7,"224,567",23
6,Quebec,R03BB,Anticholinergics,Total,M,"23,388.17",1.1,4.8,"64,739",24
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"22,010.02",1.0,2.2,"29,096",25
6,Quebec,C07AB,"Beta-blocking agents, selective",Total,M,"21,833.25",1.0,15.6,"210,301",26
6,Quebec,N02BA,Salicylic acid and derivatives,Total,M,"21,190.35",1.0,19.1,"256,758",27
6,Quebec,C09AA,"ACE inhibitors, plain",Total,M,"21,046.20",1.0,14.7,"198,204",28
6,Quebec,L02BX,Other hormone antagonists and related agents,Total,M,**,**,**,**,29
6,Quebec,B03XA,Other antianemic preparations,Total,M,"20,707.09",1.0,0.4,"4,818",30
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"20,194.84",1.0,13.3,"178,538",31
6,Quebec,N06AX,Other antidepressants,Total,M,"18,152.24",0.9,9.4,"126,299",32
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,"18,120.71",0.9,0.6,"8,515",33
6,Quebec,A11CC,Vitamin D and analogues,Total,M,"17,747.26",0.8,15.6,"209,554",34
6,Quebec,L01EX,Other protein kinase inhibitors,Total,M,"17,187.69",0.8,0.0,658,35
6,Quebec,N02AA,Natural opium alkaloids,Total,M,"16,588.88",0.8,9.2,"123,554",36
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"16,125.28",0.8,10.7,"144,168",37
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"15,462.40",0.7,0.1,990,38
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,Total,M,"14,741.90",0.7,7.9,"106,132",39
6,Quebec,A10BA,Biguanides,Total,M,"14,735.77",0.7,12.2,"163,857",40
6,Quebec,R03BA,Glucocorticoids,Total,M,"13,828.90",0.7,6.1,"82,095",41
6,Quebec,L03AA,Colony-stimulating factors,Total,M,"13,756.29",0.7,0.2,"2,758",42
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"12,769.18",0.6,1.9,"25,760",43
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"12,594.78",0.6,6.9,"93,469",44
6,Quebec,H01CB,Somatostatin and analogues,Total,M,"12,106.09",0.6,0.1,848,45
6,Quebec,C10AX,Other lipid-modifying agents,Total,M,"11,243.73",0.5,3.6,"48,623",46
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"11,002.94",0.5,4.2,"56,828",47
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"10,662.51",0.5,1.4,"18,195",48
6,Quebec,A16AB,Enzymes,Total,M,"10,317.08",0.5,0.0,12,49
6,Quebec,H03AA,Thyroid hormones,Total,M,"10,286.70",0.5,8.1,"108,937",50
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"10,089.60",0.5,10.6,"143,028",51
6,Quebec,B01AB,Heparin group,Total,M,"10,063.50",0.5,0.8,"10,774",52
6,Quebec,L04AD,Calcineurin inhibitors,Total,M,"10,028.05",0.5,0.2,"3,343",53
6,Quebec,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,M,"9,783.93",0.5,0.0,333,54
6,Quebec,N05BA,Benzodiazepine derivatives,Total,M,"9,624.04",0.5,8.8,"119,017",55
6,Quebec,J05AJ,Integrase inhibitors,Total,M,"8,696.10",0.4,0.1,"1,616",56
6,Quebec,A10BB,Sulfonylureas,Total,M,"8,684.72",0.4,5.8,"78,168",57
6,Quebec,C03CA,"Sulfonamides, plain",Total,M,"8,375.03",0.4,4.7,"63,502",58
6,Quebec,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,M,"8,106.96",0.4,0.0,182,59
6,Quebec,S01ED,Beta-blocking agents,Total,M,"7,503.73",0.4,2.9,"38,400",60
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,Total,M,"7,461.41",0.4,2.0,"27,500",61
6,Quebec,N02BE,Anilides,Total,M,"7,432.86",0.4,12.2,"164,176",62
6,Quebec,N04BA,Dopa and dopa derivatives,Total,M,"7,399.35",0.3,0.7,"9,120",63
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,"7,005.71",0.3,0.5,"6,285",64
6,Quebec,S01EE,Prostaglandin analogues,Total,M,"6,649.53",0.3,2.5,"33,921",65
6,Quebec,A07EC,Aminosalicylic acid and similar agents,Total,M,"6,601.64",0.3,0.7,"9,148",66
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,M,"6,407.18",0.3,4.6,"61,256",67
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,M,"6,279.91",0.3,4.3,"58,397",68
6,Quebec,R07AX,Other respiratory system products,Total,M,"6,216.21",0.3,0.0,30,69
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,"6,136.18",0.3,4.8,"64,810",70
6,Quebec,N07BC,Drugs used in opioid dependence,Total,M,"6,077.87",0.3,0.4,"4,755",71
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,Total,M,"5,858.59",0.3,0.2,"3,114",72
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,Total,M,"5,823.73",0.3,1.0,"13,683",73
6,Quebec,C08DB,Benzothiazepine derivatives,Total,M,"5,820.97",0.3,1.8,"24,357",74
6,Quebec,C02AC,Imidazoline receptor agonists,Total,M,"5,757.75",0.3,0.7,"9,500",75
6,Quebec,N06DA,Anticholinesterases,Total,M,"5,736.91",0.3,1.1,"14,700",76
6,Quebec,V06C,Infant formulas,Total,M,"5,721.58",0.3,0.3,"4,052",77
6,Quebec,N07XX,Other nervous system drugs,Total,M,"5,591.15",0.3,0.0,649,78
6,Quebec,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,M,"5,465.06",0.3,0.0,107,79
6,Quebec,M04AA,Preparations inhibiting uric acid production,Total,M,"5,440.58",0.3,3.9,"52,480",80
6,Quebec,R01AD,Corticosteroids,Total,M,"5,293.17",0.3,7.8,"104,478",81
6,Quebec,A12AA,Calcium,Total,M,"5,260.81",0.2,4.1,"55,383",82
6,Quebec,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,M,"5,229.89",0.2,0.3,"3,416",83
6,Quebec,M05BA,Bisphosphonates,Total,M,"5,143.05",0.2,2.4,"32,284",84
6,Quebec,C09BA,ACE inhibitors and diuretics,Total,M,"5,074.20",0.2,2.8,"37,664",85
6,Quebec,C01DA,Organic nitrates,Total,M,"4,913.48",0.2,4.2,"56,606",86
6,Quebec,N03AG,Fatty acid derivatives,Total,M,"4,907.86",0.2,1.0,"12,920",87
6,Quebec,N07BA,Drugs used in nicotine dependence,Total,M,"4,693.74",0.2,2.6,"34,648",88
6,Quebec,A06AA,"Softeners, emollients",Total,M,"4,629.52",0.2,3.5,"47,401",89
6,Quebec,B02BX,Other systemic hemostatics,Total,M,"4,621.54",0.2,0.0,120,90
6,Quebec,L01XX,Other antineoplastic agents,Total,M,"4,525.78",0.2,0.1,"1,959",91
6,Quebec,B01AE,Direct thrombin inhibitors,Total,M,"4,469.19",0.2,0.4,"5,862",92
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,"4,377.76",0.2,1.2,"16,241",93
6,Quebec,J05AE,Protease inhibitors,Total,M,"4,314.37",0.2,0.1,792,94
6,Quebec,N03AE,Benzodiazepine derivatives,Total,M,"4,231.17",0.2,2.9,"38,848",95
6,Quebec,L01XC,Monoclonal antibodies,Total,M,"4,199.96",0.2,0.0,410,96
6,Quebec,B03AA,"Iron bivalent, oral preparations",Total,M,"4,086.27",0.2,3.7,"50,355",97
6,Quebec,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,M,"3,866.63",0.2,0.0,51,98
6,Quebec,C03DA,Aldosterone antagonists,Total,M,"3,791.54",0.2,1.9,"25,986",99
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"3,675.17",0.2,0.1,"1,494",100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,"150,429.72",6.7,0.4,"7,743",1
6,Quebec,S01LA,Antineovascularization agents,Total,F,"126,463.75",5.7,0.7,"12,664",2
6,Quebec,L04AA,Selective immunosuppressants,Total,F,"81,537.43",3.6,0.5,"8,585",3
6,Quebec,B01AF,Direct factor Xa inhibitors,Total,F,"59,866.53",2.7,4.3,"75,122",4
6,Quebec,A02BC,Proton pump inhibitors,Total,F,"58,055.45",2.6,29.1,"506,041",5
6,Quebec,C10AA,HMG-CoA reductase inhibitors,Total,F,"53,831.47",2.4,25.9,"450,208",6
6,Quebec,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,F,"53,178.14",2.4,0.1,"1,304",7
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"45,572.56",2.0,5.0,"86,115",8
6,Quebec,L04AX,Other immunosuppressants,Total,F,"42,114.68",1.9,0.2,"4,241",9
6,Quebec,N03AX,Other antiepileptics,Total,F,"37,892.79",1.7,9.0,"156,110",10
6,Quebec,A11CC,Vitamin D and analogues,Total,F,"35,519.65",1.6,28.5,"494,593",11
6,Quebec,N06AX,Other antidepressants,Total,F,"34,838.06",1.6,13.6,"235,467",12
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"34,288.31",1.5,3.1,"54,097",13
6,Quebec,L04AC,Interleukin inhibitors,Total,F,"33,833.96",1.5,0.1,"2,103",14
6,Quebec,N05AX,Other antipsychotics,Total,F,"32,079.98",1.4,2.5,"43,142",15
6,Quebec,C08CA,Dihydropyridine derivatives,Total,F,"30,899.96",1.4,14.2,"246,843",16
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"29,083.71",1.3,5.9,"102,066",17
6,Quebec,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,F,"28,237.10",1.3,2.3,"39,079",18
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,Total,F,"27,992.69",1.3,12.5,"217,826",19
6,Quebec,H03AA,Thyroid hormones,Total,F,"27,273.36",1.2,17.9,"310,458",20
6,Quebec,R03BB,Anticholinergics,Total,F,"26,201.15",1.2,4.1,"71,876",21
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"25,002.53",1.1,2.0,"34,838",22
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,F,"24,995.11",1.1,14.8,"257,580",23
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"23,572.93",1.1,1.9,"32,432",24
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"23,237.31",1.0,10.4,"181,380",25
6,Quebec,C07AB,"Beta-blocking agents, selective",Total,F,"22,363.53",1.0,11.5,"199,246",26
6,Quebec,N06BA,Centrally acting sympathomimetics,Total,F,"22,060.69",1.0,2.6,"45,410",27
6,Quebec,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,F,"21,770.22",1.0,0.0,338,28
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,"21,647.39",1.0,0.8,"14,012",29
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"21,630.49",1.0,0.1,"1,444",30
6,Quebec,R03BA,Glucocorticoids,Total,F,"19,901.96",0.9,7.2,"124,483",31
6,Quebec,N02BA,Salicylic acid and derivatives,Total,F,"18,942.91",0.8,11.8,"204,140",32
6,Quebec,N02AA,Natural opium alkaloids,Total,F,"17,942.44",0.8,8.8,"152,902",33
6,Quebec,C09AA,"ACE inhibitors, plain",Total,F,"17,780.91",0.8,8.7,"151,741",34
6,Quebec,B03XA,Other antianemic preparations,Total,F,"16,958.39",0.8,0.2,"3,980",35
6,Quebec,N05BA,Benzodiazepine derivatives,Total,F,"16,596.92",0.7,12.9,"223,620",36
6,Quebec,L03AA,Colony-stimulating factors,Total,F,"16,461.56",0.7,0.2,"3,505",37
6,Quebec,A12AA,Calcium,Total,F,"16,406.05",0.7,11.8,"205,578",38
6,Quebec,M05BA,Bisphosphonates,Total,F,"16,334.87",0.7,6.9,"120,432",39
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"16,054.57",0.7,1.3,"23,229",40
6,Quebec,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,F,"14,799.49",0.7,0.0,251,41
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,Total,F,"14,686.41",0.7,2.8,"48,793",42
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"14,264.28",0.6,0.1,"1,749",43
6,Quebec,J05AP,Antivirals for treatment of HCV infections,Total,F,"13,737.64",0.6,0.0,296,44
6,Quebec,N02BE,Anilides,Total,F,"13,704.16",0.6,14.4,"249,553",45
6,Quebec,A10BA,Biguanides,Total,F,"13,388.82",0.6,7.8,"135,473",46
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"12,351.35",0.6,11.4,"198,174",47
6,Quebec,H01CB,Somatostatin and analogues,Total,F,"11,988.90",0.5,0.1,939,48
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"11,299.69",0.5,7.6,"131,229",49
6,Quebec,B01AB,Heparin group,Total,F,"10,790.33",0.5,0.8,"13,656",50
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"10,603.91",0.5,1.0,"18,139",51
6,Quebec,N06DA,Anticholinesterases,Total,F,"10,066.14",0.4,1.4,"24,652",52
6,Quebec,C03CA,"Sulfonamides, plain",Total,F,"10,020.36",0.4,4.3,"74,385",53
6,Quebec,S01XA,Other ophthalmologicals,Total,F,"9,716.58",0.4,1.4,"25,040",54
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"9,450.48",0.4,2.3,"39,715",55
6,Quebec,C10AX,Other lipid-modifying agents,Total,F,"9,389.68",0.4,2.1,"36,651",56
6,Quebec,S01ED,Beta-blocking agents,Total,F,"9,229.89",0.4,2.5,"43,910",57
6,Quebec,S01EE,Prostaglandin analogues,Total,F,"9,078.00",0.4,2.5,"43,005",58
6,Quebec,C08DB,Benzothiazepine derivatives,Total,F,"8,969.64",0.4,2.0,"35,364",59
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"8,923.17",0.4,1.2,"21,039",60
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,"8,570.33",0.4,4.6,"79,435",61
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"8,506.75",0.4,0.2,"4,145",62
6,Quebec,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,Total,F,"8,329.20",0.4,0.0,167,63
6,Quebec,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,F,"8,306.28",0.4,0.0,177,64
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,F,"8,286.60",0.4,4.5,"78,967",65
6,Quebec,L01XC,Monoclonal antibodies,Total,F,"8,154.40",0.4,0.0,721,66
6,Quebec,A16AB,Enzymes,Total,F,"7,495.73",0.3,0.0,9,67
6,Quebec,A06AA,"Softeners, emollients",Total,F,"7,368.13",0.3,4.6,"79,588",68
6,Quebec,R01AD,Corticosteroids,Total,F,"7,325.32",0.3,9.1,"158,632",69
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"7,319.73",0.3,4.2,"72,229",70
6,Quebec,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"7,315.04",0.3,5.9,"102,117",71
6,Quebec,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,F,"7,312.80",0.3,0.0,272,72
6,Quebec,A07EC,Aminosalicylic acid and similar agents,Total,F,"6,997.37",0.3,0.6,"10,762",73
6,Quebec,A10BB,Sulfonylureas,Total,F,"6,985.20",0.3,3.2,"56,344",74
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"6,803.93",0.3,0.0,250,75
6,Quebec,L03AB,Interferons,Total,F,"6,723.82",0.3,0.0,476,76
6,Quebec,L04AD,Calcineurin inhibitors,Total,F,"6,656.92",0.3,0.1,"2,181",77
6,Quebec,L02BG,Aromatase inhibitors,Total,F,"6,132.41",0.3,1.3,"21,832",78
6,Quebec,N03AE,Benzodiazepine derivatives,Total,F,"6,122.87",0.3,4.0,"68,839",79
6,Quebec,B03AA,"Iron bivalent, oral preparations",Total,F,"6,031.80",0.3,5.1,"88,633",80
6,Quebec,R07AX,Other respiratory system products,Total,F,"5,966.38",0.3,0.0,32,81
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,"5,963.70",0.3,0.2,"2,773",82
6,Quebec,L01EX,Other protein kinase inhibitors,Total,F,"5,855.92",0.3,0.0,281,83
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,Total,F,"5,811.72",0.3,1.9,"33,845",84
6,Quebec,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,Total,F,"5,528.93",0.2,0.0,168,85
6,Quebec,V06C,Infant formulas,Total,F,"5,423.73",0.2,0.3,"4,885",86
6,Quebec,N04BA,Dopa and dopa derivatives,Total,F,"5,091.61",0.2,0.4,"6,908",87
6,Quebec,A06AD,Osmotically acting laxatives,Total,F,"5,062.04",0.2,5.5,"96,149",88
6,Quebec,L03AX,Other immunostimulants,Total,F,"5,036.95",0.2,0.0,483,89
6,Quebec,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,F,"5,022.58",0.2,0.2,"4,318",90
6,Quebec,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,F,"4,953.34",0.2,0.0,63,91
6,Quebec,C01DA,Organic nitrates,Total,F,"4,804.99",0.2,2.5,"43,255",92
6,Quebec,N07BA,Drugs used in nicotine dependence,Total,F,"4,692.38",0.2,2.0,"35,155",93
6,Quebec,C03AA,"Thiazides, plain",Total,F,"4,629.14",0.2,4.1,"71,586",94
6,Quebec,L02BA,Anti-estrogens,Total,F,"4,543.22",0.2,0.4,"6,736",95
6,Quebec,L01BA,Folic acid analogues,Total,F,"4,537.20",0.2,1.1,"19,267",96
6,Quebec,A06AB,Contact laxatives,Total,F,"4,506.96",0.2,2.7,"46,749",97
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"4,454.04",0.2,4.7,"81,700",98
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,F,"4,409.51",0.2,0.2,"4,161",99
6,Quebec,N07XX,Other nervous system drugs,Total,F,"4,342.18",0.2,0.0,784,100
6,Quebec,S01LA,Antineovascularization agents,65+,Total,"204,572.75",7.3,1.4,"20,662",1
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,"126,576.43",4.5,0.4,"6,404",2
6,Quebec,B01AF,Direct factor Xa inhibitors,65+,Total,"113,445.77",4.0,9.4,"142,016",3
6,Quebec,C10AA,HMG-CoA reductase inhibitors,65+,Total,"89,660.99",3.2,51.5,"778,238",4
6,Quebec,L04AX,Other immunosuppressants,65+,Total,"77,429.57",2.7,0.3,"4,455",5
6,Quebec,A02BC,Proton pump inhibitors,65+,Total,"73,209.63",2.6,39.7,"599,443",6
6,Quebec,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,Total,"60,135.69",2.1,0.1,921,7
6,Quebec,L04AA,Selective immunosuppressants,65+,Total,"58,282.59",2.1,0.5,"7,506",8
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"54,921.27",1.9,6.2,"93,709",9
6,Quebec,C08CA,Dihydropyridine derivatives,65+,Total,"47,658.76",1.7,25.4,"383,145",10
6,Quebec,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,Total,"47,111.89",1.7,4.4,"65,790",11
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"44,083.63",1.6,4.0,"61,123",12
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"42,671.88",1.5,3.9,"58,294",13
6,Quebec,A11CC,Vitamin D and analogues,65+,Total,"41,300.19",1.5,34.0,"513,300",14
6,Quebec,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,Total,"40,561.46",1.4,0.1,978,15
6,Quebec,R03BB,Anticholinergics,65+,Total,"38,841.99",1.4,7.0,"106,081",16
6,Quebec,C07AB,"Beta-blocking agents, selective",65+,Total,"37,788.46",1.3,22.8,"345,113",17
6,Quebec,N03AX,Other antiepileptics,65+,Total,"36,292.37",1.3,11.0,"166,070",18
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"35,807.69",1.3,3.5,"52,792",19
6,Quebec,N02BA,Salicylic acid and derivatives,65+,Total,"33,526.13",1.2,25.2,"381,392",20
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"33,061.17",1.2,17.5,"263,911",21
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,"32,157.64",1.1,1.3,"20,317",22
6,Quebec,B03XA,Other antianemic preparations,65+,Total,"31,111.73",1.1,0.5,"7,227",23
6,Quebec,C09AA,"ACE inhibitors, plain",65+,Total,"30,504.99",1.1,17.8,"268,474",24
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"29,606.33",1.1,0.6,"9,534",25
6,Quebec,H03AA,Thyroid hormones,65+,Total,"29,188.50",1.0,20.4,"308,012",26
6,Quebec,N06AX,Other antidepressants,65+,Total,"28,538.85",1.0,12.4,"187,428",27
6,Quebec,L04AC,Interleukin inhibitors,65+,Total,"27,928.39",1.0,0.1,"1,805",28
6,Quebec,L02BB,Antiandrogens,65+,Total,"27,636.40",1.0,0.3,"5,224",29
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,Total,"26,541.52",0.9,17.4,"263,306",30
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"26,150.64",0.9,2.4,"36,073",31
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"23,037.25",0.8,10.7,"162,336",32
6,Quebec,L03AA,Colony-stimulating factors,65+,Total,"21,362.90",0.8,0.3,"4,430",33
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"21,318.18",0.8,0.1,"1,435",34
6,Quebec,A10BA,Biguanides,65+,Total,"20,997.15",0.7,14.5,"218,853",35
6,Quebec,L02BX,Other hormone antagonists and related agents,65+,Total,"19,944.29",0.7,0.1,"1,516",36
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,"19,419.66",0.7,0.6,"8,977",37
6,Quebec,R03BA,Glucocorticoids,65+,Total,"19,337.78",0.7,6.8,"102,981",38
6,Quebec,M05BA,Bisphosphonates,65+,Total,"19,036.10",0.7,9.0,"135,966",39
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"18,876.83",0.7,10.8,"162,578",40
6,Quebec,L01EX,Other protein kinase inhibitors,65+,Total,"18,680.20",0.7,0.1,774,41
6,Quebec,H01CB,Somatostatin and analogues,65+,Total,"18,235.91",0.6,0.1,"1,377",42
6,Quebec,A12AA,Calcium,65+,Total,"18,185.11",0.6,14.1,"213,715",43
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"17,743.23",0.6,4.0,"60,554",44
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"17,705.29",0.6,2.0,"30,074",45
6,Quebec,N05BA,Benzodiazepine derivatives,65+,Total,"17,620.05",0.6,15.9,"239,714",46
6,Quebec,N02AA,Natural opium alkaloids,65+,Total,"16,897.52",0.6,10.8,"163,465",47
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"16,856.81",0.6,5.1,"76,743",48
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,"16,422.39",0.6,0.1,"1,643",49
6,Quebec,C03CA,"Sulfonamides, plain",65+,Total,"16,318.36",0.6,8.1,"122,691",50
6,Quebec,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,Total,"16,006.81",0.6,0.0,283,51
6,Quebec,N02BE,Anilides,65+,Total,"15,879.42",0.6,18.3,"276,673",52
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"15,861.36",0.6,5.4,"81,515",53
6,Quebec,C10AX,Other lipid-modifying agents,65+,Total,"15,774.38",0.6,4.5,"67,956",54
6,Quebec,N06DA,Anticholinesterases,65+,Total,"15,606.66",0.6,2.6,"38,865",55
6,Quebec,S01ED,Beta-blocking agents,65+,Total,"15,149.47",0.5,4.9,"73,318",56
6,Quebec,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,Total,"14,591.67",0.5,0.0,313,57
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"14,581.63",0.5,12.3,"186,575",58
6,Quebec,S01EE,Prostaglandin analogues,65+,Total,"14,369.85",0.5,4.6,"69,271",59
6,Quebec,B01AB,Heparin group,65+,Total,"14,059.47",0.5,1.1,"17,061",60
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"13,875.44",0.5,2.0,"29,708",61
6,Quebec,N05AX,Other antipsychotics,65+,Total,"13,683.83",0.5,2.1,"31,974",62
6,Quebec,C08DB,Benzothiazepine derivatives,65+,Total,"12,849.64",0.5,3.4,"51,229",63
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,"12,634.45",0.4,7.9,"119,493",64
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,"12,430.66",0.4,7.9,"118,638",65
6,Quebec,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,Total,"11,978.42",0.4,0.0,419,66
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"11,855.35",0.4,5.6,"85,241",67
6,Quebec,A10BB,Sulfonylureas,65+,Total,"11,694.94",0.4,6.4,"96,492",68
6,Quebec,N04BA,Dopa and dopa derivatives,65+,Total,"11,057.58",0.4,1.0,"14,676",69
6,Quebec,S01XA,Other ophthalmologicals,65+,Total,"9,700.61",0.3,1.9,"28,312",70
6,Quebec,J05AP,Antivirals for treatment of HCV infections,65+,Total,"9,049.07",0.3,0.0,180,71
6,Quebec,C01DA,Organic nitrates,65+,Total,"8,859.75",0.3,5.7,"86,615",72
6,Quebec,A07EC,Aminosalicylic acid and similar agents,65+,Total,"8,653.07",0.3,0.8,"11,881",73
6,Quebec,A06AA,"Softeners, emollients",65+,Total,"8,574.34",0.3,6.3,"95,324",74
6,Quebec,L01XC,Monoclonal antibodies,65+,Total,"8,173.86",0.3,0.1,767,75
6,Quebec,B03AA,"Iron bivalent, oral preparations",65+,Total,"8,089.34",0.3,6.2,"93,846",76
6,Quebec,R01AD,Corticosteroids,65+,Total,"7,770.87",0.3,9.7,"146,877",77
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,"7,676.79",0.3,0.5,"8,223",78
6,Quebec,B01AE,Direct thrombin inhibitors,65+,Total,"7,267.11",0.3,0.6,"9,121",79
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"7,149.11",0.3,5.5,"82,910",80
6,Quebec,C09BA,ACE inhibitors and diuretics,65+,Total,"7,074.58",0.3,3.4,"50,645",81
6,Quebec,L04AD,Calcineurin inhibitors,65+,Total,"7,047.33",0.3,0.2,"2,640",82
6,Quebec,M04AA,Preparations inhibiting uric acid production,65+,Total,"6,932.37",0.2,4.0,"60,948",83
6,Quebec,N07XX,Other nervous system drugs,65+,Total,"6,496.58",0.2,0.1,775,84
6,Quebec,L01XX,Other antineoplastic agents,65+,Total,"6,376.50",0.2,0.2,"3,776",85
6,Quebec,C03AA,"Thiazides, plain",65+,Total,"6,149.66",0.2,6.3,"95,698",86
6,Quebec,A06AD,Osmotically acting laxatives,65+,Total,"6,103.03",0.2,7.7,"115,946",87
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"6,062.23",0.2,3.7,"55,745",88
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"6,048.14",0.2,0.0,228,89
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"5,862.22",0.2,0.2,"3,080",90
6,Quebec,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,Total,"5,723.50",0.2,0.0,80,91
6,Quebec,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,65+,Total,"5,687.68",0.2,0.0,109,92
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"5,531.49",0.2,1.4,"20,675",93
6,Quebec,A12BA,Potassium,65+,Total,"5,349.55",0.2,3.0,"45,254",94
6,Quebec,A06AB,Contact laxatives,65+,Total,"5,276.93",0.2,3.9,"58,622",95
6,Quebec,C03DA,Aldosterone antagonists,65+,Total,"5,262.12",0.2,2.6,"39,478",96
6,Quebec,B02BX,Other systemic hemostatics,65+,Total,"5,204.68",0.2,0.0,156,97
6,Quebec,L01BA,Folic acid analogues,65+,Total,"5,167.08",0.2,1.4,"21,679",98
6,Quebec,H02AB,Glucocorticoids,65+,Total,"4,962.38",0.2,8.1,"123,101",99
6,Quebec,L02BG,Aromatase inhibitors,65+,Total,"4,936.08",0.2,1.0,"15,862",100
6,Quebec,S01LA,Antineovascularization agents,65+,M,"83,984.28",6.3,1.3,"8,610",1
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,"58,093.52",4.3,0.4,"2,722",2
6,Quebec,B01AF,Direct factor Xa inhibitors,65+,M,"57,709.31",4.3,10.9,"73,780",3
6,Quebec,C10AA,HMG-CoA reductase inhibitors,65+,M,"45,421.18",3.4,61.3,"416,169",4
6,Quebec,L04AX,Other immunosuppressants,65+,M,"44,159.38",3.3,0.3,"2,069",5
6,Quebec,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,M,"40,140.66",3.0,0.1,612,6
6,Quebec,A02BC,Proton pump inhibitors,65+,M,"29,844.61",2.2,37.6,"255,226",7
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,65+,M,**,**,**,**,8
6,Quebec,L02BB,Antiandrogens,65+,M,**,**,**,**,9
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"27,243.61",2.0,5.6,"38,208",10
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"25,572.49",1.9,5.2,"35,458",11
6,Quebec,L04AA,Selective immunosuppressants,65+,M,"25,178.71",1.9,0.5,"3,243",12
6,Quebec,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,M,"23,799.87",1.8,5.1,"34,299",13
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"23,603.31",1.8,5.8,"39,151",14
6,Quebec,C08CA,Dihydropyridine derivatives,65+,M,"20,771.59",1.6,25.9,"176,077",15
6,Quebec,L02BX,Other hormone antagonists and related agents,65+,M,**,**,**,**,16
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,"18,598.55",1.4,1.7,"11,805",17
6,Quebec,R03BB,Anticholinergics,65+,M,"18,588.05",1.4,7.5,"51,191",18
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"18,084.03",1.4,23.1,"156,790",19
6,Quebec,C07AB,"Beta-blocking agents, selective",65+,M,"18,029.14",1.3,25.6,"173,438",20
6,Quebec,N02BA,Salicylic acid and derivatives,65+,M,"17,279.13",1.3,30.9,"210,024",21
6,Quebec,B03XA,Other antianemic preparations,65+,M,"17,199.92",1.3,0.6,"3,919",22
6,Quebec,C09AA,"ACE inhibitors, plain",65+,M,"16,071.58",1.2,22.0,"149,342",23
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"15,299.60",1.1,3.0,"20,175",24
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,"14,535.77",1.1,1.0,"6,733",25
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,"14,387.45",1.1,0.2,"1,455",26
6,Quebec,N03AX,Other antiepileptics,65+,M,"14,265.56",1.1,9.5,"64,802",27
6,Quebec,L01EX,Other protein kinase inhibitors,65+,M,"14,219.24",1.1,0.1,553,28
6,Quebec,A11CC,Vitamin D and analogues,65+,M,"13,521.41",1.0,23.3,"158,073",29
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,"13,106.05",1.0,16.8,"113,770",30
6,Quebec,L04AC,Interleukin inhibitors,65+,M,"11,900.09",0.9,0.1,730,31
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"11,826.38",0.9,12.5,"84,900",32
6,Quebec,A10BA,Biguanides,65+,M,"11,027.10",0.8,17.8,"121,039",33
6,Quebec,L03AA,Colony-stimulating factors,65+,M,"10,539.22",0.8,0.3,"2,103",34
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"9,746.24",0.7,0.1,652,35
6,Quebec,N06AX,Other antidepressants,65+,M,"9,022.44",0.7,9.2,"62,764",36
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"9,015.53",0.7,2.3,"15,341",37
6,Quebec,H01CB,Somatostatin and analogues,65+,M,"8,946.05",0.7,0.1,650,38
6,Quebec,C10AX,Other lipid-modifying agents,65+,M,"8,461.26",0.6,5.6,"38,306",39
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"8,314.63",0.6,2.4,"16,620",40
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"8,291.14",0.6,6.9,"46,927",41
6,Quebec,H03AA,Thyroid hormones,65+,M,"7,895.07",0.6,12.3,"83,403",42
6,Quebec,R03BA,Glucocorticoids,65+,M,"7,793.46",0.6,5.8,"39,463",43
6,Quebec,N02AA,Natural opium alkaloids,65+,M,"7,282.84",0.5,10.7,"72,910",44
6,Quebec,C03CA,"Sulfonamides, plain",65+,M,"7,269.27",0.5,8.2,"55,608",45
6,Quebec,B01AB,Heparin group,65+,M,"7,168.23",0.5,1.1,"7,787",46
6,Quebec,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,M,"7,132.31",0.5,0.0,160,47
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"6,956.86",0.5,4.5,"30,833",48
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,65+,M,"6,911.41",0.5,7.3,"49,497",49
6,Quebec,S01ED,Beta-blocking agents,65+,M,"6,706.56",0.5,5.0,"33,864",50
6,Quebec,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,M,"6,646.02",0.5,0.0,225,51
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"6,565.27",0.5,11.4,"77,513",52
6,Quebec,N04BA,Dopa and dopa derivatives,65+,M,"6,533.27",0.5,1.2,"8,350",53
6,Quebec,A10BB,Sulfonylureas,65+,M,"6,451.63",0.5,8.3,"56,016",54
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,65+,M,"6,263.25",0.5,3.4,"22,943",55
6,Quebec,J05AP,Antivirals for treatment of HCV infections,65+,M,"6,064.93",0.5,0.0,119,56
6,Quebec,S01EE,Prostaglandin analogues,65+,M,"6,011.80",0.4,4.5,"30,349",57
6,Quebec,N05BA,Benzodiazepine derivatives,65+,M,"5,658.39",0.4,11.6,"79,011",58
6,Quebec,N06DA,Anticholinesterases,65+,M,"5,649.44",0.4,2.1,"14,496",59
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,M,"5,519.46",0.4,7.9,"53,436",60
6,Quebec,N05AX,Other antipsychotics,65+,M,"5,458.94",0.4,1.7,"11,366",61
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,65+,M,"5,396.85",0.4,0.4,"2,809",62
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,M,"5,342.52",0.4,7.4,"50,442",63
6,Quebec,N02BE,Anilides,65+,M,"5,169.35",0.4,15.6,"105,617",64
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,"5,029.10",0.4,7.6,"51,785",65
6,Quebec,C08DB,Benzothiazepine derivatives,65+,M,"4,903.99",0.4,3.0,"20,370",66
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,"4,649.36",0.3,0.7,"4,911",67
6,Quebec,M04AA,Preparations inhibiting uric acid production,65+,M,"4,636.00",0.3,6.4,"43,407",68
6,Quebec,M05BA,Bisphosphonates,65+,M,"4,419.65",0.3,4.2,"28,431",69
6,Quebec,C01DA,Organic nitrates,65+,M,"4,409.36",0.3,7.1,"48,349",70
6,Quebec,A12AA,Calcium,65+,M,"4,326.71",0.3,6.9,"46,671",71
6,Quebec,A07EC,Aminosalicylic acid and similar agents,65+,M,"4,305.23",0.3,0.8,"5,655",72
6,Quebec,L04AD,Calcineurin inhibitors,65+,M,"4,282.35",0.3,0.2,"1,624",73
6,Quebec,B01AE,Direct thrombin inhibitors,65+,M,"4,184.58",0.3,0.8,"5,456",74
6,Quebec,L01XX,Other antineoplastic agents,65+,M,"4,167.36",0.3,0.2,"1,584",75
6,Quebec,N07XX,Other nervous system drugs,65+,M,"4,023.33",0.3,0.1,348,76
6,Quebec,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,M,"3,990.09",0.3,0.0,81,77
6,Quebec,C09BA,ACE inhibitors and diuretics,65+,M,"3,721.04",0.3,4.0,"27,194",78
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,65+,M,"3,451.67",0.3,1.1,"7,465",79
6,Quebec,B03AA,"Iron bivalent, oral preparations",65+,M,"3,402.28",0.3,6.1,"41,235",80
6,Quebec,R01AD,Corticosteroids,65+,M,"3,348.93",0.3,8.8,"59,810",81
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,"3,093.11",0.2,1.7,"11,546",82
6,Quebec,A06AA,"Softeners, emollients",65+,M,"3,088.01",0.2,5.2,"35,519",83
6,Quebec,L01XC,Monoclonal antibodies,65+,M,"3,081.48",0.2,0.0,301,84
6,Quebec,C03DA,Aldosterone antagonists,65+,M,"2,986.46",0.2,3.0,"20,495",85
6,Quebec,B02BX,Other systemic hemostatics,65+,M,"2,981.61",0.2,0.0,83,86
6,Quebec,J05AJ,Integrase inhibitors,65+,M,"2,957.69",0.2,0.1,421,87
6,Quebec,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,M,"2,785.47",0.2,0.0,37,88
6,Quebec,A06AD,Osmotically acting laxatives,65+,M,"2,477.40",0.2,6.9,"46,720",89
6,Quebec,L01BC,Pyrimidine analogues,65+,M,"2,250.96",0.2,1.2,"8,262",90
6,Quebec,C03AA,"Thiazides, plain",65+,M,"2,224.97",0.2,5.3,"36,250",91
6,Quebec,H02AB,Glucocorticoids,65+,M,"2,110.26",0.2,7.9,"53,580",92
6,Quebec,D07AC,"Corticosteroids, potent (group III)",65+,M,"2,099.92",0.2,8.5,"57,419",93
6,Quebec,J01DH,Carbapenems,65+,M,"2,052.64",0.2,0.2,"1,158",94
6,Quebec,A06AB,Contact laxatives,65+,M,"1,968.89",0.1,3.4,"22,866",95
6,Quebec,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,65+,M,"1,965.94",0.1,0.0,48,96
6,Quebec,A12BA,Potassium,65+,M,"1,957.59",0.1,2.6,"17,441",97
6,Quebec,V03AC,Iron-chelating agents,65+,M,"1,953.63",0.1,0.0,92,98
6,Quebec,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,65+,M,"1,938.44",0.1,0.0,43,99
6,Quebec,L01XE,Protein kinase inhibitors,65+,M,"1,933.54",0.1,0.0,240,100
6,Quebec,S01LA,Antineovascularization agents,65+,F,"120,588.46",8.1,1.4,"12,052",1
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,"68,482.91",4.6,0.4,"3,682",2
6,Quebec,B01AF,Direct factor Xa inhibitors,65+,F,"55,736.45",3.8,8.2,"68,236",3
6,Quebec,C10AA,HMG-CoA reductase inhibitors,65+,F,"44,239.80",3.0,43.5,"362,069",4
6,Quebec,A02BC,Proton pump inhibitors,65+,F,"43,365.02",2.9,41.4,"344,217",5
6,Quebec,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,F,**,**,**,**,6
6,Quebec,L04AX,Other immunosuppressants,65+,F,"33,270.19",2.2,0.3,"2,386",7
6,Quebec,L04AA,Selective immunosuppressants,65+,F,"33,103.88",2.2,0.5,"4,263",8
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"31,317.96",2.1,6.6,"54,558",9
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"30,410.84",2.1,6.0,"49,983",10
6,Quebec,A11CC,Vitamin D and analogues,65+,F,"27,778.78",1.9,42.7,"355,227",11
6,Quebec,C08CA,Dihydropyridine derivatives,65+,F,"26,887.17",1.8,24.9,"207,068",12
6,Quebec,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,F,"23,312.01",1.6,3.8,"31,491",13
6,Quebec,N03AX,Other antiepileptics,65+,F,"22,026.80",1.5,12.2,"101,268",14
6,Quebec,H03AA,Thyroid hormones,65+,F,"21,293.43",1.4,27.0,"224,609",15
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,F,"21,199.00",1.4,25.6,"212,864",16
6,Quebec,R03BB,Anticholinergics,65+,F,"20,253.94",1.4,6.6,"54,890",17
6,Quebec,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,F,"19,995.03",1.4,0.0,309,18
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"19,955.11",1.3,18.0,"150,141",19
6,Quebec,C07AB,"Beta-blocking agents, selective",65+,F,"19,759.33",1.3,20.6,"171,675",20
6,Quebec,N06AX,Other antidepressants,65+,F,"19,516.41",1.3,15.0,"124,664",21
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"17,099.39",1.2,2.7,"22,836",22
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"16,840.03",1.1,2.8,"22,915",23
6,Quebec,N02BA,Salicylic acid and derivatives,65+,F,"16,246.99",1.1,20.6,"171,368",24
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,65+,F,"16,125.84",1.1,13.6,"112,839",25
6,Quebec,L04AC,Interleukin inhibitors,65+,F,"16,028.29",1.1,0.1,"1,075",26
6,Quebec,M05BA,Bisphosphonates,65+,F,"14,616.44",1.0,12.9,"107,535",27
6,Quebec,C09AA,"ACE inhibitors, plain",65+,F,"14,433.41",1.0,14.3,"119,132",28
6,Quebec,B03XA,Other antianemic preparations,65+,F,"13,911.81",0.9,0.4,"3,308",29
6,Quebec,A12AA,Calcium,65+,F,"13,858.40",0.9,20.1,"167,044",30
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,"13,559.09",0.9,1.0,"8,512",31
6,Quebec,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,F,"12,016.73",0.8,0.0,202,32
6,Quebec,N05BA,Benzodiazepine derivatives,65+,F,"11,961.66",0.8,19.3,"160,703",33
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"11,571.94",0.8,0.1,783,34
6,Quebec,R03BA,Glucocorticoids,65+,F,"11,544.32",0.8,7.6,"63,518",35
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,65+,F,"11,479.98",0.8,4.5,"37,611",36
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"10,851.04",0.7,1.9,"15,898",37
6,Quebec,L03AA,Colony-stimulating factors,65+,F,"10,823.68",0.7,0.3,"2,327",38
6,Quebec,N02BE,Anilides,65+,F,"10,710.07",0.7,20.6,"171,056",39
6,Quebec,A10BA,Biguanides,65+,F,"9,970.05",0.7,11.8,"97,814",40
6,Quebec,N06DA,Anticholinesterases,65+,F,"9,957.22",0.7,2.9,"24,369",41
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"9,899.95",0.7,5.5,"45,910",42
6,Quebec,N02AA,Natural opium alkaloids,65+,F,"9,614.68",0.6,10.9,"90,555",43
6,Quebec,H01CB,Somatostatin and analogues,65+,F,"9,289.87",0.6,0.1,727,44
6,Quebec,C03CA,"Sulfonamides, plain",65+,F,"9,049.09",0.6,8.1,"67,083",45
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"8,689.76",0.6,1.8,"14,733",46
6,Quebec,S01ED,Beta-blocking agents,65+,F,"8,442.90",0.6,4.7,"39,454",47
6,Quebec,S01EE,Prostaglandin analogues,65+,F,"8,358.05",0.6,4.7,"38,922",48
6,Quebec,N05AX,Other antipsychotics,65+,F,"8,224.89",0.6,2.5,"20,608",49
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"8,016.36",0.5,13.1,"109,062",50
6,Quebec,C08DB,Benzothiazepine derivatives,65+,F,"7,945.65",0.5,3.7,"30,859",51
6,Quebec,S01XA,Other ophthalmologicals,65+,F,"7,886.46",0.5,2.5,"20,553",52
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"7,570.22",0.5,4.2,"34,588",53
6,Quebec,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,F,"7,459.36",0.5,0.0,153,54
6,Quebec,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,"7,401.55",0.5,8.0,"66,853",55
6,Quebec,C10AX,Other lipid-modifying agents,65+,F,"7,313.12",0.5,3.6,"29,650",56
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"7,139.88",0.5,10.0,"82,852",57
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,"7,115.00",0.5,7.9,"66,057",58
6,Quebec,B01AB,Heparin group,65+,F,"6,891.24",0.5,1.1,"9,274",59
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"5,560.81",0.4,1.6,"13,088",60
6,Quebec,A06AA,"Softeners, emollients",65+,F,"5,486.33",0.4,7.2,"59,805",61
6,Quebec,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,65+,F,**,**,**,**,62
6,Quebec,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,F,"5,332.40",0.4,0.0,194,63
6,Quebec,A10BB,Sulfonylureas,65+,F,"5,243.31",0.4,4.9,"40,476",64
6,Quebec,L01XC,Monoclonal antibodies,65+,F,"5,092.38",0.3,0.1,466,65
6,Quebec,L02BG,Aromatase inhibitors,65+,F,"4,922.40",0.3,1.9,"15,789",66
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,"4,883.89",0.3,0.3,"2,244",67
6,Quebec,B03AA,"Iron bivalent, oral preparations",65+,F,"4,687.06",0.3,6.3,"52,611",68
6,Quebec,N04BA,Dopa and dopa derivatives,65+,F,"4,524.30",0.3,0.8,"6,326",69
6,Quebec,L01EX,Other protein kinase inhibitors,65+,F,"4,460.96",0.3,0.0,221,70
6,Quebec,C01DA,Organic nitrates,65+,F,"4,450.40",0.3,4.6,"38,266",71
6,Quebec,R01AD,Corticosteroids,65+,F,"4,421.95",0.3,10.5,"87,067",72
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"4,415.59",0.3,0.0,154,73
6,Quebec,A07EC,Aminosalicylic acid and similar agents,65+,F,"4,347.83",0.3,0.7,"6,226",74
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"4,297.28",0.3,4.8,"39,542",75
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"4,270.08",0.3,0.3,"2,306",76
6,Quebec,C03AA,"Thiazides, plain",65+,F,"3,924.69",0.3,7.1,"59,448",77
6,Quebec,A06AD,Osmotically acting laxatives,65+,F,"3,625.63",0.2,8.3,"69,226",78
6,Quebec,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,65+,F,"3,602.02",0.2,0.0,108,79
6,Quebec,L02BA,Anti-estrogens,65+,F,"3,549.39",0.2,0.5,"4,379",80
6,Quebec,A12BA,Potassium,65+,F,"3,391.96",0.2,3.3,"27,813",81
6,Quebec,C09BA,ACE inhibitors and diuretics,65+,F,"3,353.54",0.2,2.8,"23,451",82
6,Quebec,L01BA,Folic acid analogues,65+,F,"3,321.96",0.2,1.6,"13,718",83
6,Quebec,A06AB,Contact laxatives,65+,F,"3,308.04",0.2,4.3,"35,756",84
6,Quebec,B01AE,Direct thrombin inhibitors,65+,F,"3,082.52",0.2,0.4,"3,665",85
6,Quebec,H05AA,Parathyroid hormones and analogues,65+,F,**,**,**,**,86
6,Quebec,N03AE,Benzodiazepine derivatives,65+,F,"3,070.26",0.2,4.5,"37,269",87
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,"3,027.42",0.2,0.4,"3,312",88
6,Quebec,J05AP,Antivirals for treatment of HCV infections,65+,F,"2,984.15",0.2,0.0,61,89
6,Quebec,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,F,"2,938.03",0.2,0.0,43,90
6,Quebec,H02AB,Glucocorticoids,65+,F,"2,852.12",0.2,8.4,"69,521",91
6,Quebec,L04AD,Calcineurin inhibitors,65+,F,"2,764.99",0.2,0.1,"1,016",92
6,Quebec,N02AB,Phenylpiperidine derivatives,65+,F,"2,567.10",0.2,0.7,"5,603",93
6,Quebec,C07AA,"Beta-blocking agents, non-selective",65+,F,"2,516.92",0.2,2.0,"16,921",94
6,Quebec,N07XX,Other nervous system drugs,65+,F,"2,473.25",0.2,0.1,427,95
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,"2,438.38",0.2,1.1,"9,129",96
6,Quebec,A03FA,Propulsives,65+,F,"2,394.34",0.2,3.4,"27,953",97
6,Quebec,S01EC,Carbonic anhydrase inhibitors,65+,F,"2,305.92",0.2,1.6,"13,165",98
6,Quebec,M04AA,Preparations inhibiting uric acid production,65+,F,"2,296.37",0.2,2.1,"17,541",99
6,Quebec,C03DA,Aldosterone antagonists,65+,F,"2,275.65",0.2,2.3,"18,983",100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,"171,665.60",11.2,0.5,"7,880",1
6,Quebec,L04AA,Selective immunosuppressants,<65,Total,"76,365.46",5.0,0.5,"7,110",2
6,Quebec,N05AX,Other antipsychotics,<65,Total,"75,920.71",4.9,3.2,"50,931",3
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"55,840.09",3.6,0.5,"7,811",4
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"55,784.11",3.6,7.1,"111,792",5
6,Quebec,N06BA,Centrally acting sympathomimetics,<65,Total,"52,166.89",3.4,6.1,"95,845",6
6,Quebec,J05AP,Antivirals for treatment of HCV infections,<65,Total,"36,624.21",2.4,0.1,787,7
6,Quebec,L04AC,Interleukin inhibitors,<65,Total,"34,206.42",2.2,0.1,"1,941",8
6,Quebec,N03AX,Other antiepileptics,<65,Total,"28,881.01",1.9,6.1,"95,109",9
6,Quebec,A02BC,Proton pump inhibitors,<65,Total,"26,143.35",1.7,17.8,"280,207",10
6,Quebec,N06AX,Other antidepressants,<65,Total,"24,451.45",1.6,11.1,"174,338",11
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"24,146.18",1.6,3.3,"52,411",12
6,Quebec,C10AA,HMG-CoA reductase inhibitors,<65,Total,"21,509.53",1.4,13.1,"206,352",13
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"19,697.34",1.3,10.3,"161,622",14
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"19,179.05",1.2,1.8,"28,607",15
6,Quebec,L04AX,Other immunosuppressants,<65,Total,"18,957.34",1.2,0.2,"3,093",16
6,Quebec,N02AA,Natural opium alkaloids,<65,Total,"17,633.80",1.1,7.2,"112,991",17
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,"16,169.96",1.1,0.7,"11,146",18
6,Quebec,A16AB,Enzymes,<65,Total,**,**,**,**,19
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"15,774.71",1.0,0.1,999,20
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"15,581.13",1.0,1.5,"23,738",21
6,Quebec,R03BA,Glucocorticoids,<65,Total,"14,393.09",0.9,6.6,"103,597",22
6,Quebec,S01LA,Antineovascularization agents,<65,Total,"13,952.67",0.9,0.1,"1,399",23
6,Quebec,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,Total,"13,295.24",0.9,0.0,341,24
6,Quebec,A11CC,Vitamin D and analogues,<65,Total,"11,966.73",0.8,12.1,"190,847",25
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"11,913.94",0.8,1.0,"16,252",26
6,Quebec,R07AX,Other respiratory system products,<65,Total,**,**,**,**,27
6,Quebec,R03BB,Anticholinergics,<65,Total,"10,747.33",0.7,1.9,"30,534",28
6,Quebec,B01AF,Direct factor Xa inhibitors,<65,Total,"10,560.53",0.7,1.1,"16,915",29
6,Quebec,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,Total,"10,537.46",0.7,1.1,"16,528",30
6,Quebec,L04AD,Calcineurin inhibitors,<65,Total,"9,637.64",0.6,0.2,"2,884",31
6,Quebec,V06C,Infant formulas,<65,Total,"9,065.94",0.6,0.5,"7,378",32
6,Quebec,C08CA,Dihydropyridine derivatives,<65,Total,"8,955.95",0.6,5.6,"88,265",33
6,Quebec,L03AA,Colony-stimulating factors,<65,Total,"8,854.95",0.6,0.1,"1,833",34
6,Quebec,N07BC,Drugs used in opioid dependence,<65,Total,"8,605.25",0.6,0.4,"6,036",35
6,Quebec,N05BA,Benzodiazepine derivatives,<65,Total,"8,600.91",0.6,6.5,"102,923",36
6,Quebec,H03AA,Thyroid hormones,<65,Total,"8,371.57",0.5,7.1,"111,383",37
6,Quebec,C09AA,"ACE inhibitors, plain",<65,Total,"8,322.12",0.5,5.2,"81,471",38
6,Quebec,J05AJ,Integrase inhibitors,<65,Total,"8,067.66",0.5,0.1,"1,741",39
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"7,859.32",0.5,9.8,"154,627",40
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"7,816.91",0.5,1.1,"17,091",41
6,Quebec,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,Total,"7,437.31",0.5,0.3,"4,887",42
6,Quebec,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"7,313.22",0.5,6.5,"102,111",43
6,Quebec,C02AC,Imidazoline receptor agonists,<65,Total,"7,307.82",0.5,0.7,"11,726",44
6,Quebec,A10BA,Biguanides,<65,Total,"7,127.44",0.5,5.1,"80,477",45
6,Quebec,B01AB,Heparin group,<65,Total,"6,794.35",0.4,0.5,"7,369",46
6,Quebec,N02BA,Salicylic acid and derivatives,<65,Total,"6,607.13",0.4,5.1,"79,506",47
6,Quebec,N07BA,Drugs used in nicotine dependence,<65,Total,"6,577.74",0.4,3.1,"48,161",48
6,Quebec,B03XA,Other antianemic preparations,<65,Total,"6,553.75",0.4,0.1,"1,571",49
6,Quebec,N03AG,Fatty acid derivatives,<65,Total,"6,494.83",0.4,1.1,"17,122",50
6,Quebec,C07AB,"Beta-blocking agents, selective",<65,Total,"6,408.32",0.4,4.1,"64,434",51
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"6,319.70",0.4,0.2,"2,559",52
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,"6,301.42",0.4,3.9,"61,637",53
6,Quebec,L03AB,Interferons,<65,Total,"5,990.74",0.4,0.0,424,54
6,Quebec,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,Total,"5,966.46",0.4,0.0,90,55
6,Quebec,H01CB,Somatostatin and analogues,<65,Total,"5,859.07",0.4,0.0,410,56
6,Quebec,N03AE,Benzodiazepine derivatives,<65,Total,"5,700.74",0.4,3.3,"51,142",57
6,Quebec,L03AX,Other immunostimulants,<65,Total,"5,260.25",0.3,0.0,519,58
6,Quebec,N02BE,Anilides,<65,Total,"5,257.61",0.3,8.7,"137,056",59
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,<65,Total,"5,201.04",0.3,1.9,"29,813",60
6,Quebec,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,Total,"5,118.31",0.3,0.0,186,61
6,Quebec,A07EC,Aminosalicylic acid and similar agents,<65,Total,"4,945.95",0.3,0.5,"8,029",62
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,"4,937.95",0.3,0.1,"2,344",63
6,Quebec,C10AX,Other lipid-modifying agents,<65,Total,"4,859.03",0.3,1.1,"17,318",64
6,Quebec,R01AD,Corticosteroids,<65,Total,"4,847.62",0.3,7.4,"116,233",65
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"4,769.23",0.3,3.0,"46,718",66
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",<65,Total,"4,733.50",0.3,3.4,"52,671",67
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,"4,664.76",0.3,0.1,"2,311",68
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"4,592.06",0.3,1.0,"15,028",69
6,Quebec,N05AE,Indole derivatives,<65,Total,"4,434.95",0.3,0.2,"3,448",70
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,<65,Total,"4,404.59",0.3,1.0,"15,739",71
6,Quebec,L01EX,Other protein kinase inhibitors,<65,Total,"4,363.41",0.3,0.0,165,72
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,<65,Total,"4,339.21",0.3,0.3,"4,419",73
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,"4,307.01",0.3,3.1,"48,983",74
6,Quebec,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,Total,"4,257.74",0.3,0.0,75,75
6,Quebec,L01XC,Monoclonal antibodies,<65,Total,"4,180.49",0.3,0.0,364,76
6,Quebec,A10BB,Sulfonylureas,<65,Total,"3,974.98",0.3,2.4,"38,020",77
6,Quebec,J05AE,Protease inhibitors,<65,Total,"3,839.88",0.2,0.0,738,78
6,Quebec,M03BX,Other centrally acting agents,<65,Total,"3,823.52",0.2,5.4,"84,448",79
6,Quebec,M01AE,Propionic acid derivatives,<65,Total,"3,766.47",0.2,13.0,"204,801",80
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,"3,738.44",0.2,0.1,"2,223",81
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"3,719.85",0.2,0.0,164,82
6,Quebec,G02BA,Intrauterine contraceptives,<65,Total,"3,691.03",0.2,0.8,"12,388",83
6,Quebec,N03AF,Carboxamide derivatives,<65,Total,"3,654.76",0.2,0.5,"7,832",84
6,Quebec,A16AX,Various alimentary tract and metabolism products,<65,Total,"3,631.30",0.2,0.0,239,85
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,"3,561.13",0.2,0.4,"6,260",86
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"3,540.76",0.2,3.9,"61,562",87
6,Quebec,A12AA,Calcium,<65,Total,"3,481.75",0.2,3.0,"47,246",88
6,Quebec,N07XX,Other nervous system drugs,<65,Total,"3,436.75",0.2,0.0,658,89
6,Quebec,A06AA,"Softeners, emollients",<65,Total,"3,423.31",0.2,2.0,"31,665",90
6,Quebec,A16AA,Amino acids and derivatives,<65,Total,"3,386.52",0.2,0.0,198,91
6,Quebec,A04AD,Other antiemetics,<65,Total,"3,260.73",0.2,0.3,"5,171",92
6,Quebec,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,Total,"3,096.47",0.2,0.0,34,93
6,Quebec,C01CA,Adrenergic and dopaminergic agents,<65,Total,"3,056.75",0.2,1.4,"21,797",94
6,Quebec,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,Total,"3,056.24",0.2,0.0,82,95
6,Quebec,J02AC,Triazole derivatives,<65,Total,"2,936.97",0.2,2.5,"39,157",96
6,Quebec,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,<65,Total,"2,869.90",0.2,0.0,64,97
6,Quebec,N02AB,Phenylpiperidine derivatives,<65,Total,"2,698.74",0.2,0.2,"3,785",98
6,Quebec,A09AA,Enzyme preparations,<65,Total,"2,666.53",0.2,0.2,"3,399",99
6,Quebec,J01DH,Carbapenems,<65,Total,"2,622.09",0.2,0.1,"1,480",100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,"89,718.80",11.5,0.6,"3,819",1
6,Quebec,N05AX,Other antipsychotics,<65,M,"52,065.62",6.7,4.3,"28,397",2
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"43,610.75",5.6,0.9,"6,250",3
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"36,600.35",4.7,8.3,"55,636",4
6,Quebec,N06BA,Centrally acting sympathomimetics,<65,M,"30,829.94",4.0,7.9,"52,415",5
6,Quebec,L04AA,Selective immunosuppressants,<65,M,"27,931.90",3.6,0.4,"2,788",6
6,Quebec,J05AP,Antivirals for treatment of HCV infections,<65,M,"25,870.71",3.3,0.1,552,7
6,Quebec,L04AC,Interleukin inhibitors,<65,M,"16,400.75",2.1,0.1,913,8
6,Quebec,N03AX,Other antiepileptics,<65,M,"13,015.03",1.7,6.0,"40,267",9
6,Quebec,C10AA,HMG-CoA reductase inhibitors,<65,M,"11,917.86",1.5,17.7,"118,213",10
6,Quebec,A02BC,Proton pump inhibitors,<65,M,"11,452.93",1.5,17.7,"118,383",11
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"11,016.55",1.4,2.5,"16,684",12
6,Quebec,L04AX,Other immunosuppressants,<65,M,"10,112.85",1.3,0.2,"1,238",13
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"9,891.58",1.3,3.1,"20,854",14
6,Quebec,A16AB,Enzymes,<65,M,**,**,**,**,15
6,Quebec,N02AA,Natural opium alkaloids,<65,M,"9,306.04",1.2,7.6,"50,644",16
6,Quebec,N06AX,Other antidepressants,<65,M,"9,129.80",1.2,9.5,"63,535",17
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,"9,107.59",1.2,2.1,"14,142",18
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,"8,081.66",1.0,0.8,"5,646",19
6,Quebec,S01LA,Antineovascularization agents,<65,M,"8,077.38",1.0,0.1,787,20
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,<65,M,"7,830.48",1.0,8.5,"56,635",21
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"6,710.41",0.9,1.3,"8,921",22
6,Quebec,B01AF,Direct factor Xa inhibitors,<65,M,"6,430.46",0.8,1.5,"10,029",23
6,Quebec,R07AX,Other respiratory system products,<65,M,**,**,**,**,24
6,Quebec,R03BA,Glucocorticoids,<65,M,"6,035.44",0.8,6.4,"42,632",25
6,Quebec,L04AD,Calcineurin inhibitors,<65,M,"5,745.70",0.7,0.3,"1,719",26
6,Quebec,J05AJ,Integrase inhibitors,<65,M,"5,738.41",0.7,0.2,"1,195",27
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"5,716.16",0.7,0.1,338,28
6,Quebec,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,M,"5,612.38",0.7,1.3,"8,940",29
6,Quebec,C02AC,Imidazoline receptor agonists,<65,M,"5,461.53",0.7,1.0,"6,758",30
6,Quebec,N07BC,Drugs used in opioid dependence,<65,M,"5,419.27",0.7,0.6,"3,683",31
6,Quebec,C09AA,"ACE inhibitors, plain",<65,M,"4,974.62",0.6,7.3,"48,862",32
6,Quebec,C08CA,Dihydropyridine derivatives,<65,M,"4,943.16",0.6,7.3,"48,490",33
6,Quebec,R03BB,Anticholinergics,<65,M,"4,800.12",0.6,2.0,"13,548",34
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"4,454.55",0.6,1.4,"9,140",35
6,Quebec,V06C,Infant formulas,<65,M,**,**,**,**,36
6,Quebec,A11CC,Vitamin D and analogues,<65,M,"4,225.85",0.5,7.7,"51,481",37
6,Quebec,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,M,"4,191.26",0.5,0.0,61,38
6,Quebec,N05BA,Benzodiazepine derivatives,<65,M,"3,965.65",0.5,6.0,"40,006",39
6,Quebec,N02BA,Salicylic acid and derivatives,<65,M,"3,911.22",0.5,7.0,"46,734",40
6,Quebec,N03AG,Fatty acid derivatives,<65,M,"3,872.46",0.5,1.5,"9,743",41
6,Quebec,C07AB,"Beta-blocking agents, selective",<65,M,"3,804.12",0.5,5.5,"36,863",42
6,Quebec,A10BA,Biguanides,<65,M,"3,708.68",0.5,6.4,"42,818",43
6,Quebec,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,M,"3,701.00",0.5,0.3,"2,187",44
6,Quebec,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,"3,584.94",0.5,0.3,"1,782",45
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"3,524.33",0.5,9.8,"65,515",46
6,Quebec,B03XA,Other antianemic preparations,<65,M,"3,507.17",0.5,0.1,899,47
6,Quebec,N07BA,Drugs used in nicotine dependence,<65,M,"3,367.57",0.4,3.6,"24,179",48
6,Quebec,L03AA,Colony-stimulating factors,<65,M,"3,217.08",0.4,0.1,655,49
6,Quebec,H01CB,Somatostatin and analogues,<65,M,"3,160.04",0.4,0.0,198,50
6,Quebec,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,M,"3,137.90",0.4,0.0,108,51
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,"3,019.23",0.4,4.6,"30,398",52
6,Quebec,L01EX,Other protein kinase inhibitors,<65,M,"2,968.45",0.4,0.0,105,53
6,Quebec,J05AE,Protease inhibitors,<65,M,**,**,**,**,54
6,Quebec,B01AB,Heparin group,<65,M,"2,895.27",0.4,0.4,"2,987",55
6,Quebec,C10AX,Other lipid-modifying agents,<65,M,"2,782.47",0.4,1.5,"10,317",56
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"2,711.80",0.3,1.5,"9,901",57
6,Quebec,N03AE,Benzodiazepine derivatives,<65,M,"2,648.13",0.3,2.9,"19,572",58
6,Quebec,H03AA,Thyroid hormones,<65,M,"2,391.63",0.3,3.8,"25,534",59
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,<65,M,"2,372.06",0.3,0.9,"6,218",60
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,"2,356.35",0.3,0.2,"1,374",61
6,Quebec,A07EC,Aminosalicylic acid and similar agents,<65,M,"2,296.41",0.3,0.5,"3,493",62
6,Quebec,N02BE,Anilides,<65,M,"2,263.52",0.3,8.8,"58,559",63
6,Quebec,A10BB,Sulfonylureas,<65,M,"2,233.09",0.3,3.3,"22,152",64
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,<65,M,"2,110.81",0.3,3.3,"21,748",65
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"2,083.03",0.3,0.1,720,66
6,Quebec,N05AE,Indole derivatives,<65,M,"2,050.56",0.3,0.2,"1,517",67
6,Quebec,R01AD,Corticosteroids,<65,M,"1,944.24",0.2,6.7,"44,668",68
6,Quebec,A16AA,Amino acids and derivatives,<65,M,"1,893.02",0.2,0.0,109,69
6,Quebec,N03AF,Carboxamide derivatives,<65,M,"1,890.47",0.2,0.6,"4,151",70
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"1,746.77",0.2,2.1,"14,031",71
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,<65,M,**,**,**,**,72
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,"1,646.99",0.2,0.4,"2,854",73
6,Quebec,B02BX,Other systemic hemostatics,<65,M,"1,639.93",0.2,0.0,37,74
6,Quebec,M03BX,Other centrally acting agents,<65,M,"1,578.51",0.2,4.9,"32,470",75
6,Quebec,N07XX,Other nervous system drugs,<65,M,"1,567.82",0.2,0.0,301,76
6,Quebec,A06AA,"Softeners, emollients",<65,M,"1,541.51",0.2,1.8,"11,882",77
6,Quebec,A09AA,Enzyme preparations,<65,M,"1,524.44",0.2,0.2,"1,422",78
6,Quebec,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,"1,501.82",0.2,0.0,316,79
6,Quebec,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,M,"1,474.97",0.2,0.0,26,80
6,Quebec,L03AB,Interferons,<65,M,"1,469.59",0.2,0.0,106,81
6,Quebec,M01AE,Propionic acid derivatives,<65,M,"1,466.30",0.2,12.1,"80,961",82
6,Quebec,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,<65,M,"1,427.22",0.2,0.0,29,83
6,Quebec,C01CA,Adrenergic and dopaminergic agents,<65,M,"1,426.18",0.2,1.4,"9,065",84
6,Quebec,J01DH,Carbapenems,<65,M,"1,424.93",0.2,0.1,784,85
6,Quebec,L02BB,Antiandrogens,<65,M,**,**,**,**,86
6,Quebec,J02AC,Triazole derivatives,<65,M,"1,361.00",0.2,0.5,"3,626",87
6,Quebec,C09BA,ACE inhibitors and diuretics,<65,M,"1,353.16",0.2,1.6,"10,470",88
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,"1,331.51",0.2,0.0,68,89
6,Quebec,A04AD,Other antiemetics,<65,M,"1,319.06",0.2,0.3,"1,980",90
6,Quebec,L03AX,Other immunostimulants,<65,M,"1,308.54",0.2,0.0,127,91
6,Quebec,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,"1,296.36",0.2,0.1,906,92
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,"1,284.64",0.2,0.7,"4,695",93
6,Quebec,R05CB,Mucolytics,<65,M,"1,273.34",0.2,0.0,208,94
6,Quebec,V03AC,Iron-chelating agents,<65,M,"1,261.19",0.2,0.0,44,95
6,Quebec,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,<65,M,"1,259.12",0.2,0.0,30,96
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,<65,M,"1,219.67",0.2,0.7,"4,865",97
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,<65,M,"1,198.15",0.2,0.7,"4,557",98
6,Quebec,B02AB,Proteinase inhibitors,<65,M,**,**,**,**,99
6,Quebec,J01GB,Other aminoglycosides,<65,M,"1,185.49",0.2,0.0,311,100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,"81,946.80",10.8,0.4,"4,061",1
6,Quebec,L04AA,Selective immunosuppressants,<65,F,"48,433.55",6.4,0.5,"4,322",2
6,Quebec,N05AX,Other antipsychotics,<65,F,"23,855.09",3.1,2.5,"22,534",3
6,Quebec,N06BA,Centrally acting sympathomimetics,<65,F,"21,336.95",2.8,4.8,"43,430",4
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"19,183.76",2.5,6.2,"56,156",5
6,Quebec,L04AC,Interleukin inhibitors,<65,F,"17,805.66",2.4,0.1,"1,028",6
6,Quebec,N03AX,Other antiepileptics,<65,F,"15,865.98",2.1,6.1,"54,842",7
6,Quebec,N06AX,Other antidepressants,<65,F,"15,321.65",2.0,12.3,"110,803",8
6,Quebec,A02BC,Proton pump inhibitors,<65,F,"14,690.43",1.9,17.9,"161,824",9
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"14,254.60",1.9,3.5,"31,557",10
6,Quebec,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,F,**,**,**,**,11
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"12,229.33",1.6,0.2,"1,561",12
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,<65,F,"11,866.86",1.6,11.6,"104,987",13
6,Quebec,J05AP,Antivirals for treatment of HCV infections,<65,F,"10,753.50",1.4,0.0,235,14
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"10,058.55",1.3,0.1,661,15
6,Quebec,C10AA,HMG-CoA reductase inhibitors,<65,F,"9,591.67",1.3,9.8,"88,139",16
6,Quebec,L04AX,Other immunosuppressants,<65,F,"8,844.49",1.2,0.2,"1,855",17
6,Quebec,R03BA,Glucocorticoids,<65,F,"8,357.65",1.1,6.7,"60,965",18
6,Quebec,N02AA,Natural opium alkaloids,<65,F,"8,327.76",1.1,6.9,"62,347",19
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"8,162.50",1.1,1.3,"11,923",20
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,"8,088.30",1.1,0.6,"5,500",21
6,Quebec,A11CC,Vitamin D and analogues,<65,F,"7,740.87",1.0,15.4,"139,366",22
6,Quebec,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,"7,312.00",1.0,11.3,"102,094",23
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,"6,473.54",0.9,1.1,"9,596",24
6,Quebec,A16AB,Enzymes,<65,F,**,**,**,**,25
6,Quebec,H03AA,Thyroid hormones,<65,F,"5,979.93",0.8,9.5,"85,849",26
6,Quebec,R03BB,Anticholinergics,<65,F,"5,947.21",0.8,1.9,"16,986",27
6,Quebec,S01LA,Antineovascularization agents,<65,F,"5,875.29",0.8,0.1,612,28
6,Quebec,L03AA,Colony-stimulating factors,<65,F,"5,637.88",0.7,0.1,"1,178",29
6,Quebec,R07AX,Other respiratory system products,<65,F,**,**,**,**,30
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"5,203.52",0.7,0.8,"7,331",31
6,Quebec,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,F,"4,925.08",0.7,0.8,"7,588",32
6,Quebec,V06C,Infant formulas,<65,F,**,**,**,**,33
6,Quebec,N05BA,Benzodiazepine derivatives,<65,F,"4,635.27",0.6,7.0,"62,917",34
6,Quebec,L03AB,Interferons,<65,F,"4,521.15",0.6,0.0,318,35
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"4,334.99",0.6,9.9,"89,112",36
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"4,236.67",0.6,0.2,"1,839",37
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,"4,159.80",0.5,5.4,"48,377",38
6,Quebec,B01AF,Direct factor Xa inhibitors,<65,F,"4,130.07",0.5,0.8,"6,886",39
6,Quebec,C08CA,Dihydropyridine derivatives,<65,F,"4,012.79",0.5,4.4,"39,775",40
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,<65,F,"3,981.37",0.5,2.8,"24,948",41
6,Quebec,L03AX,Other immunostimulants,<65,F,"3,951.72",0.5,0.0,392,42
6,Quebec,B01AB,Heparin group,<65,F,"3,899.08",0.5,0.5,"4,382",43
6,Quebec,L04AD,Calcineurin inhibitors,<65,F,"3,891.93",0.5,0.1,"1,165",44
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,<65,F,"3,877.47",0.5,0.5,"4,114",45
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",<65,F,"3,796.11",0.5,4.9,"44,716",46
6,Quebec,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,F,"3,736.30",0.5,0.3,"2,700",47
6,Quebec,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,48
6,Quebec,A10BA,Biguanides,<65,F,"3,418.77",0.5,4.2,"37,659",49
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"3,362.36",0.4,0.9,"7,951",50
6,Quebec,C09AA,"ACE inhibitors, plain",<65,F,"3,347.49",0.4,3.6,"32,609",51
6,Quebec,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,"3,282.19",0.4,3.5,"31,239",52
6,Quebec,N07BA,Drugs used in nicotine dependence,<65,F,"3,210.18",0.4,2.7,"23,982",53
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,<65,F,"3,206.44",0.4,1.2,"11,182",54
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,<65,F,**,**,**,**,55
6,Quebec,N07BC,Drugs used in opioid dependence,<65,F,"3,185.98",0.4,0.3,"2,353",56
6,Quebec,L01XC,Monoclonal antibodies,<65,F,"3,062.02",0.4,0.0,255,57
6,Quebec,N03AE,Benzodiazepine derivatives,<65,F,"3,052.61",0.4,3.5,"31,570",58
6,Quebec,B03XA,Other antianemic preparations,<65,F,"3,046.58",0.4,0.1,672,59
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"3,022.45",0.4,3.6,"32,687",60
6,Quebec,N02BE,Anilides,<65,F,"2,994.09",0.4,8.7,"78,497",61
6,Quebec,R01AD,Corticosteroids,<65,F,"2,903.38",0.4,7.9,"71,565",62
6,Quebec,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,<65,F,**,**,**,**,63
6,Quebec,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,F,"2,782.76",0.4,0.0,49,64
6,Quebec,H01CB,Somatostatin and analogues,<65,F,"2,699.03",0.4,0.0,212,65
6,Quebec,N02BA,Salicylic acid and derivatives,<65,F,"2,695.92",0.4,3.6,"32,772",66
6,Quebec,A07EC,Aminosalicylic acid and similar agents,<65,F,"2,649.54",0.3,0.5,"4,536",67
6,Quebec,N03AG,Fatty acid derivatives,<65,F,"2,622.37",0.3,0.8,"7,379",68
6,Quebec,C07AB,"Beta-blocking agents, selective",<65,F,"2,604.20",0.3,3.1,"27,571",69
6,Quebec,G03GA,Gonadotropins,<65,F,**,**,**,**,70
6,Quebec,A12AA,Calcium,<65,F,"2,547.65",0.3,4.3,"38,534",71
6,Quebec,A16AX,Various alimentary tract and metabolism products,<65,F,"2,451.67",0.3,0.0,154,72
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,"2,425.83",0.3,5.0,"45,085",73
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"2,388.35",0.3,0.0,96,74
6,Quebec,N05AE,Indole derivatives,<65,F,"2,384.39",0.3,0.2,"1,931",75
6,Quebec,J05AJ,Integrase inhibitors,<65,F,"2,329.24",0.3,0.1,546,76
6,Quebec,M01AE,Propionic acid derivatives,<65,F,"2,300.17",0.3,13.7,"123,840",77
6,Quebec,M03BX,Other centrally acting agents,<65,F,"2,245.02",0.3,5.8,"51,978",78
6,Quebec,C10AX,Other lipid-modifying agents,<65,F,"2,076.57",0.3,0.8,"7,001",79
6,Quebec,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,F,"2,015.31",0.3,0.0,20,80
6,Quebec,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,F,"1,980.41",0.3,0.0,78,81
6,Quebec,A04AD,Other antiemetics,<65,F,"1,941.67",0.3,0.4,"3,191",82
6,Quebec,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,F,"1,926.91",0.3,0.0,60,83
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,"1,914.14",0.3,0.4,"3,406",84
6,Quebec,A06AA,"Softeners, emollients",<65,F,"1,881.80",0.2,2.2,"19,783",85
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"1,880.26",0.2,0.6,"5,127",86
6,Quebec,N07XX,Other nervous system drugs,<65,F,"1,868.93",0.2,0.0,357,87
6,Quebec,C02AC,Imidazoline receptor agonists,<65,F,"1,846.29",0.2,0.5,"4,968",88
6,Quebec,S01XA,Other ophthalmologicals,<65,F,"1,830.12",0.2,0.5,"4,487",89
6,Quebec,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,F,"1,775.20",0.2,0.0,29,90
6,Quebec,N03AF,Carboxamide derivatives,<65,F,"1,764.29",0.2,0.4,"3,681",91
6,Quebec,A10BB,Sulfonylureas,<65,F,"1,741.89",0.2,1.8,"15,868",92
6,Quebec,M05BA,Bisphosphonates,<65,F,"1,718.43",0.2,1.4,"12,897",93
6,Quebec,C01CA,Adrenergic and dopaminergic agents,<65,F,"1,630.57",0.2,1.4,"12,732",94
6,Quebec,N02AB,Phenylpiperidine derivatives,<65,F,"1,610.40",0.2,0.3,"2,359",95
6,Quebec,J02AC,Triazole derivatives,<65,F,"1,575.97",0.2,3.9,"35,531",96
6,Quebec,G03AC,Progestogens,<65,F,"1,521.02",0.2,2.8,"24,949",97
6,Quebec,A16AA,Amino acids and derivatives,<65,F,"1,493.50",0.2,0.0,89,98
6,Quebec,G03DA,Pregnen (4) derivatives,<65,F,"1,492.56",0.2,2.3,"20,991",99
6,Quebec,A06AD,Osmotically acting laxatives,<65,F,"1,436.42",0.2,3.0,"26,923",100
7,Ontario,S01LA,Antineovascularization agents,Total,Total,"490,716.08",7.1,1.2,"51,453",1
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"344,602.96",5.0,0.4,"17,299",2
7,Ontario,L04AX,Other immunosuppressants,Total,Total,"251,849.13",3.7,0.4,"15,983",3
7,Ontario,B01AF,Direct factor Xa inhibitors,Total,Total,"238,660.88",3.5,6.3,"259,288",4
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"173,170.66",2.5,4.2,"171,520",5
7,Ontario,L04AA,Selective immunosuppressants,Total,Total,"164,692.07",2.4,0.6,"24,810",6
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"162,260.33",2.4,4.5,"187,117",7
7,Ontario,N05AX,Other antipsychotics,Total,Total,"160,509.49",2.3,3.0,"125,203",8
7,Ontario,J05AP,Antivirals for treatment of HCV infections,Total,Total,"158,803.93",2.3,0.1,"3,240",9
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"154,411.43",2.2,6.2,"255,678",10
7,Ontario,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,Total,"148,717.33",2.2,3.7,"154,856",11
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"134,135.26",1.9,0.3,"13,246",12
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"133,597.12",1.9,3.7,"151,675",13
7,Ontario,C10AA,HMG-CoA reductase inhibitors,Total,Total,"120,254.99",1.7,35.2,"1,453,552",14
7,Ontario,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,Total,"114,106.10",1.7,0.0,"1,467",15
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,"96,524.47",1.4,1.4,"58,510",16
7,Ontario,A02BC,Proton pump inhibitors,Total,Total,"92,070.33",1.3,23.7,"980,871",17
7,Ontario,N07BC,Drugs used in opioid dependence,Total,Total,"87,709.40",1.3,1.1,"44,142",18
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"87,285.55",1.3,3.0,"124,627",19
7,Ontario,L04AC,Interleukin inhibitors,Total,Total,"86,814.64",1.3,0.1,"5,784",20
7,Ontario,N06AX,Other antidepressants,Total,Total,"85,807.80",1.2,11.4,"469,076",21
7,Ontario,N03AX,Other antiepileptics,Total,Total,"84,942.41",1.2,8.5,"353,121",22
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"68,522.15",1.0,11.1,"456,453",23
7,Ontario,L03AA,Colony-stimulating factors,Total,Total,"65,600.76",1.0,0.2,"10,240",24
7,Ontario,N02AA,Natural opium alkaloids,Total,Total,"64,047.70",0.9,6.0,"246,861",25
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"62,034.27",0.9,0.5,"18,739",26
7,Ontario,R03BB,Anticholinergics,Total,Total,"61,716.83",0.9,3.8,"156,693",27
7,Ontario,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,Total,"61,228.04",0.9,0.0,"1,347",28
7,Ontario,C08CA,Dihydropyridine derivatives,Total,Total,"58,891.01",0.9,15.3,"633,160",29
7,Ontario,C09AA,"ACE inhibitors, plain",Total,Total,"56,284.97",0.8,16.1,"666,944",30
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"55,632.75",0.8,11.7,"483,300",31
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"54,874.44",0.8,0.1,"3,154",32
7,Ontario,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,Total,"52,527.30",0.8,0.0,879,33
7,Ontario,N06BA,Centrally acting sympathomimetics,Total,Total,"49,025.75",0.7,1.9,"80,102",34
7,Ontario,L02BX,Other hormone antagonists and related agents,Total,Total,"47,900.08",0.7,0.1,"2,695",35
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"46,421.33",0.7,3.0,"124,503",36
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"46,077.84",0.7,2.0,"81,163",37
7,Ontario,M05BA,Bisphosphonates,Total,Total,"45,491.72",0.7,4.5,"184,403",38
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"43,612.91",0.6,4.1,"168,437",39
7,Ontario,L01EX,Other protein kinase inhibitors,Total,Total,"42,430.50",0.6,0.0,"1,754",40
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"40,830.07",0.6,1.4,"57,295",41
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"38,349.77",0.6,3.5,"146,526",42
7,Ontario,R03BA,Glucocorticoids,Total,Total,"38,012.86",0.6,4.6,"189,719",43
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,Total,"37,433.37",0.5,0.5,"22,667",44
7,Ontario,L04AD,Calcineurin inhibitors,Total,Total,"37,371.34",0.5,0.3,"10,751",45
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"37,060.66",0.5,0.4,"16,569",46
7,Ontario,H01CB,Somatostatin and analogues,Total,Total,"36,179.98",0.5,0.1,"2,128",47
7,Ontario,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,Total,"36,077.70",0.5,0.0,643,48
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"36,046.67",0.5,6.4,"262,717",49
7,Ontario,L02BB,Antiandrogens,Total,Total,"35,546.35",0.5,0.2,"8,272",50
7,Ontario,S01EE,Prostaglandin analogues,Total,Total,"34,529.98",0.5,3.2,"132,490",51
7,Ontario,C07AB,"Beta-blocking agents, selective",Total,Total,"33,733.90",0.5,14.3,"591,417",52
7,Ontario,C10AX,Other lipid-modifying agents,Total,Total,"32,527.09",0.5,3.5,"144,854",53
7,Ontario,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,Total,"32,075.39",0.5,0.0,"1,009",54
7,Ontario,B03XA,Other antianemic preparations,Total,Total,"30,237.15",0.4,0.1,"3,379",55
7,Ontario,S01ED,Beta-blocking agents,Total,Total,"27,965.57",0.4,2.9,"118,373",56
7,Ontario,A16AB,Enzymes,Total,Total,"25,982.65",0.4,0.0,54,57
7,Ontario,H03AA,Thyroid hormones,Total,Total,"25,938.15",0.4,11.3,"466,237",58
7,Ontario,B01AB,Heparin group,Total,Total,"25,112.19",0.4,0.4,"14,557",59
7,Ontario,C08DB,Benzothiazepine derivatives,Total,Total,"24,783.42",0.4,2.1,"85,964",60
7,Ontario,N04BA,Dopa and dopa derivatives,Total,Total,"24,545.31",0.4,0.8,"33,563",61
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"23,760.02",0.3,0.3,"10,706",62
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"23,554.75",0.3,9.1,"377,800",63
7,Ontario,A07EC,Aminosalicylic acid and similar agents,Total,Total,"22,073.95",0.3,0.6,"26,714",64
7,Ontario,M09AX,Other drugs for disorders of the musculoskeletal system,Total,Total,"20,133.05",0.3,0.0,54,65
7,Ontario,A10BA,Biguanides,Total,Total,"19,430.93",0.3,9.3,"384,675",66
7,Ontario,C09BA,ACE inhibitors and diuretics,Total,Total,"19,387.49",0.3,3.0,"122,846",67
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"19,283.47",0.3,12.0,"494,962",68
7,Ontario,R01AD,Corticosteroids,Total,Total,"18,758.94",0.3,6.2,"255,799",69
7,Ontario,B01AE,Direct thrombin inhibitors,Total,Total,"17,556.42",0.3,0.4,"18,542",70
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"17,071.93",0.2,2.3,"94,738",71
7,Ontario,V06,General nutrients,Total,Total,"16,992.62",0.2,0.0,440,72
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"16,886.31",0.2,3.0,"123,425",73
7,Ontario,A04AD,Other antiemetics,Total,Total,"16,710.35",0.2,0.6,"23,278",74
7,Ontario,N05BA,Benzodiazepine derivatives,Total,Total,"16,229.59",0.2,6.5,"268,531",75
7,Ontario,N05AE,Indole derivatives,Total,Total,"15,940.38",0.2,0.3,"10,588",76
7,Ontario,N06DA,Anticholinesterases,Total,Total,"15,559.09",0.2,1.4,"59,343",77
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"14,880.65",0.2,0.5,"19,401",78
7,Ontario,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,Total,"14,574.18",0.2,0.0,194,79
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"14,552.06",0.2,2.8,"115,245",80
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,"13,801.07",0.2,3.3,"136,740",81
7,Ontario,B03AA,"Iron bivalent, oral preparations",Total,Total,"13,432.82",0.2,5.1,"212,510",82
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"13,415.81",0.2,0.0,598,83
7,Ontario,N03AG,Fatty acid derivatives,Total,Total,"13,225.85",0.2,0.8,"34,835",84
7,Ontario,J05AJ,Integrase inhibitors,Total,Total,"13,047.77",0.2,0.1,"2,172",85
7,Ontario,N02BE,Anilides,Total,Total,"12,947.73",0.2,8.8,"365,452",86
7,Ontario,D07AC,"Corticosteroids, potent (group III)",Total,Total,"12,127.49",0.2,9.0,"372,107",87
7,Ontario,A10BB,Sulfonylureas,Total,Total,"12,094.90",0.2,3.7,"154,800",88
7,Ontario,L03AB,Interferons,Total,Total,"11,998.34",0.2,0.0,669,89
7,Ontario,A06AB,Contact laxatives,Total,Total,"11,918.48",0.2,6.3,"259,647",90
7,Ontario,L01XE,Protein kinase inhibitors,Total,Total,"11,797.96",0.2,0.0,"1,412",91
7,Ontario,L01XC,Monoclonal antibodies,Total,Total,"11,690.69",0.2,0.0,"1,082",92
7,Ontario,C03CA,"Sulfonamides, plain",Total,Total,"11,164.92",0.2,6.1,"250,923",93
7,Ontario,H01AC,Somatropin and somatropin agonists,Total,Total,"11,152.45",0.2,0.0,973,94
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,Total,"10,949.14",0.2,0.8,"32,803",95
7,Ontario,V03AC,Iron-chelating agents,Total,Total,"10,900.63",0.2,0.0,457,96
7,Ontario,N03AE,Benzodiazepine derivatives,Total,Total,"10,894.25",0.2,2.5,"102,441",97
7,Ontario,C01CA,Adrenergic and dopaminergic agents,Total,Total,"10,843.15",0.2,1.3,"53,206",98
7,Ontario,D05AX,Other antipsoriatics for topical use,Total,Total,"10,682.63",0.2,0.7,"29,658",99
7,Ontario,A07AA,Antibiotics,Total,Total,"10,292.64",0.1,1.2,"49,256",100
7,Ontario,S01LA,Antineovascularization agents,Total,M,"213,307.76",6.1,1.2,"22,827",1
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,"167,135.96",4.8,0.4,"7,739",2
7,Ontario,L04AX,Other immunosuppressants,Total,M,"142,121.62",4.1,0.4,"6,942",3
7,Ontario,B01AF,Direct factor Xa inhibitors,Total,M,"124,552.56",3.6,7.2,"135,002",4
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"103,470.01",3.0,0.5,"10,350",5
7,Ontario,J05AP,Antivirals for treatment of HCV infections,Total,M,"103,097.28",3.0,0.1,"2,105",6
7,Ontario,N05AX,Other antipsychotics,Total,M,"99,526.31",2.9,3.2,"59,784",7
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"99,146.51",2.8,5.2,"98,122",8
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"96,556.61",2.8,5.9,"110,863",9
7,Ontario,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,M,"76,746.34",2.2,0.1,981,10
7,Ontario,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,M,"75,445.22",2.2,4.2,"79,191",11
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"72,978.01",2.1,4.3,"81,123",12
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"66,315.16",1.9,5.6,"106,089",13
7,Ontario,C10AA,HMG-CoA reductase inhibitors,Total,M,"61,530.53",1.8,40.3,"759,629",14
7,Ontario,L04AA,Selective immunosuppressants,Total,M,"58,720.27",1.7,0.5,"10,343",15
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"56,876.35",1.6,0.9,"16,753",16
7,Ontario,N07BC,Drugs used in opioid dependence,Total,M,"50,946.15",1.5,1.4,"25,674",17
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,"50,046.53",1.4,1.6,"29,616",18
7,Ontario,L02BX,Other hormone antagonists and related agents,Total,M,"47,854.28",1.4,0.1,"2,694",19
7,Ontario,L04AC,Interleukin inhibitors,Total,M,"40,255.41",1.2,0.1,"2,590",20
7,Ontario,A02BC,Proton pump inhibitors,Total,M,"38,066.87",1.1,22.0,"414,653",21
7,Ontario,N03AX,Other antiepileptics,Total,M,"37,417.82",1.1,7.6,"143,276",22
7,Ontario,L02BB,Antiandrogens,Total,M,"35,531.79",1.0,0.4,"8,237",23
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"34,702.26",1.0,13.3,"250,432",24
7,Ontario,L01EX,Other protein kinase inhibitors,Total,M,"31,594.76",0.9,0.1,"1,255",25
7,Ontario,N06AX,Other antidepressants,Total,M,"31,201.27",0.9,9.2,"172,835",26
7,Ontario,N02AA,Natural opium alkaloids,Total,M,"30,700.04",0.9,5.5,"104,317",27
7,Ontario,R03BB,Anticholinergics,Total,M,"30,434.18",0.9,4.0,"76,087",28
7,Ontario,N06BA,Centrally acting sympathomimetics,Total,M,"30,162.70",0.9,2.6,"48,495",29
7,Ontario,C09AA,"ACE inhibitors, plain",Total,M,"29,524.70",0.8,19.2,"362,427",30
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,"26,792.38",0.8,0.6,"11,951",31
7,Ontario,C08CA,Dihydropyridine derivatives,Total,M,"26,780.98",0.8,15.5,"291,653",32
7,Ontario,L03AA,Colony-stimulating factors,Total,M,"25,623.88",0.7,0.2,"4,187",33
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,Total,M,"25,505.63",0.7,8.4,"158,975",34
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"25,456.70",0.7,2.3,"42,546",35
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"23,851.77",0.7,4.2,"78,843",36
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"22,992.70",0.7,11.1,"208,211",37
7,Ontario,L04AD,Calcineurin inhibitors,Total,M,"22,920.80",0.7,0.4,"6,648",38
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"22,200.52",0.6,1.6,"30,617",39
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,M,"22,078.40",0.6,0.7,"12,608",40
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"21,317.44",0.6,0.1,"1,158",41
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"18,543.53",0.5,4.6,"87,327",42
7,Ontario,H01CB,Somatostatin and analogues,Total,M,"18,306.34",0.5,0.1,989,43
7,Ontario,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,M,"17,993.79",0.5,0.0,330,44
7,Ontario,A16AB,Enzymes,Total,M,"17,756.15",0.5,0.0,34,45
7,Ontario,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,M,"17,738.35",0.5,0.0,319,46
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,Total,M,"17,540.80",0.5,2.4,"45,965",47
7,Ontario,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,M,"17,482.02",0.5,0.0,539,48
7,Ontario,C10AX,Other lipid-modifying agents,Total,M,"17,468.20",0.5,4.3,"80,613",49
7,Ontario,B03XA,Other antianemic preparations,Total,M,"16,596.66",0.5,0.1,"1,662",50
7,Ontario,C07AB,"Beta-blocking agents, selective",Total,M,"16,579.31",0.5,16.1,"303,647",51
7,Ontario,R03BA,Glucocorticoids,Total,M,"15,947.22",0.5,4.4,"82,529",52
7,Ontario,S01EE,Prostaglandin analogues,Total,M,"15,112.35",0.4,3.1,"59,085",53
7,Ontario,N04BA,Dopa and dopa derivatives,Total,M,"14,870.81",0.4,1.0,"18,860",54
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"14,538.45",0.4,6.1,"115,085",55
7,Ontario,S01ED,Beta-blocking agents,Total,M,"12,951.31",0.4,3.0,"55,664",56
7,Ontario,B01AB,Heparin group,Total,M,"12,346.13",0.4,0.4,"6,599",57
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,Total,M,"11,393.60",0.3,0.7,"13,205",58
7,Ontario,M09AX,Other drugs for disorders of the musculoskeletal system,Total,M,"11,027.53",0.3,0.0,33,59
7,Ontario,A07EC,Aminosalicylic acid and similar agents,Total,M,"10,958.81",0.3,0.6,"11,937",60
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"10,856.91",0.3,9.1,"170,506",61
7,Ontario,B01AE,Direct thrombin inhibitors,Total,M,"10,289.03",0.3,0.6,"11,079",62
7,Ontario,C08DB,Benzothiazepine derivatives,Total,M,"10,235.38",0.3,1.9,"35,285",63
7,Ontario,C09BA,ACE inhibitors and diuretics,Total,M,"10,030.92",0.3,3.4,"63,680",64
7,Ontario,J05AJ,Integrase inhibitors,Total,M,"9,835.89",0.3,0.1,"1,514",65
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"9,808.53",0.3,0.2,"3,947",66
7,Ontario,A10BA,Biguanides,Total,M,"9,808.07",0.3,10.7,"201,661",67
7,Ontario,M05BA,Bisphosphonates,Total,M,"9,323.77",0.3,1.9,"35,101",68
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,Total,M,"8,804.21",0.3,1.0,"18,140",69
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"8,745.57",0.3,11.4,"213,995",70
7,Ontario,R01AD,Corticosteroids,Total,M,"8,598.50",0.2,5.9,"111,684",71
7,Ontario,V06,General nutrients,Total,M,"8,130.21",0.2,0.0,192,72
7,Ontario,N03AG,Fatty acid derivatives,Total,M,"7,689.72",0.2,1.0,"18,638",73
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,"7,637.74",0.2,0.5,"9,714",74
7,Ontario,A04AD,Other antiemetics,Total,M,"7,329.18",0.2,0.5,"9,596",75
7,Ontario,H01AC,Somatropin and somatropin agonists,Total,M,"7,120.15",0.2,0.0,596,76
7,Ontario,N05BA,Benzodiazepine derivatives,Total,M,"6,803.56",0.2,5.0,"94,532",77
7,Ontario,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,M,"6,478.06",0.2,0.0,81,78
7,Ontario,H03AA,Thyroid hormones,Total,M,"6,442.26",0.2,6.1,"114,785",79
7,Ontario,A10BB,Sulfonylureas,Total,M,"6,391.29",0.2,4.5,"85,592",80
7,Ontario,D05AX,Other antipsoriatics for topical use,Total,M,"6,158.66",0.2,0.8,"15,700",81
7,Ontario,N05AE,Indole derivatives,Total,M,"6,115.93",0.2,0.2,"3,912",82
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,"6,106.76",0.2,2.1,"40,007",83
7,Ontario,N06DA,Anticholinesterases,Total,M,"6,024.30",0.2,1.3,"23,579",84
7,Ontario,D07AC,"Corticosteroids, potent (group III)",Total,M,"6,015.68",0.2,9.1,"171,079",85
7,Ontario,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,Total,M,"5,894.60",0.2,0.0,137,86
7,Ontario,M04AA,Preparations inhibiting uric acid production,Total,M,"5,870.58",0.2,4.5,"84,968",87
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,"5,764.21",0.2,3.1,"59,297",88
7,Ontario,L01XE,Protein kinase inhibitors,Total,M,"5,719.70",0.2,0.0,718,89
7,Ontario,V03AC,Iron-chelating agents,Total,M,"5,500.47",0.2,0.0,239,90
7,Ontario,L01XX,Other antineoplastic agents,Total,M,"5,450.76",0.2,0.1,"2,765",91
7,Ontario,C01CA,Adrenergic and dopaminergic agents,Total,M,"5,246.66",0.2,1.3,"24,245",92
7,Ontario,A07AA,Antibiotics,Total,M,"5,236.26",0.2,1.0,"19,427",93
7,Ontario,A06AB,Contact laxatives,Total,M,"5,226.30",0.2,6.2,"117,638",94
7,Ontario,J05AE,Protease inhibitors,Total,M,"5,198.85",0.1,0.0,909,95
7,Ontario,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,Total,M,"5,159.37",0.1,0.0,143,96
7,Ontario,B03AA,"Iron bivalent, oral preparations",Total,M,"5,103.35",0.1,4.3,"81,131",97
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"5,092.91",0.1,0.2,"3,823",98
7,Ontario,A16AX,Various alimentary tract and metabolism products,Total,M,"5,024.16",0.1,0.0,36,99
7,Ontario,N03AE,Benzodiazepine derivatives,Total,M,"4,913.47",0.1,2.1,"39,416",100
7,Ontario,S01LA,Antineovascularization agents,Total,F,"277,402.29",8.1,1.3,"28,625",1
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,"177,446.29",5.2,0.4,"9,559",2
7,Ontario,B01AF,Direct factor Xa inhibitors,Total,F,"114,063.10",3.3,5.5,"124,230",3
7,Ontario,L04AX,Other immunosuppressants,Total,F,"109,726.15",3.2,0.4,"9,035",4
7,Ontario,L04AA,Selective immunosuppressants,Total,F,"105,955.16",3.1,0.6,"14,461",5
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"88,035.95",2.6,6.7,"149,493",6
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"75,870.91",2.2,5.0,"111,389",7
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"73,834.87",2.2,3.3,"73,205",8
7,Ontario,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,F,"73,166.63",2.1,3.4,"75,554",9
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"65,570.41",1.9,3.4,"76,089",10
7,Ontario,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,F,"61,050.82",1.8,0.1,"1,342",11
7,Ontario,N05AX,Other antipsychotics,Total,F,"60,824.39",1.8,2.9,"65,302",12
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"60,545.57",1.8,3.1,"70,437",13
7,Ontario,C10AA,HMG-CoA reductase inhibitors,Total,F,"58,639.04",1.7,30.9,"693,100",14
7,Ontario,J05AP,Antivirals for treatment of HCV infections,Total,F,"55,536.97",1.6,0.1,"1,132",15
7,Ontario,N06AX,Other antidepressants,Total,F,"54,552.49",1.6,13.2,"295,843",16
7,Ontario,A02BC,Proton pump inhibitors,Total,F,"53,936.63",1.6,25.2,"565,377",17
7,Ontario,N03AX,Other antiepileptics,Total,F,"47,462.91",1.4,9.3,"209,590",18
7,Ontario,L04AC,Interleukin inhibitors,Total,F,"46,559.23",1.4,0.1,"3,194",19
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,"46,437.44",1.4,1.3,"28,867",20
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,Total,F,"42,969.96",1.3,13.2,"297,145",21
7,Ontario,L03AA,Colony-stimulating factors,Total,F,"39,973.79",1.2,0.3,"6,052",22
7,Ontario,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,F,"37,359.76",1.1,0.0,486,23
7,Ontario,N07BC,Drugs used in opioid dependence,Total,F,"36,711.65",1.1,0.8,"18,429",24
7,Ontario,M05BA,Bisphosphonates,Total,F,"36,141.99",1.1,6.7,"149,207",25
7,Ontario,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,F,"34,788.95",1.0,0.0,560,26
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"33,557.00",1.0,0.1,"1,996",27
7,Ontario,N02AA,Natural opium alkaloids,Total,F,"33,328.43",1.0,6.4,"142,462",28
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"32,603.64",1.0,12.2,"274,819",29
7,Ontario,C08CA,Dihydropyridine derivatives,Total,F,"32,060.27",0.9,15.2,"341,093",30
7,Ontario,R03BB,Anticholinergics,Total,F,"31,264.77",0.9,3.6,"80,556",31
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"29,431.36",0.9,0.1,"2,785",32
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,Total,F,"28,867.24",0.8,3.5,"78,496",33
7,Ontario,C09AA,"ACE inhibitors, plain",Total,F,"26,723.92",0.8,13.6,"304,149",34
7,Ontario,R03BA,Glucocorticoids,Total,F,"22,043.58",0.6,4.8,"107,072",35
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"20,589.14",0.6,1.7,"38,557",36
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"19,786.27",0.6,2.6,"59,113",37
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"19,727.94",0.6,4.0,"89,437",38
7,Ontario,H03AA,Thyroid hormones,Total,F,"19,481.55",0.6,15.7,"351,261",39
7,Ontario,S01EE,Prostaglandin analogues,Total,F,"19,407.50",0.6,3.3,"73,376",40
7,Ontario,N06BA,Centrally acting sympathomimetics,Total,F,"18,838.43",0.6,1.4,"31,570",41
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"18,621.50",0.5,1.2,"26,668",42
7,Ontario,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,F,"18,083.91",0.5,0.0,313,43
7,Ontario,H01CB,Somatostatin and analogues,Total,F,"17,873.65",0.5,0.1,"1,139",44
7,Ontario,C07AB,"Beta-blocking agents, selective",Total,F,"17,129.38",0.5,12.8,"287,467",45
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"16,759.13",0.5,4.2,"93,426",46
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,F,"15,304.42",0.4,0.4,"10,036",47
7,Ontario,C10AX,Other lipid-modifying agents,Total,F,"15,049.08",0.4,2.9,"64,188",48
7,Ontario,S01ED,Beta-blocking agents,Total,F,"15,002.17",0.4,2.8,"62,675",49
7,Ontario,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,F,"14,593.37",0.4,0.0,470,50
7,Ontario,C08DB,Benzothiazepine derivatives,Total,F,"14,544.86",0.4,2.3,"50,668",51
7,Ontario,L04AD,Calcineurin inhibitors,Total,F,"14,434.53",0.4,0.2,"4,100",52
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"13,931.74",0.4,0.3,"6,754",53
7,Ontario,B03XA,Other antianemic preparations,Total,F,"13,640.49",0.4,0.1,"1,717",54
7,Ontario,B01AB,Heparin group,Total,F,"12,762.55",0.4,0.4,"7,953",55
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"12,686.75",0.4,9.2,"207,051",56
7,Ontario,A07EC,Aminosalicylic acid and similar agents,Total,F,"11,108.10",0.3,0.7,"14,768",57
7,Ontario,L01EX,Other protein kinase inhibitors,Total,F,"10,835.74",0.3,0.0,499,58
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"10,770.60",0.3,3.7,"83,288",59
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"10,526.58",0.3,12.5,"280,707",60
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,"10,256.92",0.3,0.2,"4,612",61
7,Ontario,R01AD,Corticosteroids,Total,F,"10,145.33",0.3,6.4,"143,891",62
7,Ontario,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"9,836.29",0.3,3.8,"85,549",63
7,Ontario,N05AE,Indole derivatives,Total,F,"9,815.87",0.3,0.3,"6,669",64
7,Ontario,N04BA,Dopa and dopa derivatives,Total,F,"9,669.94",0.3,0.7,"14,693",65
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"9,619.27",0.3,0.0,411,66
7,Ontario,A10BA,Biguanides,Total,F,"9,598.31",0.3,8.1,"182,685",67
7,Ontario,N06DA,Anticholinesterases,Total,F,"9,529.06",0.3,1.6,"35,744",68
7,Ontario,N05BA,Benzodiazepine derivatives,Total,F,"9,418.37",0.3,7.7,"173,869",69
7,Ontario,A04AD,Other antiemetics,Total,F,"9,373.73",0.3,0.6,"13,675",70
7,Ontario,C09BA,ACE inhibitors and diuretics,Total,F,"9,336.46",0.3,2.6,"59,046",71
7,Ontario,M09AX,Other drugs for disorders of the musculoskeletal system,Total,F,"9,105.51",0.3,0.0,21,72
7,Ontario,L03AB,Interferons,Total,F,"8,916.17",0.3,0.0,483,73
7,Ontario,V06,General nutrients,Total,F,"8,862.41",0.3,0.0,248,74
7,Ontario,N02BE,Anilides,Total,F,"8,331.10",0.2,9.8,"220,529",75
7,Ontario,B03AA,"Iron bivalent, oral preparations",Total,F,"8,313.09",0.2,5.8,"131,117",76
7,Ontario,L02BG,Aromatase inhibitors,Total,F,"8,275.08",0.2,1.0,"23,161",77
7,Ontario,A16AB,Enzymes,Total,F,"8,226.49",0.2,0.0,20,78
7,Ontario,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,F,"8,096.12",0.2,0.0,113,79
7,Ontario,L01XC,Monoclonal antibodies,Total,F,"8,082.37",0.2,0.0,737,80
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,"8,026.44",0.2,3.4,"77,364",81
7,Ontario,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,Total,F,"7,329.19",0.2,0.0,118,82
7,Ontario,B01AE,Direct thrombin inhibitors,Total,F,"7,266.72",0.2,0.3,"7,462",83
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,"7,229.49",0.2,0.4,"9,663",84
7,Ontario,A06AB,Contact laxatives,Total,F,"6,681.51",0.2,6.3,"141,836",85
7,Ontario,C03CA,"Sulfonamides, plain",Total,F,"6,288.44",0.2,6.2,"138,293",86
7,Ontario,D07AC,"Corticosteroids, potent (group III)",Total,F,"6,098.48",0.2,8.9,"200,744",87
7,Ontario,L01XE,Protein kinase inhibitors,Total,F,"6,078.26",0.2,0.0,694,88
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,F,"6,072.98",0.2,0.9,"19,503",89
7,Ontario,N03AE,Benzodiazepine derivatives,Total,F,"5,975.39",0.2,2.8,"62,962",90
7,Ontario,L03AX,Other immunostimulants,Total,F,"5,970.28",0.2,0.0,558,91
7,Ontario,A10BB,Sulfonylureas,Total,F,"5,688.95",0.2,3.1,"69,076",92
7,Ontario,C01CA,Adrenergic and dopaminergic agents,Total,F,"5,593.39",0.2,1.3,"28,946",93
7,Ontario,N03AG,Fatty acid derivatives,Total,F,"5,528.99",0.2,0.7,"16,166",94
7,Ontario,H02AB,Glucocorticoids,Total,F,"5,497.44",0.2,7.9,"176,944",95
7,Ontario,V03AC,Iron-chelating agents,Total,F,"5,400.16",0.2,0.0,218,96
7,Ontario,D06AX,Other antibiotics for topical use,Total,F,"5,325.17",0.2,5.5,"123,009",97
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,Total,F,"5,143.34",0.2,0.1,"1,981",98
7,Ontario,A04AA,Serotonin (5HT3) antagonists,Total,F,"5,084.06",0.1,0.7,"15,734",99
7,Ontario,A07AA,Antibiotics,Total,F,"5,048.34",0.1,1.3,"29,803",100
7,Ontario,S01LA,Antineovascularization agents,65+,Total,"465,605.23",10.2,2.0,"48,723",1
7,Ontario,B01AF,Direct factor Xa inhibitors,65+,Total,"228,739.95",5.0,9.9,"245,121",2
7,Ontario,L04AX,Other immunosuppressants,65+,Total,"199,960.42",4.4,0.4,"10,935",3
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"142,752.95",3.1,5.6,"137,822",4
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,"137,623.33",3.0,0.3,"7,329",5
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"131,461.40",2.9,6.0,"149,020",6
7,Ontario,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,Total,"130,002.06",2.8,5.4,"133,581",7
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"119,855.32",2.6,7.8,"191,952",8
7,Ontario,C10AA,HMG-CoA reductase inhibitors,65+,Total,"104,142.46",2.3,52.6,"1,299,856",9
7,Ontario,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,Total,"99,477.48",2.2,0.1,"1,283",10
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"98,505.79",2.2,4.6,"113,989",11
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"84,984.62",1.9,4.9,"121,120",12
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,"73,363.32",1.6,1.7,"42,829",13
7,Ontario,L04AA,Selective immunosuppressants,65+,Total,"73,320.90",1.6,0.6,"15,065",14
7,Ontario,A02BC,Proton pump inhibitors,65+,Total,"68,917.09",1.5,31.1,"768,788",15
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"53,995.82",1.2,0.6,"15,880",16
7,Ontario,C08CA,Dihydropyridine derivatives,65+,Total,"52,399.25",1.1,23.2,"573,570",17
7,Ontario,R03BB,Anticholinergics,65+,Total,"51,253.51",1.1,5.2,"129,104",18
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"50,736.96",1.1,17.9,"442,943",19
7,Ontario,C09AA,"ACE inhibitors, plain",65+,Total,"48,250.74",1.1,23.9,"589,971",20
7,Ontario,L04AC,Interleukin inhibitors,65+,Total,"46,967.87",1.0,0.1,"2,978",21
7,Ontario,L02BX,Other hormone antagonists and related agents,65+,Total,"46,090.68",1.0,0.1,"2,576",22
7,Ontario,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,Total,"45,263.68",1.0,0.0,971,23
7,Ontario,N06AX,Other antidepressants,65+,Total,"43,147.41",0.9,12.1,"297,951",24
7,Ontario,M05BA,Bisphosphonates,65+,Total,"42,805.51",0.9,7.0,"173,784",25
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"40,212.89",0.9,4.3,"106,335",26
7,Ontario,N03AX,Other antiepileptics,65+,Total,"40,193.34",0.9,9.4,"232,743",27
7,Ontario,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,Total,"38,271.92",0.8,0.0,642,28
7,Ontario,L03AA,Colony-stimulating factors,65+,Total,"36,947.84",0.8,0.2,"5,906",29
7,Ontario,L01EX,Other protein kinase inhibitors,65+,Total,"36,763.84",0.8,0.1,"1,521",30
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"35,455.48",0.8,2.0,"49,187",31
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"33,930.84",0.7,9.9,"245,751",32
7,Ontario,L02BB,Antiandrogens,65+,Total,"33,887.32",0.7,0.3,"8,041",33
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,"33,131.91",0.7,0.6,"14,668",34
7,Ontario,S01EE,Prostaglandin analogues,65+,Total,"33,091.95",0.7,5.1,"127,016",35
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"32,876.32",0.7,0.1,"1,764",36
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"32,718.09",0.7,10.4,"258,068",37
7,Ontario,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,Total,"31,073.85",0.7,0.0,547,38
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"29,786.34",0.7,2.2,"55,159",39
7,Ontario,N02AA,Natural opium alkaloids,65+,Total,"29,582.17",0.6,7.4,"182,940",40
7,Ontario,C07AB,"Beta-blocking agents, selective",65+,Total,"29,306.54",0.6,21.7,"536,529",41
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"28,916.04",0.6,5.4,"132,467",42
7,Ontario,C10AX,Other lipid-modifying agents,65+,Total,"28,489.57",0.6,5.3,"131,207",43
7,Ontario,B03XA,Other antianemic preparations,65+,Total,"27,946.77",0.6,0.1,"2,949",44
7,Ontario,H01CB,Somatostatin and analogues,65+,Total,"26,936.84",0.6,0.1,"1,477",45
7,Ontario,S01ED,Beta-blocking agents,65+,Total,"26,608.53",0.6,4.6,"112,567",46
7,Ontario,J05AP,Antivirals for treatment of HCV infections,65+,Total,"25,193.25",0.6,0.0,474,47
7,Ontario,N05AX,Other antipsychotics,65+,Total,"23,770.25",0.5,1.9,"46,021",48
7,Ontario,N04BA,Dopa and dopa derivatives,65+,Total,"23,235.00",0.5,1.3,"31,584",49
7,Ontario,C08DB,Benzothiazepine derivatives,65+,Total,"23,095.51",0.5,3.2,"79,940",50
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,"22,885.88",0.5,0.1,"1,954",51
7,Ontario,R03BA,Glucocorticoids,65+,Total,"22,039.17",0.5,3.7,"91,402",52
7,Ontario,H03AA,Thyroid hormones,65+,Total,"20,452.75",0.4,16.1,"398,177",53
7,Ontario,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,Total,"18,616.66",0.4,0.0,604,54
7,Ontario,B01AE,Direct thrombin inhibitors,65+,Total,"17,208.93",0.4,0.7,"18,086",55
7,Ontario,A07EC,Aminosalicylic acid and similar agents,65+,Total,"17,189.77",0.4,0.8,"20,292",56
7,Ontario,C09BA,ACE inhibitors and diuretics,65+,Total,"16,816.19",0.4,4.4,"108,266",57
7,Ontario,B01AB,Heparin group,65+,Total,"16,566.60",0.4,0.4,"10,734",58
7,Ontario,L04AD,Calcineurin inhibitors,65+,Total,"16,015.01",0.4,0.2,"5,087",59
7,Ontario,N06DA,Anticholinesterases,65+,Total,"15,279.52",0.3,2.4,"58,485",60
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"15,007.92",0.3,3.4,"82,866",61
7,Ontario,A10BA,Biguanides,65+,Total,"14,884.75",0.3,12.9,"318,598",62
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"14,167.56",0.3,4.5,"112,402",63
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"13,862.17",0.3,0.3,"7,209",64
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,"12,620.74",0.3,5.1,"126,037",65
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,"12,572.90",0.3,0.7,"16,625",66
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,Total,"12,547.23",0.3,0.5,"11,222",67
7,Ontario,R01AD,Corticosteroids,65+,Total,"12,534.03",0.3,6.7,"166,735",68
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"11,541.61",0.3,10.3,"255,478",69
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"10,676.08",0.2,3.0,"75,159",70
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"10,543.83",0.2,11.6,"287,002",71
7,Ontario,L01XE,Protein kinase inhibitors,65+,Total,"9,759.60",0.2,0.0,"1,094",72
7,Ontario,A10BB,Sulfonylureas,65+,Total,"9,653.34",0.2,5.2,"128,477",73
7,Ontario,C03CA,"Sulfonamides, plain",65+,Total,"9,593.23",0.2,9.2,"226,667",74
7,Ontario,B03AA,"Iron bivalent, oral preparations",65+,Total,"9,582.56",0.2,6.2,"153,252",75
7,Ontario,N02BE,Anilides,65+,Total,"9,442.65",0.2,10.8,"267,161",76
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"9,097.05",0.2,3.2,"80,176",77
7,Ontario,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,Total,"9,006.84",0.2,0.0,118,78
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"8,680.46",0.2,0.0,359,79
7,Ontario,A06AB,Contact laxatives,65+,Total,"8,561.60",0.2,8.5,"209,337",80
7,Ontario,D07AC,"Corticosteroids, potent (group III)",65+,Total,"8,054.08",0.2,10.1,"249,126",81
7,Ontario,L01XC,Monoclonal antibodies,65+,Total,"7,631.86",0.2,0.0,665,82
7,Ontario,C10BX,Lipid-modifying agents in combination with other drugs,65+,Total,"7,620.88",0.2,0.9,"21,182",83
7,Ontario,L02BG,Aromatase inhibitors,65+,Total,"7,536.73",0.2,0.8,"20,251",84
7,Ontario,M04AA,Preparations inhibiting uric acid production,65+,Total,"7,528.57",0.2,4.4,"109,565",85
7,Ontario,D05AX,Other antipsoriatics for topical use,65+,Total,"7,462.52",0.2,0.9,"22,112",86
7,Ontario,L01XX,Other antineoplastic agents,65+,Total,"7,394.56",0.2,0.2,"5,181",87
7,Ontario,N05BA,Benzodiazepine derivatives,65+,Total,"7,213.64",0.2,7.5,"185,250",88
7,Ontario,A07AA,Antibiotics,65+,Total,"7,032.66",0.2,1.3,"31,063",89
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",65+,Total,"6,812.73",0.1,0.7,"18,190",90
7,Ontario,H02AB,Glucocorticoids,65+,Total,"6,811.21",0.1,9.3,"230,427",91
7,Ontario,S01EC,Carbonic anhydrase inhibitors,65+,Total,"6,526.24",0.1,1.5,"36,508",92
7,Ontario,C01DA,Organic nitrates,65+,Total,"6,435.19",0.1,4.1,"101,029",93
7,Ontario,N04BC,Dopamine agonists,65+,Total,"6,189.45",0.1,0.9,"21,962",94
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,"5,959.58",0.1,2.1,"50,859",95
7,Ontario,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,65+,Total,"5,956.31",0.1,0.0,145,96
7,Ontario,C10AC,Bile acid sequestrants,65+,Total,"5,900.78",0.1,0.6,"15,813",97
7,Ontario,A04AD,Other antiemetics,65+,Total,"5,851.89",0.1,0.4,"10,925",98
7,Ontario,D06AX,Other antibiotics for topical use,65+,Total,"5,775.45",0.1,5.6,"137,760",99
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,65+,Total,"5,670.60",0.1,0.4,"10,604",100
7,Ontario,S01LA,Antineovascularization agents,65+,M,"199,276.51",8.8,1.9,"21,301",1
7,Ontario,B01AF,Direct factor Xa inhibitors,65+,M,"118,714.45",5.2,11.3,"127,058",2
7,Ontario,L04AX,Other immunosuppressants,65+,M,"117,210.90",5.2,0.4,"5,016",3
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"82,876.00",3.6,7.1,"80,015",4
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"80,353.41",3.5,8.1,"90,662",5
7,Ontario,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,M,"66,361.74",2.9,6.1,"68,717",6
7,Ontario,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,M,"65,876.41",2.9,0.1,845,7
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,"57,124.40",2.5,0.3,"2,828",8
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"55,312.84",2.4,5.5,"61,934",9
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"53,942.47",2.4,1.4,"15,858",10
7,Ontario,C10AA,HMG-CoA reductase inhibitors,65+,M,"52,898.99",2.3,60.5,"677,596",11
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"52,285.66",2.3,7.2,"80,908",12
7,Ontario,L02BX,Other hormone antagonists and related agents,65+,M,"46,044.88",2.0,0.2,"2,575",13
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,"40,508.27",1.8,2.1,"23,111",14
7,Ontario,L02BB,Antiandrogens,65+,M,**,**,**,**,15
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"32,750.01",1.4,21.0,"235,568",16
7,Ontario,A02BC,Proton pump inhibitors,65+,M,"27,803.41",1.2,28.9,"323,779",17
7,Ontario,L01EX,Other protein kinase inhibitors,65+,M,"27,655.47",1.2,0.1,"1,093",18
7,Ontario,L04AA,Selective immunosuppressants,65+,M,"25,958.66",1.1,0.6,"6,264",19
7,Ontario,R03BB,Anticholinergics,65+,M,"25,436.05",1.1,5.6,"63,306",20
7,Ontario,C09AA,"ACE inhibitors, plain",65+,M,"25,004.53",1.1,28.5,"319,183",21
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,"23,918.31",1.1,0.9,"10,550",22
7,Ontario,C08CA,Dihydropyridine derivatives,65+,M,"23,404.25",1.0,23.3,"260,875",23
7,Ontario,L04AC,Interleukin inhibitors,65+,M,"20,869.84",0.9,0.1,"1,270",24
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,"20,753.00",0.9,16.9,"189,681",25
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,"20,089.43",0.9,0.2,"1,707",26
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"19,282.23",0.8,2.3,"26,288",27
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"16,944.70",0.7,2.6,"29,352",28
7,Ontario,L03AA,Colony-stimulating factors,65+,M,"16,884.92",0.7,0.2,"2,757",29
7,Ontario,N03AX,Other antiepileptics,65+,M,"16,695.36",0.7,8.2,"92,392",30
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,65+,M,"15,869.95",0.7,3.6,"40,643",31
7,Ontario,J05AP,Antivirals for treatment of HCV infections,65+,M,"15,793.28",0.7,0.0,296,32
7,Ontario,B03XA,Other antianemic preparations,65+,M,"15,509.35",0.7,0.1,"1,451",33
7,Ontario,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,M,"15,489.74",0.7,0.0,283,34
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"15,453.95",0.7,7.0,"78,128",35
7,Ontario,C10AX,Other lipid-modifying agents,65+,M,"15,346.45",0.7,6.5,"73,020",36
7,Ontario,S01EE,Prostaglandin analogues,65+,M,"14,429.01",0.6,5.0,"56,486",37
7,Ontario,H01CB,Somatostatin and analogues,65+,M,"14,294.53",0.6,0.1,723,38
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"14,285.15",0.6,0.1,724,39
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"14,156.99",0.6,10.0,"112,279",40
7,Ontario,N06AX,Other antidepressants,65+,M,"14,035.26",0.6,9.3,"104,283",41
7,Ontario,N04BA,Dopa and dopa derivatives,65+,M,"14,017.66",0.6,1.6,"17,846",42
7,Ontario,C07AB,"Beta-blocking agents, selective",65+,M,"14,011.35",0.6,24.3,"272,268",43
7,Ontario,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,M,"13,503.87",0.6,0.0,236,44
7,Ontario,N02AA,Natural opium alkaloids,65+,M,"12,694.13",0.6,6.8,"76,042",45
7,Ontario,S01ED,Beta-blocking agents,65+,M,"12,194.94",0.5,4.7,"52,604",46
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,65+,M,"10,815.84",0.5,1.1,"12,449",47
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,65+,M,"10,521.36",0.5,7.5,"83,624",48
7,Ontario,B01AE,Direct thrombin inhibitors,65+,M,"10,057.47",0.4,1.0,"10,780",49
7,Ontario,L04AD,Calcineurin inhibitors,65+,M,"9,983.87",0.4,0.3,"3,234",50
7,Ontario,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,M,"9,856.47",0.4,0.0,315,51
7,Ontario,C08DB,Benzothiazepine derivatives,65+,M,"9,406.91",0.4,2.9,"32,400",52
7,Ontario,N05AX,Other antipsychotics,65+,M,"9,274.65",0.4,1.5,"16,619",53
7,Ontario,R03BA,Glucocorticoids,65+,M,"8,678.53",0.4,3.1,"34,845",54
7,Ontario,C09BA,ACE inhibitors and diuretics,65+,M,"8,655.58",0.4,5.0,"55,935",55
7,Ontario,B01AB,Heparin group,65+,M,"8,646.19",0.4,0.4,"4,926",56
7,Ontario,A07EC,Aminosalicylic acid and similar agents,65+,M,"8,510.59",0.4,0.8,"9,142",57
7,Ontario,M05BA,Bisphosphonates,65+,M,"8,503.97",0.4,2.9,"32,159",58
7,Ontario,A10BA,Biguanides,65+,M,"7,600.56",0.3,15.2,"170,148",59
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,M,"7,491.91",0.3,0.5,"6,088",60
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,"6,420.44",0.3,0.7,"8,262",61
7,Ontario,R01AD,Corticosteroids,65+,M,"5,877.28",0.3,6.5,"73,345",62
7,Ontario,N06DA,Anticholinesterases,65+,M,"5,871.84",0.3,2.1,"23,132",63
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,65+,M,"5,667.10",0.2,0.9,"10,560",64
7,Ontario,M04AA,Preparations inhibiting uric acid production,65+,M,"5,303.01",0.2,7.0,"78,841",65
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,"5,256.87",0.2,10.5,"117,613",66
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,"5,245.21",0.2,0.2,"2,453",67
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,"5,225.83",0.2,4.9,"54,470",68
7,Ontario,A10BB,Sulfonylureas,65+,M,"5,144.24",0.2,6.4,"71,842",69
7,Ontario,H03AA,Thyroid hormones,65+,M,"4,966.42",0.2,8.7,"97,906",70
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"4,687.15",0.2,10.6,"118,325",71
7,Ontario,L01XE,Protein kinase inhibitors,65+,M,"4,668.03",0.2,0.0,542,72
7,Ontario,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,M,"4,524.15",0.2,0.0,55,73
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"4,520.83",0.2,2.7,"30,776",74
7,Ontario,L01XX,Other antineoplastic agents,65+,M,"4,445.54",0.2,0.2,"2,268",75
7,Ontario,D05AX,Other antipsoriatics for topical use,65+,M,"4,419.84",0.2,1.1,"12,017",76
7,Ontario,C10BX,Lipid-modifying agents in combination with other drugs,65+,M,"4,155.89",0.2,1.1,"11,846",77
7,Ontario,D07AC,"Corticosteroids, potent (group III)",65+,M,"4,120.29",0.2,10.4,"116,157",78
7,Ontario,C03CA,"Sulfonamides, plain",65+,M,"4,082.63",0.2,9.0,"100,729",79
7,Ontario,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,65+,M,"3,952.95",0.2,0.0,100,80
7,Ontario,B03AA,"Iron bivalent, oral preparations",65+,M,"3,938.67",0.2,5.9,"65,874",81
7,Ontario,A06AB,Contact laxatives,65+,M,"3,689.51",0.2,8.5,"95,689",82
7,Ontario,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,65+,M,"3,408.64",0.2,0.0,105,83
7,Ontario,A07AA,Antibiotics,65+,M,"3,402.79",0.1,1.0,"11,647",84
7,Ontario,C01DA,Organic nitrates,65+,M,"3,131.14",0.1,4.9,"55,174",85
7,Ontario,S01EC,Carbonic anhydrase inhibitors,65+,M,"3,094.46",0.1,1.5,"17,179",86
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",65+,M,"3,088.30",0.1,0.6,"7,188",87
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,"3,080.21",0.1,0.2,"1,977",88
7,Ontario,N02BE,Anilides,65+,M,"3,050.97",0.1,9.0,"100,940",89
7,Ontario,C10AC,Bile acid sequestrants,65+,M,"2,987.53",0.1,0.5,"5,748",90
7,Ontario,N07BC,Drugs used in opioid dependence,65+,M,"2,962.24",0.1,0.2,"1,958",91
7,Ontario,J05AJ,Integrase inhibitors,65+,M,"2,950.37",0.1,0.0,371,92
7,Ontario,C03DA,Aldosterone antagonists,65+,M,"2,950.26",0.1,2.7,"30,776",93
7,Ontario,N04BC,Dopamine agonists,65+,M,"2,901.41",0.1,0.8,"8,515",94
7,Ontario,H02AB,Glucocorticoids,65+,M,"2,893.07",0.1,8.9,"100,079",95
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,"2,864.66",0.1,1.7,"18,967",96
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,"2,808.78",0.1,2.2,"24,703",97
7,Ontario,D06AX,Other antibiotics for topical use,65+,M,"2,629.80",0.1,5.5,"61,938",98
7,Ontario,C10AB,Fibrates,65+,M,"2,487.73",0.1,1.2,"13,551",99
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,"2,469.54",0.1,0.0,114,100
7,Ontario,S01LA,Antineovascularization agents,65+,F,"266,322.70",11.6,2.0,"27,421",1
7,Ontario,B01AF,Direct factor Xa inhibitors,65+,F,"109,990.03",4.8,8.7,"118,025",2
7,Ontario,L04AX,Other immunosuppressants,65+,F,"82,748.83",3.6,0.4,"5,916",3
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,"80,498.92",3.5,0.3,"4,501",4
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"74,154.05",3.2,8.0,"108,647",5
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"67,545.21",2.9,8.2,"111,010",6
7,Ontario,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,F,"63,591.12",2.8,4.8,"64,818",7
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"59,797.48",2.6,4.3,"57,735",8
7,Ontario,C10AA,HMG-CoA reductase inhibitors,65+,F,"51,203.70",2.2,46.1,"621,946",9
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"51,063.75",2.2,4.3,"58,309",10
7,Ontario,L04AA,Selective immunosuppressants,65+,F,"47,362.05",2.1,0.7,"8,800",11
7,Ontario,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,F,"45,086.46",2.0,0.1,966,12
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"43,169.77",1.9,3.9,"52,017",13
7,Ontario,A02BC,Proton pump inhibitors,65+,F,"41,089.23",1.8,33.0,"444,793",14
7,Ontario,M05BA,Bisphosphonates,65+,F,"34,288.33",1.5,10.5,"141,573",15
7,Ontario,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,F,"33,601.07",1.5,0.0,438,16
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,"32,848.39",1.4,1.5,"19,714",17
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"29,964.45",1.3,18.8,"253,146",18
7,Ontario,N06AX,Other antidepressants,65+,F,"29,101.84",1.3,14.3,"193,620",19
7,Ontario,C08CA,Dihydropyridine derivatives,65+,F,"28,972.87",1.3,23.2,"312,526",20
7,Ontario,L04AC,Interleukin inhibitors,65+,F,"26,098.04",1.1,0.1,"1,708",21
7,Ontario,R03BB,Anticholinergics,65+,F,"25,810.41",1.1,4.9,"65,781",22
7,Ontario,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,F,"24,768.05",1.1,0.0,406,23
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,65+,F,"24,336.30",1.1,4.9,"65,673",24
7,Ontario,N03AX,Other antiepileptics,65+,F,"23,486.31",1.0,10.4,"140,289",25
7,Ontario,C09AA,"ACE inhibitors, plain",65+,F,"23,231.05",1.0,20.1,"270,662",26
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,65+,F,"22,187.29",1.0,12.9,"174,392",27
7,Ontario,L03AA,Colony-stimulating factors,65+,F,"20,062.92",0.9,0.2,"3,149",28
7,Ontario,S01EE,Prostaglandin analogues,65+,F,"18,656.39",0.8,5.2,"70,510",29
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"18,591.17",0.8,0.1,"1,040",30
7,Ontario,N02AA,Natural opium alkaloids,65+,F,"16,887.51",0.7,7.9,"106,877",31
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"16,166.15",0.7,1.7,"22,892",32
7,Ontario,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,F,"15,584.11",0.7,0.0,264,33
7,Ontario,H03AA,Thyroid hormones,65+,F,"15,480.04",0.7,22.2,"300,207",34
7,Ontario,C07AB,"Beta-blocking agents, selective",65+,F,"15,281.42",0.7,19.6,"264,119",35
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"14,997.17",0.7,6.1,"82,795",36
7,Ontario,N05AX,Other antipsychotics,65+,F,"14,488.25",0.6,2.2,"29,394",37
7,Ontario,S01ED,Beta-blocking agents,65+,F,"14,405.22",0.6,4.4,"59,941",38
7,Ontario,C08DB,Benzothiazepine derivatives,65+,F,"13,686.50",0.6,3.5,"47,533",39
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"13,452.72",0.6,4.0,"54,297",40
7,Ontario,R03BA,Glucocorticoids,65+,F,"13,354.23",0.6,4.2,"56,537",41
7,Ontario,C10AX,Other lipid-modifying agents,65+,F,"13,141.83",0.6,4.3,"58,175",42
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"12,836.83",0.6,1.9,"25,796",43
7,Ontario,H01CB,Somatostatin and analogues,65+,F,"12,642.30",0.6,0.1,754,44
7,Ontario,B03XA,Other antianemic preparations,65+,F,"12,437.42",0.5,0.1,"1,498",45
7,Ontario,N06DA,Anticholinesterases,65+,F,"9,402.33",0.4,2.6,"35,336",46
7,Ontario,J05AP,Antivirals for treatment of HCV infections,65+,F,"9,399.97",0.4,0.0,178,47
7,Ontario,N04BA,Dopa and dopa derivatives,65+,F,"9,214.32",0.4,1.0,"13,731",48
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,"9,213.60",0.4,0.3,"4,118",49
7,Ontario,L01EX,Other protein kinase inhibitors,65+,F,"9,108.37",0.4,0.0,428,50
7,Ontario,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,F,"8,760.18",0.4,0.0,289,51
7,Ontario,A07EC,Aminosalicylic acid and similar agents,65+,F,"8,678.01",0.4,0.8,"11,147",52
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"8,609.58",0.4,0.4,"4,755",53
7,Ontario,C09BA,ACE inhibitors and diuretics,65+,F,"8,154.98",0.4,3.9,"52,305",54
7,Ontario,B01AB,Heparin group,65+,F,"7,918.66",0.3,0.4,"5,806",55
7,Ontario,L02BG,Aromatase inhibitors,65+,F,"7,517.96",0.3,1.5,"20,031",56
7,Ontario,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,"7,388.55",0.3,5.3,"71,525",57
7,Ontario,A10BA,Biguanides,65+,F,"7,272.81",0.3,11.0,"148,327",58
7,Ontario,B01AE,Direct thrombin inhibitors,65+,F,"7,151.46",0.3,0.5,"7,306",59
7,Ontario,R01AD,Corticosteroids,65+,F,"6,653.67",0.3,6.9,"93,356",60
7,Ontario,N02BE,Anilides,65+,F,"6,383.52",0.3,12.3,"166,052",61
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"6,287.36",0.3,4.1,"55,459",62
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"6,282.29",0.3,10.2,"137,815",63
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"6,210.92",0.3,0.0,245,64
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"6,152.39",0.3,3.3,"44,365",65
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,"6,144.52",0.3,0.6,"8,350",66
7,Ontario,L04AD,Calcineurin inhibitors,65+,F,"6,031.14",0.3,0.1,"1,853",67
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"5,852.51",0.3,12.5,"168,614",68
7,Ontario,B03AA,"Iron bivalent, oral preparations",65+,F,"5,636.84",0.2,6.5,"87,307",69
7,Ontario,C03CA,"Sulfonamides, plain",65+,F,"5,506.18",0.2,9.3,"125,888",70
7,Ontario,L01XC,Monoclonal antibodies,65+,F,"5,314.84",0.2,0.0,456,71
7,Ontario,L01XE,Protein kinase inhibitors,65+,F,"5,091.57",0.2,0.0,552,72
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,F,"5,042.74",0.2,0.4,"5,124",73
7,Ontario,A06AB,Contact laxatives,65+,F,"4,866.91",0.2,8.4,"113,584",74
7,Ontario,N05BA,Benzodiazepine derivatives,65+,F,"4,852.84",0.2,9.2,"124,595",75
7,Ontario,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,65+,F,"4,799.41",0.2,0.0,77,76
7,Ontario,A10BB,Sulfonylureas,65+,F,"4,501.05",0.2,4.2,"56,575",77
7,Ontario,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,F,"4,482.69",0.2,0.0,63,78
7,Ontario,D07AC,"Corticosteroids, potent (group III)",65+,F,"3,930.55",0.2,9.8,"132,918",79
7,Ontario,H02AB,Glucocorticoids,65+,F,"3,916.95",0.2,9.7,"130,317",80
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",65+,F,"3,723.89",0.2,0.8,"10,998",81
7,Ontario,A07AA,Antibiotics,65+,F,"3,622.54",0.2,1.4,"19,406",82
7,Ontario,C10BX,Lipid-modifying agents in combination with other drugs,65+,F,"3,464.19",0.2,0.7,"9,333",83
7,Ontario,A04AD,Other antiemetics,65+,F,"3,448.60",0.2,0.5,"6,589",84
7,Ontario,S01EC,Carbonic anhydrase inhibitors,65+,F,"3,429.32",0.1,1.4,"19,316",85
7,Ontario,C01DA,Organic nitrates,65+,F,"3,300.32",0.1,3.4,"45,827",86
7,Ontario,N04BC,Dopamine agonists,65+,F,"3,287.30",0.1,1.0,"13,445",87
7,Ontario,L01BA,Folic acid analogues,65+,F,"3,187.99",0.1,1.3,"17,159",88
7,Ontario,D06AX,Other antibiotics for topical use,65+,F,"3,144.40",0.1,5.6,"75,798",89
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,"3,093.40",0.1,2.4,"31,883",90
7,Ontario,D05AX,Other antipsoriatics for topical use,65+,F,"3,041.31",0.1,0.7,"10,092",91
7,Ontario,A06AD,Osmotically acting laxatives,65+,F,"2,968.59",0.1,4.5,"60,954",92
7,Ontario,L01XX,Other antineoplastic agents,65+,F,"2,949.02",0.1,0.2,"2,913",93
7,Ontario,C03AA,"Thiazides, plain",65+,F,"2,944.61",0.1,8.6,"116,016",94
7,Ontario,C10AC,Bile acid sequestrants,65+,F,"2,913.25",0.1,0.7,"10,065",95
7,Ontario,M01AH,Coxibs,65+,F,"2,903.76",0.1,3.6,"47,942",96
7,Ontario,A04AA,Serotonin (5HT3) antagonists,65+,F,"2,809.20",0.1,0.8,"10,207",97
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,F,"2,732.82",0.1,0.0,243,98
7,Ontario,C03BA,"Sulfonamides, plain",65+,F,"2,703.82",0.1,4.2,"56,970",99
7,Ontario,A16AB,Enzymes,65+,F,**,**,**,**,100
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,"206,979.64",8.9,0.6,"9,970",1
7,Ontario,N05AX,Other antipsychotics,<65,Total,"136,739.24",5.9,4.8,"79,182",2
7,Ontario,J05AP,Antivirals for treatment of HCV infections,<65,Total,"133,610.68",5.7,0.2,"2,766",3
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"111,249.38",4.8,0.7,"11,292",4
7,Ontario,L04AA,Selective immunosuppressants,<65,Total,"91,371.17",3.9,0.6,"9,745",5
7,Ontario,N07BC,Drugs used in opioid dependence,<65,Total,"83,289.87",3.6,2.5,"40,976",6
7,Ontario,L04AX,Other immunosuppressants,<65,Total,"51,888.71",2.2,0.3,"5,048",7
7,Ontario,N06BA,Centrally acting sympathomimetics,<65,Total,"46,371.79",2.0,4.5,"74,233",8
7,Ontario,N03AX,Other antiepileptics,<65,Total,"44,749.06",1.9,7.3,"120,378",9
7,Ontario,N06AX,Other antidepressants,<65,Total,"42,660.39",1.8,10.3,"171,125",10
7,Ontario,L04AC,Interleukin inhibitors,<65,Total,"39,846.76",1.7,0.2,"2,806",11
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"35,804.06",1.5,12.0,"198,385",12
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"35,091.33",1.5,2.3,"37,686",13
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"34,556.11",1.5,3.8,"63,726",14
7,Ontario,N02AA,Natural opium alkaloids,<65,Total,"34,465.52",1.5,3.9,"63,921",15
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"32,936.83",1.4,5.6,"93,278",16
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"30,798.93",1.3,2.3,"38,097",17
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"30,417.72",1.3,2.0,"33,698",18
7,Ontario,L03AA,Colony-stimulating factors,<65,Total,"28,652.92",1.2,0.3,"4,334",19
7,Ontario,S01LA,Antineovascularization agents,<65,Total,"25,110.85",1.1,0.2,"2,730",20
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,Total,"24,886.14",1.1,0.7,"11,445",21
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,"23,161.15",1.0,0.9,"15,681",22
7,Ontario,A02BC,Proton pump inhibitors,<65,Total,"23,153.24",1.0,12.8,"212,083",23
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"21,998.12",0.9,0.1,"1,390",24
7,Ontario,A16AB,Enzymes,<65,Total,"21,760.43",0.9,0.0,46,25
7,Ontario,L04AD,Calcineurin inhibitors,<65,Total,"21,356.33",0.9,0.3,"5,664",26
7,Ontario,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,"20,133.05",0.9,0.0,54,27
7,Ontario,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,Total,"18,715.27",0.8,1.3,"21,275",28
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"16,291.51",0.7,1.6,"26,004",29
7,Ontario,C10AA,HMG-CoA reductase inhibitors,<65,Total,"16,112.53",0.7,9.3,"153,696",30
7,Ontario,R03BA,Glucocorticoids,<65,Total,"15,973.70",0.7,5.9,"98,317",31
7,Ontario,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,Total,"15,964.36",0.7,0.0,376,32
7,Ontario,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,Total,"14,628.62",0.6,0.0,184,33
7,Ontario,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,Total,"14,255.38",0.6,0.0,237,34
7,Ontario,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,Total,"13,458.73",0.6,0.0,405,35
7,Ontario,N05AE,Indole derivatives,<65,Total,"13,441.70",0.6,0.5,"8,917",36
7,Ontario,V06,General nutrients,<65,Total,"13,405.89",0.6,0.0,325,37
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"12,013.13",0.5,7.4,"122,322",38
7,Ontario,H01AC,Somatropin and somatropin agonists,<65,Total,"11,075.00",0.5,0.1,954,39
7,Ontario,A04AD,Other antiemetics,<65,Total,"10,858.47",0.5,0.7,"12,353",40
7,Ontario,R03BB,Anticholinergics,<65,Total,"10,463.32",0.4,1.7,"27,589",41
7,Ontario,N03AG,Fatty acid derivatives,<65,Total,"10,294.29",0.4,1.5,"24,226",42
7,Ontario,B01AF,Direct factor Xa inhibitors,<65,Total,"9,920.92",0.4,0.9,"14,167",43
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"9,897.85",0.4,0.2,"3,497",44
7,Ontario,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"9,842.76",0.4,5.2,"85,614",45
7,Ontario,J05AJ,Integrase inhibitors,<65,Total,"9,675.55",0.4,0.1,"1,746",46
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"9,433.73",0.4,0.8,"14,059",47
7,Ontario,L03AB,Interferons,<65,Total,"9,374.85",0.4,0.0,521,48
7,Ontario,H01CB,Somatostatin and analogues,<65,Total,"9,243.15",0.4,0.0,651,49
7,Ontario,N05BA,Benzodiazepine derivatives,<65,Total,"9,015.95",0.4,5.0,"83,281",50
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"8,739.64",0.4,12.5,"207,960",51
7,Ontario,B01AB,Heparin group,<65,Total,"8,545.59",0.4,0.2,"3,823",52
7,Ontario,V03AC,Iron-chelating agents,<65,Total,"8,464.00",0.4,0.0,323,53
7,Ontario,N03AE,Benzodiazepine derivatives,<65,Total,"8,042.75",0.3,3.0,"50,283",54
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,"8,038.45",0.3,0.2,"2,859",55
7,Ontario,C09AA,"ACE inhibitors, plain",<65,Total,"8,034.23",0.3,4.6,"76,973",56
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"7,789.26",0.3,2.6,"43,249",57
7,Ontario,R07AX,Other respiratory system products,<65,Total,**,**,**,**,58
7,Ontario,L03AX,Other immunostimulants,<65,Total,"6,952.15",0.3,0.0,659,59
7,Ontario,C01CA,Adrenergic and dopaminergic agents,<65,Total,"6,877.88",0.3,1.8,"30,651",60
7,Ontario,N03AF,Carboxamide derivatives,<65,Total,"6,523.58",0.3,0.7,"11,065",61
7,Ontario,C08CA,Dihydropyridine derivatives,<65,Total,"6,491.76",0.3,3.6,"59,590",62
7,Ontario,V06C,Infant formulas,<65,Total,"6,346.82",0.3,0.2,"3,042",63
7,Ontario,R01AD,Corticosteroids,<65,Total,"6,224.91",0.3,5.4,"89,064",64
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,<65,Total,"6,208.44",0.3,1.1,"18,168",65
7,Ontario,V03AB,Antidotes,<65,Total,"6,077.07",0.3,1.5,"24,706",66
7,Ontario,A16AX,Various alimentary tract and metabolism products,<65,Total,"5,998.03",0.3,0.0,52,67
7,Ontario,L01EX,Other protein kinase inhibitors,<65,Total,"5,666.66",0.2,0.0,233,68
7,Ontario,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,Total,"5,567.34",0.2,0.0,76,69
7,Ontario,H03AA,Thyroid hormones,<65,Total,"5,485.40",0.2,4.1,"68,060",70
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,"5,374.59",0.2,0.5,"8,108",71
7,Ontario,C02AC,Imidazoline receptor agonists,<65,Total,"5,224.89",0.2,1.3,"21,128",72
7,Ontario,M03BX,Other centrally acting agents,<65,Total,"5,020.60",0.2,2.6,"43,721",73
7,Ontario,L01EJ,Janus-associated kinase (JAK) inhibitors,<65,Total,"5,003.85",0.2,0.0,96,74
7,Ontario,G02BA,Intrauterine contraceptives,<65,Total,"4,989.87",0.2,0.8,"13,071",75
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,"4,895.79",0.2,2.4,"40,357",76
7,Ontario,A07EC,Aminosalicylic acid and similar agents,<65,Total,"4,884.18",0.2,0.4,"6,422",77
7,Ontario,J05AE,Protease inhibitors,<65,Total,"4,848.94",0.2,0.1,895,78
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"4,735.35",0.2,0.0,239,79
7,Ontario,A10BA,Biguanides,<65,Total,"4,546.18",0.2,4.0,"66,077",80
7,Ontario,C07AB,"Beta-blocking agents, selective",<65,Total,"4,427.36",0.2,3.3,"54,888",81
7,Ontario,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,Total,"4,374.14",0.2,0.0,82,82
7,Ontario,A09AA,Enzyme preparations,<65,Total,"4,337.87",0.2,0.2,"2,797",83
7,Ontario,M01AE,Propionic acid derivatives,<65,Total,"4,265.90",0.2,7.3,"121,348",84
7,Ontario,J02AC,Triazole derivatives,<65,Total,"4,223.15",0.2,1.2,"19,824",85
7,Ontario,J01CA,Penicillins with extended spectrum,<65,Total,"4,214.44",0.2,14.1,"233,167",86
7,Ontario,D06AX,Other antibiotics for topical use,<65,Total,"4,136.78",0.2,5.4,"88,860",87
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,Total,"4,136.41",0.2,0.9,"14,613",88
7,Ontario,D07AC,"Corticosteroids, potent (group III)",<65,Total,"4,073.41",0.2,7.4,"122,981",89
7,Ontario,L01XC,Monoclonal antibodies,<65,Total,"4,058.83",0.2,0.0,417,90
7,Ontario,C10AX,Other lipid-modifying agents,<65,Total,"4,037.51",0.2,0.8,"13,647",91
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,"3,928.75",0.2,0.1,"1,901",92
7,Ontario,B03AA,"Iron bivalent, oral preparations",<65,Total,"3,850.26",0.2,3.6,"59,258",93
7,Ontario,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,"3,781.88",0.2,1.5,"24,799",94
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"3,532.71",0.2,1.4,"23,727",95
7,Ontario,A04AA,Serotonin (5HT3) antagonists,<65,Total,"3,520.94",0.2,0.5,"9,107",96
7,Ontario,N02BE,Anilides,<65,Total,"3,505.07",0.2,5.9,"98,290",97
7,Ontario,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,<65,Total,"3,475.09",0.1,0.0,67,98
7,Ontario,A06AB,Contact laxatives,<65,Total,"3,356.88",0.1,3.0,"50,310",99
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,<65,Total,"3,335.85",0.1,0.5,"8,833",100
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,"110,011.55",9.1,0.6,"4,911",1
7,Ontario,N05AX,Other antipsychotics,<65,M,"90,251.66",7.5,5.7,"43,165",2
7,Ontario,J05AP,Antivirals for treatment of HCV infections,<65,M,"87,303.99",7.2,0.2,"1,809",3
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"83,380.58",6.9,1.1,"8,643",4
7,Ontario,N07BC,Drugs used in opioid dependence,<65,M,"47,983.91",4.0,3.1,"23,716",5
7,Ontario,L04AA,Selective immunosuppressants,<65,M,"32,761.61",2.7,0.5,"4,079",6
7,Ontario,N06BA,Centrally acting sympathomimetics,<65,M,"28,887.35",2.4,6.0,"45,615",7
7,Ontario,L04AX,Other immunosuppressants,<65,M,"24,910.73",2.1,0.3,"1,926",8
7,Ontario,N03AX,Other antiepileptics,<65,M,"20,722.46",1.7,6.7,"50,884",9
7,Ontario,L04AC,Interleukin inhibitors,<65,M,"19,385.57",1.6,0.2,"1,320",10
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"19,330.94",1.6,6.3,"48,067",11
7,Ontario,N02AA,Natural opium alkaloids,<65,M,"18,005.91",1.5,3.7,"28,275",12
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"17,665.18",1.5,2.5,"19,189",13
7,Ontario,N06AX,Other antidepressants,<65,M,"17,166.01",1.4,9.0,"68,552",14
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,"16,270.51",1.3,2.4,"18,107",15
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"16,203.21",1.3,2.6,"20,201",16
7,Ontario,A16AB,Enzymes,<65,M,**,**,**,**,17
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,<65,M,"14,984.27",1.2,9.9,"75,351",18
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,M,"14,586.49",1.2,0.9,"6,520",19
7,Ontario,S01LA,Antineovascularization agents,<65,M,"14,031.26",1.2,0.2,"1,526",20
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"14,029.51",1.2,3.3,"25,181",21
7,Ontario,L04AD,Calcineurin inhibitors,<65,M,"12,936.93",1.1,0.4,"3,414",22
7,Ontario,M09AX,Other drugs for disorders of the musculoskeletal system,<65,M,"11,027.53",0.9,0.0,33,23
7,Ontario,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,M,"10,869.93",0.9,0.0,136,24
7,Ontario,A02BC,Proton pump inhibitors,<65,M,"10,263.46",0.8,11.9,"90,874",25
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,"9,538.25",0.8,0.9,"6,505",26
7,Ontario,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,M,"9,083.48",0.8,1.4,"10,474",27
7,Ontario,L03AA,Colony-stimulating factors,<65,M,"8,738.96",0.7,0.2,"1,430",28
7,Ontario,C10AA,HMG-CoA reductase inhibitors,<65,M,"8,631.54",0.7,10.7,"82,033",29
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"8,512.00",0.7,1.7,"13,194",30
7,Ontario,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,M,"7,625.55",0.6,0.0,224,31
7,Ontario,R03BA,Glucocorticoids,<65,M,"7,268.69",0.6,6.2,"47,684",32
7,Ontario,H01AC,Somatropin and somatropin agonists,<65,M,"7,083.55",0.6,0.1,587,33
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"7,032.29",0.6,0.1,434,34
7,Ontario,J05AJ,Integrase inhibitors,<65,M,"6,885.51",0.6,0.1,"1,143",35
7,Ontario,V06,General nutrients,<65,M,"6,528.79",0.5,0.0,142,36
7,Ontario,N03AG,Fatty acid derivatives,<65,M,"6,266.23",0.5,1.8,"13,938",37
7,Ontario,B01AF,Direct factor Xa inhibitors,<65,M,"5,838.11",0.5,1.0,"7,944",38
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,"5,600.04",0.5,6.9,"52,893",39
7,Ontario,N05AE,Indole derivatives,<65,M,"5,293.29",0.4,0.4,"3,359",40
7,Ontario,R03BB,Anticholinergics,<65,M,"4,998.13",0.4,1.7,"12,781",41
7,Ontario,A04AD,Other antiemetics,<65,M,"4,926.14",0.4,0.7,"5,261",42
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"4,563.32",0.4,0.2,"1,494",43
7,Ontario,C09AA,"ACE inhibitors, plain",<65,M,"4,520.17",0.4,5.7,"43,244",44
7,Ontario,N05BA,Benzodiazepine derivatives,<65,M,"4,443.67",0.4,4.4,"33,901",45
7,Ontario,R07AX,Other respiratory system products,<65,M,**,**,**,**,46
7,Ontario,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,M,"4,234.48",0.4,0.0,83,47
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"4,058.41",0.3,12.5,"95,670",48
7,Ontario,H01CB,Somatostatin and analogues,<65,M,"4,011.80",0.3,0.0,266,49
7,Ontario,L01EX,Other protein kinase inhibitors,<65,M,"3,939.29",0.3,0.0,162,50
7,Ontario,N03AE,Benzodiazepine derivatives,<65,M,"3,920.68",0.3,2.8,"21,139",51
7,Ontario,V03AC,Iron-chelating agents,<65,M,"3,803.97",0.3,0.0,149,52
7,Ontario,J05AE,Protease inhibitors,<65,M,"3,714.93",0.3,0.1,671,53
7,Ontario,B01AB,Heparin group,<65,M,"3,699.94",0.3,0.2,"1,673",54
7,Ontario,N03AF,Carboxamide derivatives,<65,M,"3,588.68",0.3,0.8,"5,779",55
7,Ontario,C01CA,Adrenergic and dopaminergic agents,<65,M,"3,515.96",0.3,2.0,"15,184",56
7,Ontario,C02AC,Imidazoline receptor agonists,<65,M,"3,451.64",0.3,1.5,"11,818",57
7,Ontario,C08CA,Dihydropyridine derivatives,<65,M,"3,376.73",0.3,4.0,"30,778",58
7,Ontario,V06C,Infant formulas,<65,M,**,**,**,**,59
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"3,297.98",0.3,2.0,"15,304",60
7,Ontario,V03AB,Antidotes,<65,M,"3,189.58",0.3,1.6,"12,224",61
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,<65,M,"3,137.11",0.3,1.0,"7,580",62
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"3,089.58",0.3,1.2,"9,199",63
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,<65,M,"2,933.89",0.2,0.1,895,64
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,"2,918.30",0.2,0.6,"4,329",65
7,Ontario,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,"2,874.08",0.2,0.2,"1,401",66
7,Ontario,R01AD,Corticosteroids,<65,M,"2,721.22",0.2,5.0,"38,339",67
7,Ontario,A16AX,Various alimentary tract and metabolism products,<65,M,**,**,**,**,68
7,Ontario,C07AB,"Beta-blocking agents, selective",<65,M,"2,567.95",0.2,4.1,"31,379",69
7,Ontario,L03AB,Interferons,<65,M,"2,549.55",0.2,0.0,151,70
7,Ontario,L01EJ,Janus-associated kinase (JAK) inhibitors,<65,M,"2,504.04",0.2,0.0,47,71
7,Ontario,A09AA,Enzyme preparations,<65,M,"2,483.53",0.2,0.2,"1,434",72
7,Ontario,A07EC,Aminosalicylic acid and similar agents,<65,M,"2,448.22",0.2,0.4,"2,795",73
7,Ontario,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,"2,420.90",0.2,0.1,506,74
7,Ontario,M03BX,Other centrally acting agents,<65,M,"2,258.07",0.2,2.3,"17,672",75
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,"2,239.70",0.2,2.4,"18,530",76
7,Ontario,J02AC,Triazole derivatives,<65,M,"2,217.14",0.2,0.3,"2,570",77
7,Ontario,A10BA,Biguanides,<65,M,"2,207.51",0.2,4.1,"31,513",78
7,Ontario,C10AX,Other lipid-modifying agents,<65,M,"2,121.75",0.2,1.0,"7,593",79
7,Ontario,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,M,"2,044.85",0.2,0.0,31,80
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,"2,012.70",0.2,0.2,"1,846",81
7,Ontario,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,M,"1,953.91",0.2,0.0,26,82
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,<65,M,"1,952.25",0.2,1.9,"14,864",83
7,Ontario,D06AX,Other antibiotics for topical use,<65,M,"1,949.72",0.2,5.4,"41,522",84
7,Ontario,J01CA,Penicillins with extended spectrum,<65,M,"1,946.20",0.2,13.7,"104,819",85
7,Ontario,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,<65,M,"1,941.65",0.2,0.0,37,86
7,Ontario,L03AX,Other immunostimulants,<65,M,"1,939.58",0.2,0.0,180,87
7,Ontario,D07AC,"Corticosteroids, potent (group III)",<65,M,"1,895.39",0.2,7.2,"54,922",88
7,Ontario,N05AF,Thioxanthene derivatives,<65,M,"1,864.37",0.2,0.3,"2,377",89
7,Ontario,A07AA,Antibiotics,<65,M,"1,833.47",0.2,1.0,"7,780",90
7,Ontario,L02BX,Other hormone antagonists and related agents,<65,M,"1,809.40",0.1,0.0,119,91
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,M,"1,782.92",0.1,0.8,"6,097",92
7,Ontario,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,<65,M,"1,750.73",0.1,0.0,38,93
7,Ontario,M01AE,Propionic acid derivatives,<65,M,"1,743.91",0.1,6.3,"48,425",94
7,Ontario,D05AX,Other antipsoriatics for topical use,<65,M,"1,738.82",0.1,0.5,"3,683",95
7,Ontario,L01AX,Other alkylating agents,<65,M,"1,673.94",0.1,0.0,227,96
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,<65,M,"1,670.84",0.1,0.7,"5,322",97
7,Ontario,L02BB,Antiandrogens,<65,M,**,**,**,**,98
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,"1,609.22",0.1,1.0,"7,760",99
7,Ontario,N02BE,Anilides,<65,M,"1,546.31",0.1,5.7,"43,387",100
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,"96,947.37",8.6,0.6,"5,058",1
7,Ontario,L04AA,Selective immunosuppressants,<65,F,"58,593.12",5.2,0.6,"5,661",2
7,Ontario,N05AX,Other antipsychotics,<65,F,"46,336.14",4.1,4.0,"35,908",3
7,Ontario,J05AP,Antivirals for treatment of HCV infections,<65,F,"46,137.00",4.1,0.1,954,4
7,Ontario,N07BC,Drugs used in opioid dependence,<65,F,"35,254.35",3.1,1.9,"17,221",5
7,Ontario,L04AX,Other immunosuppressants,<65,F,"26,977.31",2.4,0.3,"3,119",6
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"26,698.54",2.4,0.3,"2,542",7
7,Ontario,N06AX,Other antidepressants,<65,F,"25,450.66",2.3,11.4,"102,223",8
7,Ontario,N03AX,Other antiepileptics,<65,F,"23,976.60",2.1,7.8,"69,301",9
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,<65,F,"20,782.67",1.9,13.7,"122,753",10
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"20,490.75",1.8,4.3,"38,483",11
7,Ontario,L04AC,Interleukin inhibitors,<65,F,"20,461.19",1.8,0.2,"1,486",12
7,Ontario,L03AA,Colony-stimulating factors,<65,F,"19,910.87",1.8,0.3,"2,903",13
7,Ontario,N06BA,Centrally acting sympathomimetics,<65,F,"17,459.82",1.6,3.2,"28,581",14
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"17,375.79",1.5,2.1,"18,420",15
7,Ontario,N02AA,Natural opium alkaloids,<65,F,"16,440.92",1.5,4.0,"35,585",16
7,Ontario,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,F,"15,964.36",1.4,0.0,376,17
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"14,965.82",1.3,0.1,956,18
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"14,506.65",1.3,2.0,"17,780",19
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,"14,037.38",1.3,1.7,"15,470",20
7,Ontario,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,"13,589.06",1.2,1.0,"9,153",21
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"13,575.55",1.2,5.0,"45,072",22
7,Ontario,A02BC,Proton pump inhibitors,<65,F,"12,847.40",1.1,13.5,"120,584",23
7,Ontario,S01LA,Antineovascularization agents,<65,F,"11,079.60",1.0,0.1,"1,204",24
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,F,"10,261.68",0.9,0.5,"4,912",25
7,Ontario,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,F,"10,020.90",0.9,0.0,154,26
7,Ontario,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,**,**,**,**,27
7,Ontario,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,F,"9,575.51",0.9,1.2,"10,736",28
7,Ontario,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,"9,105.51",0.8,0.0,21,29
7,Ontario,R03BA,Glucocorticoids,<65,F,"8,689.35",0.8,5.7,"50,535",30
7,Ontario,L04AD,Calcineurin inhibitors,<65,F,"8,403.39",0.7,0.3,"2,247",31
7,Ontario,N05AE,Indole derivatives,<65,F,"8,139.83",0.7,0.6,"5,551",32
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"7,752.30",0.7,1.4,"12,761",33
7,Ontario,C10AA,HMG-CoA reductase inhibitors,<65,F,"7,435.34",0.7,8.0,"71,154",34
7,Ontario,V06,General nutrients,<65,F,"6,877.10",0.6,0.0,183,35
7,Ontario,L03AB,Interferons,<65,F,"6,825.29",0.6,0.0,370,36
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,"6,404.46",0.6,7.7,"69,236",37
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"6,333.55",0.6,0.5,"4,816",38
7,Ontario,A04AD,Other antiemetics,<65,F,"5,925.13",0.5,0.8,"7,086",39
7,Ontario,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,F,"5,833.18",0.5,0.0,181,40
7,Ontario,A16AB,Enzymes,<65,F,**,**,**,**,41
7,Ontario,R03BB,Anticholinergics,<65,F,"5,454.36",0.5,1.7,"14,775",42
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"5,322.16",0.5,0.2,"1,999",43
7,Ontario,H01CB,Somatostatin and analogues,<65,F,"5,231.34",0.5,0.0,385,44
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,<65,F,"5,099.69",0.5,0.2,"1,962",45
7,Ontario,L03AX,Other immunostimulants,<65,F,"5,012.57",0.4,0.1,479,46
7,Ontario,G02BA,Intrauterine contraceptives,<65,F,"4,982.72",0.4,1.5,"13,053",47
7,Ontario,B01AB,Heparin group,<65,F,"4,843.89",0.4,0.2,"2,147",48
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"4,674.06",0.4,12.5,"112,093",49
7,Ontario,V03AC,Iron-chelating agents,<65,F,"4,660.03",0.4,0.0,174,50
7,Ontario,N05BA,Benzodiazepine derivatives,<65,F,"4,565.53",0.4,5.5,"49,274",51
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,<65,F,"4,530.95",0.4,1.4,"12,823",52
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"4,483.24",0.4,3.1,"27,829",53
7,Ontario,N03AE,Benzodiazepine derivatives,<65,F,"4,117.07",0.4,3.3,"29,087",54
7,Ontario,B01AF,Direct factor Xa inhibitors,<65,F,"4,073.07",0.4,0.7,"6,205",55
7,Ontario,N03AG,Fatty acid derivatives,<65,F,"4,020.99",0.4,1.1,"10,259",56
7,Ontario,H03AA,Thyroid hormones,<65,F,"4,001.51",0.4,5.7,"51,054",57
7,Ontario,H01AC,Somatropin and somatropin agonists,<65,F,"3,991.45",0.4,0.0,367,58
7,Ontario,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,**,**,**,**,59
7,Ontario,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,F,"3,758.69",0.3,0.0,48,60
7,Ontario,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,F,"3,613.43",0.3,0.0,50,61
7,Ontario,C09AA,"ACE inhibitors, plain",<65,F,"3,492.87",0.3,3.7,"33,487",62
7,Ontario,R01AD,Corticosteroids,<65,F,"3,491.66",0.3,5.7,"50,535",63
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"3,408.34",0.3,0.0,166,64
7,Ontario,C01CA,Adrenergic and dopaminergic agents,<65,F,"3,358.87",0.3,1.7,"15,453",65
7,Ontario,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,**,66
7,Ontario,C08CA,Dihydropyridine derivatives,<65,F,"3,087.40",0.3,3.2,"28,567",67
7,Ontario,R07AX,Other respiratory system products,<65,F,**,**,**,**,68
7,Ontario,V06C,Infant formulas,<65,F,**,**,**,**,69
7,Ontario,N03AF,Carboxamide derivatives,<65,F,"2,931.49",0.3,0.6,"5,266",70
7,Ontario,V03AB,Antidotes,<65,F,"2,878.39",0.3,1.4,"12,467",71
7,Ontario,L01XC,Monoclonal antibodies,<65,F,"2,767.53",0.2,0.0,281,72
7,Ontario,M03BX,Other centrally acting agents,<65,F,"2,757.13",0.2,2.9,"25,949",73
7,Ontario,J05AJ,Integrase inhibitors,<65,F,"2,698.97",0.2,0.1,587,74
7,Ontario,B03AA,"Iron bivalent, oral preparations",<65,F,"2,676.24",0.2,4.9,"43,810",75
7,Ontario,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,"2,639.19",0.2,2.4,"21,673",76
7,Ontario,G03XB,Progesterone receptor modulators,<65,F,**,**,**,**,77
7,Ontario,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,<65,F,"2,529.78",0.2,0.0,41,78
7,Ontario,M01AE,Propionic acid derivatives,<65,F,"2,512.25",0.2,8.1,"72,553",79
7,Ontario,L01EJ,Janus-associated kinase (JAK) inhibitors,<65,F,"2,499.80",0.2,0.0,49,80
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,"2,455.35",0.2,0.4,"3,776",81
7,Ontario,A07EC,Aminosalicylic acid and similar agents,<65,F,"2,430.09",0.2,0.4,"3,621",82
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,F,"2,349.08",0.2,1.0,"8,505",83
7,Ontario,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,F,"2,329.29",0.2,0.0,51,84
7,Ontario,A10BA,Biguanides,<65,F,"2,325.50",0.2,3.8,"34,358",85
7,Ontario,A04AA,Serotonin (5HT3) antagonists,<65,F,"2,274.85",0.2,0.6,"5,527",86
7,Ontario,J01CA,Penicillins with extended spectrum,<65,F,"2,261.90",0.2,14.3,"127,915",87
7,Ontario,D06AX,Other antibiotics for topical use,<65,F,"2,180.77",0.2,5.3,"47,211",88
7,Ontario,D07AC,"Corticosteroids, potent (group III)",<65,F,"2,167.94",0.2,7.6,"67,826",89
7,Ontario,J02AC,Triazole derivatives,<65,F,"2,004.83",0.2,1.9,"17,230",90
7,Ontario,N02BE,Anilides,<65,F,"1,947.59",0.2,6.1,"54,477",91
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,"1,913.49",0.2,1.8,"15,935",92
7,Ontario,C10AX,Other lipid-modifying agents,<65,F,"1,907.25",0.2,0.7,"6,013",93
7,Ontario,M05BA,Bisphosphonates,<65,F,"1,853.66",0.2,0.9,"7,634",94
7,Ontario,A09AA,Enzyme preparations,<65,F,"1,849.01",0.2,0.2,"1,361",95
7,Ontario,C07AB,"Beta-blocking agents, selective",<65,F,"1,847.96",0.2,2.6,"23,348",96
7,Ontario,D10AF,Antiinfectives for treatment of acne,<65,F,"1,839.96",0.2,2.4,"21,391",97
7,Ontario,A06AB,Contact laxatives,<65,F,"1,814.60",0.2,3.2,"28,252",98
7,Ontario,G03AC,Progestogens,<65,F,"1,798.70",0.2,1.9,"17,146",99
7,Ontario,A05AA,Bile acids and derivatives,<65,F,"1,787.56",0.2,0.1,590,100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"71,137.99",18.6,0.4,"3,401",1
8,Manitoba,L04AX,Other immunosuppressants,Total,Total,"20,687.51",5.4,0.3,"2,405",2
8,Manitoba,L04AA,Selective immunosuppressants,Total,Total,"18,611.55",4.9,0.3,"2,742",3
8,Manitoba,L04AC,Interleukin inhibitors,Total,Total,"13,218.18",3.5,0.1,942,4
8,Manitoba,N05AX,Other antipsychotics,Total,Total,"7,570.49",2.0,1.6,"13,156",5
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"7,079.85",1.9,0.1,"1,131",6
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,Total,Total,"7,053.23",1.8,0.0,175,7
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"6,596.42",1.7,2.8,"22,205",8
8,Manitoba,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,Total,"6,439.87",1.7,0.0,151,9
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"6,233.92",1.6,4.6,"36,752",10
8,Manitoba,A02BC,Proton pump inhibitors,Total,Total,"5,765.73",1.5,18.4,"147,999",11
8,Manitoba,N06AX,Other antidepressants,Total,Total,"5,639.72",1.5,8.4,"67,461",12
8,Manitoba,B01AF,Direct factor Xa inhibitors,Total,Total,"5,425.47",1.4,1.9,"15,609",13
8,Manitoba,N03AX,Other antiepileptics,Total,Total,"5,225.31",1.4,5.5,"44,231",14
8,Manitoba,N02AA,Natural opium alkaloids,Total,Total,"4,692.07",1.2,3.1,"24,660",15
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"4,641.38",1.2,11.8,"95,042",16
8,Manitoba,L01EX,Other protein kinase inhibitors,Total,Total,"4,389.02",1.1,0.0,190,17
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,Total,Total,"4,369.54",1.1,18.8,"151,475",18
8,Manitoba,L03AB,Interferons,Total,Total,"4,208.99",1.1,0.0,269,19
8,Manitoba,L02BB,Antiandrogens,Total,Total,"3,893.74",1.0,0.2,"1,207",20
8,Manitoba,H01CB,Somatostatin and analogues,Total,Total,"3,796.62",1.0,0.0,184,21
8,Manitoba,N06BA,Centrally acting sympathomimetics,Total,Total,"3,756.23",1.0,2.5,"19,880",22
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"3,694.83",1.0,1.4,"11,510",23
8,Manitoba,A16AB,Enzymes,Total,Total,"3,462.85",0.9,0.0,9,24
8,Manitoba,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,Total,"3,018.27",0.8,0.0,79,25
8,Manitoba,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,Total,"2,917.22",0.8,0.0,95,26
8,Manitoba,N07BC,Drugs used in opioid dependence,Total,Total,"2,817.06",0.7,0.3,"2,367",27
8,Manitoba,C08CA,Dihydropyridine derivatives,Total,Total,"2,722.21",0.7,10.0,"80,262",28
8,Manitoba,L01XX,Other antineoplastic agents,Total,Total,"2,713.83",0.7,0.1,781,29
8,Manitoba,C09AA,"ACE inhibitors, plain",Total,Total,"2,623.90",0.7,10.5,"84,691",30
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"2,464.48",0.6,1.3,"10,689",31
8,Manitoba,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,Total,"2,454.35",0.6,0.0,52,32
8,Manitoba,L02BX,Other hormone antagonists and related agents,Total,Total,"2,421.01",0.6,0.0,94,33
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"2,414.06",0.6,1.2,"9,271",34
8,Manitoba,L04AD,Calcineurin inhibitors,Total,Total,"2,413.53",0.6,0.1,867,35
8,Manitoba,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,Total,"2,379.96",0.6,0.0,50,36
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"2,329.57",0.6,11.0,"88,423",37
8,Manitoba,C07AB,"Beta-blocking agents, selective",Total,Total,"2,302.08",0.6,8.1,"65,098",38
8,Manitoba,L03AX,Other immunostimulants,Total,Total,"2,298.10",0.6,0.0,280,39
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"2,234.02",0.6,0.0,177,40
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"2,190.25",0.6,2.3,"18,625",41
8,Manitoba,L01XC,Monoclonal antibodies,Total,Total,"2,127.60",0.6,0.0,237,42
8,Manitoba,H03AA,Thyroid hormones,Total,Total,"2,094.07",0.5,10.3,"82,939",43
8,Manitoba,B02AB,Proteinase inhibitors,Total,Total,"2,031.13",0.5,0.0,18,44
8,Manitoba,R03BB,Anticholinergics,Total,Total,"2,030.43",0.5,1.9,"15,531",45
8,Manitoba,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,Total,"1,938.21",0.5,0.6,"4,859",46
8,Manitoba,A10BA,Biguanides,Total,Total,"1,929.05",0.5,8.3,"66,880",47
8,Manitoba,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,Total,"1,823.02",0.5,0.0,24,48
8,Manitoba,N05BA,Benzodiazepine derivatives,Total,Total,"1,790.63",0.5,6.0,"48,647",49
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"1,785.67",0.5,0.0,197,50
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,Total,Total,"1,708.91",0.4,0.8,"6,665",51
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,666.68",0.4,1.6,"12,814",52
8,Manitoba,L02BG,Aromatase inhibitors,Total,Total,"1,648.74",0.4,0.7,"5,371",53
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"1,569.54",0.4,7.0,"56,498",54
8,Manitoba,N05CF,Benzodiazepine-related drugs,Total,Total,"1,487.83",0.4,5.3,"43,027",55
8,Manitoba,L01XE,Protein kinase inhibitors,Total,Total,"1,410.29",0.4,0.0,217,56
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"1,409.59",0.4,3.1,"24,557",57
8,Manitoba,R03BA,Glucocorticoids,Total,Total,"1,363.96",0.4,3.3,"26,740",58
8,Manitoba,C03CA,"Sulfonamides, plain",Total,Total,"1,357.76",0.4,3.8,"30,952",59
8,Manitoba,B01AB,Heparin group,Total,Total,"1,341.94",0.4,0.3,"2,203",60
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,337.12",0.3,10.5,"84,829",61
8,Manitoba,A10BB,Sulfonylureas,Total,Total,"1,329.93",0.3,4.0,"32,485",62
8,Manitoba,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,Total,Total,"1,307.96",0.3,0.0,20,63
8,Manitoba,M09AX,Other drugs for disorders of the musculoskeletal system,Total,Total,"1,305.05",0.3,0.0,6,64
8,Manitoba,A04AD,Other antiemetics,Total,Total,"1,253.76",0.3,0.3,"2,515",65
8,Manitoba,N03AE,Benzodiazepine derivatives,Total,Total,"1,223.51",0.3,2.1,"16,512",66
8,Manitoba,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,Total,Total,"1,188.64",0.3,0.0,20,67
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,138.43",0.3,0.7,"5,236",68
8,Manitoba,J05AE,Protease inhibitors,Total,Total,"1,107.54",0.3,0.0,241,69
8,Manitoba,A16AA,Amino acids and derivatives,Total,Total,"1,095.01",0.3,0.0,94,70
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"1,086.55",0.3,0.6,"4,924",71
8,Manitoba,J05AJ,Integrase inhibitors,Total,Total,"1,080.08",0.3,0.0,321,72
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"1,052.25",0.3,0.8,"6,337",73
8,Manitoba,N03AG,Fatty acid derivatives,Total,Total,"1,011.93",0.3,0.5,"3,850",74
8,Manitoba,N04BA,Dopa and dopa derivatives,Total,Total,966.23,0.3,0.5,"3,886",75
8,Manitoba,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,Total,Total,936.37,0.2,0.0,20,76
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,924.17,0.2,0.2,"1,263",77
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,899.69,0.2,3.4,"27,342",78
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,890.83,0.2,0.4,"2,861",79
8,Manitoba,A16AX,Various alimentary tract and metabolism products,Total,Total,840.96,0.2,0.0,8,80
8,Manitoba,H02AB,Glucocorticoids,Total,Total,800.06,0.2,6.1,"48,846",81
8,Manitoba,A05AA,Bile acids and derivatives,Total,Total,771.77,0.2,0.1,809,82
8,Manitoba,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,Total,Total,765.41,0.2,0.0,16,83
8,Manitoba,N03AF,Carboxamide derivatives,Total,Total,750.60,0.2,0.4,"3,163",84
8,Manitoba,L01AX,Other alkylating agents,Total,Total,721.38,0.2,0.0,86,85
8,Manitoba,S01EE,Prostaglandin analogues,Total,Total,720.15,0.2,1.7,"13,774",86
8,Manitoba,N02BE,Anilides,Total,Total,715.25,0.2,1.8,"14,757",87
8,Manitoba,H01AC,Somatropin and somatropin agonists,Total,Total,679.74,0.2,0.0,107,88
8,Manitoba,C08DB,Benzothiazepine derivatives,Total,Total,675.69,0.2,1.0,"8,111",89
8,Manitoba,C02AC,Imidazoline receptor agonists,Total,Total,670.96,0.2,0.6,"4,798",90
8,Manitoba,M03BX,Other centrally acting agents,Total,Total,659.05,0.2,3.1,"24,624",91
8,Manitoba,N05AE,Indole derivatives,Total,Total,644.82,0.2,0.1,666,92
8,Manitoba,R01AD,Corticosteroids,Total,Total,624.23,0.2,7.7,"61,982",93
8,Manitoba,S01ED,Beta-blocking agents,Total,Total,592.50,0.2,1.4,"11,413",94
8,Manitoba,N02AB,Phenylpiperidine derivatives,Total,Total,573.26,0.1,0.1,"1,040",95
8,Manitoba,C03AA,"Thiazides, plain",Total,Total,546.69,0.1,4.7,"37,455",96
8,Manitoba,A09AA,Enzyme preparations,Total,Total,539.70,0.1,0.1,"1,108",97
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,532.22,0.1,2.8,"22,643",98
8,Manitoba,M01AE,Propionic acid derivatives,Total,Total,518.74,0.1,6.8,"54,690",99
8,Manitoba,A12BA,Potassium,Total,Total,511.58,0.1,1.2,"9,881",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,"33,841.00",18.5,0.4,"1,524",1
8,Manitoba,L04AX,Other immunosuppressants,Total,M,"10,420.20",5.7,0.3,988,2
8,Manitoba,L04AA,Selective immunosuppressants,Total,M,"6,917.84",3.8,0.3,"1,087",3
8,Manitoba,L04AC,Interleukin inhibitors,Total,M,"6,552.21",3.6,0.1,445,4
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,Total,M,"4,822.14",2.6,0.0,118,5
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"4,796.99",2.6,0.2,754,6
8,Manitoba,N05AX,Other antipsychotics,Total,M,"4,641.04",2.5,1.8,"6,357",7
8,Manitoba,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,M,"4,263.45",2.3,0.0,98,8
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"4,059.65",2.2,2.8,"10,281",9
8,Manitoba,L02BB,Antiandrogens,Total,M,"3,893.74",2.1,0.3,"1,207",10
8,Manitoba,A16AB,Enzymes,Total,M,**,**,**,**,11
8,Manitoba,L01EX,Other protein kinase inhibitors,Total,M,"3,048.59",1.7,0.0,134,12
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,469.28",1.4,4.3,"15,725",13
8,Manitoba,L02BX,Other hormone antagonists and related agents,Total,M,"2,421.01",1.3,0.0,94,14
8,Manitoba,B01AF,Direct factor Xa inhibitors,Total,M,"2,376.56",1.3,2.2,"8,120",15
8,Manitoba,A02BC,Proton pump inhibitors,Total,M,"2,313.08",1.3,17.7,"64,068",16
8,Manitoba,N06BA,Centrally acting sympathomimetics,Total,M,"2,306.37",1.3,3.3,"12,087",17
8,Manitoba,N02AA,Natural opium alkaloids,Total,M,"2,256.14",1.2,3.0,"10,759",18
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,Total,M,"2,170.20",1.2,23.6,"85,435",19
8,Manitoba,N03AX,Other antiepileptics,Total,M,"2,132.02",1.2,4.9,"17,544",20
8,Manitoba,N06AX,Other antidepressants,Total,M,"2,077.61",1.1,6.5,"23,360",21
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"1,892.47",1.0,1.7,"6,141",22
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,797.82",1.0,8.6,"30,940",23
8,Manitoba,H01CB,Somatostatin and analogues,Total,M,"1,719.96",0.9,0.0,81,24
8,Manitoba,N07BC,Drugs used in opioid dependence,Total,M,"1,589.59",0.9,0.4,"1,311",25
8,Manitoba,L01XX,Other antineoplastic agents,Total,M,"1,545.64",0.8,0.1,318,26
8,Manitoba,L04AD,Calcineurin inhibitors,Total,M,"1,468.66",0.8,0.2,545,27
8,Manitoba,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,M,"1,461.98",0.8,0.0,36,28
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,334.47",0.7,1.5,"5,550",29
8,Manitoba,C09AA,"ACE inhibitors, plain",Total,M,"1,324.79",0.7,13.3,"48,036",30
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"1,319.96",0.7,1.5,"5,550",31
8,Manitoba,B02AB,Proteinase inhibitors,Total,M,**,**,**,**,32
8,Manitoba,C08CA,Dihydropyridine derivatives,Total,M,"1,190.76",0.7,11.1,"40,204",33
8,Manitoba,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,M,"1,178.64",0.6,0.0,27,34
8,Manitoba,C07AB,"Beta-blocking agents, selective",Total,M,"1,127.22",0.6,9.8,"35,537",35
8,Manitoba,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,M,"1,053.81",0.6,0.0,24,36
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"1,036.55",0.6,11.4,"41,238",37
8,Manitoba,A10BA,Biguanides,Total,M,953.24,0.5,10.2,"36,987",38
8,Manitoba,R03BB,Anticholinergics,Total,M,918.08,0.5,2.0,"7,325",39
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,917.28,0.5,3.0,"10,860",40
8,Manitoba,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,M,901.67,0.5,0.7,"2,561",41
8,Manitoba,L03AB,Interferons,Total,M,897.01,0.5,0.0,59,42
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,Total,M,839.98,0.5,7.2,"25,962",43
8,Manitoba,L01XE,Protein kinase inhibitors,Total,M,827.54,0.5,0.0,122,44
8,Manitoba,J05AJ,Integrase inhibitors,Total,M,797.53,0.4,0.1,182,45
8,Manitoba,J05AE,Protease inhibitors,Total,M,787.54,0.4,0.0,153,46
8,Manitoba,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,Total,M,777.54,0.4,0.0,11,47
8,Manitoba,N05BA,Benzodiazepine derivatives,Total,M,748.07,0.4,4.5,"16,285",48
8,Manitoba,L03AX,Other immunostimulants,Total,M,736.09,0.4,0.0,76,49
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,696.49,0.4,0.0,68,50
8,Manitoba,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,M,683.72,0.4,0.0,9,51
8,Manitoba,A10BB,Sulfonylureas,Total,M,669.54,0.4,5.2,"18,894",52
8,Manitoba,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,Total,M,642.82,0.4,0.0,12,53
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,603.68,0.3,7.2,"26,138",54
8,Manitoba,N03AG,Fatty acid derivatives,Total,M,599.13,0.3,0.6,"2,074",55
8,Manitoba,N05CF,Benzodiazepine-related drugs,Total,M,595.75,0.3,4.4,"15,817",56
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,581.17,0.3,0.0,69,57
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,576.44,0.3,10.4,"37,632",58
8,Manitoba,C03CA,"Sulfonamides, plain",Total,M,570.05,0.3,3.9,"14,071",59
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,566.34,0.3,0.9,"3,319",60
8,Manitoba,R03BA,Glucocorticoids,Total,M,559.88,0.3,3.5,"12,493",61
8,Manitoba,H03AA,Thyroid hormones,Total,M,559.05,0.3,5.4,"19,551",62
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,Total,M,555.64,0.3,0.6,"2,214",63
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,551.25,0.3,2.2,"7,801",64
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,515.35,0.3,0.7,"2,412",65
8,Manitoba,N03AE,Benzodiazepine derivatives,Total,M,512.13,0.3,1.7,"6,113",66
8,Manitoba,B01AB,Heparin group,Total,M,509.06,0.3,0.2,868,67
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,Total,M,505.48,0.3,0.6,"2,327",68
8,Manitoba,N04BA,Dopa and dopa derivatives,Total,M,481.73,0.3,0.6,"2,115",69
8,Manitoba,L01AX,Other alkylating agents,Total,M,468.14,0.3,0.0,54,70
8,Manitoba,A04AD,Other antiemetics,Total,M,461.58,0.3,0.3,907,71
8,Manitoba,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,442.35,0.2,3.2,"11,397",72
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,432.33,0.2,0.4,"1,483",73
8,Manitoba,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,Total,M,429.11,0.2,0.0,12,74
8,Manitoba,A16AA,Amino acids and derivatives,Total,M,421.06,0.2,0.0,48,75
8,Manitoba,N03AF,Carboxamide derivatives,Total,M,416.53,0.2,0.4,"1,530",76
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,Total,M,414.85,0.2,1.0,"3,490",77
8,Manitoba,L01XC,Monoclonal antibodies,Total,M,411.56,0.2,0.0,58,78
8,Manitoba,H01AC,Somatropin and somatropin agonists,Total,M,410.84,0.2,0.0,63,79
8,Manitoba,H02AB,Glucocorticoids,Total,M,381.13,0.2,6.1,"21,922",80
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,347.30,0.2,0.1,376,81
8,Manitoba,C02AC,Imidazoline receptor agonists,Total,M,329.81,0.2,0.5,"1,922",82
8,Manitoba,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,316.73,0.2,0.1,316,83
8,Manitoba,R07AX,Other respiratory system products,Total,M,**,**,**,*,84
8,Manitoba,M03BX,Other centrally acting agents,Total,M,299.10,0.2,3.0,"10,857",85
8,Manitoba,M04AA,Preparations inhibiting uric acid production,Total,M,296.42,0.2,3.8,"13,880",86
8,Manitoba,A09AA,Enzyme preparations,Total,M,292.51,0.2,0.1,494,87
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,270.80,0.1,2.1,"7,424",88
8,Manitoba,S01EE,Prostaglandin analogues,Total,M,270.50,0.1,1.7,"6,050",89
8,Manitoba,R01AD,Corticosteroids,Total,M,261.36,0.1,7.2,"25,997",90
8,Manitoba,C10AB,Fibrates,Total,M,260.49,0.1,1.1,"3,840",91
8,Manitoba,C08DB,Benzothiazepine derivatives,Total,M,257.74,0.1,1.0,"3,643",92
8,Manitoba,N02BE,Anilides,Total,M,256.22,0.1,1.6,"5,648",93
8,Manitoba,B01AA,Vitamin K antagonists,Total,M,252.32,0.1,1.3,"4,768",94
8,Manitoba,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,Total,M,249.81,0.1,0.0,13,95
8,Manitoba,B01AE,Direct thrombin inhibitors,Total,M,233.66,0.1,0.2,611,96
8,Manitoba,C09BA,ACE inhibitors and diuretics,Total,M,231.49,0.1,2.6,"9,508",97
8,Manitoba,N02AB,Phenylpiperidine derivatives,Total,M,230.19,0.1,0.1,427,98
8,Manitoba,N05AE,Indole derivatives,Total,M,229.59,0.1,0.1,209,99
8,Manitoba,S01ED,Beta-blocking agents,Total,M,226.19,0.1,1.5,"5,257",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,"37,296.98",18.7,0.4,"1,877",1
8,Manitoba,L04AA,Selective immunosuppressants,Total,F,"11,693.71",5.9,0.4,"1,655",2
8,Manitoba,L04AX,Other immunosuppressants,Total,F,"10,267.30",5.1,0.3,"1,417",3
8,Manitoba,L04AC,Interleukin inhibitors,Total,F,"6,665.97",3.3,0.1,497,4
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"3,764.64",1.9,4.7,"21,027",5
8,Manitoba,N06AX,Other antidepressants,Total,F,"3,562.11",1.8,10.0,"44,101",6
8,Manitoba,A02BC,Proton pump inhibitors,Total,F,"3,452.65",1.7,19.0,"83,931",7
8,Manitoba,L03AB,Interferons,Total,F,"3,311.98",1.7,0.0,210,8
8,Manitoba,N03AX,Other antiepileptics,Total,F,"3,093.29",1.5,6.0,"26,687",9
8,Manitoba,B01AF,Direct factor Xa inhibitors,Total,F,"3,048.91",1.5,1.7,"7,489",10
8,Manitoba,N05AX,Other antipsychotics,Total,F,"2,929.44",1.5,1.5,"6,799",11
8,Manitoba,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,F,**,**,**,**,12
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,843.56",1.4,14.5,"64,102",13
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"2,536.77",1.3,2.7,"11,924",14
8,Manitoba,N02AA,Natural opium alkaloids,Total,F,"2,435.92",1.2,3.1,"13,901",15
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"2,282.86",1.1,0.1,377,16
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,Total,F,"2,231.10",1.1,0.0,57,17
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,Total,F,"2,199.34",1.1,14.9,"66,040",18
8,Manitoba,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,F,"2,176.42",1.1,0.0,53,19
8,Manitoba,H01CB,Somatostatin and analogues,Total,F,"2,076.66",1.0,0.0,103,20
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"1,802.36",0.9,1.2,"5,369",21
8,Manitoba,L01XC,Monoclonal antibodies,Total,F,"1,716.04",0.9,0.0,179,22
8,Manitoba,L02BG,Aromatase inhibitors,Total,F,"1,646.39",0.8,1.2,"5,316",23
8,Manitoba,L03AX,Other immunostimulants,Total,F,"1,562.01",0.8,0.0,204,24
8,Manitoba,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,F,"1,556.29",0.8,0.0,43,25
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"1,537.53",0.8,0.0,109,26
8,Manitoba,H03AA,Thyroid hormones,Total,F,"1,535.01",0.8,14.3,"63,388",27
8,Manitoba,C08CA,Dihydropyridine derivatives,Total,F,"1,531.45",0.8,9.0,"40,058",28
8,Manitoba,N06BA,Centrally acting sympathomimetics,Total,F,"1,449.86",0.7,1.8,"7,793",29
8,Manitoba,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,F,"1,400.54",0.7,0.0,28,30
8,Manitoba,L01EX,Other protein kinase inhibitors,Total,F,"1,340.43",0.7,0.0,56,31
8,Manitoba,M09AX,Other drugs for disorders of the musculoskeletal system,Total,F,"1,305.05",0.7,0.0,6,32
8,Manitoba,C09AA,"ACE inhibitors, plain",Total,F,"1,299.11",0.7,8.3,"36,655",33
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"1,293.01",0.6,10.7,"47,185",34
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"1,272.97",0.6,1.8,"7,765",35
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,Total,F,"1,251.83",0.6,2.1,"9,324",36
8,Manitoba,N07BC,Drugs used in opioid dependence,Total,F,"1,227.47",0.6,0.2,"1,056",37
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"1,204.50",0.6,0.0,128,38
8,Manitoba,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,F,"1,201.32",0.6,0.0,23,39
8,Manitoba,C07AB,"Beta-blocking agents, selective",Total,F,"1,174.85",0.6,6.7,"29,561",40
8,Manitoba,L01XX,Other antineoplastic agents,Total,F,"1,168.19",0.6,0.1,463,41
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,Total,F,"1,153.27",0.6,1.0,"4,451",42
8,Manitoba,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,Total,F,"1,139.30",0.6,0.0,15,43
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,130.01",0.6,1.2,"5,139",44
8,Manitoba,R03BB,Anticholinergics,Total,F,"1,112.35",0.6,1.9,"8,206",45
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"1,094.10",0.5,0.8,"3,721",46
8,Manitoba,N05BA,Benzodiazepine derivatives,Total,F,"1,042.56",0.5,7.3,"32,362",47
8,Manitoba,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,F,"1,036.54",0.5,0.5,"2,298",48
8,Manitoba,A10BA,Biguanides,Total,F,975.82,0.5,6.8,"29,893",49
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,965.86,0.5,6.9,"30,360",50
8,Manitoba,L04AD,Calcineurin inhibitors,Total,F,944.87,0.5,0.1,322,51
8,Manitoba,N05CF,Benzodiazepine-related drugs,Total,F,892.07,0.4,6.1,"27,210",52
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,858.34,0.4,3.8,"16,756",53
8,Manitoba,B01AB,Heparin group,Total,F,832.88,0.4,0.3,"1,335",54
8,Manitoba,A16AX,Various alimentary tract and metabolism products,Total,F,**,**,**,**,55
8,Manitoba,B02AB,Proteinase inhibitors,Total,F,**,**,**,**,56
8,Manitoba,R03BA,Glucocorticoids,Total,F,804.08,0.4,3.2,"14,247",57
8,Manitoba,A04AD,Other antiemetics,Total,F,792.18,0.4,0.4,"1,608",58
8,Manitoba,C03CA,"Sulfonamides, plain",Total,F,787.71,0.4,3.8,"16,881",59
8,Manitoba,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,Total,F,765.41,0.4,0.0,16,60
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,760.68,0.4,10.7,"47,197",61
8,Manitoba,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,Total,F,759.53,0.4,0.0,8,62
8,Manitoba,N03AE,Benzodiazepine derivatives,Total,F,711.38,0.4,2.3,"10,399",63
8,Manitoba,A16AA,Amino acids and derivatives,Total,F,673.95,0.3,0.0,46,64
8,Manitoba,A10BB,Sulfonylureas,Total,F,660.40,0.3,3.1,"13,591",65
8,Manitoba,A05AA,Bile acids and derivatives,Total,F,652.42,0.3,0.1,651,66
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,Total,F,632.96,0.3,0.7,"2,909",67
8,Manitoba,L01XE,Protein kinase inhibitors,Total,F,582.74,0.3,0.0,95,68
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,576.87,0.3,0.2,887,69
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,571.20,0.3,0.6,"2,512",70
8,Manitoba,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,Total,F,530.42,0.3,0.0,9,71
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,485.92,0.2,0.7,"3,018",72
8,Manitoba,N04BA,Dopa and dopa derivatives,Total,F,484.51,0.2,0.4,"1,771",73
8,Manitoba,N02BE,Anilides,Total,F,459.03,0.2,2.1,"9,109",74
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,458.50,0.2,0.3,"1,378",75
8,Manitoba,S01EE,Prostaglandin analogues,Total,F,449.65,0.2,1.7,"7,724",76
8,Manitoba,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,428.67,0.2,8.1,"35,781",77
8,Manitoba,H02AB,Glucocorticoids,Total,F,418.93,0.2,6.1,"26,924",78
8,Manitoba,C08DB,Benzothiazepine derivatives,Total,F,417.95,0.2,1.0,"4,468",79
8,Manitoba,N05AE,Indole derivatives,Total,F,415.23,0.2,0.1,457,80
8,Manitoba,N03AG,Fatty acid derivatives,Total,F,412.79,0.2,0.4,"1,776",81
8,Manitoba,A16AB,Enzymes,Total,F,**,**,**,*,82
8,Manitoba,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,393.02,0.2,3.7,"16,172",83
8,Manitoba,M05BA,Bisphosphonates,Total,F,392.03,0.2,2.2,"9,567",84
8,Manitoba,S01ED,Beta-blocking agents,Total,F,366.30,0.2,1.4,"6,156",85
8,Manitoba,R01AD,Corticosteroids,Total,F,362.86,0.2,8.1,"35,985",86
8,Manitoba,M03BX,Other centrally acting agents,Total,F,359.95,0.2,3.1,"13,767",87
8,Manitoba,N02CC,Selective serotonin (5HT1) agonists,Total,F,354.79,0.2,1.9,"8,333",88
8,Manitoba,N02AB,Phenylpiperidine derivatives,Total,F,343.07,0.2,0.1,613,89
8,Manitoba,C02AC,Imidazoline receptor agonists,Total,F,341.15,0.2,0.6,"2,876",90
8,Manitoba,A12BA,Potassium,Total,F,334.76,0.2,1.4,"6,172",91
8,Manitoba,N03AF,Carboxamide derivatives,Total,F,334.06,0.2,0.4,"1,633",92
8,Manitoba,C03AA,"Thiazides, plain",Total,F,328.75,0.2,4.9,"21,710",93
8,Manitoba,J05AE,Protease inhibitors,Total,F,320.00,0.2,0.0,88,94
8,Manitoba,M01AE,Propionic acid derivatives,Total,F,310.98,0.2,7.2,"31,927",95
8,Manitoba,M01AB,Acetic acid derivatives and related substances,Total,F,295.64,0.1,2.7,"11,859",96
8,Manitoba,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,Total,F,293.55,0.1,0.0,8,97
8,Manitoba,L01BA,Folic acid analogues,Total,F,286.06,0.1,0.8,"3,516",98
8,Manitoba,A03FA,Propulsives,Total,F,283.50,0.1,2.0,"9,042",99
8,Manitoba,J05AJ,Integrase inhibitors,Total,F,282.55,0.1,0.0,139,100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,"16,062.65",10.8,0.4,793,1
8,Manitoba,L04AX,Other immunosuppressants,65+,Total,"12,098.76",8.2,0.4,797,2
8,Manitoba,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,Total,"4,797.01",3.2,0.1,118,3
8,Manitoba,B01AF,Direct factor Xa inhibitors,65+,Total,"4,705.99",3.2,6.3,"12,918",4
8,Manitoba,L04AA,Selective immunosuppressants,65+,Total,"4,011.14",2.7,0.4,846,5
8,Manitoba,L02BB,Antiandrogens,65+,Total,"3,549.15",2.4,0.5,"1,107",6
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"3,353.40",2.3,6.2,"12,875",7
8,Manitoba,L01EX,Other protein kinase inhibitors,65+,Total,"3,296.42",2.2,0.1,141,8
8,Manitoba,L04AC,Interleukin inhibitors,65+,Total,"3,048.23",2.1,0.1,224,9
8,Manitoba,A02BC,Proton pump inhibitors,65+,Total,"2,939.86",2.0,30.2,"62,341",10
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,65+,Total,"2,787.77",1.9,43.1,"88,990",11
8,Manitoba,H01CB,Somatostatin and analogues,65+,Total,"2,446.23",1.7,0.1,115,12
8,Manitoba,L02BX,Other hormone antagonists and related agents,65+,Total,"2,267.08",1.5,0.0,87,13
8,Manitoba,L01XX,Other antineoplastic agents,65+,Total,"2,108.07",1.4,0.3,565,14
8,Manitoba,C08CA,Dihydropyridine derivatives,65+,Total,"1,894.20",1.3,23.1,"47,642",15
8,Manitoba,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,Total,"1,890.45",1.3,0.0,39,16
8,Manitoba,N06AX,Other antidepressants,65+,Total,"1,867.41",1.3,9.7,"20,110",17
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"1,810.74",1.2,2.4,"4,876",18
8,Manitoba,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,Total,"1,805.07",1.2,0.0,55,19
8,Manitoba,N02AA,Natural opium alkaloids,65+,Total,"1,734.04",1.2,5.5,"11,434",20
8,Manitoba,A16AB,Enzymes,65+,Total,**,**,**,*,21
8,Manitoba,C07AB,"Beta-blocking agents, selective",65+,Total,"1,670.17",1.1,21.7,"44,799",22
8,Manitoba,C09AA,"ACE inhibitors, plain",65+,Total,"1,643.37",1.1,22.7,"46,924",23
8,Manitoba,N03AX,Other antiepileptics,65+,Total,"1,520.56",1.0,8.6,"17,802",24
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"1,492.48",1.0,0.1,106,25
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"1,456.69",1.0,6.6,"13,570",26
8,Manitoba,R03BB,Anticholinergics,65+,Total,"1,437.86",1.0,4.9,"10,146",27
8,Manitoba,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,Total,"1,371.61",0.9,0.0,30,28
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,286.52",0.9,10.4,"21,415",29
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"1,237.18",0.8,2.1,"4,259",30
8,Manitoba,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,Total,"1,192.87",0.8,1.3,"2,773",31
8,Manitoba,H03AA,Thyroid hormones,65+,Total,"1,164.56",0.8,19.5,"40,383",32
8,Manitoba,L02BG,Aromatase inhibitors,65+,Total,"1,093.58",0.7,1.1,"2,268",33
8,Manitoba,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,Total,"1,088.30",0.7,0.0,32,34
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"1,078.51",0.7,15.8,"32,675",35
8,Manitoba,C03CA,"Sulfonamides, plain",65+,Total,"1,066.06",0.7,11.8,"24,408",36
8,Manitoba,A10BA,Biguanides,65+,Total,"1,040.96",0.7,15.7,"32,459",37
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"1,012.86",0.7,1.9,"3,937",38
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,997.95,0.7,2.9,"6,062",39
8,Manitoba,N05AX,Other antipsychotics,65+,Total,997.37,0.7,1.6,"3,404",40
8,Manitoba,B02AB,Proteinase inhibitors,65+,Total,**,**,**,**,41
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,65+,Total,982.15,0.7,3.7,"7,713",42
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,65+,Total,952.77,0.6,0.0,22,43
8,Manitoba,L01XC,Monoclonal antibodies,65+,Total,914.24,0.6,0.0,102,44
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,872.82,0.6,1.8,"3,711",45
8,Manitoba,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,Total,802.89,0.5,0.0,12,46
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,789.38,0.5,11.7,"24,188",47
8,Manitoba,L01XE,Protein kinase inhibitors,65+,Total,782.94,0.5,0.1,115,48
8,Manitoba,A10BB,Sulfonylureas,65+,Total,767.86,0.5,8.1,"16,648",49
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,706.19,0.5,9.7,"20,031",50
8,Manitoba,N04BA,Dopa and dopa derivatives,65+,Total,659.43,0.4,1.5,"3,109",51
8,Manitoba,N05CF,Benzodiazepine-related drugs,65+,Total,631.52,0.4,9.3,"19,133",52
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,622.74,0.4,10.3,"21,280",53
8,Manitoba,S01EE,Prostaglandin analogues,65+,Total,616.82,0.4,5.3,"11,005",54
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,614.55,0.4,1.6,"3,261",55
8,Manitoba,L03AB,Interferons,65+,Total,609.11,0.4,0.0,35,56
8,Manitoba,L04AD,Calcineurin inhibitors,65+,Total,607.40,0.4,0.1,246,57
8,Manitoba,B01AB,Heparin group,65+,Total,583.49,0.4,0.7,"1,508",58
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,578.56,0.4,0.9,"1,815",59
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,65+,Total,577.84,0.4,1.0,"2,013",60
8,Manitoba,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,65+,Total,546.49,0.4,0.0,8,61
8,Manitoba,N05BA,Benzodiazepine derivatives,65+,Total,535.01,0.4,7.9,"16,393",62
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,531.98,0.4,0.0,66,63
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,521.47,0.4,4.2,"8,775",64
8,Manitoba,C08DB,Benzothiazepine derivatives,65+,Total,521.05,0.4,2.8,"5,785",65
8,Manitoba,S01ED,Beta-blocking agents,65+,Total,500.46,0.3,4.3,"8,956",66
8,Manitoba,R03BA,Glucocorticoids,65+,Total,464.94,0.3,2.3,"4,710",67
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,65+,Total,458.98,0.3,0.9,"1,808",68
8,Manitoba,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,65+,Total,438.09,0.3,0.0,9,69
8,Manitoba,B01AE,Direct thrombin inhibitors,65+,Total,429.22,0.3,0.5,976,70
8,Manitoba,H02AB,Glucocorticoids,65+,Total,407.25,0.3,7.1,"14,615",71
8,Manitoba,A12BA,Potassium,65+,Total,405.64,0.3,3.7,"7,651",72
8,Manitoba,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,391.45,0.3,4.4,"9,162",73
8,Manitoba,M05BA,Bisphosphonates,65+,Total,388.15,0.3,4.5,"9,345",74
8,Manitoba,A04AD,Other antiemetics,65+,Total,384.32,0.3,0.5,"1,000",75
8,Manitoba,M04AA,Preparations inhibiting uric acid production,65+,Total,372.24,0.3,5.4,"11,166",76
8,Manitoba,C01DA,Organic nitrates,65+,Total,363.22,0.2,3.6,"7,480",77
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,359.91,0.2,0.2,432,78
8,Manitoba,B01AA,Vitamin K antagonists,65+,Total,351.58,0.2,2.8,"5,757",79
8,Manitoba,C03AA,"Thiazides, plain",65+,Total,344.15,0.2,10.8,"22,275",80
8,Manitoba,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,65+,Total,297.29,0.2,0.0,12,81
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,297.17,0.2,0.0,38,82
8,Manitoba,N02BE,Anilides,65+,Total,292.31,0.2,3.2,"6,672",83
8,Manitoba,N03AE,Benzodiazepine derivatives,65+,Total,272.27,0.2,2.1,"4,390",84
8,Manitoba,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,270.36,0.2,6.5,"13,428",85
8,Manitoba,B03XA,Other antianemic preparations,65+,Total,**,**,**,**,86
8,Manitoba,C09BA,ACE inhibitors and diuretics,65+,Total,267.30,0.2,3.8,"7,818",87
8,Manitoba,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,65+,Total,**,**,**,**,88
8,Manitoba,C01AA,Digitalis glycosides,65+,Total,264.08,0.2,1.5,"3,005",89
8,Manitoba,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,262.54,0.2,0.1,244,90
8,Manitoba,N06DA,Anticholinesterases,65+,Total,262.45,0.2,1.4,"2,829",91
8,Manitoba,R01AD,Corticosteroids,65+,Total,257.86,0.2,7.6,"15,715",92
8,Manitoba,N02AB,Phenylpiperidine derivatives,65+,Total,255.74,0.2,0.3,610,93
8,Manitoba,L01AX,Other alkylating agents,65+,Total,249.25,0.2,0.0,36,94
8,Manitoba,A05AA,Bile acids and derivatives,65+,Total,242.52,0.2,0.2,316,95
8,Manitoba,C03DA,Aldosterone antagonists,65+,Total,240.23,0.2,2.4,"4,907",96
8,Manitoba,A07AA,Antibiotics,65+,Total,222.96,0.2,1.0,"2,124",97
8,Manitoba,M01AH,Coxibs,65+,Total,222.88,0.2,3.4,"7,011",98
8,Manitoba,A03FA,Propulsives,65+,Total,220.51,0.1,2.4,"4,910",99
8,Manitoba,C10AB,Fibrates,65+,Total,218.89,0.1,1.3,"2,692",100
8,Manitoba,L04AX,Other immunosuppressants,65+,M,"7,142.43",10.2,0.4,347,1
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,"7,005.37",10.0,0.3,310,2
8,Manitoba,L02BB,Antiandrogens,65+,M,"3,549.15",5.1,1.2,"1,107",3
8,Manitoba,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,M,"3,162.88",4.5,0.1,77,4
8,Manitoba,L02BX,Other hormone antagonists and related agents,65+,M,"2,267.08",3.2,0.1,87,5
8,Manitoba,L01EX,Other protein kinase inhibitors,65+,M,"2,249.49",3.2,0.1,100,6
8,Manitoba,B01AF,Direct factor Xa inhibitors,65+,M,"1,982.75",2.8,7.0,"6,544",7
8,Manitoba,A16AB,Enzymes,65+,M,**,**,**,*,8
8,Manitoba,L04AA,Selective immunosuppressants,65+,M,"1,349.92",1.9,0.4,330,9
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,65+,M,"1,287.32",1.8,50.5,"47,163",10
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"1,281.37",1.8,5.7,"5,337",11
8,Manitoba,L04AC,Interleukin inhibitors,65+,M,"1,177.74",1.7,0.1,83,12
8,Manitoba,L01XX,Other antineoplastic agents,65+,M,"1,089.49",1.6,0.2,221,13
8,Manitoba,A02BC,Proton pump inhibitors,65+,M,"1,074.84",1.5,27.7,"25,825",14
8,Manitoba,H01CB,Somatostatin and analogues,65+,M,"1,061.42",1.5,0.1,47,15
8,Manitoba,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,M,964.27,1.4,0.0,22,16
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",65+,M,923.11,1.3,2.8,"2,649",17
8,Manitoba,C09AA,"ACE inhibitors, plain",65+,M,771.81,1.1,27.0,"25,172",18
8,Manitoba,C07AB,"Beta-blocking agents, selective",65+,M,747.62,1.1,24.9,"23,283",19
8,Manitoba,C08CA,Dihydropyridine derivatives,65+,M,730.00,1.0,23.4,"21,811",20
8,Manitoba,B02AB,Proteinase inhibitors,65+,M,**,**,**,**,21
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,667.16,1.0,2.7,"2,562",22
8,Manitoba,N02AA,Natural opium alkaloids,65+,M,657.02,0.9,4.9,"4,564",23
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,65+,M,656.17,0.9,20.7,"19,364",24
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,65+,M,645.76,0.9,0.0,14,25
8,Manitoba,R03BB,Anticholinergics,65+,M,624.31,0.9,5.1,"4,763",26
8,Manitoba,N06AX,Other antidepressants,65+,M,612.91,0.9,7.4,"6,918",27
8,Manitoba,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,M,552.52,0.8,0.0,14,28
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,543.19,0.8,2.3,"2,114",29
8,Manitoba,N03AX,Other antiepileptics,65+,M,541.59,0.8,7.4,"6,937",30
8,Manitoba,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,M,517.49,0.7,1.5,"1,397",31
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,515.62,0.7,7.9,"7,366",32
8,Manitoba,A10BA,Biguanides,65+,M,501.40,0.7,19.3,"18,035",33
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,448.51,0.6,2.7,"2,544",34
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,437.73,0.6,0.1,54,35
8,Manitoba,C03CA,"Sulfonamides, plain",65+,M,435.00,0.6,11.6,"10,858",36
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,434.90,0.6,0.0,40,37
8,Manitoba,L01XE,Protein kinase inhibitors,65+,M,424.95,0.6,0.1,59,38
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,65+,M,407.88,0.6,7.0,"6,519",39
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,400.87,0.6,1.9,"1,800",40
8,Manitoba,L04AD,Calcineurin inhibitors,65+,M,398.09,0.6,0.2,169,41
8,Manitoba,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,390.76,0.6,9.8,"9,145",42
8,Manitoba,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,M,383.36,0.5,0.0,9,43
8,Manitoba,A10BB,Sulfonylureas,65+,M,381.96,0.5,10.3,"9,587",44
8,Manitoba,N05AX,Other antipsychotics,65+,M,379.36,0.5,1.4,"1,294",45
8,Manitoba,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,M,**,**,**,*,46
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,363.92,0.5,14.7,"13,691",47
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,336.14,0.5,2.0,"1,841",48
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,335.46,0.5,12.0,"11,203",49
8,Manitoba,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,65+,M,**,**,**,**,50
8,Manitoba,N04BA,Dopa and dopa derivatives,65+,M,308.66,0.4,1.8,"1,720",51
8,Manitoba,H03AA,Thyroid hormones,65+,M,289.08,0.4,11.4,"10,608",52
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,260.31,0.4,1.0,914,53
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,259.81,0.4,9.4,"8,736",54
8,Manitoba,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,65+,M,**,**,**,**,55
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,65+,M,247.24,0.4,2.4,"2,286",56
8,Manitoba,B01AB,Heparin group,65+,M,247.13,0.4,0.6,556,57
8,Manitoba,L01XC,Monoclonal antibodies,65+,M,240.97,0.3,0.0,29,58
8,Manitoba,N05CF,Benzodiazepine-related drugs,65+,M,240.06,0.3,7.4,"6,927",59
8,Manitoba,S01EE,Prostaglandin analogues,65+,M,216.45,0.3,5.0,"4,688",60
8,Manitoba,H02AB,Glucocorticoids,65+,M,202.54,0.3,7.1,"6,628",61
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,65+,M,200.76,0.3,0.8,775,62
8,Manitoba,M04AA,Preparations inhibiting uric acid production,65+,M,198.48,0.3,8.0,"7,497",63
8,Manitoba,B01AE,Direct thrombin inhibitors,65+,M,196.24,0.3,0.6,514,64
8,Manitoba,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,65+,M,**,**,**,**,65
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,65+,M,185.28,0.3,0.9,796,66
8,Manitoba,N05BA,Benzodiazepine derivatives,65+,M,184.97,0.3,5.5,"5,174",67
8,Manitoba,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,181.91,0.3,0.2,180,68
8,Manitoba,S01ED,Beta-blocking agents,65+,M,177.74,0.3,4.2,"3,923",69
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,176.98,0.3,2.9,"2,705",70
8,Manitoba,C08DB,Benzothiazepine derivatives,65+,M,176.22,0.3,2.5,"2,380",71
8,Manitoba,B01AA,Vitamin K antagonists,65+,M,173.83,0.2,3.7,"3,438",72
8,Manitoba,R03BA,Glucocorticoids,65+,M,158.12,0.2,1.9,"1,791",73
8,Manitoba,C01DA,Organic nitrates,65+,M,155.92,0.2,4.4,"4,145",74
8,Manitoba,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,65+,M,**,**,**,*,75
8,Manitoba,A12BA,Potassium,65+,M,135.40,0.2,3.0,"2,768",76
8,Manitoba,J05AJ,Integrase inhibitors,65+,M,**,**,**,**,77
8,Manitoba,L01AX,Other alkylating agents,65+,M,131.47,0.2,0.0,22,78
8,Manitoba,A04AD,Other antiemetics,65+,M,124.77,0.2,0.4,364,79
8,Manitoba,C03AA,"Thiazides, plain",65+,M,123.91,0.2,9.4,"8,800",80
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,**,**,**,**,81
8,Manitoba,C01AA,Digitalis glycosides,65+,M,113.98,0.2,1.5,"1,441",82
8,Manitoba,J05AE,Protease inhibitors,65+,M,**,**,**,**,83
8,Manitoba,C03DA,Aldosterone antagonists,65+,M,112.28,0.2,2.6,"2,439",84
8,Manitoba,C09BA,ACE inhibitors and diuretics,65+,M,110.14,0.2,4.4,"4,150",85
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,106.53,0.2,0.1,129,86
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,105.73,0.2,1.9,"1,819",87
8,Manitoba,C10AB,Fibrates,65+,M,105.21,0.2,1.5,"1,446",88
8,Manitoba,R01AD,Corticosteroids,65+,M,104.63,0.1,7.0,"6,553",89
8,Manitoba,C10AX,Other lipid-modifying agents,65+,M,97.53,0.1,2.4,"2,266",90
8,Manitoba,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,96.70,0.1,0.6,517,91
8,Manitoba,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,96.19,0.1,6.3,"5,911",92
8,Manitoba,N03AE,Benzodiazepine derivatives,65+,M,95.60,0.1,1.6,"1,516",93
8,Manitoba,B06AC,Drugs used in hereditary angioedema,65+,M,**,**,**,*,94
8,Manitoba,N06DA,Anticholinesterases,65+,M,92.56,0.1,1.2,"1,137",95
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",65+,M,92.01,0.1,8.9,"8,328",96
8,Manitoba,N02AB,Phenylpiperidine derivatives,65+,M,90.66,0.1,0.3,241,97
8,Manitoba,B03XA,Other antianemic preparations,65+,M,**,**,**,**,98
8,Manitoba,C07AG,Alpha- and beta-blocking agents,65+,M,87.04,0.1,1.0,946,99
8,Manitoba,A07AA,Antibiotics,65+,M,85.91,0.1,0.7,690,100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,"9,057.28",11.6,0.4,483,1
8,Manitoba,L04AX,Other immunosuppressants,65+,F,"4,956.33",6.3,0.4,450,2
8,Manitoba,B01AF,Direct factor Xa inhibitors,65+,F,"2,723.23",3.5,5.6,"6,374",3
8,Manitoba,L04AA,Selective immunosuppressants,65+,F,"2,661.22",3.4,0.5,516,4
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,072.02",2.7,6.7,"7,538",5
8,Manitoba,L04AC,Interleukin inhibitors,65+,F,"1,870.49",2.4,0.1,141,6
8,Manitoba,A02BC,Proton pump inhibitors,65+,F,"1,865.02",2.4,32.3,"36,516",7
8,Manitoba,L01EF,Cyclin-dependent kinase (CDK) inhibitors,65+,F,**,**,**,**,8
8,Manitoba,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,F,"1,634.13",2.1,0.0,41,9
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,65+,F,"1,500.46",1.9,37.0,"41,827",10
8,Manitoba,H01CB,Somatostatin and analogues,65+,F,"1,384.81",1.8,0.1,68,11
8,Manitoba,N06AX,Other antidepressants,65+,F,"1,254.50",1.6,11.7,"13,192",12
8,Manitoba,C08CA,Dihydropyridine derivatives,65+,F,"1,164.20",1.5,22.8,"25,831",13
8,Manitoba,L02BG,Aromatase inhibitors,65+,F,**,**,**,**,14
8,Manitoba,N02AA,Natural opium alkaloids,65+,F,"1,077.01",1.4,6.1,"6,870",15
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"1,057.59",1.4,0.1,66,16
8,Manitoba,L01EX,Other protein kinase inhibitors,65+,F,"1,046.93",1.3,0.0,41,17
8,Manitoba,L01XX,Other antineoplastic agents,65+,F,"1,018.58",1.3,0.3,344,18
8,Manitoba,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,F,988.25,1.3,0.0,21,19
8,Manitoba,N03AX,Other antiepileptics,65+,F,978.97,1.3,9.6,"10,865",20
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,941.07,1.2,5.5,"6,204",21
8,Manitoba,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,F,926.19,1.2,0.0,17,22
8,Manitoba,C07AB,"Beta-blocking agents, selective",65+,F,922.55,1.2,19.0,"21,516",23
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",65+,F,887.63,1.1,2.0,"2,227",24
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,65+,F,878.64,1.1,13.2,"14,896",25
8,Manitoba,H03AA,Thyroid hormones,65+,F,875.47,1.1,26.3,"29,775",26
8,Manitoba,C09AA,"ACE inhibitors, plain",65+,F,871.55,1.1,19.2,"21,752",27
8,Manitoba,R03BB,Anticholinergics,65+,F,813.55,1.0,4.8,"5,383",28
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,65+,F,734.91,0.9,4.8,"5,427",29
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,714.58,0.9,16.8,"18,984",30
8,Manitoba,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,F,675.39,0.9,1.2,"1,376",31
8,Manitoba,L01XC,Monoclonal antibodies,65+,F,673.27,0.9,0.1,73,32
8,Manitoba,C03CA,"Sulfonamides, plain",65+,F,631.07,0.8,12.0,"13,550",33
8,Manitoba,N05AX,Other antipsychotics,65+,F,618.01,0.8,1.9,"2,110",34
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,570.02,0.7,1.5,"1,697",35
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,549.44,0.7,3.1,"3,518",36
8,Manitoba,A10BA,Biguanides,65+,F,539.55,0.7,12.7,"14,424",37
8,Manitoba,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,F,535.78,0.7,0.0,18,38
8,Manitoba,L03AB,Interferons,65+,F,534.46,0.7,0.0,29,39
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,471.96,0.6,1.7,"1,911",40
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,469.67,0.6,1.6,"1,823",41
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,453.92,0.6,11.5,"12,985",42
8,Manitoba,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,65+,F,**,**,**,**,43
8,Manitoba,S01EE,Prostaglandin analogues,65+,F,400.38,0.5,5.6,"6,317",44
8,Manitoba,N05CF,Benzodiazepine-related drugs,65+,F,391.46,0.5,10.8,"12,206",45
8,Manitoba,A10BB,Sulfonylureas,65+,F,385.90,0.5,6.2,"7,061",46
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,65+,F,377.09,0.5,1.1,"1,238",47
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,362.93,0.5,11.1,"12,544",48
8,Manitoba,L01XE,Protein kinase inhibitors,65+,F,357.98,0.5,0.0,56,49
8,Manitoba,N04BA,Dopa and dopa derivatives,65+,F,350.77,0.4,1.2,"1,389",50
8,Manitoba,N05BA,Benzodiazepine derivatives,65+,F,350.04,0.4,9.9,"11,219",51
8,Manitoba,C08DB,Benzothiazepine derivatives,65+,F,344.83,0.4,3.0,"3,405",52
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,344.49,0.4,5.4,"6,070",53
8,Manitoba,B01AB,Heparin group,65+,F,336.37,0.4,0.8,952,54
8,Manitoba,M05BA,Bisphosphonates,65+,F,334.02,0.4,7.3,"8,314",55
8,Manitoba,S01ED,Beta-blocking agents,65+,F,322.71,0.4,4.4,"5,033",56
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,318.25,0.4,0.8,901,57
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,65+,F,307.01,0.4,0.0,8,58
8,Manitoba,R03BA,Glucocorticoids,65+,F,306.82,0.4,2.6,"2,919",59
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,278.41,0.4,1.3,"1,420",60
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,65+,F,273.70,0.4,0.9,"1,012",61
8,Manitoba,A12BA,Potassium,65+,F,270.24,0.3,4.3,"4,883",62
8,Manitoba,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,65+,F,267.26,0.3,0.0,6,63
8,Manitoba,B02AB,Proteinase inhibitors,65+,F,**,**,**,*,64
8,Manitoba,A04AD,Other antiemetics,65+,F,259.55,0.3,0.6,636,65
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,253.38,0.3,0.3,303,66
8,Manitoba,B01AE,Direct thrombin inhibitors,65+,F,232.98,0.3,0.4,462,67
8,Manitoba,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,65+,F,**,**,**,*,68
8,Manitoba,C03AA,"Thiazides, plain",65+,F,220.24,0.3,11.9,"13,475",69
8,Manitoba,N02BE,Anilides,65+,F,210.91,0.3,4.1,"4,610",70
8,Manitoba,L04AD,Calcineurin inhibitors,65+,F,209.31,0.3,0.1,77,71
8,Manitoba,C01DA,Organic nitrates,65+,F,207.30,0.3,2.9,"3,335",72
8,Manitoba,H02AB,Glucocorticoids,65+,F,204.71,0.3,7.1,"7,987",73
8,Manitoba,M05BX,Other drugs affecting bone structure and mineralization,65+,F,193.04,0.2,0.8,934,74
8,Manitoba,B03XA,Other antianemic preparations,65+,F,**,**,**,**,75
8,Manitoba,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,65+,F,**,**,**,*,76
8,Manitoba,B01AA,Vitamin K antagonists,65+,F,177.75,0.2,2.0,"2,319",77
8,Manitoba,N03AE,Benzodiazepine derivatives,65+,F,176.66,0.2,2.5,"2,874",78
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,**,**,**,**,79
8,Manitoba,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,174.17,0.2,6.6,"7,517",80
8,Manitoba,M04AA,Preparations inhibiting uric acid production,65+,F,173.76,0.2,3.2,"3,669",81
8,Manitoba,N06DA,Anticholinesterases,65+,F,169.89,0.2,1.5,"1,692",82
8,Manitoba,N02AB,Phenylpiperidine derivatives,65+,F,165.08,0.2,0.3,369,83
8,Manitoba,A05AA,Bile acids and derivatives,65+,F,164.90,0.2,0.2,251,84
8,Manitoba,C09BA,ACE inhibitors and diuretics,65+,F,157.16,0.2,3.2,"3,668",85
8,Manitoba,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,154.59,0.2,5.2,"5,935",86
8,Manitoba,M01AH,Coxibs,65+,F,153.32,0.2,4.0,"4,510",87
8,Manitoba,R01AD,Corticosteroids,65+,F,153.23,0.2,8.1,"9,162",88
8,Manitoba,L02AB,Progestogens,65+,F,150.30,0.2,0.1,155,89
8,Manitoba,C01AA,Digitalis glycosides,65+,F,150.09,0.2,1.4,"1,564",90
8,Manitoba,L01BA,Folic acid analogues,65+,F,143.77,0.2,1.4,"1,607",91
8,Manitoba,A03FA,Propulsives,65+,F,142.37,0.2,2.7,"3,102",92
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",65+,F,137.18,0.2,1.8,"2,034",93
8,Manitoba,A07AA,Antibiotics,65+,F,137.05,0.2,1.3,"1,434",94
8,Manitoba,C03DA,Aldosterone antagonists,65+,F,127.95,0.2,2.2,"2,468",95
8,Manitoba,N07CA,Antivertigo preparations,65+,F,123.10,0.2,3.4,"3,876",96
8,Manitoba,L01AX,Other alkylating agents,65+,F,117.78,0.2,0.0,14,97
8,Manitoba,R03DC,Leukotriene receptor antagonists,65+,F,113.77,0.1,1.4,"1,544",98
8,Manitoba,C10AB,Fibrates,65+,F,113.68,0.1,1.1,"1,246",99
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",65+,F,112.30,0.1,9.1,"10,280",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,"55,075.34",23.5,0.4,"2,608",1
8,Manitoba,L04AA,Selective immunosuppressants,<65,Total,"14,600.41",6.2,0.3,"1,896",2
8,Manitoba,L04AC,Interleukin inhibitors,<65,Total,"10,169.95",4.3,0.1,718,3
8,Manitoba,L04AX,Other immunosuppressants,<65,Total,"8,588.74",3.7,0.3,"1,608",4
8,Manitoba,N05AX,Other antipsychotics,<65,Total,"6,573.12",2.8,1.6,"9,752",5
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"6,547.87",2.8,0.2,"1,065",6
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,<65,Total,"6,100.46",2.6,0.0,153,7
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"5,598.47",2.4,2.7,"16,143",8
8,Manitoba,N06AX,Other antidepressants,<65,Total,"3,772.31",1.6,7.9,"47,351",9
8,Manitoba,N03AX,Other antiepileptics,<65,Total,"3,704.75",1.6,4.4,"26,429",10
8,Manitoba,N06BA,Centrally acting sympathomimetics,<65,Total,"3,694.73",1.6,3.3,"19,505",11
8,Manitoba,L03AB,Interferons,<65,Total,"3,599.88",1.5,0.0,234,12
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"3,354.86",1.4,12.3,"73,627",13
8,Manitoba,N02AA,Natural opium alkaloids,<65,Total,"2,958.03",1.3,2.2,"13,226",14
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"2,880.53",1.2,4.0,"23,877",15
8,Manitoba,A02BC,Proton pump inhibitors,<65,Total,"2,825.87",1.2,14.3,"85,658",16
8,Manitoba,N07BC,Drugs used in opioid dependence,<65,Total,"2,691.06",1.1,0.4,"2,203",17
8,Manitoba,L03AX,Other immunostimulants,<65,Total,"2,136.54",0.9,0.0,263,18
8,Manitoba,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,Total,"1,929.97",0.8,0.0,47,19
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"1,884.09",0.8,1.1,"6,634",20
8,Manitoba,L04AD,Calcineurin inhibitors,<65,Total,"1,806.13",0.8,0.1,621,21
8,Manitoba,A16AB,Enzymes,<65,Total,**,**,**,**,22
8,Manitoba,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,Total,"1,642.86",0.7,0.0,33,23
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,581.77",0.7,10.5,"62,485",24
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"1,540.19",0.7,10.7,"64,235",25
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"1,488.50",0.6,0.0,159,26
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,451.62",0.6,1.1,"6,752",27
8,Manitoba,H01CB,Somatostatin and analogues,<65,Total,"1,350.39",0.6,0.0,69,28
8,Manitoba,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,"1,305.05",0.6,0.0,6,29
8,Manitoba,N05BA,Benzodiazepine derivatives,<65,Total,"1,255.62",0.5,5.4,"32,254",30
8,Manitoba,L01XC,Monoclonal antibodies,<65,Total,"1,213.36",0.5,0.0,135,31
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"1,176.88",0.5,0.8,"5,012",32
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,<65,Total,"1,131.06",0.5,0.8,"4,652",33
8,Manitoba,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,Total,"1,112.15",0.5,0.0,40,34
8,Manitoba,L01EX,Other protein kinase inhibitors,<65,Total,"1,092.61",0.5,0.0,49,35
8,Manitoba,A16AA,Amino acids and derivatives,<65,Total,**,**,**,**,36
8,Manitoba,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,Total,"1,082.74",0.5,0.0,22,37
8,Manitoba,B02AB,Proteinase inhibitors,<65,Total,**,**,**,**,38
8,Manitoba,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,Total,"1,020.13",0.4,0.0,12,39
8,Manitoba,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,Total,"1,014.77",0.4,0.0,14,40
8,Manitoba,C09AA,"ACE inhibitors, plain",<65,Total,980.53,0.4,6.3,"37,767",41
8,Manitoba,J05AE,Protease inhibitors,<65,Total,972.29,0.4,0.0,222,42
8,Manitoba,N03AE,Benzodiazepine derivatives,<65,Total,951.24,0.4,2.0,"12,122",43
8,Manitoba,H03AA,Thyroid hormones,<65,Total,929.51,0.4,7.1,"42,556",44
8,Manitoba,J05AJ,Integrase inhibitors,<65,Total,919.84,0.4,0.0,298,45
8,Manitoba,R03BA,Glucocorticoids,<65,Total,899.02,0.4,3.7,"22,030",46
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,888.12,0.4,2.6,"15,782",47
8,Manitoba,A10BA,Biguanides,<65,Total,888.10,0.4,5.8,"34,421",48
8,Manitoba,A04AD,Other antiemetics,<65,Total,869.44,0.4,0.3,"1,515",49
8,Manitoba,N05CF,Benzodiazepine-related drugs,<65,Total,856.31,0.4,4.0,"23,894",50
8,Manitoba,A16AX,Various alimentary tract and metabolism products,<65,Total,840.96,0.4,0.0,8,51
8,Manitoba,N03AG,Fatty acid derivatives,<65,Total,828.81,0.4,0.5,"3,130",52
8,Manitoba,C08CA,Dihydropyridine derivatives,<65,Total,828.01,0.4,5.5,"32,620",53
8,Manitoba,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,<65,Total,761.47,0.3,0.0,12,54
8,Manitoba,B01AB,Heparin group,<65,Total,758.44,0.3,0.1,695,55
8,Manitoba,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,Total,745.34,0.3,0.3,"2,086",56
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,741.54,0.3,0.0,71,57
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,733.56,0.3,0.8,"5,055",58
8,Manitoba,B01AF,Direct factor Xa inhibitors,<65,Total,719.48,0.3,0.5,"2,691",59
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,714.38,0.3,10.6,"63,549",60
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,<65,Total,684.53,0.3,0.9,"5,101",61
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,<65,Total,679.46,0.3,0.6,"3,428",62
8,Manitoba,H01AC,Somatropin and somatropin agonists,<65,Total,**,**,**,**,63
8,Manitoba,C07AB,"Beta-blocking agents, selective",<65,Total,631.91,0.3,3.4,"20,299",64
8,Manitoba,L01XE,Protein kinase inhibitors,<65,Total,627.35,0.3,0.0,102,65
8,Manitoba,N03AF,Carboxamide derivatives,<65,Total,625.13,0.3,0.4,"2,150",66
8,Manitoba,L01XX,Other antineoplastic agents,<65,Total,605.76,0.3,0.0,216,67
8,Manitoba,C02AC,Imidazoline receptor agonists,<65,Total,593.00,0.3,0.6,"3,681",68
8,Manitoba,R03BB,Anticholinergics,<65,Total,592.57,0.3,0.9,"5,385",69
8,Manitoba,N05AE,Indole derivatives,<65,Total,567.48,0.2,0.1,596,70
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,564.27,0.2,0.1,831,71
8,Manitoba,A10BB,Sulfonylureas,<65,Total,562.07,0.2,2.6,"15,837",72
8,Manitoba,L02BG,Aromatase inhibitors,<65,Total,555.16,0.2,0.5,"3,103",73
8,Manitoba,A05AA,Bile acids and derivatives,<65,Total,529.25,0.2,0.1,493,74
8,Manitoba,M03BX,Other centrally acting agents,<65,Total,516.51,0.2,3.3,"19,899",75
8,Manitoba,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,<65,Total,498.28,0.2,0.0,11,76
8,Manitoba,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,<65,Total,**,**,**,**,77
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,491.03,0.2,4.0,"23,823",78
8,Manitoba,L01EJ,Janus-associated kinase (JAK) inhibitors,<65,Total,489.51,0.2,0.0,11,79
8,Manitoba,L01AX,Other alkylating agents,<65,Total,472.13,0.2,0.0,50,80
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,437.70,0.2,0.5,"3,076",81
8,Manitoba,M01AE,Propionic acid derivatives,<65,Total,434.54,0.2,8.1,"48,227",82
8,Manitoba,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,**,**,**,**,83
8,Manitoba,R07AX,Other respiratory system products,<65,Total,**,**,**,*,84
8,Manitoba,N02BE,Anilides,<65,Total,422.95,0.2,1.4,"8,085",85
8,Manitoba,A09AA,Enzyme preparations,<65,Total,397.10,0.2,0.1,655,86
8,Manitoba,H02AB,Glucocorticoids,<65,Total,392.81,0.2,5.7,"34,231",87
8,Manitoba,N02CC,Selective serotonin (5HT1) agonists,<65,Total,366.84,0.2,1.5,"9,065",88
8,Manitoba,R01AD,Corticosteroids,<65,Total,366.37,0.2,7.7,"46,267",89
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,353.24,0.2,3.0,"17,670",90
8,Manitoba,L02BB,Antiandrogens,<65,Total,344.59,0.1,0.0,100,91
8,Manitoba,M01AB,Acetic acid derivatives and related substances,<65,Total,323.69,0.1,3.2,"19,234",92
8,Manitoba,C02CA,Alpha-adrenoreceptor antagonists,<65,Total,321.75,0.1,0.3,"1,897",93
8,Manitoba,N02AB,Phenylpiperidine derivatives,<65,Total,317.51,0.1,0.1,430,94
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,312.27,0.1,0.2,"1,046",95
8,Manitoba,N04BA,Dopa and dopa derivatives,<65,Total,306.80,0.1,0.1,777,96
8,Manitoba,C03CA,"Sulfonamides, plain",<65,Total,291.70,0.1,1.1,"6,544",97
8,Manitoba,S01XA,Other ophthalmologicals,<65,Total,268.68,0.1,0.0,244,98
8,Manitoba,R03DC,Leukotriene receptor antagonists,<65,Total,268.08,0.1,1.5,"9,152",99
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",<65,Total,267.97,0.1,0.9,"5,176",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,"26,835.63",23.8,0.5,"1,214",1
8,Manitoba,L04AA,Selective immunosuppressants,<65,M,"5,567.92",4.9,0.3,757,2
8,Manitoba,L04AC,Interleukin inhibitors,<65,M,"5,374.47",4.8,0.1,362,3
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"4,359.26",3.9,0.3,700,4
8,Manitoba,N05AX,Other antipsychotics,<65,M,"4,261.69",3.8,1.9,"5,063",5
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,<65,M,"4,176.37",3.7,0.0,104,6
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"3,611.15",3.2,2.9,"7,737",7
8,Manitoba,L04AX,Other immunosuppressants,<65,M,"3,277.77",2.9,0.2,641,8
8,Manitoba,N06BA,Centrally acting sympathomimetics,<65,M,"2,271.41",2.0,4.4,"11,913",9
8,Manitoba,N02AA,Natural opium alkaloids,<65,M,"1,599.12",1.4,2.3,"6,195",10
8,Manitoba,N03AX,Other antiepileptics,<65,M,"1,590.44",1.4,4.0,"10,607",11
8,Manitoba,N07BC,Drugs used in opioid dependence,<65,M,"1,530.35",1.4,0.5,"1,240",12
8,Manitoba,N06AX,Other antidepressants,<65,M,"1,464.70",1.3,6.1,"16,442",13
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,<65,M,"1,389.94",1.2,9.1,"24,421",14
8,Manitoba,A16AB,Enzymes,<65,M,**,**,**,**,15
8,Manitoba,A02BC,Proton pump inhibitors,<65,M,"1,238.24",1.1,14.3,"38,243",16
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"1,187.91",1.1,3.9,"10,388",17
8,Manitoba,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,M,"1,100.57",1.0,0.0,21,18
8,Manitoba,L04AD,Calcineurin inhibitors,<65,M,"1,070.57",1.0,0.1,376,19
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",<65,M,969.35,0.9,1.3,"3,492",20
8,Manitoba,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,M,909.45,0.8,0.0,22,21
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,<65,M,882.88,0.8,14.3,"38,272",22
8,Manitoba,L03AB,Interferons,<65,M,822.36,0.7,0.0,53,23
8,Manitoba,L01EX,Other protein kinase inhibitors,<65,M,799.10,0.7,0.0,34,24
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,791.29,0.7,1.3,"3,436",25
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,701.09,0.6,11.2,"30,035",26
8,Manitoba,J05AE,Protease inhibitors,<65,M,**,**,**,**,27
8,Manitoba,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,M,670.46,0.6,0.0,15,28
8,Manitoba,J05AJ,Integrase inhibitors,<65,M,**,**,**,**,29
8,Manitoba,H01CB,Somatostatin and analogues,<65,M,658.54,0.6,0.0,34,30
8,Manitoba,L03AX,Other immunostimulants,<65,M,655.07,0.6,0.0,69,31
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,652.80,0.6,1.1,"2,988",32
8,Manitoba,N05BA,Benzodiazepine derivatives,<65,M,563.10,0.5,4.1,"11,111",33
8,Manitoba,C09AA,"ACE inhibitors, plain",<65,M,552.97,0.5,8.5,"22,864",34
8,Manitoba,N03AG,Fatty acid derivatives,<65,M,515.98,0.5,0.7,"1,762",35
8,Manitoba,B02AB,Proteinase inhibitors,<65,M,**,**,**,*,36
8,Manitoba,C08CA,Dihydropyridine derivatives,<65,M,460.76,0.4,6.9,"18,393",37
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,**,**,**,**,38
8,Manitoba,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,<65,M,**,**,**,**,39
8,Manitoba,L01XX,Other antineoplastic agents,<65,M,456.15,0.4,0.0,97,40
8,Manitoba,A10BA,Biguanides,<65,M,451.83,0.4,7.1,"18,952",41
8,Manitoba,A16AA,Amino acids and derivatives,<65,M,**,**,**,**,42
8,Manitoba,N03AE,Benzodiazepine derivatives,<65,M,416.52,0.4,1.7,"4,597",43
8,Manitoba,H01AC,Somatropin and somatropin agonists,<65,M,**,**,**,**,44
8,Manitoba,L01XE,Protein kinase inhibitors,<65,M,402.59,0.4,0.0,63,45
8,Manitoba,R03BA,Glucocorticoids,<65,M,401.76,0.4,4.0,"10,702",46
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,401.66,0.4,1.3,"3,494",47
8,Manitoba,B01AF,Direct factor Xa inhibitors,<65,M,393.80,0.3,0.6,"1,576",48
8,Manitoba,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,<65,M,**,**,**,**,49
8,Manitoba,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,M,384.19,0.3,0.4,"1,164",50
8,Manitoba,C07AB,"Beta-blocking agents, selective",<65,M,379.60,0.3,4.6,"12,254",51
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,374.28,0.3,1.9,"5,096",52
8,Manitoba,N03AF,Carboxamide derivatives,<65,M,358.74,0.3,0.4,"1,090",53
8,Manitoba,N05CF,Benzodiazepine-related drugs,<65,M,355.69,0.3,3.3,"8,890",54
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,<65,M,354.88,0.3,0.5,"1,439",55
8,Manitoba,L02BB,Antiandrogens,<65,M,344.59,0.3,0.0,100,56
8,Manitoba,A04AD,Other antiemetics,<65,M,336.82,0.3,0.2,543,57
8,Manitoba,L01AX,Other alkylating agents,<65,M,336.67,0.3,0.0,32,58
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,<65,M,320.20,0.3,0.6,"1,531",59
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,316.63,0.3,10.8,"28,896",60
8,Manitoba,C02AC,Imidazoline receptor agonists,<65,M,309.93,0.3,0.6,"1,618",61
8,Manitoba,R07AX,Other respiratory system products,<65,M,**,**,**,*,62
8,Manitoba,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,M,**,**,**,**,63
8,Manitoba,R03BB,Anticholinergics,<65,M,293.77,0.3,1.0,"2,562",64
8,Manitoba,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,M,**,**,**,**,65
8,Manitoba,A10BB,Sulfonylureas,<65,M,287.58,0.3,3.5,"9,307",66
8,Manitoba,H03AA,Thyroid hormones,<65,M,269.97,0.2,3.3,"8,943",67
8,Manitoba,B01AB,Heparin group,<65,M,261.93,0.2,0.1,312,68
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,261.60,0.2,0.0,28,69
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,240.77,0.2,0.1,247,70
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,239.76,0.2,4.6,"12,447",71
8,Manitoba,M03BX,Other centrally acting agents,<65,M,239.06,0.2,3.3,"8,838",72
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,230.20,0.2,0.6,"1,478",73
8,Manitoba,A09AA,Enzyme preparations,<65,M,220.02,0.2,0.1,285,74
8,Manitoba,L01EJ,Janus-associated kinase (JAK) inhibitors,<65,M,214.37,0.2,0.0,5,75
8,Manitoba,N05AE,Indole derivatives,<65,M,208.43,0.2,0.1,189,76
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,<65,M,183.81,0.2,2.5,"6,598",77
8,Manitoba,H02AB,Glucocorticoids,<65,M,178.59,0.2,5.7,"15,294",78
8,Manitoba,M01AE,Propionic acid derivatives,<65,M,177.15,0.2,7.4,"19,834",79
8,Manitoba,N02BE,Anilides,<65,M,174.83,0.2,1.3,"3,586",80
8,Manitoba,N04BA,Dopa and dopa derivatives,<65,M,173.07,0.2,0.1,395,81
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,172.02,0.2,0.2,569,82
8,Manitoba,L01XC,Monoclonal antibodies,<65,M,170.59,0.2,0.0,29,83
8,Manitoba,H01AX,Other anterior pituitary lobe hormones and analogues,<65,M,**,**,**,*,84
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,<65,M,167.61,0.1,0.4,"1,204",85
8,Manitoba,R05CB,Mucolytics,<65,M,**,**,**,**,86
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,165.07,0.1,2.1,"5,605",87
8,Manitoba,R01AD,Corticosteroids,<65,M,156.74,0.1,7.3,"19,444",88
8,Manitoba,C10AB,Fibrates,<65,M,155.28,0.1,0.9,"2,394",89
8,Manitoba,L02BX,Other hormone antagonists and related agents,<65,M,153.93,0.1,0.0,7,90
8,Manitoba,M01AB,Acetic acid derivatives and related substances,<65,M,140.07,0.1,4.1,"10,878",91
8,Manitoba,N02AB,Phenylpiperidine derivatives,<65,M,139.52,0.1,0.1,186,92
8,Manitoba,C03CA,"Sulfonamides, plain",<65,M,135.06,0.1,1.2,"3,213",93
8,Manitoba,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,134.82,0.1,0.1,136,94
8,Manitoba,J02AC,Triazole derivatives,<65,M,132.66,0.1,0.4,"1,117",95
8,Manitoba,N05AA,Phenothiazines with aliphatic side-chain,<65,M,129.65,0.1,0.2,427,96
8,Manitoba,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,**,**,**,**,97
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",<65,M,123.12,0.1,0.7,"1,879",98
8,Manitoba,C09BA,ACE inhibitors and diuretics,<65,M,121.35,0.1,2.0,"5,358",99
8,Manitoba,N04AC,Ethers of tropine or tropine derivatives,<65,M,119.82,0.1,0.2,481,100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,"28,239.70",23.2,0.4,"1,394",1
8,Manitoba,L04AA,Selective immunosuppressants,<65,F,"9,032.49",7.4,0.3,"1,139",2
8,Manitoba,L04AX,Other immunosuppressants,<65,F,"5,310.97",4.4,0.3,967,3
8,Manitoba,L04AC,Interleukin inhibitors,<65,F,"4,795.48",3.9,0.1,356,4
8,Manitoba,L03AB,Interferons,<65,F,"2,777.52",2.3,0.1,181,5
8,Manitoba,N05AX,Other antipsychotics,<65,F,"2,311.44",1.9,1.4,"4,689",6
8,Manitoba,N06AX,Other antidepressants,<65,F,"2,307.61",1.9,9.4,"30,909",7
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"2,188.60",1.8,0.1,365,8
8,Manitoba,N03AX,Other antiepileptics,<65,F,"2,114.32",1.7,4.8,"15,822",9
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"1,987.33",1.6,2.6,"8,406",10
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,964.92",1.6,14.9,"49,206",11
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,<65,F,"1,924.09",1.6,0.0,49,12
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"1,692.62",1.4,4.1,"13,489",13
8,Manitoba,A02BC,Proton pump inhibitors,<65,F,"1,587.63",1.3,14.4,"47,415",14
8,Manitoba,L03AX,Other immunostimulants,<65,F,"1,481.48",1.2,0.1,194,15
8,Manitoba,N06BA,Centrally acting sympathomimetics,<65,F,"1,423.32",1.2,2.3,"7,592",16
8,Manitoba,N02AA,Natural opium alkaloids,<65,F,"1,358.91",1.1,2.1,"7,031",17
8,Manitoba,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,"1,305.05",1.1,0.0,6,18
8,Manitoba,N07BC,Drugs used in opioid dependence,<65,F,"1,160.71",1.0,0.3,963,19
8,Manitoba,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,F,**,**,**,**,20
8,Manitoba,L01XC,Monoclonal antibodies,<65,F,"1,042.77",0.9,0.0,106,21
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,**,**,**,**,22
8,Manitoba,L01EA,BCR-ABL tyrosine kinase inhibitors,<65,F,"1,020.52",0.8,0.0,25,23
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",<65,F,914.74,0.8,1.0,"3,142",24
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,839.10,0.7,10.4,"34,200",25
8,Manitoba,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,**,26
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,<65,F,776.18,0.6,1.0,"3,213",27
8,Manitoba,L04AD,Calcineurin inhibitors,<65,F,735.56,0.6,0.1,245,28
8,Manitoba,L01EG,Mammalian target of rapamycin (MTOR) kinase inhibitors,<65,F,**,**,**,**,29
8,Manitoba,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,<65,F,**,**,**,**,30
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,<65,F,698.89,0.6,7.3,"24,213",31
8,Manitoba,N05BA,Benzodiazepine derivatives,<65,F,692.52,0.6,6.4,"21,143",32
8,Manitoba,H01CB,Somatostatin and analogues,<65,F,691.85,0.6,0.0,35,33
8,Manitoba,A16AA,Amino acids and derivatives,<65,F,**,**,**,**,34
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,660.34,0.5,1.0,"3,316",35
8,Manitoba,H03AA,Thyroid hormones,<65,F,659.54,0.5,10.2,"33,613",36
8,Manitoba,L02BG,Aromatase inhibitors,<65,F,**,**,**,**,37
8,Manitoba,B02AB,Proteinase inhibitors,<65,F,**,**,**,**,38
8,Manitoba,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,F,542.30,0.4,0.0,12,39
8,Manitoba,N03AE,Benzodiazepine derivatives,<65,F,534.72,0.4,2.3,"7,525",40
8,Manitoba,A04AD,Other antiemetics,<65,F,532.63,0.4,0.3,972,41
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,524.08,0.4,0.6,"2,024",42
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,<65,F,516.92,0.4,1.2,"3,897",43
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,513.85,0.4,3.2,"10,686",44
8,Manitoba,N05CF,Benzodiazepine-related drugs,<65,F,500.62,0.4,4.6,"15,004",45
8,Manitoba,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,<65,F,498.15,0.4,0.0,10,46
8,Manitoba,R03BA,Glucocorticoids,<65,F,497.26,0.4,3.4,"11,328",47
8,Manitoba,B01AB,Heparin group,<65,F,496.51,0.4,0.1,383,48
8,Manitoba,A05AA,Bile acids and derivatives,<65,F,487.52,0.4,0.1,400,49
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,479.94,0.4,0.0,43,50
8,Manitoba,A10BA,Biguanides,<65,F,436.26,0.4,4.7,"15,469",51
8,Manitoba,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,428.37,0.4,10.9,"35,776",52
8,Manitoba,C09AA,"ACE inhibitors, plain",<65,F,427.56,0.4,4.5,"14,903",53
8,Manitoba,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,<65,F,412.29,0.3,0.0,7,54
8,Manitoba,A16AB,Enzymes,<65,F,**,**,**,*,55
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,397.75,0.3,10.5,"34,653",56
8,Manitoba,C08CA,Dihydropyridine derivatives,<65,F,367.25,0.3,4.3,"14,227",57
8,Manitoba,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,F,361.15,0.3,0.3,922,58
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,<65,F,359.26,0.3,0.6,"1,897",59
8,Manitoba,N05AE,Indole derivatives,<65,F,359.05,0.3,0.1,407,60
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,331.90,0.3,0.5,"1,561",61
8,Manitoba,B01AF,Direct factor Xa inhibitors,<65,F,325.68,0.3,0.3,"1,115",62
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,323.49,0.3,0.2,584,63
8,Manitoba,N03AG,Fatty acid derivatives,<65,F,312.82,0.3,0.4,"1,368",64
8,Manitoba,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,<65,F,**,**,**,**,65
8,Manitoba,N02CC,Selective serotonin (5HT1) agonists,<65,F,300.18,0.2,2.3,"7,525",66
8,Manitoba,R03BB,Anticholinergics,<65,F,298.80,0.2,0.9,"2,823",67
8,Manitoba,J05AE,Protease inhibitors,<65,F,**,**,**,**,68
8,Manitoba,L01EX,Other protein kinase inhibitors,<65,F,293.50,0.2,0.0,15,69
8,Manitoba,C02AC,Imidazoline receptor agonists,<65,F,283.06,0.2,0.6,"2,063",70
8,Manitoba,M03BX,Other centrally acting agents,<65,F,277.45,0.2,3.4,"11,061",71
8,Manitoba,L01EJ,Janus-associated kinase (JAK) inhibitors,<65,F,275.13,0.2,0.0,6,72
8,Manitoba,A10BB,Sulfonylureas,<65,F,274.49,0.2,2.0,"6,530",73
8,Manitoba,H01AC,Somatropin and somatropin agonists,<65,F,**,**,**,**,74
8,Manitoba,N03AF,Carboxamide derivatives,<65,F,266.39,0.2,0.3,"1,060",75
8,Manitoba,M01AE,Propionic acid derivatives,<65,F,257.39,0.2,8.6,"28,393",76
8,Manitoba,J05AJ,Integrase inhibitors,<65,F,**,**,**,**,77
8,Manitoba,G02BA,Intrauterine contraceptives,<65,F,252.81,0.2,1.8,"6,015",78
8,Manitoba,C07AB,"Beta-blocking agents, selective",<65,F,252.30,0.2,2.4,"8,045",79
8,Manitoba,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,251.28,0.2,3.5,"11,376",80
8,Manitoba,N02BE,Anilides,<65,F,248.12,0.2,1.4,"4,499",81
8,Manitoba,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,238.43,0.2,3.1,"10,237",82
8,Manitoba,B06AC,Drugs used in hereditary angioedema,<65,F,**,**,**,**,83
8,Manitoba,L01XE,Protein kinase inhibitors,<65,F,224.76,0.2,0.0,39,84
8,Manitoba,H02AB,Glucocorticoids,<65,F,214.22,0.2,5.7,"18,937",85
8,Manitoba,C02CA,Alpha-adrenoreceptor antagonists,<65,F,212.90,0.2,0.4,"1,175",86
8,Manitoba,R01AD,Corticosteroids,<65,F,209.64,0.2,8.1,"26,823",87
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,207.50,0.2,0.5,"1,598",88
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,188.17,0.2,3.7,"12,065",89
8,Manitoba,M01AB,Acetic acid derivatives and related substances,<65,F,183.62,0.2,2.5,"8,356",90
8,Manitoba,N02AB,Phenylpiperidine derivatives,<65,F,177.99,0.1,0.1,244,91
8,Manitoba,A09AA,Enzyme preparations,<65,F,177.08,0.1,0.1,370,92
8,Manitoba,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,**,**,**,**,93
8,Manitoba,S01XA,Other ophthalmologicals,<65,F,166.44,0.1,0.0,134,94
8,Manitoba,R03DC,Leukotriene receptor antagonists,<65,F,163.76,0.1,1.6,"5,183",95
8,Manitoba,C03CA,"Sulfonamides, plain",<65,F,156.64,0.1,1.0,"3,331",96
8,Manitoba,L01XX,Other antineoplastic agents,<65,F,149.61,0.1,0.0,119,97
8,Manitoba,G03AC,Progestogens,<65,F,**,**,**,**,98
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",<65,F,148.01,0.1,8.1,"26,791",99
8,Manitoba,N05AN,Lithium,<65,F,144.96,0.1,0.3,999,100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"86,447.65",19.9,0.5,"3,531",1
9,Saskatchewan,L04AA,Selective immunosuppressants,Total,Total,"28,595.01",6.6,0.4,"2,979",2
9,Saskatchewan,L04AC,Interleukin inhibitors,Total,Total,"21,518.90",5.0,0.2,"1,123",3
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,Total,Total,"15,383.40",3.5,0.1,379,4
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,Total,Total,"12,439.18",2.9,2.9,"20,641",5
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"10,454.06",2.4,0.2,"1,444",6
9,Saskatchewan,N05AX,Other antipsychotics,Total,Total,"10,082.05",2.3,1.5,"10,930",7
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,Total,Total,"9,486.90",2.2,2.3,"16,700",8
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"9,363.75",2.2,2.4,"17,130",9
9,Saskatchewan,L04AX,Other immunosuppressants,Total,Total,"7,154.00",1.6,0.3,"2,311",10
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"6,735.95",1.6,1.8,"13,104",11
9,Saskatchewan,N02AA,Natural opium alkaloids,Total,Total,"6,148.10",1.4,5.6,"39,973",12
9,Saskatchewan,S01LA,Antineovascularization agents,Total,Total,"5,738.76",1.3,0.5,"3,610",13
9,Saskatchewan,A02BC,Proton pump inhibitors,Total,Total,"5,695.76",1.3,18.2,"129,529",14
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"5,415.53",1.2,3.3,"23,529",15
9,Saskatchewan,N03AX,Other antiepileptics,Total,Total,"5,271.79",1.2,5.8,"41,467",16
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,Total,Total,"5,183.41",1.2,18.0,"128,525",17
9,Saskatchewan,B03XA,Other antianemic preparations,Total,Total,"4,463.61",1.0,0.2,"1,154",18
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"4,174.04",1.0,1.7,"12,114",19
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"4,162.23",1.0,1.2,"8,398",20
9,Saskatchewan,N06AX,Other antidepressants,Total,Total,"4,100.12",0.9,8.9,"63,670",21
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"4,087.82",0.9,11.7,"83,674",22
9,Saskatchewan,C08CA,Dihydropyridine derivatives,Total,Total,"3,656.58",0.8,8.0,"57,046",23
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"3,510.50",0.8,0.0,252,24
9,Saskatchewan,R03BA,Glucocorticoids,Total,Total,"3,394.39",0.8,5.2,"37,393",25
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"3,340.27",0.8,1.5,"10,461",26
9,Saskatchewan,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,Total,"3,209.03",0.7,0.7,"4,681",27
9,Saskatchewan,R03BB,Anticholinergics,Total,Total,"3,130.76",0.7,1.7,"12,166",28
9,Saskatchewan,L04AD,Calcineurin inhibitors,Total,Total,"3,082.84",0.7,0.1,817,29
9,Saskatchewan,C09AA,"ACE inhibitors, plain",Total,Total,"3,006.21",0.7,10.4,"74,030",30
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",Total,Total,"2,433.17",0.6,7.8,"55,660",31
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"2,418.93",0.6,7.3,"52,034",32
9,Saskatchewan,N07BC,Drugs used in opioid dependence,Total,Total,"2,401.59",0.6,0.4,"2,855",33
9,Saskatchewan,L01XC,Monoclonal antibodies,Total,Total,"2,339.88",0.5,0.0,235,34
9,Saskatchewan,B01AB,Heparin group,Total,Total,"2,282.73",0.5,0.2,"1,312",35
9,Saskatchewan,L03AB,Interferons,Total,Total,"2,078.71",0.5,0.0,135,36
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,983.10",0.5,0.6,"4,317",37
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,Total,Total,"1,937.03",0.4,0.0,17,38
9,Saskatchewan,L03AX,Other immunostimulants,Total,Total,"1,926.63",0.4,0.0,173,39
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"1,726.67",0.4,1.9,"13,345",40
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,710.32",0.4,1.5,"10,408",41
9,Saskatchewan,H03AA,Thyroid hormones,Total,Total,"1,702.09",0.4,9.8,"69,665",42
9,Saskatchewan,A05AA,Bile acids and derivatives,Total,Total,"1,680.28",0.4,0.1,766,43
9,Saskatchewan,A10BA,Biguanides,Total,Total,"1,597.34",0.4,7.8,"55,797",44
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,Total,Total,"1,574.34",0.4,3.7,"26,435",45
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"1,526.77",0.4,0.3,"2,232",46
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"1,482.43",0.3,3.5,"24,690",47
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"1,271.06",0.3,0.3,"2,276",48
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,"1,259.54",0.3,3.9,"27,940",49
9,Saskatchewan,L01EX,Other protein kinase inhibitors,Total,Total,"1,255.77",0.3,0.0,52,50
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"1,231.87",0.3,0.0,58,51
9,Saskatchewan,C03CA,"Sulfonamides, plain",Total,Total,"1,227.09",0.3,3.9,"27,890",52
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,202.28",0.3,10.4,"74,187",53
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"1,190.96",0.3,0.1,670,54
9,Saskatchewan,S01EE,Prostaglandin analogues,Total,Total,"1,116.35",0.3,1.0,"7,424",55
9,Saskatchewan,S01ED,Beta-blocking agents,Total,Total,"1,102.44",0.3,1.1,"7,794",56
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,"1,080.53",0.2,0.2,"1,625",57
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"1,031.67",0.2,3.6,"25,737",58
9,Saskatchewan,N03AG,Fatty acid derivatives,Total,Total,916.55,0.2,0.6,"4,278",59
9,Saskatchewan,J01DB,First-generation cephalosporins,Total,Total,912.67,0.2,7.4,"53,019",60
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,Total,Total,912.17,0.2,0.2,"1,128",61
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,906.36,0.2,0.1,978,62
9,Saskatchewan,J05AJ,Integrase inhibitors,Total,Total,883.99,0.2,0.0,221,63
9,Saskatchewan,R05CB,Mucolytics,Total,Total,879.53,0.2,0.0,110,64
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,872.18,0.2,2.1,"15,129",65
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,Total,Total,862.59,0.2,1.2,"8,813",66
9,Saskatchewan,N04BA,Dopa and dopa derivatives,Total,Total,836.55,0.2,0.4,"2,673",67
9,Saskatchewan,A09AA,Enzyme preparations,Total,Total,828.69,0.2,0.1,"1,006",68
9,Saskatchewan,C08DB,Benzothiazepine derivatives,Total,Total,817.90,0.2,0.8,"5,866",69
9,Saskatchewan,A11CC,Vitamin D and analogues,Total,Total,785.67,0.2,0.8,"5,578",70
9,Saskatchewan,B01AE,Direct thrombin inhibitors,Total,Total,784.81,0.2,0.1,"1,034",71
9,Saskatchewan,A10BB,Sulfonylureas,Total,Total,774.80,0.2,2.9,"20,485",72
9,Saskatchewan,H02AB,Glucocorticoids,Total,Total,736.91,0.2,7.0,"50,216",73
9,Saskatchewan,N05BA,Benzodiazepine derivatives,Total,Total,727.76,0.2,3.3,"23,732",74
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",Total,Total,719.80,0.2,1.4,"9,798",75
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,Total,Total,694.18,0.2,0.8,"5,834",76
9,Saskatchewan,R07AX,Other respiratory system products,Total,Total,**,**,**,*,77
9,Saskatchewan,A16AB,Enzymes,Total,Total,656.87,0.2,0.0,7,78
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,651.61,0.2,4.7,"33,614",79
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,648.17,0.1,3.8,"27,159",80
9,Saskatchewan,A12BA,Potassium,Total,Total,639.22,0.1,1.7,"11,874",81
9,Saskatchewan,C01DA,Organic nitrates,Total,Total,630.39,0.1,1.4,"9,832",82
9,Saskatchewan,M03BX,Other centrally acting agents,Total,Total,626.63,0.1,1.7,"12,012",83
9,Saskatchewan,J02AC,Triazole derivatives,Total,Total,626.40,0.1,1.4,"10,033",84
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,Total,Total,619.49,0.1,2.3,"16,170",85
9,Saskatchewan,H01CB,Somatostatin and analogues,Total,Total,599.87,0.1,0.0,28,86
9,Saskatchewan,B02BX,Other systemic hemostatics,Total,Total,598.82,0.1,0.0,12,87
9,Saskatchewan,R01AD,Corticosteroids,Total,Total,592.69,0.1,7.1,"50,269",88
9,Saskatchewan,M05BA,Bisphosphonates,Total,Total,577.04,0.1,0.8,"5,869",89
9,Saskatchewan,C10AX,Other lipid-modifying agents,Total,Total,569.95,0.1,0.9,"6,612",90
9,Saskatchewan,N03AF,Carboxamide derivatives,Total,Total,561.92,0.1,0.4,"2,632",91
9,Saskatchewan,L01BA,Folic acid analogues,Total,Total,559.20,0.1,0.7,"5,062",92
9,Saskatchewan,C03DA,Aldosterone antagonists,Total,Total,558.28,0.1,1.7,"12,063",93
9,Saskatchewan,B03AC,"Iron, parenteral preparations",Total,Total,549.17,0.1,0.2,"1,102",94
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,Total,Total,532.64,0.1,0.0,49,95
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,Total,Total,531.52,0.1,0.6,"4,565",96
9,Saskatchewan,A07AA,Antibiotics,Total,Total,527.87,0.1,0.9,"6,386",97
9,Saskatchewan,M01AE,Propionic acid derivatives,Total,Total,521.45,0.1,7.0,"49,916",98
9,Saskatchewan,N05AF,Thioxanthene derivatives,Total,Total,519.54,0.1,0.1,"1,044",99
9,Saskatchewan,A06AD,Osmotically acting laxatives,Total,Total,518.35,0.1,0.6,"4,595",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,"42,194.12",19.6,0.5,"1,577",1
9,Saskatchewan,L04AA,Selective immunosuppressants,Total,M,"11,427.93",5.3,0.4,"1,273",2
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,Total,M,"10,998.71",5.1,0.1,276,3
9,Saskatchewan,L04AC,Interleukin inhibitors,Total,M,"10,539.05",4.9,0.2,536,4
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"7,668.83",3.6,0.3,"1,092",5
9,Saskatchewan,N05AX,Other antipsychotics,Total,M,"6,347.39",3.0,1.7,"5,647",6
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,Total,M,"6,260.67",2.9,3.1,"10,160",7
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,Total,M,"6,100.19",2.8,3.4,"11,005",8
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"5,347.64",2.5,3.0,"9,661",9
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"3,232.78",1.5,3.2,"10,357",10
9,Saskatchewan,N02AA,Natural opium alkaloids,Total,M,"2,980.41",1.4,5.5,"17,941",11
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,969.10",1.4,1.8,"5,804",12
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,Total,M,"2,675.99",1.2,22.7,"73,876",13
9,Saskatchewan,B03XA,Other antianemic preparations,Total,M,"2,570.22",1.2,0.2,653,14
9,Saskatchewan,L04AX,Other immunosuppressants,Total,M,"2,514.98",1.2,0.3,930,15
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"2,513.36",1.2,1.7,"5,370",16
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"2,430.69",1.1,2.1,"6,710",17
9,Saskatchewan,A02BC,Proton pump inhibitors,Total,M,"2,389.61",1.1,17.8,"57,829",18
9,Saskatchewan,N03AX,Other antiepileptics,Total,M,"2,344.39",1.1,5.1,"16,719",19
9,Saskatchewan,S01LA,Antineovascularization agents,Total,M,"2,153.55",1.0,0.5,"1,516",20
9,Saskatchewan,L04AD,Calcineurin inhibitors,Total,M,"1,877.01",0.9,0.2,510,21
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"1,749.46",0.8,1.6,"5,123",22
9,Saskatchewan,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,M,"1,711.85",0.8,0.8,"2,590",23
9,Saskatchewan,C08CA,Dihydropyridine derivatives,Total,M,"1,707.83",0.8,9.0,"29,338",24
9,Saskatchewan,R03BA,Glucocorticoids,Total,M,"1,656.33",0.8,5.6,"18,119",25
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,539.62",0.7,8.4,"27,255",26
9,Saskatchewan,C09AA,"ACE inhibitors, plain",Total,M,"1,534.72",0.7,13.1,"42,394",27
9,Saskatchewan,R03BB,Anticholinergics,Total,M,"1,507.53",0.7,1.8,"5,885",28
9,Saskatchewan,N06AX,Other antidepressants,Total,M,"1,459.56",0.7,7.0,"22,776",29
9,Saskatchewan,N07BC,Drugs used in opioid dependence,Total,M,"1,300.64",0.6,0.5,"1,649",30
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",Total,M,"1,176.75",0.5,9.2,"29,772",31
9,Saskatchewan,B01AB,Heparin group,Total,M,"1,120.42",0.5,0.2,558,32
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"1,055.16",0.5,0.0,80,33
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"1,015.10",0.5,7.6,"24,622",34
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,973.98,0.5,2.5,"8,137",35
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,970.65,0.5,7.6,"24,533",36
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,Total,M,970.06,0.5,0.6,"1,991",37
9,Saskatchewan,L01EX,Other protein kinase inhibitors,Total,M,883.04,0.4,0.0,36,38
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,878.56,0.4,0.4,"1,346",39
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,864.76,0.4,0.2,498,40
9,Saskatchewan,L01XC,Monoclonal antibodies,Total,M,856.76,0.4,0.0,95,41
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,Total,M,845.79,0.4,4.7,"15,395",42
9,Saskatchewan,A10BA,Biguanides,Total,M,841.15,0.4,9.7,"31,421",43
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,697.96,0.3,0.3,976,44
9,Saskatchewan,R07AX,Other respiratory system products,Total,M,**,**,**,*,45
9,Saskatchewan,A16AB,Enzymes,Total,M,**,**,**,**,46
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,Total,M,644.48,0.3,0.0,10,47
9,Saskatchewan,A05AA,Bile acids and derivatives,Total,M,626.66,0.3,0.1,167,48
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,570.22,0.3,10.8,"35,121",49
9,Saskatchewan,A09AA,Enzyme preparations,Total,M,563.06,0.3,0.2,556,50
9,Saskatchewan,J05AJ,Integrase inhibitors,Total,M,553.13,0.3,0.0,125,51
9,Saskatchewan,N03AG,Fatty acid derivatives,Total,M,542.79,0.3,0.7,"2,344",52
9,Saskatchewan,C03CA,"Sulfonamides, plain",Total,M,537.66,0.3,3.9,"12,674",53
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,522.09,0.2,4.2,"13,752",54
9,Saskatchewan,R05CB,Mucolytics,Total,M,520.42,0.2,0.0,63,55
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,502.28,0.2,2.3,"7,507",56
9,Saskatchewan,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,493.34,0.2,2.6,"8,514",57
9,Saskatchewan,N04BA,Dopa and dopa derivatives,Total,M,492.11,0.2,0.5,"1,478",58
9,Saskatchewan,L03AB,Interferons,Total,M,480.48,0.2,0.0,33,59
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,Total,M,457.45,0.2,1.2,"3,949",60
9,Saskatchewan,H03AA,Thyroid hormones,Total,M,449.76,0.2,5.1,"16,444",61
9,Saskatchewan,S01ED,Beta-blocking agents,Total,M,446.70,0.2,1.1,"3,515",62
9,Saskatchewan,J01DB,First-generation cephalosporins,Total,M,445.96,0.2,7.8,"25,390",63
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,Total,M,435.90,0.2,0.9,"2,773",64
9,Saskatchewan,B01AE,Direct thrombin inhibitors,Total,M,421.57,0.2,0.2,618,65
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,Total,M,421.28,0.2,0.9,"3,004",66
9,Saskatchewan,S01EE,Prostaglandin analogues,Total,M,418.31,0.2,0.9,"3,075",67
9,Saskatchewan,A10BB,Sulfonylureas,Total,M,416.31,0.2,3.8,"12,378",68
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,414.21,0.2,0.0,23,69
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,Total,M,410.89,0.2,3.9,"12,578",70
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,Total,M,410.87,0.2,0.0,35,71
9,Saskatchewan,L03AX,Other immunostimulants,Total,M,410.55,0.2,0.0,38,72
9,Saskatchewan,A11CC,Vitamin D and analogues,Total,M,406.93,0.2,0.8,"2,587",73
9,Saskatchewan,H01CB,Somatostatin and analogues,Total,M,**,**,**,**,74
9,Saskatchewan,A16AA,Amino acids and derivatives,Total,M,373.31,0.2,0.0,32,75
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,Total,M,370.45,0.2,0.1,408,76
9,Saskatchewan,C08DB,Benzothiazepine derivatives,Total,M,331.34,0.2,0.8,"2,556",77
9,Saskatchewan,H02AB,Glucocorticoids,Total,M,327.54,0.2,7.0,"22,836",78
9,Saskatchewan,N05AF,Thioxanthene derivatives,Total,M,318.90,0.1,0.2,622,79
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",Total,M,310.67,0.1,1.2,"3,982",80
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,Total,M,308.88,0.1,0.7,"2,358",81
9,Saskatchewan,N05BA,Benzodiazepine derivatives,Total,M,302.04,0.1,2.6,"8,352",82
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,294.41,0.1,0.1,255,83
9,Saskatchewan,C01DA,Organic nitrates,Total,M,290.95,0.1,1.7,"5,597",84
9,Saskatchewan,B03AC,"Iron, parenteral preparations",Total,M,289.70,0.1,0.1,482,85
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,289.62,0.1,2.7,"8,801",86
9,Saskatchewan,J01DF,Monobactams,Total,M,288.87,0.1,0.0,19,87
9,Saskatchewan,A06AD,Osmotically acting laxatives,Total,M,278.49,0.1,0.7,"2,202",88
9,Saskatchewan,N03AF,Carboxamide derivatives,Total,M,276.41,0.1,0.4,"1,266",89
9,Saskatchewan,C03DA,Aldosterone antagonists,Total,M,275.95,0.1,1.7,"5,530",90
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,271.71,0.1,4.8,"15,747",91
9,Saskatchewan,M03BX,Other centrally acting agents,Total,M,268.52,0.1,1.7,"5,386",92
9,Saskatchewan,B01AA,Vitamin K antagonists,Total,M,265.57,0.1,1.6,"5,129",93
9,Saskatchewan,C10AX,Other lipid-modifying agents,Total,M,263.44,0.1,1.2,"3,933",94
9,Saskatchewan,R01AD,Corticosteroids,Total,M,260.25,0.1,6.5,"21,116",95
9,Saskatchewan,M01AE,Propionic acid derivatives,Total,M,258.12,0.1,7.2,"23,359",96
9,Saskatchewan,J05AE,Protease inhibitors,Total,M,247.83,0.1,0.0,50,97
9,Saskatchewan,N02BE,Anilides,Total,M,246.20,0.1,2.0,"6,418",98
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,Total,M,245.54,0.1,4.0,"12,828",99
9,Saskatchewan,A06AB,Contact laxatives,Total,M,239.98,0.1,0.6,"1,937",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,"44,253.53",20.2,0.5,"1,954",1
9,Saskatchewan,L04AA,Selective immunosuppressants,Total,F,"17,167.09",7.8,0.4,"1,706",2
9,Saskatchewan,L04AC,Interleukin inhibitors,Total,F,"10,979.86",5.0,0.2,587,3
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,Total,F,"6,338.99",2.9,2.5,"9,636",4
9,Saskatchewan,L04AX,Other immunosuppressants,Total,F,"4,639.02",2.1,0.4,"1,381",5
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,Total,F,"4,384.70",2.0,0.0,103,6
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"4,016.11",1.8,1.9,"7,469",7
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"3,766.85",1.7,1.9,"7,300",8
9,Saskatchewan,N05AX,Other antipsychotics,Total,F,"3,734.65",1.7,1.4,"5,283",9
9,Saskatchewan,S01LA,Antineovascularization agents,Total,F,"3,585.21",1.6,0.5,"2,094",10
9,Saskatchewan,A02BC,Proton pump inhibitors,Total,F,"3,306.15",1.5,18.5,"71,700",11
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,Total,F,"3,226.24",1.5,1.7,"6,540",12
9,Saskatchewan,N02AA,Natural opium alkaloids,Total,F,"3,167.69",1.4,5.7,"22,032",13
9,Saskatchewan,N03AX,Other antiepileptics,Total,F,"2,927.40",1.3,6.4,"24,748",14
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"2,785.23",1.3,0.1,352,15
9,Saskatchewan,N06AX,Other antidepressants,Total,F,"2,640.56",1.2,10.5,"40,894",16
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,548.20",1.2,14.6,"56,419",17
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,Total,F,"2,507.42",1.1,14.1,"54,649",18
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"2,455.34",1.1,0.0,172,19
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"2,182.74",1.0,3.4,"13,172",20
9,Saskatchewan,C08CA,Dihydropyridine derivatives,Total,F,"1,948.75",0.9,7.1,"27,708",21
9,Saskatchewan,B03XA,Other antianemic preparations,Total,F,"1,893.39",0.9,0.1,501,22
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,743.35",0.8,1.4,"5,404",23
9,Saskatchewan,R03BA,Glucocorticoids,Total,F,"1,738.06",0.8,5.0,"19,274",24
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"1,648.87",0.8,0.8,"3,028",25
9,Saskatchewan,R03BB,Anticholinergics,Total,F,"1,623.22",0.7,1.6,"6,281",26
9,Saskatchewan,L03AB,Interferons,Total,F,"1,598.23",0.7,0.0,102,27
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"1,590.81",0.7,1.4,"5,338",28
9,Saskatchewan,L03AX,Other immunostimulants,Total,F,"1,516.08",0.7,0.0,135,29
9,Saskatchewan,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,F,"1,497.19",0.7,0.5,"2,091",30
9,Saskatchewan,L01XC,Monoclonal antibodies,Total,F,"1,483.12",0.7,0.0,140,31
9,Saskatchewan,C09AA,"ACE inhibitors, plain",Total,F,"1,471.49",0.7,8.2,"31,636",32
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"1,448.27",0.7,7.1,"27,501",33
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,Total,F,"1,292.54",0.6,0.0,7,34
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,Total,F,"1,274.41",0.6,2.0,"7,635",35
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",Total,F,"1,256.42",0.6,6.7,"25,888",36
9,Saskatchewan,H03AA,Thyroid hormones,Total,F,"1,252.34",0.6,13.7,"53,221",37
9,Saskatchewan,L04AD,Calcineurin inhibitors,Total,F,"1,205.82",0.6,0.1,307,38
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"1,170.09",0.5,0.5,"2,084",39
9,Saskatchewan,B01AB,Heparin group,Total,F,"1,162.31",0.5,0.2,754,40
9,Saskatchewan,N07BC,Drugs used in opioid dependence,Total,F,"1,100.94",0.5,0.3,"1,206",41
9,Saskatchewan,A05AA,Bile acids and derivatives,Total,F,"1,053.61",0.5,0.2,599,42
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,Total,F,"1,013.04",0.5,0.6,"2,326",43
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,980.15,0.4,4.4,"17,183",44
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,855.65,0.4,3.9,"14,968",45
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,817.66,0.4,0.0,35,46
9,Saskatchewan,A10BA,Biguanides,Total,F,756.19,0.3,6.3,"24,376",47
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,752.68,0.3,1.3,"5,208",48
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,737.45,0.3,3.7,"14,188",49
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,Total,F,728.55,0.3,2.8,"11,040",50
9,Saskatchewan,S01EE,Prostaglandin analogues,Total,F,698.03,0.3,1.1,"4,349",51
9,Saskatchewan,C03CA,"Sulfonamides, plain",Total,F,689.43,0.3,3.9,"15,216",52
9,Saskatchewan,S01ED,Beta-blocking agents,Total,F,655.73,0.3,1.1,"4,279",53
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,648.21,0.3,0.2,886,54
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,632.07,0.3,10.1,"39,066",55
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,611.95,0.3,0.2,723,56
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,Total,F,541.72,0.2,0.2,720,57
9,Saskatchewan,C08DB,Benzothiazepine derivatives,Total,F,486.56,0.2,0.9,"3,310",58
9,Saskatchewan,M05BA,Bisphosphonates,Total,F,482.15,0.2,1.3,"5,110",59
9,Saskatchewan,J01DB,First-generation cephalosporins,Total,F,466.71,0.2,7.1,"27,629",60
9,Saskatchewan,N05BA,Benzodiazepine derivatives,Total,F,425.72,0.2,4.0,"15,380",61
9,Saskatchewan,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,**,**,**,**,62
9,Saskatchewan,A12BA,Potassium,Total,F,414.82,0.2,1.9,"7,457",63
9,Saskatchewan,H02AB,Glucocorticoids,Total,F,409.36,0.2,7.1,"27,380",64
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",Total,F,409.13,0.2,1.5,"5,816",65
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,Total,F,405.14,0.2,1.3,"4,864",66
9,Saskatchewan,J02AC,Triazole derivatives,Total,F,394.23,0.2,2.2,"8,416",67
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,F,382.57,0.2,0.2,649,68
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,379.91,0.2,4.6,"17,867",69
9,Saskatchewan,A11CC,Vitamin D and analogues,Total,F,378.75,0.2,0.8,"2,991",70
9,Saskatchewan,N03AG,Fatty acid derivatives,Total,F,373.76,0.2,0.5,"1,934",71
9,Saskatchewan,L01EX,Other protein kinase inhibitors,Total,F,372.73,0.2,0.0,16,72
9,Saskatchewan,B02BX,Other systemic hemostatics,Total,F,367.31,0.2,0.0,7,73
9,Saskatchewan,B01AE,Direct thrombin inhibitors,Total,F,363.24,0.2,0.1,416,74
9,Saskatchewan,L02AE,Gonadotropin-releasing hormone analogues,Total,F,362.38,0.2,0.0,170,75
9,Saskatchewan,L01BA,Folic acid analogues,Total,F,359.23,0.2,0.8,"3,146",76
9,Saskatchewan,R05CB,Mucolytics,Total,F,359.11,0.2,0.0,47,77
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,358.55,0.2,4.7,"18,358",78
9,Saskatchewan,A10BB,Sulfonylureas,Total,F,358.49,0.2,2.1,"8,107",79
9,Saskatchewan,M03BX,Other centrally acting agents,Total,F,358.11,0.2,1.7,"6,626",80
9,Saskatchewan,N04BA,Dopa and dopa derivatives,Total,F,344.44,0.2,0.3,"1,195",81
9,Saskatchewan,C01DA,Organic nitrates,Total,F,339.43,0.2,1.1,"4,235",82
9,Saskatchewan,R01AD,Corticosteroids,Total,F,332.44,0.2,7.5,"29,153",83
9,Saskatchewan,J05AJ,Integrase inhibitors,Total,F,330.85,0.2,0.0,96,84
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,326.20,0.1,0.0,172,85
9,Saskatchewan,G03XB,Progesterone receptor modulators,Total,F,**,**,**,**,86
9,Saskatchewan,C10AX,Other lipid-modifying agents,Total,F,306.51,0.1,0.7,"2,679",87
9,Saskatchewan,A07AA,Antibiotics,Total,F,298.29,0.1,1.0,"3,965",88
9,Saskatchewan,N03AF,Carboxamide derivatives,Total,F,285.51,0.1,0.4,"1,366",89
9,Saskatchewan,C03DA,Aldosterone antagonists,Total,F,282.33,0.1,1.7,"6,533",90
9,Saskatchewan,G02BA,Intrauterine contraceptives,Total,F,**,**,**,**,91
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,Total,F,272.90,0.1,0.7,"2,830",92
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,Total,F,270.32,0.1,2.6,"10,244",93
9,Saskatchewan,A09AA,Enzyme preparations,Total,F,265.63,0.1,0.1,450,94
9,Saskatchewan,M01AH,Coxibs,Total,F,264.82,0.1,2.1,"7,977",95
9,Saskatchewan,M01AE,Propionic acid derivatives,Total,F,263.33,0.1,6.8,"26,557",96
9,Saskatchewan,B03AC,"Iron, parenteral preparations",Total,F,259.47,0.1,0.2,620,97
9,Saskatchewan,N03AE,Benzodiazepine derivatives,Total,F,252.61,0.1,1.5,"5,683",98
9,Saskatchewan,C03AA,"Thiazides, plain",Total,F,247.83,0.1,4.1,"16,086",99
9,Saskatchewan,N04BC,Dopamine agonists,Total,F,246.90,0.1,0.6,"2,247",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,"19,444.04",11.7,0.5,887,1
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,65+,Total,"11,536.76",6.9,9.2,"16,408",2
9,Saskatchewan,L04AA,Selective immunosuppressants,65+,Total,"6,013.39",3.6,0.5,902,3
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"5,782.76",3.5,4.9,"8,792",4
9,Saskatchewan,S01LA,Antineovascularization agents,65+,Total,"5,288.22",3.2,1.7,"3,079",5
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"4,919.65",3.0,4.0,"7,221",6
9,Saskatchewan,L04AC,Interleukin inhibitors,65+,Total,"4,030.63",2.4,0.1,246,7
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,65+,Total,"3,641.45",2.2,42.0,"75,281",8
9,Saskatchewan,A02BC,Proton pump inhibitors,65+,Total,"3,410.45",2.0,31.0,"55,580",9
9,Saskatchewan,C08CA,Dihydropyridine derivatives,65+,Total,"2,873.02",1.7,20.3,"36,357",10
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"2,814.86",1.7,4.1,"7,262",11
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"2,804.66",1.7,2.3,"4,205",12
9,Saskatchewan,N02AA,Natural opium alkaloids,65+,Total,"2,680.06",1.6,8.2,"14,744",13
9,Saskatchewan,B03XA,Other antianemic preparations,65+,Total,"2,654.28",1.6,0.4,717,14
9,Saskatchewan,R03BB,Anticholinergics,65+,Total,"2,567.32",1.5,4.8,"8,612",15
9,Saskatchewan,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,Total,"2,501.75",1.5,1.7,"2,971",16
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"2,147.01",1.3,3.1,"5,463",17
9,Saskatchewan,C09AA,"ACE inhibitors, plain",65+,Total,"2,048.61",1.2,23.2,"41,610",18
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",65+,Total,"1,899.47",1.1,21.9,"39,141",19
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"1,885.77",1.1,17.7,"31,678",20
9,Saskatchewan,N03AX,Other antiepileptics,65+,Total,"1,826.17",1.1,9.1,"16,224",21
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,65+,Total,"1,689.17",1.0,0.0,39,22
9,Saskatchewan,N06AX,Other antidepressants,65+,Total,"1,685.62",1.0,10.3,"18,409",23
9,Saskatchewan,R03BA,Glucocorticoids,65+,Total,"1,560.78",0.9,4.3,"7,743",24
9,Saskatchewan,L04AX,Other immunosuppressants,65+,Total,"1,460.96",0.9,0.3,608,25
9,Saskatchewan,N05AX,Other antipsychotics,65+,Total,"1,396.44",0.8,1.9,"3,462",26
9,Saskatchewan,B01AB,Heparin group,65+,Total,"1,355.97",0.8,0.5,819,27
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,337.39",0.8,10.2,"18,237",28
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"1,232.84",0.7,3.6,"6,477",29
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"1,200.80",0.7,1.1,"1,969",30
9,Saskatchewan,L01XC,Monoclonal antibodies,65+,Total,"1,195.64",0.7,0.1,110,31
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"1,155.25",0.7,0.8,"1,345",32
9,Saskatchewan,H03AA,Thyroid hormones,65+,Total,"1,135.01",0.7,19.6,"35,088",33
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,65+,Total,"1,109.30",0.7,7.3,"13,114",34
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"1,073.18",0.6,5.0,"8,937",35
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,65+,Total,"1,044.38",0.6,0.7,"1,310",36
9,Saskatchewan,S01EE,Prostaglandin analogues,65+,Total,"1,029.36",0.6,3.3,"5,947",37
9,Saskatchewan,L01EX,Other protein kinase inhibitors,65+,Total,"1,018.33",0.6,0.0,43,38
9,Saskatchewan,C03CA,"Sulfonamides, plain",65+,Total,"1,002.10",0.6,12.3,"22,046",39
9,Saskatchewan,S01ED,Beta-blocking agents,65+,Total,992.09,0.6,3.4,"6,136",40
9,Saskatchewan,A10BA,Biguanides,65+,Total,980.22,0.6,15.9,"28,562",41
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,976.29,0.6,9.5,"16,948",42
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,952.62,0.6,3.9,"6,902",43
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,924.67,0.6,0.0,82,44
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,922.33,0.6,0.3,448,45
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,859.92,0.5,10.3,"18,477",46
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,847.54,0.5,0.0,53,47
9,Saskatchewan,N04BA,Dopa and dopa derivatives,65+,Total,763.99,0.5,1.3,"2,258",48
9,Saskatchewan,B01AE,Direct thrombin inhibitors,65+,Total,745.87,0.4,0.5,877,49
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,726.35,0.4,4.7,"8,339",50
9,Saskatchewan,C08DB,Benzothiazepine derivatives,65+,Total,676.43,0.4,2.3,"4,149",51
9,Saskatchewan,L04AD,Calcineurin inhibitors,65+,Total,641.83,0.4,0.1,216,52
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,630.36,0.4,3.6,"6,445",53
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,607.72,0.4,0.6,"1,122",54
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,556.54,0.3,10.0,"17,936",55
9,Saskatchewan,C01DA,Organic nitrates,65+,Total,553.65,0.3,4.1,"7,402",56
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,65+,Total,533.96,0.3,0.4,741,57
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,65+,Total,**,**,**,*,58
9,Saskatchewan,A12BA,Potassium,65+,Total,515.81,0.3,5.1,"9,154",59
9,Saskatchewan,M05BA,Bisphosphonates,65+,Total,487.86,0.3,2.8,"5,026",60
9,Saskatchewan,A10BB,Sulfonylureas,65+,Total,484.11,0.3,6.0,"10,784",61
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,65+,Total,478.34,0.3,1.7,"3,134",62
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,65+,Total,476.41,0.3,5.4,"9,654",63
9,Saskatchewan,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,449.56,0.3,3.7,"6,576",64
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",65+,Total,445.33,0.3,2.4,"4,331",65
9,Saskatchewan,B02BX,Other systemic hemostatics,65+,Total,420.10,0.3,0.0,6,66
9,Saskatchewan,A05AA,Bile acids and derivatives,65+,Total,405.06,0.2,0.2,301,67
9,Saskatchewan,C03DA,Aldosterone antagonists,65+,Total,404.37,0.2,4.2,"7,556",68
9,Saskatchewan,B01AA,Vitamin K antagonists,65+,Total,403.65,0.2,3.9,"6,910",69
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,401.74,0.2,0.0,22,70
9,Saskatchewan,C10AX,Other lipid-modifying agents,65+,Total,401.17,0.2,2.7,"4,846",71
9,Saskatchewan,L03AB,Interferons,65+,Total,384.20,0.2,0.0,23,72
9,Saskatchewan,H02AB,Glucocorticoids,65+,Total,376.17,0.2,9.2,"16,416",73
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,373.82,0.2,0.2,300,74
9,Saskatchewan,C01AA,Digitalis glycosides,65+,Total,339.98,0.2,1.8,"3,138",75
9,Saskatchewan,H01CB,Somatostatin and analogues,65+,Total,**,**,**,**,76
9,Saskatchewan,L03AX,Other immunostimulants,65+,Total,335.05,0.2,0.0,26,77
9,Saskatchewan,B03AC,"Iron, parenteral preparations",65+,Total,309.84,0.2,0.3,547,78
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,305.40,0.2,5.7,"10,177",79
9,Saskatchewan,R01AD,Corticosteroids,65+,Total,302.15,0.2,7.4,"13,341",80
9,Saskatchewan,L01BA,Folic acid analogues,65+,Total,296.25,0.2,1.2,"2,234",81
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,65+,Total,288.18,0.2,0.7,"1,298",82
9,Saskatchewan,C03AA,"Thiazides, plain",65+,Total,287.87,0.2,9.3,"16,662",83
9,Saskatchewan,A07AA,Antibiotics,65+,Total,287.25,0.2,1.2,"2,158",84
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,284.20,0.2,3.0,"5,442",85
9,Saskatchewan,N04BC,Dopamine agonists,65+,Total,283.49,0.2,1.1,"1,968",86
9,Saskatchewan,N05BA,Benzodiazepine derivatives,65+,Total,266.03,0.2,4.5,"8,037",87
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,263.59,0.2,0.5,845,88
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,65+,Total,253.06,0.2,3.8,"6,818",89
9,Saskatchewan,M01AH,Coxibs,65+,Total,248.50,0.1,3.5,"6,255",90
9,Saskatchewan,C10BX,Lipid-modifying agents in combination with other drugs,65+,Total,248.35,0.1,0.5,878,91
9,Saskatchewan,C10AB,Fibrates,65+,Total,245.59,0.1,1.3,"2,299",92
9,Saskatchewan,D01AC,Imidazole and triazole derivatives,65+,Total,235.84,0.1,3.2,"5,752",93
9,Saskatchewan,A11CC,Vitamin D and analogues,65+,Total,233.20,0.1,0.8,"1,359",94
9,Saskatchewan,A09AA,Enzyme preparations,65+,Total,213.80,0.1,0.2,435,95
9,Saskatchewan,A03FA,Propulsives,65+,Total,209.03,0.1,2.7,"4,923",96
9,Saskatchewan,S01EC,Carbonic anhydrase inhibitors,65+,Total,207.93,0.1,1.0,"1,740",97
9,Saskatchewan,B03BB,Folic acid and derivatives,65+,Total,201.00,0.1,2.7,"4,812",98
9,Saskatchewan,A06AB,Contact laxatives,65+,Total,197.17,0.1,1.1,"1,913",99
9,Saskatchewan,C10AC,Bile acid sequestrants,65+,Total,194.79,0.1,0.6,"1,032",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,"8,050.61",10.4,0.4,344,1
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,65+,M,"5,559.57",7.2,10.2,"8,417",2
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"3,435.43",4.4,6.1,"5,068",3
9,Saskatchewan,L04AA,Selective immunosuppressants,65+,M,"2,449.23",3.2,0.5,386,4
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"2,172.69",2.8,3.9,"3,192",5
9,Saskatchewan,S01LA,Antineovascularization agents,65+,M,"1,909.70",2.5,1.4,"1,183",6
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,65+,M,"1,823.25",2.4,49.4,"40,834",7
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"1,778.89",2.3,3.3,"2,755",8
9,Saskatchewan,L04AC,Interleukin inhibitors,65+,M,"1,760.06",2.3,0.1,105,9
9,Saskatchewan,B03XA,Other antianemic preparations,65+,M,"1,531.99",2.0,0.5,397,10
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"1,472.72",1.9,4.4,"3,625",11
9,Saskatchewan,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,M,"1,337.07",1.7,2.0,"1,631",12
9,Saskatchewan,A02BC,Proton pump inhibitors,65+,M,"1,337.04",1.7,29.2,"24,115",13
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"1,328.42",1.7,3.8,"3,146",14
9,Saskatchewan,C08CA,Dihydropyridine derivatives,65+,M,"1,260.35",1.6,20.5,"16,927",15
9,Saskatchewan,R03BB,Anticholinergics,65+,M,"1,231.79",1.6,5.1,"4,237",16
9,Saskatchewan,N02AA,Natural opium alkaloids,65+,M,"1,229.96",1.6,7.7,"6,342",17
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,65+,M,"1,154.26",1.5,0.0,28,18
9,Saskatchewan,C09AA,"ACE inhibitors, plain",65+,M,989.69,1.3,27.3,"22,594",19
9,Saskatchewan,L04AX,Other immunosuppressants,65+,M,962.40,1.2,0.3,283,20
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",65+,M,862.18,1.1,24.0,"19,870",21
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,65+,M,851.09,1.1,22.0,"18,199",22
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,820.14,1.1,0.1,74,23
9,Saskatchewan,N03AX,Other antiepileptics,65+,M,774.57,1.0,8.1,"6,702",24
9,Saskatchewan,B01AB,Heparin group,65+,M,714.58,0.9,0.5,378,25
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,713.04,0.9,16.6,"13,723",26
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,695.31,0.9,1.0,839,27
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,690.80,0.9,0.4,340,28
9,Saskatchewan,L01EX,Other protein kinase inhibitors,65+,M,**,**,**,**,29
9,Saskatchewan,R03BA,Glucocorticoids,65+,M,669.22,0.9,4.1,"3,368",30
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,645.36,0.8,6.3,"5,196",31
9,Saskatchewan,N05AX,Other antipsychotics,65+,M,620.20,0.8,1.6,"1,350",32
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,65+,M,582.05,0.8,8.7,"7,234",33
9,Saskatchewan,N06AX,Other antidepressants,65+,M,546.07,0.7,7.8,"6,430",34
9,Saskatchewan,A10BA,Biguanides,65+,M,523.14,0.7,19.9,"16,482",35
9,Saskatchewan,L01XC,Monoclonal antibodies,65+,M,513.23,0.7,0.1,51,36
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,65+,M,512.09,0.7,0.8,627,37
9,Saskatchewan,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,448.63,0.6,7.9,"6,544",38
9,Saskatchewan,N04BA,Dopa and dopa derivatives,65+,M,447.12,0.6,1.5,"1,268",39
9,Saskatchewan,C03CA,"Sulfonamides, plain",65+,M,427.34,0.6,12.0,"9,943",40
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,65+,M,426.63,0.6,7.0,"5,803",41
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,424.14,0.5,3.4,"2,831",42
9,Saskatchewan,L04AD,Calcineurin inhibitors,65+,M,416.25,0.5,0.2,145,43
9,Saskatchewan,B01AE,Direct thrombin inhibitors,65+,M,393.04,0.5,0.6,498,44
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,391.34,0.5,0.8,670,45
9,Saskatchewan,S01ED,Beta-blocking agents,65+,M,385.43,0.5,3.1,"2,561",46
9,Saskatchewan,S01EE,Prostaglandin analogues,65+,M,378.73,0.5,2.8,"2,336",47
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,378.14,0.5,9.1,"7,566",48
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,321.63,0.4,0.0,20,49
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,65+,M,303.16,0.4,2.2,"1,788",50
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,65+,M,299.89,0.4,8.2,"6,785",51
9,Saskatchewan,H03AA,Thyroid hormones,65+,M,288.49,0.4,11.1,"9,141",52
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,65+,M,282.00,0.4,2.4,"1,946",53
9,Saskatchewan,A10BB,Sulfonylureas,65+,M,261.47,0.3,7.8,"6,424",54
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,257.21,0.3,9.7,"8,060",55
9,Saskatchewan,C08DB,Benzothiazepine derivatives,65+,M,256.50,0.3,2.0,"1,677",56
9,Saskatchewan,C01DA,Organic nitrates,65+,M,243.30,0.3,4.8,"3,953",57
9,Saskatchewan,H01CB,Somatostatin and analogues,65+,M,**,**,**,**,58
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,218.58,0.3,3.0,"2,511",59
9,Saskatchewan,B01AA,Vitamin K antagonists,65+,M,206.22,0.3,4.7,"3,861",60
9,Saskatchewan,C03DA,Aldosterone antagonists,65+,M,201.68,0.3,4.6,"3,805",61
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",65+,M,182.55,0.2,2.3,"1,939",62
9,Saskatchewan,C10AX,Other lipid-modifying agents,65+,M,182.34,0.2,3.3,"2,723",63
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,65+,M,174.08,0.2,0.3,250,64
9,Saskatchewan,A12BA,Potassium,65+,M,170.13,0.2,4.0,"3,293",65
9,Saskatchewan,B03AC,"Iron, parenteral preparations",65+,M,168.19,0.2,0.3,274,66
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,65+,M,167.63,0.2,0.9,704,67
9,Saskatchewan,H02AB,Glucocorticoids,65+,M,162.57,0.2,9.1,"7,550",68
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,154.18,0.2,0.6,480,69
9,Saskatchewan,C01AA,Digitalis glycosides,65+,M,148.71,0.2,1.8,"1,466",70
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,148.44,0.2,0.0,8,71
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,141.87,0.2,2.4,"2,002",72
9,Saskatchewan,C10AB,Fibrates,65+,M,141.54,0.2,1.6,"1,309",73
9,Saskatchewan,R01AD,Corticosteroids,65+,M,134.79,0.2,7.0,"5,751",74
9,Saskatchewan,A09AA,Enzyme preparations,65+,M,133.46,0.2,0.3,219,75
9,Saskatchewan,A07AA,Antibiotics,65+,M,131.83,0.2,0.9,753,76
9,Saskatchewan,C10BX,Lipid-modifying agents in combination with other drugs,65+,M,131.67,0.2,0.6,511,77
9,Saskatchewan,A11CC,Vitamin D and analogues,65+,M,124.28,0.2,0.8,642,78
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,123.88,0.2,5.6,"4,652",79
9,Saskatchewan,B02BX,Other systemic hemostatics,65+,M,**,**,**,*,80
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,65+,M,116.23,0.2,4.5,"3,713",81
9,Saskatchewan,J02AC,Triazole derivatives,65+,M,115.62,0.1,0.7,571,82
9,Saskatchewan,N04BC,Dopamine agonists,65+,M,113.34,0.1,0.9,755,83
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,110.63,0.1,0.1,77,84
9,Saskatchewan,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,107.83,0.1,0.3,227,85
9,Saskatchewan,D01AC,Imidazole and triazole derivatives,65+,M,103.97,0.1,3.0,"2,513",86
9,Saskatchewan,L01BA,Folic acid analogues,65+,M,102.99,0.1,1.0,838,87
9,Saskatchewan,A06AD,Osmotically acting laxatives,65+,M,102.77,0.1,1.0,859,88
9,Saskatchewan,C03AA,"Thiazides, plain",65+,M,102.02,0.1,7.8,"6,426",89
9,Saskatchewan,N07BC,Drugs used in opioid dependence,65+,M,98.26,0.1,0.2,194,90
9,Saskatchewan,A06AB,Contact laxatives,65+,M,93.09,0.1,1.1,883,91
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",65+,M,92.87,0.1,5.9,"4,887",92
9,Saskatchewan,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,M,86.87,0.1,6.0,"4,971",93
9,Saskatchewan,B03BB,Folic acid and derivatives,65+,M,86.24,0.1,2.7,"2,208",94
9,Saskatchewan,N05BA,Benzodiazepine derivatives,65+,M,85.73,0.1,3.2,"2,653",95
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,65+,M,85.52,0.1,0.2,151,96
9,Saskatchewan,N03AG,Fatty acid derivatives,65+,M,83.91,0.1,0.5,378,97
9,Saskatchewan,C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,65+,M,83.10,0.1,0.8,640,98
9,Saskatchewan,M01AH,Coxibs,65+,M,81.98,0.1,2.8,"2,304",99
9,Saskatchewan,G03BA,3-oxoandrosten (4) derivatives,65+,M,81.48,0.1,0.7,616,100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,"11,393.42",12.8,0.6,543,1
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,65+,F,"5,977.18",6.7,8.3,"7,991",2
9,Saskatchewan,L04AA,Selective immunosuppressants,65+,F,"3,564.16",4.0,0.5,516,3
9,Saskatchewan,S01LA,Antineovascularization agents,65+,F,"3,378.52",3.8,2.0,"1,896",4
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,746.95",3.1,4.2,"4,029",5
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"2,347.32",2.6,3.9,"3,724",6
9,Saskatchewan,L04AC,Interleukin inhibitors,65+,F,"2,270.57",2.6,0.1,141,7
9,Saskatchewan,A02BC,Proton pump inhibitors,65+,F,"2,073.41",2.3,32.6,"31,465",8
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,65+,F,"1,818.20",2.0,35.7,"34,447",9
9,Saskatchewan,C08CA,Dihydropyridine derivatives,65+,F,"1,612.68",1.8,20.2,"19,430",10
9,Saskatchewan,N02AA,Natural opium alkaloids,65+,F,"1,450.11",1.6,8.7,"8,402",11
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"1,342.14",1.5,3.8,"3,637",12
9,Saskatchewan,R03BB,Anticholinergics,65+,F,"1,335.53",1.5,4.5,"4,375",13
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"1,172.73",1.3,18.6,"17,955",14
9,Saskatchewan,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,F,"1,164.67",1.3,1.4,"1,340",15
9,Saskatchewan,N06AX,Other antidepressants,65+,F,"1,139.55",1.3,12.4,"11,979",16
9,Saskatchewan,B03XA,Other antianemic preparations,65+,F,"1,122.29",1.3,0.3,320,17
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"1,115.28",1.3,1.9,"1,818",18
9,Saskatchewan,C09AA,"ACE inhibitors, plain",65+,F,"1,058.92",1.2,19.7,"19,016",19
9,Saskatchewan,N03AX,Other antiepileptics,65+,F,"1,051.60",1.2,9.9,"9,522",20
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",65+,F,"1,037.28",1.2,20.0,"19,271",21
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"1,025.78",1.2,1.5,"1,450",22
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,65+,F,929.69,1.0,4.9,"4,689",23
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,65+,F,910.75,1.0,12.9,"12,434",24
9,Saskatchewan,R03BA,Glucocorticoids,65+,F,891.56,1.0,4.5,"4,375",25
9,Saskatchewan,H03AA,Thyroid hormones,65+,F,846.52,1.0,26.9,"25,947",26
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,818.59,0.9,2.4,"2,317",27
9,Saskatchewan,N05AX,Other antipsychotics,65+,F,776.24,0.9,2.2,"2,112",28
9,Saskatchewan,L01XC,Monoclonal antibodies,65+,F,682.41,0.8,0.1,59,29
9,Saskatchewan,S01EE,Prostaglandin analogues,65+,F,650.64,0.7,3.7,"3,611",30
9,Saskatchewan,B01AB,Heparin group,65+,F,641.39,0.7,0.5,441,31
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,**,**,**,**,32
9,Saskatchewan,S01ED,Beta-blocking agents,65+,F,606.66,0.7,3.7,"3,575",33
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,598.14,0.7,9.7,"9,382",34
9,Saskatchewan,C03CA,"Sulfonamides, plain",65+,F,574.76,0.6,12.6,"12,103",35
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,65+,F,534.91,0.6,0.0,11,36
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,65+,F,532.29,0.6,0.7,683,37
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,528.48,0.6,4.2,"4,071",38
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,65+,F,527.25,0.6,6.1,"5,880",39
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,525.91,0.6,0.0,33,40
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,65+,F,**,**,**,*,41
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,507.77,0.6,6.0,"5,828",42
9,Saskatchewan,L04AX,Other immunosuppressants,65+,F,498.55,0.6,0.3,325,43
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,459.94,0.5,0.5,506,44
9,Saskatchewan,A10BA,Biguanides,65+,F,457.08,0.5,12.5,"12,080",45
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,427.83,0.5,3.9,"3,741",46
9,Saskatchewan,M05BA,Bisphosphonates,65+,F,420.94,0.5,4.6,"4,437",47
9,Saskatchewan,C08DB,Benzothiazepine derivatives,65+,F,419.93,0.5,2.6,"2,472",48
9,Saskatchewan,A05AA,Bile acids and derivatives,65+,F,376.54,0.4,0.2,235,49
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,65+,F,359.88,0.4,0.5,491,50
9,Saskatchewan,L03AB,Interferons,65+,F,**,**,**,**,51
9,Saskatchewan,B01AE,Direct thrombin inhibitors,65+,F,352.83,0.4,0.4,379,52
9,Saskatchewan,A12BA,Potassium,65+,F,345.69,0.4,6.1,"5,861",53
9,Saskatchewan,L01EX,Other protein kinase inhibitors,65+,F,**,**,**,**,54
9,Saskatchewan,N04BA,Dopa and dopa derivatives,65+,F,316.87,0.4,1.0,990,55
9,Saskatchewan,C01DA,Organic nitrates,65+,F,310.36,0.3,3.6,"3,449",56
9,Saskatchewan,B02BX,Other systemic hemostatics,65+,F,**,**,**,*,57
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,299.33,0.3,10.2,"9,876",58
9,Saskatchewan,L03AX,Other immunostimulants,65+,F,290.76,0.3,0.0,21,59
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,263.19,0.3,0.2,223,60
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",65+,F,262.78,0.3,2.5,"2,392",61
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,253.31,0.3,0.0,14,62
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,231.53,0.3,0.1,108,63
9,Saskatchewan,L04AD,Calcineurin inhibitors,65+,F,225.58,0.3,0.1,71,64
9,Saskatchewan,A10BB,Sulfonylureas,65+,F,222.64,0.3,4.5,"4,360",65
9,Saskatchewan,C10AX,Other lipid-modifying agents,65+,F,218.82,0.2,2.2,"2,123",66
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,216.38,0.2,0.5,452,67
9,Saskatchewan,H02AB,Glucocorticoids,65+,F,213.61,0.2,9.2,"8,866",68
9,Saskatchewan,C03DA,Aldosterone antagonists,65+,F,202.69,0.2,3.9,"3,751",69
9,Saskatchewan,B01AA,Vitamin K antagonists,65+,F,197.43,0.2,3.2,"3,049",70
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,65+,F,196.34,0.2,1.2,"1,188",71
9,Saskatchewan,L01BA,Folic acid analogues,65+,F,193.26,0.2,1.4,"1,396",72
9,Saskatchewan,C01AA,Digitalis glycosides,65+,F,191.28,0.2,1.7,"1,672",73
9,Saskatchewan,C03AA,"Thiazides, plain",65+,F,185.85,0.2,10.6,"10,236",74
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,181.52,0.2,5.7,"5,525",75
9,Saskatchewan,N05BA,Benzodiazepine derivatives,65+,F,180.30,0.2,5.6,"5,384",76
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,65+,F,176.52,0.2,3.0,"2,869",77
9,Saskatchewan,N04BC,Dopamine agonists,65+,F,170.15,0.2,1.3,"1,213",78
9,Saskatchewan,R01AD,Corticosteroids,65+,F,167.36,0.2,7.9,"7,590",79
9,Saskatchewan,M01AH,Coxibs,65+,F,166.52,0.2,4.1,"3,951",80
9,Saskatchewan,A07AA,Antibiotics,65+,F,155.43,0.2,1.5,"1,405",81
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,142.32,0.2,3.6,"3,440",82
9,Saskatchewan,B03AC,"Iron, parenteral preparations",65+,F,141.65,0.2,0.3,273,83
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,65+,F,136.83,0.2,3.2,"3,105",84
9,Saskatchewan,A03FA,Propulsives,65+,F,133.93,0.2,3.1,"2,972",85
9,Saskatchewan,D01AC,Imidazole and triazole derivatives,65+,F,131.88,0.1,3.4,"3,239",86
9,Saskatchewan,S01EC,Carbonic anhydrase inhibitors,65+,F,127.63,0.1,1.0,"1,009",87
9,Saskatchewan,J01XE,Nitrofuran derivatives,65+,F,123.04,0.1,10.2,"9,828",88
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,65+,F,120.55,0.1,0.6,594,89
9,Saskatchewan,C10BX,Lipid-modifying agents in combination with other drugs,65+,F,116.69,0.1,0.4,367,90
9,Saskatchewan,C10AC,Bile acid sequestrants,65+,F,114.86,0.1,0.7,638,91
9,Saskatchewan,B03BB,Folic acid and derivatives,65+,F,114.76,0.1,2.7,"2,604",92
9,Saskatchewan,H01CB,Somatostatin and analogues,65+,F,**,**,**,**,93
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,109.41,0.1,0.4,365,94
9,Saskatchewan,A11CC,Vitamin D and analogues,65+,F,108.91,0.1,0.7,717,95
9,Saskatchewan,M03BX,Other centrally acting agents,65+,F,106.15,0.1,1.6,"1,547",96
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,F,104.53,0.1,0.0,8,97
9,Saskatchewan,A06AB,Contact laxatives,65+,F,104.09,0.1,1.1,"1,030",98
9,Saskatchewan,C10AB,Fibrates,65+,F,104.05,0.1,1.0,990,99
9,Saskatchewan,N07CA,Antivertigo preparations,65+,F,103.69,0.1,3.2,"3,118",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,"67,003.62",25.0,0.5,"2,644",1
9,Saskatchewan,L04AA,Selective immunosuppressants,<65,Total,"22,581.63",8.4,0.4,"2,077",2
9,Saskatchewan,L04AC,Interleukin inhibitors,<65,Total,"17,488.27",6.5,0.2,877,3
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,<65,Total,"13,694.24",5.1,0.1,340,4
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"9,529.39",3.6,0.3,"1,362",5
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,<65,Total,"9,361.52",3.5,3.1,"16,404",6
9,Saskatchewan,N05AX,Other antipsychotics,<65,Total,"8,685.61",3.2,1.4,"7,468",7
9,Saskatchewan,L04AX,Other immunosuppressants,<65,Total,"5,693.05",2.1,0.3,"1,703",8
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"4,462.90",1.7,3.1,"16,627",9
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"3,580.99",1.3,1.6,"8,338",10
9,Saskatchewan,N02AA,Natural opium alkaloids,<65,Total,"3,468.04",1.3,4.7,"25,229",11
9,Saskatchewan,N03AX,Other antiepileptics,<65,Total,"3,445.62",1.3,4.7,"25,243",12
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"2,750.43",1.0,12.3,"65,437",13
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"2,662.95",1.0,0.0,199,14
9,Saskatchewan,L04AD,Calcineurin inhibitors,<65,Total,"2,441.01",0.9,0.1,601,15
9,Saskatchewan,N06AX,Other antidepressants,<65,Total,"2,414.50",0.9,8.5,"45,261",16
9,Saskatchewan,A02BC,Proton pump inhibitors,<65,Total,"2,285.31",0.9,13.9,"73,949",17
9,Saskatchewan,N07BC,Drugs used in opioid dependence,<65,Total,"2,235.54",0.8,0.5,"2,472",18
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"2,027.03",0.8,1.2,"6,651",19
9,Saskatchewan,R03BA,Glucocorticoids,<65,Total,"1,833.60",0.7,5.6,"29,650",20
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"1,816.30",0.7,1.1,"5,883",21
9,Saskatchewan,B03XA,Other antianemic preparations,<65,Total,"1,809.32",0.7,0.1,437,22
9,Saskatchewan,L03AB,Interferons,<65,Total,"1,694.51",0.6,0.0,112,23
9,Saskatchewan,L03AX,Other immunostimulants,<65,Total,"1,591.58",0.6,0.0,147,24
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,541.96",0.6,10.0,"53,244",25
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,<65,Total,**,**,**,**,26
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"1,357.56",0.5,0.8,"4,193",27
9,Saskatchewan,A05AA,Bile acids and derivatives,<65,Total,"1,275.21",0.5,0.1,465,28
9,Saskatchewan,L01XC,Monoclonal antibodies,<65,Total,"1,144.24",0.4,0.0,125,29
9,Saskatchewan,C09AA,"ACE inhibitors, plain",<65,Total,957.60,0.4,6.1,"32,420",30
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,<65,Total,938.72,0.4,0.6,"3,007",31
9,Saskatchewan,B01AB,Heparin group,<65,Total,926.76,0.3,0.1,493,32
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,<65,Total,902.42,0.3,0.8,"4,233",33
9,Saskatchewan,R05CB,Mucolytics,<65,Total,840.10,0.3,0.0,83,34
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,830.13,0.3,0.0,36,35
9,Saskatchewan,J05AJ,Integrase inhibitors,<65,Total,**,**,**,**,36
9,Saskatchewan,J01DB,First-generation cephalosporins,<65,Total,785.67,0.3,7.4,"39,278",37
9,Saskatchewan,C08CA,Dihydropyridine derivatives,<65,Total,783.56,0.3,3.9,"20,689",38
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,756.07,0.3,3.1,"16,351",39
9,Saskatchewan,N03AG,Fatty acid derivatives,<65,Total,747.73,0.3,0.7,"3,473",40
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,<65,Total,742.02,0.3,1.4,"7,624",41
9,Saskatchewan,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,Total,707.28,0.3,0.3,"1,710",42
9,Saskatchewan,R07AX,Other respiratory system products,<65,Total,**,**,**,*,43
9,Saskatchewan,A16AB,Enzymes,<65,Total,656.87,0.2,0.0,7,44
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,653.48,0.2,0.8,"4,408",45
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,645.74,0.2,10.5,"56,251",46
9,Saskatchewan,A10BA,Biguanides,<65,Total,617.12,0.2,5.1,"27,235",47
9,Saskatchewan,A09AA,Enzyme preparations,<65,Total,614.89,0.2,0.1,571,48
9,Saskatchewan,H03AA,Thyroid hormones,<65,Total,567.08,0.2,6.5,"34,577",49
9,Saskatchewan,R03BB,Anticholinergics,<65,Total,563.44,0.2,0.7,"3,554",50
9,Saskatchewan,A11CC,Vitamin D and analogues,<65,Total,552.48,0.2,0.8,"4,219",51
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",<65,Total,533.71,0.2,3.1,"16,519",52
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,533.16,0.2,3.8,"20,356",53
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,<65,Total,532.64,0.2,0.0,49,54
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,532.54,0.2,0.1,678,55
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,525.42,0.2,0.6,"3,199",56
9,Saskatchewan,J01DF,Monobactams,<65,Total,500.16,0.2,0.0,33,57
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,<65,Total,477.47,0.2,0.7,"3,931",58
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,472.81,0.2,0.1,503,59
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,<65,Total,465.04,0.2,2.5,"13,321",60
9,Saskatchewan,N03AF,Carboxamide derivatives,<65,Total,462.90,0.2,0.3,"1,816",61
9,Saskatchewan,N05BA,Benzodiazepine derivatives,<65,Total,461.73,0.2,2.9,"15,695",62
9,Saskatchewan,M03BX,Other centrally acting agents,<65,Total,451.79,0.2,1.7,"9,301",63
9,Saskatchewan,A16AA,Amino acids and derivatives,<65,Total,**,**,**,**,64
9,Saskatchewan,S01LA,Antineovascularization agents,<65,Total,450.54,0.2,0.1,531,65
9,Saskatchewan,J02AC,Triazole derivatives,<65,Total,445.50,0.2,1.5,"7,826",66
9,Saskatchewan,N05AF,Thioxanthene derivatives,<65,Total,432.69,0.2,0.2,855,67
9,Saskatchewan,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,422.39,0.2,6.4,"34,300",68
9,Saskatchewan,M01AE,Propionic acid derivatives,<65,Total,415.84,0.2,8.1,"43,360",69
9,Saskatchewan,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,402.84,0.2,0.0,184,70
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,<65,Total,378.20,0.1,0.1,387,71
9,Saskatchewan,J01CA,Penicillins with extended spectrum,<65,Total,377.76,0.1,15.4,"82,051",72
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,371.52,0.1,0.2,887,73
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,363.97,0.1,4.1,"21,717",74
9,Saskatchewan,H02AB,Glucocorticoids,<65,Total,360.73,0.1,6.3,"33,800",75
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,346.21,0.1,4.4,"23,437",76
9,Saskatchewan,J05AE,Protease inhibitors,<65,Total,**,**,**,**,77
9,Saskatchewan,J01GB,Other aminoglycosides,<65,Total,337.07,0.1,0.0,50,78
9,Saskatchewan,N02BE,Anilides,<65,Total,323.83,0.1,1.7,"8,982",79
9,Saskatchewan,A06AD,Osmotically acting laxatives,<65,Total,323.70,0.1,0.5,"2,834",80
9,Saskatchewan,N03AE,Benzodiazepine derivatives,<65,Total,317.29,0.1,1.2,"6,439",81
9,Saskatchewan,G03XB,Progesterone receptor modulators,<65,Total,314.66,0.1,0.2,868,82
9,Saskatchewan,C02AC,Imidazoline receptor agonists,<65,Total,313.30,0.1,0.7,"3,749",83
9,Saskatchewan,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,298.99,0.1,5.2,"27,987",84
9,Saskatchewan,A10BB,Sulfonylureas,<65,Total,290.69,0.1,1.8,"9,701",85
9,Saskatchewan,R01AD,Corticosteroids,<65,Total,290.55,0.1,6.9,"36,928",86
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,Total,283.26,0.1,2.1,"10,992",87
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",<65,Total,274.48,0.1,1.0,"5,467",88
9,Saskatchewan,V06,General nutrients,<65,Total,269.43,0.1,0.0,42,89
9,Saskatchewan,G02BA,Intrauterine contraceptives,<65,Total,269.39,0.1,1.1,"5,877",90
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,268.63,0.1,0.0,222,91
9,Saskatchewan,A06AB,Contact laxatives,<65,Total,265.43,0.1,0.4,"2,033",92
9,Saskatchewan,H01CB,Somatostatin and analogues,<65,Total,**,**,**,**,93
9,Saskatchewan,L01BA,Folic acid analogues,<65,Total,262.95,0.1,0.5,"2,828",94
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,<65,Total,262.80,0.1,3.0,"16,254",95
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",<65,Total,257.80,0.1,5.3,"28,028",96
9,Saskatchewan,G03AC,Progestogens,<65,Total,253.13,0.1,1.5,"8,009",97
9,Saskatchewan,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,251.02,0.1,0.0,159,98
9,Saskatchewan,D06AX,Other antibiotics for topical use,<65,Total,245.99,0.1,3.2,"17,002",99
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,<65,Total,243.33,0.1,0.6,"3,267",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,"34,143.51",24.8,0.5,"1,233",1
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,<65,M,"9,844.45",7.2,0.1,248,2
9,Saskatchewan,L04AA,Selective immunosuppressants,<65,M,"8,978.70",6.5,0.4,887,3
9,Saskatchewan,L04AC,Interleukin inhibitors,<65,M,"8,778.99",6.4,0.2,431,4
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"6,848.69",5.0,0.4,"1,018",5
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,<65,M,"6,206.04",4.5,4.1,"10,011",6
9,Saskatchewan,N05AX,Other antipsychotics,<65,M,"5,727.20",4.2,1.8,"4,297",7
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"2,808.64",2.0,3.1,"7,526",8
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"1,912.21",1.4,1.9,"4,593",9
9,Saskatchewan,N02AA,Natural opium alkaloids,<65,M,"1,750.46",1.3,4.8,"11,599",10
9,Saskatchewan,N03AX,Other antiepileptics,<65,M,"1,569.82",1.1,4.1,"10,017",11
9,Saskatchewan,L04AX,Other immunosuppressants,<65,M,"1,552.58",1.1,0.3,647,12
9,Saskatchewan,L04AD,Calcineurin inhibitors,<65,M,"1,460.77",1.1,0.2,365,13
9,Saskatchewan,N07BC,Drugs used in opioid dependence,<65,M,"1,202.38",0.9,0.6,"1,455",14
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,<65,M,"1,112.98",0.8,8.9,"21,452",15
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"1,102.27",0.8,1.5,"3,564",16
9,Saskatchewan,A02BC,Proton pump inhibitors,<65,M,"1,052.57",0.8,13.9,"33,714",17
9,Saskatchewan,B03XA,Other antianemic preparations,<65,M,"1,038.23",0.8,0.1,256,18
9,Saskatchewan,R03BA,Glucocorticoids,<65,M,987.11,0.7,6.1,"14,751",19
9,Saskatchewan,N06AX,Other antidepressants,<65,M,913.49,0.7,6.8,"16,346",20
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,<65,M,852.75,0.6,13.7,"33,042",21
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,796.41,0.6,1.1,"2,612",22
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,734.47,0.5,1.1,"2,615",23
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,733.53,0.5,0.0,60,24
9,Saskatchewan,R07AX,Other respiratory system products,<65,M,**,**,**,*,25
9,Saskatchewan,A16AB,Enzymes,<65,M,**,**,**,**,26
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,<65,M,**,**,**,**,27
9,Saskatchewan,A05AA,Bile acids and derivatives,<65,M,598.14,0.4,0.0,101,28
9,Saskatchewan,C09AA,"ACE inhibitors, plain",<65,M,545.03,0.4,8.2,"19,800",29
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,<65,M,540.61,0.4,1.1,"2,588",30
9,Saskatchewan,R05CB,Mucolytics,<65,M,501.77,0.4,0.0,54,31
9,Saskatchewan,J05AJ,Integrase inhibitors,<65,M,**,**,**,**,32
9,Saskatchewan,N03AG,Fatty acid derivatives,<65,M,458.88,0.3,0.8,"1,966",33
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,<65,M,457.97,0.3,0.6,"1,364",34
9,Saskatchewan,L03AB,Interferons,<65,M,**,**,**,**,35
9,Saskatchewan,C08CA,Dihydropyridine derivatives,<65,M,447.48,0.3,5.1,"12,411",36
9,Saskatchewan,A09AA,Enzyme preparations,<65,M,429.60,0.3,0.1,337,37
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,<65,M,410.87,0.3,0.0,35,38
9,Saskatchewan,B01AB,Heparin group,<65,M,405.84,0.3,0.1,180,39
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,<65,M,404.69,0.3,1.4,"3,483",40
9,Saskatchewan,J01DB,First-generation cephalosporins,<65,M,388.82,0.3,7.7,"18,674",41
9,Saskatchewan,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,M,374.77,0.3,0.4,959,42
9,Saskatchewan,A16AA,Amino acids and derivatives,<65,M,**,**,**,**,43
9,Saskatchewan,L03AX,Other immunostimulants,<65,M,366.26,0.3,0.0,33,44
9,Saskatchewan,L01XC,Monoclonal antibodies,<65,M,343.54,0.2,0.0,44,45
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,328.63,0.2,1.2,"2,941",46
9,Saskatchewan,A10BA,Biguanides,<65,M,318.01,0.2,6.2,"14,939",47
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",<65,M,314.57,0.2,4.1,"9,902",48
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,313.01,0.2,11.2,"27,061",49
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,306.63,0.2,0.1,306,50
9,Saskatchewan,J01DF,Monobactams,<65,M,288.87,0.2,0.0,19,51
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,283.70,0.2,2.1,"4,996",52
9,Saskatchewan,A11CC,Vitamin D and analogues,<65,M,282.65,0.2,0.8,"1,945",53
9,Saskatchewan,N05AF,Thioxanthene derivatives,<65,M,280.95,0.2,0.2,543,54
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,276.74,0.2,0.6,"1,498",55
9,Saskatchewan,R03BB,Anticholinergics,<65,M,275.74,0.2,0.7,"1,648",56
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,265.77,0.2,0.0,15,57
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,<65,M,263.74,0.2,3.4,"8,161",58
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,257.62,0.2,4.5,"10,810",59
9,Saskatchewan,S01LA,Antineovascularization agents,<65,M,243.85,0.2,0.1,333,60
9,Saskatchewan,N03AF,Carboxamide derivatives,<65,M,234.05,0.2,0.4,909,61
9,Saskatchewan,J05AE,Protease inhibitors,<65,M,**,**,**,**,62
9,Saskatchewan,N05BA,Benzodiazepine derivatives,<65,M,216.30,0.2,2.4,"5,699",63
9,Saskatchewan,J01GB,Other aminoglycosides,<65,M,**,**,**,**,64
9,Saskatchewan,M01AE,Propionic acid derivatives,<65,M,208.73,0.2,8.3,"20,161",65
9,Saskatchewan,M03BX,Other centrally acting agents,<65,M,199.83,0.1,1.7,"4,222",66
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,<65,M,196.37,0.1,0.1,158,67
9,Saskatchewan,C02AC,Imidazoline receptor agonists,<65,M,195.51,0.1,0.8,"2,043",68
9,Saskatchewan,L01EX,Other protein kinase inhibitors,<65,M,**,**,**,**,69
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,183.78,0.1,0.1,178,70
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,183.25,0.1,0.2,507,71
9,Saskatchewan,N02BE,Anilides,<65,M,181.11,0.1,2.3,"5,612",72
9,Saskatchewan,J01CA,Penicillins with extended spectrum,<65,M,177.20,0.1,15.6,"37,714",73
9,Saskatchewan,A06AD,Osmotically acting laxatives,<65,M,175.72,0.1,0.6,"1,343",74
9,Saskatchewan,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,173.96,0.1,0.1,158,75
9,Saskatchewan,H02AB,Glucocorticoids,<65,M,164.98,0.1,6.3,"15,286",76
9,Saskatchewan,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,164.06,0.1,0.0,108,77
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,<65,M,164.02,0.1,2.7,"6,423",78
9,Saskatchewan,H03AA,Thyroid hormones,<65,M,161.27,0.1,3.0,"7,303",79
9,Saskatchewan,H01CB,Somatostatin and analogues,<65,M,**,**,**,**,80
9,Saskatchewan,A10BB,Sulfonylureas,<65,M,154.84,0.1,2.5,"5,954",81
9,Saskatchewan,N03AE,Benzodiazepine derivatives,<65,M,151.43,0.1,1.0,"2,489",82
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,147.83,0.1,4.6,"11,095",83
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,147.75,0.1,2.8,"6,799",84
9,Saskatchewan,A06AB,Contact laxatives,<65,M,146.89,0.1,0.4,"1,054",85
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,M,143.95,0.1,2.6,"6,186",86
9,Saskatchewan,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,143.82,0.1,5.2,"12,616",87
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,<65,M,141.25,0.1,0.7,"1,654",88
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,<65,M,139.28,0.1,0.4,"1,058",89
9,Saskatchewan,V06,General nutrients,<65,M,134.12,0.1,0.0,21,90
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,<65,M,132.74,0.1,0.4,985,91
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,<65,M,129.30,0.1,3.8,"9,115",92
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",<65,M,128.12,0.1,0.8,"2,043",93
9,Saskatchewan,R01AD,Corticosteroids,<65,M,125.46,0.1,6.3,"15,365",94
9,Saskatchewan,D06AX,Other antibiotics for topical use,<65,M,125.31,0.1,3.3,"8,083",95
9,Saskatchewan,B03AC,"Iron, parenteral preparations",<65,M,121.52,0.1,0.1,208,96
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",<65,M,119.08,0.1,4.8,"11,734",97
9,Saskatchewan,D09AA,Medicated dressings with antiinfectives,<65,M,**,**,**,**,98
9,Saskatchewan,J02AC,Triazole derivatives,<65,M,116.55,0.1,0.4,"1,046",99
9,Saskatchewan,A11AA,Multivitamins with minerals,<65,M,116.42,0.1,0.4,982,100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,"32,860.11",25.3,0.5,"1,411",1
9,Saskatchewan,L04AA,Selective immunosuppressants,<65,F,"13,602.93",10.5,0.4,"1,190",2
9,Saskatchewan,L04AC,Interleukin inhibitors,<65,F,"8,709.28",6.7,0.2,446,3
9,Saskatchewan,L04AX,Other immunosuppressants,<65,F,"4,140.47",3.2,0.4,"1,056",4
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,<65,F,"3,849.79",3.0,0.0,92,5
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,<65,F,"3,155.47",2.4,2.2,"6,393",6
9,Saskatchewan,N05AX,Other antipsychotics,<65,F,"2,958.41",2.3,1.1,"3,171",7
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"2,680.70",2.1,0.1,344,8
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"1,929.43",1.5,0.0,139,9
9,Saskatchewan,N03AX,Other antiepileptics,<65,F,"1,875.80",1.4,5.2,"15,226",10
9,Saskatchewan,N02AA,Natural opium alkaloids,<65,F,"1,717.58",1.3,4.7,"13,630",11
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"1,668.78",1.3,1.3,"3,745",12
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"1,654.27",1.3,3.1,"9,101",13
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,637.45",1.3,15.1,"43,985",14
9,Saskatchewan,N06AX,Other antidepressants,<65,F,"1,501.02",1.2,9.9,"28,915",15
9,Saskatchewan,L03AB,Interferons,<65,F,**,**,**,**,16
9,Saskatchewan,A02BC,Proton pump inhibitors,<65,F,"1,232.74",0.9,13.8,"40,235",17
9,Saskatchewan,L03AX,Other immunostimulants,<65,F,"1,225.32",0.9,0.0,114,18
9,Saskatchewan,N07BC,Drugs used in opioid dependence,<65,F,"1,033.16",0.8,0.3,"1,017",19
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"1,019.89",0.8,1.1,"3,271",20
9,Saskatchewan,L04AD,Calcineurin inhibitors,<65,F,980.24,0.8,0.1,236,21
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,924.75,0.7,1.1,"3,087",22
9,Saskatchewan,R03BA,Glucocorticoids,<65,F,846.50,0.7,5.1,"14,899",23
9,Saskatchewan,L01XC,Monoclonal antibodies,<65,F,800.71,0.6,0.0,81,24
9,Saskatchewan,B03XA,Other antianemic preparations,<65,F,771.10,0.6,0.1,181,25
9,Saskatchewan,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,**,26
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,<65,F,689.21,0.5,6.9,"20,202",27
9,Saskatchewan,A05AA,Bile acids and derivatives,<65,F,677.07,0.5,0.1,364,28
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,623.09,0.5,0.5,"1,578",29
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,564.35,0.4,0.0,21,30
9,Saskatchewan,B01AB,Heparin group,<65,F,520.92,0.4,0.1,313,31
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,<65,F,480.75,0.4,0.6,"1,643",32
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,472.37,0.4,3.9,"11,355",33
9,Saskatchewan,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,**,**,**,**,34
9,Saskatchewan,C09AA,"ACE inhibitors, plain",<65,F,412.57,0.3,4.3,"12,620",35
9,Saskatchewan,H03AA,Thyroid hormones,<65,F,405.82,0.3,9.4,"27,274",36
9,Saskatchewan,J01DB,First-generation cephalosporins,<65,F,396.86,0.3,7.1,"20,604",37
9,Saskatchewan,L02AE,Gonadotropin-releasing hormone analogues,<65,F,362.38,0.3,0.1,170,38
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,<65,F,361.81,0.3,0.6,"1,645",39
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,348.76,0.3,0.2,500,40
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,<65,F,344.73,0.3,1.0,"2,946",41
9,Saskatchewan,R05CB,Mucolytics,<65,F,338.33,0.3,0.0,29,42
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,<65,F,337.33,0.3,1.4,"4,141",43
9,Saskatchewan,C08CA,Dihydropyridine derivatives,<65,F,336.07,0.3,2.8,"8,278",44
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,332.74,0.3,10.0,"29,190",45
9,Saskatchewan,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,F,332.51,0.3,0.3,751,46
9,Saskatchewan,J02AC,Triazole derivatives,<65,F,328.95,0.3,2.3,"6,780",47
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,324.86,0.2,0.5,"1,467",48
9,Saskatchewan,J05AJ,Integrase inhibitors,<65,F,**,**,**,**,49
9,Saskatchewan,G03XB,Progesterone receptor modulators,<65,F,**,**,**,**,50
9,Saskatchewan,A10BA,Biguanides,<65,F,299.12,0.2,4.2,"12,296",51
9,Saskatchewan,N03AG,Fatty acid derivatives,<65,F,288.85,0.2,0.5,"1,507",52
9,Saskatchewan,R03BB,Anticholinergics,<65,F,287.69,0.2,0.7,"1,906",53
9,Saskatchewan,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,275.54,0.2,3.3,"9,546",54
9,Saskatchewan,A11CC,Vitamin D and analogues,<65,F,269.83,0.2,0.8,"2,274",55
9,Saskatchewan,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,56
9,Saskatchewan,M03BX,Other centrally acting agents,<65,F,251.96,0.2,1.7,"5,079",57
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,248.67,0.2,0.6,"1,701",58
9,Saskatchewan,N05BA,Benzodiazepine derivatives,<65,F,245.42,0.2,3.4,"9,996",59
9,Saskatchewan,N03AF,Carboxamide derivatives,<65,F,228.85,0.2,0.3,907,60
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,**,**,**,**,61
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",<65,F,219.13,0.2,2.3,"6,617",62
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,216.23,0.2,5.1,"14,918",63
9,Saskatchewan,J01DF,Monobactams,<65,F,211.29,0.2,0.0,14,64
9,Saskatchewan,M01AE,Propionic acid derivatives,<65,F,207.11,0.2,8.0,"23,199",65
9,Saskatchewan,S01LA,Antineovascularization agents,<65,F,206.69,0.2,0.1,198,66
9,Saskatchewan,G03AC,Progestogens,<65,F,**,**,**,**,67
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,<65,F,201.30,0.2,1.8,"5,160",68
9,Saskatchewan,J01CA,Penicillins with extended spectrum,<65,F,200.57,0.2,15.2,"44,337",69
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,198.39,0.2,4.2,"12,342",70
9,Saskatchewan,H02AB,Glucocorticoids,<65,F,195.76,0.2,6.4,"18,514",71
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,188.27,0.1,0.1,380,72
9,Saskatchewan,A09AA,Enzyme preparations,<65,F,185.29,0.1,0.1,234,73
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,<65,F,181.84,0.1,0.1,229,74
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,F,166.18,0.1,0.1,197,75
9,Saskatchewan,L01BA,Folic acid analogues,<65,F,165.96,0.1,0.6,"1,750",76
9,Saskatchewan,N03AE,Benzodiazepine derivatives,<65,F,165.86,0.1,1.4,"3,950",77
9,Saskatchewan,R01AD,Corticosteroids,<65,F,165.09,0.1,7.4,"21,563",78
9,Saskatchewan,R06AA,Aminoalkyl ethers,<65,F,158.61,0.1,1.9,"5,664",79
9,Saskatchewan,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,155.17,0.1,5.3,"15,371",80
9,Saskatchewan,N05AF,Thioxanthene derivatives,<65,F,151.75,0.1,0.1,312,81
9,Saskatchewan,A06AD,Osmotically acting laxatives,<65,F,147.97,0.1,0.5,"1,491",82
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",<65,F,146.36,0.1,1.2,"3,424",83
9,Saskatchewan,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,F,144.76,0.1,0.0,12,84
9,Saskatchewan,A07AA,Antibiotics,<65,F,142.87,0.1,0.9,"2,560",85
9,Saskatchewan,N02BE,Anilides,<65,F,142.73,0.1,1.2,"3,370",86
9,Saskatchewan,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,F,139.31,0.1,1.6,"4,806",87
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",<65,F,138.72,0.1,5.6,"16,294",88
9,Saskatchewan,A10BB,Sulfonylureas,<65,F,135.85,0.1,1.3,"3,747",89
9,Saskatchewan,V06,General nutrients,<65,F,135.31,0.1,0.0,21,90
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,<65,F,133.49,0.1,2.5,"7,139",91
9,Saskatchewan,N05AE,Indole derivatives,<65,F,125.41,0.1,0.0,122,92
9,Saskatchewan,A04AA,Serotonin (5HT3) antagonists,<65,F,125.24,0.1,0.0,119,93
9,Saskatchewan,J01GB,Other aminoglycosides,<65,F,**,**,**,**,94
9,Saskatchewan,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,**,**,**,**,95
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,<65,F,121.77,0.1,0.0,14,96
9,Saskatchewan,D06AX,Other antibiotics for topical use,<65,F,120.68,0.1,3.1,"8,919",97
9,Saskatchewan,G04BE,Drugs used in erectile dysfunction,<65,F,**,**,**,**,98
9,Saskatchewan,A06AB,Contact laxatives,<65,F,118.53,0.1,0.3,979,99
9,Saskatchewan,B03AC,"Iron, parenteral preparations",<65,F,117.82,0.1,0.1,347,100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"164,083.13",16.6,1.3,"8,408",1
10,Alberta,L04AA,Selective immunosuppressants,Total,Total,"51,909.63",5.3,0.7,"4,379",2
10,Alberta,B01AF,Direct factor Xa inhibitors,Total,Total,"41,862.73",4.2,7.4,"47,533",3
10,Alberta,L04AC,Interleukin inhibitors,Total,Total,"30,577.16",3.1,0.3,"2,103",4
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"26,872.43",2.7,6.2,"39,957",5
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"25,163.90",2.5,4.7,"29,868",6
10,Alberta,C10AA,HMG-CoA reductase inhibitors,Total,Total,"24,904.45",2.5,43.9,"281,673",7
10,Alberta,J05AP,Antivirals for treatment of HCV infections,Total,Total,"22,508.62",2.3,0.1,447,8
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"21,178.85",2.1,4.1,"26,403",9
10,Alberta,L04AX,Other immunosuppressants,Total,Total,"19,254.47",1.9,0.7,"4,547",10
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"17,365.39",1.8,0.1,860,11
10,Alberta,A02BC,Proton pump inhibitors,Total,Total,"17,226.75",1.7,30.6,"196,138",12
10,Alberta,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,Total,"15,087.53",1.5,2.6,"16,802",13
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"14,406.57",1.5,18.0,"115,549",14
10,Alberta,S01LA,Antineovascularization agents,Total,Total,"14,274.28",1.4,0.2,"1,503",15
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,"13,907.54",1.4,1.3,"8,354",16
10,Alberta,R03BB,Anticholinergics,Total,Total,"13,803.16",1.4,6.0,"38,363",17
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"13,764.85",1.4,2.3,"14,900",18
10,Alberta,C09AA,"ACE inhibitors, plain",Total,Total,"12,600.17",1.3,21.7,"138,905",19
10,Alberta,N06AX,Other antidepressants,Total,Total,"11,475.64",1.2,12.3,"78,711",20
10,Alberta,H03AA,Thyroid hormones,Total,Total,"11,091.22",1.1,21.1,"135,124",21
10,Alberta,N02AA,Natural opium alkaloids,Total,Total,"10,912.45",1.1,3.9,"25,192",22
10,Alberta,C08CA,Dihydropyridine derivatives,Total,Total,"10,782.30",1.1,19.2,"123,150",23
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",Total,Total,"10,446.87",1.1,13.8,"88,397",24
10,Alberta,B03XA,Other antianemic preparations,Total,Total,"9,435.88",1.0,0.4,"2,281",25
10,Alberta,C07AB,"Beta-blocking agents, selective",Total,Total,"9,312.47",0.9,18.4,"117,871",26
10,Alberta,N03AX,Other antiepileptics,Total,Total,"8,820.30",0.9,9.4,"60,256",27
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"8,768.92",0.9,11.0,"70,765",28
10,Alberta,B01AB,Heparin group,Total,Total,"8,477.06",0.9,1.0,"6,523",29
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"7,407.08",0.7,0.7,"4,371",30
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"7,382.07",0.7,5.8,"37,236",31
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"7,283.03",0.7,2.4,"15,698",32
10,Alberta,H01CB,Somatostatin and analogues,Total,Total,"6,957.51",0.7,0.1,362,33
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"6,782.31",0.7,1.6,"9,985",34
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,Total,Total,"6,689.68",0.7,0.0,18,35
10,Alberta,L03AX,Other immunostimulants,Total,Total,"6,639.52",0.7,0.1,592,36
10,Alberta,L01EX,Other protein kinase inhibitors,Total,Total,"6,608.11",0.7,0.0,296,37
10,Alberta,M05BA,Bisphosphonates,Total,Total,"6,225.76",0.6,8.0,"51,078",38
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"6,114.74",0.6,3.5,"22,546",39
10,Alberta,A10BA,Biguanides,Total,Total,"5,751.55",0.6,14.2,"91,336",40
10,Alberta,R03BA,Glucocorticoids,Total,Total,"5,732.91",0.6,4.1,"26,087",41
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"5,703.28",0.6,10.1,"64,630",42
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"5,378.21",0.5,3.8,"24,427",43
10,Alberta,A07EC,Aminosalicylic acid and similar agents,Total,Total,"5,242.83",0.5,0.9,"5,804",44
10,Alberta,N04BA,Dopa and dopa derivatives,Total,Total,"5,209.79",0.5,1.0,"6,565",45
10,Alberta,L03AB,Interferons,Total,Total,"5,043.99",0.5,0.0,292,46
10,Alberta,N05AX,Other antipsychotics,Total,Total,"4,782.71",0.5,1.2,"7,769",47
10,Alberta,C08DB,Benzothiazepine derivatives,Total,Total,"4,699.46",0.5,2.5,"16,034",48
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,Total,"4,661.59",0.5,6.7,"42,950",49
10,Alberta,S01ED,Beta-blocking agents,Total,Total,"4,584.54",0.5,3.0,"19,436",50
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"4,565.40",0.5,0.3,"1,905",51
10,Alberta,N05CF,Benzodiazepine-related drugs,Total,Total,"4,233.64",0.4,10.2,"65,209",52
10,Alberta,A16AB,Enzymes,Total,Total,"4,140.01",0.4,0.0,12,53
10,Alberta,C09BA,ACE inhibitors and diuretics,Total,Total,"4,127.97",0.4,4.2,"26,904",54
10,Alberta,L01XC,Monoclonal antibodies,Total,Total,"3,966.92",0.4,0.1,325,55
10,Alberta,S01EE,Prostaglandin analogues,Total,Total,"3,937.91",0.4,3.4,"21,878",56
10,Alberta,L03AA,Colony-stimulating factors,Total,Total,"3,914.45",0.4,0.1,815,57
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"3,895.12",0.4,10.4,"66,388",58
10,Alberta,A04AA,Serotonin (5HT3) antagonists,Total,Total,"3,760.73",0.4,2.0,"12,699",59
10,Alberta,R07AX,Other respiratory system products,Total,Total,"3,623.22",0.4,0.0,16,60
10,Alberta,B01AE,Direct thrombin inhibitors,Total,Total,"3,316.06",0.3,0.5,"3,436",61
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"3,257.68",0.3,3.0,"19,035",62
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"3,257.64",0.3,0.8,"4,975",63
10,Alberta,N06BA,Centrally acting sympathomimetics,Total,Total,"3,226.09",0.3,0.8,"5,084",64
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"3,139.40",0.3,4.0,"25,843",65
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"3,124.50",0.3,10.5,"67,104",66
10,Alberta,C03CA,"Sulfonamides, plain",Total,Total,"3,101.33",0.3,7.7,"49,298",67
10,Alberta,N07BC,Drugs used in opioid dependence,Total,Total,"2,438.53",0.2,0.3,"1,955",68
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"2,393.65",0.2,3.4,"21,492",69
10,Alberta,M04AA,Preparations inhibiting uric acid production,Total,Total,"2,341.76",0.2,4.4,"28,017",70
10,Alberta,A16AX,Various alimentary tract and metabolism products,Total,Total,"2,305.26",0.2,0.0,11,71
10,Alberta,A09AA,Enzyme preparations,Total,Total,"2,284.94",0.2,0.3,"2,117",72
10,Alberta,C07AG,Alpha- and beta-blocking agents,Total,Total,"2,265.97",0.2,1.7,"11,114",73
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,Total,"2,243.31",0.2,0.2,"1,370",74
10,Alberta,L01BA,Folic acid analogues,Total,Total,"2,209.36",0.2,1.6,"10,215",75
10,Alberta,A10BB,Sulfonylureas,Total,Total,"2,146.11",0.2,4.2,"27,232",76
10,Alberta,C01DA,Organic nitrates,Total,Total,"2,130.08",0.2,3.9,"24,943",77
10,Alberta,C03AA,"Thiazides, plain",Total,Total,"2,101.46",0.2,7.1,"45,765",78
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,"2,047.70",0.2,3.8,"24,672",79
10,Alberta,H02AB,Glucocorticoids,Total,Total,"1,981.84",0.2,8.9,"57,199",80
10,Alberta,C10AX,Other lipid-modifying agents,Total,Total,"1,947.08",0.2,1.7,"11,139",81
10,Alberta,M01AB,Acetic acid derivatives and related substances,Total,Total,"1,917.84",0.2,6.4,"40,957",82
10,Alberta,A07AA,Antibiotics,Total,Total,"1,916.51",0.2,1.3,"8,413",83
10,Alberta,N05BA,Benzodiazepine derivatives,Total,Total,"1,900.45",0.2,6.0,"38,416",84
10,Alberta,D07AC,"Corticosteroids, potent (group III)",Total,Total,"1,824.43",0.2,8.6,"55,033",85
10,Alberta,C03DA,Aldosterone antagonists,Total,Total,"1,753.60",0.2,3.0,"19,345",86
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,Total,Total,"1,612.35",0.2,0.8,"5,170",87
10,Alberta,N06DA,Anticholinesterases,Total,Total,"1,605.30",0.2,0.9,"6,009",88
10,Alberta,R01AD,Corticosteroids,Total,Total,"1,553.42",0.2,6.2,"40,059",89
10,Alberta,V03AC,Iron-chelating agents,Total,Total,"1,532.46",0.2,0.0,117,90
10,Alberta,G03DA,Pregnen (4) derivatives,Total,Total,"1,487.56",0.2,0.8,"4,910",91
10,Alberta,A04AD,Other antiemetics,Total,Total,"1,450.35",0.1,0.4,"2,523",92
10,Alberta,B01AA,Vitamin K antagonists,Total,Total,"1,400.15",0.1,2.1,"13,199",93
10,Alberta,D05AX,Other antipsoriatics for topical use,Total,Total,"1,348.39",0.1,0.8,"5,375",94
10,Alberta,A12BA,Potassium,Total,Total,"1,266.86",0.1,2.7,"17,204",95
10,Alberta,C03BA,"Sulfonamides, plain",Total,Total,"1,241.25",0.1,3.0,"18,944",96
10,Alberta,J01MA,Fluoroquinolones,Total,Total,"1,171.11",0.1,7.2,"46,204",97
10,Alberta,J02AC,Triazole derivatives,Total,Total,"1,168.77",0.1,1.5,"9,473",98
10,Alberta,A05AA,Bile acids and derivatives,Total,Total,"1,154.60",0.1,0.2,"1,443",99
10,Alberta,C10AB,Fibrates,Total,Total,"1,025.95",0.1,1.2,"7,491",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,"85,042.29",17.9,1.4,"4,023",1
10,Alberta,B01AF,Direct factor Xa inhibitors,Total,M,"22,285.40",4.7,8.7,"25,124",2
10,Alberta,L04AA,Selective immunosuppressants,Total,M,"18,956.72",4.0,0.5,"1,427",3
10,Alberta,J05AP,Antivirals for treatment of HCV infections,Total,M,"15,694.03",3.3,0.1,313,4
10,Alberta,L04AC,Interleukin inhibitors,Total,M,"15,102.81",3.2,0.3,989,5
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"15,034.88",3.2,5.9,"16,970",6
10,Alberta,C10AA,HMG-CoA reductase inhibitors,Total,M,"13,662.53",2.9,53.0,"153,392",7
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"13,419.78",2.8,5.7,"16,452",8
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"12,073.67",2.5,6.1,"17,582",9
10,Alberta,L04AX,Other immunosuppressants,Total,M,"9,033.60",1.9,0.6,"1,881",10
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"8,343.08",1.8,3.1,"8,911",11
10,Alberta,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,M,"8,251.01",1.7,3.2,"9,126",12
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"7,570.28",1.6,0.1,362,13
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,"7,452.87",1.6,1.5,"4,393",14
10,Alberta,A02BC,Proton pump inhibitors,Total,M,"7,302.87",1.5,29.3,"84,766",15
10,Alberta,R03BB,Anticholinergics,Total,M,"6,934.62",1.5,6.6,"18,987",16
10,Alberta,C09AA,"ACE inhibitors, plain",Total,M,"6,736.69",1.4,26.4,"76,377",17
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"6,030.05",1.3,17.2,"49,794",18
10,Alberta,S01LA,Antineovascularization agents,Total,M,"5,849.77",1.2,0.2,630,19
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"5,616.83",1.2,21.8,"63,093",20
10,Alberta,B03XA,Other antianemic preparations,Total,M,"5,546.05",1.2,0.5,"1,318",21
10,Alberta,C08CA,Dihydropyridine derivatives,Total,M,"5,030.53",1.1,20.1,"58,179",22
10,Alberta,N02AA,Natural opium alkaloids,Total,M,"4,971.29",1.0,3.7,"10,580",23
10,Alberta,C07AB,"Beta-blocking agents, selective",Total,M,"4,883.14",1.0,22.1,"64,082",24
10,Alberta,L01EX,Other protein kinase inhibitors,Total,M,"4,513.17",0.9,0.1,198,25
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"4,433.76",0.9,3.0,"8,811",26
10,Alberta,B01AB,Heparin group,Total,M,"4,430.51",0.9,1.0,"2,936",27
10,Alberta,H01CB,Somatostatin and analogues,Total,M,"3,879.35",0.8,0.1,178,28
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",Total,M,"3,702.75",0.8,11.3,"32,793",29
10,Alberta,N06AX,Other antidepressants,Total,M,"3,615.68",0.8,9.2,"26,706",30
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"3,593.71",0.8,5.3,"15,358",31
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,Total,M,"3,527.31",0.7,0.0,10,32
10,Alberta,N03AX,Other antiepileptics,Total,M,"3,517.13",0.7,8.2,"23,781",33
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"3,515.78",0.7,1.8,"5,086",34
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,"3,498.41",0.7,0.5,"1,466",35
10,Alberta,N04BA,Dopa and dopa derivatives,Total,M,"3,210.82",0.7,1.3,"3,748",36
10,Alberta,A10BA,Biguanides,Total,M,"3,201.56",0.7,17.5,"50,755",37
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"3,089.19",0.6,8.7,"25,211",38
10,Alberta,H03AA,Thyroid hormones,Total,M,"2,926.42",0.6,12.8,"37,021",39
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,Total,M,"2,752.40",0.6,7.7,"22,302",40
10,Alberta,A16AB,Enzymes,Total,M,"2,642.94",0.6,0.0,7,41
10,Alberta,A07EC,Aminosalicylic acid and similar agents,Total,M,"2,610.73",0.5,0.9,"2,642",42
10,Alberta,R03BA,Glucocorticoids,Total,M,"2,497.41",0.5,3.8,"10,927",43
10,Alberta,C09BA,ACE inhibitors and diuretics,Total,M,"2,261.46",0.5,5.1,"14,638",44
10,Alberta,R07AX,Other respiratory system products,Total,M,"2,139.89",0.4,0.0,10,45
10,Alberta,S01ED,Beta-blocking agents,Total,M,"2,128.87",0.4,3.2,"9,278",46
10,Alberta,N05AX,Other antipsychotics,Total,M,"2,069.70",0.4,1.1,"3,058",47
10,Alberta,C08DB,Benzothiazepine derivatives,Total,M,"2,061.83",0.4,2.4,"6,908",48
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,M,"2,032.29",0.4,6.6,"18,984",49
10,Alberta,B01AE,Direct thrombin inhibitors,Total,M,"1,983.94",0.4,0.7,"2,090",50
10,Alberta,L03AX,Other immunostimulants,Total,M,"1,929.37",0.4,0.1,161,51
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,Total,M,"1,865.50",0.4,2.4,"7,028",52
10,Alberta,S01EE,Prostaglandin analogues,Total,M,"1,727.32",0.4,3.4,"9,730",53
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"1,696.75",0.4,10.7,"30,882",54
10,Alberta,M04AA,Preparations inhibiting uric acid production,Total,M,"1,692.96",0.4,7.0,"20,394",55
10,Alberta,N05CF,Benzodiazepine-related drugs,Total,M,"1,554.87",0.3,8.3,"24,119",56
10,Alberta,N06BA,Centrally acting sympathomimetics,Total,M,"1,547.63",0.3,0.8,"2,404",57
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"1,481.83",0.3,2.7,"7,708",58
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"1,463.18",0.3,0.3,965,59
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"1,402.90",0.3,9.8,"28,224",60
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"1,384.17",0.3,0.3,857,61
10,Alberta,C03CA,"Sulfonamides, plain",Total,M,"1,380.57",0.3,7.9,"22,799",62
10,Alberta,L03AB,Interferons,Total,M,"1,370.12",0.3,0.0,74,63
10,Alberta,C07AG,Alpha- and beta-blocking agents,Total,M,"1,339.65",0.3,2.3,"6,559",64
10,Alberta,L03AA,Colony-stimulating factors,Total,M,"1,332.15",0.3,0.1,296,65
10,Alberta,N07BC,Drugs used in opioid dependence,Total,M,"1,259.46",0.3,0.3,"1,000",66
10,Alberta,A10BB,Sulfonylureas,Total,M,"1,259.22",0.3,5.5,"15,975",67
10,Alberta,L01XC,Monoclonal antibodies,Total,M,"1,245.69",0.3,0.0,98,68
10,Alberta,A04AA,Serotonin (5HT3) antagonists,Total,M,"1,236.89",0.3,1.5,"4,410",69
10,Alberta,A09AA,Enzyme preparations,Total,M,"1,175.17",0.2,0.3,971,70
10,Alberta,C01DA,Organic nitrates,Total,M,"1,098.98",0.2,5.0,"14,431",71
10,Alberta,C10AX,Other lipid-modifying agents,Total,M,"1,085.85",0.2,2.2,"6,501",72
10,Alberta,C03DA,Aldosterone antagonists,Total,M,981.66,0.2,3.4,"9,911",73
10,Alberta,M01AB,Acetic acid derivatives and related substances,Total,M,963.87,0.2,7.4,"21,349",74
10,Alberta,A07AA,Antibiotics,Total,M,926.20,0.2,1.0,"2,960",75
10,Alberta,D07AC,"Corticosteroids, potent (group III)",Total,M,922.13,0.2,8.8,"25,600",76
10,Alberta,H02AB,Glucocorticoids,Total,M,904.82,0.2,9.0,"25,930",77
10,Alberta,M05BA,Bisphosphonates,Total,M,877.82,0.2,2.5,"7,181",78
10,Alberta,A16AA,Amino acids and derivatives,Total,M,877.16,0.2,0.0,7,79
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,854.27,0.2,2.9,"8,500",80
10,Alberta,V03AC,Iron-chelating agents,Total,M,853.01,0.2,0.0,68,81
10,Alberta,C03AA,"Thiazides, plain",Total,M,796.43,0.2,6.1,"17,703",82
10,Alberta,L01BA,Folic acid analogues,Total,M,786.96,0.2,1.2,"3,608",83
10,Alberta,D05AX,Other antipsoriatics for topical use,Total,M,786.68,0.2,1.0,"2,885",84
10,Alberta,B01AA,Vitamin K antagonists,Total,M,762.12,0.2,2.6,"7,453",85
10,Alberta,R01AD,Corticosteroids,Total,M,708.96,0.1,5.9,"17,125",86
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,690.41,0.1,2.2,"6,337",87
10,Alberta,G03BA,3-oxoandrosten (4) derivatives,Total,M,610.98,0.1,1.1,"3,201",88
10,Alberta,N06DA,Anticholinesterases,Total,M,610.04,0.1,0.8,"2,352",89
10,Alberta,N05BA,Benzodiazepine derivatives,Total,M,593.23,0.1,4.1,"11,865",90
10,Alberta,J02AC,Triazole derivatives,Total,M,587.02,0.1,0.7,"2,089",91
10,Alberta,C10AB,Fibrates,Total,M,571.01,0.1,1.5,"4,202",92
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,569.25,0.1,0.3,824,93
10,Alberta,C03BA,"Sulfonamides, plain",Total,M,562.71,0.1,3.0,"8,695",94
10,Alberta,A04AD,Other antiemetics,Total,M,553.58,0.1,0.3,971,95
10,Alberta,J01MA,Fluoroquinolones,Total,M,517.88,0.1,7.1,"20,470",96
10,Alberta,C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,Total,M,484.74,0.1,0.8,"2,293",97
10,Alberta,D01AC,Imidazole and triazole derivatives,Total,M,452.21,0.1,2.7,"7,713",98
10,Alberta,M01AE,Propionic acid derivatives,Total,M,449.72,0.1,4.4,"12,670",99
10,Alberta,M04AC,Preparations with no effect on uric acid metabolism,Total,M,448.43,0.1,3.8,"10,864",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,"79,040.84",15.4,1.2,"4,385",1
10,Alberta,L04AA,Selective immunosuppressants,Total,F,"32,952.91",6.4,0.8,"2,952",2
10,Alberta,B01AF,Direct factor Xa inhibitors,Total,F,"19,577.34",3.8,6.4,"22,409",3
10,Alberta,L04AC,Interleukin inhibitors,Total,F,"15,474.35",3.0,0.3,"1,114",4
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"14,798.77",2.9,6.4,"22,375",5
10,Alberta,C10AA,HMG-CoA reductase inhibitors,Total,F,"11,241.88",2.2,36.5,"128,280",6
10,Alberta,L04AX,Other immunosuppressants,Total,F,"10,220.88",2.0,0.8,"2,666",7
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"10,129.01",2.0,3.7,"12,898",8
10,Alberta,A02BC,Proton pump inhibitors,Total,F,"9,923.82",1.9,31.7,"111,371",9
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"9,795.11",1.9,0.1,498,10
10,Alberta,S01LA,Antineovascularization agents,Total,F,"8,424.51",1.6,0.2,873,11
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"8,376.51",1.6,18.7,"65,755",12
10,Alberta,H03AA,Thyroid hormones,Total,F,"8,164.80",1.6,27.9,"98,103",13
10,Alberta,N06AX,Other antidepressants,Total,F,"7,859.96",1.5,14.8,"52,005",14
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"7,759.07",1.5,2.8,"9,951",15
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"7,341.03",1.4,10.5,"36,978",16
10,Alberta,R03BB,Anticholinergics,Total,F,"6,868.54",1.3,5.5,"19,376",17
10,Alberta,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,F,"6,836.52",1.3,2.2,"7,676",18
10,Alberta,J05AP,Antivirals for treatment of HCV infections,Total,F,"6,814.59",1.3,0.0,134,19
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",Total,F,"6,744.12",1.3,15.8,"55,604",20
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,"6,454.67",1.3,1.1,"3,961",21
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,Total,F,"6,016.52",1.2,13.8,"48,463",22
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"5,943.90",1.2,1.0,"3,406",23
10,Alberta,N02AA,Natural opium alkaloids,Total,F,"5,941.16",1.2,4.2,"14,612",24
10,Alberta,C09AA,"ACE inhibitors, plain",Total,F,"5,863.48",1.1,17.8,"62,528",25
10,Alberta,C08CA,Dihydropyridine derivatives,Total,F,"5,751.77",1.1,18.5,"64,971",26
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"5,421.76",1.1,1.7,"5,989",27
10,Alberta,M05BA,Bisphosphonates,Total,F,"5,347.94",1.0,12.5,"43,897",28
10,Alberta,N03AX,Other antiepileptics,Total,F,"5,303.17",1.0,10.4,"36,475",29
10,Alberta,L03AX,Other immunostimulants,Total,F,"4,710.15",0.9,0.1,431,30
10,Alberta,C07AB,"Beta-blocking agents, selective",Total,F,"4,429.33",0.9,15.3,"53,789",31
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,Total,F,"4,249.24",0.8,4.4,"15,518",32
10,Alberta,B01AB,Heparin group,Total,F,"4,046.55",0.8,1.0,"3,587",33
10,Alberta,B03XA,Other antianemic preparations,Total,F,"3,889.83",0.8,0.3,963,34
10,Alberta,L03AB,Interferons,Total,F,"3,673.87",0.7,0.1,218,35
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"3,266.53",0.6,1.4,"4,899",36
10,Alberta,R03BA,Glucocorticoids,Total,F,"3,235.09",0.6,4.3,"15,159",37
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,Total,F,"3,162.37",0.6,0.0,8,38
10,Alberta,H01CB,Somatostatin and analogues,Total,F,"3,078.16",0.6,0.1,184,39
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"2,994.62",0.6,1.3,"4,567",40
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"2,849.28",0.6,2.0,"6,887",41
10,Alberta,L01XC,Monoclonal antibodies,Total,F,"2,721.23",0.5,0.1,227,42
10,Alberta,N05AX,Other antipsychotics,Total,F,"2,713.02",0.5,1.3,"4,711",43
10,Alberta,N05CF,Benzodiazepine-related drugs,Total,F,"2,678.77",0.5,11.7,"41,090",44
10,Alberta,C08DB,Benzothiazepine derivatives,Total,F,"2,637.64",0.5,2.6,"9,126",45
10,Alberta,A07EC,Aminosalicylic acid and similar agents,Total,F,"2,632.10",0.5,0.9,"3,162",46
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,Total,F,"2,629.30",0.5,6.8,"23,966",47
10,Alberta,L03AA,Colony-stimulating factors,Total,F,"2,582.30",0.5,0.1,519,48
10,Alberta,A10BA,Biguanides,Total,F,"2,549.99",0.5,11.5,"40,581",49
10,Alberta,A04AA,Serotonin (5HT3) antagonists,Total,F,"2,523.83",0.5,2.4,"8,289",50
10,Alberta,S01ED,Beta-blocking agents,Total,F,"2,455.67",0.5,2.9,"10,158",51
10,Alberta,A16AX,Various alimentary tract and metabolism products,Total,F,**,**,**,**,52
10,Alberta,S01EE,Prostaglandin analogues,Total,F,"2,210.60",0.4,3.5,"12,148",53
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"2,198.37",0.4,10.1,"35,506",54
10,Alberta,L01EX,Other protein kinase inhibitors,Total,F,"2,094.94",0.4,0.0,98,55
10,Alberta,N04BA,Dopa and dopa derivatives,Total,F,"1,998.97",0.4,0.8,"2,817",56
10,Alberta,C09BA,ACE inhibitors and diuretics,Total,F,"1,866.50",0.4,3.5,"12,266",57
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"1,784.50",0.3,2.6,"9,069",58
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"1,775.84",0.3,3.2,"11,327",59
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"1,721.58",0.3,11.1,"38,879",60
10,Alberta,C03CA,"Sulfonamides, plain",Total,F,"1,720.76",0.3,7.5,"26,499",61
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"1,703.24",0.3,4.3,"15,155",62
10,Alberta,N06BA,Centrally acting sympathomimetics,Total,F,"1,678.46",0.3,0.8,"2,680",63
10,Alberta,A16AB,Enzymes,Total,F,"1,497.07",0.3,0.0,5,64
10,Alberta,R07AX,Other respiratory system products,Total,F,"1,483.33",0.3,0.0,6,65
10,Alberta,G03DA,Pregnen (4) derivatives,Total,F,"1,473.51",0.3,1.4,"4,844",66
10,Alberta,L01BA,Folic acid analogues,Total,F,"1,422.40",0.3,1.9,"6,607",67
10,Alberta,B01AE,Direct thrombin inhibitors,Total,F,"1,332.12",0.3,0.4,"1,346",68
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,Total,F,"1,321.63",0.3,1.2,"4,387",69
10,Alberta,N05BA,Benzodiazepine derivatives,Total,F,"1,307.22",0.3,7.6,"26,551",70
10,Alberta,C03AA,"Thiazides, plain",Total,F,"1,305.03",0.3,8.0,"28,062",71
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"1,193.42",0.2,4.6,"16,172",72
10,Alberta,N07BC,Drugs used in opioid dependence,Total,F,"1,179.07",0.2,0.3,955,73
10,Alberta,A09AA,Enzyme preparations,Total,F,"1,109.77",0.2,0.3,"1,146",74
10,Alberta,H02AB,Glucocorticoids,Total,F,"1,077.01",0.2,8.9,"31,268",75
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,"1,066.99",0.2,0.1,439,76
10,Alberta,C01DA,Organic nitrates,Total,F,"1,031.10",0.2,3.0,"10,512",77
10,Alberta,N06DA,Anticholinesterases,Total,F,995.26,0.2,1.0,"3,657",78
10,Alberta,A07AA,Antibiotics,Total,F,990.32,0.2,1.6,"5,453",79
10,Alberta,M01AB,Acetic acid derivatives and related substances,Total,F,953.96,0.2,5.6,"19,608",80
10,Alberta,C07AG,Alpha- and beta-blocking agents,Total,F,926.32,0.2,1.3,"4,555",81
10,Alberta,A05AA,Bile acids and derivatives,Total,F,922.88,0.2,0.3,"1,039",82
10,Alberta,D07AC,"Corticosteroids, potent (group III)",Total,F,902.30,0.2,8.4,"29,433",83
10,Alberta,A04AD,Other antiemetics,Total,F,896.77,0.2,0.4,"1,552",84
10,Alberta,A10BB,Sulfonylureas,Total,F,886.89,0.2,3.2,"11,257",85
10,Alberta,C10AX,Other lipid-modifying agents,Total,F,861.22,0.2,1.3,"4,638",86
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,F,859.14,0.2,0.1,513,87
10,Alberta,R01AD,Corticosteroids,Total,F,844.45,0.2,6.5,"22,934",88
10,Alberta,A12BA,Potassium,Total,F,828.37,0.2,3.1,"10,994",89
10,Alberta,C03DA,Aldosterone antagonists,Total,F,771.94,0.2,2.7,"9,434",90
10,Alberta,V03AC,Iron-chelating agents,Total,F,679.45,0.1,0.0,49,91
10,Alberta,C03BA,"Sulfonamides, plain",Total,F,678.54,0.1,2.9,"10,249",92
10,Alberta,N05AE,Indole derivatives,Total,F,676.69,0.1,0.2,529,93
10,Alberta,J01MA,Fluoroquinolones,Total,F,653.23,0.1,7.3,"25,734",94
10,Alberta,M04AA,Preparations inhibiting uric acid production,Total,F,648.79,0.1,2.2,"7,623",95
10,Alberta,P01BA,Aminoquinolines,Total,F,647.95,0.1,1.8,"6,391",96
10,Alberta,B01AA,Vitamin K antagonists,Total,F,638.03,0.1,1.6,"5,746",97
10,Alberta,G03EB,"Androgen, progestogen and estrogen in combination",Total,F,621.20,0.1,0.4,"1,395",98
10,Alberta,A03FA,Propulsives,Total,F,602.15,0.1,3.1,"10,880",99
10,Alberta,J01XE,Nitrofuran derivatives,Total,F,593.44,0.1,6.8,"24,014",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,"49,597.59",7.2,0.5,"2,591",1
10,Alberta,B01AF,Direct factor Xa inhibitors,65+,Total,"40,812.15",6.0,8.3,"45,932",2
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"24,441.73",3.6,6.4,"35,404",3
10,Alberta,C10AA,HMG-CoA reductase inhibitors,65+,Total,"23,609.54",3.4,47.2,"261,585",4
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"21,142.86",3.1,4.6,"25,396",5
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"18,684.51",2.7,4.1,"22,827",6
10,Alberta,L04AA,Selective immunosuppressants,65+,Total,"17,623.51",2.6,0.4,"2,203",7
10,Alberta,A02BC,Proton pump inhibitors,65+,Total,"15,962.12",2.3,31.9,"176,651",8
10,Alberta,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,Total,"14,049.46",2.0,2.8,"15,414",9
10,Alberta,S01LA,Antineovascularization agents,65+,Total,"13,976.42",2.0,0.3,"1,468",10
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"13,715.46",2.0,19.4,"107,733",11
10,Alberta,R03BB,Anticholinergics,65+,Total,"13,203.74",1.9,6.5,"36,211",12
10,Alberta,L04AC,Interleukin inhibitors,65+,Total,"12,637.52",1.8,0.2,832,13
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"12,210.55",1.8,2.3,"12,898",14
10,Alberta,C09AA,"ACE inhibitors, plain",65+,Total,"11,934.00",1.7,23.2,"128,837",15
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,"11,401.08",1.7,1.2,"6,717",16
10,Alberta,C08CA,Dihydropyridine derivatives,65+,Total,"10,287.98",1.5,20.9,"115,633",17
10,Alberta,H03AA,Thyroid hormones,65+,Total,"10,237.47",1.5,22.1,"122,355",18
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",65+,Total,"9,867.18",1.4,14.8,"81,765",19
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"9,838.30",1.4,0.1,453,20
10,Alberta,J05AP,Antivirals for treatment of HCV infections,65+,Total,"9,788.41",1.4,0.0,187,21
10,Alberta,N06AX,Other antidepressants,65+,Total,"9,696.50",1.4,11.9,"66,081",22
10,Alberta,L04AX,Other immunosuppressants,65+,Total,"9,217.57",1.3,0.5,"2,902",23
10,Alberta,C07AB,"Beta-blocking agents, selective",65+,Total,"8,967.78",1.3,20.2,"111,855",24
10,Alberta,N02AA,Natural opium alkaloids,65+,Total,"7,885.79",1.2,3.9,"21,513",25
10,Alberta,B03XA,Other antianemic preparations,65+,Total,"7,838.46",1.1,0.3,"1,926",26
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"7,477.36",1.1,10.6,"58,483",27
10,Alberta,N03AX,Other antiepileptics,65+,Total,"7,263.69",1.1,9.4,"52,173",28
10,Alberta,B01AB,Heparin group,65+,Total,"6,978.62",1.0,1.0,"5,769",29
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"6,571.50",1.0,5.8,"32,040",30
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"6,539.20",1.0,1.7,"9,555",31
10,Alberta,L01EX,Other protein kinase inhibitors,65+,Total,"6,204.95",0.9,0.1,279,32
10,Alberta,M05BA,Bisphosphonates,65+,Total,"5,993.28",0.9,8.8,"48,845",33
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"5,752.42",0.8,3.8,"20,883",34
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"5,736.69",0.8,2.3,"12,588",35
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"5,575.90",0.8,11.3,"62,539",36
10,Alberta,A10BA,Biguanides,65+,Total,"5,367.16",0.8,15.0,"83,109",37
10,Alberta,R03BA,Glucocorticoids,65+,Total,"5,091.96",0.7,4.0,"22,207",38
10,Alberta,N04BA,Dopa and dopa derivatives,65+,Total,"5,081.40",0.7,1.1,"6,316",39
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"5,079.07",0.7,4.2,"23,246",40
10,Alberta,H01CB,Somatostatin and analogues,65+,Total,"5,055.80",0.7,0.0,261,41
10,Alberta,C08DB,Benzothiazepine derivatives,65+,Total,"4,480.69",0.7,2.7,"15,137",42
10,Alberta,S01ED,Beta-blocking agents,65+,Total,"4,476.77",0.7,3.4,"18,816",43
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,"4,385.55",0.6,7.2,"39,668",44
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,"4,205.25",0.6,0.3,"1,741",45
10,Alberta,A07EC,Aminosalicylic acid and similar agents,65+,Total,"3,938.04",0.6,0.8,"4,284",46
10,Alberta,N05CF,Benzodiazepine-related drugs,65+,Total,"3,851.29",0.6,10.5,"58,335",47
10,Alberta,S01EE,Prostaglandin analogues,65+,Total,"3,847.95",0.6,3.8,"21,184",48
10,Alberta,C09BA,ACE inhibitors and diuretics,65+,Total,"3,819.78",0.6,4.4,"24,381",49
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"3,703.70",0.5,0.4,"2,440",50
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"3,415.55",0.5,10.5,"58,373",51
10,Alberta,B01AE,Direct thrombin inhibitors,65+,Total,"3,239.34",0.5,0.6,"3,324",52
10,Alberta,N05AX,Other antipsychotics,65+,Total,"3,236.98",0.5,1.1,"6,040",53
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"3,198.51",0.5,0.9,"4,874",54
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"3,080.64",0.4,4.5,"25,106",55
10,Alberta,C03CA,"Sulfonamides, plain",65+,Total,"3,012.23",0.4,8.5,"47,172",56
10,Alberta,L03AA,Colony-stimulating factors,65+,Total,"2,901.08",0.4,0.1,610,57
10,Alberta,A04AA,Serotonin (5HT3) antagonists,65+,Total,"2,853.16",0.4,1.9,"10,352",58
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"2,777.98",0.4,10.5,"58,022",59
10,Alberta,L01XC,Monoclonal antibodies,65+,Total,"2,552.54",0.4,0.0,206,60
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"2,442.42",0.4,2.8,"15,462",61
10,Alberta,M04AA,Preparations inhibiting uric acid production,65+,Total,"2,233.75",0.3,4.7,"26,322",62
10,Alberta,C07AG,Alpha- and beta-blocking agents,65+,Total,"2,101.23",0.3,1.9,"10,261",63
10,Alberta,C01DA,Organic nitrates,65+,Total,"2,080.73",0.3,4.3,"24,009",64
10,Alberta,C03AA,"Thiazides, plain",65+,Total,"2,002.06",0.3,7.7,"42,751",65
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"1,998.24",0.3,3.2,"18,005",66
10,Alberta,A10BB,Sulfonylureas,65+,Total,"1,989.93",0.3,4.5,"24,692",67
10,Alberta,L01BA,Folic acid analogues,65+,Total,"1,818.03",0.3,1.4,"8,006",68
10,Alberta,H02AB,Glucocorticoids,65+,Total,"1,692.15",0.2,8.9,"49,279",69
10,Alberta,D07AC,"Corticosteroids, potent (group III)",65+,Total,"1,681.96",0.2,9.0,"49,929",70
10,Alberta,C10AX,Other lipid-modifying agents,65+,Total,"1,680.42",0.2,1.9,"10,432",71
10,Alberta,M01AB,Acetic acid derivatives and related substances,65+,Total,"1,673.68",0.2,6.3,"35,154",72
10,Alberta,N05BA,Benzodiazepine derivatives,65+,Total,"1,636.14",0.2,5.9,"32,502",73
10,Alberta,C03DA,Aldosterone antagonists,65+,Total,"1,631.82",0.2,3.2,"17,797",74
10,Alberta,A07AA,Antibiotics,65+,Total,"1,613.68",0.2,1.3,"7,390",75
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,"1,608.64",0.2,3.7,"20,409",76
10,Alberta,N06DA,Anticholinesterases,65+,Total,"1,598.31",0.2,1.1,"5,975",77
10,Alberta,A09AA,Enzyme preparations,65+,Total,"1,514.39",0.2,0.3,"1,726",78
10,Alberta,N07BC,Drugs used in opioid dependence,65+,Total,**,**,**,**,79
10,Alberta,R01AD,Corticosteroids,65+,Total,"1,405.84",0.2,6.4,"35,374",80
10,Alberta,B01AA,Vitamin K antagonists,65+,Total,"1,342.24",0.2,2.3,"12,545",81
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,Total,"1,241.42",0.2,0.1,746,82
10,Alberta,A12BA,Potassium,65+,Total,"1,213.04",0.2,2.9,"16,238",83
10,Alberta,C03BA,"Sulfonamides, plain",65+,Total,"1,179.54",0.2,3.2,"17,725",84
10,Alberta,D05AX,Other antipsoriatics for topical use,65+,Total,"1,138.72",0.2,0.8,"4,575",85
10,Alberta,G03DA,Pregnen (4) derivatives,65+,Total,"1,067.38",0.2,0.6,"3,299",86
10,Alberta,A04AD,Other antiemetics,65+,Total,"1,009.12",0.1,0.3,"1,907",87
10,Alberta,A16AB,Enzymes,65+,Total,**,**,**,*,88
10,Alberta,J01MA,Fluoroquinolones,65+,Total,972.89,0.1,7.6,"42,172",89
10,Alberta,L03AX,Other immunostimulants,65+,Total,958.18,0.1,0.0,74,90
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,65+,Total,947.82,0.1,0.5,"2,676",91
10,Alberta,J02AC,Triazole derivatives,65+,Total,940.53,0.1,1.4,"7,710",92
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,931.94,0.1,0.3,"1,418",93
10,Alberta,C10AB,Fibrates,65+,Total,923.11,0.1,1.2,"6,565",94
10,Alberta,N06BA,Centrally acting sympathomimetics,65+,Total,897.09,0.1,0.3,"1,641",95
10,Alberta,S01EC,Carbonic anhydrase inhibitors,65+,Total,879.46,0.1,1.0,"5,548",96
10,Alberta,D01AC,Imidazole and triazole derivatives,65+,Total,866.82,0.1,2.7,"14,834",97
10,Alberta,C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,65+,Total,853.40,0.1,0.7,"4,021",98
10,Alberta,M01AE,Propionic acid derivatives,65+,Total,843.11,0.1,4.3,"23,708",99
10,Alberta,N04BC,Dopamine agonists,65+,Total,811.64,0.1,0.9,"4,930",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,"22,807.29",6.9,0.4,"1,122",1
10,Alberta,B01AF,Direct factor Xa inhibitors,65+,M,"21,700.98",6.5,9.4,"24,300",2
10,Alberta,C10AA,HMG-CoA reductase inhibitors,65+,M,"12,978.60",3.9,55.8,"143,886",3
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"12,694.10",3.8,5.7,"14,623",4
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"11,965.18",3.6,5.6,"14,481",5
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"11,084.07",3.3,6.1,"15,850",6
10,Alberta,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,M,"7,715.32",2.3,3.3,"8,444",7
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"7,463.37",2.2,3.0,"7,846",8
10,Alberta,L04AA,Selective immunosuppressants,65+,M,"6,993.21",2.1,0.3,754,9
10,Alberta,J05AP,Antivirals for treatment of HCV infections,65+,M,"6,896.39",2.1,0.1,134,10
10,Alberta,A02BC,Proton pump inhibitors,65+,M,"6,821.12",2.0,30.2,"77,751",11
10,Alberta,R03BB,Anticholinergics,65+,M,"6,690.04",2.0,7.0,"18,147",12
10,Alberta,C09AA,"ACE inhibitors, plain",65+,M,"6,381.18",1.9,27.7,"71,432",13
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,"6,287.98",1.9,1.4,"3,658",14
10,Alberta,L04AX,Other immunosuppressants,65+,M,"5,860.38",1.8,0.5,"1,232",15
10,Alberta,L04AC,Interleukin inhibitors,65+,M,"5,755.41",1.7,0.1,353,16
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,"5,738.42",1.7,18.2,"46,844",17
10,Alberta,S01LA,Antineovascularization agents,65+,M,**,**,**,**,18
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"5,497.08",1.7,23.7,"61,210",19
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"4,850.72",1.5,0.1,220,20
10,Alberta,C08CA,Dihydropyridine derivatives,65+,M,"4,765.85",1.4,21.2,"54,662",21
10,Alberta,B03XA,Other antianemic preparations,65+,M,"4,703.51",1.4,0.4,"1,125",22
10,Alberta,C07AB,"Beta-blocking agents, selective",65+,M,"4,682.95",1.4,23.6,"60,940",23
10,Alberta,L01EX,Other protein kinase inhibitors,65+,M,"4,239.93",1.3,0.1,186,24
10,Alberta,B01AB,Heparin group,65+,M,"3,849.94",1.2,1.0,"2,648",25
10,Alberta,N02AA,Natural opium alkaloids,65+,M,"3,615.32",1.1,3.5,"9,121",26
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",65+,M,"3,533.76",1.1,12.0,"30,864",27
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"3,513.06",1.1,2.8,"7,175",28
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"3,408.70",1.0,1.9,"4,889",29
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"3,381.05",1.0,5.7,"14,614",30
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,"3,236.02",1.0,0.5,"1,347",31
10,Alberta,N04BA,Dopa and dopa derivatives,65+,M,"3,133.05",0.9,1.4,"3,636",32
10,Alberta,N06AX,Other antidepressants,65+,M,"3,127.67",0.9,9.0,"23,185",33
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"3,036.43",0.9,9.5,"24,576",34
10,Alberta,N03AX,Other antiepileptics,65+,M,"3,008.54",0.9,8.2,"21,229",35
10,Alberta,A10BA,Biguanides,65+,M,"3,007.69",0.9,18.2,"47,002",36
10,Alberta,H01CB,Somatostatin and analogues,65+,M,"2,788.48",0.8,0.1,130,37
10,Alberta,H03AA,Thyroid hormones,65+,M,"2,768.43",0.8,13.5,"34,891",38
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,65+,M,"2,365.95",0.7,7.3,"18,865",39
10,Alberta,R03BA,Glucocorticoids,65+,M,"2,234.98",0.7,3.7,"9,473",40
10,Alberta,C09BA,ACE inhibitors and diuretics,65+,M,"2,099.38",0.6,5.2,"13,437",41
10,Alberta,S01ED,Beta-blocking agents,65+,M,"2,080.74",0.6,3.5,"9,017",42
10,Alberta,A07EC,Aminosalicylic acid and similar agents,65+,M,"1,997.59",0.6,0.8,"2,021",43
10,Alberta,C08DB,Benzothiazepine derivatives,65+,M,"1,950.58",0.6,2.5,"6,514",44
10,Alberta,B01AE,Direct thrombin inhibitors,65+,M,"1,932.88",0.6,0.8,"2,018",45
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,M,"1,913.79",0.6,6.9,"17,729",46
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,65+,M,"1,800.33",0.5,2.6,"6,696",47
10,Alberta,S01EE,Prostaglandin analogues,65+,M,"1,694.63",0.5,3.7,"9,484",48
10,Alberta,M04AA,Preparations inhibiting uric acid production,65+,M,"1,611.04",0.5,7.4,"19,166",49
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,"1,521.46",0.5,10.8,"27,806",50
10,Alberta,N05CF,Benzodiazepine-related drugs,65+,M,"1,429.26",0.4,8.6,"22,069",51
10,Alberta,C03CA,"Sulfonamides, plain",65+,M,"1,338.94",0.4,8.5,"21,905",52
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"1,259.88",0.4,9.6,"24,838",53
10,Alberta,N05AX,Other antipsychotics,65+,M,"1,244.27",0.4,0.9,"2,309",54
10,Alberta,C07AG,Alpha- and beta-blocking agents,65+,M,"1,240.98",0.4,2.4,"6,090",55
10,Alberta,A10BB,Sulfonylureas,65+,M,"1,174.71",0.4,5.7,"14,673",56
10,Alberta,L03AA,Colony-stimulating factors,65+,M,"1,119.67",0.3,0.1,255,57
10,Alberta,C01DA,Organic nitrates,65+,M,"1,068.95",0.3,5.4,"13,860",58
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"1,056.37",0.3,2.5,"6,457",59
10,Alberta,A04AA,Serotonin (5HT3) antagonists,65+,M,"1,023.56",0.3,1.5,"3,788",60
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,"1,011.22",0.3,0.3,706,61
10,Alberta,C10AX,Other lipid-modifying agents,65+,M,936.32,0.3,2.4,"6,080",62
10,Alberta,C03DA,Aldosterone antagonists,65+,M,918.37,0.3,3.6,"9,290",63
10,Alberta,L01XC,Monoclonal antibodies,65+,M,871.34,0.3,0.0,66,64
10,Alberta,D07AC,"Corticosteroids, potent (group III)",65+,M,869.22,0.3,9.3,"23,856",65
10,Alberta,M01AB,Acetic acid derivatives and related substances,65+,M,866.69,0.3,7.4,"19,063",66
10,Alberta,M05BA,Bisphosphonates,65+,M,854.16,0.3,2.7,"6,945",67
10,Alberta,H02AB,Glucocorticoids,65+,M,785.92,0.2,8.9,"22,910",68
10,Alberta,A07AA,Antibiotics,65+,M,781.81,0.2,1.0,"2,648",69
10,Alberta,C03AA,"Thiazides, plain",65+,M,757.86,0.2,6.5,"16,701",70
10,Alberta,A09AA,Enzyme preparations,65+,M,752.67,0.2,0.3,785,71
10,Alberta,N07BC,Drugs used in opioid dependence,65+,M,**,**,**,**,72
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,735.66,0.2,0.2,463,73
10,Alberta,B01AA,Vitamin K antagonists,65+,M,731.70,0.2,2.8,"7,119",74
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,695.55,0.2,2.9,"7,416",75
10,Alberta,D05AX,Other antipsoriatics for topical use,65+,M,672.30,0.2,1.0,"2,537",76
10,Alberta,R01AD,Corticosteroids,65+,M,656.35,0.2,6.0,"15,587",77
10,Alberta,L01BA,Folic acid analogues,65+,M,653.67,0.2,1.1,"2,868",78
10,Alberta,A16AB,Enzymes,65+,M,**,**,**,*,79
10,Alberta,N06DA,Anticholinesterases,65+,M,606.17,0.2,0.9,"2,338",80
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,582.83,0.2,2.1,"5,491",81
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,536.62,0.2,0.3,774,82
10,Alberta,C03BA,"Sulfonamides, plain",65+,M,531.48,0.2,3.2,"8,146",83
10,Alberta,N05BA,Benzodiazepine derivatives,65+,M,514.07,0.2,4.0,"10,253",84
10,Alberta,C10AB,Fibrates,65+,M,511.60,0.2,1.4,"3,692",85
10,Alberta,J02AC,Triazole derivatives,65+,M,491.35,0.1,0.7,"1,844",86
10,Alberta,G03BA,3-oxoandrosten (4) derivatives,65+,M,473.82,0.1,1.0,"2,523",87
10,Alberta,J01MA,Fluoroquinolones,65+,M,468.07,0.1,7.4,"19,110",88
10,Alberta,C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,65+,M,455.27,0.1,0.8,"2,120",89
10,Alberta,V03AC,Iron-chelating agents,65+,M,438.10,0.1,0.0,48,90
10,Alberta,D01AC,Imidazole and triazole derivatives,65+,M,426.37,0.1,2.8,"7,168",91
10,Alberta,S01EC,Carbonic anhydrase inhibitors,65+,M,424.64,0.1,1.1,"2,720",92
10,Alberta,M04AC,Preparations with no effect on uric acid metabolism,65+,M,423.76,0.1,4.0,"10,198",93
10,Alberta,A12BA,Potassium,65+,M,420.75,0.1,2.3,"5,918",94
10,Alberta,A10BX,"Other blood glucose–lowering drugs, excluding insulins",65+,M,409.83,0.1,1.4,"3,591",95
10,Alberta,A04AD,Other antiemetics,65+,M,406.48,0.1,0.3,761,96
10,Alberta,J01DB,First-generation cephalosporins,65+,M,406.37,0.1,7.5,"19,444",97
10,Alberta,N06BA,Centrally acting sympathomimetics,65+,M,394.08,0.1,0.3,719,98
10,Alberta,M01AE,Propionic acid derivatives,65+,M,390.37,0.1,4.3,"11,005",99
10,Alberta,D06AX,Other antibiotics for topical use,65+,M,382.03,0.1,4.8,"12,361",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,"26,790.29",7.6,0.5,"1,469",1
10,Alberta,B01AF,Direct factor Xa inhibitors,65+,F,"19,111.17",5.4,7.3,"21,632",2
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"13,357.66",3.8,6.6,"19,554",3
10,Alberta,C10AA,HMG-CoA reductase inhibitors,65+,F,"10,630.90",3.0,39.7,"117,698",4
10,Alberta,L04AA,Selective immunosuppressants,65+,F,"10,630.30",3.0,0.5,"1,449",5
10,Alberta,A02BC,Proton pump inhibitors,65+,F,"9,140.94",2.6,33.4,"98,899",6
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"8,448.76",2.4,3.6,"10,773",7
10,Alberta,S01LA,Antineovascularization agents,65+,F,**,**,**,**,8
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"7,977.04",2.3,20.5,"60,889",9
10,Alberta,H03AA,Thyroid hormones,65+,F,"7,469.05",2.1,29.5,"87,464",10
10,Alberta,L04AC,Interleukin inhibitors,65+,F,"6,882.11",2.0,0.2,479,11
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"6,719.34",1.9,2.8,"8,346",12
10,Alberta,N06AX,Other antidepressants,65+,F,"6,568.83",1.9,14.5,"42,896",13
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"6,539.64",1.9,10.7,"31,841",14
10,Alberta,R03BB,Anticholinergics,65+,F,"6,513.71",1.8,6.1,"18,064",15
10,Alberta,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,F,"6,334.14",1.8,2.4,"6,970",16
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",65+,F,"6,333.42",1.8,17.2,"50,901",17
10,Alberta,C09AA,"ACE inhibitors, plain",65+,F,"5,552.82",1.6,19.4,"57,405",18
10,Alberta,C08CA,Dihydropyridine derivatives,65+,F,"5,522.13",1.6,20.6,"60,971",19
10,Alberta,M05BA,Bisphosphonates,65+,F,"5,139.12",1.5,14.1,"41,900",20
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,"5,113.10",1.5,1.0,"3,059",21
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,65+,F,"5,111.41",1.5,13.4,"39,618",22
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"4,987.58",1.4,0.1,233,23
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"4,747.17",1.3,1.7,"5,052",24
10,Alberta,C07AB,"Beta-blocking agents, selective",65+,F,"4,284.83",1.2,17.2,"50,915",25
10,Alberta,N02AA,Natural opium alkaloids,65+,F,"4,270.48",1.2,4.2,"12,392",26
10,Alberta,N03AX,Other antiepileptics,65+,F,"4,255.15",1.2,10.4,"30,944",27
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,65+,F,"3,952.09",1.1,4.8,"14,187",28
10,Alberta,L04AX,Other immunosuppressants,65+,F,"3,357.19",1.0,0.6,"1,670",29
10,Alberta,B03XA,Other antianemic preparations,65+,F,"3,134.94",0.9,0.3,801,30
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"3,130.50",0.9,1.6,"4,666",31
10,Alberta,B01AB,Heparin group,65+,F,"3,128.68",0.9,1.1,"3,121",32
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"2,938.37",0.8,1.5,"4,471",33
10,Alberta,J05AP,Antivirals for treatment of HCV infections,65+,F,"2,892.02",0.8,0.0,53,34
10,Alberta,R03BA,Glucocorticoids,65+,F,"2,856.58",0.8,4.3,"12,733",35
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"2,692.48",0.8,0.6,"1,734",36
10,Alberta,C08DB,Benzothiazepine derivatives,65+,F,"2,530.11",0.7,2.9,"8,623",37
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,"2,471.75",0.7,7.4,"21,939",38
10,Alberta,N05CF,Benzodiazepine-related drugs,65+,F,"2,422.03",0.7,12.2,"36,266",39
10,Alberta,S01ED,Beta-blocking agents,65+,F,"2,396.03",0.7,3.3,"9,799",40
10,Alberta,A10BA,Biguanides,65+,F,"2,359.47",0.7,12.2,"36,107",41
10,Alberta,H01CB,Somatostatin and analogues,65+,F,"2,267.32",0.6,0.0,131,42
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"2,223.63",0.6,1.8,"5,413",43
10,Alberta,S01EE,Prostaglandin analogues,65+,F,"2,153.32",0.6,3.9,"11,700",44
10,Alberta,N05AX,Other antipsychotics,65+,F,"1,992.70",0.6,1.3,"3,731",45
10,Alberta,L01EX,Other protein kinase inhibitors,65+,F,"1,965.02",0.6,0.0,93,46
10,Alberta,N04BA,Dopa and dopa derivatives,65+,F,"1,948.36",0.6,0.9,"2,680",47
10,Alberta,A07EC,Aminosalicylic acid and similar agents,65+,F,"1,940.46",0.6,0.8,"2,263",48
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"1,894.09",0.5,10.3,"30,567",49
10,Alberta,A04AA,Serotonin (5HT3) antagonists,65+,F,"1,829.60",0.5,2.2,"6,564",50
10,Alberta,L03AA,Colony-stimulating factors,65+,F,"1,781.40",0.5,0.1,355,51
10,Alberta,C09BA,ACE inhibitors and diuretics,65+,F,"1,720.39",0.5,3.7,"10,944",52
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"1,698.02",0.5,2.9,"8,632",53
10,Alberta,L01XC,Monoclonal antibodies,65+,F,"1,681.20",0.5,0.0,140,54
10,Alberta,C03CA,"Sulfonamides, plain",65+,F,"1,673.29",0.5,8.5,"25,267",55
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"1,518.08",0.4,11.2,"33,183",56
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"1,415.42",0.4,4.2,"12,514",57
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"1,386.05",0.4,3.0,"9,005",58
10,Alberta,B01AE,Direct thrombin inhibitors,65+,F,"1,306.46",0.4,0.4,"1,306",59
10,Alberta,C03AA,"Thiazides, plain",65+,F,"1,244.20",0.4,8.8,"26,050",60
10,Alberta,L01BA,Folic acid analogues,65+,F,"1,164.37",0.3,1.7,"5,138",61
10,Alberta,N05BA,Benzodiazepine derivatives,65+,F,"1,122.07",0.3,7.5,"22,249",62
10,Alberta,G03DA,Pregnen (4) derivatives,65+,F,"1,057.72",0.3,1.1,"3,251",63
10,Alberta,C01DA,Organic nitrates,65+,F,"1,011.78",0.3,3.4,"10,149",64
10,Alberta,N06DA,Anticholinesterases,65+,F,992.14,0.3,1.2,"3,637",65
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,969.23,0.3,0.1,394,66
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,913.08,0.3,4.4,"12,993",67
10,Alberta,H02AB,Glucocorticoids,65+,F,906.22,0.3,8.9,"26,368",68
10,Alberta,C07AG,Alpha- and beta-blocking agents,65+,F,860.26,0.2,1.4,"4,171",69
10,Alberta,A07AA,Antibiotics,65+,F,831.88,0.2,1.6,"4,742",70
10,Alberta,A10BB,Sulfonylureas,65+,F,815.22,0.2,3.4,"10,019",71
10,Alberta,D07AC,"Corticosteroids, potent (group III)",65+,F,812.75,0.2,8.8,"26,073",72
10,Alberta,M01AB,Acetic acid derivatives and related substances,65+,F,806.98,0.2,5.4,"16,091",73
10,Alberta,A12BA,Potassium,65+,F,792.29,0.2,3.5,"10,320",74
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,65+,F,790.53,0.2,0.7,"2,219",75
10,Alberta,A09AA,Enzyme preparations,65+,F,761.72,0.2,0.3,941,76
10,Alberta,R01AD,Corticosteroids,65+,F,749.49,0.2,6.7,"19,787",77
10,Alberta,C10AX,Other lipid-modifying agents,65+,F,744.10,0.2,1.5,"4,352",78
10,Alberta,C03DA,Aldosterone antagonists,65+,F,713.45,0.2,2.9,"8,507",79
10,Alberta,N07BC,Drugs used in opioid dependence,65+,F,**,**,**,**,80
10,Alberta,L03AX,Other immunostimulants,65+,F,658.63,0.2,0.0,52,81
10,Alberta,C03BA,"Sulfonamides, plain",65+,F,648.06,0.2,3.2,"9,579",82
10,Alberta,M04AA,Preparations inhibiting uric acid production,65+,F,622.70,0.2,2.4,"7,156",83
10,Alberta,B01AA,Vitamin K antagonists,65+,F,610.54,0.2,1.8,"5,426",84
10,Alberta,A04AD,Other antiemetics,65+,F,602.64,0.2,0.4,"1,146",85
10,Alberta,L03AB,Interferons,65+,F,593.81,0.2,0.0,33,86
10,Alberta,A05AA,Bile acids and derivatives,65+,F,569.36,0.2,0.3,841,87
10,Alberta,J01XE,Nitrofuran derivatives,65+,F,541.41,0.2,7.2,"21,460",88
10,Alberta,G03EB,"Androgen, progestogen and estrogen in combination",65+,F,536.39,0.2,0.4,"1,121",89
10,Alberta,P01BA,Aminoquinolines,65+,F,531.12,0.2,1.7,"4,983",90
10,Alberta,A03FA,Propulsives,65+,F,514.09,0.1,3.1,"9,215",91
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,F,505.76,0.1,0.1,283,92
10,Alberta,J01MA,Fluoroquinolones,65+,F,504.81,0.1,7.8,"23,062",93
10,Alberta,N06BA,Centrally acting sympathomimetics,65+,F,503.01,0.1,0.3,922,94
10,Alberta,N04BC,Dopamine agonists,65+,F,495.84,0.1,1.1,"3,120",95
10,Alberta,N03AE,Benzodiazepine derivatives,65+,F,470.74,0.1,2.2,"6,441",96
10,Alberta,D05AX,Other antipsoriatics for topical use,65+,F,466.42,0.1,0.7,"2,038",97
10,Alberta,S01EC,Carbonic anhydrase inhibitors,65+,F,454.82,0.1,1.0,"2,828",98
10,Alberta,M01AE,Propionic acid derivatives,65+,F,452.75,0.1,4.3,"12,703",99
10,Alberta,S01BA,"Corticosteroids, plain",65+,F,451.47,0.1,3.9,"11,456",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,"114,485.55",37.8,6.7,"5,817",1
10,Alberta,L04AA,Selective immunosuppressants,<65,Total,"34,286.12",11.3,2.5,"2,176",2
10,Alberta,L04AC,Interleukin inhibitors,<65,Total,"17,939.64",5.9,1.5,"1,271",3
10,Alberta,J05AP,Antivirals for treatment of HCV infections,<65,Total,"12,720.21",4.2,0.3,260,4
10,Alberta,L04AX,Other immunosuppressants,<65,Total,"10,036.90",3.3,1.9,"1,645",5
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"7,527.09",2.5,0.5,407,6
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,<65,Total,"6,689.68",2.2,0.0,18,7
10,Alberta,L03AX,Other immunostimulants,<65,Total,"5,681.34",1.9,0.6,518,8
10,Alberta,L03AB,Interferons,<65,Total,"4,259.16",1.4,0.3,250,9
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"4,021.03",1.3,5.1,"4,472",10
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"3,703.38",1.2,2.2,"1,931",11
10,Alberta,R07AX,Other respiratory system products,<65,Total,"3,623.22",1.2,0.0,16,12
10,Alberta,A16AB,Enzymes,<65,Total,**,**,**,**,13
10,Alberta,N02AA,Natural opium alkaloids,<65,Total,"3,026.65",1.0,4.2,"3,679",14
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,"2,506.46",0.8,1.9,"1,637",15
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"2,494.33",0.8,4.1,"3,576",16
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"2,430.70",0.8,5.2,"4,553",17
10,Alberta,N06BA,Centrally acting sympathomimetics,<65,Total,"2,329.00",0.8,4.0,"3,443",18
10,Alberta,A16AX,Various alimentary tract and metabolism products,<65,Total,**,**,**,**,19
10,Alberta,H01CB,Somatostatin and analogues,<65,Total,"1,901.72",0.6,0.1,101,20
10,Alberta,N06AX,Other antidepressants,<65,Total,"1,779.14",0.6,14.5,"12,630",21
10,Alberta,B03XA,Other antianemic preparations,<65,Total,"1,597.43",0.5,0.4,355,22
10,Alberta,N03AX,Other antiepileptics,<65,Total,"1,556.61",0.5,9.3,"8,083",23
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"1,554.30",0.5,2.3,"2,002",24
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,546.34",0.5,3.6,"3,110",25
10,Alberta,N05AX,Other antipsychotics,<65,Total,"1,545.74",0.5,2.0,"1,729",26
10,Alberta,B01AB,Heparin group,<65,Total,"1,498.45",0.5,0.9,754,27
10,Alberta,L01XC,Monoclonal antibodies,<65,Total,"1,414.38",0.5,0.1,119,28
10,Alberta,A07EC,Aminosalicylic acid and similar agents,<65,Total,"1,304.79",0.4,1.7,"1,520",29
10,Alberta,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,294.91",0.4,23.1,"20,088",30
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"1,291.57",0.4,14.1,"12,282",31
10,Alberta,A02BC,Proton pump inhibitors,<65,Total,"1,264.63",0.4,22.4,"19,487",32
10,Alberta,B01AF,Direct factor Xa inhibitors,<65,Total,"1,050.59",0.3,1.8,"1,601",33
10,Alberta,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,Total,"1,038.07",0.3,1.6,"1,388",34
10,Alberta,L03AA,Colony-stimulating factors,<65,Total,"1,013.37",0.3,0.2,205,35
10,Alberta,N07BC,Drugs used in opioid dependence,<65,Total,**,**,**,**,36
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"1,001.88",0.3,0.7,624,37
10,Alberta,A04AA,Serotonin (5HT3) antagonists,<65,Total,907.57,0.3,2.7,"2,347",38
10,Alberta,A16AA,Amino acids and derivatives,<65,Total,905.87,0.3,0.0,13,39
10,Alberta,H03AA,Thyroid hormones,<65,Total,853.74,0.3,14.7,"12,769",40
10,Alberta,V03AC,Iron-chelating agents,<65,Total,832.58,0.3,0.0,39,41
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,815.26,0.3,4.1,"3,573",42
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,810.57,0.3,6.0,"5,196",43
10,Alberta,A09AA,Enzyme preparations,<65,Total,770.55,0.3,0.4,391,44
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,691.11,0.2,9.0,"7,816",45
10,Alberta,C09AA,"ACE inhibitors, plain",<65,Total,666.17,0.2,11.6,"10,068",46
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,<65,Total,664.54,0.2,2.9,"2,494",47
10,Alberta,J01DF,Monobactams,<65,Total,**,**,**,**,48
10,Alberta,R03BA,Glucocorticoids,<65,Total,640.95,0.2,4.5,"3,880",49
10,Alberta,R03BB,Anticholinergics,<65,Total,599.42,0.2,2.5,"2,152",50
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",<65,Total,579.69,0.2,7.6,"6,632",51
10,Alberta,N05AE,Indole derivatives,<65,Total,524.06,0.2,0.5,413,52
10,Alberta,C08CA,Dihydropyridine derivatives,<65,Total,494.32,0.2,8.6,"7,517",53
10,Alberta,H01AC,Somatropin and somatropin agonists,<65,Total,488.52,0.2,0.1,62,54
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,479.57,0.2,9.2,"8,015",55
10,Alberta,J01GB,Other aminoglycosides,<65,Total,452.83,0.1,0.1,71,56
10,Alberta,A04AD,Other antiemetics,<65,Total,441.23,0.1,0.7,616,57
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,439.06,0.1,4.9,"4,263",58
10,Alberta,G03DA,Pregnen (4) derivatives,<65,Total,420.18,0.1,1.9,"1,611",59
10,Alberta,A05AA,Bile acids and derivatives,<65,Total,405.50,0.1,0.3,287,60
10,Alberta,L01EX,Other protein kinase inhibitors,<65,Total,403.16,0.1,0.0,17,61
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,395.41,0.1,4.0,"3,487",62
10,Alberta,L01BA,Folic acid analogues,<65,Total,391.32,0.1,2.5,"2,209",63
10,Alberta,A10BA,Biguanides,<65,Total,384.39,0.1,9.5,"8,227",64
10,Alberta,N05CF,Benzodiazepine-related drugs,<65,Total,382.35,0.1,7.9,"6,874",65
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,<65,Total,362.32,0.1,1.9,"1,663",66
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,360.14,0.1,0.2,164,67
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,346.52,0.1,10.4,"9,082",68
10,Alberta,C07AB,"Beta-blocking agents, selective",<65,Total,344.69,0.1,6.9,"6,016",69
10,Alberta,C09BA,ACE inhibitors and diuretics,<65,Total,308.19,0.1,2.9,"2,523",70
10,Alberta,A07AA,Antibiotics,<65,Total,302.83,0.1,1.2,"1,023",71
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,299.14,0.1,1.4,"1,181",72
10,Alberta,S01LA,Antineovascularization agents,<65,Total,297.86,0.1,0.0,35,73
10,Alberta,H02AB,Glucocorticoids,<65,Total,289.69,0.1,9.1,"7,920",74
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,Total,276.04,0.1,3.8,"3,282",75
10,Alberta,S01XA,Other ophthalmologicals,<65,Total,**,**,**,**,76
10,Alberta,N02AB,Phenylpiperidine derivatives,<65,Total,270.86,0.1,0.4,370,77
10,Alberta,C10AX,Other lipid-modifying agents,<65,Total,266.66,0.1,0.8,707,78
10,Alberta,N05BA,Benzodiazepine derivatives,<65,Total,264.31,0.1,6.8,"5,914",79
10,Alberta,M01AB,Acetic acid derivatives and related substances,<65,Total,244.16,0.1,6.7,"5,803",80
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,243.11,0.1,0.5,430,81
10,Alberta,M03BX,Other centrally acting agents,<65,Total,240.72,0.1,5.4,"4,695",82
10,Alberta,P01AX,Other agents against amebiasis and other protozoal diseases,<65,Total,234.53,0.1,0.1,54,83
10,Alberta,M05BA,Bisphosphonates,<65,Total,232.48,0.1,2.6,"2,233",84
10,Alberta,J02AC,Triazole derivatives,<65,Total,228.24,0.1,2.0,"1,763",85
10,Alberta,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,**,**,**,**,86
10,Alberta,C08DB,Benzothiazepine derivatives,<65,Total,218.77,0.1,1.0,897,87
10,Alberta,D05AX,Other antipsoriatics for topical use,<65,Total,209.67,0.1,0.9,800,88
10,Alberta,J01MA,Fluoroquinolones,<65,Total,198.22,0.1,4.6,"4,032",89
10,Alberta,C01CA,Adrenergic and dopaminergic agents,<65,Total,194.13,0.1,1.6,"1,427",90
10,Alberta,G02BA,Intrauterine contraceptives,<65,Total,189.43,0.1,0.7,572,91
10,Alberta,N07XX,Other nervous system drugs,<65,Total,176.87,0.1,0.0,21,92
10,Alberta,V04CJ,Tests for thyreoidea function,<65,Total,173.16,0.1,0.1,84,93
10,Alberta,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,168.86,0.1,2.4,"2,088",94
10,Alberta,C07AG,Alpha- and beta-blocking agents,<65,Total,164.74,0.1,1.0,853,95
10,Alberta,M01AE,Propionic acid derivatives,<65,Total,156.82,0.1,5.4,"4,686",96
10,Alberta,A10BB,Sulfonylureas,<65,Total,156.18,0.1,2.9,"2,540",97
10,Alberta,N03AG,Fatty acid derivatives,<65,Total,153.40,0.1,0.9,740,98
10,Alberta,P01BA,Aminoquinolines,<65,Total,151.07,0.0,2.0,"1,754",99
10,Alberta,N03AF,Carboxamide derivatives,<65,Total,150.43,0.0,0.7,623,100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,"62,235.00",43.5,9.2,"2,901",1
10,Alberta,L04AA,Selective immunosuppressants,<65,M,"11,963.51",8.4,2.1,673,2
10,Alberta,L04AC,Interleukin inhibitors,<65,M,"9,347.40",6.5,2.0,636,3
10,Alberta,J05AP,Antivirals for treatment of HCV infections,<65,M,"8,797.64",6.1,0.6,179,4
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,<65,M,"3,527.31",2.5,0.0,10,5
10,Alberta,L04AX,Other immunosuppressants,<65,M,"3,173.22",2.2,2.0,649,6
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"2,719.56",1.9,0.4,142,7
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"2,340.78",1.6,7.4,"2,347",8
10,Alberta,R07AX,Other respiratory system products,<65,M,"2,139.89",1.5,0.0,10,9
10,Alberta,A16AB,Enzymes,<65,M,**,**,**,**,10
10,Alberta,L03AX,Other immunostimulants,<65,M,"1,629.82",1.1,0.4,139,11
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"1,454.60",1.0,6.2,"1,971",12
10,Alberta,N02AA,Natural opium alkaloids,<65,M,"1,355.97",0.9,4.6,"1,459",13
10,Alberta,L03AB,Interferons,<65,M,"1,179.09",0.8,0.2,65,14
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,"1,164.89",0.8,2.3,735,15
10,Alberta,N06BA,Centrally acting sympathomimetics,<65,M,"1,153.55",0.8,5.3,"1,685",16
10,Alberta,H01CB,Somatostatin and analogues,<65,M,"1,090.88",0.8,0.2,48,17
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,989.60,0.7,5.5,"1,732",18
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,920.70,0.6,5.2,"1,636",19
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,879.71,0.6,3.4,"1,065",20
10,Alberta,A16AA,Amino acids and derivatives,<65,M,877.16,0.6,0.0,7,21
10,Alberta,B03XA,Other antianemic preparations,<65,M,842.54,0.6,0.6,193,22
10,Alberta,N05AX,Other antipsychotics,<65,M,825.43,0.6,2.4,749,23
10,Alberta,C10AA,HMG-CoA reductase inhibitors,<65,M,683.93,0.5,30.0,"9,506",24
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,648.51,0.5,1.2,394,25
10,Alberta,A07EC,Aminosalicylic acid and similar agents,<65,M,613.15,0.4,2.0,621,26
10,Alberta,B01AF,Direct factor Xa inhibitors,<65,M,584.42,0.4,2.6,824,27
10,Alberta,B01AB,Heparin group,<65,M,580.57,0.4,0.9,288,28
10,Alberta,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,M,535.69,0.4,2.2,682,29
10,Alberta,N07BC,Drugs used in opioid dependence,<65,M,**,**,**,**,30
10,Alberta,N03AX,Other antiepileptics,<65,M,508.59,0.4,8.1,"2,552",31
10,Alberta,N06AX,Other antidepressants,<65,M,488.01,0.3,11.1,"3,521",32
10,Alberta,A02BC,Proton pump inhibitors,<65,M,481.75,0.3,22.1,"7,015",33
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,451.96,0.3,0.8,259,34
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,425.47,0.3,3.9,"1,251",35
10,Alberta,A09AA,Enzyme preparations,<65,M,422.50,0.3,0.6,186,36
10,Alberta,V03AC,Iron-chelating agents,<65,M,414.91,0.3,0.1,20,37
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,<65,M,386.45,0.3,10.8,"3,437",38
10,Alberta,L01XC,Monoclonal antibodies,<65,M,374.35,0.3,0.1,32,39
10,Alberta,C09AA,"ACE inhibitors, plain",<65,M,355.50,0.2,15.6,"4,945",40
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,291.63,0.2,9.3,"2,950",41
10,Alberta,J01GB,Other aminoglycosides,<65,M,285.08,0.2,0.1,37,42
10,Alberta,L01EX,Other protein kinase inhibitors,<65,M,273.24,0.2,0.0,12,43
10,Alberta,H01AC,Somatropin and somatropin agonists,<65,M,**,**,**,**,44
10,Alberta,C08CA,Dihydropyridine derivatives,<65,M,264.68,0.2,11.1,"3,517",45
10,Alberta,R03BA,Glucocorticoids,<65,M,262.43,0.2,4.6,"1,454",46
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,262.39,0.2,0.4,119,47
10,Alberta,J01DF,Monobactams,<65,M,**,**,**,**,48
10,Alberta,S01XA,Other ophthalmologicals,<65,M,**,**,**,**,49
10,Alberta,R03BB,Anticholinergics,<65,M,244.58,0.2,2.7,840,50
10,Alberta,A04AA,Serotonin (5HT3) antagonists,<65,M,213.33,0.1,2.0,622,51
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,212.66,0.1,2.3,744,52
10,Alberta,L03AA,Colony-stimulating factors,<65,M,212.48,0.1,0.1,41,53
10,Alberta,C07AB,"Beta-blocking agents, selective",<65,M,200.19,0.1,9.9,"3,142",54
10,Alberta,A10BA,Biguanides,<65,M,193.87,0.1,11.8,"3,753",55
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,175.29,0.1,9.7,"3,076",56
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",<65,M,168.99,0.1,6.1,"1,929",57
10,Alberta,S01LA,Antineovascularization agents,<65,M,**,**,**,**,58
10,Alberta,C09BA,ACE inhibitors and diuretics,<65,M,162.08,0.1,3.8,"1,201",59
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,158.72,0.1,3.4,"1,084",60
10,Alberta,N05AE,Indole derivatives,<65,M,158.43,0.1,0.4,126,61
10,Alberta,H03AA,Thyroid hormones,<65,M,157.99,0.1,6.7,"2,130",62
10,Alberta,C10AX,Other lipid-modifying agents,<65,M,149.53,0.1,1.3,421,63
10,Alberta,A04AD,Other antiemetics,<65,M,147.10,0.1,0.7,210,64
10,Alberta,A07AA,Antibiotics,<65,M,144.39,0.1,1.0,312,65
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,143.02,0.1,10.7,"3,386",66
10,Alberta,G03BA,3-oxoandrosten (4) derivatives,<65,M,137.16,0.1,2.1,678,67
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,<65,M,133.43,0.1,1.0,326,68
10,Alberta,L01BA,Folic acid analogues,<65,M,133.29,0.1,2.3,740,69
10,Alberta,N05CF,Benzodiazepine-related drugs,<65,M,125.61,0.1,6.5,"2,050",70
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,<65,M,119.75,0.1,5.9,"1,883",71
10,Alberta,H02AB,Glucocorticoids,<65,M,118.90,0.1,9.5,"3,020",72
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,M,118.49,0.1,4.0,"1,255",73
10,Alberta,D05AX,Other antipsoriatics for topical use,<65,M,114.38,0.1,1.1,348,74
10,Alberta,C08DB,Benzothiazepine derivatives,<65,M,111.25,0.1,1.2,394,75
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,107.59,0.1,2.7,846,76
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,107.08,0.1,0.6,197,77
10,Alberta,C07AG,Alpha- and beta-blocking agents,<65,M,98.68,0.1,1.5,469,78
10,Alberta,M01AB,Acetic acid derivatives and related substances,<65,M,97.18,0.1,7.2,"2,286",79
10,Alberta,J02AC,Triazole derivatives,<65,M,95.67,0.1,0.8,245,80
10,Alberta,N02AB,Phenylpiperidine derivatives,<65,M,92.99,0.1,0.4,125,81
10,Alberta,M03BX,Other centrally acting agents,<65,M,84.66,0.1,4.8,"1,533",82
10,Alberta,A10BB,Sulfonylureas,<65,M,84.51,0.1,4.1,"1,302",83
10,Alberta,M04AA,Preparations inhibiting uric acid production,<65,M,81.92,0.1,3.9,"1,228",84
10,Alberta,V06C,Infant formulas,<65,M,80.59,0.1,0.0,14,85
10,Alberta,N03AG,Fatty acid derivatives,<65,M,80.13,0.1,1.1,339,86
10,Alberta,N05BA,Benzodiazepine derivatives,<65,M,79.16,0.1,5.1,"1,612",87
10,Alberta,N04BA,Dopa and dopa derivatives,<65,M,77.77,0.1,0.4,112,88
10,Alberta,C01CA,Adrenergic and dopaminergic agents,<65,M,70.95,0.0,1.5,472,89
10,Alberta,H01BA,Vasopressin and analogues,<65,M,69.86,0.0,0.2,57,90
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,<65,M,65.17,0.0,1.0,332,91
10,Alberta,C03DA,Aldosterone antagonists,<65,M,63.29,0.0,2.0,621,92
10,Alberta,P01AX,Other agents against amebiasis and other protozoal diseases,<65,M,63.18,0.0,0.1,20,93
10,Alberta,N03AF,Carboxamide derivatives,<65,M,61.02,0.0,0.8,240,94
10,Alberta,C10AB,Fibrates,<65,M,59.41,0.0,1.6,510,95
10,Alberta,M01AE,Propionic acid derivatives,<65,M,59.35,0.0,5.3,"1,665",96
10,Alberta,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,55.86,0.0,0.5,145,97
10,Alberta,N07XX,Other nervous system drugs,<65,M,55.85,0.0,0.0,12,98
10,Alberta,D07AC,"Corticosteroids, potent (group III)",<65,M,52.91,0.0,5.5,"1,744",99
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,<65,M,52.76,0.0,2.0,635,100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,"52,250.55",32.8,5.3,"2,916",1
10,Alberta,L04AA,Selective immunosuppressants,<65,F,"22,322.61",14.0,2.7,"1,503",2
10,Alberta,L04AC,Interleukin inhibitors,<65,F,"8,592.24",5.4,1.1,635,3
10,Alberta,L04AX,Other immunosuppressants,<65,F,"6,863.68",4.3,1.8,996,4
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"4,807.53",3.0,0.5,265,5
10,Alberta,L03AX,Other immunostimulants,<65,F,"4,051.52",2.5,0.7,379,6
10,Alberta,J05AP,Antivirals for treatment of HCV infections,<65,F,"3,922.57",2.5,0.1,81,7
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"3,251.42",2.0,3.0,"1,672",8
10,Alberta,M09AX,Other drugs for disorders of the musculoskeletal system,<65,F,"3,162.37",2.0,0.0,8,9
10,Alberta,L03AB,Interferons,<65,F,"3,080.07",1.9,0.3,185,10
10,Alberta,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,**,11
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"1,680.25",1.1,3.8,"2,125",12
10,Alberta,N02AA,Natural opium alkaloids,<65,F,"1,670.68",1.0,4.0,"2,220",13
10,Alberta,R07AX,Other respiratory system products,<65,F,"1,483.33",0.9,0.0,6,14
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"1,441.10",0.9,5.1,"2,821",15
10,Alberta,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,"1,341.57",0.8,1.6,902,16
10,Alberta,N06AX,Other antidepressants,<65,F,"1,291.13",0.8,16.5,"9,109",17
10,Alberta,N06BA,Centrally acting sympathomimetics,<65,F,"1,175.44",0.7,3.2,"1,758",18
10,Alberta,A16AB,Enzymes,<65,F,**,**,**,*,19
10,Alberta,N03AX,Other antiepileptics,<65,F,"1,048.02",0.7,10.0,"5,531",20
10,Alberta,L01XC,Monoclonal antibodies,<65,F,"1,040.03",0.7,0.2,87,21
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"1,039.73",0.7,2.9,"1,605",22
10,Alberta,B01AB,Heparin group,<65,F,917.87,0.6,0.8,466,23
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,<65,F,905.12,0.6,16.0,"8,845",24
10,Alberta,H01CB,Somatostatin and analogues,<65,F,810.84,0.5,0.1,53,25
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,801.39,0.5,9.3,"5,137",26
10,Alberta,L03AA,Colony-stimulating factors,<65,F,800.90,0.5,0.3,164,27
10,Alberta,A02BC,Proton pump inhibitors,<65,F,782.88,0.5,22.6,"12,472",28
10,Alberta,B03XA,Other antianemic preparations,<65,F,754.88,0.5,0.3,162,29
10,Alberta,N05AX,Other antipsychotics,<65,F,720.31,0.5,1.8,980,30
10,Alberta,H03AA,Thyroid hormones,<65,F,695.75,0.4,19.3,"10,639",31
10,Alberta,A04AA,Serotonin (5HT3) antagonists,<65,F,694.23,0.4,3.1,"1,725",32
10,Alberta,A07EC,Aminosalicylic acid and similar agents,<65,F,691.64,0.4,1.6,899,33
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,674.59,0.4,1.7,937,34
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,625.65,0.4,2.7,"1,474",35
10,Alberta,C10AA,HMG-CoA reductase inhibitors,<65,F,610.97,0.4,19.2,"10,582",36
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,<65,F,531.11,0.3,3.9,"2,168",37
10,Alberta,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,F,502.37,0.3,1.3,706,38
10,Alberta,N07BC,Drugs used in opioid dependence,<65,F,**,**,**,**,39
10,Alberta,B01AF,Direct factor Xa inhibitors,<65,F,466.17,0.3,1.4,777,40
10,Alberta,V03AC,Iron-chelating agents,<65,F,417.67,0.3,0.0,19,41
10,Alberta,G03DA,Pregnen (4) derivatives,<65,F,415.79,0.3,2.9,"1,593",42
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",<65,F,410.69,0.3,8.5,"4,703",43
10,Alberta,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,399.47,0.3,8.8,"4,866",44
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,389.79,0.2,4.2,"2,322",45
10,Alberta,J01DF,Monobactams,<65,F,**,**,**,**,46
10,Alberta,R03BA,Glucocorticoids,<65,F,378.52,0.2,4.4,"2,426",47
10,Alberta,N05AE,Indole derivatives,<65,F,365.63,0.2,0.5,287,48
10,Alberta,R03BB,Anticholinergics,<65,F,354.84,0.2,2.4,"1,312",49
10,Alberta,A05AA,Bile acids and derivatives,<65,F,353.52,0.2,0.4,198,50
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,353.38,0.2,0.4,230,51
10,Alberta,A09AA,Enzyme preparations,<65,F,348.05,0.2,0.4,205,52
10,Alberta,C09AA,"ACE inhibitors, plain",<65,F,310.67,0.2,9.3,"5,123",53
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,304.28,0.2,8.9,"4,939",54
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,<65,F,297.15,0.2,2.4,"1,331",55
10,Alberta,A04AD,Other antiemetics,<65,F,294.13,0.2,0.7,406,56
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,287.82,0.2,4.8,"2,641",57
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,280.34,0.2,5.8,"3,179",58
10,Alberta,L01BA,Folic acid analogues,<65,F,258.03,0.2,2.7,"1,469",59
10,Alberta,N05CF,Benzodiazepine-related drugs,<65,F,256.74,0.2,8.7,"4,824",60
10,Alberta,C08CA,Dihydropyridine derivatives,<65,F,229.63,0.1,7.2,"4,000",61
10,Alberta,H01AC,Somatropin and somatropin agonists,<65,F,**,**,**,**,62
10,Alberta,M05BA,Bisphosphonates,<65,F,208.82,0.1,3.6,"1,997",63
10,Alberta,L02AE,Gonadotropin-releasing hormone analogues,<65,F,**,**,**,**,64
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,203.50,0.1,10.3,"5,696",65
10,Alberta,A10BA,Biguanides,<65,F,190.51,0.1,8.1,"4,474",66
10,Alberta,G02BA,Intrauterine contraceptives,<65,F,**,**,**,**,67
10,Alberta,N05BA,Benzodiazepine derivatives,<65,F,185.15,0.1,7.8,"4,302",68
10,Alberta,N02AB,Phenylpiperidine derivatives,<65,F,177.87,0.1,0.4,245,69
10,Alberta,P01AX,Other agents against amebiasis and other protozoal diseases,<65,F,171.34,0.1,0.1,34,70
10,Alberta,H02AB,Glucocorticoids,<65,F,170.79,0.1,8.9,"4,900",71
10,Alberta,J01GB,Other aminoglycosides,<65,F,167.75,0.1,0.1,34,72
10,Alberta,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,167.51,0.1,3.7,"2,067",73
10,Alberta,A07AA,Antibiotics,<65,F,158.44,0.1,1.3,711,74
10,Alberta,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,<65,F,157.54,0.1,3.7,"2,027",75
10,Alberta,M03BX,Other centrally acting agents,<65,F,156.06,0.1,5.7,"3,162",76
10,Alberta,J01MA,Fluoroquinolones,<65,F,148.41,0.1,4.8,"2,672",77
10,Alberta,M01AB,Acetic acid derivatives and related substances,<65,F,146.98,0.1,6.4,"3,517",78
10,Alberta,C09BA,ACE inhibitors and diuretics,<65,F,146.11,0.1,2.4,"1,322",79
10,Alberta,C07AB,"Beta-blocking agents, selective",<65,F,144.50,0.1,5.2,"2,874",80
10,Alberta,V04CJ,Tests for thyreoidea function,<65,F,**,**,**,**,81
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,136.04,0.1,0.4,233,82
10,Alberta,S01LA,Antineovascularization agents,<65,F,**,**,**,**,83
10,Alberta,J02AC,Triazole derivatives,<65,F,132.57,0.1,2.7,"1,518",84
10,Alberta,L01EX,Other protein kinase inhibitors,<65,F,129.92,0.1,0.0,5,85
10,Alberta,C01CA,Adrenergic and dopaminergic agents,<65,F,123.19,0.1,1.7,955,86
10,Alberta,N07XX,Other nervous system drugs,<65,F,121.02,0.1,0.0,9,87
10,Alberta,C10AX,Other lipid-modifying agents,<65,F,117.13,0.1,0.5,286,88
10,Alberta,P01BA,Aminoquinolines,<65,F,116.82,0.1,2.5,"1,408",89
10,Alberta,C08DB,Benzothiazepine derivatives,<65,F,107.52,0.1,0.9,503,90
10,Alberta,N01AH,Opioid anesthetics,<65,F,106.18,0.1,0.2,91,91
10,Alberta,N03AE,Benzodiazepine derivatives,<65,F,101.00,0.1,2.9,"1,578",92
10,Alberta,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,F,97.76,0.1,0.1,45,93
10,Alberta,M01AE,Propionic acid derivatives,<65,F,97.46,0.1,5.5,"3,021",94
10,Alberta,D05AX,Other antipsoriatics for topical use,<65,F,95.29,0.1,0.8,452,95
10,Alberta,R01AD,Corticosteroids,<65,F,94.97,0.1,5.7,"3,147",96
10,Alberta,D07AC,"Corticosteroids, potent (group III)",<65,F,89.56,0.1,6.1,"3,360",97
10,Alberta,N03AF,Carboxamide derivatives,<65,F,89.40,0.1,0.7,383,98
10,Alberta,A03FA,Propulsives,<65,F,88.06,0.1,3.0,"1,665",99
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,86.48,0.1,0.8,437,100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"178,051.14",14.8,0.5,"13,163",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,Total,Total,"92,749.10",7.7,0.1,"1,981",2
11,British Columbia,L04AA,Selective immunosuppressants,Total,Total,"65,256.89",5.4,0.3,"8,623",3
11,British Columbia,N05AX,Other antipsychotics,Total,Total,"56,528.95",4.7,1.4,"41,576",4
11,British Columbia,N07BC,Drugs used in opioid dependence,Total,Total,"40,799.58",3.4,1.0,"27,998",5
11,British Columbia,L04AC,Interleukin inhibitors,Total,Total,"34,868.62",2.9,0.1,"2,785",6
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"34,127.18",2.8,3.8,"108,412",7
11,British Columbia,N02AA,Natural opium alkaloids,Total,Total,"34,061.34",2.8,3.5,"101,542",8
11,British Columbia,B01AF,Direct factor Xa inhibitors,Total,Total,"26,627.90",2.2,1.8,"53,070",9
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"24,015.99",2.0,12.4,"355,715",10
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,Total,Total,"23,344.60",1.9,19.0,"545,150",11
11,British Columbia,N06AX,Other antidepressants,Total,Total,"21,008.39",1.7,8.4,"242,975",12
11,British Columbia,N03AX,Other antiepileptics,Total,Total,"19,706.31",1.6,5.4,"154,313",13
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"18,246.81",1.5,2.0,"57,066",14
11,British Columbia,A02BC,Proton pump inhibitors,Total,Total,"17,457.68",1.4,6.6,"189,098",15
11,British Columbia,C08CA,Dihydropyridine derivatives,Total,Total,"13,873.74",1.1,9.3,"267,171",16
11,British Columbia,C09AA,"ACE inhibitors, plain",Total,Total,"12,647.57",1.0,12.5,"359,088",17
11,British Columbia,N07BA,Drugs used in nicotine dependence,Total,Total,"12,378.79",1.0,2.8,"81,526",18
11,British Columbia,L04AX,Other immunosuppressants,Total,Total,"12,170.19",1.0,0.2,"6,451",19
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"11,739.37",1.0,0.9,"26,217",20
11,British Columbia,L01XC,Monoclonal antibodies,Total,Total,"11,730.83",1.0,0.0,"1,217",21
11,British Columbia,C07AB,"Beta-blocking agents, selective",Total,Total,"11,455.52",0.9,8.3,"237,537",22
11,British Columbia,N06BA,Centrally acting sympathomimetics,Total,Total,"10,731.92",0.9,1.3,"36,717",23
11,British Columbia,B02AB,Proteinase inhibitors,Total,Total,"10,721.10",0.9,0.0,108,24
11,British Columbia,H03AA,Thyroid hormones,Total,Total,"10,515.11",0.9,9.7,"279,153",25
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"9,197.51",0.8,1.6,"45,441",26
11,British Columbia,R03BB,Anticholinergics,Total,Total,"7,986.24",0.7,1.8,"52,955",27
11,British Columbia,A10BA,Biguanides,Total,Total,"7,805.97",0.6,7.2,"207,825",28
11,British Columbia,R03BA,Glucocorticoids,Total,Total,"7,708.01",0.6,4.1,"117,519",29
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,"7,443.01",0.6,3.0,"86,066",30
11,British Columbia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,Total,"7,395.45",0.6,0.5,"14,636",31
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"6,718.71",0.6,0.0,483,32
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"6,692.43",0.6,0.7,"21,022",33
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,Total,Total,"6,571.77",0.5,0.8,"22,680",34
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"6,267.86",0.5,0.0,222,35
11,British Columbia,N03AG,Fatty acid derivatives,Total,Total,"5,921.40",0.5,0.6,"18,393",36
11,British Columbia,L01EX,Other protein kinase inhibitors,Total,Total,"5,877.06",0.5,0.0,248,37
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"5,546.91",0.5,9.7,"278,626",38
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"5,464.16",0.5,1.2,"35,379",39
11,British Columbia,N05BA,Benzodiazepine derivatives,Total,Total,"5,311.74",0.4,6.6,"190,539",40
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"5,105.00",0.4,10.3,"297,026",41
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"4,980.72",0.4,2.8,"80,163",42
11,British Columbia,L03AA,Colony-stimulating factors,Total,Total,"4,934.04",0.4,0.1,"2,133",43
11,British Columbia,C03CA,"Sulfonamides, plain",Total,Total,"4,837.91",0.4,3.0,"86,540",44
11,British Columbia,B01AB,Heparin group,Total,Total,"4,768.28",0.4,0.3,"7,368",45
11,British Columbia,N04BA,Dopa and dopa derivatives,Total,Total,"4,453.83",0.4,0.5,"14,105",46
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"4,444.27",0.4,0.6,"17,195",47
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"4,401.37",0.4,0.2,"4,396",48
11,British Columbia,A09AA,Enzyme preparations,Total,Total,"4,374.60",0.4,0.2,"6,036",49
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,"4,210.89",0.3,0.1,"3,334",50
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"4,189.08",0.3,0.3,"9,787",51
11,British Columbia,V03AC,Iron-chelating agents,Total,Total,"4,132.07",0.3,0.0,174,52
11,British Columbia,B03AA,"Iron bivalent, oral preparations",Total,Total,"3,917.49",0.3,1.7,"48,166",53
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"3,755.51",0.3,3.7,"106,209",54
11,British Columbia,S01ED,Beta-blocking agents,Total,Total,"3,508.48",0.3,1.5,"44,527",55
11,British Columbia,N03AE,Benzodiazepine derivatives,Total,Total,"3,381.48",0.3,1.4,"39,848",56
11,British Columbia,A10BB,Sulfonylureas,Total,Total,"3,358.66",0.3,1.4,"39,759",57
11,British Columbia,N03AF,Carboxamide derivatives,Total,Total,"3,311.93",0.3,0.4,"12,054",58
11,British Columbia,A04AD,Other antiemetics,Total,Total,"3,283.99",0.3,0.2,"6,820",59
11,British Columbia,S01EE,Prostaglandin analogues,Total,Total,"3,181.54",0.3,1.4,"41,652",60
11,British Columbia,M01AE,Propionic acid derivatives,Total,Total,"3,164.90",0.3,5.5,"157,554",61
11,British Columbia,C08DB,Benzothiazepine derivatives,Total,Total,"3,112.15",0.3,1.1,"32,222",62
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"3,074.98",0.3,0.5,"14,284",63
11,British Columbia,M03BX,Other centrally acting agents,Total,Total,"2,960.55",0.2,4.1,"118,236",64
11,British Columbia,C03AA,"Thiazides, plain",Total,Total,"2,875.69",0.2,5.0,"145,261",65
11,British Columbia,L03AB,Interferons,Total,Total,"2,875.26",0.2,0.0,188,66
11,British Columbia,H02AB,Glucocorticoids,Total,Total,"2,710.77",0.2,7.2,"207,503",67
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"2,573.67",0.2,0.1,"3,069",68
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,Total,Total,"2,556.34",0.2,1.6,"45,860",69
11,British Columbia,A05AA,Bile acids and derivatives,Total,Total,"2,385.10",0.2,0.1,"3,654",70
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"2,360.40",0.2,0.2,"6,302",71
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,Total,"2,334.26",0.2,0.1,"4,038",72
11,British Columbia,R05CB,Mucolytics,Total,Total,"2,332.19",0.2,0.0,537,73
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,"2,314.41",0.2,4.6,"132,072",74
11,British Columbia,B01AA,Vitamin K antagonists,Total,Total,"2,281.57",0.2,1.1,"31,394",75
11,British Columbia,M04AA,Preparations inhibiting uric acid production,Total,Total,"2,269.54",0.2,2.2,"63,147",76
11,British Columbia,N05CF,Benzodiazepine-related drugs,Total,Total,"2,258.79",0.2,0.8,"23,520",77
11,British Columbia,L03AX,Other immunostimulants,Total,Total,"2,219.99",0.2,0.0,331,78
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",Total,Total,"2,165.07",0.2,8.8,"254,189",79
11,British Columbia,C01DA,Organic nitrates,Total,Total,"2,112.09",0.2,1.4,"41,655",80
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",Total,Total,"2,099.49",0.2,1.2,"35,077",81
11,British Columbia,N07BB,Drugs used in alcohol dependence,Total,Total,"2,098.73",0.2,0.3,"8,552",82
11,British Columbia,H01AC,Somatropin and somatropin agonists,Total,Total,"2,037.44",0.2,0.0,231,83
11,British Columbia,N06DA,Anticholinesterases,Total,Total,"1,909.08",0.2,0.3,"8,030",84
11,British Columbia,C03DA,Aldosterone antagonists,Total,Total,"1,900.06",0.2,1.6,"46,991",85
11,British Columbia,L01BA,Folic acid analogues,Total,Total,"1,872.89",0.2,0.9,"26,175",86
11,British Columbia,N05AN,Lithium,Total,Total,"1,844.12",0.2,0.3,"9,511",87
11,British Columbia,G04BE,Drugs used in erectile dysfunction,Total,Total,"1,843.79",0.2,0.0,494,88
11,British Columbia,C10AX,Other lipid-modifying agents,Total,Total,"1,840.46",0.2,0.1,"2,166",89
11,British Columbia,A03FA,Propulsives,Total,Total,"1,811.74",0.2,1.7,"48,271",90
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,"1,705.98",0.1,4.2,"120,964",91
11,British Columbia,N02AB,Phenylpiperidine derivatives,Total,Total,"1,692.58",0.1,0.1,"3,084",92
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"1,679.49",0.1,1.8,"52,533",93
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,Total,Total,"1,671.34",0.1,0.3,"9,986",94
11,British Columbia,J02AC,Triazole derivatives,Total,Total,"1,661.42",0.1,0.1,"1,437",95
11,British Columbia,B01AE,Direct thrombin inhibitors,Total,Total,"1,653.92",0.1,0.1,"2,489",96
11,British Columbia,M05BA,Bisphosphonates,Total,Total,"1,653.04",0.1,0.4,"12,273",97
11,British Columbia,A02BA,H2-receptor antagonists,Total,Total,"1,602.06",0.1,1.2,"34,225",98
11,British Columbia,N05AF,Thioxanthene derivatives,Total,Total,"1,563.78",0.1,0.1,"2,449",99
11,British Columbia,C02AC,Imidazoline receptor agonists,Total,Total,"1,544.68",0.1,0.5,"13,948",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,"87,889.32",14.7,0.5,"6,205",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,Total,M,"63,517.02",10.6,0.1,"1,348",2
11,British Columbia,N05AX,Other antipsychotics,Total,M,"35,388.85",5.9,1.7,"21,783",3
11,British Columbia,N07BC,Drugs used in opioid dependence,Total,M,"27,838.31",4.7,1.5,"18,758",4
11,British Columbia,L04AA,Selective immunosuppressants,Total,M,"22,490.85",3.8,0.2,"2,785",5
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"20,982.21",3.5,3.9,"50,385",6
11,British Columbia,N02AA,Natural opium alkaloids,Total,M,"20,294.92",3.4,3.6,"46,136",7
11,British Columbia,L04AC,Interleukin inhibitors,Total,M,"16,517.87",2.8,0.1,"1,246",8
11,British Columbia,B01AF,Direct factor Xa inhibitors,Total,M,"12,276.28",2.1,2.2,"28,116",9
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,Total,M,"11,246.52",1.9,24.9,"319,044",10
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,Total,M,"9,429.99",1.6,9.4,"119,878",11
11,British Columbia,N06AX,Other antidepressants,Total,M,"9,018.55",1.5,7.1,"91,030",12
11,British Columbia,N03AX,Other antiepileptics,Total,M,"8,872.92",1.5,4.9,"62,349",13
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"7,620.96",1.3,1.9,"24,219",14
11,British Columbia,A02BC,Proton pump inhibitors,Total,M,"7,117.48",1.2,6.3,"80,332",15
11,British Columbia,N07BA,Drugs used in nicotine dependence,Total,M,"6,995.63",1.2,3.6,"45,968",16
11,British Columbia,B02AB,Proteinase inhibitors,Total,M,"6,586.94",1.1,0.0,60,17
11,British Columbia,N06BA,Centrally acting sympathomimetics,Total,M,"6,383.66",1.1,1.6,"21,027",18
11,British Columbia,C09AA,"ACE inhibitors, plain",Total,M,"6,318.08",1.1,16.3,"208,551",19
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"6,129.72",1.0,1.1,"14,368",20
11,British Columbia,C08CA,Dihydropyridine derivatives,Total,M,"5,623.49",0.9,10.8,"138,276",21
11,British Columbia,C07AB,"Beta-blocking agents, selective",Total,M,"5,320.83",0.9,10.3,"131,871",22
11,British Columbia,L04AX,Other immunosuppressants,Total,M,"4,937.29",0.8,0.2,"2,565",23
11,British Columbia,L01EX,Other protein kinase inhibitors,Total,M,"4,689.27",0.8,0.0,193,24
11,British Columbia,R03BB,Anticholinergics,Total,M,"3,868.65",0.6,2.0,"26,218",25
11,British Columbia,A10BA,Biguanides,Total,M,"3,770.64",0.6,9.1,"116,429",26
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"3,624.82",0.6,1.0,"12,795",27
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"3,606.69",0.6,7.9,"101,039",28
11,British Columbia,N03AG,Fatty acid derivatives,Total,M,"3,500.41",0.6,0.8,"9,986",29
11,British Columbia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,M,"3,277.02",0.5,0.6,"7,334",30
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"3,243.43",0.5,2.3,"29,034",31
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,"3,194.52",0.5,0.2,"2,634",32
11,British Columbia,R03BA,Glucocorticoids,Total,M,"3,143.84",0.5,4.0,"51,432",33
11,British Columbia,L01XC,Monoclonal antibodies,Total,M,"3,127.37",0.5,0.0,348,34
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,Total,M,"3,050.41",0.5,0.8,"10,008",35
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"3,028.42",0.5,1.5,"19,275",36
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"2,989.42",0.5,0.0,213,37
11,British Columbia,H03AA,Thyroid hormones,Total,M,"2,492.96",0.4,4.8,"61,917",38
11,British Columbia,A09AA,Enzyme preparations,Total,M,"2,491.47",0.4,0.2,"2,833",39
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"2,449.17",0.4,10.4,"132,619",40
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"2,375.77",0.4,0.7,"9,169",41
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,"2,351.57",0.4,2.7,"34,888",42
11,British Columbia,N04BA,Dopa and dopa derivatives,Total,M,"2,349.66",0.4,0.6,"8,012",43
11,British Columbia,B01AB,Heparin group,Total,M,"2,290.54",0.4,0.3,"3,220",44
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"2,279.46",0.4,10.1,"129,207",45
11,British Columbia,N05BA,Benzodiazepine derivatives,Total,M,"2,174.48",0.4,4.9,"63,069",46
11,British Columbia,C03CA,"Sulfonamides, plain",Total,M,"2,080.21",0.3,3.3,"41,691",47
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"2,078.53",0.3,0.4,"5,575",48
11,British Columbia,V03AC,Iron-chelating agents,Total,M,"2,057.04",0.3,0.0,91,49
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,"1,930.78",0.3,2.0,"25,404",50
11,British Columbia,N03AF,Carboxamide derivatives,Total,M,"1,852.54",0.3,0.5,"5,803",51
11,British Columbia,M01AE,Propionic acid derivatives,Total,M,"1,777.08",0.3,5.6,"71,281",52
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"1,735.83",0.3,0.1,"1,442",53
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,"1,682.57",0.3,0.0,56,54
11,British Columbia,L03AA,Colony-stimulating factors,Total,M,"1,623.39",0.3,0.1,658,55
11,British Columbia,A10BB,Sulfonylureas,Total,M,"1,592.36",0.3,1.7,"22,233",56
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,"1,583.48",0.3,0.5,"6,846",57
11,British Columbia,N03AE,Benzodiazepine derivatives,Total,M,"1,522.61",0.3,1.2,"14,986",58
11,British Columbia,B03AA,"Iron bivalent, oral preparations",Total,M,"1,486.80",0.2,1.3,"17,046",59
11,British Columbia,A04AD,Other antiemetics,Total,M,"1,486.54",0.2,0.2,"2,904",60
11,British Columbia,S01ED,Beta-blocking agents,Total,M,"1,467.60",0.2,1.7,"22,330",61
11,British Columbia,M04AA,Preparations inhibiting uric acid production,Total,M,"1,367.03",0.2,3.9,"50,033",62
11,British Columbia,M03BX,Other centrally acting agents,Total,M,"1,349.44",0.2,4.0,"51,056",63
11,British Columbia,H01AC,Somatropin and somatropin agonists,Total,M,"1,346.61",0.2,0.0,153,64
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"1,272.56",0.2,0.2,"2,396",65
11,British Columbia,S01EE,Prostaglandin analogues,Total,M,"1,219.20",0.2,1.5,"19,712",66
11,British Columbia,R05CB,Mucolytics,Total,M,"1,215.50",0.2,0.0,283,67
11,British Columbia,N07BB,Drugs used in alcohol dependence,Total,M,"1,201.50",0.2,0.4,"4,903",68
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,"1,197.94",0.2,0.3,"3,462",69
11,British Columbia,B01AA,Vitamin K antagonists,Total,M,"1,176.05",0.2,1.5,"18,910",70
11,British Columbia,H02AB,Glucocorticoids,Total,M,"1,121.91",0.2,7.3,"93,225",71
11,British Columbia,C08DB,Benzothiazepine derivatives,Total,M,"1,116.97",0.2,1.1,"14,700",72
11,British Columbia,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"1,071.10",0.2,0.7,"9,154",73
11,British Columbia,C03AA,"Thiazides, plain",Total,M,"1,055.28",0.2,4.9,"62,659",74
11,British Columbia,N05AF,Thioxanthene derivatives,Total,M,"1,019.52",0.2,0.1,"1,544",75
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",Total,M,"1,009.36",0.2,8.7,"111,788",76
11,British Columbia,N05AN,Lithium,Total,M,979.22,0.2,0.4,"4,491",77
11,British Columbia,N05CF,Benzodiazepine-related drugs,Total,M,963.29,0.2,0.7,"8,329",78
11,British Columbia,C03DA,Aldosterone antagonists,Total,M,929.89,0.2,1.7,"21,192",79
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,Total,M,925.43,0.2,0.0,533,80
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",Total,M,918.44,0.2,1.1,"14,610",81
11,British Columbia,C01DA,Organic nitrates,Total,M,907.69,0.2,1.9,"23,920",82
11,British Columbia,J02AC,Triazole derivatives,Total,M,889.70,0.1,0.1,691,83
11,British Columbia,C10AX,Other lipid-modifying agents,Total,M,851.41,0.1,0.1,"1,215",84
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,Total,M,849.21,0.1,0.3,"3,302",85
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,841.13,0.1,0.3,"4,058",86
11,British Columbia,C02AC,Imidazoline receptor agonists,Total,M,836.31,0.1,0.5,"6,115",87
11,British Columbia,B01AE,Direct thrombin inhibitors,Total,M,806.84,0.1,0.1,"1,389",88
11,British Columbia,C07AG,Alpha- and beta-blocking agents,Total,M,790.20,0.1,0.4,"5,006",89
11,British Columbia,A02BA,H2-receptor antagonists,Total,M,772.08,0.1,1.0,"13,219",90
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,762.26,0.1,3.5,"44,804",91
11,British Columbia,N02AB,Phenylpiperidine derivatives,Total,M,760.71,0.1,0.1,"1,278",92
11,British Columbia,L03AB,Interferons,Total,M,743.32,0.1,0.0,52,93
11,British Columbia,A03FA,Propulsives,Total,M,684.20,0.1,1.1,"14,663",94
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,Total,M,654.37,0.1,0.4,"5,091",95
11,British Columbia,N06DA,Anticholinesterases,Total,M,645.10,0.1,0.3,"3,340",96
11,British Columbia,L01BA,Folic acid analogues,Total,M,594.25,0.1,0.8,"9,635",97
11,British Columbia,J01DB,First-generation cephalosporins,Total,M,586.34,0.1,7.0,"90,266",98
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,Total,M,572.43,0.1,0.3,"4,195",99
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,Total,M,563.64,0.1,0.7,"8,808",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,"90,161.82",14.8,0.4,"6,958",1
11,British Columbia,L04AA,Selective immunosuppressants,Total,F,"42,766.04",7.0,0.4,"5,838",2
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,Total,F,"29,232.08",4.8,0.0,633,3
11,British Columbia,N05AX,Other antipsychotics,Total,F,"21,140.11",3.5,1.2,"19,793",4
11,British Columbia,L04AC,Interleukin inhibitors,Total,F,"18,350.75",3.0,0.1,"1,539",5
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,Total,F,"14,586.00",2.4,14.8,"235,836",6
11,British Columbia,B01AF,Direct factor Xa inhibitors,Total,F,"14,351.62",2.4,1.6,"24,954",7
11,British Columbia,N02AA,Natural opium alkaloids,Total,F,"13,766.42",2.3,3.5,"55,406",8
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"13,144.97",2.2,3.6,"58,027",9
11,British Columbia,N07BC,Drugs used in opioid dependence,Total,F,"12,961.27",2.1,0.6,"9,240",10
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,Total,F,"12,098.08",2.0,14.2,"226,106",11
11,British Columbia,N06AX,Other antidepressants,Total,F,"11,989.84",2.0,9.5,"151,943",12
11,British Columbia,N03AX,Other antiepileptics,Total,F,"10,833.39",1.8,5.8,"91,964",13
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"10,625.85",1.7,2.1,"32,847",14
11,British Columbia,A02BC,Proton pump inhibitors,Total,F,"10,340.20",1.7,6.8,"108,766",15
11,British Columbia,L01XC,Monoclonal antibodies,Total,F,"8,603.46",1.4,0.1,869,16
11,British Columbia,C08CA,Dihydropyridine derivatives,Total,F,"8,250.25",1.4,8.1,"128,895",17
11,British Columbia,H03AA,Thyroid hormones,Total,F,"8,022.15",1.3,13.6,"217,236",18
11,British Columbia,L04AX,Other immunosuppressants,Total,F,"7,232.90",1.2,0.2,"3,886",19
11,British Columbia,C09AA,"ACE inhibitors, plain",Total,F,"6,329.48",1.0,9.4,"150,537",20
11,British Columbia,C07AB,"Beta-blocking agents, selective",Total,F,"6,134.69",1.0,6.6,"105,666",21
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"5,954.08",1.0,1.0,"16,407",22
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"5,609.65",0.9,0.7,"11,849",23
11,British Columbia,N07BA,Drugs used in nicotine dependence,Total,F,"5,383.16",0.9,2.2,"35,558",24
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,"5,091.44",0.8,3.2,"51,178",25
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"4,585.30",0.8,0.0,166,26
11,British Columbia,R03BA,Glucocorticoids,Total,F,"4,563.98",0.8,4.1,"66,086",27
11,British Columbia,N06BA,Centrally acting sympathomimetics,Total,F,"4,348.26",0.7,1.0,"15,690",28
11,British Columbia,B02AB,Proteinase inhibitors,Total,F,"4,134.16",0.7,0.0,48,29
11,British Columbia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,Total,F,"4,118.43",0.7,0.5,"7,302",30
11,British Columbia,R03BB,Anticholinergics,Total,F,"4,117.59",0.7,1.7,"26,737",31
11,British Columbia,A10BA,Biguanides,Total,F,"4,035.33",0.7,5.7,"91,396",32
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"3,729.30",0.6,0.0,270,33
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,Total,F,"3,521.36",0.6,0.8,"12,672",34
11,British Columbia,L03AA,Colony-stimulating factors,Total,F,"3,310.65",0.5,0.1,"1,475",35
11,British Columbia,N05BA,Benzodiazepine derivatives,Total,F,"3,137.26",0.5,8.0,"127,469",36
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"3,097.74",0.5,9.2,"146,007",37
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"3,067.61",0.5,0.5,"8,227",38
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"3,049.94",0.5,3.4,"54,759",39
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"2,825.53",0.5,10.5,"167,818",40
11,British Columbia,C03CA,"Sulfonamides, plain",Total,F,"2,757.70",0.5,2.8,"44,849",41
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"2,665.54",0.4,0.2,"2,954",42
11,British Columbia,B01AB,Heparin group,Total,F,"2,477.74",0.4,0.3,"4,148",43
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"2,435.75",0.4,1.0,"16,104",44
11,British Columbia,B03AA,"Iron bivalent, oral preparations",Total,F,"2,430.69",0.4,2.0,"31,120",45
11,British Columbia,N03AG,Fatty acid derivatives,Total,F,"2,420.99",0.4,0.5,"8,407",46
11,British Columbia,L03AB,Interferons,Total,F,"2,131.94",0.4,0.0,136,47
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"2,110.55",0.3,0.3,"4,212",48
11,British Columbia,N04BA,Dopa and dopa derivatives,Total,F,"2,104.18",0.3,0.4,"6,093",49
11,British Columbia,V03AC,Iron-chelating agents,Total,F,"2,075.03",0.3,0.0,83,50
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"2,068.50",0.3,0.5,"8,026",51
11,British Columbia,S01ED,Beta-blocking agents,Total,F,"2,040.88",0.3,1.4,"22,197",52
11,British Columbia,C08DB,Benzothiazepine derivatives,Total,F,"1,995.18",0.3,1.1,"17,522",53
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,Total,F,"1,992.70",0.3,2.3,"37,052",54
11,British Columbia,S01EE,Prostaglandin analogues,Total,F,"1,962.34",0.3,1.4,"21,940",55
11,British Columbia,A05AA,Bile acids and derivatives,Total,F,"1,945.18",0.3,0.2,"2,625",56
11,British Columbia,A09AA,Enzyme preparations,Total,F,"1,883.13",0.3,0.2,"3,203",57
11,British Columbia,N03AE,Benzodiazepine derivatives,Total,F,"1,858.86",0.3,1.6,"24,862",58
11,British Columbia,C03AA,"Thiazides, plain",Total,F,"1,820.41",0.3,5.2,"82,602",59
11,British Columbia,A04AD,Other antiemetics,Total,F,"1,797.45",0.3,0.2,"3,916",60
11,British Columbia,A10BB,Sulfonylureas,Total,F,"1,766.30",0.3,1.1,"17,526",61
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"1,705.08",0.3,7.6,"120,915",62
11,British Columbia,L03AX,Other immunostimulants,Total,F,"1,691.57",0.3,0.0,256,63
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"1,648.23",0.3,0.2,"2,536",64
11,British Columbia,M03BX,Other centrally acting agents,Total,F,"1,611.11",0.3,4.2,"67,178",65
11,British Columbia,H02AB,Glucocorticoids,Total,F,"1,588.87",0.3,7.2,"114,278",66
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"1,552.15",0.3,5.5,"87,268",67
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,"1,491.50",0.2,0.5,"7,438",68
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"1,470.85",0.2,3.2,"51,256",69
11,British Columbia,N03AF,Carboxamide derivatives,Total,F,"1,459.39",0.2,0.4,"6,251",70
11,British Columbia,M01AE,Propionic acid derivatives,Total,F,"1,387.81",0.2,5.4,"86,272",71
11,British Columbia,G04BE,Drugs used in erectile dysfunction,Total,F,"1,313.81",0.2,0.0,283,72
11,British Columbia,N05CF,Benzodiazepine-related drugs,Total,F,"1,295.49",0.2,1.0,"15,191",73
11,British Columbia,L01BA,Folic acid analogues,Total,F,"1,278.64",0.2,1.0,"16,540",74
11,British Columbia,N06DA,Anticholinesterases,Total,F,"1,263.99",0.2,0.3,"4,690",75
11,British Columbia,G02BA,Intrauterine contraceptives,Total,F,"1,239.78",0.2,1.6,"26,211",76
11,British Columbia,M05BA,Bisphosphonates,Total,F,"1,210.65",0.2,0.6,"9,985",77
11,British Columbia,C01DA,Organic nitrates,Total,F,"1,204.40",0.2,1.1,"17,735",78
11,British Columbia,L01EX,Other protein kinase inhibitors,Total,F,"1,187.78",0.2,0.0,55,79
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",Total,F,"1,181.05",0.2,1.3,"20,467",80
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,"1,162.46",0.2,0.2,"2,840",81
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",Total,F,"1,155.71",0.2,8.9,"142,401",82
11,British Columbia,A03FA,Propulsives,Total,F,"1,127.54",0.2,2.1,"33,608",83
11,British Columbia,R05CB,Mucolytics,Total,F,"1,116.69",0.2,0.0,254,84
11,British Columbia,B01AA,Vitamin K antagonists,Total,F,"1,105.52",0.2,0.8,"12,484",85
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,Total,F,"1,098.91",0.2,0.4,"5,791",86
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,F,"1,061.70",0.2,0.1,"1,642",87
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,F,"1,016.38",0.2,0.0,700,88
11,British Columbia,C10AX,Other lipid-modifying agents,Total,F,989.06,0.2,0.1,951,89
11,British Columbia,C03DA,Aldosterone antagonists,Total,F,970.17,0.2,1.6,"25,799",90
11,British Columbia,N02AB,Phenylpiperidine derivatives,Total,F,931.87,0.2,0.1,"1,806",91
11,British Columbia,M04AA,Preparations inhibiting uric acid production,Total,F,902.52,0.1,0.8,"13,114",92
11,British Columbia,C05BA,Heparins or heparinoids for topical use,Total,F,902.05,0.1,0.1,"1,043",93
11,British Columbia,N07BB,Drugs used in alcohol dependence,Total,F,897.23,0.1,0.2,"3,649",94
11,British Columbia,N05AN,Lithium,Total,F,864.90,0.1,0.3,"5,020",95
11,British Columbia,B01AE,Direct thrombin inhibitors,Total,F,847.08,0.1,0.1,"1,100",96
11,British Columbia,A02BA,H2-receptor antagonists,Total,F,829.99,0.1,1.3,"21,006",97
11,British Columbia,J02AC,Triazole derivatives,Total,F,771.72,0.1,0.0,746,98
11,British Columbia,J01XE,Nitrofuran derivatives,Total,F,765.24,0.1,7.9,"126,544",99
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,Total,F,742.06,0.1,1.4,"22,689",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,"42,288.52",9.3,0.4,"3,195",1
11,British Columbia,B01AF,Direct factor Xa inhibitors,65+,Total,"23,853.92",5.2,5.3,"44,977",2
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,65+,Total,"20,760.94",4.5,0.1,433,3
11,British Columbia,L04AA,Selective immunosuppressants,65+,Total,"17,768.47",3.9,0.4,"3,044",4
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,65+,Total,"17,484.74",3.8,41.5,"352,952",5
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"11,997.40",2.6,3.5,"30,078",6
11,British Columbia,C08CA,Dihydropyridine derivatives,65+,Total,"11,221.24",2.5,21.1,"179,363",7
11,British Columbia,A02BC,Proton pump inhibitors,65+,Total,"10,279.32",2.3,13.1,"111,759",8
11,British Columbia,L04AC,Interleukin inhibitors,65+,Total,"9,958.05",2.2,0.1,772,9
11,British Columbia,C07AB,"Beta-blocking agents, selective",65+,Total,"9,131.60",2.0,20.2,"171,506",10
11,British Columbia,C09AA,"ACE inhibitors, plain",65+,Total,"8,952.31",2.0,26.0,"221,346",11
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"7,235.11",1.6,10.2,"86,431",12
11,British Columbia,N02AA,Natural opium alkaloids,65+,Total,"6,817.20",1.5,5.8,"48,979",13
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"6,707.64",1.5,1.6,"13,929",14
11,British Columbia,N06AX,Other antidepressants,65+,Total,"6,650.74",1.5,10.0,"85,522",15
11,British Columbia,H03AA,Thyroid hormones,65+,Total,"6,535.79",1.4,16.7,"142,442",16
11,British Columbia,N05AX,Other antipsychotics,65+,Total,"6,488.79",1.4,1.4,"11,535",17
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,"6,344.81",1.4,7.8,"66,508",18
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"5,884.76",1.3,4.0,"34,385",19
11,British Columbia,R03BB,Anticholinergics,65+,Total,"5,852.73",1.3,4.2,"36,125",20
11,British Columbia,N03AX,Other antiepileptics,65+,Total,"5,775.92",1.3,7.4,"63,346",21
11,British Columbia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,Total,"5,631.04",1.2,1.2,"10,490",22
11,British Columbia,L01EX,Other protein kinase inhibitors,65+,Total,"5,301.49",1.2,0.0,226,23
11,British Columbia,A10BA,Biguanides,65+,Total,"5,106.93",1.1,13.6,"115,518",24
11,British Columbia,B02AB,Proteinase inhibitors,65+,Total,"4,949.95",1.1,0.0,49,25
11,British Columbia,L01XC,Monoclonal antibodies,65+,Total,"4,805.17",1.1,0.1,461,26
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"4,570.07",1.0,4.0,"34,369",27
11,British Columbia,C03CA,"Sulfonamides, plain",65+,Total,"3,976.89",0.9,8.3,"70,718",28
11,British Columbia,N04BA,Dopa and dopa derivatives,65+,Total,"3,929.71",0.9,1.4,"11,654",29
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"3,927.78",0.9,1.3,"11,181",30
11,British Columbia,R03BA,Glucocorticoids,65+,Total,"3,538.27",0.8,3.3,"27,782",31
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"3,362.51",0.7,1.5,"12,421",32
11,British Columbia,L04AX,Other immunosuppressants,65+,Total,"3,099.98",0.7,0.2,"2,126",33
11,British Columbia,S01ED,Beta-blocking agents,65+,Total,"3,088.43",0.7,4.1,"34,911",34
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"3,088.01",0.7,9.2,"78,133",35
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,"2,992.64",0.7,0.3,"2,248",36
11,British Columbia,S01EE,Prostaglandin analogues,65+,Total,"2,838.41",0.6,4.0,"34,112",37
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"2,835.31",0.6,0.0,197,38
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"2,794.40",0.6,0.7,"5,713",39
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,65+,Total,"2,695.61",0.6,0.9,"7,943",40
11,British Columbia,C08DB,Benzothiazepine derivatives,65+,Total,"2,601.48",0.6,2.8,"24,213",41
11,British Columbia,N07BC,Drugs used in opioid dependence,65+,Total,"2,566.56",0.6,0.3,"2,330",42
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"2,532.52",0.6,10.1,"86,124",43
11,British Columbia,B01AB,Heparin group,65+,Total,"2,529.28",0.6,0.5,"4,352",44
11,British Columbia,B03AA,"Iron bivalent, oral preparations",65+,Total,"2,426.43",0.5,3.3,"27,803",45
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"2,405.89",0.5,0.0,84,46
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"2,372.97",0.5,10.1,"85,921",47
11,British Columbia,A10BB,Sulfonylureas,65+,Total,"2,266.02",0.5,2.9,"24,568",48
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"2,222.57",0.5,1.6,"14,025",49
11,British Columbia,N05BA,Benzodiazepine derivatives,65+,Total,"2,208.34",0.5,8.0,"67,916",50
11,British Columbia,N07BA,Drugs used in nicotine dependence,65+,Total,"2,150.67",0.5,1.6,"13,507",51
11,British Columbia,C03AA,"Thiazides, plain",65+,Total,"2,103.54",0.5,11.1,"94,456",52
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"1,975.76",0.4,0.3,"2,605",53
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"1,920.54",0.4,3.4,"29,244",54
11,British Columbia,C01DA,Organic nitrates,65+,Total,"1,906.86",0.4,3.7,"31,431",55
11,British Columbia,N06DA,Anticholinesterases,65+,Total,"1,855.85",0.4,0.9,"7,754",56
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"1,846.23",0.4,0.9,"7,275",57
11,British Columbia,M04AA,Preparations inhibiting uric acid production,65+,Total,"1,844.46",0.4,4.7,"40,043",58
11,British Columbia,B01AA,Vitamin K antagonists,65+,Total,"1,819.01",0.4,2.9,"24,825",59
11,British Columbia,L03AA,Colony-stimulating factors,65+,Total,"1,726.67",0.4,0.1,772,60
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,"1,698.49",0.4,0.5,"4,537",61
11,British Columbia,H02AB,Glucocorticoids,65+,Total,"1,589.07",0.3,9.7,"82,904",62
11,British Columbia,B01AE,Direct thrombin inhibitors,65+,Total,"1,537.15",0.3,0.3,"2,292",63
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"1,381.18",0.3,0.2,"1,786",64
11,British Columbia,M05BA,Bisphosphonates,65+,Total,"1,362.85",0.3,1.2,"10,488",65
11,British Columbia,V03AC,Iron-chelating agents,65+,Total,"1,291.91",0.3,0.0,83,66
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",65+,Total,"1,166.89",0.3,9.3,"79,526",67
11,British Columbia,C03DA,Aldosterone antagonists,65+,Total,"1,165.04",0.3,3.1,"26,721",68
11,British Columbia,A09AA,Enzyme preparations,65+,Total,"1,149.36",0.3,0.4,"3,118",69
11,British Columbia,N03AG,Fatty acid derivatives,65+,Total,"1,136.11",0.2,0.5,"3,951",70
11,British Columbia,A03FA,Propulsives,65+,Total,"1,126.85",0.2,2.3,"19,847",71
11,British Columbia,C10AX,Other lipid-modifying agents,65+,Total,"1,118.22",0.2,0.1,"1,225",72
11,British Columbia,A04AD,Other antiemetics,65+,Total,"1,081.19",0.2,0.3,"2,626",73
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,"1,074.33",0.2,0.6,"4,798",74
11,British Columbia,L01BA,Folic acid analogues,65+,Total,"1,027.68",0.2,1.5,"12,474",75
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,Total,"1,005.98",0.2,0.2,"1,340",76
11,British Columbia,S01EC,Carbonic anhydrase inhibitors,65+,Total,976.58,0.2,1.5,"12,440",77
11,British Columbia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,965.33,0.2,1.0,"8,304",78
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",65+,Total,960.24,0.2,1.7,"14,224",79
11,British Columbia,N03AE,Benzodiazepine derivatives,65+,Total,910.79,0.2,1.5,"12,541",80
11,British Columbia,C01AA,Digitalis glycosides,65+,Total,908.31,0.2,1.1,"9,045",81
11,British Columbia,N05CF,Benzodiazepine-related drugs,65+,Total,884.37,0.2,1.6,"13,337",82
11,British Columbia,C07AG,Alpha- and beta-blocking agents,65+,Total,880.23,0.2,0.6,"5,178",83
11,British Columbia,A05AA,Bile acids and derivatives,65+,Total,867.60,0.2,0.2,"1,459",84
11,British Columbia,N02AB,Phenylpiperidine derivatives,65+,Total,845.41,0.2,0.2,"1,908",85
11,British Columbia,G04BE,Drugs used in erectile dysfunction,65+,Total,823.82,0.2,0.0,208,86
11,British Columbia,C02DB,Hydrazinophthalazine derivatives,65+,Total,743.75,0.2,0.9,"7,971",87
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,742.12,0.2,3.5,"29,400",88
11,British Columbia,A12BA,Potassium,65+,Total,723.37,0.2,2.0,"17,107",89
11,British Columbia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,Total,712.72,0.2,1.3,"11,174",90
11,British Columbia,A02BA,H2-receptor antagonists,65+,Total,678.24,0.1,1.6,"13,538",91
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,65+,Total,664.49,0.1,0.6,"4,978",92
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,655.16,0.1,2.7,"22,837",93
11,British Columbia,M03BX,Other centrally acting agents,65+,Total,637.20,0.1,2.9,"24,636",94
11,British Columbia,S01BA,"Corticosteroids, plain",65+,Total,614.60,0.1,4.4,"37,187",95
11,British Columbia,A07AA,Antibiotics,65+,Total,605.56,0.1,1.0,"8,786",96
11,British Columbia,A11CC,Vitamin D and analogues,65+,Total,602.30,0.1,0.6,"5,420",97
11,British Columbia,B02BX,Other systemic hemostatics,65+,Total,601.30,0.1,0.0,18,98
11,British Columbia,J02AC,Triazole derivatives,65+,Total,**,**,**,**,99
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,65+,Total,588.09,0.1,0.8,"6,396",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,"18,849.34",9.2,0.3,"1,359",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,65+,M,"14,986.32",7.3,0.1,307,2
11,British Columbia,B01AF,Direct factor Xa inhibitors,65+,M,"10,542.05",5.1,5.8,"23,099",3
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,65+,M,"7,893.24",3.8,49.6,"197,360",4
11,British Columbia,L04AA,Selective immunosuppressants,65+,M,"5,695.69",2.8,0.2,985,5
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"4,913.80",2.4,3.3,"12,942",6
11,British Columbia,L04AC,Interleukin inhibitors,65+,M,"4,494.24",2.2,0.1,322,7
11,British Columbia,L01EX,Other protein kinase inhibitors,65+,M,**,**,**,**,8
11,British Columbia,C08CA,Dihydropyridine derivatives,65+,M,"4,145.60",2.0,21.8,"86,804",9
11,British Columbia,C09AA,"ACE inhibitors, plain",65+,M,"4,090.45",2.0,31.0,"123,499",10
11,British Columbia,C07AB,"Beta-blocking agents, selective",65+,M,"3,886.05",1.9,23.1,"91,752",11
11,British Columbia,A02BC,Proton pump inhibitors,65+,M,"3,608.72",1.8,11.5,"45,785",12
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"3,459.03",1.7,1.9,"7,600",13
11,British Columbia,N02AA,Natural opium alkaloids,65+,M,"3,287.10",1.6,5.3,"20,949",14
11,British Columbia,B02AB,Proteinase inhibitors,65+,M,"3,154.67",1.5,0.0,28,15
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"2,972.37",1.4,19.1,"76,145",16
11,British Columbia,N05AX,Other antipsychotics,65+,M,"2,782.30",1.4,1.2,"4,668",17
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"2,773.89",1.3,3.9,"15,356",18
11,British Columbia,R03BB,Anticholinergics,65+,M,"2,744.81",1.3,4.5,"18,045",19
11,British Columbia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,M,"2,416.29",1.2,1.3,"5,128",20
11,British Columbia,A10BA,Biguanides,65+,M,"2,361.24",1.1,16.4,"65,117",21
11,British Columbia,N06AX,Other antidepressants,65+,M,"2,313.03",1.1,7.9,"31,621",22
11,British Columbia,L04AX,Other immunosuppressants,65+,M,"2,300.52",1.1,0.2,932,23
11,British Columbia,N03AX,Other antiepileptics,65+,M,"2,287.19",1.1,6.4,"25,360",24
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,65+,M,"2,266.18",1.1,7.1,"28,216",25
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,"2,234.43",1.1,0.4,"1,762",26
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"2,149.29",1.0,1.7,"6,896",27
11,British Columbia,N04BA,Dopa and dopa derivatives,65+,M,"2,082.31",1.0,1.7,"6,705",28
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,"1,889.94",0.9,6.5,"25,941",29
11,British Columbia,N07BC,Drugs used in opioid dependence,65+,M,"1,847.76",0.9,0.4,"1,514",30
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"1,795.21",0.9,5.2,"20,857",31
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"1,736.28",0.8,1.7,"6,598",32
11,British Columbia,C03CA,"Sulfonamides, plain",65+,M,"1,627.02",0.8,8.5,"33,640",33
11,British Columbia,H03AA,Thyroid hormones,65+,M,"1,483.43",0.7,9.0,"35,780",34
11,British Columbia,L01XC,Monoclonal antibodies,65+,M,"1,380.81",0.7,0.0,144,35
11,British Columbia,R03BA,Glucocorticoids,65+,M,"1,380.32",0.7,2.7,"10,939",36
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"1,367.36",0.7,0.8,"3,206",37
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"1,262.22",0.6,2.0,"7,975",38
11,British Columbia,B01AB,Heparin group,65+,M,"1,245.07",0.6,0.5,"1,949",39
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"1,241.80",0.6,0.0,83,40
11,British Columbia,S01ED,Beta-blocking agents,65+,M,"1,238.68",0.6,4.3,"16,958",41
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,65+,M,"1,153.12",0.6,0.9,"3,571",42
11,British Columbia,N07BA,Drugs used in nicotine dependence,65+,M,"1,137.45",0.6,1.8,"7,174",43
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"1,099.97",0.5,9.2,"36,658",44
11,British Columbia,S01EE,Prostaglandin analogues,65+,M,"1,062.78",0.5,4.0,"15,835",45
11,British Columbia,M04AA,Preparations inhibiting uric acid production,65+,M,"1,049.60",0.5,7.5,"29,660",46
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,"1,009.77",0.5,10.4,"41,501",47
11,British Columbia,A10BB,Sulfonylureas,65+,M,"1,006.10",0.5,3.4,"13,458",48
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,977.28,0.5,1.0,"4,136",49
11,British Columbia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,**,**,**,**,50
11,British Columbia,B03AA,"Iron bivalent, oral preparations",65+,M,917.83,0.4,3.0,"11,931",51
11,British Columbia,B01AA,Vitamin K antagonists,65+,M,896.16,0.4,3.7,"14,734",52
11,British Columbia,C08DB,Benzothiazepine derivatives,65+,M,854.26,0.4,2.6,"10,370",53
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,848.22,0.4,0.6,"2,448",54
11,British Columbia,C01DA,Organic nitrates,65+,M,783.37,0.4,4.3,"17,272",55
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,65+,M,781.89,0.4,0.1,429,56
11,British Columbia,N05BA,Benzodiazepine derivatives,65+,M,771.66,0.4,5.7,"22,843",57
11,British Columbia,V03AC,Iron-chelating agents,65+,M,756.40,0.4,0.0,50,58
11,British Columbia,B01AE,Direct thrombin inhibitors,65+,M,718.23,0.3,0.3,"1,236",59
11,British Columbia,C03AA,"Thiazides, plain",65+,M,692.52,0.3,9.9,"39,349",60
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,655.76,0.3,0.8,"2,989",61
11,British Columbia,L03AA,Colony-stimulating factors,65+,M,649.82,0.3,0.1,291,62
11,British Columbia,H02AB,Glucocorticoids,65+,M,649.19,0.3,9.6,"38,049",63
11,British Columbia,N06DA,Anticholinesterases,65+,M,612.97,0.3,0.8,"3,206",64
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,603.28,0.3,2.3,"9,038",65
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,575.02,0.3,0.0,18,66
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",65+,M,551.89,0.3,9.3,"37,117",67
11,British Columbia,C03DA,Aldosterone antagonists,65+,M,548.52,0.3,3.5,"14,065",68
11,British Columbia,N03AG,Fatty acid derivatives,65+,M,543.13,0.3,0.5,"1,847",69
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,514.30,0.3,0.2,777,70
11,British Columbia,C07AG,Alpha- and beta-blocking agents,65+,M,482.50,0.2,0.8,"3,179",71
11,British Columbia,A04AD,Other antiemetics,65+,M,469.80,0.2,0.3,"1,118",72
11,British Columbia,A09AA,Enzyme preparations,65+,M,466.14,0.2,0.3,"1,385",73
11,British Columbia,C10AX,Other lipid-modifying agents,65+,M,464.89,0.2,0.2,643,74
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,447.26,0.2,0.1,555,75
11,British Columbia,A03FA,Propulsives,65+,M,408.28,0.2,1.9,"7,698",76
11,British Columbia,S01EC,Carbonic anhydrase inhibitors,65+,M,402.27,0.2,1.5,"6,041",77
11,British Columbia,N02AB,Phenylpiperidine derivatives,65+,M,375.67,0.2,0.2,799,78
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",65+,M,362.96,0.2,1.6,"6,455",79
11,British Columbia,C01AA,Digitalis glycosides,65+,M,357.50,0.2,1.1,"4,257",80
11,British Columbia,B02BX,Other systemic hemostatics,65+,M,**,**,**,**,81
11,British Columbia,N03AE,Benzodiazepine derivatives,65+,M,325.10,0.2,1.1,"4,551",82
11,British Columbia,M05BA,Bisphosphonates,65+,M,317.85,0.2,0.4,"1,766",83
11,British Columbia,N05CF,Benzodiazepine-related drugs,65+,M,310.96,0.2,1.1,"4,378",84
11,British Columbia,L01BA,Folic acid analogues,65+,M,302.43,0.1,1.1,"4,560",85
11,British Columbia,C02DB,Hydrazinophthalazine derivatives,65+,M,290.48,0.1,1.0,"3,865",86
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,288.97,0.1,2.7,"10,932",87
11,British Columbia,A07AA,Antibiotics,65+,M,282.46,0.1,0.8,"3,175",88
11,British Columbia,H01AX,Other anterior pituitary lobe hormones and analogues,65+,M,**,**,**,*,89
11,British Columbia,A11CC,Vitamin D and analogues,65+,M,277.13,0.1,0.6,"2,574",90
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,65+,M,273.92,0.1,0.8,"3,220",91
11,British Columbia,A02BA,H2-receptor antagonists,65+,M,270.24,0.1,1.4,"5,435",92
11,British Columbia,J02AC,Triazole derivatives,65+,M,267.92,0.1,0.1,276,93
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,65+,M,265.93,0.1,0.6,"2,309",94
11,British Columbia,M03BX,Other centrally acting agents,65+,M,265.34,0.1,2.6,"10,434",95
11,British Columbia,C01BD,"Antiarrhythmics, class III",65+,M,240.23,0.1,0.9,"3,436",96
11,British Columbia,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,M,235.54,0.1,4.8,"19,204",97
11,British Columbia,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",65+,M,234.48,0.1,0.5,"1,998",98
11,British Columbia,S01BA,"Corticosteroids, plain",65+,M,229.25,0.1,4.1,"16,341",99
11,British Columbia,A12BA,Potassium,65+,M,223.78,0.1,1.6,"6,434",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,"23,439.18",9.3,0.4,"1,836",1
11,British Columbia,B01AF,Direct factor Xa inhibitors,65+,F,"13,311.87",5.3,4.8,"21,878",2
11,British Columbia,L04AA,Selective immunosuppressants,65+,F,"12,072.78",4.8,0.5,"2,059",3
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,65+,F,"9,591.50",3.8,34.3,"155,592",4
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"7,083.59",2.8,3.8,"17,136",5
11,British Columbia,C08CA,Dihydropyridine derivatives,65+,F,"7,075.64",2.8,20.4,"92,559",6
11,British Columbia,A02BC,Proton pump inhibitors,65+,F,"6,670.60",2.7,14.6,"65,974",7
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,65+,F,"5,774.62",2.3,0.0,126,8
11,British Columbia,L04AC,Interleukin inhibitors,65+,F,"5,463.81",2.2,0.1,450,9
11,British Columbia,C07AB,"Beta-blocking agents, selective",65+,F,"5,245.56",2.1,17.6,"79,754",10
11,British Columbia,H03AA,Thyroid hormones,65+,F,"5,052.36",2.0,23.5,"106,662",11
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,65+,F,"4,968.93",2.0,12.8,"58,215",12
11,British Columbia,C09AA,"ACE inhibitors, plain",65+,F,"4,861.86",1.9,21.6,"97,847",13
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,"4,454.87",1.8,9.0,"40,567",14
11,British Columbia,N06AX,Other antidepressants,65+,F,"4,337.71",1.7,11.9,"53,901",15
11,British Columbia,N05AX,Other antipsychotics,65+,F,"3,706.48",1.5,1.5,"6,867",16
11,British Columbia,N02AA,Natural opium alkaloids,65+,F,"3,530.10",1.4,6.2,"28,030",17
11,British Columbia,N03AX,Other antiepileptics,65+,F,"3,488.73",1.4,8.4,"37,986",18
11,British Columbia,L01XC,Monoclonal antibodies,65+,F,"3,424.35",1.4,0.1,317,19
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"3,248.60",1.3,1.4,"6,329",20
11,British Columbia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,65+,F,"3,214.75",1.3,1.2,"5,362",21
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"3,110.87",1.2,4.2,"19,029",22
11,British Columbia,R03BB,Anticholinergics,65+,F,"3,107.92",1.2,4.0,"18,080",23
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"2,774.86",1.1,3.0,"13,512",24
11,British Columbia,A10BA,Biguanides,65+,F,"2,745.69",1.1,11.1,"50,401",25
11,British Columbia,C03CA,"Sulfonamides, plain",65+,F,"2,349.88",0.9,8.2,"37,078",26
11,British Columbia,R03BA,Glucocorticoids,65+,F,"2,157.95",0.9,3.7,"16,843",27
11,British Columbia,S01ED,Beta-blocking agents,65+,F,"1,849.76",0.7,4.0,"17,953",28
11,British Columbia,N04BA,Dopa and dopa derivatives,65+,F,"1,847.40",0.7,1.1,"4,949",29
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"1,830.87",0.7,0.0,66,30
11,British Columbia,B02AB,Proteinase inhibitors,65+,F,"1,795.28",0.7,0.0,21,31
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"1,778.49",0.7,0.9,"4,285",32
11,British Columbia,S01EE,Prostaglandin analogues,65+,F,"1,775.63",0.7,4.0,"18,277",33
11,British Columbia,C08DB,Benzothiazepine derivatives,65+,F,"1,747.21",0.7,3.1,"13,843",34
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"1,626.23",0.6,1.3,"5,823",35
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"1,593.51",0.6,0.0,114,36
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,65+,F,"1,542.49",0.6,1.0,"4,372",37
11,British Columbia,B03AA,"Iron bivalent, oral preparations",65+,F,"1,508.61",0.6,3.5,"15,872",38
11,British Columbia,N05BA,Benzodiazepine derivatives,65+,F,"1,436.67",0.6,9.9,"45,073",39
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"1,432.55",0.6,10.9,"49,466",40
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"1,427.03",0.6,0.6,"2,507",41
11,British Columbia,C03AA,"Thiazides, plain",65+,F,"1,411.02",0.6,12.2,"55,107",42
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"1,363.20",0.5,9.8,"44,420",43
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"1,317.26",0.5,4.5,"20,206",44
11,British Columbia,B01AB,Heparin group,65+,F,"1,284.21",0.5,0.5,"2,403",45
11,British Columbia,A10BB,Sulfonylureas,65+,F,"1,259.92",0.5,2.5,"11,110",46
11,British Columbia,N06DA,Anticholinesterases,65+,F,"1,242.88",0.5,1.0,"4,548",47
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"1,193.87",0.5,0.5,"2,176",48
11,British Columbia,L01EX,Other protein kinase inhibitors,65+,F,**,**,**,**,49
11,British Columbia,C01DA,Organic nitrates,65+,F,"1,123.48",0.4,3.1,"14,159",50
11,British Columbia,L03AA,Colony-stimulating factors,65+,F,"1,076.86",0.4,0.1,481,51
11,British Columbia,M05BA,Bisphosphonates,65+,F,"1,044.99",0.4,1.9,"8,722",52
11,British Columbia,N07BA,Drugs used in nicotine dependence,65+,F,"1,013.22",0.4,1.4,"6,333",53
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,960.35,0.4,1.3,"6,050",54
11,British Columbia,H02AB,Glucocorticoids,65+,F,939.88,0.4,9.9,"44,855",55
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,933.92,0.4,0.3,"1,231",56
11,British Columbia,B01AA,Vitamin K antagonists,65+,F,922.85,0.4,2.2,"10,091",57
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,868.96,0.3,0.7,"3,139",58
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,850.27,0.3,0.5,"2,089",59
11,British Columbia,B01AE,Direct thrombin inhibitors,65+,F,818.91,0.3,0.2,"1,056",60
11,British Columbia,L04AX,Other immunosuppressants,65+,F,799.47,0.3,0.3,"1,194",61
11,British Columbia,M04AA,Preparations inhibiting uric acid production,65+,F,794.86,0.3,2.3,"10,383",62
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,F,758.22,0.3,0.1,486,63
11,British Columbia,L01BA,Folic acid analogues,65+,F,725.25,0.3,1.7,"7,914",64
11,British Columbia,N07BC,Drugs used in opioid dependence,65+,F,718.80,0.3,0.2,816,65
11,British Columbia,A03FA,Propulsives,65+,F,718.58,0.3,2.7,"12,149",66
11,British Columbia,A09AA,Enzyme preparations,65+,F,683.22,0.3,0.4,"1,733",67
11,British Columbia,C10AX,Other lipid-modifying agents,65+,F,653.34,0.3,0.1,582,68
11,British Columbia,A05AA,Bile acids and derivatives,65+,F,645.84,0.3,0.2,"1,106",69
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,644.09,0.3,5.0,"22,761",70
11,British Columbia,C03DA,Aldosterone antagonists,65+,F,616.52,0.2,2.8,"12,656",71
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",65+,F,615.00,0.2,9.4,"42,409",72
11,British Columbia,A04AD,Other antiemetics,65+,F,611.40,0.2,0.3,"1,508",73
11,British Columbia,G04BE,Drugs used in erectile dysfunction,65+,F,609.68,0.2,0.0,118,74
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",65+,F,597.28,0.2,1.7,"7,769",75
11,British Columbia,N03AG,Fatty acid derivatives,65+,F,592.98,0.2,0.5,"2,104",76
11,British Columbia,N03AE,Benzodiazepine derivatives,65+,F,585.69,0.2,1.8,"7,990",77
11,British Columbia,S01EC,Carbonic anhydrase inhibitors,65+,F,574.32,0.2,1.4,"6,399",78
11,British Columbia,N05CF,Benzodiazepine-related drugs,65+,F,573.40,0.2,2.0,"8,959",79
11,British Columbia,C01AA,Digitalis glycosides,65+,F,550.80,0.2,1.1,"4,788",80
11,British Columbia,V03AC,Iron-chelating agents,65+,F,535.50,0.2,0.0,33,81
11,British Columbia,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,513.50,0.2,1.6,"7,086",82
11,British Columbia,A12BA,Potassium,65+,F,499.59,0.2,2.4,"10,673",83
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,F,491.68,0.2,0.1,563,84
11,British Columbia,N02AB,Phenylpiperidine derivatives,65+,F,469.74,0.2,0.2,"1,109",85
11,British Columbia,C02DB,Hydrazinophthalazine derivatives,65+,F,453.27,0.2,0.9,"4,106",86
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,453.15,0.2,4.1,"18,468",87
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,65+,F,447.73,0.2,1.1,"5,111",88
11,British Columbia,C05BA,Heparins or heparinoids for topical use,65+,F,443.32,0.2,0.1,401,89
11,British Columbia,J01XE,Nitrofuran derivatives,65+,F,422.73,0.2,8.3,"37,508",90
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,418.57,0.2,0.4,"1,809",91
11,British Columbia,A02BA,H2-receptor antagonists,65+,F,408.00,0.2,1.8,"8,103",92
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,65+,F,398.56,0.2,0.6,"2,669",93
11,British Columbia,C07AG,Alpha- and beta-blocking agents,65+,F,397.72,0.2,0.4,"1,999",94
11,British Columbia,P01BA,Aminoquinolines,65+,F,388.46,0.2,1.6,"7,054",95
11,British Columbia,S01BA,"Corticosteroids, plain",65+,F,385.35,0.2,4.6,"20,846",96
11,British Columbia,M03BX,Other centrally acting agents,65+,F,371.85,0.1,3.1,"14,202",97
11,British Columbia,A11CC,Vitamin D and analogues,65+,F,325.17,0.1,0.6,"2,846",98
11,British Columbia,J02AC,Triazole derivatives,65+,F,323.39,0.1,0.1,292,99
11,British Columbia,A07AA,Antibiotics,65+,F,323.10,0.1,1.2,"5,611",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,"135,762.62",18.1,0.5,"9,968",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,<65,Total,"71,988.16",9.6,0.1,"1,548",2
11,British Columbia,N05AX,Other antipsychotics,<65,Total,"50,040.17",6.7,1.5,"30,041",3
11,British Columbia,L04AA,Selective immunosuppressants,<65,Total,"47,488.42",6.3,0.3,"5,579",4
11,British Columbia,N07BC,Drugs used in opioid dependence,<65,Total,"38,233.02",5.1,1.3,"25,668",5
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"28,242.43",3.8,3.7,"74,027",6
11,British Columbia,N02AA,Natural opium alkaloids,<65,Total,"27,244.13",3.6,2.6,"52,563",7
11,British Columbia,L04AC,Interleukin inhibitors,<65,Total,"24,910.56",3.3,0.1,"2,013",8
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"16,780.88",2.2,13.3,"269,283",9
11,British Columbia,N06AX,Other antidepressants,<65,Total,"14,357.65",1.9,7.8,"157,451",10
11,British Columbia,N03AX,Other antiepileptics,<65,Total,"13,930.39",1.9,4.5,"90,967",11
11,British Columbia,N06BA,Centrally acting sympathomimetics,<65,Total,"10,306.53",1.4,1.7,"34,820",12
11,British Columbia,N07BA,Drugs used in nicotine dependence,<65,Total,"10,228.12",1.4,3.4,"68,019",13
11,British Columbia,L04AX,Other immunosuppressants,<65,Total,"9,070.20",1.2,0.2,"4,325",14
11,British Columbia,A02BC,Proton pump inhibitors,<65,Total,"7,178.36",1.0,3.8,"77,339",15
11,British Columbia,L01XC,Monoclonal antibodies,<65,Total,"6,925.66",0.9,0.0,756,16
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"6,249.42",0.8,1.3,"26,988",17
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,<65,Total,"5,859.86",0.8,9.5,"192,198",18
11,British Columbia,B02AB,Proteinase inhibitors,<65,Total,"5,771.15",0.8,0.0,59,19
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"5,031.73",0.7,0.6,"12,288",20
11,British Columbia,N03AG,Fatty acid derivatives,<65,Total,"4,785.28",0.6,0.7,"14,442",21
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"4,627.44",0.6,0.5,"11,072",22
11,British Columbia,R03BA,Glucocorticoids,<65,Total,"4,169.74",0.6,4.4,"89,737",23
11,British Columbia,H03AA,Thyroid hormones,<65,Total,"3,979.32",0.5,6.7,"136,711",24
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"3,883.40",0.5,0.0,286,25
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,<65,Total,"3,876.16",0.5,0.7,"14,737",26
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"3,861.97",0.5,0.0,138,27
11,British Columbia,C09AA,"ACE inhibitors, plain",<65,Total,"3,695.26",0.5,6.8,"137,742",28
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"3,241.59",0.4,1.1,"21,354",29
11,British Columbia,A09AA,Enzyme preparations,<65,Total,"3,225.24",0.4,0.1,"2,918",30
11,British Columbia,L03AA,Colony-stimulating factors,<65,Total,"3,207.36",0.4,0.1,"1,361",31
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"3,173.94",0.4,9.5,"192,705",32
11,British Columbia,N05BA,Benzodiazepine derivatives,<65,Total,"3,103.41",0.4,6.1,"122,622",33
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"3,060.18",0.4,2.5,"50,919",34
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"3,020.19",0.4,0.1,"2,610",35
11,British Columbia,N03AF,Carboxamide derivatives,<65,Total,"2,859.28",0.4,0.4,"8,168",36
11,British Columbia,V03AC,Iron-chelating agents,<65,Total,"2,840.16",0.4,0.0,91,37
11,British Columbia,B01AF,Direct factor Xa inhibitors,<65,Total,"2,773.98",0.4,0.4,"8,093",38
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"2,764.65",0.4,0.5,"9,841",39
11,British Columbia,M01AE,Propionic acid derivatives,<65,Total,"2,713.48",0.4,6.5,"131,006",40
11,British Columbia,A10BA,Biguanides,<65,Total,"2,699.04",0.4,4.6,"92,307",41
11,British Columbia,C08CA,Dihydropyridine derivatives,<65,Total,"2,652.50",0.4,4.3,"87,808",42
11,British Columbia,L03AB,Interferons,<65,Total,"2,589.50",0.3,0.0,167,43
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"2,572.48",0.3,10.4,"210,902",44
11,British Columbia,N03AE,Benzodiazepine derivatives,<65,Total,"2,470.69",0.3,1.3,"27,307",45
11,British Columbia,C07AB,"Beta-blocking agents, selective",<65,Total,"2,323.92",0.3,3.3,"66,031",46
11,British Columbia,M03BX,Other centrally acting agents,<65,Total,"2,323.35",0.3,4.6,"93,598",47
11,British Columbia,B01AB,Heparin group,<65,Total,"2,239.00",0.3,0.1,"3,016",48
11,British Columbia,A04AD,Other antiemetics,<65,Total,"2,202.79",0.3,0.2,"4,194",49
11,British Columbia,R05CB,Mucolytics,<65,Total,"2,174.55",0.3,0.0,297,50
11,British Columbia,R03BB,Anticholinergics,<65,Total,"2,133.50",0.3,0.8,"16,830",51
11,British Columbia,L03AX,Other immunostimulants,<65,Total,"2,108.73",0.3,0.0,313,52
11,British Columbia,H01AC,Somatropin and somatropin agonists,<65,Total,**,**,**,**,53
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,<65,Total,"1,968.25",0.3,1.9,"39,464",54
11,British Columbia,N07BB,Drugs used in alcohol dependence,<65,Total,"1,804.97",0.2,0.4,"7,412",55
11,British Columbia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,Total,"1,764.41",0.2,0.2,"4,146",56
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"1,704.96",0.2,6.0,"120,945",57
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"1,572.29",0.2,5.1,"102,672",58
11,British Columbia,N05AN,Lithium,<65,Total,"1,542.58",0.2,0.4,"7,608",59
11,British Columbia,A05AA,Bile acids and derivatives,<65,Total,"1,517.50",0.2,0.1,"2,195",60
11,British Columbia,B03AA,"Iron bivalent, oral preparations",<65,Total,"1,491.05",0.2,1.0,"20,363",61
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"1,394.68",0.2,0.2,"4,074",62
11,British Columbia,N05CF,Benzodiazepine-related drugs,<65,Total,"1,374.42",0.2,0.5,"10,183",63
11,British Columbia,C02AC,Imidazoline receptor agonists,<65,Total,"1,370.70",0.2,0.6,"11,531",64
11,British Columbia,N05AF,Thioxanthene derivatives,<65,Total,"1,334.48",0.2,0.1,"1,989",65
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"1,328.29",0.2,0.1,"2,698",66
11,British Columbia,G02BA,Intrauterine contraceptives,<65,Total,"1,235.99",0.2,1.3,"26,183",67
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,"1,228.75",0.2,0.3,"7,009",68
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,"1,218.25",0.2,0.1,"1,086",69
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,<65,Total,"1,195.22",0.2,0.2,"4,571",70
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",<65,Total,"1,139.25",0.2,1.0,"20,853",71
11,British Columbia,H02AB,Glucocorticoids,<65,Total,"1,121.70",0.1,6.2,"124,599",72
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,"1,098.20",0.1,1.0,"19,558",73
11,British Columbia,A10BB,Sulfonylureas,<65,Total,"1,092.64",0.1,0.8,"15,191",74
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,"1,081.76",0.1,0.2,"4,774",75
11,British Columbia,J02AC,Triazole derivatives,<65,Total,**,**,**,**,76
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,"1,024.33",0.1,1.5,"29,696",77
11,British Columbia,G04BE,Drugs used in erectile dysfunction,<65,Total,"1,019.97",0.1,0.0,286,78
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,<65,Total,"1,006.86",0.1,0.2,"5,008",79
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",<65,Total,998.18,0.1,8.6,"174,663",80
11,British Columbia,N05BE,Azaspirodecanedione derivatives,<65,Total,979.51,0.1,0.4,"7,639",81
11,British Columbia,J01DF,Monobactams,<65,Total,**,**,**,**,82
11,British Columbia,N05AE,Indole derivatives,<65,Total,950.96,0.1,0.0,691,83
11,British Columbia,A02BA,H2-receptor antagonists,<65,Total,923.82,0.1,1.0,"20,687",84
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,<65,Total,913.28,0.1,1.7,"34,567",85
11,British Columbia,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,**,**,**,**,86
11,British Columbia,C03CA,"Sulfonamides, plain",<65,Total,861.01,0.1,0.8,"15,822",87
11,British Columbia,N02AB,Phenylpiperidine derivatives,<65,Total,847.17,0.1,0.1,"1,176",88
11,British Columbia,L01BA,Folic acid analogues,<65,Total,845.21,0.1,0.7,"13,701",89
11,British Columbia,J01DB,First-generation cephalosporins,<65,Total,798.98,0.1,6.7,"134,916",90
11,British Columbia,J01CA,Penicillins with extended spectrum,<65,Total,775.35,0.1,14.1,"284,608",91
11,British Columbia,C03AA,"Thiazides, plain",<65,Total,772.15,0.1,2.5,"50,805",92
11,British Columbia,J01GB,Other aminoglycosides,<65,Total,749.16,0.1,0.0,174,93
11,British Columbia,C03DA,Aldosterone antagonists,<65,Total,735.01,0.1,1.0,"20,270",94
11,British Columbia,A16AX,Various alimentary tract and metabolism products,<65,Total,731.90,0.1,0.0,47,95
11,British Columbia,C10AX,Other lipid-modifying agents,<65,Total,722.24,0.1,0.0,941,96
11,British Columbia,J01AA,Tetracyclines,<65,Total,705.88,0.1,4.0,"81,324",97
11,British Columbia,A03FA,Propulsives,<65,Total,684.89,0.1,1.4,"28,424",98
11,British Columbia,H01AX,Other anterior pituitary lobe hormones and analogues,<65,Total,**,**,**,**,99
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,<65,Total,674.37,0.1,0.2,"3,694",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,"69,039.98",17.6,0.5,"4,846",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,<65,M,"48,530.70",12.4,0.1,"1,041",2
11,British Columbia,N05AX,Other antipsychotics,<65,M,"32,606.54",8.3,1.9,"17,115",3
11,British Columbia,N07BC,Drugs used in opioid dependence,<65,M,"25,990.55",6.6,2.0,"17,244",4
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"18,208.32",4.6,4.0,"35,029",5
11,British Columbia,N02AA,Natural opium alkaloids,<65,M,"17,007.82",4.3,2.9,"25,187",6
11,British Columbia,L04AA,Selective immunosuppressants,<65,M,"16,795.16",4.3,0.2,"1,800",7
11,British Columbia,L04AC,Interleukin inhibitors,<65,M,"12,023.63",3.1,0.1,924,8
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,<65,M,"7,163.81",1.8,10.4,"91,662",9
11,British Columbia,N06AX,Other antidepressants,<65,M,"6,705.52",1.7,6.7,"59,409",10
11,British Columbia,N03AX,Other antiepileptics,<65,M,"6,585.73",1.7,4.2,"36,989",11
11,British Columbia,N06BA,Centrally acting sympathomimetics,<65,M,"6,190.33",1.6,2.3,"20,101",12
11,British Columbia,N07BA,Drugs used in nicotine dependence,<65,M,"5,858.18",1.5,4.4,"38,794",13
11,British Columbia,A02BC,Proton pump inhibitors,<65,M,"3,508.76",0.9,3.9,"34,547",14
11,British Columbia,B02AB,Proteinase inhibitors,<65,M,"3,432.28",0.9,0.0,32,15
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,<65,M,"3,353.28",0.9,13.8,"121,684",16
11,British Columbia,N03AG,Fatty acid derivatives,<65,M,"2,957.28",0.8,0.9,"8,139",17
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"2,707.16",0.7,1.3,"11,277",18
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"2,670.69",0.7,0.8,"6,768",19
11,British Columbia,L04AX,Other immunosuppressants,<65,M,"2,636.78",0.7,0.2,"1,633",20
11,British Columbia,C09AA,"ACE inhibitors, plain",<65,M,"2,227.63",0.6,9.6,"85,052",21
11,British Columbia,A09AA,Enzyme preparations,<65,M,"2,025.34",0.5,0.2,"1,448",22
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,<65,M,"1,897.29",0.5,0.7,"6,437",23
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"1,766.19",0.4,1.3,"11,300",24
11,British Columbia,R03BA,Glucocorticoids,<65,M,"1,763.52",0.4,4.6,"40,493",25
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"1,747.62",0.4,0.0,130,26
11,British Columbia,L01XC,Monoclonal antibodies,<65,M,"1,746.55",0.4,0.0,204,27
11,British Columbia,B01AF,Direct factor Xa inhibitors,<65,M,"1,734.22",0.4,0.6,"5,017",28
11,British Columbia,N03AF,Carboxamide derivatives,<65,M,"1,653.31",0.4,0.5,"4,044",29
11,British Columbia,M01AE,Propionic acid derivatives,<65,M,"1,561.86",0.4,6.7,"58,945",30
11,British Columbia,C08CA,Dihydropyridine derivatives,<65,M,"1,477.89",0.4,5.8,"51,472",31
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"1,475.53",0.4,0.7,"5,899",32
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"1,448.22",0.4,0.9,"8,177",33
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,"1,439.40",0.4,10.3,"91,118",34
11,British Columbia,C07AB,"Beta-blocking agents, selective",<65,M,"1,434.79",0.4,4.5,"40,119",35
11,British Columbia,A10BA,Biguanides,<65,M,"1,409.40",0.4,5.8,"51,312",36
11,British Columbia,N05BA,Benzodiazepine derivatives,<65,M,"1,402.82",0.4,4.6,"40,226",37
11,British Columbia,H01AC,Somatropin and somatropin agonists,<65,M,**,**,**,**,38
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"1,327.50",0.3,1.9,"16,366",39
11,British Columbia,V03AC,Iron-chelating agents,<65,M,"1,300.63",0.3,0.0,41,40
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"1,288.57",0.3,0.1,887,41
11,British Columbia,N03AE,Benzodiazepine derivatives,<65,M,"1,197.51",0.3,1.2,"10,435",42
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"1,179.49",0.3,10.5,"92,549",43
11,British Columbia,R05CB,Mucolytics,<65,M,"1,154.20",0.3,0.0,153,44
11,British Columbia,R03BB,Anticholinergics,<65,M,"1,123.84",0.3,0.9,"8,173",45
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,"1,107.55",0.3,0.0,38,46
11,British Columbia,M03BX,Other centrally acting agents,<65,M,"1,084.10",0.3,4.6,"40,622",47
11,British Columbia,B01AB,Heparin group,<65,M,"1,045.47",0.3,0.1,"1,271",48
11,British Columbia,A04AD,Other antiemetics,<65,M,"1,016.75",0.3,0.2,"1,786",49
11,British Columbia,H03AA,Thyroid hormones,<65,M,"1,009.53",0.3,3.0,"26,137",50
11,British Columbia,N07BB,Drugs used in alcohol dependence,<65,M,"1,004.54",0.3,0.5,"4,212",51
11,British Columbia,L03AA,Colony-stimulating factors,<65,M,973.57,0.2,0.0,367,52
11,British Columbia,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,960.09,0.2,0.1,872,53
11,British Columbia,N05AF,Thioxanthene derivatives,<65,M,901.11,0.2,0.2,"1,325",54
11,British Columbia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,M,860.73,0.2,0.2,"2,206",55
11,British Columbia,N05AN,Lithium,<65,M,844.36,0.2,0.4,"3,639",56
11,British Columbia,C02AC,Imidazoline receptor agonists,<65,M,786.31,0.2,0.6,"5,459",57
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,758.26,0.2,0.2,"1,619",58
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,<65,M,734.03,0.2,0.3,"2,738",59
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,711.17,0.2,0.3,"2,369",60
11,British Columbia,N05CF,Benzodiazepine-related drugs,<65,M,652.33,0.2,0.4,"3,951",61
11,British Columbia,L03AB,Interferons,<65,M,650.10,0.2,0.0,45,62
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,639.50,0.2,0.3,"2,571",63
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,<65,M,634.32,0.2,2.8,"24,894",64
11,British Columbia,J02AC,Triazole derivatives,<65,M,621.79,0.2,0.0,415,65
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,606.21,0.2,0.3,"2,710",66
11,British Columbia,A10BB,Sulfonylureas,<65,M,586.26,0.1,1.0,"8,775",67
11,British Columbia,B03AA,"Iron bivalent, oral preparations",<65,M,568.97,0.1,0.6,"5,115",68
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",<65,M,555.48,0.1,0.9,"8,155",69
11,British Columbia,L01EX,Other protein kinase inhibitors,<65,M,**,**,**,**,70
11,British Columbia,L03AX,Other immunostimulants,<65,M,**,**,**,**,71
11,British Columbia,A02BA,H2-receptor antagonists,<65,M,501.84,0.1,0.9,"7,784",72
11,British Columbia,J01GB,Other aminoglycosides,<65,M,474.28,0.1,0.0,93,73
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,473.29,0.1,3.8,"33,872",74
11,British Columbia,H02AB,Glucocorticoids,<65,M,472.71,0.1,6.2,"55,176",75
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,461.64,0.1,1.0,"8,947",76
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",<65,M,457.47,0.1,8.5,"74,671",77
11,British Columbia,C03CA,"Sulfonamides, plain",<65,M,453.19,0.1,0.9,"8,051",78
11,British Columbia,J01DF,Monobactams,<65,M,**,**,**,**,79
11,British Columbia,G03BA,3-oxoandrosten (4) derivatives,<65,M,**,**,**,**,80
11,British Columbia,A16AX,Various alimentary tract and metabolism products,<65,M,435.96,0.1,0.0,14,81
11,British Columbia,N05BE,Azaspirodecanedione derivatives,<65,M,423.62,0.1,0.3,"2,760",82
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,<65,M,423.28,0.1,0.9,"7,523",83
11,British Columbia,J01DB,First-generation cephalosporins,<65,M,418.26,0.1,7.3,"64,422",84
11,British Columbia,C10AX,Other lipid-modifying agents,<65,M,386.52,0.1,0.1,572,85
11,British Columbia,N02AB,Phenylpiperidine derivatives,<65,M,385.04,0.1,0.1,479,86
11,British Columbia,N05AE,Indole derivatives,<65,M,384.63,0.1,0.0,267,87
11,British Columbia,C03DA,Aldosterone antagonists,<65,M,381.37,0.1,0.8,"7,127",88
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,<65,M,380.45,0.1,0.2,"1,871",89
11,British Columbia,C03AA,"Thiazides, plain",<65,M,362.76,0.1,2.6,"23,310",90
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,<65,M,358.51,0.1,1.7,"15,406",91
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,349.71,0.1,0.1,"1,014",92
11,British Columbia,J01AA,Tetracyclines,<65,M,349.46,0.1,4.0,"34,974",93
11,British Columbia,J01CA,Penicillins with extended spectrum,<65,M,342.80,0.1,15.0,"132,398",94
11,British Columbia,N03AB,Hydantoin derivatives,<65,M,326.91,0.1,0.3,"2,342",95
11,British Columbia,M04AA,Preparations inhibiting uric acid production,<65,M,317.42,0.1,2.3,"20,373",96
11,British Columbia,G04BE,Drugs used in erectile dysfunction,<65,M,315.84,0.1,0.0,121,97
11,British Columbia,C07AG,Alpha- and beta-blocking agents,<65,M,307.69,0.1,0.2,"1,827",98
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,<65,M,306.51,0.1,0.2,"1,886",99
11,British Columbia,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,304.50,0.1,4.7,"41,667",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,"66,722.64",18.7,0.4,"5,122",1
11,British Columbia,L04AA,Selective immunosuppressants,<65,F,"30,693.26",8.6,0.3,"3,779",2
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,<65,F,"23,457.46",6.6,0.0,507,3
11,British Columbia,N05AX,Other antipsychotics,<65,F,"17,433.62",4.9,1.1,"12,926",4
11,British Columbia,L04AC,Interleukin inhibitors,<65,F,"12,886.93",3.6,0.1,"1,089",5
11,British Columbia,N07BC,Drugs used in opioid dependence,<65,F,"12,242.47",3.4,0.7,"8,424",6
11,British Columbia,N02AA,Natural opium alkaloids,<65,F,"10,236.32",2.9,2.4,"27,376",7
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"10,034.11",2.8,3.4,"38,998",8
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,<65,F,"9,617.07",2.7,15.6,"177,621",9
11,British Columbia,N06AX,Other antidepressants,<65,F,"7,652.13",2.1,8.6,"98,042",10
11,British Columbia,N03AX,Other antiepileptics,<65,F,"7,344.66",2.1,4.7,"53,978",11
11,British Columbia,L04AX,Other immunosuppressants,<65,F,"6,433.43",1.8,0.2,"2,692",12
11,British Columbia,L01XC,Monoclonal antibodies,<65,F,"5,179.11",1.4,0.0,552,13
11,British Columbia,N07BA,Drugs used in nicotine dependence,<65,F,"4,369.94",1.2,2.6,"29,225",14
11,British Columbia,N06BA,Centrally acting sympathomimetics,<65,F,"4,116.21",1.2,1.3,"14,719",15
11,British Columbia,A02BC,Proton pump inhibitors,<65,F,"3,669.60",1.0,3.7,"42,792",16
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"3,542.26",1.0,1.4,"15,711",17
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"3,179.22",0.9,0.3,"2,895",18
11,British Columbia,H03AA,Thyroid hormones,<65,F,"2,969.79",0.8,9.7,"110,574",19
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"2,754.43",0.8,0.0,100,20
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,<65,F,"2,506.58",0.7,6.2,"70,514",21
11,British Columbia,R03BA,Glucocorticoids,<65,F,"2,406.03",0.7,4.3,"49,243",22
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"2,361.04",0.7,0.5,"5,520",23
11,British Columbia,B02AB,Proteinase inhibitors,<65,F,"2,338.88",0.7,0.0,27,24
11,British Columbia,L03AA,Colony-stimulating factors,<65,F,"2,233.79",0.6,0.1,994,25
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"2,135.78",0.6,0.0,156,26
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,<65,F,"1,978.87",0.6,0.7,"8,300",27
11,British Columbia,L03AB,Interferons,<65,F,"1,939.40",0.5,0.0,122,28
11,British Columbia,N03AG,Fatty acid derivatives,<65,F,"1,828.01",0.5,0.6,"6,303",29
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,"1,734.54",0.5,8.9,"101,587",30
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"1,732.68",0.5,3.0,"34,553",31
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"1,731.62",0.5,0.2,"1,723",32
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,"1,704.06",0.5,10.6,"120,896",33
11,British Columbia,N05BA,Benzodiazepine derivatives,<65,F,"1,700.59",0.5,7.2,"82,396",34
11,British Columbia,L03AX,Other immunostimulants,<65,F,**,**,**,**,35
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,<65,F,"1,544.96",0.4,2.8,"31,941",36
11,British Columbia,V03AC,Iron-chelating agents,<65,F,"1,539.53",0.4,0.0,50,37
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"1,475.40",0.4,0.9,"10,054",38
11,British Columbia,C09AA,"ACE inhibitors, plain",<65,F,"1,467.62",0.4,4.6,"52,690",39
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"1,392.97",0.4,10.4,"118,352",40
11,British Columbia,A05AA,Bile acids and derivatives,<65,F,"1,299.33",0.4,0.1,"1,519",41
11,British Columbia,A10BA,Biguanides,<65,F,"1,289.64",0.4,3.6,"40,995",42
11,British Columbia,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"1,289.12",0.4,0.3,"3,942",43
11,British Columbia,N03AE,Benzodiazepine derivatives,<65,F,"1,273.18",0.4,1.5,"16,872",44
11,British Columbia,M03BX,Other centrally acting agents,<65,F,"1,239.25",0.3,4.6,"52,976",45
11,British Columbia,G02BA,Intrauterine contraceptives,<65,F,"1,233.68",0.3,2.3,"26,172",46
11,British Columbia,N03AF,Carboxamide derivatives,<65,F,"1,205.97",0.3,0.4,"4,124",47
11,British Columbia,A09AA,Enzyme preparations,<65,F,"1,199.91",0.3,0.1,"1,470",48
11,British Columbia,B01AB,Heparin group,<65,F,"1,193.54",0.3,0.2,"1,745",49
11,British Columbia,A04AD,Other antiemetics,<65,F,"1,186.05",0.3,0.2,"2,408",50
11,British Columbia,C08CA,Dihydropyridine derivatives,<65,F,"1,174.61",0.3,3.2,"36,336",51
11,British Columbia,M01AE,Propionic acid derivatives,<65,F,"1,151.62",0.3,6.3,"72,061",52
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,"1,099.00",0.3,6.0,"68,800",53
11,British Columbia,B01AF,Direct factor Xa inhibitors,<65,F,"1,039.75",0.3,0.3,"3,076",54
11,British Columbia,R05CB,Mucolytics,<65,F,"1,020.35",0.3,0.0,144,55
11,British Columbia,R03BB,Anticholinergics,<65,F,"1,009.67",0.3,0.8,"8,657",56
11,British Columbia,B03AA,"Iron bivalent, oral preparations",<65,F,922.08,0.3,1.3,"15,248",57
11,British Columbia,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,F,903.68,0.3,0.2,"1,940",58
11,British Columbia,C07AB,"Beta-blocking agents, selective",<65,F,889.13,0.2,2.3,"25,912",59
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,826.76,0.2,2.5,"28,495",60
11,British Columbia,N07BB,Drugs used in alcohol dependence,<65,F,800.44,0.2,0.3,"3,200",61
11,British Columbia,N05CF,Benzodiazepine-related drugs,<65,F,722.09,0.2,0.5,"6,232",62
11,British Columbia,G04BE,Drugs used in erectile dysfunction,<65,F,704.13,0.2,0.0,165,63
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,<65,F,700.35,0.2,0.3,"3,122",64
11,British Columbia,N05AN,Lithium,<65,F,698.22,0.2,0.3,"3,969",65
11,British Columbia,H01AC,Somatropin and somatropin agonists,<65,F,**,**,**,**,66
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,683.51,0.2,0.1,"1,705",67
11,British Columbia,H02AB,Glucocorticoids,<65,F,648.99,0.2,6.1,"69,423",68
11,British Columbia,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,636.56,0.2,0.9,"10,611",69
11,British Columbia,L02AE,Gonadotropin-releasing hormone analogues,<65,F,**,**,**,**,70
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,622.54,0.2,0.4,"4,299",71
11,British Columbia,C02AC,Imidazoline receptor agonists,<65,F,584.39,0.2,0.5,"6,072",72
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",<65,F,583.77,0.2,1.1,"12,698",73
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,570.02,0.2,0.1,"1,079",74
11,British Columbia,N05AE,Indole derivatives,<65,F,566.33,0.2,0.0,424,75
11,British Columbia,N05BE,Azaspirodecanedione derivatives,<65,F,555.89,0.2,0.4,"4,879",76
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,<65,F,554.57,0.2,1.7,"19,160",77
11,British Columbia,L01BA,Folic acid analogues,<65,F,553.38,0.2,0.8,"8,626",78
11,British Columbia,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,**,**,**,**,79
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",<65,F,540.71,0.2,8.8,"99,992",80
11,British Columbia,J01DF,Monobactams,<65,F,**,**,**,**,81
11,British Columbia,A10BB,Sulfonylureas,<65,F,506.38,0.1,0.6,"6,416",82
11,British Columbia,G03AC,Progestogens,<65,F,**,**,**,**,83
11,British Columbia,H01AX,Other anterior pituitary lobe hormones and analogues,<65,F,**,**,**,**,84
11,British Columbia,N02AB,Phenylpiperidine derivatives,<65,F,462.13,0.1,0.1,697,85
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,<65,F,461.19,0.1,0.2,"1,833",86
11,British Columbia,C05BA,Heparins or heparinoids for topical use,<65,F,458.73,0.1,0.1,642,87
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,<65,F,454.36,0.1,0.0,360,88
11,British Columbia,J02AC,Triazole derivatives,<65,F,448.33,0.1,0.0,454,89
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,442.27,0.1,0.2,"2,203",90
11,British Columbia,N05AF,Thioxanthene derivatives,<65,F,433.37,0.1,0.1,664,91
11,British Columbia,J01CA,Penicillins with extended spectrum,<65,F,432.55,0.1,13.3,"152,210",92
11,British Columbia,A02BA,H2-receptor antagonists,<65,F,421.99,0.1,1.1,"12,903",93
11,British Columbia,C03AA,"Thiazides, plain",<65,F,409.39,0.1,2.4,"27,495",94
11,British Columbia,A03FA,Propulsives,<65,F,408.97,0.1,1.9,"21,459",95
11,British Columbia,C03CA,"Sulfonamides, plain",<65,F,407.82,0.1,0.7,"7,771",96
11,British Columbia,J01DB,First-generation cephalosporins,<65,F,380.72,0.1,6.2,"70,494",97
11,British Columbia,G04BD,Drugs for urinary frequency and incontinence,<65,F,367.60,0.1,0.3,"3,074",98
11,British Columbia,C02CA,Alpha-adrenoreceptor antagonists,<65,F,358.19,0.1,0.3,"3,018",99
11,British Columbia,J01AA,Tetracyclines,<65,F,356.41,0.1,4.1,"46,350",100
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,Total,"1,262.71",9.8,0.9,78,1
12,Yukon,J05AP,Antivirals for treatment of HCV infections,Total,Total,810.78,6.3,0.2,15,2
12,Yukon,L04AA,Selective immunosuppressants,Total,Total,662.62,5.1,0.9,72,3
12,Yukon,S01LA,Antineovascularization agents,Total,Total,**,**,**,**,4
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,322.41,2.5,0.3,27,5
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,261.62,2.0,3.4,285,6
12,Yukon,R07AX,Other respiratory system products,Total,Total,**,**,**,*,7
12,Yukon,L04AX,Other immunosuppressants,Total,Total,254.83,2.0,0.4,36,8
12,Yukon,C10AA,HMG-CoA reductase inhibitors,Total,Total,222.64,1.7,21.2,"1,783",9
12,Yukon,R03BB,Anticholinergics,Total,Total,190.71,1.5,5.8,491,10
12,Yukon,L04AC,Interleukin inhibitors,Total,Total,190.00,1.5,0.2,18,11
12,Yukon,C09AA,"ACE inhibitors, plain",Total,Total,171.42,1.3,17.9,"1,500",12
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,168.48,1.3,2.7,228,13
12,Yukon,A02BC,Proton pump inhibitors,Total,Total,151.66,1.2,16.2,"1,363",14
12,Yukon,N03AX,Other antiepileptics,Total,Total,126.75,1.0,6.2,523,15
12,Yukon,B01AF,Direct factor Xa inhibitors,Total,Total,123.29,1.0,1.5,123,16
12,Yukon,C08CA,Dihydropyridine derivatives,Total,Total,106.09,0.8,10.9,917,17
12,Yukon,N06AX,Other antidepressants,Total,Total,105.06,0.8,7.5,626,18
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,101.25,0.8,0.4,32,19
12,Yukon,R03BA,Glucocorticoids,Total,Total,101.06,0.8,4.0,339,20
12,Yukon,N02AA,Natural opium alkaloids,Total,Total,100.21,0.8,4.6,384,21
12,Yukon,B01AB,Heparin group,Total,Total,94.33,0.7,0.6,47,22
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,Total,Total,92.88,0.7,7.1,595,23
12,Yukon,N05AX,Other antipsychotics,Total,Total,91.52,0.7,0.8,70,24
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,Total,87.73,0.7,7.7,647,25
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,87.29,0.7,2.3,192,26
12,Yukon,L04AD,Calcineurin inhibitors,Total,Total,86.46,0.7,0.3,24,27
12,Yukon,N04BA,Dopa and dopa derivatives,Total,Total,85.69,0.7,0.5,46,28
12,Yukon,H03AA,Thyroid hormones,Total,Total,85.61,0.7,10.7,900,29
12,Yukon,C07AB,"Beta-blocking agents, selective",Total,Total,78.14,0.6,9.9,830,30
12,Yukon,N06BA,Centrally acting sympathomimetics,Total,Total,71.15,0.6,1.1,92,31
12,Yukon,L02BB,Antiandrogens,Total,Total,**,**,**,**,32
12,Yukon,A16AX,Various alimentary tract and metabolism products,Total,Total,**,**,**,*,33
12,Yukon,L01XC,Monoclonal antibodies,Total,Total,68.88,0.5,0.2,15,34
12,Yukon,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,Total,**,**,**,*,35
12,Yukon,A10BA,Biguanides,Total,Total,65.70,0.5,9.6,806,36
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,64.48,0.5,10.1,852,37
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,62.42,0.5,12.1,"1,013",38
12,Yukon,A07EC,Aminosalicylic acid and similar agents,Total,Total,62.13,0.5,1.0,82,39
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,58.65,0.5,2.2,184,40
12,Yukon,L02BX,Other hormone antagonists and related agents,Total,Total,57.89,0.4,0.1,6,41
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,52.07,0.4,5.5,465,42
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,45.74,0.4,1.0,83,43
12,Yukon,R05CB,Mucolytics,Total,Total,**,**,**,*,44
12,Yukon,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,Total,**,**,**,*,45
12,Yukon,L03AB,Interferons,Total,Total,**,**,**,*,46
12,Yukon,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,Total,**,**,**,*,47
12,Yukon,S01ED,Beta-blocking agents,Total,Total,38.81,0.3,1.7,140,48
12,Yukon,L01EX,Other protein kinase inhibitors,Total,Total,**,**,**,*,49
12,Yukon,B03XA,Other antianemic preparations,Total,Total,37.66,0.3,0.1,12,50
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,37.40,0.3,2.8,237,51
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,37.21,0.3,6.6,558,52
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,36.70,0.3,0.3,21,53
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,35.83,0.3,0.3,29,54
12,Yukon,C03AA,"Thiazides, plain",Total,Total,32.18,0.2,7.0,590,55
12,Yukon,C03CA,"Sulfonamides, plain",Total,Total,29.79,0.2,4.3,361,56
12,Yukon,A10BB,Sulfonylureas,Total,Total,29.70,0.2,3.6,299,57
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,28.95,0.2,2.5,211,58
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,Total,Total,28.55,0.2,1.2,100,59
12,Yukon,L02BG,Aromatase inhibitors,Total,Total,27.82,0.2,0.5,39,60
12,Yukon,H01CB,Somatostatin and analogues,Total,Total,**,**,**,*,61
12,Yukon,N05CF,Benzodiazepine-related drugs,Total,Total,27.24,0.2,5.0,420,62
12,Yukon,R05DA,Opium alkaloids and derivatives,Total,Total,26.79,0.2,1.3,113,63
12,Yukon,H02AB,Glucocorticoids,Total,Total,26.66,0.2,7.7,647,64
12,Yukon,S01EE,Prostaglandin analogues,Total,Total,26.10,0.2,1.7,139,65
12,Yukon,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,Total,**,**,**,*,66
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,25.00,0.2,0.4,32,67
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,24.81,0.2,2.2,185,68
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,Total,Total,**,**,**,*,69
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,24.19,0.2,0.5,46,70
12,Yukon,M01AB,Acetic acid derivatives and related substances,Total,Total,23.15,0.2,3.2,272,71
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,23.11,0.2,0.4,31,72
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,22.72,0.2,1.7,139,73
12,Yukon,M04AA,Preparations inhibiting uric acid production,Total,Total,22.29,0.2,2.4,199,74
12,Yukon,A09AA,Enzyme preparations,Total,Total,21.66,0.2,0.3,24,75
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,Total,Total,21.20,0.2,1.2,102,76
12,Yukon,N03AE,Benzodiazepine derivatives,Total,Total,20.53,0.2,1.8,148,77
12,Yukon,C08DB,Benzothiazepine derivatives,Total,Total,20.50,0.2,1.3,110,78
12,Yukon,R01AD,Corticosteroids,Total,Total,20.43,0.2,4.2,352,79
12,Yukon,M05BA,Bisphosphonates,Total,Total,20.27,0.2,1.7,143,80
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,**,**,**,*,81
12,Yukon,C03DA,Aldosterone antagonists,Total,Total,20.03,0.2,2.3,190,82
12,Yukon,N02AB,Phenylpiperidine derivatives,Total,Total,19.67,0.2,0.4,32,83
12,Yukon,C01DA,Organic nitrates,Total,Total,19.32,0.1,2.6,221,84
12,Yukon,L03AA,Colony-stimulating factors,Total,Total,19.29,0.1,0.2,14,85
12,Yukon,B01AA,Vitamin K antagonists,Total,Total,19.18,0.1,1.7,142,86
12,Yukon,N03AF,Carboxamide derivatives,Total,Total,19.06,0.1,0.3,28,87
12,Yukon,S01EC,Carbonic anhydrase inhibitors,Total,Total,18.78,0.1,0.7,57,88
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,18.74,0.1,0.1,10,89
12,Yukon,L01BA,Folic acid analogues,Total,Total,18.15,0.1,1.2,99,90
12,Yukon,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,Total,17.57,0.1,0.1,11,91
12,Yukon,C07AA,"Beta-blocking agents, non-selective",Total,Total,17.45,0.1,1.2,97,92
12,Yukon,L01BC,Pyrimidine analogues,Total,Total,17.44,0.1,0.4,31,93
12,Yukon,D07AC,"Corticosteroids, potent (group III)",Total,Total,16.68,0.1,5.2,436,94
12,Yukon,H01AC,Somatropin and somatropin agonists,Total,Total,**,**,**,*,95
12,Yukon,L01XE,Protein kinase inhibitors,Total,Total,**,**,**,*,96
12,Yukon,N05BA,Benzodiazepine derivatives,Total,Total,14.96,0.1,3.5,293,97
12,Yukon,M01AE,Propionic acid derivatives,Total,Total,14.67,0.1,4.2,352,98
12,Yukon,D05AX,Other antipsoriatics for topical use,Total,Total,13.55,0.1,0.4,33,99
12,Yukon,A11CC,Vitamin D and analogues,Total,Total,13.28,0.1,7.7,649,100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,Total,M,810.78,11.1,0.4,15,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,M,594.40,8.1,0.8,32,2
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,264.73,3.6,0.5,21,3
12,Yukon,S01LA,Antineovascularization agents,Total,M,**,**,**,**,4
12,Yukon,L04AA,Selective immunosuppressants,Total,M,179.03,2.4,0.6,25,5
12,Yukon,L04AX,Other immunosuppressants,Total,M,170.81,2.3,0.5,22,6
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,150.98,2.1,3.7,154,7
12,Yukon,L04AC,Interleukin inhibitors,Total,M,148.90,2.0,0.3,11,8
12,Yukon,C10AA,HMG-CoA reductase inhibitors,Total,M,138.25,1.9,27.5,"1,132",9
12,Yukon,R03BB,Anticholinergics,Total,M,114.05,1.6,6.6,274,10
12,Yukon,C09AA,"ACE inhibitors, plain",Total,M,105.04,1.4,22.7,937,11
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,Total,M,**,**,**,**,12
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",Total,M,97.76,1.3,3.3,136,13
12,Yukon,N04BA,Dopa and dopa derivatives,Total,M,80.37,1.1,0.8,33,14
12,Yukon,B01AF,Direct factor Xa inhibitors,Total,M,79.38,1.1,1.9,80,15
12,Yukon,A02BC,Proton pump inhibitors,Total,M,74.08,1.0,16.2,666,16
12,Yukon,L02BB,Antiandrogens,Total,M,70.08,1.0,0.3,11,17
12,Yukon,A16AX,Various alimentary tract and metabolism products,Total,M,**,**,**,*,18
12,Yukon,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,Total,M,**,**,**,*,19
12,Yukon,N05AX,Other antipsychotics,Total,M,64.96,0.9,1.0,43,20
12,Yukon,B01AB,Heparin group,Total,M,63.33,0.9,0.6,26,21
12,Yukon,C08CA,Dihydropyridine derivatives,Total,M,62.84,0.9,13.0,536,22
12,Yukon,L02BX,Other hormone antagonists and related agents,Total,M,57.89,0.8,0.1,6,23
12,Yukon,L04AD,Calcineurin inhibitors,Total,M,55.44,0.8,0.3,14,24
12,Yukon,N03AX,Other antiepileptics,Total,M,55.21,0.8,5.6,229,25
12,Yukon,R03BA,Glucocorticoids,Total,M,52.02,0.7,3.6,149,26
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,51.79,0.7,2.5,105,27
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,Total,M,50.41,0.7,11.0,454,28
12,Yukon,C07AB,"Beta-blocking agents, selective",Total,M,48.78,0.7,12.7,524,29
12,Yukon,N02AA,Natural opium alkaloids,Total,M,48.56,0.7,4.9,203,30
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,M,41.94,0.6,7.5,309,31
12,Yukon,A10BA,Biguanides,Total,M,41.55,0.6,11.9,492,32
12,Yukon,N06AX,Other antidepressants,Total,M,40.47,0.6,6.0,247,33
12,Yukon,L01EA,BCR-ABL tyrosine kinase inhibitors,Total,M,**,**,**,*,34
12,Yukon,N06BA,Centrally acting sympathomimetics,Total,M,37.92,0.5,1.1,45,35
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,36.06,0.5,10.5,431,36
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,36.05,0.5,16.1,662,37
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,35.20,0.5,2.2,92,38
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,Total,M,34.50,0.5,5.3,220,39
12,Yukon,B03XA,Other antianemic preparations,Total,M,28.31,0.4,0.1,5,40
12,Yukon,L01XC,Monoclonal antibodies,Total,M,27.79,0.4,0.2,9,41
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,27.51,0.4,1.1,44,42
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,Total,M,**,**,**,*,43
12,Yukon,H01CB,Somatostatin and analogues,Total,M,**,**,**,*,44
12,Yukon,H03AA,Thyroid hormones,Total,M,24.03,0.3,6.3,259,45
12,Yukon,S01ED,Beta-blocking agents,Total,M,22.94,0.3,2.0,81,46
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,22.72,0.3,3.4,139,47
12,Yukon,A07EC,Aminosalicylic acid and similar agents,Total,M,22.67,0.3,0.7,28,48
12,Yukon,R05CB,Mucolytics,Total,M,**,**,**,*,49
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,**,**,**,*,50
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,20.13,0.3,7.2,298,51
12,Yukon,A10BB,Sulfonylureas,Total,M,19.66,0.3,4.8,196,52
12,Yukon,C03CA,"Sulfonamides, plain",Total,M,18.26,0.2,5.3,217,53
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,18.18,0.2,0.6,23,54
12,Yukon,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",Total,M,17.57,0.2,0.3,11,55
12,Yukon,M04AA,Preparations inhibiting uric acid production,Total,M,17.07,0.2,3.8,158,56
12,Yukon,C03AA,"Thiazides, plain",Total,M,15.96,0.2,7.4,304,57
12,Yukon,H01AC,Somatropin and somatropin agonists,Total,M,**,**,**,*,58
12,Yukon,R05DA,Opium alkaloids and derivatives,Total,M,14.71,0.2,1.1,47,59
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,14.41,0.2,0.7,28,60
12,Yukon,L01BC,Pyrimidine analogues,Total,M,13.76,0.2,0.4,18,61
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,13.73,0.2,0.2,10,62
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,13.43,0.2,0.4,18,63
12,Yukon,C03DA,Aldosterone antagonists,Total,M,13.39,0.2,2.9,119,64
12,Yukon,L01EX,Other protein kinase inhibitors,Total,M,**,**,**,*,65
12,Yukon,B01AA,Vitamin K antagonists,Total,M,13.20,0.2,2.3,96,66
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,**,**,**,**,67
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,12.65,0.2,1.9,78,68
12,Yukon,N05CF,Benzodiazepine-related drugs,Total,M,12.38,0.2,4.2,173,69
12,Yukon,H02AB,Glucocorticoids,Total,M,12.23,0.2,7.8,320,70
12,Yukon,M01AB,Acetic acid derivatives and related substances,Total,M,12.06,0.2,3.9,160,71
12,Yukon,S01EC,Carbonic anhydrase inhibitors,Total,M,11.61,0.2,0.7,29,72
12,Yukon,C01DA,Organic nitrates,Total,M,11.52,0.2,3.7,151,73
12,Yukon,A09AA,Enzyme preparations,Total,M,11.42,0.2,0.3,14,74
12,Yukon,L01XB,Methylhydrazines,Total,M,**,**,**,*,75
12,Yukon,D05AX,Other antipsoriatics for topical use,Total,M,11.09,0.2,0.4,18,76
12,Yukon,L01XE,Protein kinase inhibitors,Total,M,**,**,**,*,77
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,**,**,**,*,78
12,Yukon,S01EE,Prostaglandin analogues,Total,M,10.66,0.1,1.5,61,79
12,Yukon,R01AD,Corticosteroids,Total,M,10.61,0.1,4.0,163,80
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,Total,M,10.05,0.1,1.0,43,81
12,Yukon,D07AC,"Corticosteroids, potent (group III)",Total,M,10.04,0.1,5.8,238,82
12,Yukon,J05AE,Protease inhibitors,Total,M,**,**,**,*,83
12,Yukon,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,M,**,**,**,**,84
12,Yukon,N02AB,Phenylpiperidine derivatives,Total,M,9.88,0.1,0.4,17,85
12,Yukon,N03AE,Benzodiazepine derivatives,Total,M,9.65,0.1,1.7,70,86
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,9.34,0.1,1.8,73,87
12,Yukon,C08DB,Benzothiazepine derivatives,Total,M,9.27,0.1,1.3,55,88
12,Yukon,L03AA,Colony-stimulating factors,Total,M,**,**,**,**,89
12,Yukon,L01XJ,Hedgehog pathway inhibitors,Total,M,**,**,**,*,90
12,Yukon,M01AE,Propionic acid derivatives,Total,M,7.54,0.1,4.2,175,91
12,Yukon,C07AA,"Beta-blocking agents, non-selective",Total,M,7.44,0.1,1.1,45,92
12,Yukon,C07AG,Alpha- and beta-blocking agents,Total,M,7.30,0.1,0.8,32,93
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,Total,M,7.20,0.1,0.6,26,94
12,Yukon,L01BA,Folic acid analogues,Total,M,6.92,0.1,0.9,36,95
12,Yukon,M03BX,Other centrally acting agents,Total,M,6.86,0.1,2.6,107,96
12,Yukon,N07BB,Drugs used in alcohol dependence,Total,M,6.80,0.1,0.2,10,97
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,**,**,**,**,98
12,Yukon,J02AC,Triazole derivatives,Total,M,6.25,0.1,0.3,13,99
12,Yukon,N05BA,Benzodiazepine derivatives,Total,M,6.23,0.1,2.5,101,100
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,Total,F,668.31,12.0,1.1,46,1
12,Yukon,L04AA,Selective immunosuppressants,Total,F,483.60,8.6,1.1,47,2
12,Yukon,R07AX,Other respiratory system products,Total,F,**,**,**,*,3
12,Yukon,S01LA,Antineovascularization agents,Total,F,**,**,**,**,4
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,110.64,2.0,3.1,131,5
12,Yukon,C10AA,HMG-CoA reductase inhibitors,Total,F,84.40,1.5,15.2,651,6
12,Yukon,L04AX,Other immunosuppressants,Total,F,84.02,1.5,0.3,14,7
12,Yukon,A02BC,Proton pump inhibitors,Total,F,77.58,1.4,16.3,697,8
12,Yukon,R03BB,Anticholinergics,Total,F,76.66,1.4,5.1,217,9
12,Yukon,N03AX,Other antiepileptics,Total,F,71.55,1.3,6.9,294,10
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",Total,F,70.72,1.3,2.2,92,11
12,Yukon,C09AA,"ACE inhibitors, plain",Total,F,66.38,1.2,13.2,563,12
12,Yukon,N06AX,Other antidepressants,Total,F,64.59,1.2,8.9,379,13
12,Yukon,H03AA,Thyroid hormones,Total,F,61.58,1.1,15.0,641,14
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,Total,F,58.38,1.0,8.8,375,15
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,57.68,1.0,0.1,6,16
12,Yukon,N02AA,Natural opium alkaloids,Total,F,51.66,0.9,4.2,181,17
12,Yukon,R03BA,Glucocorticoids,Total,F,49.04,0.9,4.4,190,18
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",Total,F,45.79,0.8,7.9,338,19
12,Yukon,B01AF,Direct factor Xa inhibitors,Total,F,43.91,0.8,1.0,43,20
12,Yukon,C08CA,Dihydropyridine derivatives,Total,F,43.26,0.8,8.9,381,21
12,Yukon,L04AC,Interleukin inhibitors,Total,F,41.10,0.7,0.2,7,22
12,Yukon,L01XC,Monoclonal antibodies,Total,F,41.09,0.7,0.1,6,23
12,Yukon,L01EJ,Janus-associated kinase (JAK) inhibitors,Total,F,**,**,**,*,24
12,Yukon,L03AB,Interferons,Total,F,**,**,**,*,25
12,Yukon,A07EC,Aminosalicylic acid and similar agents,Total,F,39.46,0.7,1.3,54,26
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,37.40,0.7,5.5,237,27
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,35.50,0.6,2.0,87,28
12,Yukon,N06BA,Centrally acting sympathomimetics,Total,F,33.22,0.6,1.1,47,29
12,Yukon,L04AD,Calcineurin inhibitors,Total,F,31.02,0.6,0.2,10,30
12,Yukon,B01AB,Heparin group,Total,F,31.00,0.6,0.5,21,31
12,Yukon,C07AB,"Beta-blocking agents, selective",Total,F,29.37,0.5,7.2,306,32
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,28.42,0.5,9.9,421,33
12,Yukon,L02BG,Aromatase inhibitors,Total,F,27.82,0.5,0.9,39,34
12,Yukon,N05AX,Other antipsychotics,Total,F,26.56,0.5,0.6,27,35
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,26.37,0.5,8.2,351,36
12,Yukon,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,Total,F,**,**,**,*,37
12,Yukon,L01EX,Other protein kinase inhibitors,Total,F,**,**,**,*,38
12,Yukon,A10BA,Biguanides,Total,F,24.15,0.4,7.3,314,39
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,23.45,0.4,2.2,92,40
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,22.97,0.4,0.3,11,41
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,**,**,**,**,42
12,Yukon,R05CB,Mucolytics,Total,F,**,**,**,*,43
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,Total,F,21.35,0.4,1.7,74,44
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,18.23,0.3,0.9,39,45
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,Total,F,**,**,**,**,46
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,17.08,0.3,6.1,260,47
12,Yukon,M05BA,Bisphosphonates,Total,F,16.33,0.3,2.7,116,48
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,16.30,0.3,3.1,133,49
12,Yukon,C03AA,"Thiazides, plain",Total,F,16.22,0.3,6.7,286,50
12,Yukon,S01ED,Beta-blocking agents,Total,F,15.87,0.3,1.4,59,51
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,15.47,0.3,2.6,112,52
12,Yukon,S01EE,Prostaglandin analogues,Total,F,15.44,0.3,1.8,78,53
12,Yukon,N03AF,Carboxamide derivatives,Total,F,15.36,0.3,0.3,12,54
12,Yukon,N05CF,Benzodiazepine-related drugs,Total,F,14.86,0.3,5.8,247,55
12,Yukon,H02AB,Glucocorticoids,Total,F,14.43,0.3,7.7,327,56
12,Yukon,R05DA,Opium alkaloids and derivatives,Total,F,12.08,0.2,1.5,66,57
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,11.58,0.2,0.3,14,58
12,Yukon,C03CA,"Sulfonamides, plain",Total,F,11.53,0.2,3.4,144,59
12,Yukon,L01EF,Cyclin-dependent kinase (CDK) inhibitors,Total,F,**,**,**,*,60
12,Yukon,L01BA,Folic acid analogues,Total,F,11.23,0.2,1.5,63,61
12,Yukon,C08DB,Benzothiazepine derivatives,Total,F,11.23,0.2,1.3,55,62
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,Total,F,11.15,0.2,1.4,59,63
12,Yukon,M01AB,Acetic acid derivatives and related substances,Total,F,11.09,0.2,2.6,112,64
12,Yukon,N03AE,Benzodiazepine derivatives,Total,F,10.88,0.2,1.8,78,65
12,Yukon,L03AA,Colony-stimulating factors,Total,F,**,**,**,**,66
12,Yukon,A09AA,Enzyme preparations,Total,F,10.23,0.2,0.2,10,67
12,Yukon,A10BB,Sulfonylureas,Total,F,10.04,0.2,2.4,103,68
12,Yukon,C07AA,"Beta-blocking agents, non-selective",Total,F,10.01,0.2,1.2,52,69
12,Yukon,R01AD,Corticosteroids,Total,F,9.81,0.2,4.4,189,70
12,Yukon,N02AB,Phenylpiperidine derivatives,Total,F,9.78,0.2,0.4,15,71
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,9.77,0.2,0.4,18,72
12,Yukon,B03XA,Other antianemic preparations,Total,F,9.35,0.2,0.2,7,73
12,Yukon,N05BA,Benzodiazepine derivatives,Total,F,8.73,0.2,4.5,192,74
12,Yukon,A07AA,Antibiotics,Total,F,7.80,0.1,0.8,35,75
12,Yukon,C01DA,Organic nitrates,Total,F,7.80,0.1,1.6,70,76
12,Yukon,L01AX,Other alkylating agents,Total,F,**,**,**,*,77
12,Yukon,A11CC,Vitamin D and analogues,Total,F,7.49,0.1,8.5,363,78
12,Yukon,S01EC,Carbonic anhydrase inhibitors,Total,F,7.17,0.1,0.7,28,79
12,Yukon,M01AE,Propionic acid derivatives,Total,F,7.13,0.1,4.1,177,80
12,Yukon,P01AX,Other agents against amebiasis and other protozoal diseases,Total,F,**,**,**,*,81
12,Yukon,S01GX,Other antiallergics,Total,F,7.03,0.1,1.6,69,82
12,Yukon,M01AH,Coxibs,Total,F,6.86,0.1,1.6,68,83
12,Yukon,A04AD,Other antiemetics,Total,F,6.75,0.1,0.2,10,84
12,Yukon,D07AC,"Corticosteroids, potent (group III)",Total,F,6.64,0.1,4.6,198,85
12,Yukon,C03DA,Aldosterone antagonists,Total,F,6.64,0.1,1.7,71,86
12,Yukon,L03AX,Other immunostimulants,Total,F,**,**,**,*,87
12,Yukon,M03BX,Other centrally acting agents,Total,F,6.36,0.1,2.8,121,88
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,Total,F,6.25,0.1,0.7,30,89
12,Yukon,B01AA,Vitamin K antagonists,Total,F,5.97,0.1,1.1,46,90
12,Yukon,J01XE,Nitrofuran derivatives,Total,F,5.82,0.1,3.5,149,91
12,Yukon,S01BA,"Corticosteroids, plain",Total,F,5.50,0.1,2.4,104,92
12,Yukon,C09BA,ACE inhibitors and diuretics,Total,F,5.40,0.1,0.6,26,93
12,Yukon,N04BA,Dopa and dopa derivatives,Total,F,5.32,0.1,0.3,13,94
12,Yukon,M04AA,Preparations inhibiting uric acid production,Total,F,5.22,0.1,1.0,41,95
12,Yukon,C03BA,"Sulfonamides, plain",Total,F,4.93,0.1,1.6,69,96
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,4.92,0.1,0.2,8,97
12,Yukon,R03DC,Leukotriene receptor antagonists,Total,F,4.85,0.1,0.7,28,98
12,Yukon,L01XE,Protein kinase inhibitors,Total,F,**,**,**,*,99
12,Yukon,D06BB,Antivirals,Total,F,**,**,**,**,100
12,Yukon,S01LA,Antineovascularization agents,65+,Total,**,**,**,**,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,Total,340.61,4.5,0.4,18,2
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,195.55,2.6,4.3,199,3
12,Yukon,C10AA,HMG-CoA reductase inhibitors,65+,Total,185.71,2.4,32.0,"1,497",4
12,Yukon,J05AP,Antivirals for treatment of HCV infections,65+,Total,**,**,**,*,5
12,Yukon,R03BB,Anticholinergics,65+,Total,149.68,2.0,8.3,388,6
12,Yukon,C09AA,"ACE inhibitors, plain",65+,Total,145.71,1.9,27.0,"1,264",7
12,Yukon,A02BC,Proton pump inhibitors,65+,Total,141.68,1.9,26.9,"1,256",8
12,Yukon,L04AX,Other immunosuppressants,65+,Total,128.56,1.7,0.3,15,9
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,**,**,**,**,10
12,Yukon,B01AF,Direct factor Xa inhibitors,65+,Total,108.00,1.4,2.3,106,11
12,Yukon,C08CA,Dihydropyridine derivatives,65+,Total,94.61,1.2,17.0,793,12
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,91.52,1.2,2.5,119,13
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,90.98,1.2,0.6,26,14
12,Yukon,N04BA,Dopa and dopa derivatives,65+,Total,83.17,1.1,0.9,41,15
12,Yukon,L04AA,Selective immunosuppressants,65+,Total,75.99,1.0,0.4,21,16
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,Total,75.50,1.0,11.5,539,17
12,Yukon,N02AA,Natural opium alkaloids,65+,Total,72.22,1.0,7.0,325,18
12,Yukon,H03AA,Thyroid hormones,65+,Total,71.50,0.9,16.1,752,19
12,Yukon,L02BB,Antiandrogens,65+,Total,**,**,**,**,20
12,Yukon,C07AB,"Beta-blocking agents, selective",65+,Total,67.33,0.9,15.2,710,21
12,Yukon,R03BA,Glucocorticoids,65+,Total,66.30,0.9,4.9,231,22
12,Yukon,L04AC,Interleukin inhibitors,65+,Total,62.98,0.8,0.1,5,23
12,Yukon,N03AX,Other antiepileptics,65+,Total,62.81,0.8,7.2,335,24
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,58.52,0.8,20.9,978,25
12,Yukon,N06AX,Other antidepressants,65+,Total,58.09,0.8,8.2,385,26
12,Yukon,L02BX,Other hormone antagonists and related agents,65+,Total,57.89,0.8,0.1,6,27
12,Yukon,B01AB,Heparin group,65+,Total,57.12,0.8,0.7,35,28
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,65+,Total,50.95,0.7,7.5,353,29
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,50.90,0.7,9.8,456,30
12,Yukon,A10BA,Biguanides,65+,Total,48.95,0.6,12.8,599,31
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,47.23,0.6,13.4,625,32
12,Yukon,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,Total,**,**,**,*,33
12,Yukon,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,Total,**,**,**,*,34
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,38.34,0.5,1.7,78,35
12,Yukon,S01ED,Beta-blocking agents,65+,Total,35.80,0.5,2.8,130,36
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,33.90,0.4,4.6,216,37
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,33.59,0.4,1.2,57,38
12,Yukon,A07EC,Aminosalicylic acid and similar agents,65+,Total,33.58,0.4,0.9,42,39
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,29.78,0.4,10.6,495,40
12,Yukon,C03AA,"Thiazides, plain",65+,Total,27.58,0.4,10.9,508,41
12,Yukon,C03CA,"Sulfonamides, plain",65+,Total,27.35,0.4,6.7,313,42
12,Yukon,H01CB,Somatostatin and analogues,65+,Total,**,**,**,*,43
12,Yukon,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,Total,**,**,**,*,44
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,65+,Total,25.91,0.3,1.9,91,45
12,Yukon,N05CF,Benzodiazepine-related drugs,65+,Total,25.55,0.3,8.4,395,46
12,Yukon,S01EE,Prostaglandin analogues,65+,Total,25.24,0.3,2.8,131,47
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,65+,Total,**,**,**,*,48
12,Yukon,B03XA,Other antianemic preparations,65+,Total,24.64,0.3,0.1,7,49
12,Yukon,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,Total,**,**,**,*,50
12,Yukon,L01EX,Other protein kinase inhibitors,65+,Total,**,**,**,*,51
12,Yukon,L04AD,Calcineurin inhibitors,65+,Total,23.48,0.3,0.2,8,52
12,Yukon,A10BB,Sulfonylureas,65+,Total,23.10,0.3,4.4,207,53
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,**,**,**,**,54
12,Yukon,L02BG,Aromatase inhibitors,65+,Total,21.12,0.3,0.6,27,55
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,20.84,0.3,3.6,166,56
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,20.46,0.3,0.5,24,57
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,**,**,**,*,58
12,Yukon,M04AA,Preparations inhibiting uric acid production,65+,Total,20.00,0.3,3.8,178,59
12,Yukon,R01AD,Corticosteroids,65+,Total,19.92,0.3,7.2,336,60
12,Yukon,R05DA,Opium alkaloids and derivatives,65+,Total,19.45,0.3,2.2,101,61
12,Yukon,H02AB,Glucocorticoids,65+,Total,19.26,0.3,10.4,485,62
12,Yukon,M05BA,Bisphosphonates,65+,Total,18.81,0.2,2.8,129,63
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,18.58,0.2,0.7,34,64
12,Yukon,C08DB,Benzothiazepine derivatives,65+,Total,18.53,0.2,2.1,100,65
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,18.36,0.2,3.4,160,66
12,Yukon,M01AB,Acetic acid derivatives and related substances,65+,Total,17.92,0.2,5.0,234,67
12,Yukon,C01DA,Organic nitrates,65+,Total,17.83,0.2,4.3,200,68
12,Yukon,S01EC,Carbonic anhydrase inhibitors,65+,Total,17.09,0.2,1.1,52,69
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,**,**,**,**,70
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,16.77,0.2,0.4,18,71
12,Yukon,C03DA,Aldosterone antagonists,65+,Total,16.51,0.2,3.2,149,72
12,Yukon,B01AA,Vitamin K antagonists,65+,Total,16.05,0.2,2.7,125,73
12,Yukon,L03AA,Colony-stimulating factors,65+,Total,15.03,0.2,0.2,8,74
12,Yukon,D07AC,"Corticosteroids, potent (group III)",65+,Total,14.72,0.2,8.8,411,75
12,Yukon,C07AA,"Beta-blocking agents, non-selective",65+,Total,14.09,0.2,1.7,78,76
12,Yukon,N05BA,Benzodiazepine derivatives,65+,Total,13.57,0.2,5.8,269,77
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,13.44,0.2,0.4,18,78
12,Yukon,L01BA,Folic acid analogues,65+,Total,12.89,0.2,1.3,61,79
12,Yukon,L01BC,Pyrimidine analogues,65+,Total,12.83,0.2,0.6,26,80
12,Yukon,M01AE,Propionic acid derivatives,65+,Total,12.51,0.2,6.6,308,81
12,Yukon,A11CC,Vitamin D and analogues,65+,Total,12.32,0.2,13.6,636,82
12,Yukon,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,Total,**,**,**,**,83
12,Yukon,S01BA,"Corticosteroids, plain",65+,Total,11.31,0.1,4.1,193,84
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,10.87,0.1,1.5,71,85
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,**,**,**,*,86
12,Yukon,N02AB,Phenylpiperidine derivatives,65+,Total,**,**,**,**,87
12,Yukon,S01GX,Other antiallergics,65+,Total,**,**,**,**,88
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,65+,Total,**,**,**,**,89
12,Yukon,C09BA,ACE inhibitors and diuretics,65+,Total,9.83,0.1,1.2,56,90
12,Yukon,A04AD,Other antiemetics,65+,Total,9.64,0.1,0.3,13,91
12,Yukon,L01XE,Protein kinase inhibitors,65+,Total,**,**,**,*,92
12,Yukon,M01AH,Coxibs,65+,Total,9.20,0.1,1.9,87,93
12,Yukon,D05AX,Other antipsoriatics for topical use,65+,Total,9.12,0.1,0.5,25,94
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,8.93,0.1,0.1,6,95
12,Yukon,N07BB,Drugs used in alcohol dependence,65+,Total,8.82,0.1,0.4,17,96
12,Yukon,L01XJ,Hedgehog pathway inhibitors,65+,Total,**,**,**,*,97
12,Yukon,C07AG,Alpha- and beta-blocking agents,65+,Total,7.78,0.1,0.7,35,98
12,Yukon,M03BX,Other centrally acting agents,65+,Total,7.77,0.1,4.0,188,99
12,Yukon,L01AX,Other alkylating agents,65+,Total,**,**,**,*,100
12,Yukon,S01LA,Antineovascularization agents,65+,M,**,**,**,**,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,M,185.76,4.2,0.2,6,2
12,Yukon,J05AP,Antivirals for treatment of HCV infections,65+,M,**,**,**,*,3
12,Yukon,C10AA,HMG-CoA reductase inhibitors,65+,M,118.43,2.7,39.2,973,4
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,**,**,**,**,5
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,110.46,2.5,4.3,107,6
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,65+,M,**,**,**,**,7
12,Yukon,C09AA,"ACE inhibitors, plain",65+,M,89.18,2.0,32.2,800,8
12,Yukon,R03BB,Anticholinergics,65+,M,89.18,2.0,8.8,219,9
12,Yukon,L04AX,Other immunosuppressants,65+,M,82.28,1.9,0.4,10,10
12,Yukon,N04BA,Dopa and dopa derivatives,65+,M,77.85,1.8,1.1,28,11
12,Yukon,A02BC,Proton pump inhibitors,65+,M,71.23,1.6,25.6,636,12
12,Yukon,B01AF,Direct factor Xa inhibitors,65+,M,69.94,1.6,2.8,70,13
12,Yukon,L02BB,Antiandrogens,65+,M,**,**,**,**,14
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",65+,M,59.26,1.3,3.1,77,15
12,Yukon,L02BX,Other hormone antagonists and related agents,65+,M,57.89,1.3,0.2,6,16
12,Yukon,C08CA,Dihydropyridine derivatives,65+,M,56.50,1.3,18.6,462,17
12,Yukon,L04AC,Interleukin inhibitors,65+,M,**,**,**,*,18
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,65+,M,49.23,1.1,17.9,445,19
12,Yukon,C07AB,"Beta-blocking agents, selective",65+,M,42.66,1.0,18.2,452,20
12,Yukon,L01EA,BCR-ABL tyrosine kinase inhibitors,65+,M,**,**,**,*,21
12,Yukon,B01AB,Heparin group,65+,M,**,**,**,**,22
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,M,35.24,0.8,10.5,260,23
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,33.18,0.8,25.8,640,24
12,Yukon,N02AA,Natural opium alkaloids,65+,M,32.98,0.7,7.3,181,25
12,Yukon,R03BA,Glucocorticoids,65+,M,32.64,0.7,4.2,105,26
12,Yukon,A10BA,Biguanides,65+,M,31.81,0.7,15.3,379,27
12,Yukon,N03AX,Other antiepileptics,65+,M,26.75,0.6,6.2,155,28
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,26.08,0.6,12.8,319,29
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,65+,M,**,**,**,*,30
12,Yukon,H01CB,Somatostatin and analogues,65+,M,**,**,**,*,31
12,Yukon,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,65+,M,**,**,**,*,32
12,Yukon,N06AX,Other antidepressants,65+,M,22.90,0.5,6.4,159,33
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,**,**,**,**,34
12,Yukon,B03XA,Other antianemic preparations,65+,M,**,**,**,*,35
12,Yukon,H03AA,Thyroid hormones,65+,M,21.11,0.5,9.2,228,36
12,Yukon,S01ED,Beta-blocking agents,65+,M,**,**,**,**,37
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,20.59,0.5,1.2,30,38
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,**,**,**,*,39
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,19.80,0.4,1.7,42,40
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,65+,M,18.99,0.4,5.6,138,41
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,**,**,**,**,42
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,16.82,0.4,11.2,279,43
12,Yukon,C03CA,"Sulfonamides, plain",65+,M,16.82,0.4,7.7,191,44
12,Yukon,A10BB,Sulfonylureas,65+,M,16.28,0.4,5.9,147,45
12,Yukon,L04AD,Calcineurin inhibitors,65+,M,**,**,**,**,46
12,Yukon,M04AA,Preparations inhibiting uric acid production,65+,M,15.11,0.3,5.7,142,47
12,Yukon,C03AA,"Thiazides, plain",65+,M,13.86,0.3,10.7,265,48
12,Yukon,A07EC,Aminosalicylic acid and similar agents,65+,M,12.42,0.3,0.6,15,49
12,Yukon,N05CF,Benzodiazepine-related drugs,65+,M,**,**,**,**,50
12,Yukon,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",65+,M,**,**,**,**,51
12,Yukon,B01AA,Vitamin K antagonists,65+,M,11.44,0.3,3.5,87,52
12,Yukon,R05DA,Opium alkaloids and derivatives,65+,M,**,**,**,**,53
12,Yukon,C03DA,Aldosterone antagonists,65+,M,11.34,0.3,3.9,97,54
12,Yukon,M01AB,Acetic acid derivatives and related substances,65+,M,10.96,0.2,5.9,146,55
12,Yukon,C01DA,Organic nitrates,65+,M,10.88,0.2,5.6,139,56
12,Yukon,L04AA,Selective immunosuppressants,65+,M,10.87,0.2,0.3,7,57
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,**,**,**,*,58
12,Yukon,S01EC,Carbonic anhydrase inhibitors,65+,M,**,**,**,**,59
12,Yukon,R01AD,Corticosteroids,65+,M,**,**,**,**,60
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,**,**,**,**,61
12,Yukon,S01EE,Prostaglandin analogues,65+,M,**,**,**,**,62
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,**,**,**,**,63
12,Yukon,D07AC,"Corticosteroids, potent (group III)",65+,M,9.54,0.2,9.3,230,64
12,Yukon,L01BC,Pyrimidine analogues,65+,M,9.15,0.2,0.5,13,65
12,Yukon,C08DB,Benzothiazepine derivatives,65+,M,**,**,**,**,66
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,**,**,**,**,67
12,Yukon,H02AB,Glucocorticoids,65+,M,8.23,0.2,10.1,251,68
12,Yukon,L01XJ,Hedgehog pathway inhibitors,65+,M,**,**,**,*,69
12,Yukon,D05AX,Other antipsoriatics for topical use,65+,M,**,**,**,**,70
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,65+,M,**,**,**,**,71
12,Yukon,L03AA,Colony-stimulating factors,65+,M,**,**,**,*,72
12,Yukon,L01XC,Monoclonal antibodies,65+,M,**,**,**,**,73
12,Yukon,M01AE,Propionic acid derivatives,65+,M,6.84,0.2,6.6,164,74
12,Yukon,N07BB,Drugs used in alcohol dependence,65+,M,**,**,**,**,75
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,6.61,0.1,2.4,60,76
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,**,**,**,**,77
12,Yukon,S01BA,"Corticosteroids, plain",65+,M,**,**,**,**,78
12,Yukon,C07AA,"Beta-blocking agents, non-selective",65+,M,5.72,0.1,1.5,37,79
12,Yukon,C07AG,Alpha- and beta-blocking agents,65+,M,**,**,**,**,80
12,Yukon,A11CC,Vitamin D and analogues,65+,M,5.34,0.1,11.3,281,81
12,Yukon,C09BA,ACE inhibitors and diuretics,65+,M,5.31,0.1,1.4,36,82
12,Yukon,G03BA,3-oxoandrosten (4) derivatives,65+,M,**,**,**,**,83
12,Yukon,N05BA,Benzodiazepine derivatives,65+,M,5.22,0.1,3.7,93,84
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,65+,M,5.15,0.1,0.8,21,85
12,Yukon,J02AC,Triazole derivatives,65+,M,**,**,**,**,86
12,Yukon,L01BA,Folic acid analogues,65+,M,5.01,0.1,1.0,25,87
12,Yukon,L01XE,Protein kinase inhibitors,65+,M,**,**,**,*,88
12,Yukon,J01XA,Glycopeptide antibacterials,65+,M,**,**,**,*,89
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,65+,M,**,**,**,**,90
12,Yukon,J01FA,Macrolides,65+,M,4.61,0.1,3.5,88,91
12,Yukon,A12BA,Potassium,65+,M,**,**,**,**,92
12,Yukon,C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,65+,M,**,**,**,**,93
12,Yukon,C01AA,Digitalis glycosides,65+,M,**,**,**,**,94
12,Yukon,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,M,**,**,**,**,95
12,Yukon,N02AB,Phenylpiperidine derivatives,65+,M,**,**,**,**,96
12,Yukon,A04AD,Other antiemetics,65+,M,**,**,**,**,97
12,Yukon,J01MA,Fluoroquinolones,65+,M,**,**,**,**,98
12,Yukon,J01DB,First-generation cephalosporins,65+,M,**,**,**,**,99
12,Yukon,N07BA,Drugs used in nicotine dependence,65+,M,**,**,**,**,100
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,65+,F,154.84,4.9,0.5,12,1
12,Yukon,S01LA,Antineovascularization agents,65+,F,**,**,**,**,2
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,85.09,2.7,4.2,92,3
12,Yukon,A02BC,Proton pump inhibitors,65+,F,70.45,2.2,28.3,620,4
12,Yukon,C10AA,HMG-CoA reductase inhibitors,65+,F,67.28,2.1,23.9,524,5
12,Yukon,L04AA,Selective immunosuppressants,65+,F,65.12,2.0,0.6,14,6
12,Yukon,R03BB,Anticholinergics,65+,F,60.50,1.9,7.7,169,7
12,Yukon,C09AA,"ACE inhibitors, plain",65+,F,56.53,1.8,21.2,464,8
12,Yukon,H03AA,Thyroid hormones,65+,F,50.39,1.6,23.9,524,9
12,Yukon,L04AX,Other immunosuppressants,65+,F,46.28,1.5,0.2,5,10
12,Yukon,L01EJ,Janus-associated kinase (JAK) inhibitors,65+,F,**,**,**,*,11
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",65+,F,40.26,1.3,12.7,279,12
12,Yukon,N02AA,Natural opium alkaloids,65+,F,39.24,1.2,6.6,144,13
12,Yukon,C08CA,Dihydropyridine derivatives,65+,F,38.11,1.2,15.1,331,14
12,Yukon,B01AF,Direct factor Xa inhibitors,65+,F,38.07,1.2,1.6,36,15
12,Yukon,N03AX,Other antiepileptics,65+,F,36.06,1.1,8.2,180,16
12,Yukon,N06AX,Other antidepressants,65+,F,35.19,1.1,10.3,226,17
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,33.90,1.1,9.8,216,18
12,Yukon,R03BA,Glucocorticoids,65+,F,33.66,1.1,5.7,126,19
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",65+,F,32.26,1.0,1.9,42,20
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,65+,F,31.96,1.0,9.8,215,21
12,Yukon,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,65+,F,**,**,**,*,22
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,25.33,0.8,15.4,338,23
12,Yukon,C07AB,"Beta-blocking agents, selective",65+,F,24.67,0.8,11.8,258,24
12,Yukon,L01EX,Other protein kinase inhibitors,65+,F,**,**,**,*,25
12,Yukon,A07EC,Aminosalicylic acid and similar agents,65+,F,21.16,0.7,1.2,27,26
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,21.15,0.7,14.0,306,27
12,Yukon,L02BG,Aromatase inhibitors,65+,F,21.12,0.7,1.2,27,28
12,Yukon,B01AB,Heparin group,65+,F,**,**,**,**,29
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,65+,F,**,**,**,**,30
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,18.54,0.6,1.6,36,31
12,Yukon,A10BA,Biguanides,65+,F,17.14,0.5,10.0,220,32
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,65+,F,**,**,**,**,33
12,Yukon,M05BA,Bisphosphonates,65+,F,15.76,0.5,5.0,109,34
12,Yukon,S01EE,Prostaglandin analogues,65+,F,**,**,**,**,35
12,Yukon,S01ED,Beta-blocking agents,65+,F,**,**,**,**,36
12,Yukon,N05CF,Benzodiazepine-related drugs,65+,F,**,**,**,**,37
12,Yukon,C03AA,"Thiazides, plain",65+,F,13.71,0.4,11.1,243,38
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,13.01,0.4,1.2,27,39
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,12.95,0.4,9.8,216,40
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,**,**,**,**,41
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,11.75,0.4,4.6,100,42
12,Yukon,H02AB,Glucocorticoids,65+,F,11.03,0.3,10.7,234,43
12,Yukon,L04AC,Interleukin inhibitors,65+,F,**,**,**,*,44
12,Yukon,C03CA,"Sulfonamides, plain",65+,F,10.53,0.3,5.6,122,45
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,**,**,**,**,46
12,Yukon,C08DB,Benzothiazepine derivatives,65+,F,**,**,**,**,47
12,Yukon,R01AD,Corticosteroids,65+,F,**,**,**,**,48
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,**,**,**,*,49
12,Yukon,C07AA,"Beta-blocking agents, non-selective",65+,F,8.36,0.3,1.9,41,50
12,Yukon,N05BA,Benzodiazepine derivatives,65+,F,8.35,0.3,8.0,176,51
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,**,**,**,**,52
12,Yukon,R05DA,Opium alkaloids and derivatives,65+,F,**,**,**,**,53
12,Yukon,L03AA,Colony-stimulating factors,65+,F,**,**,**,*,54
12,Yukon,L04AD,Calcineurin inhibitors,65+,F,**,**,**,*,55
12,Yukon,L01BA,Folic acid analogues,65+,F,7.89,0.2,1.6,36,56
12,Yukon,L01AX,Other alkylating agents,65+,F,**,**,**,*,57
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,7.40,0.2,1.6,36,58
12,Yukon,A11CC,Vitamin D and analogues,65+,F,6.98,0.2,16.2,355,59
12,Yukon,M01AB,Acetic acid derivatives and related substances,65+,F,6.96,0.2,4.0,88,60
12,Yukon,C01DA,Organic nitrates,65+,F,6.95,0.2,2.8,61,61
12,Yukon,A10BB,Sulfonylureas,65+,F,6.82,0.2,2.7,60,62
12,Yukon,S01GX,Other antiallergics,65+,F,**,**,**,**,63
12,Yukon,N02AB,Phenylpiperidine derivatives,65+,F,**,**,**,**,64
12,Yukon,M01AH,Coxibs,65+,F,**,**,**,**,65
12,Yukon,S01EC,Carbonic anhydrase inhibitors,65+,F,**,**,**,**,66
12,Yukon,N05AX,Other antipsychotics,65+,F,5.94,0.2,0.5,12,67
12,Yukon,M01AE,Propionic acid derivatives,65+,F,5.66,0.2,6.6,144,68
12,Yukon,A04AD,Other antiemetics,65+,F,**,**,**,**,69
12,Yukon,N04BA,Dopa and dopa derivatives,65+,F,5.32,0.2,0.6,13,70
12,Yukon,S01BA,"Corticosteroids, plain",65+,F,**,**,**,**,71
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,65+,F,**,**,**,**,72
12,Yukon,D07AC,"Corticosteroids, potent (group III)",65+,F,5.18,0.2,8.3,181,73
12,Yukon,C03DA,Aldosterone antagonists,65+,F,5.17,0.2,2.4,52,74
12,Yukon,J01XE,Nitrofuran derivatives,65+,F,**,**,**,**,75
12,Yukon,M04AA,Preparations inhibiting uric acid production,65+,F,4.89,0.2,1.6,36,76
12,Yukon,B01AA,Vitamin K antagonists,65+,F,4.62,0.1,1.7,38,77
12,Yukon,L01XE,Protein kinase inhibitors,65+,F,**,**,**,*,78
12,Yukon,C09BA,ACE inhibitors and diuretics,65+,F,4.52,0.1,0.9,20,79
12,Yukon,C03BA,"Sulfonamides, plain",65+,F,4.27,0.1,2.6,58,80
12,Yukon,A07AA,Antibiotics,65+,F,**,**,**,**,81
12,Yukon,M03BX,Other centrally acting agents,65+,F,4.10,0.1,4.4,96,82
12,Yukon,N04BC,Dopamine agonists,65+,F,**,**,**,**,83
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,**,**,**,*,84
12,Yukon,R03DC,Leukotriene receptor antagonists,65+,F,3.79,0.1,0.9,20,85
12,Yukon,L01BC,Pyrimidine analogues,65+,F,3.68,0.1,0.6,13,86
12,Yukon,L01CB,Podophyllotoxin derivatives,65+,F,**,**,**,*,87
12,Yukon,D06BB,Antivirals,65+,F,3.50,0.1,1.6,34,88
12,Yukon,N06BA,Centrally acting sympathomimetics,65+,F,3.31,0.1,0.3,6,89
12,Yukon,V03AC,Iron-chelating agents,65+,F,**,**,**,*,90
12,Yukon,S01AE,Fluoroquinolones,65+,F,3.17,0.1,4.2,92,91
12,Yukon,V03AF,Detoxifying agents for antineoplastic treatment,65+,F,**,**,**,*,92
12,Yukon,A12AA,Calcium,65+,F,**,**,**,**,93
12,Yukon,D01AC,Imidazole and triazole derivatives,65+,F,**,**,**,**,94
12,Yukon,N03AE,Benzodiazepine derivatives,65+,F,3.01,0.1,1.3,28,95
12,Yukon,C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,65+,F,2.96,0.1,1.2,26,96
12,Yukon,R06AE,Piperazine derivatives,65+,F,**,**,**,**,97
12,Yukon,N06DA,Anticholinesterases,65+,F,**,**,**,**,98
12,Yukon,A12BA,Potassium,65+,F,**,**,**,**,99
12,Yukon,C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,65+,F,**,**,**,**,100
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,Total,922.11,17.3,1.6,60,1
12,Yukon,J05AP,Antivirals for treatment of HCV infections,<65,Total,**,**,**,**,2
12,Yukon,L04AA,Selective immunosuppressants,<65,Total,586.64,11.0,1.4,51,3
12,Yukon,R07AX,Other respiratory system products,<65,Total,**,**,**,*,4
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,**,**,**,**,5
12,Yukon,L04AC,Interleukin inhibitors,<65,Total,127.01,2.4,0.3,13,6
12,Yukon,L04AX,Other immunosuppressants,<65,Total,126.27,2.4,0.6,21,7
12,Yukon,N05AX,Other antipsychotics,<65,Total,84.46,1.6,1.3,48,8
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,76.96,1.4,2.9,109,9
12,Yukon,A16AX,Various alimentary tract and metabolism products,<65,Total,**,**,**,*,10
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,66.06,1.2,2.3,86,11
12,Yukon,N06BA,Centrally acting sympathomimetics,<65,Total,65.33,1.2,2.1,79,12
12,Yukon,N03AX,Other antiepileptics,<65,Total,63.95,1.2,5.1,188,13
12,Yukon,L04AD,Calcineurin inhibitors,<65,Total,62.98,1.2,0.4,16,14
12,Yukon,L01XC,Monoclonal antibodies,<65,Total,**,**,**,**,15
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,48.95,0.9,3.1,114,16
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,47.78,0.9,3.0,113,17
12,Yukon,N06AX,Other antidepressants,<65,Total,46.97,0.9,6.5,241,18
12,Yukon,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,Total,**,**,**,*,19
12,Yukon,R05CB,Mucolytics,<65,Total,**,**,**,*,20
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,<65,Total,41.93,0.8,6.5,242,21
12,Yukon,R03BB,Anticholinergics,<65,Total,41.03,0.8,2.8,103,22
12,Yukon,S01LA,Antineovascularization agents,<65,Total,**,**,**,**,23
12,Yukon,L03AB,Interferons,<65,Total,**,**,**,*,24
12,Yukon,B01AB,Heparin group,<65,Total,37.21,0.7,0.3,12,25
12,Yukon,C10AA,HMG-CoA reductase inhibitors,<65,Total,36.94,0.7,7.7,286,26
12,Yukon,R03BA,Glucocorticoids,<65,Total,34.76,0.7,2.9,108,27
12,Yukon,A07EC,Aminosalicylic acid and similar agents,<65,Total,28.55,0.5,1.1,40,28
12,Yukon,N02AA,Natural opium alkaloids,<65,Total,27.99,0.5,1.6,59,29
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,27.77,0.5,0.4,15,30
12,Yukon,C09AA,"ACE inhibitors, plain",<65,Total,25.71,0.5,6.3,236,31
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,19.06,0.4,0.3,11,32
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,17.24,0.3,6.1,227,33
12,Yukon,A09AA,Enzyme preparations,<65,Total,17.11,0.3,0.3,11,34
12,Yukon,A10BA,Biguanides,<65,Total,16.76,0.3,5.6,207,35
12,Yukon,H01AC,Somatropin and somatropin agonists,<65,Total,**,**,**,*,36
12,Yukon,N03AF,Carboxamide derivatives,<65,Total,15.86,0.3,0.3,13,37
12,Yukon,B01AF,Direct factor Xa inhibitors,<65,Total,15.29,0.3,0.5,17,38
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,<65,Total,14.79,0.3,1.9,72,39
12,Yukon,H03AA,Thyroid hormones,<65,Total,14.11,0.3,4.0,148,40
12,Yukon,N03AE,Benzodiazepine derivatives,<65,Total,13.72,0.3,2.3,86,41
12,Yukon,L01EX,Other protein kinase inhibitors,<65,Total,**,**,**,*,42
12,Yukon,B03XA,Other antianemic preparations,<65,Total,13.02,0.2,0.1,5,43
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,Total,12.23,0.2,2.9,108,44
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,12.14,0.2,0.7,26,45
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,11.56,0.2,0.4,14,46
12,Yukon,C08CA,Dihydropyridine derivatives,<65,Total,11.48,0.2,3.3,124,47
12,Yukon,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,Total,**,**,**,*,48
12,Yukon,L01XB,Methylhydrazines,<65,Total,**,**,**,*,49
12,Yukon,C07AB,"Beta-blocking agents, selective",<65,Total,10.81,0.2,3.2,120,50
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,10.59,0.2,1.4,51,51
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,10.27,0.2,0.2,6,52
12,Yukon,L03AX,Other immunostimulants,<65,Total,**,**,**,*,53
12,Yukon,A02BC,Proton pump inhibitors,<65,Total,9.97,0.2,2.9,107,54
12,Yukon,J05AE,Protease inhibitors,<65,Total,**,**,**,*,55
12,Yukon,N02AB,Phenylpiperidine derivatives,<65,Total,**,**,**,**,56
12,Yukon,P01AX,Other agents against amebiasis and other protozoal diseases,<65,Total,**,**,**,*,57
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,7.43,0.1,1.7,63,58
12,Yukon,H02AB,Glucocorticoids,<65,Total,7.41,0.1,4.4,162,59
12,Yukon,R05DA,Opium alkaloids and derivatives,<65,Total,7.34,0.1,0.3,12,60
12,Yukon,N05AE,Indole derivatives,<65,Total,6.76,0.1,0.2,6,61
12,Yukon,L02BG,Aromatase inhibitors,<65,Total,6.71,0.1,0.3,12,62
12,Yukon,A10BB,Sulfonylureas,<65,Total,6.60,0.1,2.5,92,63
12,Yukon,N03AG,Fatty acid derivatives,<65,Total,6.59,0.1,0.6,21,64
12,Yukon,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,Total,**,**,**,**,65
12,Yukon,L01XE,Protein kinase inhibitors,<65,Total,**,**,**,*,66
12,Yukon,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,Total,**,**,**,**,67
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,5.61,0.1,0.3,12,68
12,Yukon,M03BX,Other centrally acting agents,<65,Total,5.44,0.1,1.1,40,69
12,Yukon,L01BA,Folic acid analogues,<65,Total,5.25,0.1,1.0,38,70
12,Yukon,M01AB,Acetic acid derivatives and related substances,<65,Total,5.23,0.1,1.0,38,71
12,Yukon,A07EA,Corticosteroids acting locally,<65,Total,**,**,**,**,72
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,**,**,**,**,73
12,Yukon,N05AN,Lithium,<65,Total,4.77,0.1,0.8,28,74
12,Yukon,L01BC,Pyrimidine analogues,<65,Total,4.61,0.1,0.1,5,75
12,Yukon,C03AA,"Thiazides, plain",<65,Total,4.60,0.1,2.2,82,76
12,Yukon,D05AX,Other antipsoriatics for topical use,<65,Total,4.43,0.1,0.2,8,77
12,Yukon,L03AA,Colony-stimulating factors,<65,Total,4.26,0.1,0.2,6,78
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,3.96,0.1,0.5,19,79
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,3.91,0.1,0.9,35,80
12,Yukon,C02AC,Imidazoline receptor agonists,<65,Total,3.77,0.1,0.3,11,81
12,Yukon,N05AF,Thioxanthene derivatives,<65,Total,3.74,0.1,0.1,5,82
12,Yukon,B02BA,Vitamin K,<65,Total,**,**,**,*,83
12,Yukon,A07AA,Antibiotics,<65,Total,3.70,0.1,0.1,5,84
12,Yukon,H01BA,Vasopressin and analogues,<65,Total,**,**,**,*,85
12,Yukon,C03DA,Aldosterone antagonists,<65,Total,3.52,0.1,1.1,41,86
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,3.49,0.1,0.6,21,87
12,Yukon,C07AA,"Beta-blocking agents, non-selective",<65,Total,3.36,0.1,0.5,19,88
12,Yukon,B01AA,Vitamin K antagonists,<65,Total,3.12,0.1,0.5,17,89
12,Yukon,N05AD,Butyrophenone derivatives,<65,Total,3.05,0.1,0.4,14,90
12,Yukon,S01ED,Beta-blocking agents,<65,Total,3.01,0.1,0.3,10,91
12,Yukon,L02BA,Anti-estrogens,<65,Total,**,**,**,*,92
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,2.65,0.0,0.2,7,93
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,<65,Total,2.64,0.0,0.2,9,94
12,Yukon,N04BA,Dopa and dopa derivatives,<65,Total,2.52,0.0,0.1,5,95
12,Yukon,A05AA,Bile acids and derivatives,<65,Total,**,**,**,**,96
12,Yukon,N04AC,Ethers of tropine or tropine derivatives,<65,Total,**,**,**,**,97
12,Yukon,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,Total,**,**,**,*,98
12,Yukon,C03CA,"Sulfonamides, plain",<65,Total,2.44,0.0,1.3,48,99
12,Yukon,C03BA,"Sulfonamides, plain",<65,Total,2.39,0.0,0.8,31,100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,<65,M,**,**,**,**,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,M,408.63,14.1,1.6,26,2
12,Yukon,L04AA,Selective immunosuppressants,<65,M,168.16,5.8,1.1,18,3
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,**,**,**,**,4
12,Yukon,L04AC,Interleukin inhibitors,<65,M,**,**,**,**,5
12,Yukon,L04AX,Other immunosuppressants,<65,M,88.52,3.0,0.7,12,6
12,Yukon,A16AX,Various alimentary tract and metabolism products,<65,M,**,**,**,*,7
12,Yukon,N05AX,Other antipsychotics,<65,M,63.84,2.2,2.0,33,8
12,Yukon,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,<65,M,**,**,**,*,9
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,40.52,1.4,2.9,47,10
12,Yukon,L04AD,Calcineurin inhibitors,<65,M,**,**,**,**,11
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",<65,M,38.50,1.3,3.6,59,12
12,Yukon,N06BA,Centrally acting sympathomimetics,<65,M,35.42,1.2,2.3,38,13
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,31.99,1.1,3.8,63,14
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,31.73,1.1,3.5,57,15
12,Yukon,N03AX,Other antiepileptics,<65,M,28.46,1.0,4.5,74,16
12,Yukon,B01AB,Heparin group,<65,M,**,**,**,**,17
12,Yukon,R03BB,Anticholinergics,<65,M,24.87,0.9,3.4,55,18
12,Yukon,R05CB,Mucolytics,<65,M,**,**,**,*,19
12,Yukon,L01XC,Monoclonal antibodies,<65,M,**,**,**,*,20
12,Yukon,C10AA,HMG-CoA reductase inhibitors,<65,M,19.82,0.7,9.7,159,21
12,Yukon,R03BA,Glucocorticoids,<65,M,19.38,0.7,2.7,44,22
12,Yukon,N06AX,Other antidepressants,<65,M,17.57,0.6,5.4,88,23
12,Yukon,H01AC,Somatropin and somatropin agonists,<65,M,**,**,**,*,24
12,Yukon,C09AA,"ACE inhibitors, plain",<65,M,15.86,0.5,8.4,137,25
12,Yukon,N02AA,Natural opium alkaloids,<65,M,15.57,0.5,1.3,22,26
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,<65,M,15.51,0.5,5.0,82,27
12,Yukon,S01LA,Antineovascularization agents,<65,M,**,**,**,*,28
12,Yukon,L01EX,Other protein kinase inhibitors,<65,M,**,**,**,*,29
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,**,**,**,**,30
12,Yukon,L01XB,Methylhydrazines,<65,M,**,**,**,*,31
12,Yukon,A07EC,Aminosalicylic acid and similar agents,<65,M,10.25,0.4,0.8,13,32
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,9.97,0.3,6.8,112,33
12,Yukon,J05AE,Protease inhibitors,<65,M,**,**,**,*,34
12,Yukon,A10BA,Biguanides,<65,M,9.75,0.3,6.9,113,35
12,Yukon,A09AA,Enzyme preparations,<65,M,**,**,**,**,36
12,Yukon,B01AF,Direct factor Xa inhibitors,<65,M,9.44,0.3,0.6,10,37
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,<65,M,**,**,**,**,38
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,6.92,0.2,0.9,14,39
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,**,**,**,*,40
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,M,6.70,0.2,3.0,49,41
12,Yukon,C08CA,Dihydropyridine derivatives,<65,M,6.33,0.2,4.5,74,42
12,Yukon,B03XA,Other antianemic preparations,<65,M,**,**,**,*,43
12,Yukon,C07AB,"Beta-blocking agents, selective",<65,M,6.11,0.2,4.4,72,44
12,Yukon,C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",<65,M,**,**,**,**,45
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,6.04,0.2,1.1,18,46
12,Yukon,L01XE,Protein kinase inhibitors,<65,M,**,**,**,*,47
12,Yukon,N03AE,Benzodiazepine derivatives,<65,M,5.85,0.2,2.2,36,48
12,Yukon,N02AB,Phenylpiperidine derivatives,<65,M,**,**,**,*,49
12,Yukon,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,M,**,**,**,*,50
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,<65,M,4.90,0.2,1.3,22,51
12,Yukon,L01BC,Pyrimidine analogues,<65,M,4.61,0.2,0.3,5,52
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,**,**,**,**,53
12,Yukon,N03AG,Fatty acid derivatives,<65,M,**,**,**,**,54
12,Yukon,H02AB,Glucocorticoids,<65,M,4.00,0.1,4.2,69,55
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,**,**,**,**,56
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,**,**,**,*,57
12,Yukon,N05AF,Thioxanthene derivatives,<65,M,**,**,**,*,58
12,Yukon,B02BA,Vitamin K,<65,M,**,**,**,*,59
12,Yukon,L03AX,Other immunostimulants,<65,M,**,**,**,*,60
12,Yukon,D05AX,Other antipsoriatics for topical use,<65,M,**,**,**,*,61
12,Yukon,A10BB,Sulfonylureas,<65,M,3.38,0.1,3.0,49,62
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,3.30,0.1,1.2,19,63
12,Yukon,R05DA,Opium alkaloids and derivatives,<65,M,**,**,**,*,64
12,Yukon,M03BX,Other centrally acting agents,<65,M,3.19,0.1,0.9,15,65
12,Yukon,H01BA,Vasopressin and analogues,<65,M,**,**,**,*,66
12,Yukon,H03AA,Thyroid hormones,<65,M,2.92,0.1,1.9,31,67
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,2.87,0.1,1.3,22,68
12,Yukon,A02BC,Proton pump inhibitors,<65,M,2.85,0.1,1.8,30,69
12,Yukon,N05AE,Indole derivatives,<65,M,**,**,**,*,70
12,Yukon,C02AC,Imidazoline receptor agonists,<65,M,**,**,**,**,71
12,Yukon,N04BA,Dopa and dopa derivatives,<65,M,2.52,0.1,0.3,5,72
12,Yukon,N05AN,Lithium,<65,M,**,**,**,**,73
12,Yukon,N04AC,Ethers of tropine or tropine derivatives,<65,M,**,**,**,**,74
12,Yukon,N05AD,Butyrophenone derivatives,<65,M,2.20,0.1,0.4,7,75
12,Yukon,C03AA,"Thiazides, plain",<65,M,2.09,0.1,2.4,39,76
12,Yukon,C03DA,Aldosterone antagonists,<65,M,2.05,0.1,1.3,22,77
12,Yukon,A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,<65,M,**,**,**,*,78
12,Yukon,S01ED,Beta-blocking agents,<65,M,**,**,**,**,79
12,Yukon,M04AA,Preparations inhibiting uric acid production,<65,M,1.95,0.1,1.0,16,80
12,Yukon,L01BA,Folic acid analogues,<65,M,1.91,0.1,0.7,11,81
12,Yukon,B01AA,Vitamin K antagonists,<65,M,1.77,0.1,0.5,9,82
12,Yukon,C03BA,"Sulfonamides, plain",<65,M,1.73,0.1,1.2,20,83
12,Yukon,L03AA,Colony-stimulating factors,<65,M,**,**,**,*,84
12,Yukon,C07AA,"Beta-blocking agents, non-selective",<65,M,1.71,0.1,0.5,8,85
12,Yukon,A07EA,Corticosteroids acting locally,<65,M,**,**,**,**,86
12,Yukon,C07AG,Alpha- and beta-blocking agents,<65,M,**,**,**,**,87
12,Yukon,N04BD,Monoamine oxidase B inhibitors,<65,M,**,**,**,*,88
12,Yukon,L01XX,Other antineoplastic agents,<65,M,**,**,**,*,89
12,Yukon,C03CA,"Sulfonamides, plain",<65,M,1.43,0.0,1.6,26,90
12,Yukon,J02AC,Triazole derivatives,<65,M,**,**,**,*,91
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,<65,M,1.17,0.0,0.5,9,92
12,Yukon,M01AB,Acetic acid derivatives and related substances,<65,M,1.10,0.0,0.9,14,93
12,Yukon,N03AF,Carboxamide derivatives,<65,M,1.06,0.0,0.4,7,94
12,Yukon,A05AA,Bile acids and derivatives,<65,M,**,**,**,*,95
12,Yukon,N05BA,Benzodiazepine derivatives,<65,M,1.01,0.0,0.5,8,96
12,Yukon,R03DC,Leukotriene receptor antagonists,<65,M,1.00,0.0,0.5,8,97
12,Yukon,R03B,"Other drugs for obstructive airway diseases, inhalants",<65,M,**,**,**,*,98
12,Yukon,L01BB,Purine analogues,<65,M,**,**,**,*,99
12,Yukon,G03BA,3-oxoandrosten (4) derivatives,<65,M,**,**,**,*,100
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-alpha) inhibitors,<65,F,513.47,21.3,1.6,34,1
12,Yukon,L04AA,Selective immunosuppressants,<65,F,418.48,17.4,1.6,33,2
12,Yukon,R07AX,Other respiratory system products,<65,F,**,**,**,*,3
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,**,**,**,**,4
12,Yukon,L01XC,Monoclonal antibodies,<65,F,**,**,**,*,5
12,Yukon,L03AB,Interferons,<65,F,**,**,**,*,6
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",<65,F,38.46,1.6,2.4,50,7
12,Yukon,L04AX,Other immunosuppressants,<65,F,37.75,1.6,0.4,9,8
12,Yukon,N03AX,Other antiepileptics,<65,F,35.49,1.5,5.5,114,9
12,Yukon,L04AC,Interleukin inhibitors,<65,F,**,**,**,**,10
12,Yukon,N06BA,Centrally acting sympathomimetics,<65,F,29.91,1.2,2.0,41,11
12,Yukon,N06AX,Other antidepressants,<65,F,29.40,1.2,7.4,153,12
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,<65,F,26.42,1.1,7.7,160,13
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,25.55,1.1,1.9,39,14
12,Yukon,S01LA,Antineovascularization agents,<65,F,**,**,**,*,15
12,Yukon,L04AD,Calcineurin inhibitors,<65,F,**,**,**,**,16
12,Yukon,R05CB,Mucolytics,<65,F,**,**,**,*,17
12,Yukon,N05AX,Other antipsychotics,<65,F,20.62,0.9,0.7,15,18
12,Yukon,A07EC,Aminosalicylic acid and similar agents,<65,F,18.30,0.8,1.3,27,19
12,Yukon,C10AA,HMG-CoA reductase inhibitors,<65,F,17.12,0.7,6.1,127,20
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,16.96,0.7,2.5,51,21
12,Yukon,R03BB,Anticholinergics,<65,F,16.16,0.7,2.3,48,22
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,16.05,0.7,2.7,56,23
12,Yukon,R03BA,Glucocorticoids,<65,F,15.38,0.6,3.1,64,24
12,Yukon,N03AF,Carboxamide derivatives,<65,F,14.80,0.6,0.3,6,25
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,**,**,**,**,26
12,Yukon,N02AA,Natural opium alkaloids,<65,F,12.42,0.5,1.8,37,27
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,**,**,**,**,28
12,Yukon,B01AB,Heparin group,<65,F,**,**,**,**,29
12,Yukon,L01EF,Cyclin-dependent kinase (CDK) inhibitors,<65,F,**,**,**,*,30
12,Yukon,H03AA,Thyroid hormones,<65,F,11.19,0.5,5.6,117,31
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,<65,F,9.89,0.4,2.4,50,32
12,Yukon,C09AA,"ACE inhibitors, plain",<65,F,9.85,0.4,4.8,99,33
12,Yukon,N03AE,Benzodiazepine derivatives,<65,F,7.87,0.3,2.4,50,34
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,**,**,**,**,35
12,Yukon,A09AA,Enzyme preparations,<65,F,**,**,**,**,36
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,7.27,0.3,5.5,115,37
12,Yukon,A02BC,Proton pump inhibitors,<65,F,7.13,0.3,3.7,77,38
12,Yukon,P01AX,Other agents against amebiasis and other protozoal diseases,<65,F,**,**,**,*,39
12,Yukon,A10BA,Biguanides,<65,F,7.01,0.3,4.5,94,40
12,Yukon,L02BG,Aromatase inhibitors,<65,F,6.71,0.3,0.6,12,41
12,Yukon,B03XA,Other antianemic preparations,<65,F,**,**,**,*,42
12,Yukon,L03AX,Other immunostimulants,<65,F,**,**,**,*,43
12,Yukon,B01AF,Direct factor Xa inhibitors,<65,F,5.85,0.2,0.3,7,44
12,Yukon,C09CA,"Angiotensin II receptor blockers (ARBs), plain",<65,F,5.53,0.2,2.8,59,45
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,5.22,0.2,0.6,12,46
12,Yukon,C08CA,Dihydropyridine derivatives,<65,F,5.15,0.2,2.4,50,47
12,Yukon,C07AB,"Beta-blocking agents, selective",<65,F,4.70,0.2,2.3,48,48
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,4.55,0.2,1.6,33,49
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,4.13,0.2,2.1,44,50
12,Yukon,M01AB,Acetic acid derivatives and related substances,<65,F,4.13,0.2,1.2,24,51
12,Yukon,N05AE,Indole derivatives,<65,F,**,**,**,*,52
12,Yukon,R05DA,Opium alkaloids and derivatives,<65,F,**,**,**,**,53
12,Yukon,A07AA,Antibiotics,<65,F,**,**,**,*,54
12,Yukon,A07EA,Corticosteroids acting locally,<65,F,**,**,**,*,55
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,3.49,0.1,1.0,21,56
12,Yukon,H02AB,Glucocorticoids,<65,F,3.40,0.1,4.5,93,57
12,Yukon,L01BA,Folic acid analogues,<65,F,3.34,0.1,1.3,27,58
12,Yukon,N02AB,Phenylpiperidine derivatives,<65,F,**,**,**,*,59
12,Yukon,A10BB,Sulfonylureas,<65,F,3.22,0.1,2.1,43,60
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,**,**,**,**,61
12,Yukon,L02BA,Anti-estrogens,<65,F,**,**,**,*,62
12,Yukon,L03AA,Colony-stimulating factors,<65,F,**,**,**,*,63
12,Yukon,C03AA,"Thiazides, plain",<65,F,2.51,0.1,2.1,43,64
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,<65,F,**,**,**,**,65
12,Yukon,N03AG,Fatty acid derivatives,<65,F,**,**,**,**,66
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,**,**,**,**,67
12,Yukon,N05AN,Lithium,<65,F,**,**,**,**,68
12,Yukon,M03BX,Other centrally acting agents,<65,F,2.25,0.1,1.2,25,69
12,Yukon,J01GB,Other aminoglycosides,<65,F,**,**,**,*,70
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,<65,F,**,**,**,*,71
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,**,**,**,*,72
12,Yukon,C07AA,"Beta-blocking agents, non-selective",<65,F,1.65,0.1,0.5,11,73
12,Yukon,C03DA,Aldosterone antagonists,<65,F,1.47,0.1,0.9,19,74
12,Yukon,D07AC,"Corticosteroids, potent (group III)",<65,F,1.47,0.1,0.8,17,75
12,Yukon,A05AA,Bile acids and derivatives,<65,F,**,**,**,*,76
12,Yukon,M01AE,Propionic acid derivatives,<65,F,1.46,0.1,1.6,33,77
12,Yukon,B01AA,Vitamin K antagonists,<65,F,1.36,0.1,0.4,8,78
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,<65,F,**,**,**,*,79
12,Yukon,P01BA,Aminoquinolines,<65,F,**,**,**,**,80
12,Yukon,N07AA,Anticholinesterases,<65,F,**,**,**,*,81
12,Yukon,A04AD,Other antiemetics,<65,F,**,**,**,**,82
12,Yukon,C08DB,Benzothiazepine derivatives,<65,F,**,**,**,*,83
12,Yukon,C02AC,Imidazoline receptor agonists,<65,F,**,**,**,**,84
12,Yukon,N05CF,Benzodiazepine-related drugs,<65,F,**,**,**,**,85
12,Yukon,J01DB,First-generation cephalosporins,<65,F,**,**,**,**,86
12,Yukon,C10AB,Fibrates,<65,F,**,**,**,*,87
12,Yukon,R03DC,Leukotriene receptor antagonists,<65,F,1.06,0.0,0.4,8,88
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,1.04,0.0,0.6,13,89
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,<65,F,**,**,**,*,90
12,Yukon,C03DB,Other potassium-sparing agents,<65,F,**,**,**,*,91
12,Yukon,C03CA,"Sulfonamides, plain",<65,F,1.01,0.0,1.1,22,92
12,Yukon,S01ED,Beta-blocking agents,<65,F,**,**,**,*,93
12,Yukon,D06BB,Antivirals,<65,F,0.97,0.0,0.3,6,94
12,Yukon,D05AX,Other antipsoriatics for topical use,<65,F,**,**,**,*,95
12,Yukon,N05BE,Azaspirodecanedione derivatives,<65,F,**,**,**,*,95
12,Yukon,C09BA,ACE inhibitors and diuretics,<65,F,0.87,0.0,0.3,6,97
12,Yukon,J02AC,Triazole derivatives,<65,F,**,**,**,*,98
12,Yukon,S01EC,Carbonic anhydrase inhibitors,<65,F,**,**,**,*,99
12,Yukon,C01DA,Organic nitrates,<65,F,0.85,0.0,0.4,9,100